cdr3,v_gene,j_gene,lcdr3,lv_gene,Antibody_ID,Antigen_target,Neutralization,Source,Reference
CAGGSGISTPMDVW,IGHV5-51,IGHJ1,CQQYYSTPYTF,IGKV4-1,CR3022,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
CAGGSGISTPMDVW,IGHV5-51,IGHJ2,CQQYYSTPYTF,IGKV4-1,CR3022,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
CAGGSGISTPMDVW,IGHV5-51,IGHJ3,CQQYYSTPYTF,IGKV4-1,CR3022,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
CAGGSGISTPMDVW,IGHV5-51,IGHJ4,CQQYYSTPYTF,IGKV4-1,CR3022,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
CAGGSGISTPMDVW,IGHV5-51,IGHJ5,CQQYYSTPYTF,IGKV4-1,CR3022,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
CAGGSGISTPMDVW,IGHV5-51,IGHJ6,CQQYYSTPYTF,IGKV4-1,CR3022,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
CAKDRFQFARSWYGDYFDYW,IGHV3-30,IGHJ1,,IGKV2-30,S110,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CAKDRFQFARSWYGDYFDYW,IGHV3-30,IGHJ2,,IGKV2-30,S110,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CAKDRFQFARSWYGDYFDYW,IGHV3-30,IGHJ3,,IGKV2-30,S110,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CAKDRFQFARSWYGDYFDYW,IGHV3-30,IGHJ4,,IGKV2-30,S110,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CAKDRFQFARSWYGDYFDYW,IGHV3-30,IGHJ5,,IGKV2-30,S110,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CAKDRFQFARSWYGDYFDYW,IGHV3-30,IGHJ6,,IGKV2-30,S110,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARINTAAYDYDSTTFDIW,IGHV2-26,IGHJ1,,IGKV1-39,S124,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARINTAAYDYDSTTFDIW,IGHV2-26,IGHJ2,,IGKV1-39,S124,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARINTAAYDYDSTTFDIW,IGHV2-26,IGHJ3,,IGKV1-39,S124,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARINTAAYDYDSTTFDIW,IGHV2-26,IGHJ4,,IGKV1-39,S124,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARINTAAYDYDSTTFDIW,IGHV2-26,IGHJ5,,IGKV1-39,S124,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARINTAAYDYDSTTFDIW,IGHV2-26,IGHJ6,,IGKV1-39,S124,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDYTRGAWFGESLIGGFDNW,IGHV1-18,IGHJ1,,IGKV3-20,S309,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDYTRGAWFGESLIGGFDNW,IGHV1-18,IGHJ2,,IGKV3-20,S309,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDYTRGAWFGESLIGGFDNW,IGHV1-18,IGHJ3,,IGKV3-20,S309,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDYTRGAWFGESLIGGFDNW,IGHV1-18,IGHJ4,,IGKV3-20,S309,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDYTRGAWFGESLIGGFDNW,IGHV1-18,IGHJ5,,IGKV3-20,S309,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDYTRGAWFGESLIGGFDNW,IGHV1-18,IGHJ6,,IGKV3-20,S309,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLWWNDQAHYYGMDVW,IGHV3-7,IGHJ1,,IGLV3-25,S315,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLWWNDQAHYYGMDVW,IGHV3-7,IGHJ2,,IGLV3-25,S315,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLWWNDQAHYYGMDVW,IGHV3-7,IGHJ3,,IGLV3-25,S315,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLWWNDQAHYYGMDVW,IGHV3-7,IGHJ4,,IGLV3-25,S315,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLWWNDQAHYYGMDVW,IGHV3-7,IGHJ5,,IGLV3-25,S315,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLWWNDQAHYYGMDVW,IGHV3-7,IGHJ6,,IGLV3-25,S315,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARERDDIFPMGLNAFDIW,IGHV3-23,IGHJ1,,IGKV1-5,S303,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARERDDIFPMGLNAFDIW,IGHV3-23,IGHJ2,,IGKV1-5,S303,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARERDDIFPMGLNAFDIW,IGHV3-23,IGHJ3,,IGKV1-5,S303,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARERDDIFPMGLNAFDIW,IGHV3-23,IGHJ4,,IGKV1-5,S303,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARERDDIFPMGLNAFDIW,IGHV3-23,IGHJ5,,IGKV1-5,S303,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARERDDIFPMGLNAFDIW,IGHV3-23,IGHJ6,,IGKV1-5,S303,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARGDSSGYYYYFDYW,IGHV3-13,IGHJ1,,IGKV1-39,S304,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARGDSSGYYYYFDYW,IGHV3-13,IGHJ2,,IGKV1-39,S304,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARGDSSGYYYYFDYW,IGHV3-13,IGHJ3,,IGKV1-39,S304,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARGDSSGYYYYFDYW,IGHV3-13,IGHJ4,,IGKV1-39,S304,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARGDSSGYYYYFDYW,IGHV3-13,IGHJ5,,IGKV1-39,S304,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARGDSSGYYYYFDYW,IGHV3-13,IGHJ6,,IGKV1-39,S304,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CASDYFDSSGYYHSFDYW,IGHV1-18,IGHJ1,,IGKV3-11,S305,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CASDYFDSSGYYHSFDYW,IGHV1-18,IGHJ2,,IGKV3-11,S305,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CASDYFDSSGYYHSFDYW,IGHV1-18,IGHJ3,,IGKV3-11,S305,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CASDYFDSSGYYHSFDYW,IGHV1-18,IGHJ4,,IGKV3-11,S305,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CASDYFDSSGYYHSFDYW,IGHV1-18,IGHJ5,,IGKV3-11,S305,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CASDYFDSSGYYHSFDYW,IGHV1-18,IGHJ6,,IGKV3-11,S305,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CATRTYDSSGYRPYYYGLDVW,IGHV1-69,IGHJ1,,IGLV2-23,S310,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CATRTYDSSGYRPYYYGLDVW,IGHV1-69,IGHJ2,,IGLV2-23,S310,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CATRTYDSSGYRPYYYGLDVW,IGHV1-69,IGHJ3,,IGLV2-23,S310,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CATRTYDSSGYRPYYYGLDVW,IGHV1-69,IGHJ4,,IGLV2-23,S310,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CATRTYDSSGYRPYYYGLDVW,IGHV1-69,IGHJ5,,IGLV2-23,S310,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CATRTYDSSGYRPYYYGLDVW,IGHV1-69,IGHJ6,,IGLV2-23,S310,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
CARDLVVYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPFTF,IGKV1-9,BD-494,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPFTF,IGKV1-9,BD-494,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPFTF,IGKV1-9,BD-494,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPFTF,IGKV1-9,BD-494,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPFTF,IGKV1-9,BD-494,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPFTF,IGKV1-9,BD-494,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-66,IGHJ1,CQQLNSYPLTF,IGKV1-9,BD-498,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-66,IGHJ2,CQQLNSYPLTF,IGKV1-9,BD-498,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-66,IGHJ3,CQQLNSYPLTF,IGKV1-9,BD-498,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-66,IGHJ4,CQQLNSYPLTF,IGKV1-9,BD-498,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-66,IGHJ5,CQQLNSYPLTF,IGKV1-9,BD-498,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-66,IGHJ6,CQQLNSYPLTF,IGKV1-9,BD-498,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAMSYGMDVW,IGHV3-53,IGHJ1,CQQSYSTPPDTF,IGKV1D-39,BD-500,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAMSYGMDVW,IGHV3-53,IGHJ2,CQQSYSTPPDTF,IGKV1D-39,BD-500,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAMSYGMDVW,IGHV3-53,IGHJ3,CQQSYSTPPDTF,IGKV1D-39,BD-500,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAMSYGMDVW,IGHV3-53,IGHJ4,CQQSYSTPPDTF,IGKV1D-39,BD-500,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAMSYGMDVW,IGHV3-53,IGHJ5,CQQSYSTPPDTF,IGKV1D-39,BD-500,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAMSYGMDVW,IGHV3-53,IGHJ6,CQQSYSTPPDTF,IGKV1D-39,BD-500,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAAVYGIDVW,IGHV3-53,IGHJ1,CQQSYTTPLFTF,IGKV1D-39,BD-503,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAAVYGIDVW,IGHV3-53,IGHJ2,CQQSYTTPLFTF,IGKV1D-39,BD-503,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAAVYGIDVW,IGHV3-53,IGHJ3,CQQSYTTPLFTF,IGKV1D-39,BD-503,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAAVYGIDVW,IGHV3-53,IGHJ4,CQQSYTTPLFTF,IGKV1D-39,BD-503,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAAVYGIDVW,IGHV3-53,IGHJ5,CQQSYTTPLFTF,IGKV1D-39,BD-503,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAAVYGIDVW,IGHV3-53,IGHJ6,CQQSYTTPLFTF,IGKV1D-39,BD-503,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLISRGMDVW,IGHV3-66,IGHJ1,CQQSYTTPLFTF,IGKV1-9,BD-504,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLISRGMDVW,IGHV3-66,IGHJ2,CQQSYTTPLFTF,IGKV1-9,BD-504,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLISRGMDVW,IGHV3-66,IGHJ3,CQQSYTTPLFTF,IGKV1-9,BD-504,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLISRGMDVW,IGHV3-66,IGHJ4,CQQSYTTPLFTF,IGKV1-9,BD-504,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLISRGMDVW,IGHV3-66,IGHJ5,CQQSYTTPLFTF,IGKV1-9,BD-504,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLISRGMDVW,IGHV3-66,IGHJ6,CQQSYTTPLFTF,IGKV1-9,BD-504,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDRVVYGMDVW,IGHV3-53,IGHJ1,CHQYDNLPPTF,IGKV1D-33,BD-505,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDRVVYGMDVW,IGHV3-53,IGHJ2,CHQYDNLPPTF,IGKV1D-33,BD-505,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDRVVYGMDVW,IGHV3-53,IGHJ3,CHQYDNLPPTF,IGKV1D-33,BD-505,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDRVVYGMDVW,IGHV3-53,IGHJ4,CHQYDNLPPTF,IGKV1D-33,BD-505,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDRVVYGMDVW,IGHV3-53,IGHJ5,CHQYDNLPPTF,IGKV1D-33,BD-505,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDRVVYGMDVW,IGHV3-53,IGHJ6,CHQYDNLPPTF,IGKV1D-33,BD-505,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVSYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPLTF,IGKV1-9,BD-506,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVSYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPLTF,IGKV1-9,BD-506,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVSYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPLTF,IGKV1-9,BD-506,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVSYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPLTF,IGKV1-9,BD-506,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVSYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPLTF,IGKV1-9,BD-506,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVSYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPLTF,IGKV1-9,BD-506,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ1,CQQLNSNPPITF,IGKV1-9,BD-507,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ2,CQQLNSNPPITF,IGKV1-9,BD-507,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ3,CQQLNSNPPITF,IGKV1-9,BD-507,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ4,CQQLNSNPPITF,IGKV1-9,BD-507,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ5,CQQLNSNPPITF,IGKV1-9,BD-507,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLVVYGMDVW,IGHV3-53,IGHJ6,CQQLNSNPPITF,IGKV1-9,BD-507,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAQNYGMDVW,IGHV3-53,IGHJ1,CQQSYSTPPYTF,IGKV1D-39,BD-508,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAQNYGMDVW,IGHV3-53,IGHJ2,CQQSYSTPPYTF,IGKV1D-39,BD-508,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAQNYGMDVW,IGHV3-53,IGHJ3,CQQSYSTPPYTF,IGKV1D-39,BD-508,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAQNYGMDVW,IGHV3-53,IGHJ4,CQQSYSTPPYTF,IGKV1D-39,BD-508,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAQNYGMDVW,IGHV3-53,IGHJ5,CQQSYSTPPYTF,IGKV1D-39,BD-508,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDAQNYGMDVW,IGHV3-53,IGHJ6,CQQSYSTPPYTF,IGKV1D-39,BD-508,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CARDLDVYGLDVW,IGHV3-53,IGHJ1,CQQLNSYPPKFTF,IGKV1-9,CC12.1,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDLDVYGLDVW,IGHV3-53,IGHJ2,CQQLNSYPPKFTF,IGKV1-9,CC12.1,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDLDVYGLDVW,IGHV3-53,IGHJ3,CQQLNSYPPKFTF,IGKV1-9,CC12.1,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDLDVYGLDVW,IGHV3-53,IGHJ4,CQQLNSYPPKFTF,IGKV1-9,CC12.1,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDLDVYGLDVW,IGHV3-53,IGHJ5,CQQLNSYPPKFTF,IGKV1-9,CC12.1,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDLDVYGLDVW,IGHV3-53,IGHJ6,CQQLNSYPPKFTF,IGKV1-9,CC12.1,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDYGDLYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,CC12.2,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDYGDLYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,CC12.2,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDYGDLYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,CC12.2,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDYGDLYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,CC12.2,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDYGDLYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,CC12.2,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDYGDLYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,CC12.2,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFGDFYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,CC12.3,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFGDFYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,CC12.3,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFGDFYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,CC12.3,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFGDFYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,CC12.3,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFGDFYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,CC12.3,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFGDFYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,CC12.3,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATESWVYGSGSYSSGAFDIW,IGHV1-2,IGHJ1,CTSYAGSNNFVF,IGLV2-8,CC12.4,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATESWVYGSGSYSSGAFDIW,IGHV1-2,IGHJ2,CTSYAGSNNFVF,IGLV2-8,CC12.4,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATESWVYGSGSYSSGAFDIW,IGHV1-2,IGHJ3,CTSYAGSNNFVF,IGLV2-8,CC12.4,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATESWVYGSGSYSSGAFDIW,IGHV1-2,IGHJ4,CTSYAGSNNFVF,IGLV2-8,CC12.4,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATESWVYGSGSYSSGAFDIW,IGHV1-2,IGHJ5,CTSYAGSNNFVF,IGLV2-8,CC12.4,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATESWVYGSGSYSSGAFDIW,IGHV1-2,IGHJ6,CTSYAGSNNFVF,IGLV2-8,CC12.4,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ1,CSSYTSSSTQVF,IGLV2-14,CC12.5,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ2,CSSYTSSSTQVF,IGLV2-14,CC12.5,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ3,CSSYTSSSTQVF,IGLV2-14,CC12.5,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ4,CSSYTSSSTQVF,IGLV2-14,CC12.5,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ5,CSSYTSSSTQVF,IGLV2-14,CC12.5,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ6,CSSYTSSSTQVF,IGLV2-14,CC12.5,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ1,CSSYTVSSTQVF,IGLV2-14,CC12.6,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ2,CSSYTVSSTQVF,IGLV2-14,CC12.6,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ3,CSSYTVSSTQVF,IGLV2-14,CC12.6,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ4,CSSYTVSSTQVF,IGLV2-14,CC12.6,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ5,CSSYTVSSTQVF,IGLV2-14,CC12.6,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ6,CSSYTVSSTQVF,IGLV2-14,CC12.6,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDFW,IGHV1-2,IGHJ1,CSSYTISSAQVF,IGLV2-14,CC12.7,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDFW,IGHV1-2,IGHJ2,CSSYTISSAQVF,IGLV2-14,CC12.7,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDFW,IGHV1-2,IGHJ3,CSSYTISSAQVF,IGLV2-14,CC12.7,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDFW,IGHV1-2,IGHJ4,CSSYTISSAQVF,IGLV2-14,CC12.7,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDFW,IGHV1-2,IGHJ5,CSSYTISSAQVF,IGLV2-14,CC12.7,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDFW,IGHV1-2,IGHJ6,CSSYTISSAQVF,IGLV2-14,CC12.7,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ1,CSSYTSSSAQLF,IGLV2-14,CC12.8,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ2,CSSYTSSSAQLF,IGLV2-14,CC12.8,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ3,CSSYTSSSAQLF,IGLV2-14,CC12.8,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ4,CSSYTSSSAQLF,IGLV2-14,CC12.8,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ5,CSSYTSSSAQLF,IGLV2-14,CC12.8,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ6,CSSYTSSSAQLF,IGLV2-14,CC12.8,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ1,CSSYTSSSAQVF,IGLV2-14,CC12.9,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ2,CSSYTSSSAQVF,IGLV2-14,CC12.9,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ3,CSSYTSSSAQVF,IGLV2-14,CC12.9,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ4,CSSYTSSSAQVF,IGLV2-14,CC12.9,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ5,CSSYTSSSAQVF,IGLV2-14,CC12.9,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ6,CSSYTSSSAQVF,IGLV2-14,CC12.9,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTHFDYW,IGHV1-2,IGHJ1,CSSYAGSSTQVF,IGLV2-14,CC12.10,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTHFDYW,IGHV1-2,IGHJ2,CSSYAGSSTQVF,IGLV2-14,CC12.10,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTHFDYW,IGHV1-2,IGHJ3,CSSYAGSSTQVF,IGLV2-14,CC12.10,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTHFDYW,IGHV1-2,IGHJ4,CSSYAGSSTQVF,IGLV2-14,CC12.10,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTHFDYW,IGHV1-2,IGHJ5,CSSYAGSSTQVF,IGLV2-14,CC12.10,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTHFDYW,IGHV1-2,IGHJ6,CSSYAGSSTQVF,IGLV2-14,CC12.10,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ1,CSSYTSSSAQLF,IGLV2-14,CC12.11,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ2,CSSYTSSSAQLF,IGLV2-14,CC12.11,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ3,CSSYTSSSAQLF,IGLV2-14,CC12.11,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ4,CSSYTSSSAQLF,IGLV2-14,CC12.11,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ5,CSSYTSSSAQLF,IGLV2-14,CC12.11,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ6,CSSYTSSSAQLF,IGLV2-14,CC12.11,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ1,CSSYTSGSTQVF,IGLV2-14,CC12.12,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ2,CSSYTSGSTQVF,IGLV2-14,CC12.12,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ3,CSSYTSGSTQVF,IGLV2-14,CC12.12,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ4,CSSYTSGSTQVF,IGLV2-14,CC12.12,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ5,CSSYTSGSTQVF,IGLV2-14,CC12.12,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGPRYSGTYFDYW,IGHV1-2,IGHJ6,CSSYTSGSTQVF,IGLV2-14,CC12.12,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPYGYSSIWDGQGGHW,IGHV3-53,IGHJ1,CQQYDNLPITF,IGKV1-33,CC12.13,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPYGYSSIWDGQGGHW,IGHV3-53,IGHJ2,CQQYDNLPITF,IGKV1-33,CC12.13,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPYGYSSIWDGQGGHW,IGHV3-53,IGHJ3,CQQYDNLPITF,IGKV1-33,CC12.13,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPYGYSSIWDGQGGHW,IGHV3-53,IGHJ4,CQQYDNLPITF,IGKV1-33,CC12.13,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPYGYSSIWDGQGGHW,IGHV3-53,IGHJ5,CQQYDNLPITF,IGKV1-33,CC12.13,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPYGYSSIWDGQGGHW,IGHV3-53,IGHJ6,CQQYDNLPITF,IGKV1-33,CC12.13,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGGYCSDGSCYVQDRLIYYYSGLDVW,IGHV3-21,IGHJ1,CMQGTHWPPTF,IGKV2-30,CC12.14,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGGYCSDGSCYVQDRLIYYYSGLDVW,IGHV3-21,IGHJ2,CMQGTHWPPTF,IGKV2-30,CC12.14,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGGYCSDGSCYVQDRLIYYYSGLDVW,IGHV3-21,IGHJ3,CMQGTHWPPTF,IGKV2-30,CC12.14,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGGYCSDGSCYVQDRLIYYYSGLDVW,IGHV3-21,IGHJ4,CMQGTHWPPTF,IGKV2-30,CC12.14,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGGYCSDGSCYVQDRLIYYYSGLDVW,IGHV3-21,IGHJ5,CMQGTHWPPTF,IGKV2-30,CC12.14,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARGGYCSDGSCYVQDRLIYYYSGLDVW,IGHV3-21,IGHJ6,CMQGTHWPPTF,IGKV2-30,CC12.14,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDRRRRYCTNGVCYRPEEIDYW,IGHV3-48,IGHJ1,CQSYDSSLSGVVF,IGLV1-40,CC12.15,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDRRRRYCTNGVCYRPEEIDYW,IGHV3-48,IGHJ2,CQSYDSSLSGVVF,IGLV1-40,CC12.15,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDRRRRYCTNGVCYRPEEIDYW,IGHV3-48,IGHJ3,CQSYDSSLSGVVF,IGLV1-40,CC12.15,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDRRRRYCTNGVCYRPEEIDYW,IGHV3-48,IGHJ4,CQSYDSSLSGVVF,IGLV1-40,CC12.15,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDRRRRYCTNGVCYRPEEIDYW,IGHV3-48,IGHJ5,CQSYDSSLSGVVF,IGLV1-40,CC12.15,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDRRRRYCTNGVCYRPEEIDYW,IGHV3-48,IGHJ6,CQSYDSSLSGVVF,IGLV1-40,CC12.15,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPFPGAVAGTGYLQYW,IGHV3-33,IGHJ1,CQVWDSSSDPWVF,IGLV3-21,CC12.16,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPFPGAVAGTGYLQYW,IGHV3-33,IGHJ2,CQVWDSSSDPWVF,IGLV3-21,CC12.16,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPFPGAVAGTGYLQYW,IGHV3-33,IGHJ3,CQVWDSSSDPWVF,IGLV3-21,CC12.16,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPFPGAVAGTGYLQYW,IGHV3-33,IGHJ4,CQVWDSSSDPWVF,IGLV3-21,CC12.16,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPFPGAVAGTGYLQYW,IGHV3-33,IGHJ5,CQVWDSSSDPWVF,IGLV3-21,CC12.16,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDPFPGAVAGTGYLQYW,IGHV3-33,IGHJ6,CQVWDSSSDPWVF,IGLV3-21,CC12.16,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKSSGSYYYYYYGMDVW,IGHV3-30,IGHJ1,CQVWDSSSDHPVVF,IGLV3-21,CC12.17,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKSSGSYYYYYYGMDVW,IGHV3-30,IGHJ2,CQVWDSSSDHPVVF,IGLV3-21,CC12.17,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKSSGSYYYYYYGMDVW,IGHV3-30,IGHJ3,CQVWDSSSDHPVVF,IGLV3-21,CC12.17,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKSSGSYYYYYYGMDVW,IGHV3-30,IGHJ4,CQVWDSSSDHPVVF,IGLV3-21,CC12.17,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKSSGSYYYYYYGMDVW,IGHV3-30,IGHJ5,CQVWDSSSDHPVVF,IGLV3-21,CC12.17,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKSSGSYYYYYYGMDVW,IGHV3-30,IGHJ6,CQVWDSSSDHPVVF,IGLV3-21,CC12.17,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARLHCGGDCYLDYW,IGHV1-46,IGHJ1,CQSYDSSNHEEIWVF,IGLV6-57,CC12.18,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARLHCGGDCYLDYW,IGHV1-46,IGHJ2,CQSYDSSNHEEIWVF,IGLV6-57,CC12.18,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARLHCGGDCYLDYW,IGHV1-46,IGHJ3,CQSYDSSNHEEIWVF,IGLV6-57,CC12.18,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARLHCGGDCYLDYW,IGHV1-46,IGHJ4,CQSYDSSNHEEIWVF,IGLV6-57,CC12.18,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARLHCGGDCYLDYW,IGHV1-46,IGHJ5,CQSYDSSNHEEIWVF,IGLV6-57,CC12.18,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARLHCGGDCYLDYW,IGHV1-46,IGHJ6,CQSYDSSNHEEIWVF,IGLV6-57,CC12.18,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKGSGSGSYPNYYYYYGMDVW,IGHV3-23,IGHJ1,CQVWDNNSDHLVF,IGLV3-21,CC12.19,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKGSGSGSYPNYYYYYGMDVW,IGHV3-23,IGHJ2,CQVWDNNSDHLVF,IGLV3-21,CC12.19,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKGSGSGSYPNYYYYYGMDVW,IGHV3-23,IGHJ3,CQVWDNNSDHLVF,IGLV3-21,CC12.19,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKGSGSGSYPNYYYYYGMDVW,IGHV3-23,IGHJ4,CQVWDNNSDHLVF,IGLV3-21,CC12.19,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKGSGSGSYPNYYYYYGMDVW,IGHV3-23,IGHJ5,CQVWDNNSDHLVF,IGLV3-21,CC12.19,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKGSGSGSYPNYYYYYGMDVW,IGHV3-23,IGHJ6,CQVWDNNSDHLVF,IGLV3-21,CC12.19,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQAYYDILTGYLNPPKNYYYYGMDVW,IGHV3-30,IGHJ1,CAAWDDSLSGRVVF,IGLV1-47,CC12.20,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQAYYDILTGYLNPPKNYYYYGMDVW,IGHV3-30,IGHJ2,CAAWDDSLSGRVVF,IGLV1-47,CC12.20,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQAYYDILTGYLNPPKNYYYYGMDVW,IGHV3-30,IGHJ3,CAAWDDSLSGRVVF,IGLV1-47,CC12.20,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQAYYDILTGYLNPPKNYYYYGMDVW,IGHV3-30,IGHJ4,CAAWDDSLSGRVVF,IGLV1-47,CC12.20,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQAYYDILTGYLNPPKNYYYYGMDVW,IGHV3-30,IGHJ5,CAAWDDSLSGRVVF,IGLV1-47,CC12.20,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQAYYDILTGYLNPPKNYYYYGMDVW,IGHV3-30,IGHJ6,CAAWDDSLSGRVVF,IGLV1-47,CC12.20,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATAFSIFGVVPPDYW,IGHV1-24,IGHJ1,CAAWDDSLNGPVF,IGLV1-44,CC12.21,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATAFSIFGVVPPDYW,IGHV1-24,IGHJ2,CAAWDDSLNGPVF,IGLV1-44,CC12.21,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATAFSIFGVVPPDYW,IGHV1-24,IGHJ3,CAAWDDSLNGPVF,IGLV1-44,CC12.21,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATAFSIFGVVPPDYW,IGHV1-24,IGHJ4,CAAWDDSLNGPVF,IGLV1-44,CC12.21,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATAFSIFGVVPPDYW,IGHV1-24,IGHJ5,CAAWDDSLNGPVF,IGLV1-44,CC12.21,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATAFSIFGVVPPDYW,IGHV1-24,IGHJ6,CAAWDDSLNGPVF,IGLV1-44,CC12.21,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATGFAQNMVLLTPYW,IGHV1-24,IGHJ1,CQQYNNWPPITF,IGKV3-15,CC12.22,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATGFAQNMVLLTPYW,IGHV1-24,IGHJ2,CQQYNNWPPITF,IGKV3-15,CC12.22,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATGFAQNMVLLTPYW,IGHV1-24,IGHJ3,CQQYNNWPPITF,IGKV3-15,CC12.22,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATGFAQNMVLLTPYW,IGHV1-24,IGHJ4,CQQYNNWPPITF,IGKV3-15,CC12.22,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATGFAQNMVLLTPYW,IGHV1-24,IGHJ5,CQQYNNWPPITF,IGKV3-15,CC12.22,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CATGFAQNMVLLTPYW,IGHV1-24,IGHJ6,CQQYNNWPPITF,IGKV3-15,CC12.22,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARQGDCSTTSCAYDYW,IGHV4-39,IGHJ1,CQSADSSGTYLVVF,IGLV3-25,CC12.23,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARQGDCSTTSCAYDYW,IGHV4-39,IGHJ2,CQSADSSGTYLVVF,IGLV3-25,CC12.23,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARQGDCSTTSCAYDYW,IGHV4-39,IGHJ3,CQSADSSGTYLVVF,IGLV3-25,CC12.23,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARQGDCSTTSCAYDYW,IGHV4-39,IGHJ4,CQSADSSGTYLVVF,IGLV3-25,CC12.23,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARQGDCSTTSCAYDYW,IGHV4-39,IGHJ5,CQSADSSGTYLVVF,IGLV3-25,CC12.23,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARQGDCSTTSCAYDYW,IGHV4-39,IGHJ6,CQSADSSGTYLVVF,IGLV3-25,CC12.23,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRTGNYYYGMDVW,IGHV3-30,IGHJ1,CQQSYSTPWTF,IGKV1-39,CC12.24,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRTGNYYYGMDVW,IGHV3-30,IGHJ2,CQQSYSTPWTF,IGKV1-39,CC12.24,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRTGNYYYGMDVW,IGHV3-30,IGHJ3,CQQSYSTPWTF,IGKV1-39,CC12.24,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRTGNYYYGMDVW,IGHV3-30,IGHJ4,CQQSYSTPWTF,IGKV1-39,CC12.24,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRTGNYYYGMDVW,IGHV3-30,IGHJ5,CQQSYSTPWTF,IGKV1-39,CC12.24,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRTGNYYYGMDVW,IGHV3-30,IGHJ6,CQQSYSTPWTF,IGKV1-39,CC12.24,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRYYEFWSGYSNWFDPW,IGHV3-23,IGHJ1,CAAWDDSLNGPVF,IGLV1-44,CC12.25,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRYYEFWSGYSNWFDPW,IGHV3-23,IGHJ2,CAAWDDSLNGPVF,IGLV1-44,CC12.25,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRYYEFWSGYSNWFDPW,IGHV3-23,IGHJ3,CAAWDDSLNGPVF,IGLV1-44,CC12.25,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRYYEFWSGYSNWFDPW,IGHV3-23,IGHJ4,CAAWDDSLNGPVF,IGLV1-44,CC12.25,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRYYEFWSGYSNWFDPW,IGHV3-23,IGHJ5,CAAWDDSLNGPVF,IGLV1-44,CC12.25,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDRYYEFWSGYSNWFDPW,IGHV3-23,IGHJ6,CAAWDDSLNGPVF,IGLV1-44,CC12.25,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVNYYDSSGYPSFHFDYW,IGHV5-51,IGHJ1,CLLYYGGAQRWVF,IGLV7-43,CC12.26,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVNYYDSSGYPSFHFDYW,IGHV5-51,IGHJ2,CLLYYGGAQRWVF,IGLV7-43,CC12.26,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVNYYDSSGYPSFHFDYW,IGHV5-51,IGHJ3,CLLYYGGAQRWVF,IGLV7-43,CC12.26,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVNYYDSSGYPSFHFDYW,IGHV5-51,IGHJ4,CLLYYGGAQRWVF,IGLV7-43,CC12.26,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVNYYDSSGYPSFHFDYW,IGHV5-51,IGHJ5,CLLYYGGAQRWVF,IGLV7-43,CC12.26,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVNYYDSSGYPSFHFDYW,IGHV5-51,IGHJ6,CLLYYGGAQRWVF,IGLV7-43,CC12.26,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAREMPAAMGYYYYGMDVW,IGHV1-2,IGHJ1,CYSYAGSSTFVFVF,IGLV2-23,CC12.27,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAREMPAAMGYYYYGMDVW,IGHV1-2,IGHJ2,CYSYAGSSTFVFVF,IGLV2-23,CC12.27,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAREMPAAMGYYYYGMDVW,IGHV1-2,IGHJ3,CYSYAGSSTFVFVF,IGLV2-23,CC12.27,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAREMPAAMGYYYYGMDVW,IGHV1-2,IGHJ4,CYSYAGSSTFVFVF,IGLV2-23,CC12.27,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAREMPAAMGYYYYGMDVW,IGHV1-2,IGHJ5,CYSYAGSSTFVFVF,IGLV2-23,CC12.27,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAREMPAAMGYYYYGMDVW,IGHV1-2,IGHJ6,CYSYAGSSTFVFVF,IGLV2-23,CC12.27,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKANKYSSSEFDFW,IGHV3-23,IGHJ1,CAAWDDSLSGWVF,IGLV1-47,CC12.28,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKANKYSSSEFDFW,IGHV3-23,IGHJ2,CAAWDDSLSGWVF,IGLV1-47,CC12.28,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKANKYSSSEFDFW,IGHV3-23,IGHJ3,CAAWDDSLSGWVF,IGLV1-47,CC12.28,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKANKYSSSEFDFW,IGHV3-23,IGHJ4,CAAWDDSLSGWVF,IGLV1-47,CC12.28,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKANKYSSSEFDFW,IGHV3-23,IGHJ5,CAAWDDSLSGWVF,IGLV1-47,CC12.28,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKANKYSSSEFDFW,IGHV3-23,IGHJ6,CAAWDDSLSGWVF,IGLV1-47,CC12.28,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAVYYYDSGSPGWFDPW,IGHV7-4-1,IGHJ1,CQQSYSTPPTF,IGKV1-39,CC6.29,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAVYYYDSGSPGWFDPW,IGHV7-4-1,IGHJ2,CQQSYSTPPTF,IGKV1-39,CC6.29,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAVYYYDSGSPGWFDPW,IGHV7-4-1,IGHJ3,CQQSYSTPPTF,IGKV1-39,CC6.29,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAVYYYDSGSPGWFDPW,IGHV7-4-1,IGHJ4,CQQSYSTPPTF,IGKV1-39,CC6.29,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAVYYYDSGSPGWFDPW,IGHV7-4-1,IGHJ5,CQQSYSTPPTF,IGKV1-39,CC6.29,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAVYYYDSGSPGWFDPW,IGHV7-4-1,IGHJ6,CQQSYSTPPTF,IGKV1-39,CC6.29,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFRYCSSTRCYFWFDPW,IGHV1-69,IGHJ1,CQQSYSTPRTF,IGKV1-39,CC6.30,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFRYCSSTRCYFWFDPW,IGHV1-69,IGHJ2,CQQSYSTPRTF,IGKV1-39,CC6.30,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFRYCSSTRCYFWFDPW,IGHV1-69,IGHJ3,CQQSYSTPRTF,IGKV1-39,CC6.30,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFRYCSSTRCYFWFDPW,IGHV1-69,IGHJ4,CQQSYSTPRTF,IGKV1-39,CC6.30,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFRYCSSTRCYFWFDPW,IGHV1-69,IGHJ5,CQQSYSTPRTF,IGKV1-39,CC6.30,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARDFRYCSSTRCYFWFDPW,IGHV1-69,IGHJ6,CQQSYSTPRTF,IGKV1-39,CC6.30,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARWYDSTGSIDYW,IGHV1-46,IGHJ1,CLQHNSYPILTF,IGKV1-17,CC6.31,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARWYDSTGSIDYW,IGHV1-46,IGHJ2,CLQHNSYPILTF,IGKV1-17,CC6.31,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARWYDSTGSIDYW,IGHV1-46,IGHJ3,CLQHNSYPILTF,IGKV1-17,CC6.31,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARWYDSTGSIDYW,IGHV1-46,IGHJ4,CLQHNSYPILTF,IGKV1-17,CC6.31,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARWYDSTGSIDYW,IGHV1-46,IGHJ5,CLQHNSYPILTF,IGKV1-17,CC6.31,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARWYDSTGSIDYW,IGHV1-46,IGHJ6,CLQHNSYPILTF,IGKV1-17,CC6.31,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQGYSYGNYFDYW,IGHV3-9,IGHJ1,CQVWDSSSDHPYVF,IGLV3-21,CC6.32,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQGYSYGNYFDYW,IGHV3-9,IGHJ2,CQVWDSSSDHPYVF,IGLV3-21,CC6.32,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQGYSYGNYFDYW,IGHV3-9,IGHJ3,CQVWDSSSDHPYVF,IGLV3-21,CC6.32,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQGYSYGNYFDYW,IGHV3-9,IGHJ4,CQVWDSSSDHPYVF,IGLV3-21,CC6.32,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQGYSYGNYFDYW,IGHV3-9,IGHJ5,CQVWDSSSDHPYVF,IGLV3-21,CC6.32,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CAKDQGYSYGNYFDYW,IGHV3-9,IGHJ6,CQVWDSSSDHPYVF,IGLV3-21,CC6.32,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CALRNQWDLLVYW,IGHV1-69,IGHJ1,CQHYGSSLWTF,IGKV3-20,CC6.33,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CALRNQWDLLVYW,IGHV1-69,IGHJ2,CQHYGSSLWTF,IGKV3-20,CC6.33,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CALRNQWDLLVYW,IGHV1-69,IGHJ3,CQHYGSSLWTF,IGKV3-20,CC6.33,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CALRNQWDLLVYW,IGHV1-69,IGHJ4,CQHYGSSLWTF,IGKV3-20,CC6.33,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CALRNQWDLLVYW,IGHV1-69,IGHJ5,CQHYGSSLWTF,IGKV3-20,CC6.33,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CALRNQWDLLVYW,IGHV1-69,IGHJ6,CQHYGSSLWTF,IGKV3-20,CC6.33,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CARVSSGYYFTPFDYW,IGHV4-39,IGHJ1,,IGKV3-20,COVA1-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVSSGYYFTPFDYW,IGHV4-39,IGHJ2,,IGKV3-20,COVA1-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVSSGYYFTPFDYW,IGHV4-39,IGHJ3,,IGKV3-20,COVA1-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVSSGYYFTPFDYW,IGHV4-39,IGHJ4,,IGKV3-20,COVA1-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVSSGYYFTPFDYW,IGHV4-39,IGHJ5,,IGKV3-20,COVA1-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVSSGYYFTPFDYW,IGHV4-39,IGHJ6,,IGKV3-20,COVA1-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARARGGSYNDAFDIW,IGHV3-30,IGHJ1,,IGLV2-14,COVA1-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARARGGSYNDAFDIW,IGHV3-30,IGHJ2,,IGLV2-14,COVA1-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARARGGSYNDAFDIW,IGHV3-30,IGHJ3,,IGLV2-14,COVA1-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARARGGSYNDAFDIW,IGHV3-30,IGHJ4,,IGLV2-14,COVA1-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARARGGSYNDAFDIW,IGHV3-30,IGHJ5,,IGLV2-14,COVA1-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARARGGSYNDAFDIW,IGHV3-30,IGHJ6,,IGLV2-14,COVA1-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDGQYYDFWSGYLGARTNPHYYYYMDVW,IGHV3-30,IGHJ1,,IGKV1-27,COVA1-03,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDGQYYDFWSGYLGARTNPHYYYYMDVW,IGHV3-30,IGHJ2,,IGKV1-27,COVA1-03,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDGQYYDFWSGYLGARTNPHYYYYMDVW,IGHV3-30,IGHJ3,,IGKV1-27,COVA1-03,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDGQYYDFWSGYLGARTNPHYYYYMDVW,IGHV3-30,IGHJ4,,IGKV1-27,COVA1-03,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDGQYYDFWSGYLGARTNPHYYYYMDVW,IGHV3-30,IGHJ5,,IGKV1-27,COVA1-03,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDGQYYDFWSGYLGARTNPHYYYYMDVW,IGHV3-30,IGHJ6,,IGKV1-27,COVA1-03,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARIPGYDSSGYYRGDYW,IGHV1-69,IGHJ1,,IGKV3-11,COVA1-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARIPGYDSSGYYRGDYW,IGHV1-69,IGHJ2,,IGKV3-11,COVA1-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARIPGYDSSGYYRGDYW,IGHV1-69,IGHJ3,,IGKV3-11,COVA1-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARIPGYDSSGYYRGDYW,IGHV1-69,IGHJ4,,IGKV3-11,COVA1-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARIPGYDSSGYYRGDYW,IGHV1-69,IGHJ5,,IGKV3-11,COVA1-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARIPGYDSSGYYRGDYW,IGHV1-69,IGHJ6,,IGKV3-11,COVA1-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSRVRGVSNWFDPW,IGHV1-24,IGHJ1,,IGLV2-23,COVA1-05,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSRVRGVSNWFDPW,IGHV1-24,IGHJ2,,IGLV2-23,COVA1-05,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSRVRGVSNWFDPW,IGHV1-24,IGHJ3,,IGLV2-23,COVA1-05,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSRVRGVSNWFDPW,IGHV1-24,IGHJ4,,IGLV2-23,COVA1-05,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSRVRGVSNWFDPW,IGHV1-24,IGHJ5,,IGLV2-23,COVA1-05,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSRVRGVSNWFDPW,IGHV1-24,IGHJ6,,IGLV2-23,COVA1-05,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDMGEAVAGTHYGMDVW,IGHV3-9,IGHJ1,,IGLV3-1,COVA1-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDMGEAVAGTHYGMDVW,IGHV3-9,IGHJ2,,IGLV3-1,COVA1-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDMGEAVAGTHYGMDVW,IGHV3-9,IGHJ3,,IGLV3-1,COVA1-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDMGEAVAGTHYGMDVW,IGHV3-9,IGHJ4,,IGLV3-1,COVA1-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDMGEAVAGTHYGMDVW,IGHV3-9,IGHJ5,,IGLV3-1,COVA1-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDMGEAVAGTHYGMDVW,IGHV3-9,IGHJ6,,IGLV3-1,COVA1-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGAYDSSGYSNDYW,IGHV1-69,IGHJ1,,IGKV3-11,COVA1-07,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGAYDSSGYSNDYW,IGHV1-69,IGHJ2,,IGKV3-11,COVA1-07,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGAYDSSGYSNDYW,IGHV1-69,IGHJ3,,IGKV3-11,COVA1-07,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGAYDSSGYSNDYW,IGHV1-69,IGHJ4,,IGKV3-11,COVA1-07,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGAYDSSGYSNDYW,IGHV1-69,IGHJ5,,IGKV3-11,COVA1-07,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGAYDSSGYSNDYW,IGHV1-69,IGHJ6,,IGKV3-11,COVA1-07,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREDYYDSSGSFDYW,IGHV3-30,IGHJ1,,IGLV2-14,COVA1-08,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREDYYDSSGSFDYW,IGHV3-30,IGHJ2,,IGLV2-14,COVA1-08,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREDYYDSSGSFDYW,IGHV3-30,IGHJ3,,IGLV2-14,COVA1-08,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREDYYDSSGSFDYW,IGHV3-30,IGHJ4,,IGLV2-14,COVA1-08,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREDYYDSSGSFDYW,IGHV3-30,IGHJ5,,IGLV2-14,COVA1-08,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREDYYDSSGSFDYW,IGHV3-30,IGHJ6,,IGLV2-14,COVA1-08,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHSQGWLQQAVAFDIW,IGHV4-59,IGHJ1,,IGKV1-39,COVA1-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHSQGWLQQAVAFDIW,IGHV4-59,IGHJ2,,IGKV1-39,COVA1-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHSQGWLQQAVAFDIW,IGHV4-59,IGHJ3,,IGKV1-39,COVA1-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHSQGWLQQAVAFDIW,IGHV4-59,IGHJ4,,IGKV1-39,COVA1-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHSQGWLQQAVAFDIW,IGHV4-59,IGHJ5,,IGKV1-39,COVA1-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHSQGWLQQAVAFDIW,IGHV4-59,IGHJ6,,IGKV1-39,COVA1-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGYYYDPSGYYSRSFSFDYW,IGHV3-66,IGHJ1,,IGLV2-14,COVA1-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGYYYDPSGYYSRSFSFDYW,IGHV3-66,IGHJ2,,IGLV2-14,COVA1-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGYYYDPSGYYSRSFSFDYW,IGHV3-66,IGHJ3,,IGLV2-14,COVA1-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGYYYDPSGYYSRSFSFDYW,IGHV3-66,IGHJ4,,IGLV2-14,COVA1-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGYYYDPSGYYSRSFSFDYW,IGHV3-66,IGHJ5,,IGLV2-14,COVA1-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGYYYDPSGYYSRSFSFDYW,IGHV3-66,IGHJ6,,IGLV2-14,COVA1-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFGYW,IGHV3-30,IGHJ1,,IGLV3-1,COVA1-11,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFGYW,IGHV3-30,IGHJ2,,IGLV3-1,COVA1-11,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFGYW,IGHV3-30,IGHJ3,,IGLV3-1,COVA1-11,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFGYW,IGHV3-30,IGHJ4,,IGLV3-1,COVA1-11,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFGYW,IGHV3-30,IGHJ5,,IGLV3-1,COVA1-11,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFGYW,IGHV3-30,IGHJ6,,IGLV3-1,COVA1-11,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVWATVSGTMDVW,IGHV1-2,IGHJ1,,IGLV2-8,COVA1-12,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVWATVSGTMDVW,IGHV1-2,IGHJ2,,IGLV2-8,COVA1-12,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVWATVSGTMDVW,IGHV1-2,IGHJ3,,IGLV2-8,COVA1-12,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVWATVSGTMDVW,IGHV1-2,IGHJ4,,IGLV2-8,COVA1-12,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVWATVSGTMDVW,IGHV1-2,IGHJ5,,IGLV2-8,COVA1-12,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVWATVSGTMDVW,IGHV1-2,IGHJ6,,IGLV2-8,COVA1-12,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARETPTSTYSSGWYNYYYYMDVW,IGHV3-7,IGHJ1,,IGKV1-5,COVA1-13,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARETPTSTYSSGWYNYYYYMDVW,IGHV3-7,IGHJ2,,IGKV1-5,COVA1-13,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARETPTSTYSSGWYNYYYYMDVW,IGHV3-7,IGHJ3,,IGKV1-5,COVA1-13,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARETPTSTYSSGWYNYYYYMDVW,IGHV3-7,IGHJ4,,IGKV1-5,COVA1-13,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARETPTSTYSSGWYNYYYYMDVW,IGHV3-7,IGHJ5,,IGKV1-5,COVA1-13,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARETPTSTYSSGWYNYYYYMDVW,IGHV3-7,IGHJ6,,IGKV1-5,COVA1-13,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGEVNGYRGAFDIW,IGHV4-59,IGHJ1,,IGKV3-20,COVA1-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGEVNGYRGAFDIW,IGHV4-59,IGHJ2,,IGKV3-20,COVA1-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGEVNGYRGAFDIW,IGHV4-59,IGHJ3,,IGKV3-20,COVA1-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGEVNGYRGAFDIW,IGHV4-59,IGHJ4,,IGKV3-20,COVA1-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGEVNGYRGAFDIW,IGHV4-59,IGHJ5,,IGKV3-20,COVA1-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGEVNGYRGAFDIW,IGHV4-59,IGHJ6,,IGKV3-20,COVA1-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPRGGNYLAGFDPW,IGHV3-30,IGHJ1,,IGLV2-14,COVA1-15,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPRGGNYLAGFDPW,IGHV3-30,IGHJ2,,IGLV2-14,COVA1-15,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPRGGNYLAGFDPW,IGHV3-30,IGHJ3,,IGLV2-14,COVA1-15,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPRGGNYLAGFDPW,IGHV3-30,IGHJ4,,IGLV2-14,COVA1-15,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPRGGNYLAGFDPW,IGHV3-30,IGHJ5,,IGLV2-14,COVA1-15,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPRGGNYLAGFDPW,IGHV3-30,IGHJ6,,IGLV2-14,COVA1-15,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPPRNYYDRSGYYQRAEYFQHW,IGHV1-46,IGHJ1,,IGKV1-33,COVA1-16,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPPRNYYDRSGYYQRAEYFQHW,IGHV1-46,IGHJ2,,IGKV1-33,COVA1-16,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPPRNYYDRSGYYQRAEYFQHW,IGHV1-46,IGHJ3,,IGKV1-33,COVA1-16,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPPRNYYDRSGYYQRAEYFQHW,IGHV1-46,IGHJ4,,IGKV1-33,COVA1-16,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPPRNYYDRSGYYQRAEYFQHW,IGHV1-46,IGHJ5,,IGKV1-33,COVA1-16,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPPRNYYDRSGYYQRAEYFQHW,IGHV1-46,IGHJ6,,IGKV1-33,COVA1-16,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAVAARPGNFDYW,IGHV1-2,IGHJ1,,IGLV1-51,COVA1-17,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAVAARPGNFDYW,IGHV1-2,IGHJ2,,IGLV1-51,COVA1-17,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAVAARPGNFDYW,IGHV1-2,IGHJ3,,IGLV1-51,COVA1-17,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAVAARPGNFDYW,IGHV1-2,IGHJ4,,IGLV1-51,COVA1-17,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAVAARPGNFDYW,IGHV1-2,IGHJ5,,IGLV1-51,COVA1-17,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAVAARPGNFDYW,IGHV1-2,IGHJ6,,IGLV1-51,COVA1-17,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVEWAAAGTFYW,IGHV3-66,IGHJ1,,IGLV7-46,COVA1-18,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVEWAAAGTFYW,IGHV3-66,IGHJ2,,IGLV7-46,COVA1-18,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVEWAAAGTFYW,IGHV3-66,IGHJ3,,IGLV7-46,COVA1-18,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVEWAAAGTFYW,IGHV3-66,IGHJ4,,IGLV7-46,COVA1-18,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVEWAAAGTFYW,IGHV3-66,IGHJ5,,IGLV7-46,COVA1-18,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVEWAAAGTFYW,IGHV3-66,IGHJ6,,IGLV7-46,COVA1-18,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKSDYYDSSGYYPAAFDIW,IGHV3-21,IGHJ1,,IGKV3-15,COVA1-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKSDYYDSSGYYPAAFDIW,IGHV3-21,IGHJ2,,IGKV3-15,COVA1-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKSDYYDSSGYYPAAFDIW,IGHV3-21,IGHJ3,,IGKV3-15,COVA1-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKSDYYDSSGYYPAAFDIW,IGHV3-21,IGHJ4,,IGKV3-15,COVA1-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKSDYYDSSGYYPAAFDIW,IGHV3-21,IGHJ5,,IGKV3-15,COVA1-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKSDYYDSSGYYPAAFDIW,IGHV3-21,IGHJ6,,IGKV3-15,COVA1-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGDQNLYCSGDSCYYHYYGMDVW,IGHV3-21,IGHJ1,,IGLV3-21,COVA1-20,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGDQNLYCSGDSCYYHYYGMDVW,IGHV3-21,IGHJ2,,IGLV3-21,COVA1-20,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGDQNLYCSGDSCYYHYYGMDVW,IGHV3-21,IGHJ3,,IGLV3-21,COVA1-20,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGDQNLYCSGDSCYYHYYGMDVW,IGHV3-21,IGHJ4,,IGLV3-21,COVA1-20,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGDQNLYCSGDSCYYHYYGMDVW,IGHV3-21,IGHJ5,,IGLV3-21,COVA1-20,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGDQNLYCSGDSCYYHYYGMDVW,IGHV3-21,IGHJ6,,IGLV3-21,COVA1-20,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDSEYYDILTGYLAPTHYYYYYMDVW,IGHV3-30,IGHJ1,,IGKV3-15,COVA1-21,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDSEYYDILTGYLAPTHYYYYYMDVW,IGHV3-30,IGHJ2,,IGKV3-15,COVA1-21,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDSEYYDILTGYLAPTHYYYYYMDVW,IGHV3-30,IGHJ3,,IGKV3-15,COVA1-21,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDSEYYDILTGYLAPTHYYYYYMDVW,IGHV3-30,IGHJ4,,IGKV3-15,COVA1-21,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDSEYYDILTGYLAPTHYYYYYMDVW,IGHV3-30,IGHJ5,,IGKV3-15,COVA1-21,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDSEYYDILTGYLAPTHYYYYYMDVW,IGHV3-30,IGHJ6,,IGKV3-15,COVA1-21,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVDTAMVQTLDDYGMDVW,IGHV1-18,IGHJ1,,IGLV3-1,COVA1-22,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVDTAMVQTLDDYGMDVW,IGHV1-18,IGHJ2,,IGLV3-1,COVA1-22,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVDTAMVQTLDDYGMDVW,IGHV1-18,IGHJ3,,IGLV3-1,COVA1-22,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVDTAMVQTLDDYGMDVW,IGHV1-18,IGHJ4,,IGLV3-1,COVA1-22,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVDTAMVQTLDDYGMDVW,IGHV1-18,IGHJ5,,IGLV3-1,COVA1-22,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLVDTAMVQTLDDYGMDVW,IGHV1-18,IGHJ6,,IGLV3-1,COVA1-22,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARYYYDSRGYTSIDFW,IGHV5-51,IGHJ1,,IGLV3-25,COVA1-23,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARYYYDSRGYTSIDFW,IGHV5-51,IGHJ2,,IGLV3-25,COVA1-23,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARYYYDSRGYTSIDFW,IGHV5-51,IGHJ3,,IGLV3-25,COVA1-23,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARYYYDSRGYTSIDFW,IGHV5-51,IGHJ4,,IGLV3-25,COVA1-23,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARYYYDSRGYTSIDFW,IGHV5-51,IGHJ5,,IGLV3-25,COVA1-23,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARYYYDSRGYTSIDFW,IGHV5-51,IGHJ6,,IGLV3-25,COVA1-23,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPPPDDSSGWTMGYFDYW,IGHV3-33,IGHJ1,,IGLV1-51,COVA1-24,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPPPDDSSGWTMGYFDYW,IGHV3-33,IGHJ2,,IGLV1-51,COVA1-24,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPPPDDSSGWTMGYFDYW,IGHV3-33,IGHJ3,,IGLV1-51,COVA1-24,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPPPDDSSGWTMGYFDYW,IGHV3-33,IGHJ4,,IGLV1-51,COVA1-24,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPPPDDSSGWTMGYFDYW,IGHV3-33,IGHJ5,,IGLV1-51,COVA1-24,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPPPDDSSGWTMGYFDYW,IGHV3-33,IGHJ6,,IGLV1-51,COVA1-24,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLNYDFWSGYYSYALYYMDVW,IGHV4-39,IGHJ1,,IGKV1-5,COVA1-25,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLNYDFWSGYYSYALYYMDVW,IGHV4-39,IGHJ2,,IGKV1-5,COVA1-25,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLNYDFWSGYYSYALYYMDVW,IGHV4-39,IGHJ3,,IGKV1-5,COVA1-25,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLNYDFWSGYYSYALYYMDVW,IGHV4-39,IGHJ4,,IGKV1-5,COVA1-25,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLNYDFWSGYYSYALYYMDVW,IGHV4-39,IGHJ5,,IGKV1-5,COVA1-25,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLNYDFWSGYYSYALYYMDVW,IGHV4-39,IGHJ6,,IGKV1-5,COVA1-25,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQQLDYYDSSGCFDYW,IGHV4-31,IGHJ1,,IGKV1-9,COVA1-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQQLDYYDSSGCFDYW,IGHV4-31,IGHJ2,,IGKV1-9,COVA1-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQQLDYYDSSGCFDYW,IGHV4-31,IGHJ3,,IGKV1-9,COVA1-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQQLDYYDSSGCFDYW,IGHV4-31,IGHJ4,,IGKV1-9,COVA1-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQQLDYYDSSGCFDYW,IGHV4-31,IGHJ5,,IGKV1-9,COVA1-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQQLDYYDSSGCFDYW,IGHV4-31,IGHJ6,,IGKV1-9,COVA1-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAMGSYRSPFDYW,IGHV3-30,IGHJ1,,IGKV3-20,COVA1-27,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAMGSYRSPFDYW,IGHV3-30,IGHJ2,,IGKV3-20,COVA1-27,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAMGSYRSPFDYW,IGHV3-30,IGHJ3,,IGKV3-20,COVA1-27,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAMGSYRSPFDYW,IGHV3-30,IGHJ4,,IGKV3-20,COVA1-27,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAMGSYRSPFDYW,IGHV3-30,IGHJ5,,IGKV3-20,COVA1-27,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAMGSYRSPFDYW,IGHV3-30,IGHJ6,,IGKV3-20,COVA1-27,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGDRYPVGYFDLW,IGHV3-13,IGHJ1,,IGKV1-39,COVA2-01,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGDRYPVGYFDLW,IGHV3-13,IGHJ2,,IGKV1-39,COVA2-01,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGDRYPVGYFDLW,IGHV3-13,IGHJ3,,IGKV1-39,COVA2-01,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGDRYPVGYFDLW,IGHV3-13,IGHJ4,,IGKV1-39,COVA2-01,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGDRYPVGYFDLW,IGHV3-13,IGHJ5,,IGKV1-39,COVA2-01,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGDRYPVGYFDLW,IGHV3-13,IGHJ6,,IGKV1-39,COVA2-01,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRSTSRWGYYYMDVW,IGHV4-39,IGHJ1,,IGKV1-39,COVA2-02,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRSTSRWGYYYMDVW,IGHV4-39,IGHJ2,,IGKV1-39,COVA2-02,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRSTSRWGYYYMDVW,IGHV4-39,IGHJ3,,IGKV1-39,COVA2-02,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRSTSRWGYYYMDVW,IGHV4-39,IGHJ4,,IGKV1-39,COVA2-02,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRSTSRWGYYYMDVW,IGHV4-39,IGHJ5,,IGKV1-39,COVA2-02,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRSTSRWGYYYMDVW,IGHV4-39,IGHJ6,,IGKV1-39,COVA2-02,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREANSDFWSGYLGYFDYW,IGHV3-48,IGHJ1,,IGKV3-11,COVA2-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREANSDFWSGYLGYFDYW,IGHV3-48,IGHJ2,,IGKV3-11,COVA2-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREANSDFWSGYLGYFDYW,IGHV3-48,IGHJ3,,IGKV3-11,COVA2-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREANSDFWSGYLGYFDYW,IGHV3-48,IGHJ4,,IGKV3-11,COVA2-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREANSDFWSGYLGYFDYW,IGHV3-48,IGHJ5,,IGKV3-11,COVA2-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREANSDFWSGYLGYFDYW,IGHV3-48,IGHJ6,,IGKV3-11,COVA2-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLERAGGMDVW,IGHV3-53,IGHJ1,,IGKV3-20,COVA2-04,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLERAGGMDVW,IGHV3-53,IGHJ2,,IGKV3-20,COVA2-04,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLERAGGMDVW,IGHV3-53,IGHJ3,,IGKV3-20,COVA2-04,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLERAGGMDVW,IGHV3-53,IGHJ4,,IGKV3-20,COVA2-04,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLERAGGMDVW,IGHV3-53,IGHJ5,,IGKV3-20,COVA2-04,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLERAGGMDVW,IGHV3-53,IGHJ6,,IGKV3-20,COVA2-04,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHMRPSIAARPGYQYYMDVW,IGHV5-51,IGHJ1,,IGKV1-33,COVA2-05,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHMRPSIAARPGYQYYMDVW,IGHV5-51,IGHJ2,,IGKV1-33,COVA2-05,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHMRPSIAARPGYQYYMDVW,IGHV5-51,IGHJ3,,IGKV1-33,COVA2-05,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHMRPSIAARPGYQYYMDVW,IGHV5-51,IGHJ4,,IGKV1-33,COVA2-05,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHMRPSIAARPGYQYYMDVW,IGHV5-51,IGHJ5,,IGKV1-33,COVA2-05,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHMRPSIAARPGYQYYMDVW,IGHV5-51,IGHJ6,,IGKV1-33,COVA2-05,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGWSLDSW,IGHV4-59,IGHJ1,,IGKV3-20,COVA2-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGWSLDSW,IGHV4-59,IGHJ2,,IGKV3-20,COVA2-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGWSLDSW,IGHV4-59,IGHJ3,,IGKV3-20,COVA2-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGWSLDSW,IGHV4-59,IGHJ4,,IGKV3-20,COVA2-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGWSLDSW,IGHV4-59,IGHJ5,,IGKV3-20,COVA2-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGGWSLDSW,IGHV4-59,IGHJ6,,IGKV3-20,COVA2-06,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ1,,IGKV3-20,COVA2-07,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ2,,IGKV3-20,COVA2-07,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ3,,IGKV3-20,COVA2-07,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ4,,IGKV3-20,COVA2-07,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ5,,IGKV3-20,COVA2-07,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ6,,IGKV3-20,COVA2-07,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVIGGNYFGAFDIW,IGHV3-30,IGHJ1,,IGKV3-15,COVA2-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVIGGNYFGAFDIW,IGHV3-30,IGHJ2,,IGKV3-15,COVA2-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVIGGNYFGAFDIW,IGHV3-30,IGHJ3,,IGKV3-15,COVA2-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVIGGNYFGAFDIW,IGHV3-30,IGHJ4,,IGKV3-15,COVA2-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVIGGNYFGAFDIW,IGHV3-30,IGHJ5,,IGKV3-15,COVA2-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVIGGNYFGAFDIW,IGHV3-30,IGHJ6,,IGKV3-15,COVA2-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGRNYVLQFSEWPHPRAHFDNW,IGHV4-34,IGHJ1,,IGKV4-1,COVA2-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGRNYVLQFSEWPHPRAHFDNW,IGHV4-34,IGHJ2,,IGKV4-1,COVA2-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGRNYVLQFSEWPHPRAHFDNW,IGHV4-34,IGHJ3,,IGKV4-1,COVA2-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGRNYVLQFSEWPHPRAHFDNW,IGHV4-34,IGHJ4,,IGKV4-1,COVA2-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGRNYVLQFSEWPHPRAHFDNW,IGHV4-34,IGHJ5,,IGKV4-1,COVA2-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGRNYVLQFSEWPHPRAHFDNW,IGHV4-34,IGHJ6,,IGKV4-1,COVA2-09,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKGLRGQQLVIPTEYFQHW,IGHV3-23,IGHJ1,,IGKV3-20,COVA2-10,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKGLRGQQLVIPTEYFQHW,IGHV3-23,IGHJ2,,IGKV3-20,COVA2-10,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKGLRGQQLVIPTEYFQHW,IGHV3-23,IGHJ3,,IGKV3-20,COVA2-10,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKGLRGQQLVIPTEYFQHW,IGHV3-23,IGHJ4,,IGKV3-20,COVA2-10,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKGLRGQQLVIPTEYFQHW,IGHV3-23,IGHJ5,,IGKV3-20,COVA2-10,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKGLRGQQLVIPTEYFQHW,IGHV3-23,IGHJ6,,IGKV3-20,COVA2-10,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRGCSSTSCYGSYFDYW,IGHV3-21,IGHJ1,,IGKV3-20,COVA2-11,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRGCSSTSCYGSYFDYW,IGHV3-21,IGHJ2,,IGKV3-20,COVA2-11,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRGCSSTSCYGSYFDYW,IGHV3-21,IGHJ3,,IGKV3-20,COVA2-11,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRGCSSTSCYGSYFDYW,IGHV3-21,IGHJ4,,IGKV3-20,COVA2-11,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRGCSSTSCYGSYFDYW,IGHV3-21,IGHJ5,,IGKV3-20,COVA2-11,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRGCSSTSCYGSYFDYW,IGHV3-21,IGHJ6,,IGKV3-20,COVA2-11,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDQPLPDILTGYYTGPLDYW,IGHV3-53,IGHJ1,,IGKV3-15,COVA2-12,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDQPLPDILTGYYTGPLDYW,IGHV3-53,IGHJ2,,IGKV3-15,COVA2-12,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDQPLPDILTGYYTGPLDYW,IGHV3-53,IGHJ3,,IGKV3-15,COVA2-12,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDQPLPDILTGYYTGPLDYW,IGHV3-53,IGHJ4,,IGKV3-15,COVA2-12,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDQPLPDILTGYYTGPLDYW,IGHV3-53,IGHJ5,,IGKV3-15,COVA2-12,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDQPLPDILTGYYTGPLDYW,IGHV3-53,IGHJ6,,IGKV3-15,COVA2-12,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLDTMGGMDVW,IGHV1-69,IGHJ1,,IGKV3-20,COVA2-13,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLDTMGGMDVW,IGHV1-69,IGHJ2,,IGKV3-20,COVA2-13,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLDTMGGMDVW,IGHV1-69,IGHJ3,,IGKV3-20,COVA2-13,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLDTMGGMDVW,IGHV1-69,IGHJ4,,IGKV3-20,COVA2-13,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLDTMGGMDVW,IGHV1-69,IGHJ5,,IGKV3-20,COVA2-13,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDLDTMGGMDVW,IGHV1-69,IGHJ6,,IGKV3-20,COVA2-13,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVRYYDSSGYYEDYW,IGHV1-69,IGHJ1,,IGKV3-11,COVA2-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVRYYDSSGYYEDYW,IGHV1-69,IGHJ2,,IGKV3-11,COVA2-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVRYYDSSGYYEDYW,IGHV1-69,IGHJ3,,IGKV3-11,COVA2-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVRYYDSSGYYEDYW,IGHV1-69,IGHJ4,,IGKV3-11,COVA2-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVRYYDSSGYYEDYW,IGHV1-69,IGHJ5,,IGKV3-11,COVA2-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVRYYDSSGYYEDYW,IGHV1-69,IGHJ6,,IGKV3-11,COVA2-14,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDTGYCGDDCYIKLIRGGPDYW,IGHV3-23,IGHJ1,,IGKV2-30,COVA2-15,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDTGYCGDDCYIKLIRGGPDYW,IGHV3-23,IGHJ2,,IGKV2-30,COVA2-15,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDTGYCGDDCYIKLIRGGPDYW,IGHV3-23,IGHJ3,,IGKV2-30,COVA2-15,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDTGYCGDDCYIKLIRGGPDYW,IGHV3-23,IGHJ4,,IGKV2-30,COVA2-15,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDTGYCGDDCYIKLIRGGPDYW,IGHV3-23,IGHJ5,,IGKV2-30,COVA2-15,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDTGYCGDDCYIKLIRGGPDYW,IGHV3-23,IGHJ6,,IGKV2-30,COVA2-15,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASSDSSGFVGSRGFDYW,IGHV1-69,IGHJ1,,IGKV1-17,COVA2-16,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASSDSSGFVGSRGFDYW,IGHV1-69,IGHJ2,,IGKV1-17,COVA2-16,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASSDSSGFVGSRGFDYW,IGHV1-69,IGHJ3,,IGKV1-17,COVA2-16,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASSDSSGFVGSRGFDYW,IGHV1-69,IGHJ4,,IGKV1-17,COVA2-16,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASSDSSGFVGSRGFDYW,IGHV1-69,IGHJ5,,IGKV1-17,COVA2-16,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASSDSSGFVGSRGFDYW,IGHV1-69,IGHJ6,,IGKV1-17,COVA2-16,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASFGDDSGDEGVRW,IGHV1-69,IGHJ1,,IGKV3-11,COVA2-17,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASFGDDSGDEGVRW,IGHV1-69,IGHJ2,,IGKV3-11,COVA2-17,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASFGDDSGDEGVRW,IGHV1-69,IGHJ3,,IGKV3-11,COVA2-17,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASFGDDSGDEGVRW,IGHV1-69,IGHJ4,,IGKV3-11,COVA2-17,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASFGDDSGDEGVRW,IGHV1-69,IGHJ5,,IGKV3-11,COVA2-17,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASFGDDSGDEGVRW,IGHV1-69,IGHJ6,,IGKV3-11,COVA2-17,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVYSYDSSGYYLEYW,IGHV1-69,IGHJ1,,IGKV3-11,COVA2-18,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVYSYDSSGYYLEYW,IGHV1-69,IGHJ2,,IGKV3-11,COVA2-18,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVYSYDSSGYYLEYW,IGHV1-69,IGHJ3,,IGKV3-11,COVA2-18,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVYSYDSSGYYLEYW,IGHV1-69,IGHJ4,,IGKV3-11,COVA2-18,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVYSYDSSGYYLEYW,IGHV1-69,IGHJ5,,IGKV3-11,COVA2-18,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVYSYDSSGYYLEYW,IGHV1-69,IGHJ6,,IGKV3-11,COVA2-18,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASVVGGRIAAAGCLGYW,IGHV1-18,IGHJ1,,IGKV3-20,COVA2-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASVVGGRIAAAGCLGYW,IGHV1-18,IGHJ2,,IGKV3-20,COVA2-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASVVGGRIAAAGCLGYW,IGHV1-18,IGHJ3,,IGKV3-20,COVA2-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASVVGGRIAAAGCLGYW,IGHV1-18,IGHJ4,,IGKV3-20,COVA2-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASVVGGRIAAAGCLGYW,IGHV1-18,IGHJ5,,IGKV3-20,COVA2-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASVVGGRIAAAGCLGYW,IGHV1-18,IGHJ6,,IGKV3-20,COVA2-19,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASPLLLTPPDYYYYMDVW,IGHV3-53,IGHJ1,,IGKV1-17,COVA2-20,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASPLLLTPPDYYYYMDVW,IGHV3-53,IGHJ2,,IGKV1-17,COVA2-20,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASPLLLTPPDYYYYMDVW,IGHV3-53,IGHJ3,,IGKV1-17,COVA2-20,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASPLLLTPPDYYYYMDVW,IGHV3-53,IGHJ4,,IGKV1-17,COVA2-20,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASPLLLTPPDYYYYMDVW,IGHV3-53,IGHJ5,,IGKV1-17,COVA2-20,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASPLLLTPPDYYYYMDVW,IGHV3-53,IGHJ6,,IGKV1-17,COVA2-20,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKYNDRFDYW,IGHV4-4,IGHJ1,,IGKV1-5,COVA2-21,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKYNDRFDYW,IGHV4-4,IGHJ2,,IGKV1-5,COVA2-21,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKYNDRFDYW,IGHV4-4,IGHJ3,,IGKV1-5,COVA2-21,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKYNDRFDYW,IGHV4-4,IGHJ4,,IGKV1-5,COVA2-21,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKYNDRFDYW,IGHV4-4,IGHJ5,,IGKV1-5,COVA2-21,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARWKYNDRFDYW,IGHV4-4,IGHJ6,,IGKV1-5,COVA2-21,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRYCSSTSCYAGVYFDYW,IGHV1-69,IGHJ1,,IGKV1-33,COVA2-22,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRYCSSTSCYAGVYFDYW,IGHV1-69,IGHJ2,,IGKV1-33,COVA2-22,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRYCSSTSCYAGVYFDYW,IGHV1-69,IGHJ3,,IGKV1-33,COVA2-22,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRYCSSTSCYAGVYFDYW,IGHV1-69,IGHJ4,,IGKV1-33,COVA2-22,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRYCSSTSCYAGVYFDYW,IGHV1-69,IGHJ5,,IGKV1-33,COVA2-22,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPRYCSSTSCYAGVYFDYW,IGHV1-69,IGHJ6,,IGKV1-33,COVA2-22,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGFGDVEEMATIKDAFDIW,IGHV1-2,IGHJ1,,IGKV3-20,COVA2-23,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGFGDVEEMATIKDAFDIW,IGHV1-2,IGHJ2,,IGKV3-20,COVA2-23,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGFGDVEEMATIKDAFDIW,IGHV1-2,IGHJ3,,IGKV3-20,COVA2-23,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGFGDVEEMATIKDAFDIW,IGHV1-2,IGHJ4,,IGKV3-20,COVA2-23,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGFGDVEEMATIKDAFDIW,IGHV1-2,IGHJ5,,IGKV3-20,COVA2-23,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGFGDVEEMATIKDAFDIW,IGHV1-2,IGHJ6,,IGKV3-20,COVA2-23,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPNPAGGYDSSGWVDAFDIW,IGHV5-10-1,IGHJ1,,IGKV1-39,COVA2-24,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPNPAGGYDSSGWVDAFDIW,IGHV5-10-1,IGHJ2,,IGKV1-39,COVA2-24,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPNPAGGYDSSGWVDAFDIW,IGHV5-10-1,IGHJ3,,IGKV1-39,COVA2-24,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPNPAGGYDSSGWVDAFDIW,IGHV5-10-1,IGHJ4,,IGKV1-39,COVA2-24,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPNPAGGYDSSGWVDAFDIW,IGHV5-10-1,IGHJ5,,IGKV1-39,COVA2-24,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARPNPAGGYDSSGWVDAFDIW,IGHV5-10-1,IGHJ6,,IGKV1-39,COVA2-24,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATGPTIAAAATNWFDPGW,IGHV1-24,IGHJ1,,IGLV2-14,COVA2-25,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATGPTIAAAATNWFDPGW,IGHV1-24,IGHJ2,,IGLV2-14,COVA2-25,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATGPTIAAAATNWFDPGW,IGHV1-24,IGHJ3,,IGLV2-14,COVA2-25,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATGPTIAAAATNWFDPGW,IGHV1-24,IGHJ4,,IGLV2-14,COVA2-25,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATGPTIAAAATNWFDPGW,IGHV1-24,IGHJ5,,IGLV2-14,COVA2-25,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATGPTIAAAATNWFDPGW,IGHV1-24,IGHJ6,,IGLV2-14,COVA2-25,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CTTDRGDSYGYYYCMDVW,IGHV3-15,IGHJ1,,IGLV3-1,COVA2-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CTTDRGDSYGYYYCMDVW,IGHV3-15,IGHJ2,,IGLV3-1,COVA2-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CTTDRGDSYGYYYCMDVW,IGHV3-15,IGHJ3,,IGLV3-1,COVA2-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CTTDRGDSYGYYYCMDVW,IGHV3-15,IGHJ4,,IGLV3-1,COVA2-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CTTDRGDSYGYYYCMDVW,IGHV3-15,IGHJ5,,IGLV3-1,COVA2-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CTTDRGDSYGYYYCMDVW,IGHV3-15,IGHJ6,,IGLV3-1,COVA2-26,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVVGSSWYPVDAFDIW,IGHV1-8,IGHJ1,,IGLV2-14,COVA2-27,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVVGSSWYPVDAFDIW,IGHV1-8,IGHJ2,,IGLV2-14,COVA2-27,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVVGSSWYPVDAFDIW,IGHV1-8,IGHJ3,,IGLV2-14,COVA2-27,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVVGSSWYPVDAFDIW,IGHV1-8,IGHJ4,,IGLV2-14,COVA2-27,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVVGSSWYPVDAFDIW,IGHV1-8,IGHJ5,,IGLV2-14,COVA2-27,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVVGSSWYPVDAFDIW,IGHV1-8,IGHJ6,,IGLV2-14,COVA2-27,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDKAPPCSSGWYYFDYW,IGHV3-30,IGHJ1,,IGKV3-15,COVA2-28,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDKAPPCSSGWYYFDYW,IGHV3-30,IGHJ2,,IGKV3-15,COVA2-28,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDKAPPCSSGWYYFDYW,IGHV3-30,IGHJ3,,IGKV3-15,COVA2-28,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDKAPPCSSGWYYFDYW,IGHV3-30,IGHJ4,,IGKV3-15,COVA2-28,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDKAPPCSSGWYYFDYW,IGHV3-30,IGHJ5,,IGKV3-15,COVA2-28,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKDKAPPCSSGWYYFDYW,IGHV3-30,IGHJ6,,IGKV3-15,COVA2-28,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGVEDPVVPAAIPWCWFDPW,IGHV4-30-2,IGHJ1,,IGKV1-39,COVA2-29,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGVEDPVVPAAIPWCWFDPW,IGHV4-30-2,IGHJ2,,IGKV1-39,COVA2-29,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGVEDPVVPAAIPWCWFDPW,IGHV4-30-2,IGHJ3,,IGKV1-39,COVA2-29,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGVEDPVVPAAIPWCWFDPW,IGHV4-30-2,IGHJ4,,IGKV1-39,COVA2-29,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGVEDPVVPAAIPWCWFDPW,IGHV4-30-2,IGHJ5,,IGKV1-39,COVA2-29,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGVEDPVVPAAIPWCWFDPW,IGHV4-30-2,IGHJ6,,IGKV1-39,COVA2-29,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASLPVVPAAIGPLPAFDIW,IGHV3-30,IGHJ1,,IGLV3-21,COVA2-30,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASLPVVPAAIGPLPAFDIW,IGHV3-30,IGHJ2,,IGLV3-21,COVA2-30,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASLPVVPAAIGPLPAFDIW,IGHV3-30,IGHJ3,,IGLV3-21,COVA2-30,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASLPVVPAAIGPLPAFDIW,IGHV3-30,IGHJ4,,IGLV3-21,COVA2-30,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASLPVVPAAIGPLPAFDIW,IGHV3-30,IGHJ5,,IGLV3-21,COVA2-30,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CASLPVVPAAIGPLPAFDIW,IGHV3-30,IGHJ6,,IGLV3-21,COVA2-30,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CRKMLTIFGKVNQTMLLISGAKGQW,IGHV1-2,IGHJ1,,IGKV2D-29,COVA2-31,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CRKMLTIFGKVNQTMLLISGAKGQW,IGHV1-2,IGHJ2,,IGKV2D-29,COVA2-31,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CRKMLTIFGKVNQTMLLISGAKGQW,IGHV1-2,IGHJ3,,IGKV2D-29,COVA2-31,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CRKMLTIFGKVNQTMLLISGAKGQW,IGHV1-2,IGHJ4,,IGKV2D-29,COVA2-31,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CRKMLTIFGKVNQTMLLISGAKGQW,IGHV1-2,IGHJ5,,IGKV2D-29,COVA2-31,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CRKMLTIFGKVNQTMLLISGAKGQW,IGHV1-2,IGHJ6,,IGKV2D-29,COVA2-31,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARTHSYDNSGQYFDYW,IGHV1-69,IGHJ1,,IGKV3-11,COVA2-32,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARTHSYDNSGQYFDYW,IGHV1-69,IGHJ2,,IGKV3-11,COVA2-32,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARTHSYDNSGQYFDYW,IGHV1-69,IGHJ3,,IGKV3-11,COVA2-32,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARTHSYDNSGQYFDYW,IGHV1-69,IGHJ4,,IGKV3-11,COVA2-32,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARTHSYDNSGQYFDYW,IGHV1-69,IGHJ5,,IGKV3-11,COVA2-32,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARTHSYDNSGQYFDYW,IGHV1-69,IGHJ6,,IGKV3-11,COVA2-32,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLKVITIFGVVRDDYGMDVW,IGHV5-10-1,IGHJ1,,IGLV2-23,COVA2-33,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLKVITIFGVVRDDYGMDVW,IGHV5-10-1,IGHJ2,,IGLV2-23,COVA2-33,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLKVITIFGVVRDDYGMDVW,IGHV5-10-1,IGHJ3,,IGLV2-23,COVA2-33,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLKVITIFGVVRDDYGMDVW,IGHV5-10-1,IGHJ4,,IGLV2-23,COVA2-33,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLKVITIFGVVRDDYGMDVW,IGHV5-10-1,IGHJ5,,IGLV2-23,COVA2-33,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARLKVITIFGVVRDDYGMDVW,IGHV5-10-1,IGHJ6,,IGLV2-23,COVA2-33,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFDYW,IGHV3-30,IGHJ1,,IGLV2-14,COVA2-34,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFDYW,IGHV3-30,IGHJ2,,IGLV2-14,COVA2-34,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFDYW,IGHV3-30,IGHJ3,,IGLV2-14,COVA2-34,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFDYW,IGHV3-30,IGHJ4,,IGLV2-14,COVA2-34,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFDYW,IGHV3-30,IGHJ5,,IGLV2-14,COVA2-34,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARSASGSYYGAFDYW,IGHV3-30,IGHJ6,,IGLV2-14,COVA2-34,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGSNESCSGGFCSDSW,IGHV3-33,IGHJ1,,IGLV3-21,COVA2-35,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGSNESCSGGFCSDSW,IGHV3-33,IGHJ2,,IGLV3-21,COVA2-35,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGSNESCSGGFCSDSW,IGHV3-33,IGHJ3,,IGLV3-21,COVA2-35,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGSNESCSGGFCSDSW,IGHV3-33,IGHJ4,,IGLV3-21,COVA2-35,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGSNESCSGGFCSDSW,IGHV3-33,IGHJ5,,IGLV3-21,COVA2-35,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDGSNESCSGGFCSDSW,IGHV3-33,IGHJ6,,IGLV3-21,COVA2-35,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHNPDYYDSSGPLDYW,IGHV5-51,IGHJ1,,IGKV1-5,COVA2-36,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHNPDYYDSSGPLDYW,IGHV5-51,IGHJ2,,IGKV1-5,COVA2-36,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHNPDYYDSSGPLDYW,IGHV5-51,IGHJ3,,IGKV1-5,COVA2-36,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHNPDYYDSSGPLDYW,IGHV5-51,IGHJ4,,IGKV1-5,COVA2-36,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHNPDYYDSSGPLDYW,IGHV5-51,IGHJ5,,IGKV1-5,COVA2-36,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHNPDYYDSSGPLDYW,IGHV5-51,IGHJ6,,IGKV1-5,COVA2-36,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSPAVMSVGWVDPW,IGHV1-24,IGHJ1,,IGLV1-40,COVA2-37,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSPAVMSVGWVDPW,IGHV1-24,IGHJ2,,IGLV1-40,COVA2-37,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSPAVMSVGWVDPW,IGHV1-24,IGHJ3,,IGLV1-40,COVA2-37,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSPAVMSVGWVDPW,IGHV1-24,IGHJ4,,IGLV1-40,COVA2-37,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSPAVMSVGWVDPW,IGHV1-24,IGHJ5,,IGLV1-40,COVA2-37,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATSPAVMSVGWVDPW,IGHV1-24,IGHJ6,,IGLV1-40,COVA2-37,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQVRQWLEDDAFDIW,IGHV4-39,IGHJ1,,IGKV1-17,COVA2-38,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQVRQWLEDDAFDIW,IGHV4-39,IGHJ2,,IGKV1-17,COVA2-38,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQVRQWLEDDAFDIW,IGHV4-39,IGHJ3,,IGKV1-17,COVA2-38,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQVRQWLEDDAFDIW,IGHV4-39,IGHJ4,,IGKV1-17,COVA2-38,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQVRQWLEDDAFDIW,IGHV4-39,IGHJ5,,IGKV1-17,COVA2-38,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARQVRQWLEDDAFDIW,IGHV4-39,IGHJ6,,IGKV1-17,COVA2-38,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAHVDTAMVESGAFDIW,IGHV3-53,IGHJ1,,IGLV2-23,COVA2-39,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAHVDTAMVESGAFDIW,IGHV3-53,IGHJ2,,IGLV2-23,COVA2-39,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAHVDTAMVESGAFDIW,IGHV3-53,IGHJ3,,IGLV2-23,COVA2-39,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAHVDTAMVESGAFDIW,IGHV3-53,IGHJ4,,IGLV2-23,COVA2-39,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAHVDTAMVESGAFDIW,IGHV3-53,IGHJ5,,IGLV2-23,COVA2-39,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARAHVDTAMVESGAFDIW,IGHV3-53,IGHJ6,,IGLV2-23,COVA2-39,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGRYCSGGRCGWFDPW,IGHV4-4,IGHJ1,,IGLV2-23,COVA2-40,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGRYCSGGRCGWFDPW,IGHV4-4,IGHJ2,,IGLV2-23,COVA2-40,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGRYCSGGRCGWFDPW,IGHV4-4,IGHJ3,,IGLV2-23,COVA2-40,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGRYCSGGRCGWFDPW,IGHV4-4,IGHJ4,,IGLV2-23,COVA2-40,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGRYCSGGRCGWFDPW,IGHV4-4,IGHJ5,,IGLV2-23,COVA2-40,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAGRYCSGGRCGWFDPW,IGHV4-4,IGHJ6,,IGLV2-23,COVA2-40,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVQKDIVVVPVALADYYYYGMDVW,IGHV3-21,IGHJ1,,IGKV3-15,COVA2-41,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVQKDIVVVPVALADYYYYGMDVW,IGHV3-21,IGHJ2,,IGKV3-15,COVA2-41,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVQKDIVVVPVALADYYYYGMDVW,IGHV3-21,IGHJ3,,IGKV3-15,COVA2-41,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVQKDIVVVPVALADYYYYGMDVW,IGHV3-21,IGHJ4,,IGKV3-15,COVA2-41,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVQKDIVVVPVALADYYYYGMDVW,IGHV3-21,IGHJ5,,IGKV3-15,COVA2-41,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVQKDIVVVPVALADYYYYGMDVW,IGHV3-21,IGHJ6,,IGKV3-15,COVA2-41,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEGSGGGSQNWFDLW,IGHV4-31,IGHJ1,,IGKV3-11,COVA2-42,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEGSGGGSQNWFDLW,IGHV4-31,IGHJ2,,IGKV3-11,COVA2-42,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEGSGGGSQNWFDLW,IGHV4-31,IGHJ3,,IGKV3-11,COVA2-42,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEGSGGGSQNWFDLW,IGHV4-31,IGHJ4,,IGKV3-11,COVA2-42,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEGSGGGSQNWFDLW,IGHV4-31,IGHJ5,,IGKV3-11,COVA2-42,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEGSGGGSQNWFDLW,IGHV4-31,IGHJ6,,IGKV3-11,COVA2-42,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARFDYGYPYSSWSVLSIDYW,IGHV1-18,IGHJ1,,IGKV1-17,COVA2-43,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARFDYGYPYSSWSVLSIDYW,IGHV1-18,IGHJ2,,IGKV1-17,COVA2-43,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARFDYGYPYSSWSVLSIDYW,IGHV1-18,IGHJ3,,IGKV1-17,COVA2-43,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARFDYGYPYSSWSVLSIDYW,IGHV1-18,IGHJ4,,IGKV1-17,COVA2-43,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARFDYGYPYSSWSVLSIDYW,IGHV1-18,IGHJ5,,IGKV1-17,COVA2-43,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARFDYGYPYSSWSVLSIDYW,IGHV1-18,IGHJ6,,IGKV1-17,COVA2-43,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREGSRQWLVIYFDYW,IGHV3-30,IGHJ1,,IGKV1-39,COVA2-44,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREGSRQWLVIYFDYW,IGHV3-30,IGHJ2,,IGKV1-39,COVA2-44,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREGSRQWLVIYFDYW,IGHV3-30,IGHJ3,,IGKV1-39,COVA2-44,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREGSRQWLVIYFDYW,IGHV3-30,IGHJ4,,IGKV1-39,COVA2-44,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREGSRQWLVIYFDYW,IGHV3-30,IGHJ5,,IGKV1-39,COVA2-44,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREGSRQWLVIYFDYW,IGHV3-30,IGHJ6,,IGKV1-39,COVA2-44,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGDGDYYDSSGYYRPTLYNWLDPW,IGHV1-2,IGHJ1,,IGKV3-20,COVA2-45,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGDGDYYDSSGYYRPTLYNWLDPW,IGHV1-2,IGHJ2,,IGKV3-20,COVA2-45,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGDGDYYDSSGYYRPTLYNWLDPW,IGHV1-2,IGHJ3,,IGKV3-20,COVA2-45,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGDGDYYDSSGYYRPTLYNWLDPW,IGHV1-2,IGHJ4,,IGKV3-20,COVA2-45,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGDGDYYDSSGYYRPTLYNWLDPW,IGHV1-2,IGHJ5,,IGKV3-20,COVA2-45,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGDGDYYDSSGYYRPTLYNWLDPW,IGHV1-2,IGHJ6,,IGKV3-20,COVA2-45,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHPSGLYQLLNW,IGHV4-39,IGHJ1,,IGKV1-33,COVA2-46,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHPSGLYQLLNW,IGHV4-39,IGHJ2,,IGKV1-33,COVA2-46,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHPSGLYQLLNW,IGHV4-39,IGHJ3,,IGKV1-33,COVA2-46,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHPSGLYQLLNW,IGHV4-39,IGHJ4,,IGKV1-33,COVA2-46,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHPSGLYQLLNW,IGHV4-39,IGHJ5,,IGKV1-33,COVA2-46,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARHPSGLYQLLNW,IGHV4-39,IGHJ6,,IGKV1-33,COVA2-46,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKVATYYYDRSGYYYGGALDYW,IGHV3-9,IGHJ1,,IGKV4-1,COVA2-47,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKVATYYYDRSGYYYGGALDYW,IGHV3-9,IGHJ2,,IGKV4-1,COVA2-47,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKVATYYYDRSGYYYGGALDYW,IGHV3-9,IGHJ3,,IGKV4-1,COVA2-47,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKVATYYYDRSGYYYGGALDYW,IGHV3-9,IGHJ4,,IGKV4-1,COVA2-47,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKVATYYYDRSGYYYGGALDYW,IGHV3-9,IGHJ5,,IGKV4-1,COVA2-47,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKVATYYYDRSGYYYGGALDYW,IGHV3-9,IGHJ6,,IGKV4-1,COVA2-47,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ1,,IGKV1-39,COVA3-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ2,,IGKV1-39,COVA3-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ3,,IGKV1-39,COVA3-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ4,,IGKV1-39,COVA3-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ5,,IGKV1-39,COVA3-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ6,,IGKV1-39,COVA3-01,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDWEEQWLVAFDYW,IGHV3-7,IGHJ1,,IGLV3-1,COVA3-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDWEEQWLVAFDYW,IGHV3-7,IGHJ2,,IGLV3-1,COVA3-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDWEEQWLVAFDYW,IGHV3-7,IGHJ3,,IGLV3-1,COVA3-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDWEEQWLVAFDYW,IGHV3-7,IGHJ4,,IGLV3-1,COVA3-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDWEEQWLVAFDYW,IGHV3-7,IGHJ5,,IGLV3-1,COVA3-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDWEEQWLVAFDYW,IGHV3-7,IGHJ6,,IGLV3-1,COVA3-02,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEIAVAGCFDYW,IGHV3-23,IGHJ1,,IGLV3-25,COVA3-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEIAVAGCFDYW,IGHV3-23,IGHJ2,,IGLV3-25,COVA3-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEIAVAGCFDYW,IGHV3-23,IGHJ3,,IGLV3-25,COVA3-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEIAVAGCFDYW,IGHV3-23,IGHJ4,,IGLV3-25,COVA3-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEIAVAGCFDYW,IGHV3-23,IGHJ5,,IGLV3-25,COVA3-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKEIAVAGCFDYW,IGHV3-23,IGHJ6,,IGLV3-25,COVA3-03,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGSVKSTAGYDFWSGDPFDYW,IGHV3-33,IGHJ1,,IGLV3-21,COVA3-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGSVKSTAGYDFWSGDPFDYW,IGHV3-33,IGHJ2,,IGLV3-21,COVA3-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGSVKSTAGYDFWSGDPFDYW,IGHV3-33,IGHJ3,,IGLV3-21,COVA3-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGSVKSTAGYDFWSGDPFDYW,IGHV3-33,IGHJ4,,IGLV3-21,COVA3-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGSVKSTAGYDFWSGDPFDYW,IGHV3-33,IGHJ5,,IGLV3-21,COVA3-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARVGSVKSTAGYDFWSGDPFDYW,IGHV3-33,IGHJ6,,IGLV3-21,COVA3-04,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATAYSVDTAMVRGVGYW,IGHV1-24,IGHJ1,,IGLV1-44,COVA3-05,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATAYSVDTAMVRGVGYW,IGHV1-24,IGHJ2,,IGLV1-44,COVA3-05,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATAYSVDTAMVRGVGYW,IGHV1-24,IGHJ3,,IGLV1-44,COVA3-05,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATAYSVDTAMVRGVGYW,IGHV1-24,IGHJ4,,IGLV1-44,COVA3-05,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATAYSVDTAMVRGVGYW,IGHV1-24,IGHJ5,,IGLV1-44,COVA3-05,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CATAYSVDTAMVRGVGYW,IGHV1-24,IGHJ6,,IGLV1-44,COVA3-05,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDAPDYYDSSGPTYFDYW,IGHV1-69,IGHJ1,,IGKV4-1,COVA3-06,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDAPDYYDSSGPTYFDYW,IGHV1-69,IGHJ2,,IGKV4-1,COVA3-06,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDAPDYYDSSGPTYFDYW,IGHV1-69,IGHJ3,,IGKV4-1,COVA3-06,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDAPDYYDSSGPTYFDYW,IGHV1-69,IGHJ4,,IGKV4-1,COVA3-06,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDAPDYYDSSGPTYFDYW,IGHV1-69,IGHJ5,,IGKV4-1,COVA3-06,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARDAPDYYDSSGPTYFDYW,IGHV1-69,IGHJ6,,IGKV4-1,COVA3-06,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKMGPDPAHDYGRKNDAFDIW,IGHV3-9,IGHJ1,,IGKV3-20,COVA3-07,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKMGPDPAHDYGRKNDAFDIW,IGHV3-9,IGHJ2,,IGKV3-20,COVA3-07,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKMGPDPAHDYGRKNDAFDIW,IGHV3-9,IGHJ3,,IGKV3-20,COVA3-07,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKMGPDPAHDYGRKNDAFDIW,IGHV3-9,IGHJ4,,IGKV3-20,COVA3-07,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKMGPDPAHDYGRKNDAFDIW,IGHV3-9,IGHJ5,,IGKV3-20,COVA3-07,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKMGPDPAHDYGRKNDAFDIW,IGHV3-9,IGHJ6,,IGKV3-20,COVA3-07,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKAEPEVGGYDYYMDVW,IGHV3-9,IGHJ1,,IGKV1-39,COVA3-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKAEPEVGGYDYYMDVW,IGHV3-9,IGHJ2,,IGKV1-39,COVA3-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKAEPEVGGYDYYMDVW,IGHV3-9,IGHJ3,,IGKV1-39,COVA3-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKAEPEVGGYDYYMDVW,IGHV3-9,IGHJ4,,IGKV1-39,COVA3-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKAEPEVGGYDYYMDVW,IGHV3-9,IGHJ5,,IGKV1-39,COVA3-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAKAEPEVGGYDYYMDVW,IGHV3-9,IGHJ6,,IGKV1-39,COVA3-08,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ1,,IGKV1-39,COVA3-09,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ2,,IGKV1-39,COVA3-09,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ3,,IGKV1-39,COVA3-09,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ4,,IGKV1-39,COVA3-09,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ5,,IGKV1-39,COVA3-09,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARGPAATYYYYMDVW,IGHV4-59,IGHJ6,,IGKV1-39,COVA3-09,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGYTYGADFYGLDVW,IGHV5-51,IGHJ1,,IGKV4-1,COVA3-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGYTYGADFYGLDVW,IGHV5-51,IGHJ2,,IGKV4-1,COVA3-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGYTYGADFYGLDVW,IGHV5-51,IGHJ3,,IGKV4-1,COVA3-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGYTYGADFYGLDVW,IGHV5-51,IGHJ4,,IGKV4-1,COVA3-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGYTYGADFYGLDVW,IGHV5-51,IGHJ5,,IGKV4-1,COVA3-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CARRGYTYGADFYGLDVW,IGHV5-51,IGHJ6,,IGKV4-1,COVA3-10,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
CAREAYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPPYTF,IGKV1-9,B38,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CAREAYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPPYTF,IGKV1-9,B38,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CAREAYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPPYTF,IGKV1-9,B38,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CAREAYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPPYTF,IGKV1-9,B38,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CAREAYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPPYTF,IGKV1-9,B38,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CAREAYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPPYTF,IGKV1-9,B38,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARVPYCSSTSCHRDWYFDLW,IGHV1-2,IGHJ1,CMQRIEFPLTF,IGKV2-40,H4,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARVPYCSSTSCHRDWYFDLW,IGHV1-2,IGHJ2,CMQRIEFPLTF,IGKV2-40,H4,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARVPYCSSTSCHRDWYFDLW,IGHV1-2,IGHJ3,CMQRIEFPLTF,IGKV2-40,H4,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARVPYCSSTSCHRDWYFDLW,IGHV1-2,IGHJ4,CMQRIEFPLTF,IGKV2-40,H4,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARVPYCSSTSCHRDWYFDLW,IGHV1-2,IGHJ5,CMQRIEFPLTF,IGKV2-40,H4,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARVPYCSSTSCHRDWYFDLW,IGHV1-2,IGHJ6,CMQRIEFPLTF,IGKV2-40,H4,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
CARGAEYYDFWSGYYSAYFDYW,IGHV3-64,IGHJ1,CSMGAQPDLCAF,IGLV1-47,1M-1D2,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGAEYYDFWSGYYSAYFDYW,IGHV3-64,IGHJ2,CSMGAQPDLCAF,IGLV1-47,1M-1D2,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGAEYYDFWSGYYSAYFDYW,IGHV3-64,IGHJ3,CSMGAQPDLCAF,IGLV1-47,1M-1D2,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGAEYYDFWSGYYSAYFDYW,IGHV3-64,IGHJ4,CSMGAQPDLCAF,IGLV1-47,1M-1D2,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGAEYYDFWSGYYSAYFDYW,IGHV3-64,IGHJ5,CSMGAQPDLCAF,IGLV1-47,1M-1D2,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGAEYYDFWSGYYSAYFDYW,IGHV3-64,IGHJ6,CSMGAQPDLCAF,IGLV1-47,1M-1D2,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGGGSYYYWFDPW,IGHV3-30,IGHJ1,CQQYYSTF,IGKV4-1,2M-13A3,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGGGSYYYWFDPW,IGHV3-30,IGHJ2,CQQYYSTF,IGKV4-1,2M-13A3,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGGGSYYYWFDPW,IGHV3-30,IGHJ3,CQQYYSTF,IGKV4-1,2M-13A3,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGGGSYYYWFDPW,IGHV3-30,IGHJ4,CQQYYSTF,IGKV4-1,2M-13A3,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGGGSYYYWFDPW,IGHV3-30,IGHJ5,CQQYYSTF,IGKV4-1,2M-13A3,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGGGSYYYWFDPW,IGHV3-30,IGHJ6,CQQYYSTF,IGKV4-1,2M-13A3,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGYSSSWYGVRGVDPW,IGHV4-34,IGHJ1,CQQYGSSRSWTF,IGKV3-20,2M-13D11,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGYSSSWYGVRGVDPW,IGHV4-34,IGHJ2,CQQYGSSRSWTF,IGKV3-20,2M-13D11,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGYSSSWYGVRGVDPW,IGHV4-34,IGHJ3,CQQYGSSRSWTF,IGKV3-20,2M-13D11,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGYSSSWYGVRGVDPW,IGHV4-34,IGHJ4,CQQYGSSRSWTF,IGKV3-20,2M-13D11,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGYSSSWYGVRGVDPW,IGHV4-34,IGHJ5,CQQYGSSRSWTF,IGKV3-20,2M-13D11,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGYSSSWYGVRGVDPW,IGHV4-34,IGHJ6,CQQYGSSRSWTF,IGKV3-20,2M-13D11,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKGSDIVVVPVGNWFDPW,IGHV3-30,IGHJ1,CQQSYSTFTLYTF,IGKV1-39,2M-14B2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKGSDIVVVPVGNWFDPW,IGHV3-30,IGHJ2,CQQSYSTFTLYTF,IGKV1-39,2M-14B2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKGSDIVVVPVGNWFDPW,IGHV3-30,IGHJ3,CQQSYSTFTLYTF,IGKV1-39,2M-14B2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKGSDIVVVPVGNWFDPW,IGHV3-30,IGHJ4,CQQSYSTFTLYTF,IGKV1-39,2M-14B2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKGSDIVVVPVGNWFDPW,IGHV3-30,IGHJ5,CQQSYSTFTLYTF,IGKV1-39,2M-14B2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKGSDIVVVPVGNWFDPW,IGHV3-30,IGHJ6,CQQSYSTFTLYTF,IGKV1-39,2M-14B2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARATWLRGVMDVW,IGHV3-66,IGHJ1,CQSYDSSNHWVF,IGLV6-57,2M-10B11,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARATWLRGVMDVW,IGHV3-66,IGHJ2,CQSYDSSNHWVF,IGLV6-57,2M-10B11,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARATWLRGVMDVW,IGHV3-66,IGHJ3,CQSYDSSNHWVF,IGLV6-57,2M-10B11,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARATWLRGVMDVW,IGHV3-66,IGHJ4,CQSYDSSNHWVF,IGLV6-57,2M-10B11,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARATWLRGVMDVW,IGHV3-66,IGHJ5,CQSYDSSNHWVF,IGLV6-57,2M-10B11,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARATWLRGVMDVW,IGHV3-66,IGHJ6,CQSYDSSNHWVF,IGLV6-57,2M-10B11,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARVQRYYPDSSGFYGRRFDIW,IGHV4-61,IGHJ1,CQQSHSFPFTF,IGKV1-39,2M-14E4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARVQRYYPDSSGFYGRRFDIW,IGHV4-61,IGHJ2,CQQSHSFPFTF,IGKV1-39,2M-14E4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARVQRYYPDSSGFYGRRFDIW,IGHV4-61,IGHJ3,CQQSHSFPFTF,IGKV1-39,2M-14E4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARVQRYYPDSSGFYGRRFDIW,IGHV4-61,IGHJ4,CQQSHSFPFTF,IGKV1-39,2M-14E4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARVQRYYPDSSGFYGRRFDIW,IGHV4-61,IGHJ5,CQQSHSFPFTF,IGKV1-39,2M-14E4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARVQRYYPDSSGFYGRRFDIW,IGHV4-61,IGHJ6,CQQSHSFPFTF,IGKV1-39,2M-14E4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSGGGSYRGPFDYW,IGHV3-30,IGHJ1,CQQLNSYVTF,IGKV1-9,2M-14E5,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSGGGSYRGPFDYW,IGHV3-30,IGHJ2,CQQLNSYVTF,IGKV1-9,2M-14E5,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSGGGSYRGPFDYW,IGHV3-30,IGHJ3,CQQLNSYVTF,IGKV1-9,2M-14E5,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSGGGSYRGPFDYW,IGHV3-30,IGHJ4,CQQLNSYVTF,IGKV1-9,2M-14E5,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSGGGSYRGPFDYW,IGHV3-30,IGHJ5,CQQLNSYVTF,IGKV1-9,2M-14E5,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSGGGSYRGPFDYW,IGHV3-30,IGHJ6,CQQLNSYVTF,IGKV1-9,2M-14E5,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKIGLGLGGLLRRYFDYW,IGHV3-23,IGHJ1,CQQRTNWPLF,IGKV3-11,2M-2D4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKIGLGLGGLLRRYFDYW,IGHV3-23,IGHJ2,CQQRTNWPLF,IGKV3-11,2M-2D4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKIGLGLGGLLRRYFDYW,IGHV3-23,IGHJ3,CQQRTNWPLF,IGKV3-11,2M-2D4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKIGLGLGGLLRRYFDYW,IGHV3-23,IGHJ4,CQQRTNWPLF,IGKV3-11,2M-2D4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKIGLGLGGLLRRYFDYW,IGHV3-23,IGHJ5,CQQRTNWPLF,IGKV3-11,2M-2D4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKIGLGLGGLLRRYFDYW,IGHV3-23,IGHJ6,CQQRTNWPLF,IGKV3-11,2M-2D4,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CDANYDYVVAQTGYGRW,IGHV3-11,IGHJ1,CQQNYSTWTF,IGKV1-39,2M-2G12,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CDANYDYVVAQTGYGRW,IGHV3-11,IGHJ2,CQQNYSTWTF,IGKV1-39,2M-2G12,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CDANYDYVVAQTGYGRW,IGHV3-11,IGHJ3,CQQNYSTWTF,IGKV1-39,2M-2G12,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CDANYDYVVAQTGYGRW,IGHV3-11,IGHJ4,CQQNYSTWTF,IGKV1-39,2M-2G12,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CDANYDYVVAQTGYGRW,IGHV3-11,IGHJ5,CQQNYSTWTF,IGKV1-39,2M-2G12,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CDANYDYVVAQTGYGRW,IGHV3-11,IGHJ6,CQQNYSTWTF,IGKV1-39,2M-2G12,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARERGDSSGYYEIITTANRRFGMDVW,IGHV1-46,IGHJ1,CCSYAVSSTWVF,IGLV2-23,2M-4G4,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARERGDSSGYYEIITTANRRFGMDVW,IGHV1-46,IGHJ2,CCSYAVSSTWVF,IGLV2-23,2M-4G4,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARERGDSSGYYEIITTANRRFGMDVW,IGHV1-46,IGHJ3,CCSYAVSSTWVF,IGLV2-23,2M-4G4,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARERGDSSGYYEIITTANRRFGMDVW,IGHV1-46,IGHJ4,CCSYAVSSTWVF,IGLV2-23,2M-4G4,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARERGDSSGYYEIITTANRRFGMDVW,IGHV1-46,IGHJ5,CCSYAVSSTWVF,IGLV2-23,2M-4G4,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARERGDSSGYYEIITTANRRFGMDVW,IGHV1-46,IGHJ6,CCSYAVSSTWVF,IGLV2-23,2M-4G4,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGDRIQLWLLDAFDIW,IGHV4-39,IGHJ1,CCSTGAQPEWLGF,IGLV1-47,2M-2D1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGDRIQLWLLDAFDIW,IGHV4-39,IGHJ2,CCSTGAQPEWLGF,IGLV1-47,2M-2D1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGDRIQLWLLDAFDIW,IGHV4-39,IGHJ3,CCSTGAQPEWLGF,IGLV1-47,2M-2D1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGDRIQLWLLDAFDIW,IGHV4-39,IGHJ4,CCSTGAQPEWLGF,IGLV1-47,2M-2D1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGDRIQLWLLDAFDIW,IGHV4-39,IGHJ5,CCSTGAQPEWLGF,IGLV1-47,2M-2D1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARGDRIQLWLLDAFDIW,IGHV4-39,IGHJ6,CCSTGAQPEWLGF,IGLV1-47,2M-2D1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARIPGWDRGTDRNWNDDW,IGHV1-69,IGHJ1,CQQRSNWPPAFTF,IGKV3-11,2M-7E9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARIPGWDRGTDRNWNDDW,IGHV1-69,IGHJ2,CQQRSNWPPAFTF,IGKV3-11,2M-7E9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARIPGWDRGTDRNWNDDW,IGHV1-69,IGHJ3,CQQRSNWPPAFTF,IGKV3-11,2M-7E9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARIPGWDRGTDRNWNDDW,IGHV1-69,IGHJ4,CQQRSNWPPAFTF,IGKV3-11,2M-7E9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARIPGWDRGTDRNWNDDW,IGHV1-69,IGHJ5,CQQRSNWPPAFTF,IGKV3-11,2M-7E9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARIPGWDRGTDRNWNDDW,IGHV1-69,IGHJ6,CQQRSNWPPAFTF,IGKV3-11,2M-7E9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARTYSFDSSGYYYDYW,IGHV1-69,IGHJ1,CQQHSNWPPKITF,IGKV3-11,2M-8E7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARTYSFDSSGYYYDYW,IGHV1-69,IGHJ2,CQQHSNWPPKITF,IGKV3-11,2M-8E7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARTYSFDSSGYYYDYW,IGHV1-69,IGHJ3,CQQHSNWPPKITF,IGKV3-11,2M-8E7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARTYSFDSSGYYYDYW,IGHV1-69,IGHJ4,CQQHSNWPPKITF,IGKV3-11,2M-8E7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARTYSFDSSGYYYDYW,IGHV1-69,IGHJ5,CQQHSNWPPKITF,IGKV3-11,2M-8E7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARTYSFDSSGYYYDYW,IGHV1-69,IGHJ6,CQQHSNWPPKITF,IGKV3-11,2M-8E7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAFYDSNWSVGSYFDSW,IGHV3-30,IGHJ1,CQQYYNNQWTF,IGKV4-1,2M-8H10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAFYDSNWSVGSYFDSW,IGHV3-30,IGHJ2,CQQYYNNQWTF,IGKV4-1,2M-8H10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAFYDSNWSVGSYFDSW,IGHV3-30,IGHJ3,CQQYYNNQWTF,IGKV4-1,2M-8H10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAFYDSNWSVGSYFDSW,IGHV3-30,IGHJ4,CQQYYNNQWTF,IGKV4-1,2M-8H10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAFYDSNWSVGSYFDSW,IGHV3-30,IGHJ5,CQQYYNNQWTF,IGKV4-1,2M-8H10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAFYDSNWSVGSYFDSW,IGHV3-30,IGHJ6,CQQYYNNQWTF,IGKV4-1,2M-8H10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDSVRREYTHARVPFDNW,IGHV3-9,IGHJ1,CQQSFVSPRTF,IGKV1-39,2M-9F10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDSVRREYTHARVPFDNW,IGHV3-9,IGHJ2,CQQSFVSPRTF,IGKV1-39,2M-9F10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDSVRREYTHARVPFDNW,IGHV3-9,IGHJ3,CQQSFVSPRTF,IGKV1-39,2M-9F10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDSVRREYTHARVPFDNW,IGHV3-9,IGHJ4,CQQSFVSPRTF,IGKV1-39,2M-9F10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDSVRREYTHARVPFDNW,IGHV3-9,IGHJ5,CQQSFVSPRTF,IGKV1-39,2M-9F10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDSVRREYTHARVPFDNW,IGHV3-9,IGHJ6,CQQSFVSPRTF,IGKV1-39,2M-9F10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKSSKIFYLGESREVDYW,IGHV3-30,IGHJ1,CLQHKSYPLTF,IGKV1-17,2M-9H1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKSSKIFYLGESREVDYW,IGHV3-30,IGHJ2,CLQHKSYPLTF,IGKV1-17,2M-9H1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKSSKIFYLGESREVDYW,IGHV3-30,IGHJ3,CLQHKSYPLTF,IGKV1-17,2M-9H1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKSSKIFYLGESREVDYW,IGHV3-30,IGHJ4,CLQHKSYPLTF,IGKV1-17,2M-9H1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKSSKIFYLGESREVDYW,IGHV3-30,IGHJ5,CLQHKSYPLTF,IGKV1-17,2M-9H1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKSSKIFYLGESREVDYW,IGHV3-30,IGHJ6,CLQHKSYPLTF,IGKV1-17,2M-9H1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDVRYCSSTSCYFSAFDIW,IGHV3-9,IGHJ1,CQQSYSTPRTF,IGKV1-39,2M-12D7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDVRYCSSTSCYFSAFDIW,IGHV3-9,IGHJ2,CQQSYSTPRTF,IGKV1-39,2M-12D7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDVRYCSSTSCYFSAFDIW,IGHV3-9,IGHJ3,CQQSYSTPRTF,IGKV1-39,2M-12D7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDVRYCSSTSCYFSAFDIW,IGHV3-9,IGHJ4,CQQSYSTPRTF,IGKV1-39,2M-12D7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDVRYCSSTSCYFSAFDIW,IGHV3-9,IGHJ5,CQQSYSTPRTF,IGKV1-39,2M-12D7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDVRYCSSTSCYFSAFDIW,IGHV3-9,IGHJ6,CQQSYSTPRTF,IGKV1-39,2M-12D7,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARRGDGLYYYGMDVW,IGHV5-51,IGHJ1,CMQALQTPQTF,IGKV2-28,0304-2F8,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARRGDGLYYYGMDVW,IGHV5-51,IGHJ2,CMQALQTPQTF,IGKV2-28,0304-2F8,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARRGDGLYYYGMDVW,IGHV5-51,IGHJ3,CMQALQTPQTF,IGKV2-28,0304-2F8,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARRGDGLYYYGMDVW,IGHV5-51,IGHJ4,CMQALQTPQTF,IGKV2-28,0304-2F8,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARRGDGLYYYGMDVW,IGHV5-51,IGHJ5,CMQALQTPQTF,IGKV2-28,0304-2F8,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARRGDGLYYYGMDVW,IGHV5-51,IGHJ6,CMQALQTPQTF,IGKV2-28,0304-2F8,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDRIAPVGKFFGWYFDLW,IGHV4-59,IGHJ1,CQQYNKWPPWTF,IGKV3-15,0304-3H3,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDRIAPVGKFFGWYFDLW,IGHV4-59,IGHJ2,CQQYNKWPPWTF,IGKV3-15,0304-3H3,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDRIAPVGKFFGWYFDLW,IGHV4-59,IGHJ3,CQQYNKWPPWTF,IGKV3-15,0304-3H3,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDRIAPVGKFFGWYFDLW,IGHV4-59,IGHJ4,CQQYNKWPPWTF,IGKV3-15,0304-3H3,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDRIAPVGKFFGWYFDLW,IGHV4-59,IGHJ5,CQQYNKWPPWTF,IGKV3-15,0304-3H3,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDRIAPVGKFFGWYFDLW,IGHV4-59,IGHJ6,CQQYNKWPPWTF,IGKV3-15,0304-3H3,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARELFTAVAGKGGIDYW,IGHV4-39,IGHJ1,CHQYYNTPRTF,IGKV4-1,0304-4A2,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARELFTAVAGKGGIDYW,IGHV4-39,IGHJ2,CHQYYNTPRTF,IGKV4-1,0304-4A2,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARELFTAVAGKGGIDYW,IGHV4-39,IGHJ3,CHQYYNTPRTF,IGKV4-1,0304-4A2,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARELFTAVAGKGGIDYW,IGHV4-39,IGHJ4,CHQYYNTPRTF,IGKV4-1,0304-4A2,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARELFTAVAGKGGIDYW,IGHV4-39,IGHJ5,CHQYYNTPRTF,IGKV4-1,0304-4A2,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARELFTAVAGKGGIDYW,IGHV4-39,IGHJ6,CHQYYNTPRTF,IGKV4-1,0304-4A2,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSSSRGFDYW,IGHV3-64,IGHJ1,CQQYYSSPYAF,IGKV4-1,0304-4A10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSSSRGFDYW,IGHV3-64,IGHJ2,CQQYYSSPYAF,IGKV4-1,0304-4A10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSSSRGFDYW,IGHV3-64,IGHJ3,CQQYYSSPYAF,IGKV4-1,0304-4A10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSSSRGFDYW,IGHV3-64,IGHJ4,CQQYYSSPYAF,IGKV4-1,0304-4A10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSSSRGFDYW,IGHV3-64,IGHJ5,CQQYYSSPYAF,IGKV4-1,0304-4A10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARSSSRGFDYW,IGHV3-64,IGHJ6,CQQYYSSPYAF,IGKV4-1,0304-4A10,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDFKGGSSSWYTPEIEYGMDVW,IGHV3-30,IGHJ1,CQQRSNWPPTF,IGKV3-11,0317-A1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDFKGGSSSWYTPEIEYGMDVW,IGHV3-30,IGHJ2,CQQRSNWPPTF,IGKV3-11,0317-A1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDFKGGSSSWYTPEIEYGMDVW,IGHV3-30,IGHJ3,CQQRSNWPPTF,IGKV3-11,0317-A1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDFKGGSSSWYTPEIEYGMDVW,IGHV3-30,IGHJ4,CQQRSNWPPTF,IGKV3-11,0317-A1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDFKGGSSSWYTPEIEYGMDVW,IGHV3-30,IGHJ5,CQQRSNWPPTF,IGKV3-11,0317-A1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDFKGGSSSWYTPEIEYGMDVW,IGHV3-30,IGHJ6,CQQRSNWPPTF,IGKV3-11,0317-A1,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARLIRHEAHTYCSGGSCYSPDYYYGMDVW,IGHV7-4-1,IGHJ1,CQQSYSTPPTF,IGKV1-39,0317-A2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARLIRHEAHTYCSGGSCYSPDYYYGMDVW,IGHV7-4-1,IGHJ2,CQQSYSTPPTF,IGKV1-39,0317-A2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARLIRHEAHTYCSGGSCYSPDYYYGMDVW,IGHV7-4-1,IGHJ3,CQQSYSTPPTF,IGKV1-39,0317-A2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARLIRHEAHTYCSGGSCYSPDYYYGMDVW,IGHV7-4-1,IGHJ4,CQQSYSTPPTF,IGKV1-39,0317-A2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARLIRHEAHTYCSGGSCYSPDYYYGMDVW,IGHV7-4-1,IGHJ5,CQQSYSTPPTF,IGKV1-39,0317-A2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARLIRHEAHTYCSGGSCYSPDYYYGMDVW,IGHV7-4-1,IGHJ6,CQQSYSTPPTF,IGKV1-39,0317-A2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASNPPLGEPYFDIW,IGHV3-48,IGHJ1,CQQTYRPPWTF,IGKV1-39,0317-A3,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASNPPLGEPYFDIW,IGHV3-48,IGHJ2,CQQTYRPPWTF,IGKV1-39,0317-A3,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASNPPLGEPYFDIW,IGHV3-48,IGHJ3,CQQTYRPPWTF,IGKV1-39,0317-A3,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASNPPLGEPYFDIW,IGHV3-48,IGHJ4,CQQTYRPPWTF,IGKV1-39,0317-A3,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASNPPLGEPYFDIW,IGHV3-48,IGHJ5,CQQTYRPPWTF,IGKV1-39,0317-A3,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASNPPLGEPYFDIW,IGHV3-48,IGHJ6,CQQTYRPPWTF,IGKV1-39,0317-A3,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARWGGGMQYLDVW,IGHV3-30-3,IGHJ1,CMQTLQTPYTF,IGKV2-28,0317-A7,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARWGGGMQYLDVW,IGHV3-30-3,IGHJ2,CMQTLQTPYTF,IGKV2-28,0317-A7,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARWGGGMQYLDVW,IGHV3-30-3,IGHJ3,CMQTLQTPYTF,IGKV2-28,0317-A7,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARWGGGMQYLDVW,IGHV3-30-3,IGHJ4,CMQTLQTPYTF,IGKV2-28,0317-A7,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARWGGGMQYLDVW,IGHV3-30-3,IGHJ5,CMQTLQTPYTF,IGKV2-28,0317-A7,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARWGGGMQYLDVW,IGHV3-30-3,IGHJ6,CMQTLQTPYTF,IGKV2-28,0317-A7,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGPNYDFWSGYYQTFDYW,IGHV7-4-1,IGHJ1,CQQYDNLPLTF,IGKV1-33,0317-A8,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGPNYDFWSGYYQTFDYW,IGHV7-4-1,IGHJ2,CQQYDNLPLTF,IGKV1-33,0317-A8,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGPNYDFWSGYYQTFDYW,IGHV7-4-1,IGHJ3,CQQYDNLPLTF,IGKV1-33,0317-A8,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGPNYDFWSGYYQTFDYW,IGHV7-4-1,IGHJ4,CQQYDNLPLTF,IGKV1-33,0317-A8,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGPNYDFWSGYYQTFDYW,IGHV7-4-1,IGHJ5,CQQYDNLPLTF,IGKV1-33,0317-A8,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARAGPNYDFWSGYYQTFDYW,IGHV7-4-1,IGHJ6,CQQYDNLPLTF,IGKV1-33,0317-A8,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATAMDGYYYYYGMDVW,IGHV1-24,IGHJ1,CMQATQFPYTF,IGKV2-24,0317-A9,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATAMDGYYYYYGMDVW,IGHV1-24,IGHJ2,CMQATQFPYTF,IGKV2-24,0317-A9,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATAMDGYYYYYGMDVW,IGHV1-24,IGHJ3,CMQATQFPYTF,IGKV2-24,0317-A9,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATAMDGYYYYYGMDVW,IGHV1-24,IGHJ4,CMQATQFPYTF,IGKV2-24,0317-A9,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATAMDGYYYYYGMDVW,IGHV1-24,IGHJ5,CMQATQFPYTF,IGKV2-24,0317-A9,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATAMDGYYYYYGMDVW,IGHV1-24,IGHJ6,CMQATQFPYTF,IGKV2-24,0317-A9,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASAGSSWYGDAFDIW,IGHV5-51,IGHJ1,CQQYYSTYGSF,IGKV4-1,0317-B1,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASAGSSWYGDAFDIW,IGHV5-51,IGHJ2,CQQYYSTYGSF,IGKV4-1,0317-B1,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASAGSSWYGDAFDIW,IGHV5-51,IGHJ3,CQQYYSTYGSF,IGKV4-1,0317-B1,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASAGSSWYGDAFDIW,IGHV5-51,IGHJ4,CQQYYSTYGSF,IGKV4-1,0317-B1,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASAGSSWYGDAFDIW,IGHV5-51,IGHJ5,CQQYYSTYGSF,IGKV4-1,0317-B1,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CASAGSSWYGDAFDIW,IGHV5-51,IGHJ6,CQQYYSTYGSF,IGKV4-1,0317-B1,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATIFGVANNWFDPW,IGHV1-24,IGHJ1,CGTWDSSLSVVVF,IGLV1-51,0317-C4,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATIFGVANNWFDPW,IGHV1-24,IGHJ2,CGTWDSSLSVVVF,IGLV1-51,0317-C4,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATIFGVANNWFDPW,IGHV1-24,IGHJ3,CGTWDSSLSVVVF,IGLV1-51,0317-C4,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATIFGVANNWFDPW,IGHV1-24,IGHJ4,CGTWDSSLSVVVF,IGLV1-51,0317-C4,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATIFGVANNWFDPW,IGHV1-24,IGHJ5,CGTWDSSLSVVVF,IGLV1-51,0317-C4,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATATIFGVANNWFDPW,IGHV1-24,IGHJ6,CGTWDSSLSVVVF,IGLV1-51,0317-C4,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDLGYYDILTGQLGGYYYYYGMDVW,IGHV3-30,IGHJ1,CAAWDDSLNGVVF,IGLV1-44,0317-C9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDLGYYDILTGQLGGYYYYYGMDVW,IGHV3-30,IGHJ2,CAAWDDSLNGVVF,IGLV1-44,0317-C9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDLGYYDILTGQLGGYYYYYGMDVW,IGHV3-30,IGHJ3,CAAWDDSLNGVVF,IGLV1-44,0317-C9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDLGYYDILTGQLGGYYYYYGMDVW,IGHV3-30,IGHJ4,CAAWDDSLNGVVF,IGLV1-44,0317-C9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDLGYYDILTGQLGGYYYYYGMDVW,IGHV3-30,IGHJ5,CAAWDDSLNGVVF,IGLV1-44,0317-C9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKDLGYYDILTGQLGGYYYYYGMDVW,IGHV3-30,IGHJ6,CAAWDDSLNGVVF,IGLV1-44,0317-C9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATSTAVAGTPDLFDYYYGMDVW,IGHV1-24,IGHJ1,CTQATQFPYTF,IGKV2-24,4A8,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATSTAVAGTPDLFDYYYGMDVW,IGHV1-24,IGHJ2,CTQATQFPYTF,IGKV2-24,4A8,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATSTAVAGTPDLFDYYYGMDVW,IGHV1-24,IGHJ3,CTQATQFPYTF,IGKV2-24,4A8,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATSTAVAGTPDLFDYYYGMDVW,IGHV1-24,IGHJ4,CTQATQFPYTF,IGKV2-24,4A8,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATSTAVAGTPDLFDYYYGMDVW,IGHV1-24,IGHJ5,CTQATQFPYTF,IGKV2-24,4A8,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CATSTAVAGTPDLFDYYYGMDVW,IGHV1-24,IGHJ6,CTQATQFPYTF,IGKV2-24,4A8,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKVSAIFWLGQGLSPIDVW,IGHV3-30,IGHJ1,CHQYSKWPVTF,IGKV3-15,9A1,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKVSAIFWLGQGLSPIDVW,IGHV3-30,IGHJ2,CHQYSKWPVTF,IGKV3-15,9A1,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKVSAIFWLGQGLSPIDVW,IGHV3-30,IGHJ3,CHQYSKWPVTF,IGKV3-15,9A1,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKVSAIFWLGQGLSPIDVW,IGHV3-30,IGHJ4,CHQYSKWPVTF,IGKV3-15,9A1,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKVSAIFWLGQGLSPIDVW,IGHV3-30,IGHJ5,CHQYSKWPVTF,IGKV3-15,9A1,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAKVSAIFWLGQGLSPIDVW,IGHV3-30,IGHJ6,CHQYSKWPVTF,IGKV3-15,9A1,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ1,CLQHNSYPLTF,IGKV1-17,8D2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ2,CLQHNSYPLTF,IGKV1-17,8D2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ3,CLQHNSYPLTF,IGKV1-17,8D2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ4,CLQHNSYPLTF,IGKV1-17,8D2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ5,CLQHNSYPLTF,IGKV1-17,8D2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ6,CLQHNSYPLTF,IGKV1-17,8D2,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARPTIGYSYGSDYW,IGHV3-7,IGHJ1,CQAWDSSTGVF,IGLV3-1,8D9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARPTIGYSYGSDYW,IGHV3-7,IGHJ2,CQAWDSSTGVF,IGLV3-1,8D9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARPTIGYSYGSDYW,IGHV3-7,IGHJ3,CQAWDSSTGVF,IGLV3-1,8D9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARPTIGYSYGSDYW,IGHV3-7,IGHJ4,CQAWDSSTGVF,IGLV3-1,8D9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARPTIGYSYGSDYW,IGHV3-7,IGHJ5,CQAWDSSTGVF,IGLV3-1,8D9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARPTIGYSYGSDYW,IGHV3-7,IGHJ6,CQAWDSSTGVF,IGLV3-1,8D9,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ1,CLQHNNYPLTF,IGKV1-17,10C10,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ2,CLQHNNYPLTF,IGKV1-17,10C10,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ3,CLQHNNYPLTF,IGKV1-17,10C10,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ4,CLQHNNYPLTF,IGKV1-17,10C10,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ5,CLQHNNYPLTF,IGKV1-17,10C10,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CARDWDYDILTGSWFGAFDIW,IGHV3-7,IGHJ6,CLQHNNYPLTF,IGKV1-17,10C10,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CAREGYCSGGSCYSGYYYYYGMDVW,IGHV1-18,IGHJ1,CQQRRNWGTF,IGKV3-11,CA1,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CAREGYCSGGSCYSGYYYYYGMDVW,IGHV1-18,IGHJ2,CQQRRNWGTF,IGKV3-11,CA1,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CAREGYCSGGSCYSGYYYYYGMDVW,IGHV1-18,IGHJ3,CQQRRNWGTF,IGKV3-11,CA1,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CAREGYCSGGSCYSGYYYYYGMDVW,IGHV1-18,IGHJ4,CQQRRNWGTF,IGKV3-11,CA1,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CAREGYCSGGSCYSGYYYYYGMDVW,IGHV1-18,IGHJ5,CQQRRNWGTF,IGKV3-11,CA1,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CAREGYCSGGSCYSGYYYYYGMDVW,IGHV1-18,IGHJ6,CQQRRNWGTF,IGKV3-11,CA1,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARVLPMYGDYLDYW,IGHV3-66,IGHJ1,CQQSYSTPPEYTF,IGKV1-39,CB6,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARVLPMYGDYLDYW,IGHV3-66,IGHJ2,CQQSYSTPPEYTF,IGKV1-39,CB6,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARVLPMYGDYLDYW,IGHV3-66,IGHJ3,CQQSYSTPPEYTF,IGKV1-39,CB6,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARVLPMYGDYLDYW,IGHV3-66,IGHJ4,CQQSYSTPPEYTF,IGKV1-39,CB6,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARVLPMYGDYLDYW,IGHV3-66,IGHJ5,CQQSYSTPPEYTF,IGKV1-39,CB6,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARVLPMYGDYLDYW,IGHV3-66,IGHJ6,CQQSYSTPPEYTF,IGKV1-39,CB6,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CARGEGWELPYDYW,IGHV3-53,IGHJ1,CSSYEGSNNFVVF,IGLV2-8,C105,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
CARGEGWELPYDYW,IGHV3-53,IGHJ2,CSSYEGSNNFVVF,IGLV2-8,C105,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
CARGEGWELPYDYW,IGHV3-53,IGHJ3,CSSYEGSNNFVVF,IGLV2-8,C105,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
CARGEGWELPYDYW,IGHV3-53,IGHJ4,CSSYEGSNNFVVF,IGLV2-8,C105,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
CARGEGWELPYDYW,IGHV3-53,IGHJ5,CSSYEGSNNFVVF,IGLV2-8,C105,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
CARGEGWELPYDYW,IGHV3-53,IGHJ6,CSSYEGSNNFVVF,IGLV2-8,C105,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
CANHPLASGDEYYYYYMDVW,IGHV3-23,IGHJ1,CQQYGSSRALTF,IGKV3-20,COV072_P3_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDEYYYYYMDVW,IGHV3-23,IGHJ2,CQQYGSSRALTF,IGKV3-20,COV072_P3_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDEYYYYYMDVW,IGHV3-23,IGHJ3,CQQYGSSRALTF,IGKV3-20,COV072_P3_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDEYYYYYMDVW,IGHV3-23,IGHJ4,CQQYGSSRALTF,IGKV3-20,COV072_P3_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDEYYYYYMDVW,IGHV3-23,IGHJ5,CQQYGSSRALTF,IGKV3-20,COV072_P3_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDEYYYYYMDVW,IGHV3-23,IGHJ6,CQQYGSSRALTF,IGKV3-20,COV072_P3_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDDYYHYYMDVW,IGHV3-23,IGHJ1,CQQYGSSRALTF,IGKV3-20,COV072_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDDYYHYYMDVW,IGHV3-23,IGHJ2,CQQYGSSRALTF,IGKV3-20,COV072_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDDYYHYYMDVW,IGHV3-23,IGHJ3,CQQYGSSRALTF,IGKV3-20,COV072_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDDYYHYYMDVW,IGHV3-23,IGHJ4,CQQYGSSRALTF,IGKV3-20,COV072_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDDYYHYYMDVW,IGHV3-23,IGHJ5,CQQYGSSRALTF,IGKV3-20,COV072_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANHPLASGDDYYHYYMDVW,IGHV3-23,IGHJ6,CQQYGSSRALTF,IGKV3-20,COV072_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANSPCSSASCKSGYYYYYMDVW,IGHV3-23,IGHJ1,CQQYGSSRSLTF,IGKV3-20,COV072_Plate2_HC_66-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANSPCSSASCKSGYYYYYMDVW,IGHV3-23,IGHJ2,CQQYGSSRSLTF,IGKV3-20,COV072_Plate2_HC_66-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANSPCSSASCKSGYYYYYMDVW,IGHV3-23,IGHJ3,CQQYGSSRSLTF,IGKV3-20,COV072_Plate2_HC_66-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANSPCSSASCKSGYYYYYMDVW,IGHV3-23,IGHJ4,CQQYGSSRSLTF,IGKV3-20,COV072_Plate2_HC_66-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANSPCSSASCKSGYYYYYMDVW,IGHV3-23,IGHJ5,CQQYGSSRSLTF,IGKV3-20,COV072_Plate2_HC_66-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CANSPCSSASCKSGYYYYYMDVW,IGHV3-23,IGHJ6,CQQYGSSRSLTF,IGKV3-20,COV072_Plate2_HC_66-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSRPTPDWYFDLW,IGHV1-46,IGHJ1,CQVWDSSSDHPGVVF,IGLV3-21,COV072_P3_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSRPTPDWYFDLW,IGHV1-46,IGHJ2,CQVWDSSSDHPGVVF,IGLV3-21,COV072_P3_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSRPTPDWYFDLW,IGHV1-46,IGHJ3,CQVWDSSSDHPGVVF,IGLV3-21,COV072_P3_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSRPTPDWYFDLW,IGHV1-46,IGHJ4,CQVWDSSSDHPGVVF,IGLV3-21,COV072_P3_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSRPTPDWYFDLW,IGHV1-46,IGHJ5,CQVWDSSSDHPGVVF,IGLV3-21,COV072_P3_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSRPTPDWYFDLW,IGHV1-46,IGHJ6,CQVWDSSSDHPGVVF,IGLV3-21,COV072_P3_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSRPTPDWYFDLW,IGHV1-46,IGHJ1,CQVWDGGSDHPGVVF,IGLV3-21,COV072_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSRPTPDWYFDLW,IGHV1-46,IGHJ2,CQVWDGGSDHPGVVF,IGLV3-21,COV072_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSRPTPDWYFDLW,IGHV1-46,IGHJ3,CQVWDGGSDHPGVVF,IGLV3-21,COV072_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSRPTPDWYFDLW,IGHV1-46,IGHJ4,CQVWDGGSDHPGVVF,IGLV3-21,COV072_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSRPTPDWYFDLW,IGHV1-46,IGHJ5,CQVWDGGSDHPGVVF,IGLV3-21,COV072_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSRPTPDWYFDLW,IGHV1-46,IGHJ6,CQVWDGGSDHPGVVF,IGLV3-21,COV072_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVNQAVTTPFSMDVW,IGHV1-69,IGHJ1,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVNQAVTTPFSMDVW,IGHV1-69,IGHJ2,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVNQAVTTPFSMDVW,IGHV1-69,IGHJ3,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVNQAVTTPFSMDVW,IGHV1-69,IGHJ4,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVNQAVTTPFSMDVW,IGHV1-69,IGHJ5,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVNQAVTTPFSMDVW,IGHV1-69,IGHJ6,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANQPVTTPFSMDVW,IGHV1-69,IGHJ1,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANQPVTTPFSMDVW,IGHV1-69,IGHJ2,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANQPVTTPFSMDVW,IGHV1-69,IGHJ3,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANQPVTTPFSMDVW,IGHV1-69,IGHJ4,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANQPVTTPFSMDVW,IGHV1-69,IGHJ5,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANQPVTTPFSMDVW,IGHV1-69,IGHJ6,CQQYNNWPITF,IGKV3-15,COV072_P3_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ1,CQVWDSSSDRPGVVF,IGLV3-21,COV072_P3_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ2,CQVWDSSSDRPGVVF,IGLV3-21,COV072_P3_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ3,CQVWDSSSDRPGVVF,IGLV3-21,COV072_P3_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ4,CQVWDSSSDRPGVVF,IGLV3-21,COV072_P3_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ5,CQVWDSSSDRPGVVF,IGLV3-21,COV072_P3_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ6,CQVWDSSSDRPGVVF,IGLV3-21,COV072_P3_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ1,CQVWDSSSDRPGVVF,IGLV3-21,COV072_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ2,CQVWDSSSDRPGVVF,IGLV3-21,COV072_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ3,CQVWDSSSDRPGVVF,IGLV3-21,COV072_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ4,CQVWDSSSDRPGVVF,IGLV3-21,COV072_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ5,CQVWDSSSDRPGVVF,IGLV3-21,COV072_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLITGPTYQYFHYW,IGHV3-23,IGHJ6,CQVWDSSSDRPGVVF,IGLV3-21,COV072_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTSMVTWFDYW,IGHV3-30-3,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV072_P3_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTSMVTWFDYW,IGHV3-30-3,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV072_P3_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTSMVTWFDYW,IGHV3-30-3,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV072_P3_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTSMVTWFDYW,IGHV3-30-3,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV072_P3_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTSMVTWFDYW,IGHV3-30-3,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV072_P3_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTSMVTWFDYW,IGHV3-30-3,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV072_P3_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTAMVTWFDYW,IGHV3-30-3,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV072_Plate2_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTAMVTWFDYW,IGHV3-30-3,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV072_Plate2_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTAMVTWFDYW,IGHV3-30-3,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV072_Plate2_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTAMVTWFDYW,IGHV3-30-3,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV072_Plate2_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTAMVTWFDYW,IGHV3-30-3,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV072_Plate2_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDVDTAMVTWFDYW,IGHV3-30-3,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV072_Plate2_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGDYGMDVW,IGHV3-66,IGHJ1,CQQLNSYPPYTF,IGKV1-9,COV072_P3_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGDYGMDVW,IGHV3-66,IGHJ2,CQQLNSYPPYTF,IGKV1-9,COV072_P3_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGDYGMDVW,IGHV3-66,IGHJ3,CQQLNSYPPYTF,IGKV1-9,COV072_P3_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGDYGMDVW,IGHV3-66,IGHJ4,CQQLNSYPPYTF,IGKV1-9,COV072_P3_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGDYGMDVW,IGHV3-66,IGHJ5,CQQLNSYPPYTF,IGKV1-9,COV072_P3_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGDYGMDVW,IGHV3-66,IGHJ6,CQQLNSYPPYTF,IGKV1-9,COV072_P3_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-66,IGHJ1,CQQLNSYSYTF,IGKV1-9,COV072_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-66,IGHJ2,CQQLNSYSYTF,IGKV1-9,COV072_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-66,IGHJ3,CQQLNSYSYTF,IGKV1-9,COV072_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-66,IGHJ4,CQQLNSYSYTF,IGKV1-9,COV072_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-66,IGHJ5,CQQLNSYSYTF,IGKV1-9,COV072_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-66,IGHJ6,CQQLNSYSYTF,IGKV1-9,COV072_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALQGPWLGADYW,IGHV3-7,IGHJ1,CQSYDSSKGVF,IGLV6-57,COV072_P3_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALQGPWLGADYW,IGHV3-7,IGHJ2,CQSYDSSKGVF,IGLV6-57,COV072_P3_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALQGPWLGADYW,IGHV3-7,IGHJ3,CQSYDSSKGVF,IGLV6-57,COV072_P3_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALQGPWLGADYW,IGHV3-7,IGHJ4,CQSYDSSKGVF,IGLV6-57,COV072_P3_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALQGPWLGADYW,IGHV3-7,IGHJ5,CQSYDSSKGVF,IGLV6-57,COV072_P3_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALQGPWLGADYW,IGHV3-7,IGHJ6,CQSYDSSKGVF,IGLV6-57,COV072_P3_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTWLRSSFDYW,IGHV3-7,IGHJ1,CQSYDSSNWVF,IGLV6-57,COV072_Plate2_HC_33-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTWLRSSFDYW,IGHV3-7,IGHJ2,CQSYDSSNWVF,IGLV6-57,COV072_Plate2_HC_33-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTWLRSSFDYW,IGHV3-7,IGHJ3,CQSYDSSNWVF,IGLV6-57,COV072_Plate2_HC_33-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTWLRSSFDYW,IGHV3-7,IGHJ4,CQSYDSSNWVF,IGLV6-57,COV072_Plate2_HC_33-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTWLRSSFDYW,IGHV3-7,IGHJ5,CQSYDSSNWVF,IGLV6-57,COV072_Plate2_HC_33-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTWLRSSFDYW,IGHV3-7,IGHJ6,CQSYDSSNWVF,IGLV6-57,COV072_Plate2_HC_33-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGDTAMGPEYFDYW,IGHV4-4,IGHJ1,CSSYTSSSTLLF,IGLV2-14,COV072_P3_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGDTAMGPEYFDYW,IGHV4-4,IGHJ2,CSSYTSSSTLLF,IGLV2-14,COV072_P3_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGDTAMGPEYFDYW,IGHV4-4,IGHJ3,CSSYTSSSTLLF,IGLV2-14,COV072_P3_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGDTAMGPEYFDYW,IGHV4-4,IGHJ4,CSSYTSSSTLLF,IGLV2-14,COV072_P3_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGDTAMGPEYFDYW,IGHV4-4,IGHJ5,CSSYTSSSTLLF,IGLV2-14,COV072_P3_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGDTAMGPEYFDYW,IGHV4-4,IGHJ6,CSSYTSSSTLLF,IGLV2-14,COV072_P3_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGDRAMGPEYFDYW,IGHV4-4,IGHJ1,CSSFTSSSTLLF,IGLV2-14,COV072_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGDRAMGPEYFDYW,IGHV4-4,IGHJ2,CSSFTSSSTLLF,IGLV2-14,COV072_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGDRAMGPEYFDYW,IGHV4-4,IGHJ3,CSSFTSSSTLLF,IGLV2-14,COV072_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGDRAMGPEYFDYW,IGHV4-4,IGHJ4,CSSFTSSSTLLF,IGLV2-14,COV072_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGDRAMGPEYFDYW,IGHV4-4,IGHJ5,CSSFTSSSTLLF,IGLV2-14,COV072_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGDRAMGPEYFDYW,IGHV4-4,IGHJ6,CSSFTSSSTLLF,IGLV2-14,COV072_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGITGTIEYYFDYW,IGHV1-18,IGHJ1,CQQRSNWPPGVTF,IGKV3-11,COV072_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGITGTIEYYFDYW,IGHV1-18,IGHJ2,CQQRSNWPPGVTF,IGKV3-11,COV072_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGITGTIEYYFDYW,IGHV1-18,IGHJ3,CQQRSNWPPGVTF,IGKV3-11,COV072_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGITGTIEYYFDYW,IGHV1-18,IGHJ4,CQQRSNWPPGVTF,IGKV3-11,COV072_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGITGTIEYYFDYW,IGHV1-18,IGHJ5,CQQRSNWPPGVTF,IGKV3-11,COV072_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGITGTIEYYFDYW,IGHV1-18,IGHJ6,CQQRSNWPPGVTF,IGKV3-11,COV072_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGIIVAGSLNW,IGHV1-18,IGHJ1,CQSYDSSTWVF,IGLV6-57,COV072_P3_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGIIVAGSLNW,IGHV1-18,IGHJ2,CQSYDSSTWVF,IGLV6-57,COV072_P3_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGIIVAGSLNW,IGHV1-18,IGHJ3,CQSYDSSTWVF,IGLV6-57,COV072_P3_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGIIVAGSLNW,IGHV1-18,IGHJ4,CQSYDSSTWVF,IGLV6-57,COV072_P3_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGIIVAGSLNW,IGHV1-18,IGHJ5,CQSYDSSTWVF,IGLV6-57,COV072_P3_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGIIVAGSLNW,IGHV1-18,IGHJ6,CQSYDSSTWVF,IGLV6-57,COV072_P3_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNAEIAARKGGMDVW,IGHV1-24,IGHJ1,CMQALQTPWTF,IGKV2-28,COV072_P3_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNAEIAARKGGMDVW,IGHV1-24,IGHJ2,CMQALQTPWTF,IGKV2-28,COV072_P3_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNAEIAARKGGMDVW,IGHV1-24,IGHJ3,CMQALQTPWTF,IGKV2-28,COV072_P3_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNAEIAARKGGMDVW,IGHV1-24,IGHJ4,CMQALQTPWTF,IGKV2-28,COV072_P3_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNAEIAARKGGMDVW,IGHV1-24,IGHJ5,CMQALQTPWTF,IGKV2-28,COV072_P3_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNAEIAARKGGMDVW,IGHV1-24,IGHJ6,CMQALQTPWTF,IGKV2-28,COV072_P3_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYIPASDAFDIW,IGHV1-46,IGHJ1,CCSYAGSYTRYVF,IGLV2-11,COV072_P3_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYIPASDAFDIW,IGHV1-46,IGHJ2,CCSYAGSYTRYVF,IGLV2-11,COV072_P3_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYIPASDAFDIW,IGHV1-46,IGHJ3,CCSYAGSYTRYVF,IGLV2-11,COV072_P3_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYIPASDAFDIW,IGHV1-46,IGHJ4,CCSYAGSYTRYVF,IGLV2-11,COV072_P3_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYIPASDAFDIW,IGHV1-46,IGHJ5,CCSYAGSYTRYVF,IGLV2-11,COV072_P3_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYIPASDAFDIW,IGHV1-46,IGHJ6,CCSYAGSYTRYVF,IGLV2-11,COV072_P3_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIALVPAAMGLDYW,IGHV1-46,IGHJ1,CQQSYRTRLTF,IGKV1-39,COV072_P3_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIALVPAAMGLDYW,IGHV1-46,IGHJ2,CQQSYRTRLTF,IGKV1-39,COV072_P3_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIALVPAAMGLDYW,IGHV1-46,IGHJ3,CQQSYRTRLTF,IGKV1-39,COV072_P3_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIALVPAAMGLDYW,IGHV1-46,IGHJ4,CQQSYRTRLTF,IGKV1-39,COV072_P3_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIALVPAAMGLDYW,IGHV1-46,IGHJ5,CQQSYRTRLTF,IGKV1-39,COV072_P3_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIALVPAAMGLDYW,IGHV1-46,IGHJ6,CQQSYRTRLTF,IGKV1-39,COV072_P3_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAVDCNSTSCYDAFDIW,IGHV1-58,IGHJ1,CQQYDISPWTF,IGKV3-20,COV072_P3_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAVDCNSTSCYDAFDIW,IGHV1-58,IGHJ2,CQQYDISPWTF,IGKV3-20,COV072_P3_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAVDCNSTSCYDAFDIW,IGHV1-58,IGHJ3,CQQYDISPWTF,IGKV3-20,COV072_P3_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAVDCNSTSCYDAFDIW,IGHV1-58,IGHJ4,CQQYDISPWTF,IGKV3-20,COV072_P3_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAVDCNSTSCYDAFDIW,IGHV1-58,IGHJ5,CQQYDISPWTF,IGKV3-20,COV072_P3_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAVDCNSTSCYDAFDIW,IGHV1-58,IGHJ6,CQQYDISPWTF,IGKV3-20,COV072_P3_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVSLTLPIAAAPRFWFDSW,IGHV1-69,IGHJ1,CQQYHNWPPALTF,IGKV3-15,COV072_P3_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVSLTLPIAAAPRFWFDSW,IGHV1-69,IGHJ2,CQQYHNWPPALTF,IGKV3-15,COV072_P3_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVSLTLPIAAAPRFWFDSW,IGHV1-69,IGHJ3,CQQYHNWPPALTF,IGKV3-15,COV072_P3_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVSLTLPIAAAPRFWFDSW,IGHV1-69,IGHJ4,CQQYHNWPPALTF,IGKV3-15,COV072_P3_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVSLTLPIAAAPRFWFDSW,IGHV1-69,IGHJ5,CQQYHNWPPALTF,IGKV3-15,COV072_P3_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVSLTLPIAAAPRFWFDSW,IGHV1-69,IGHJ6,CQQYHNWPPALTF,IGKV3-15,COV072_P3_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVAATPGNFDIW,IGHV1-69,IGHJ1,CQQYNNGLTF,IGKV3-15,COV072_P3_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVAATPGNFDIW,IGHV1-69,IGHJ2,CQQYNNGLTF,IGKV3-15,COV072_P3_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVAATPGNFDIW,IGHV1-69,IGHJ3,CQQYNNGLTF,IGKV3-15,COV072_P3_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVAATPGNFDIW,IGHV1-69,IGHJ4,CQQYNNGLTF,IGKV3-15,COV072_P3_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVAATPGNFDIW,IGHV1-69,IGHJ5,CQQYNNGLTF,IGKV3-15,COV072_P3_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVAATPGNFDIW,IGHV1-69,IGHJ6,CQQYNNGLTF,IGKV3-15,COV072_P3_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLLDPQLDDAFDIW,IGHV1-69,IGHJ1,CQQYGSSPWTF,IGKV3-20,COV072_P3_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLLDPQLDDAFDIW,IGHV1-69,IGHJ2,CQQYGSSPWTF,IGKV3-20,COV072_P3_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLLDPQLDDAFDIW,IGHV1-69,IGHJ3,CQQYGSSPWTF,IGKV3-20,COV072_P3_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLLDPQLDDAFDIW,IGHV1-69,IGHJ4,CQQYGSSPWTF,IGKV3-20,COV072_P3_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLLDPQLDDAFDIW,IGHV1-69,IGHJ5,CQQYGSSPWTF,IGKV3-20,COV072_P3_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLLDPQLDDAFDIW,IGHV1-69,IGHJ6,CQQYGSSPWTF,IGKV3-20,COV072_P3_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYSYGQLYYFDYW,IGHV1-69,IGHJ1,CQQYANSRTF,IGKV3-20,COV072_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYSYGQLYYFDYW,IGHV1-69,IGHJ2,CQQYANSRTF,IGKV3-20,COV072_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYSYGQLYYFDYW,IGHV1-69,IGHJ3,CQQYANSRTF,IGKV3-20,COV072_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYSYGQLYYFDYW,IGHV1-69,IGHJ4,CQQYANSRTF,IGKV3-20,COV072_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYSYGQLYYFDYW,IGHV1-69,IGHJ5,CQQYANSRTF,IGKV3-20,COV072_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYSYGQLYYFDYW,IGHV1-69,IGHJ6,CQQYANSRTF,IGKV3-20,COV072_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFSNYCTSTSCYDYW,IGHV1-69,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,COV072_P3_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFSNYCTSTSCYDYW,IGHV1-69,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,COV072_P3_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFSNYCTSTSCYDYW,IGHV1-69,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,COV072_P3_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFSNYCTSTSCYDYW,IGHV1-69,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,COV072_P3_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFSNYCTSTSCYDYW,IGHV1-69,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,COV072_P3_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFSNYCTSTSCYDYW,IGHV1-69,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,COV072_P3_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGYSGYGLDRFDYW,IGHV3-11,IGHJ1,CQQYDNLPLTF,IGKV1-33,COV072_P3_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGYSGYGLDRFDYW,IGHV3-11,IGHJ2,CQQYDNLPLTF,IGKV1-33,COV072_P3_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGYSGYGLDRFDYW,IGHV3-11,IGHJ3,CQQYDNLPLTF,IGKV1-33,COV072_P3_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGYSGYGLDRFDYW,IGHV3-11,IGHJ4,CQQYDNLPLTF,IGKV1-33,COV072_P3_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGYSGYGLDRFDYW,IGHV3-11,IGHJ5,CQQYDNLPLTF,IGKV1-33,COV072_P3_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGYSGYGLDRFDYW,IGHV3-11,IGHJ6,CQQYDNLPLTF,IGKV1-33,COV072_P3_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNITMVRGVIVRPNDGGYYYALDVW,IGHV3-11,IGHJ1,CQQSYSTRALTF,IGKV1-39,COV072_P3_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNITMVRGVIVRPNDGGYYYALDVW,IGHV3-11,IGHJ2,CQQSYSTRALTF,IGKV1-39,COV072_P3_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNITMVRGVIVRPNDGGYYYALDVW,IGHV3-11,IGHJ3,CQQSYSTRALTF,IGKV1-39,COV072_P3_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNITMVRGVIVRPNDGGYYYALDVW,IGHV3-11,IGHJ4,CQQSYSTRALTF,IGKV1-39,COV072_P3_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNITMVRGVIVRPNDGGYYYALDVW,IGHV3-11,IGHJ5,CQQSYSTRALTF,IGKV1-39,COV072_P3_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNITMVRGVIVRPNDGGYYYALDVW,IGHV3-11,IGHJ6,CQQSYSTRALTF,IGKV1-39,COV072_P3_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDYSIRYYYGMDVW,IGHV3-15,IGHJ1,CQSADSSGTYEVF,IGLV3-25,COV072_P3_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDYSIRYYYGMDVW,IGHV3-15,IGHJ2,CQSADSSGTYEVF,IGLV3-25,COV072_P3_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDYSIRYYYGMDVW,IGHV3-15,IGHJ3,CQSADSSGTYEVF,IGLV3-25,COV072_P3_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDYSIRYYYGMDVW,IGHV3-15,IGHJ4,CQSADSSGTYEVF,IGLV3-25,COV072_P3_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDYSIRYYYGMDVW,IGHV3-15,IGHJ5,CQSADSSGTYEVF,IGLV3-25,COV072_P3_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDYSIRYYYGMDVW,IGHV3-15,IGHJ6,CQSADSSGTYEVF,IGLV3-25,COV072_P3_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAKLEIAHYGGSPGFDYW,IGHV3-21,IGHJ1,CQAWDSSTGVVF,IGLV3-1,COV072_P3_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAKLEIAHYGGSPGFDYW,IGHV3-21,IGHJ2,CQAWDSSTGVVF,IGLV3-1,COV072_P3_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAKLEIAHYGGSPGFDYW,IGHV3-21,IGHJ3,CQAWDSSTGVVF,IGLV3-1,COV072_P3_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAKLEIAHYGGSPGFDYW,IGHV3-21,IGHJ4,CQAWDSSTGVVF,IGLV3-1,COV072_P3_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAKLEIAHYGGSPGFDYW,IGHV3-21,IGHJ5,CQAWDSSTGVVF,IGLV3-1,COV072_P3_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAKLEIAHYGGSPGFDYW,IGHV3-21,IGHJ6,CQAWDSSTGVVF,IGLV3-1,COV072_P3_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMGLELPGLDYGMDVW,IGHV3-21,IGHJ1,CAAWDDSFNGPVF,IGLV1-36,COV072_P3_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMGLELPGLDYGMDVW,IGHV3-21,IGHJ2,CAAWDDSFNGPVF,IGLV1-36,COV072_P3_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMGLELPGLDYGMDVW,IGHV3-21,IGHJ3,CAAWDDSFNGPVF,IGLV1-36,COV072_P3_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMGLELPGLDYGMDVW,IGHV3-21,IGHJ4,CAAWDDSFNGPVF,IGLV1-36,COV072_P3_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMGLELPGLDYGMDVW,IGHV3-21,IGHJ5,CAAWDDSFNGPVF,IGLV1-36,COV072_P3_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMGLELPGLDYGMDVW,IGHV3-21,IGHJ6,CAAWDDSFNGPVF,IGLV1-36,COV072_P3_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDYGEYVFSNAFDIW,IGHV3-23,IGHJ1,CCSYAGTSTYVF,IGLV2-23,COV072_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDYGEYVFSNAFDIW,IGHV3-23,IGHJ2,CCSYAGTSTYVF,IGLV2-23,COV072_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDYGEYVFSNAFDIW,IGHV3-23,IGHJ3,CCSYAGTSTYVF,IGLV2-23,COV072_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDYGEYVFSNAFDIW,IGHV3-23,IGHJ4,CCSYAGTSTYVF,IGLV2-23,COV072_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDYGEYVFSNAFDIW,IGHV3-23,IGHJ5,CCSYAGTSTYVF,IGLV2-23,COV072_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDYGEYVFSNAFDIW,IGHV3-23,IGHJ6,CCSYAGTSTYVF,IGLV2-23,COV072_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSKTVERLPYCGGDCFSAIDYW,IGHV3-23,IGHJ1,CQQYDNLPPFTF,IGKV1-33,COV072_P3_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSKTVERLPYCGGDCFSAIDYW,IGHV3-23,IGHJ2,CQQYDNLPPFTF,IGKV1-33,COV072_P3_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSKTVERLPYCGGDCFSAIDYW,IGHV3-23,IGHJ3,CQQYDNLPPFTF,IGKV1-33,COV072_P3_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSKTVERLPYCGGDCFSAIDYW,IGHV3-23,IGHJ4,CQQYDNLPPFTF,IGKV1-33,COV072_P3_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSKTVERLPYCGGDCFSAIDYW,IGHV3-23,IGHJ5,CQQYDNLPPFTF,IGKV1-33,COV072_P3_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSKTVERLPYCGGDCFSAIDYW,IGHV3-23,IGHJ6,CQQYDNLPPFTF,IGKV1-33,COV072_P3_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGPAAAYGWYYYYMDVW,IGHV3-23,IGHJ1,CQKYNSALGFTF,IGKV1-27,COV072_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGPAAAYGWYYYYMDVW,IGHV3-23,IGHJ2,CQKYNSALGFTF,IGKV1-27,COV072_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGPAAAYGWYYYYMDVW,IGHV3-23,IGHJ3,CQKYNSALGFTF,IGKV1-27,COV072_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGPAAAYGWYYYYMDVW,IGHV3-23,IGHJ4,CQKYNSALGFTF,IGKV1-27,COV072_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGPAAAYGWYYYYMDVW,IGHV3-23,IGHJ5,CQKYNSALGFTF,IGKV1-27,COV072_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGPAAAYGWYYYYMDVW,IGHV3-23,IGHJ6,CQKYNSALGFTF,IGKV1-27,COV072_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGPGFDIW,IGHV3-30,IGHJ1,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGPGFDIW,IGHV3-30,IGHJ2,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGPGFDIW,IGHV3-30,IGHJ3,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGPGFDIW,IGHV3-30,IGHJ4,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGPGFDIW,IGHV3-30,IGHJ5,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGPGFDIW,IGHV3-30,IGHJ6,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHSDYW,IGHV3-30,IGHJ1,CQQYNSYPWTF,IGKV1-5,COV072_P3_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHSDYW,IGHV3-30,IGHJ2,CQQYNSYPWTF,IGKV1-5,COV072_P3_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHSDYW,IGHV3-30,IGHJ3,CQQYNSYPWTF,IGKV1-5,COV072_P3_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHSDYW,IGHV3-30,IGHJ4,CQQYNSYPWTF,IGKV1-5,COV072_P3_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHSDYW,IGHV3-30,IGHJ5,CQQYNSYPWTF,IGKV1-5,COV072_P3_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHSDYW,IGHV3-30,IGHJ6,CQQYNSYPWTF,IGKV1-5,COV072_P3_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGSGFDIW,IGHV3-30,IGHJ1,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGSGFDIW,IGHV3-30,IGHJ2,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGSGFDIW,IGHV3-30,IGHJ3,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGSGFDIW,IGHV3-30,IGHJ4,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGSGFDIW,IGHV3-30,IGHJ5,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGPRFGWSYRGGSGFDIW,IGHV3-30,IGHJ6,CQQYDNLPITF,IGKV1-33,COV072_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLGLYCSGGNCYSGALDYW,IGHV3-30,IGHJ1,CQQYDNLPFTF,IGKV1-33,COV072_P3_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLGLYCSGGNCYSGALDYW,IGHV3-30,IGHJ2,CQQYDNLPFTF,IGKV1-33,COV072_P3_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLGLYCSGGNCYSGALDYW,IGHV3-30,IGHJ3,CQQYDNLPFTF,IGKV1-33,COV072_P3_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLGLYCSGGNCYSGALDYW,IGHV3-30,IGHJ4,CQQYDNLPFTF,IGKV1-33,COV072_P3_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLGLYCSGGNCYSGALDYW,IGHV3-30,IGHJ5,CQQYDNLPFTF,IGKV1-33,COV072_P3_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLGLYCSGGNCYSGALDYW,IGHV3-30,IGHJ6,CQQYDNLPFTF,IGKV1-33,COV072_P3_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQNGLYCSGGSCYLGYFDYW,IGHV3-30,IGHJ1,CLQYDNLPLTF,IGKV1-33,COV072_P3_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQNGLYCSGGSCYLGYFDYW,IGHV3-30,IGHJ2,CLQYDNLPLTF,IGKV1-33,COV072_P3_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQNGLYCSGGSCYLGYFDYW,IGHV3-30,IGHJ3,CLQYDNLPLTF,IGKV1-33,COV072_P3_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQNGLYCSGGSCYLGYFDYW,IGHV3-30,IGHJ4,CLQYDNLPLTF,IGKV1-33,COV072_P3_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQNGLYCSGGSCYLGYFDYW,IGHV3-30,IGHJ5,CLQYDNLPLTF,IGKV1-33,COV072_P3_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQNGLYCSGGSCYLGYFDYW,IGHV3-30,IGHJ6,CLQYDNLPLTF,IGKV1-33,COV072_P3_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGRDYYDSSGYYLLDHYYGMDVW,IGHV3-30,IGHJ1,CQSYDSSLSGFYVF,IGLV1-40,COV072_P3_HC_56-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGRDYYDSSGYYLLDHYYGMDVW,IGHV3-30,IGHJ2,CQSYDSSLSGFYVF,IGLV1-40,COV072_P3_HC_56-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGRDYYDSSGYYLLDHYYGMDVW,IGHV3-30,IGHJ3,CQSYDSSLSGFYVF,IGLV1-40,COV072_P3_HC_56-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGRDYYDSSGYYLLDHYYGMDVW,IGHV3-30,IGHJ4,CQSYDSSLSGFYVF,IGLV1-40,COV072_P3_HC_56-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGRDYYDSSGYYLLDHYYGMDVW,IGHV3-30,IGHJ5,CQSYDSSLSGFYVF,IGLV1-40,COV072_P3_HC_56-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGRDYYDSSGYYLLDHYYGMDVW,IGHV3-30,IGHJ6,CQSYDSSLSGFYVF,IGLV1-40,COV072_P3_HC_56-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGAYSYYYYMDVW,IGHV3-30,IGHJ1,CQQYDNLPLTF,IGKV1-33,COV072_Plate2_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGAYSYYYYMDVW,IGHV3-30,IGHJ2,CQQYDNLPLTF,IGKV1-33,COV072_Plate2_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGAYSYYYYMDVW,IGHV3-30,IGHJ3,CQQYDNLPLTF,IGKV1-33,COV072_Plate2_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGAYSYYYYMDVW,IGHV3-30,IGHJ4,CQQYDNLPLTF,IGKV1-33,COV072_Plate2_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGAYSYYYYMDVW,IGHV3-30,IGHJ5,CQQYDNLPLTF,IGKV1-33,COV072_Plate2_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGAYSYYYYMDVW,IGHV3-30,IGHJ6,CQQYDNLPLTF,IGKV1-33,COV072_Plate2_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDTAMVDYFDYW,IGHV3-30-3,IGHJ1,CQQSYSTFMYTF,IGKV1-39,COV072_P3_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDTAMVDYFDYW,IGHV3-30-3,IGHJ2,CQQSYSTFMYTF,IGKV1-39,COV072_P3_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDTAMVDYFDYW,IGHV3-30-3,IGHJ3,CQQSYSTFMYTF,IGKV1-39,COV072_P3_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDTAMVDYFDYW,IGHV3-30-3,IGHJ4,CQQSYSTFMYTF,IGKV1-39,COV072_P3_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDTAMVDYFDYW,IGHV3-30-3,IGHJ5,CQQSYSTFMYTF,IGKV1-39,COV072_P3_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSDTAMVDYFDYW,IGHV3-30-3,IGHJ6,CQQSYSTFMYTF,IGKV1-39,COV072_P3_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDLKYSYGLYYFDYW,IGHV3-30-3,IGHJ1,CQQTYITPPSF,IGKV1-39,COV072_P3_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDLKYSYGLYYFDYW,IGHV3-30-3,IGHJ2,CQQTYITPPSF,IGKV1-39,COV072_P3_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDLKYSYGLYYFDYW,IGHV3-30-3,IGHJ3,CQQTYITPPSF,IGKV1-39,COV072_P3_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDLKYSYGLYYFDYW,IGHV3-30-3,IGHJ4,CQQTYITPPSF,IGKV1-39,COV072_P3_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDLKYSYGLYYFDYW,IGHV3-30-3,IGHJ5,CQQTYITPPSF,IGKV1-39,COV072_P3_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDLKYSYGLYYFDYW,IGHV3-30-3,IGHJ6,CQQTYITPPSF,IGKV1-39,COV072_P3_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHFDYW,IGHV3-30-3,IGHJ1,CQQYNSYPWTF,IGKV1-5,COV072_Plate2_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHFDYW,IGHV3-30-3,IGHJ2,CQQYNSYPWTF,IGKV1-5,COV072_Plate2_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHFDYW,IGHV3-30-3,IGHJ3,CQQYNSYPWTF,IGKV1-5,COV072_Plate2_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHFDYW,IGHV3-30-3,IGHJ4,CQQYNSYPWTF,IGKV1-5,COV072_Plate2_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHFDYW,IGHV3-30-3,IGHJ5,CQQYNSYPWTF,IGKV1-5,COV072_Plate2_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSGYLFHFDYW,IGHV3-30-3,IGHJ6,CQQYNSYPWTF,IGKV1-5,COV072_Plate2_HC_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARNDGSSGWYPERGGGFDYW,IGHV3-30-3,IGHJ1,CQSYDSSLSGLWVF,IGLV1-40,COV072_P3_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARNDGSSGWYPERGGGFDYW,IGHV3-30-3,IGHJ2,CQSYDSSLSGLWVF,IGLV1-40,COV072_P3_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARNDGSSGWYPERGGGFDYW,IGHV3-30-3,IGHJ3,CQSYDSSLSGLWVF,IGLV1-40,COV072_P3_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARNDGSSGWYPERGGGFDYW,IGHV3-30-3,IGHJ4,CQSYDSSLSGLWVF,IGLV1-40,COV072_P3_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARNDGSSGWYPERGGGFDYW,IGHV3-30-3,IGHJ5,CQSYDSSLSGLWVF,IGLV1-40,COV072_P3_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARNDGSSGWYPERGGGFDYW,IGHV3-30-3,IGHJ6,CQSYDSSLSGLWVF,IGLV1-40,COV072_P3_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALSFIAVAGIDYW,IGHV3-30-3,IGHJ1,CQSYDSTTHVVF,IGLV6-57,COV072_P3_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALSFIAVAGIDYW,IGHV3-30-3,IGHJ2,CQSYDSTTHVVF,IGLV6-57,COV072_P3_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALSFIAVAGIDYW,IGHV3-30-3,IGHJ3,CQSYDSTTHVVF,IGLV6-57,COV072_P3_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALSFIAVAGIDYW,IGHV3-30-3,IGHJ4,CQSYDSTTHVVF,IGLV6-57,COV072_P3_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALSFIAVAGIDYW,IGHV3-30-3,IGHJ5,CQSYDSTTHVVF,IGLV6-57,COV072_P3_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARALSFIAVAGIDYW,IGHV3-30-3,IGHJ6,CQSYDSTTHVVF,IGLV6-57,COV072_P3_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARADLGYCTNGVCYVDYW,IGHV3-30-3,IGHJ1,CQSYDSSNWVF,IGLV6-57,COV072_P3_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARADLGYCTNGVCYVDYW,IGHV3-30-3,IGHJ2,CQSYDSSNWVF,IGLV6-57,COV072_P3_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARADLGYCTNGVCYVDYW,IGHV3-30-3,IGHJ3,CQSYDSSNWVF,IGLV6-57,COV072_P3_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARADLGYCTNGVCYVDYW,IGHV3-30-3,IGHJ4,CQSYDSSNWVF,IGLV6-57,COV072_P3_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARADLGYCTNGVCYVDYW,IGHV3-30-3,IGHJ5,CQSYDSSNWVF,IGLV6-57,COV072_P3_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARADLGYCTNGVCYVDYW,IGHV3-30-3,IGHJ6,CQSYDSSNWVF,IGLV6-57,COV072_P3_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRLGAYYNYFGMDVW,IGHV3-30-3,IGHJ1,CMQALQTFTF,IGKV2-28,COV072_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRLGAYYNYFGMDVW,IGHV3-30-3,IGHJ2,CMQALQTFTF,IGKV2-28,COV072_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRLGAYYNYFGMDVW,IGHV3-30-3,IGHJ3,CMQALQTFTF,IGKV2-28,COV072_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRLGAYYNYFGMDVW,IGHV3-30-3,IGHJ4,CMQALQTFTF,IGKV2-28,COV072_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRLGAYYNYFGMDVW,IGHV3-30-3,IGHJ5,CMQALQTFTF,IGKV2-28,COV072_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRLGAYYNYFGMDVW,IGHV3-30-3,IGHJ6,CMQALQTFTF,IGKV2-28,COV072_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGQPYCGGDCYFYYFDYW,IGHV3-30-3,IGHJ1,CQQYDNLPPITF,IGKV1-33,COV072_P3_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGQPYCGGDCYFYYFDYW,IGHV3-30-3,IGHJ2,CQQYDNLPPITF,IGKV1-33,COV072_P3_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGQPYCGGDCYFYYFDYW,IGHV3-30-3,IGHJ3,CQQYDNLPPITF,IGKV1-33,COV072_P3_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGQPYCGGDCYFYYFDYW,IGHV3-30-3,IGHJ4,CQQYDNLPPITF,IGKV1-33,COV072_P3_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGQPYCGGDCYFYYFDYW,IGHV3-30-3,IGHJ5,CQQYDNLPPITF,IGKV1-33,COV072_P3_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGQPYCGGDCYFYYFDYW,IGHV3-30-3,IGHJ6,CQQYDNLPPITF,IGKV1-33,COV072_P3_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTGIAAAGTANPPFDYW,IGHV3-33,IGHJ1,CQQYDNLPYTF,IGKV1-33,COV072_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTGIAAAGTANPPFDYW,IGHV3-33,IGHJ2,CQQYDNLPYTF,IGKV1-33,COV072_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTGIAAAGTANPPFDYW,IGHV3-33,IGHJ3,CQQYDNLPYTF,IGKV1-33,COV072_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTGIAAAGTANPPFDYW,IGHV3-33,IGHJ4,CQQYDNLPYTF,IGKV1-33,COV072_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTGIAAAGTANPPFDYW,IGHV3-33,IGHJ5,CQQYDNLPYTF,IGKV1-33,COV072_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTGIAAAGTANPPFDYW,IGHV3-33,IGHJ6,CQQYDNLPYTF,IGKV1-33,COV072_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATSLFGIISLDYW,IGHV3-33,IGHJ1,CLQDYNYPYTF,IGKV1-6,COV072_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATSLFGIISLDYW,IGHV3-33,IGHJ2,CLQDYNYPYTF,IGKV1-6,COV072_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATSLFGIISLDYW,IGHV3-33,IGHJ3,CLQDYNYPYTF,IGKV1-6,COV072_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATSLFGIISLDYW,IGHV3-33,IGHJ4,CLQDYNYPYTF,IGKV1-6,COV072_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATSLFGIISLDYW,IGHV3-33,IGHJ5,CLQDYNYPYTF,IGKV1-6,COV072_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATSLFGIISLDYW,IGHV3-33,IGHJ6,CLQDYNYPYTF,IGKV1-6,COV072_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWEIVVAGMDVW,IGHV3-33,IGHJ1,CMQGTHCPFTF,IGKV2-30,COV072_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWEIVVAGMDVW,IGHV3-33,IGHJ2,CMQGTHCPFTF,IGKV2-30,COV072_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWEIVVAGMDVW,IGHV3-33,IGHJ3,CMQGTHCPFTF,IGKV2-30,COV072_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWEIVVAGMDVW,IGHV3-33,IGHJ4,CMQGTHCPFTF,IGKV2-30,COV072_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWEIVVAGMDVW,IGHV3-33,IGHJ5,CMQGTHCPFTF,IGKV2-30,COV072_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWEIVVAGMDVW,IGHV3-33,IGHJ6,CMQGTHCPFTF,IGKV2-30,COV072_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEWDSGSYQYYDYYMDVW,IGHV3-33,IGHJ1,CVLYMGSSNWVF,IGLV8-61,COV072_P3_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEWDSGSYQYYDYYMDVW,IGHV3-33,IGHJ2,CVLYMGSSNWVF,IGLV8-61,COV072_P3_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEWDSGSYQYYDYYMDVW,IGHV3-33,IGHJ3,CVLYMGSSNWVF,IGLV8-61,COV072_P3_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEWDSGSYQYYDYYMDVW,IGHV3-33,IGHJ4,CVLYMGSSNWVF,IGLV8-61,COV072_P3_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEWDSGSYQYYDYYMDVW,IGHV3-33,IGHJ5,CVLYMGSSNWVF,IGLV8-61,COV072_P3_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEWDSGSYQYYDYYMDVW,IGHV3-33,IGHJ6,CVLYMGSSNWVF,IGLV8-61,COV072_P3_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLNYRPQYYYYYGMDVW,IGHV3-43,IGHJ1,CMQALQTPWTF,IGKV2-28,COV072_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLNYRPQYYYYYGMDVW,IGHV3-43,IGHJ2,CMQALQTPWTF,IGKV2-28,COV072_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLNYRPQYYYYYGMDVW,IGHV3-43,IGHJ3,CMQALQTPWTF,IGKV2-28,COV072_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLNYRPQYYYYYGMDVW,IGHV3-43,IGHJ4,CMQALQTPWTF,IGKV2-28,COV072_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLNYRPQYYYYYGMDVW,IGHV3-43,IGHJ5,CMQALQTPWTF,IGKV2-28,COV072_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLNYRPQYYYYYGMDVW,IGHV3-43,IGHJ6,CMQALQTPWTF,IGKV2-28,COV072_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFYFDAFDIW,IGHV3-53,IGHJ1,CQQLNSYPLLTF,IGKV1-9,COV072_P3_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFYFDAFDIW,IGHV3-53,IGHJ2,CQQLNSYPLLTF,IGKV1-9,COV072_P3_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFYFDAFDIW,IGHV3-53,IGHJ3,CQQLNSYPLLTF,IGKV1-9,COV072_P3_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFYFDAFDIW,IGHV3-53,IGHJ4,CQQLNSYPLLTF,IGKV1-9,COV072_P3_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFYFDAFDIW,IGHV3-53,IGHJ5,CQQLNSYPLLTF,IGKV1-9,COV072_P3_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFYFDAFDIW,IGHV3-53,IGHJ6,CQQLNSYPLLTF,IGKV1-9,COV072_P3_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDPVPGRGDAYW,IGHV3-53,IGHJ1,CQQYDNLPITF,IGKV1-33,COV072_P3_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDPVPGRGDAYW,IGHV3-53,IGHJ2,CQQYDNLPITF,IGKV1-33,COV072_P3_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDPVPGRGDAYW,IGHV3-53,IGHJ3,CQQYDNLPITF,IGKV1-33,COV072_P3_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDPVPGRGDAYW,IGHV3-53,IGHJ4,CQQYDNLPITF,IGKV1-33,COV072_P3_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDPVPGRGDAYW,IGHV3-53,IGHJ5,CQQYDNLPITF,IGKV1-33,COV072_P3_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDPVPGRGDAYW,IGHV3-53,IGHJ6,CQQYDNLPITF,IGKV1-33,COV072_P3_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYDFWSGYDGGYFDYW,IGHV3-53,IGHJ1,CCSYAGSSTWVF,IGLV2-23,COV072_P3_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYDFWSGYDGGYFDYW,IGHV3-53,IGHJ2,CCSYAGSSTWVF,IGLV2-23,COV072_P3_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYDFWSGYDGGYFDYW,IGHV3-53,IGHJ3,CCSYAGSSTWVF,IGLV2-23,COV072_P3_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYDFWSGYDGGYFDYW,IGHV3-53,IGHJ4,CCSYAGSSTWVF,IGLV2-23,COV072_P3_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYDFWSGYDGGYFDYW,IGHV3-53,IGHJ5,CCSYAGSSTWVF,IGLV2-23,COV072_P3_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYDFWSGYDGGYFDYW,IGHV3-53,IGHJ6,CCSYAGSSTWVF,IGLV2-23,COV072_P3_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPTF,IGKV1-9,COV072_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPTF,IGKV1-9,COV072_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPTF,IGKV1-9,COV072_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPTF,IGKV1-9,COV072_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPTF,IGKV1-9,COV072_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYYYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPTF,IGKV1-9,COV072_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKDITMIVDVFEYW,IGHV3-64D,IGHJ1,CQQSYTTPYTF,IGKV1-39,COV072_P3_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKDITMIVDVFEYW,IGHV3-64D,IGHJ2,CQQSYTTPYTF,IGKV1-39,COV072_P3_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKDITMIVDVFEYW,IGHV3-64D,IGHJ3,CQQSYTTPYTF,IGKV1-39,COV072_P3_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKDITMIVDVFEYW,IGHV3-64D,IGHJ4,CQQSYTTPYTF,IGKV1-39,COV072_P3_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKDITMIVDVFEYW,IGHV3-64D,IGHJ5,CQQSYTTPYTF,IGKV1-39,COV072_P3_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKDITMIVDVFEYW,IGHV3-64D,IGHJ6,CQQSYTTPYTF,IGKV1-39,COV072_P3_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIAGRLDYW,IGHV3-66,IGHJ1,CQHYDSLSRLTF,IGKV1-33,COV072_P3_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIAGRLDYW,IGHV3-66,IGHJ2,CQHYDSLSRLTF,IGKV1-33,COV072_P3_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIAGRLDYW,IGHV3-66,IGHJ3,CQHYDSLSRLTF,IGKV1-33,COV072_P3_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIAGRLDYW,IGHV3-66,IGHJ4,CQHYDSLSRLTF,IGKV1-33,COV072_P3_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIAGRLDYW,IGHV3-66,IGHJ5,CQHYDSLSRLTF,IGKV1-33,COV072_P3_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIAGRLDYW,IGHV3-66,IGHJ6,CQHYDSLSRLTF,IGKV1-33,COV072_P3_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVYGADYW,IGHV3-66,IGHJ1,CQQLNSYPPPF,IGKV1-9,COV072_P3_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVYGADYW,IGHV3-66,IGHJ2,CQQLNSYPPPF,IGKV1-9,COV072_P3_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVYGADYW,IGHV3-66,IGHJ3,CQQLNSYPPPF,IGKV1-9,COV072_P3_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVYGADYW,IGHV3-66,IGHJ4,CQQLNSYPPPF,IGKV1-9,COV072_P3_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVYGADYW,IGHV3-66,IGHJ5,CQQLNSYPPPF,IGKV1-9,COV072_P3_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVYGADYW,IGHV3-66,IGHJ6,CQQLNSYPPPF,IGKV1-9,COV072_P3_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLQYYGMDVW,IGHV3-66,IGHJ1,CQQPDSFTF,IGKV1-9,COV072_Plate2_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLQYYGMDVW,IGHV3-66,IGHJ2,CQQPDSFTF,IGKV1-9,COV072_Plate2_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLQYYGMDVW,IGHV3-66,IGHJ3,CQQPDSFTF,IGKV1-9,COV072_Plate2_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLQYYGMDVW,IGHV3-66,IGHJ4,CQQPDSFTF,IGKV1-9,COV072_Plate2_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLQYYGMDVW,IGHV3-66,IGHJ5,CQQPDSFTF,IGKV1-9,COV072_Plate2_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLQYYGMDVW,IGHV3-66,IGHJ6,CQQPDSFTF,IGKV1-9,COV072_Plate2_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASHLMPDAFDIW,IGHV3-66,IGHJ1,CCSYGGSSTSFYVF,IGLV2-23,COV072_Plate2_HC_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASHLMPDAFDIW,IGHV3-66,IGHJ2,CCSYGGSSTSFYVF,IGLV2-23,COV072_Plate2_HC_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASHLMPDAFDIW,IGHV3-66,IGHJ3,CCSYGGSSTSFYVF,IGLV2-23,COV072_Plate2_HC_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASHLMPDAFDIW,IGHV3-66,IGHJ4,CCSYGGSSTSFYVF,IGLV2-23,COV072_Plate2_HC_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASHLMPDAFDIW,IGHV3-66,IGHJ5,CCSYGGSSTSFYVF,IGLV2-23,COV072_Plate2_HC_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASHLMPDAFDIW,IGHV3-66,IGHJ6,CCSYGGSSTSFYVF,IGLV2-23,COV072_Plate2_HC_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQVSWYNLDAFDIW,IGHV3-7,IGHJ1,CMQGTHWPKTF,IGKV2-30,COV072_Plate2_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQVSWYNLDAFDIW,IGHV3-7,IGHJ2,CMQGTHWPKTF,IGKV2-30,COV072_Plate2_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQVSWYNLDAFDIW,IGHV3-7,IGHJ3,CMQGTHWPKTF,IGKV2-30,COV072_Plate2_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQVSWYNLDAFDIW,IGHV3-7,IGHJ4,CMQGTHWPKTF,IGKV2-30,COV072_Plate2_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQVSWYNLDAFDIW,IGHV3-7,IGHJ5,CMQGTHWPKTF,IGKV2-30,COV072_Plate2_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQVSWYNLDAFDIW,IGHV3-7,IGHJ6,CMQGTHWPKTF,IGKV2-30,COV072_Plate2_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTGRITFGGGDDAFDIW,IGHV3-7,IGHJ1,CQVWDSSSDHRVF,IGLV3-21,COV072_Plate2_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTGRITFGGGDDAFDIW,IGHV3-7,IGHJ2,CQVWDSSSDHRVF,IGLV3-21,COV072_Plate2_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTGRITFGGGDDAFDIW,IGHV3-7,IGHJ3,CQVWDSSSDHRVF,IGLV3-21,COV072_Plate2_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTGRITFGGGDDAFDIW,IGHV3-7,IGHJ4,CQVWDSSSDHRVF,IGLV3-21,COV072_Plate2_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTGRITFGGGDDAFDIW,IGHV3-7,IGHJ5,CQVWDSSSDHRVF,IGLV3-21,COV072_Plate2_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTGRITFGGGDDAFDIW,IGHV3-7,IGHJ6,CQVWDSSSDHRVF,IGLV3-21,COV072_Plate2_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRVVMSGIAAAGQNDYW,IGHV4-30-4,IGHJ1,CQQYDILPPMYTF,IGKV1-33,COV072_Plate2_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRVVMSGIAAAGQNDYW,IGHV4-30-4,IGHJ2,CQQYDILPPMYTF,IGKV1-33,COV072_Plate2_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRVVMSGIAAAGQNDYW,IGHV4-30-4,IGHJ3,CQQYDILPPMYTF,IGKV1-33,COV072_Plate2_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRVVMSGIAAAGQNDYW,IGHV4-30-4,IGHJ4,CQQYDILPPMYTF,IGKV1-33,COV072_Plate2_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRVVMSGIAAAGQNDYW,IGHV4-30-4,IGHJ5,CQQYDILPPMYTF,IGKV1-33,COV072_Plate2_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRVVMSGIAAAGQNDYW,IGHV4-30-4,IGHJ6,CQQYDILPPMYTF,IGKV1-33,COV072_Plate2_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTYYYDSSGYYFQYYFDCW,IGHV4-30-4,IGHJ1,CQQYGSSPLTF,IGKV3-20,COV072_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTYYYDSSGYYFQYYFDCW,IGHV4-30-4,IGHJ2,CQQYGSSPLTF,IGKV3-20,COV072_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTYYYDSSGYYFQYYFDCW,IGHV4-30-4,IGHJ3,CQQYGSSPLTF,IGKV3-20,COV072_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTYYYDSSGYYFQYYFDCW,IGHV4-30-4,IGHJ4,CQQYGSSPLTF,IGKV3-20,COV072_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTYYYDSSGYYFQYYFDCW,IGHV4-30-4,IGHJ5,CQQYGSSPLTF,IGKV3-20,COV072_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTYYYDSSGYYFQYYFDCW,IGHV4-30-4,IGHJ6,CQQYGSSPLTF,IGKV3-20,COV072_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNYDDYVPAEYFQDW,IGHV4-31,IGHJ1,CQQRSNWPPLTF,IGKV3-11,COV072_Plate2_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNYDDYVPAEYFQDW,IGHV4-31,IGHJ2,CQQRSNWPPLTF,IGKV3-11,COV072_Plate2_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNYDDYVPAEYFQDW,IGHV4-31,IGHJ3,CQQRSNWPPLTF,IGKV3-11,COV072_Plate2_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNYDDYVPAEYFQDW,IGHV4-31,IGHJ4,CQQRSNWPPLTF,IGKV3-11,COV072_Plate2_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNYDDYVPAEYFQDW,IGHV4-31,IGHJ5,CQQRSNWPPLTF,IGKV3-11,COV072_Plate2_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATNYDDYVPAEYFQDW,IGHV4-31,IGHJ6,CQQRSNWPPLTF,IGKV3-11,COV072_Plate2_HC_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSCSSTSCPFDYW,IGHV4-31,IGHJ1,CQQYDNLPFTF,IGKV1-33,COV072_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSCSSTSCPFDYW,IGHV4-31,IGHJ2,CQQYDNLPFTF,IGKV1-33,COV072_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSCSSTSCPFDYW,IGHV4-31,IGHJ3,CQQYDNLPFTF,IGKV1-33,COV072_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSCSSTSCPFDYW,IGHV4-31,IGHJ4,CQQYDNLPFTF,IGKV1-33,COV072_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSCSSTSCPFDYW,IGHV4-31,IGHJ5,CQQYDNLPFTF,IGKV1-33,COV072_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSCSSTSCPFDYW,IGHV4-31,IGHJ6,CQQYDNLPFTF,IGKV1-33,COV072_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVLITDYYFDYW,IGHV4-31,IGHJ1,CQSADSSGTRF,IGLV3-25,COV072_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVLITDYYFDYW,IGHV4-31,IGHJ2,CQSADSSGTRF,IGLV3-25,COV072_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVLITDYYFDYW,IGHV4-31,IGHJ3,CQSADSSGTRF,IGLV3-25,COV072_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVLITDYYFDYW,IGHV4-31,IGHJ4,CQSADSSGTRF,IGLV3-25,COV072_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVLITDYYFDYW,IGHV4-31,IGHJ5,CQSADSSGTRF,IGLV3-25,COV072_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVVLITDYYFDYW,IGHV4-31,IGHJ6,CQSADSSGTRF,IGLV3-25,COV072_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGAVAGGDFDYW,IGHV4-34,IGHJ1,CQVWDGTSDHPGWVF,IGLV3-21,COV072_P3_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGAVAGGDFDYW,IGHV4-34,IGHJ2,CQVWDGTSDHPGWVF,IGLV3-21,COV072_P3_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGAVAGGDFDYW,IGHV4-34,IGHJ3,CQVWDGTSDHPGWVF,IGLV3-21,COV072_P3_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGAVAGGDFDYW,IGHV4-34,IGHJ4,CQVWDGTSDHPGWVF,IGLV3-21,COV072_P3_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGAVAGGDFDYW,IGHV4-34,IGHJ5,CQVWDGTSDHPGWVF,IGLV3-21,COV072_P3_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGAVAGGDFDYW,IGHV4-34,IGHJ6,CQVWDGTSDHPGWVF,IGLV3-21,COV072_P3_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPPGDYYYMDVW,IGHV4-39,IGHJ1,CQQSYSIPQITF,IGKV1-39,COV072_Plate2_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPPGDYYYMDVW,IGHV4-39,IGHJ2,CQQSYSIPQITF,IGKV1-39,COV072_Plate2_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPPGDYYYMDVW,IGHV4-39,IGHJ3,CQQSYSIPQITF,IGKV1-39,COV072_Plate2_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPPGDYYYMDVW,IGHV4-39,IGHJ4,CQQSYSIPQITF,IGKV1-39,COV072_Plate2_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPPGDYYYMDVW,IGHV4-39,IGHJ5,CQQSYSIPQITF,IGKV1-39,COV072_Plate2_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPPGDYYYMDVW,IGHV4-39,IGHJ6,CQQSYSIPQITF,IGKV1-39,COV072_Plate2_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRGLPPWFDPW,IGHV4-59,IGHJ1,CQSYDSSNVVF,IGLV6-57,COV072_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRGLPPWFDPW,IGHV4-59,IGHJ2,CQSYDSSNVVF,IGLV6-57,COV072_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRGLPPWFDPW,IGHV4-59,IGHJ3,CQSYDSSNVVF,IGLV6-57,COV072_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRGLPPWFDPW,IGHV4-59,IGHJ4,CQSYDSSNVVF,IGLV6-57,COV072_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRGLPPWFDPW,IGHV4-59,IGHJ5,CQSYDSSNVVF,IGLV6-57,COV072_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRGLPPWFDPW,IGHV4-59,IGHJ6,CQSYDSSNVVF,IGLV6-57,COV072_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPDMSSSSSPHYWYFDLW,IGHV4-59,IGHJ1,CQVWDSSSGHFHVVF,IGLV3-21,COV072_P3_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPDMSSSSSPHYWYFDLW,IGHV4-59,IGHJ2,CQVWDSSSGHFHVVF,IGLV3-21,COV072_P3_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPDMSSSSSPHYWYFDLW,IGHV4-59,IGHJ3,CQVWDSSSGHFHVVF,IGLV3-21,COV072_P3_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPDMSSSSSPHYWYFDLW,IGHV4-59,IGHJ4,CQVWDSSSGHFHVVF,IGLV3-21,COV072_P3_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPDMSSSSSPHYWYFDLW,IGHV4-59,IGHJ5,CQVWDSSSGHFHVVF,IGLV3-21,COV072_P3_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPDMSSSSSPHYWYFDLW,IGHV4-59,IGHJ6,CQVWDSSSGHFHVVF,IGLV3-21,COV072_P3_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGGSYYNNGDGMDVW,IGHV5-51,IGHJ1,CQAWDSSTPHVVF,IGLV3-1,COV072_P3_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGGSYYNNGDGMDVW,IGHV5-51,IGHJ2,CQAWDSSTPHVVF,IGLV3-1,COV072_P3_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGGSYYNNGDGMDVW,IGHV5-51,IGHJ3,CQAWDSSTPHVVF,IGLV3-1,COV072_P3_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGGSYYNNGDGMDVW,IGHV5-51,IGHJ4,CQAWDSSTPHVVF,IGLV3-1,COV072_P3_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGGSYYNNGDGMDVW,IGHV5-51,IGHJ5,CQAWDSSTPHVVF,IGLV3-1,COV072_P3_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGGSYYNNGDGMDVW,IGHV5-51,IGHJ6,CQAWDSSTPHVVF,IGLV3-1,COV072_P3_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGSYYISHGMDVW,IGHV6-1,IGHJ1,CQQYNNWPPWTF,IGKV3D-15,COV072_P3_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGSYYISHGMDVW,IGHV6-1,IGHJ2,CQQYNNWPPWTF,IGKV3D-15,COV072_P3_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGSYYISHGMDVW,IGHV6-1,IGHJ3,CQQYNNWPPWTF,IGKV3D-15,COV072_P3_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGSYYISHGMDVW,IGHV6-1,IGHJ4,CQQYNNWPPWTF,IGKV3D-15,COV072_P3_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGSYYISHGMDVW,IGHV6-1,IGHJ5,CQQYNNWPPWTF,IGKV3D-15,COV072_P3_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGSYYISHGMDVW,IGHV6-1,IGHJ6,CQQYNNWPPWTF,IGKV3D-15,COV072_P3_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_B4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_B4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_B4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_B4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_B4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_B4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_F6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_F6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_F6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_F6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_F6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_F6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_G8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_G8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_G8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_G8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_G8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P1_HC_G8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_A2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_A2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_A2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_A2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_A2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_A2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_B12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSVLYVF,IGLV1-40,COVD57_P2_HC_C10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSVLYVF,IGLV1-40,COVD57_P2_HC_C10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSVLYVF,IGLV1-40,COVD57_P2_HC_C10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSVLYVF,IGLV1-40,COVD57_P2_HC_C10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSVLYVF,IGLV1-40,COVD57_P2_HC_C10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSVLYVF,IGLV1-40,COVD57_P2_HC_C10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_D10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_D10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_D10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_D10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_D10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_D10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ1,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_E1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ2,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_E1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ3,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_E1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ4,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_E1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ5,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_E1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVAVDWYFDLW,IGHV5-51,IGHJ6,CQSYDSSLSALYVF,IGLV1-40,COVD57_P2_HC_E1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ1,CQQRSSWFVTF,IGKV3-11,COVD57_P1_HC_F3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ2,CQQRSSWFVTF,IGKV3-11,COVD57_P1_HC_F3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ3,CQQRSSWFVTF,IGKV3-11,COVD57_P1_HC_F3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ4,CQQRSSWFVTF,IGKV3-11,COVD57_P1_HC_F3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ5,CQQRSSWFVTF,IGKV3-11,COVD57_P1_HC_F3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ6,CQQRSSWFVTF,IGKV3-11,COVD57_P1_HC_F3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVSSPKDWSHYYYYMDVW,IGHV4-59,IGHJ1,CQQRSTWFVTF,IGKV3-11,COVD57_P2_HC_A6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVSSPKDWSHYYYYMDVW,IGHV4-59,IGHJ2,CQQRSTWFVTF,IGKV3-11,COVD57_P2_HC_A6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVSSPKDWSHYYYYMDVW,IGHV4-59,IGHJ3,CQQRSTWFVTF,IGKV3-11,COVD57_P2_HC_A6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVSSPKDWSHYYYYMDVW,IGHV4-59,IGHJ4,CQQRSTWFVTF,IGKV3-11,COVD57_P2_HC_A6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVSSPKDWSHYYYYMDVW,IGHV4-59,IGHJ5,CQQRSTWFVTF,IGKV3-11,COVD57_P2_HC_A6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVSSPKDWSHYYYYMDVW,IGHV4-59,IGHJ6,CQQRSTWFVTF,IGKV3-11,COVD57_P2_HC_A6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ1,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ2,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ3,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ4,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ5,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ6,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ1,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_D11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ2,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_D11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ3,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_D11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ4,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_D11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ5,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_D11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ6,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_D11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ1,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ2,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ3,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ4,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ5,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVVVQSAKDWSHYYYYMDVW,IGHV4-59,IGHJ6,CQQRSSWFVTF,IGKV3-11,COVD57_P2_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ1,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ2,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ3,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ4,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ5,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ6,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_B11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ1,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ2,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ3,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ4,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ5,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ6,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ1,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_E2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ2,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_E2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ3,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_E2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ4,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_E2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ5,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_E2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ6,CMQALQTPPTF,IGKV2-28,COVD57_P2_HC_E2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ1,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ2,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ3,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ4,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ5,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ6,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ1,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_F5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ2,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_F5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ3,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_F5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ4,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_F5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ5,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_F5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ6,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_F5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ1,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_H2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ2,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_H2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ3,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_H2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ4,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_H2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ5,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_H2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQPESTIWYYFDYW,IGHV3-7,IGHJ6,CQSADSSGSYVVF,IGLV3-25,COVD57_P1_HC_H2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ1,CMQALQTLTF,IGKV2-28,COVD57_P1_HC_D12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ2,CMQALQTLTF,IGKV2-28,COVD57_P1_HC_D12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ3,CMQALQTLTF,IGKV2-28,COVD57_P1_HC_D12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ4,CMQALQTLTF,IGKV2-28,COVD57_P1_HC_D12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ5,CMQALQTLTF,IGKV2-28,COVD57_P1_HC_D12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ6,CMQALQTLTF,IGKV2-28,COVD57_P1_HC_D12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ1,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_B6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ2,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_B6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ3,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_B6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ4,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_B6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ5,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_B6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ6,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_B6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ1,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_H7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ2,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_H7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ3,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_H7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ4,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_H7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ5,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_H7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRRSFSRPSSIDYW,IGHV4-34,IGHJ6,CMQALQTLTF,IGKV2-28,COVD57_P2_HC_H7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAANHCSGGSCYDGFDIW,IGHV1-58,IGHJ1,CQQYGSSPWMF,IGKV3-20,COVD57_P1_HC_E6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAANHCSGGSCYDGFDIW,IGHV1-58,IGHJ2,CQQYGSSPWMF,IGKV3-20,COVD57_P1_HC_E6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAANHCSGGSCYDGFDIW,IGHV1-58,IGHJ3,CQQYGSSPWMF,IGKV3-20,COVD57_P1_HC_E6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAANHCSGGSCYDGFDIW,IGHV1-58,IGHJ4,CQQYGSSPWMF,IGKV3-20,COVD57_P1_HC_E6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAANHCSGGSCYDGFDIW,IGHV1-58,IGHJ5,CQQYGSSPWMF,IGKV3-20,COVD57_P1_HC_E6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAANHCSGGSCYDGFDIW,IGHV1-58,IGHJ6,CQQYGSSPWMF,IGKV3-20,COVD57_P1_HC_E6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCNDAFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,COVD57_P2_HC_H6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCNDAFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,COVD57_P2_HC_H6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCNDAFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,COVD57_P2_HC_H6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCNDAFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,COVD57_P2_HC_H6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCNDAFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,COVD57_P2_HC_H6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCNDAFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,COVD57_P2_HC_H6-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ1,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_A10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ2,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_A10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ3,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_A10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ4,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_A10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ5,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_A10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ6,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_A10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ1,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_C4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ2,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_C4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ3,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_C4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ4,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_C4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ5,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_C4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDPHCSSTSCPIFYYYYMDVW,IGHV3-15,IGHJ6,CQVWDSSSDQGVF,IGLV3-21,COVD57_P2_HC_C4-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ1,CQSYDINSRWVF,IGLV6-57,COVD57_P1_HC_E9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ2,CQSYDINSRWVF,IGLV6-57,COVD57_P1_HC_E9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ3,CQSYDINSRWVF,IGLV6-57,COVD57_P1_HC_E9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ4,CQSYDINSRWVF,IGLV6-57,COVD57_P1_HC_E9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ5,CQSYDINSRWVF,IGLV6-57,COVD57_P1_HC_E9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ6,CQSYDINSRWVF,IGLV6-57,COVD57_P1_HC_E9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ1,CQSYDINSRWVF,IGLV6-57,COVD57_P2_HC_G5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ2,CQSYDINSRWVF,IGLV6-57,COVD57_P2_HC_G5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ3,CQSYDINSRWVF,IGLV6-57,COVD57_P2_HC_G5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ4,CQSYDINSRWVF,IGLV6-57,COVD57_P2_HC_G5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ5,CQSYDINSRWVF,IGLV6-57,COVD57_P2_HC_G5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPMGYCTNGVCYPDSW,IGHV3-30,IGHJ6,CQSYDINSRWVF,IGLV6-57,COVD57_P2_HC_G5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ1,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ2,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ3,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ4,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ5,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ6,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_F10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ1,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_H3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ2,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_H3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ3,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_H3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ4,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_H3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ5,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_H3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGFGVVITYGSGTDPLFDYW,IGHV4-34,IGHJ6,CQSYDSSLSGSRVF,IGLV1-40,COVD57_P1_HC_H3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYLERYFDGGQRWISYYYMDVW,IGHV1-2,IGHJ1,CSSYTPNSTLVVF,IGLV2-14,COVD57_P1_HC_A5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYLERYFDGGQRWISYYYMDVW,IGHV1-2,IGHJ2,CSSYTPNSTLVVF,IGLV2-14,COVD57_P1_HC_A5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYLERYFDGGQRWISYYYMDVW,IGHV1-2,IGHJ3,CSSYTPNSTLVVF,IGLV2-14,COVD57_P1_HC_A5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYLERYFDGGQRWISYYYMDVW,IGHV1-2,IGHJ4,CSSYTPNSTLVVF,IGLV2-14,COVD57_P1_HC_A5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYLERYFDGGQRWISYYYMDVW,IGHV1-2,IGHJ5,CSSYTPNSTLVVF,IGLV2-14,COVD57_P1_HC_A5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYLERYFDGGQRWISYYYMDVW,IGHV1-2,IGHJ6,CSSYTPNSTLVVF,IGLV2-14,COVD57_P1_HC_A5-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPDILEVVAATGSLDDW,IGHV1-46,IGHJ1,CSSYAGITNLVF,IGLV2-8,COVD57_P1_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPDILEVVAATGSLDDW,IGHV1-46,IGHJ2,CSSYAGITNLVF,IGLV2-8,COVD57_P1_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPDILEVVAATGSLDDW,IGHV1-46,IGHJ3,CSSYAGITNLVF,IGLV2-8,COVD57_P1_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPDILEVVAATGSLDDW,IGHV1-46,IGHJ4,CSSYAGITNLVF,IGLV2-8,COVD57_P1_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPDILEVVAATGSLDDW,IGHV1-46,IGHJ5,CSSYAGITNLVF,IGLV2-8,COVD57_P1_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPDILEVVAATGSLDDW,IGHV1-46,IGHJ6,CSSYAGITNLVF,IGLV2-8,COVD57_P1_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ1,CYSYGGNNNAVF,IGLV2-8,COVD57_P1_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ2,CYSYGGNNNAVF,IGLV2-8,COVD57_P1_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ3,CYSYGGNNNAVF,IGLV2-8,COVD57_P1_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ4,CYSYGGNNNAVF,IGLV2-8,COVD57_P1_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ5,CYSYGGNNNAVF,IGLV2-8,COVD57_P1_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ6,CYSYGGNNNAVF,IGLV2-8,COVD57_P1_HC_A11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGYSGYGSTYYMDVW,IGHV1-69,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,COVD57_P2_HC_B1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGYSGYGSTYYMDVW,IGHV1-69,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,COVD57_P2_HC_B1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGYSGYGSTYYMDVW,IGHV1-69,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,COVD57_P2_HC_B1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGYSGYGSTYYMDVW,IGHV1-69,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,COVD57_P2_HC_B1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGYSGYGSTYYMDVW,IGHV1-69,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,COVD57_P2_HC_B1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGYSGYGSTYYMDVW,IGHV1-69,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,COVD57_P2_HC_B1-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ1,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_F11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ2,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_F11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ3,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_F11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ4,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_F11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ5,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_F11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEYSSSWYSRGYYGMDVW,IGHV1-69,IGHJ6,CMQALQTPPTF,IGKV2-28,COVD57_P1_HC_F11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGPDYFDYW,IGHV1-69-2,IGHJ1,CQQYNNWPRTF,IGKV3-15,COVD57_P2_HC_G11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGPDYFDYW,IGHV1-69-2,IGHJ2,CQQYNNWPRTF,IGKV3-15,COVD57_P2_HC_G11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGPDYFDYW,IGHV1-69-2,IGHJ3,CQQYNNWPRTF,IGKV3-15,COVD57_P2_HC_G11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGPDYFDYW,IGHV1-69-2,IGHJ4,CQQYNNWPRTF,IGKV3-15,COVD57_P2_HC_G11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGPDYFDYW,IGHV1-69-2,IGHJ5,CQQYNNWPRTF,IGKV3-15,COVD57_P2_HC_G11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSGPDYFDYW,IGHV1-69-2,IGHJ6,CQQYNNWPRTF,IGKV3-15,COVD57_P2_HC_G11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTTFNHYYYMDVW,IGHV3-13,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COVD57_P2_HC_C12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTTFNHYYYMDVW,IGHV3-13,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COVD57_P2_HC_C12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTTFNHYYYMDVW,IGHV3-13,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COVD57_P2_HC_C12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTTFNHYYYMDVW,IGHV3-13,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COVD57_P2_HC_C12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTTFNHYYYMDVW,IGHV3-13,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COVD57_P2_HC_C12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTTFNHYYYMDVW,IGHV3-13,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COVD57_P2_HC_C12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDVGADSSSAYYYYYMDVW,IGHV3-15,IGHJ1,CQQYGSSPYTF,IGKV3D-20,COVD57_P2_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDVGADSSSAYYYYYMDVW,IGHV3-15,IGHJ2,CQQYGSSPYTF,IGKV3D-20,COVD57_P2_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDVGADSSSAYYYYYMDVW,IGHV3-15,IGHJ3,CQQYGSSPYTF,IGKV3D-20,COVD57_P2_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDVGADSSSAYYYYYMDVW,IGHV3-15,IGHJ4,CQQYGSSPYTF,IGKV3D-20,COVD57_P2_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDVGADSSSAYYYYYMDVW,IGHV3-15,IGHJ5,CQQYGSSPYTF,IGKV3D-20,COVD57_P2_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDVGADSSSAYYYYYMDVW,IGHV3-15,IGHJ6,CQQYGSSPYTF,IGKV3D-20,COVD57_P2_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ1,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_E11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ2,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_E11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ3,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_E11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ4,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_E11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ5,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_E11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ6,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_E11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTGSMIVELLGYW,IGHV3-23,IGHJ1,CQSYDTSLRVVF,IGLV1-40,COVD57_P2_HC_H12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTGSMIVELLGYW,IGHV3-23,IGHJ2,CQSYDTSLRVVF,IGLV1-40,COVD57_P2_HC_H12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTGSMIVELLGYW,IGHV3-23,IGHJ3,CQSYDTSLRVVF,IGLV1-40,COVD57_P2_HC_H12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTGSMIVELLGYW,IGHV3-23,IGHJ4,CQSYDTSLRVVF,IGLV1-40,COVD57_P2_HC_H12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTGSMIVELLGYW,IGHV3-23,IGHJ5,CQSYDTSLRVVF,IGLV1-40,COVD57_P2_HC_H12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTGSMIVELLGYW,IGHV3-23,IGHJ6,CQSYDTSLRVVF,IGLV1-40,COVD57_P2_HC_H12-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRARSVTMVWYRYYMDVW,IGHV3-49,IGHJ1,CMQSIQLPYTF,IGKV2D-29,COVD57_P1_HC_B8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRARSVTMVWYRYYMDVW,IGHV3-49,IGHJ2,CMQSIQLPYTF,IGKV2D-29,COVD57_P1_HC_B8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRARSVTMVWYRYYMDVW,IGHV3-49,IGHJ3,CMQSIQLPYTF,IGKV2D-29,COVD57_P1_HC_B8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRARSVTMVWYRYYMDVW,IGHV3-49,IGHJ4,CMQSIQLPYTF,IGKV2D-29,COVD57_P1_HC_B8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRARSVTMVWYRYYMDVW,IGHV3-49,IGHJ5,CMQSIQLPYTF,IGKV2D-29,COVD57_P1_HC_B8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRARSVTMVWYRYYMDVW,IGHV3-49,IGHJ6,CMQSIQLPYTF,IGKV2D-29,COVD57_P1_HC_B8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGPFLPSLYSSSRDAFDIW,IGHV3-64,IGHJ1,CQVWDSSSDPHYVF,IGLV3-21,COVD57_P2_HC_C2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGPFLPSLYSSSRDAFDIW,IGHV3-64,IGHJ2,CQVWDSSSDPHYVF,IGLV3-21,COVD57_P2_HC_C2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGPFLPSLYSSSRDAFDIW,IGHV3-64,IGHJ3,CQVWDSSSDPHYVF,IGLV3-21,COVD57_P2_HC_C2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGPFLPSLYSSSRDAFDIW,IGHV3-64,IGHJ4,CQVWDSSSDPHYVF,IGLV3-21,COVD57_P2_HC_C2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGPFLPSLYSSSRDAFDIW,IGHV3-64,IGHJ5,CQVWDSSSDPHYVF,IGLV3-21,COVD57_P2_HC_C2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGPFLPSLYSSSRDAFDIW,IGHV3-64,IGHJ6,CQVWDSSSDPHYVF,IGLV3-21,COVD57_P2_HC_C2-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPIAAAGSYFDYW,IGHV3-64,IGHJ1,CQVWDSSSDPHWVF,IGLV3-21,COVD57_P1_HC_C8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPIAAAGSYFDYW,IGHV3-64,IGHJ2,CQVWDSSSDPHWVF,IGLV3-21,COVD57_P1_HC_C8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPIAAAGSYFDYW,IGHV3-64,IGHJ3,CQVWDSSSDPHWVF,IGLV3-21,COVD57_P1_HC_C8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPIAAAGSYFDYW,IGHV3-64,IGHJ4,CQVWDSSSDPHWVF,IGLV3-21,COVD57_P1_HC_C8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPIAAAGSYFDYW,IGHV3-64,IGHJ5,CQVWDSSSDPHWVF,IGLV3-21,COVD57_P1_HC_C8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPIAAAGSYFDYW,IGHV3-64,IGHJ6,CQVWDSSSDPHWVF,IGLV3-21,COVD57_P1_HC_C8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAVYGMDVW,IGHV3-66,IGHJ1,CQQLNSYPPVTF,IGKV1-9,COVD57_P1_HC_F9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAVYGMDVW,IGHV3-66,IGHJ2,CQQLNSYPPVTF,IGKV1-9,COVD57_P1_HC_F9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAVYGMDVW,IGHV3-66,IGHJ3,CQQLNSYPPVTF,IGKV1-9,COVD57_P1_HC_F9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAVYGMDVW,IGHV3-66,IGHJ4,CQQLNSYPPVTF,IGKV1-9,COVD57_P1_HC_F9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAVYGMDVW,IGHV3-66,IGHJ5,CQQLNSYPPVTF,IGKV1-9,COVD57_P1_HC_F9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAVYGMDVW,IGHV3-66,IGHJ6,CQQLNSYPPVTF,IGKV1-9,COVD57_P1_HC_F9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGEGQRETDYW,IGHV3-66,IGHJ1,CQQYDNLPRTF,IGKV1-33,COVD57_P1_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGEGQRETDYW,IGHV3-66,IGHJ2,CQQYDNLPRTF,IGKV1-33,COVD57_P1_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGEGQRETDYW,IGHV3-66,IGHJ3,CQQYDNLPRTF,IGKV1-33,COVD57_P1_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGEGQRETDYW,IGHV3-66,IGHJ4,CQQYDNLPRTF,IGKV1-33,COVD57_P1_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGEGQRETDYW,IGHV3-66,IGHJ5,CQQYDNLPRTF,IGKV1-33,COVD57_P1_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGEGQRETDYW,IGHV3-66,IGHJ6,CQQYDNLPRTF,IGKV1-33,COVD57_P1_HC_C3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ1,CQQSYSSPLWTF,IGKV1-39,COVD57_P1_HC_G3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ2,CQQSYSSPLWTF,IGKV1-39,COVD57_P1_HC_G3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ3,CQQSYSSPLWTF,IGKV1-39,COVD57_P1_HC_G3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ4,CQQSYSSPLWTF,IGKV1-39,COVD57_P1_HC_G3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ5,CQQSYSSPLWTF,IGKV1-39,COVD57_P1_HC_G3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ6,CQQSYSSPLWTF,IGKV1-39,COVD57_P1_HC_G3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ1,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ2,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ3,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ4,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ5,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ6,CQQYDNWPLF,IGKV3-15,COVD57_P2_HC_B7-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAYVSSVSEDYFDYW,IGHV4-34,IGHJ1,CQQSYTTPYTF,IGKV1-39,COVD57_P1_HC_H10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAYVSSVSEDYFDYW,IGHV4-34,IGHJ2,CQQSYTTPYTF,IGKV1-39,COVD57_P1_HC_H10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAYVSSVSEDYFDYW,IGHV4-34,IGHJ3,CQQSYTTPYTF,IGKV1-39,COVD57_P1_HC_H10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAYVSSVSEDYFDYW,IGHV4-34,IGHJ4,CQQSYTTPYTF,IGKV1-39,COVD57_P1_HC_H10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAYVSSVSEDYFDYW,IGHV4-34,IGHJ5,CQQSYTTPYTF,IGKV1-39,COVD57_P1_HC_H10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAYVSSVSEDYFDYW,IGHV4-34,IGHJ6,CQQSYTTPYTF,IGKV1-39,COVD57_P1_HC_H10-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWMPRDYYYYGMDVW,IGHV4-34,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD57_P1_HC_B9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWMPRDYYYYGMDVW,IGHV4-34,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD57_P1_HC_B9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWMPRDYYYYGMDVW,IGHV4-34,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD57_P1_HC_B9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWMPRDYYYYGMDVW,IGHV4-34,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD57_P1_HC_B9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWMPRDYYYYGMDVW,IGHV4-34,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD57_P1_HC_B9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWMPRDYYYYGMDVW,IGHV4-34,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD57_P1_HC_B9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGAKGDSDWYFDLW,IGHV4-34,IGHJ1,CQQGDNWPRMYTF,IGKV3-11,COVD57_P2_HC_E3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGAKGDSDWYFDLW,IGHV4-34,IGHJ2,CQQGDNWPRMYTF,IGKV3-11,COVD57_P2_HC_E3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGAKGDSDWYFDLW,IGHV4-34,IGHJ3,CQQGDNWPRMYTF,IGKV3-11,COVD57_P2_HC_E3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGAKGDSDWYFDLW,IGHV4-34,IGHJ4,CQQGDNWPRMYTF,IGKV3-11,COVD57_P2_HC_E3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGAKGDSDWYFDLW,IGHV4-34,IGHJ5,CQQGDNWPRMYTF,IGKV3-11,COVD57_P2_HC_E3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGAKGDSDWYFDLW,IGHV4-34,IGHJ6,CQQGDNWPRMYTF,IGKV3-11,COVD57_P2_HC_E3-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHYDILTALSWFDPW,IGHV4-59,IGHJ1,CGTWDSSLSAYWVF,IGLV1-51,COVD57_P2_HC_F8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHYDILTALSWFDPW,IGHV4-59,IGHJ2,CGTWDSSLSAYWVF,IGLV1-51,COVD57_P2_HC_F8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHYDILTALSWFDPW,IGHV4-59,IGHJ3,CGTWDSSLSAYWVF,IGLV1-51,COVD57_P2_HC_F8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHYDILTALSWFDPW,IGHV4-59,IGHJ4,CGTWDSSLSAYWVF,IGLV1-51,COVD57_P2_HC_F8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHYDILTALSWFDPW,IGHV4-59,IGHJ5,CGTWDSSLSAYWVF,IGLV1-51,COVD57_P2_HC_F8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHYDILTALSWFDPW,IGHV4-59,IGHJ6,CGTWDSSLSAYWVF,IGLV1-51,COVD57_P2_HC_F8-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLLSTEWLFNWFDPW,IGHV4-59,IGHJ1,CQAWDSSTAYVF,IGLV3-1,COVD57_P2_HC_H11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLLSTEWLFNWFDPW,IGHV4-59,IGHJ2,CQAWDSSTAYVF,IGLV3-1,COVD57_P2_HC_H11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLLSTEWLFNWFDPW,IGHV4-59,IGHJ3,CQAWDSSTAYVF,IGLV3-1,COVD57_P2_HC_H11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLLSTEWLFNWFDPW,IGHV4-59,IGHJ4,CQAWDSSTAYVF,IGLV3-1,COVD57_P2_HC_H11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLLSTEWLFNWFDPW,IGHV4-59,IGHJ5,CQAWDSSTAYVF,IGLV3-1,COVD57_P2_HC_H11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLLSTEWLFNWFDPW,IGHV4-59,IGHJ6,CQAWDSSTAYVF,IGLV3-1,COVD57_P2_HC_H11-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGIAVDWYFDLW,IGHV5-51,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD57_P2_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGIAVDWYFDLW,IGHV5-51,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD57_P2_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGIAVDWYFDLW,IGHV5-51,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD57_P2_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGIAVDWYFDLW,IGHV5-51,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD57_P2_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGIAVDWYFDLW,IGHV5-51,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD57_P2_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGIAVDWYFDLW,IGHV5-51,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD57_P2_HC_A9-1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGEYYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COV107_Plate1_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDYGDFYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDYGDFYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDYGDFYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDYGDFYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDYGDFYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDYGDFYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ1,CQQYHTTPRTF,IGKV3-20,COV107_Plate1_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ2,CQQYHTTPRTF,IGKV3-20,COV107_Plate1_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ3,CQQYHTTPRTF,IGKV3-20,COV107_Plate1_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ4,CQQYHTTPRTF,IGKV3-20,COV107_Plate1_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ5,CQQYHTTPRTF,IGKV3-20,COV107_Plate1_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ6,CQQYHTTPRTF,IGKV3-20,COV107_Plate1_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSNLSPGAFDIW,IGHV4-34,IGHJ1,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSNLSPGAFDIW,IGHV4-34,IGHJ2,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSNLSPGAFDIW,IGHV4-34,IGHJ3,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSNLSPGAFDIW,IGHV4-34,IGHJ4,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSNLSPGAFDIW,IGHV4-34,IGHJ5,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSNLSPGAFDIW,IGHV4-34,IGHJ6,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKTLLFSDFSPGAFDIW,IGHV4-34,IGHJ1,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKTLLFSDFSPGAFDIW,IGHV4-34,IGHJ2,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKTLLFSDFSPGAFDIW,IGHV4-34,IGHJ3,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKTLLFSDFSPGAFDIW,IGHV4-34,IGHJ4,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKTLLFSDFSPGAFDIW,IGHV4-34,IGHJ5,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKTLLFSDFSPGAFDIW,IGHV4-34,IGHJ6,CQQYGTTPRTF,IGKV3-20,COV107_Plate1_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLHSDLSPGAFDIW,IGHV4-34,IGHJ1,CQQYVTTPRTF,IGKV3-20,COV107_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLHSDLSPGAFDIW,IGHV4-34,IGHJ2,CQQYVTTPRTF,IGKV3-20,COV107_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLHSDLSPGAFDIW,IGHV4-34,IGHJ3,CQQYVTTPRTF,IGKV3-20,COV107_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLHSDLSPGAFDIW,IGHV4-34,IGHJ4,CQQYVTTPRTF,IGKV3-20,COV107_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLHSDLSPGAFDIW,IGHV4-34,IGHJ5,CQQYVTTPRTF,IGKV3-20,COV107_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLHSDLSPGAFDIW,IGHV4-34,IGHJ6,CQQYVTTPRTF,IGKV3-20,COV107_Plate2_HC_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ1,CQQYTTTPRTF,IGKV3-20,COV107_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ2,CQQYTTTPRTF,IGKV3-20,COV107_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ3,CQQYTTTPRTF,IGKV3-20,COV107_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ4,CQQYTTTPRTF,IGKV3-20,COV107_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ5,CQQYTTTPRTF,IGKV3-20,COV107_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARKPLLYSDFSPGAFDIW,IGHV4-34,IGHJ6,CQQYTTTPRTF,IGKV3-20,COV107_Plate2_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ1,CSSYAGSNNFVVF,IGLV2-8,COV107_Plate1_HC_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ2,CSSYAGSNNFVVF,IGLV2-8,COV107_Plate1_HC_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ3,CSSYAGSNNFVVF,IGLV2-8,COV107_Plate1_HC_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ4,CSSYAGSNNFVVF,IGLV2-8,COV107_Plate1_HC_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ5,CSSYAGSNNFVVF,IGLV2-8,COV107_Plate1_HC_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ6,CSSYAGSNNFVVF,IGLV2-8,COV107_Plate1_HC_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ1,CSSYAGSNNFVLF,IGLV2-8,COV107_Plate1_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ2,CSSYAGSNNFVLF,IGLV2-8,COV107_Plate1_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ3,CSSYAGSNNFVLF,IGLV2-8,COV107_Plate1_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ4,CSSYAGSNNFVLF,IGLV2-8,COV107_Plate1_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ5,CSSYAGSNNFVLF,IGLV2-8,COV107_Plate1_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWDLPYDYW,IGHV3-53,IGHJ6,CSSYAGSNNFVLF,IGLV2-8,COV107_Plate1_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWELPYDYW,IGHV3-53,IGHJ1,CSSYEGSNNFVVF,IGLV2-8,COV107_Plate2_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWELPYDYW,IGHV3-53,IGHJ2,CSSYEGSNNFVVF,IGLV2-8,COV107_Plate2_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWELPYDYW,IGHV3-53,IGHJ3,CSSYEGSNNFVVF,IGLV2-8,COV107_Plate2_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWELPYDYW,IGHV3-53,IGHJ4,CSSYEGSNNFVVF,IGLV2-8,COV107_Plate2_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWELPYDYW,IGHV3-53,IGHJ5,CSSYEGSNNFVVF,IGLV2-8,COV107_Plate2_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEGWELPYDYW,IGHV3-53,IGHJ6,CSSYEGSNNFVVF,IGLV2-8,COV107_Plate2_HC_4-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ1,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ2,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ3,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ4,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ5,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ6,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_63-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ1,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ2,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ3,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ4,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ5,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGEAVAGTTGFFDYW,IGHV1-18,IGHJ6,CAAWDDSLSGFVVF,IGLV1-47,COV107_Plate1_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVIVSMVRGVIFRMDVW,IGHV1-2,IGHJ1,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVIVSMVRGVIFRMDVW,IGHV1-2,IGHJ2,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVIVSMVRGVIFRMDVW,IGHV1-2,IGHJ3,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVIVSMVRGVIFRMDVW,IGHV1-2,IGHJ4,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVIVSMVRGVIFRMDVW,IGHV1-2,IGHJ5,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVIVSMVRGVIFRMDVW,IGHV1-2,IGHJ6,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_13-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAHPRRIQGVFFLGPGVW,IGHV1-2,IGHJ1,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAHPRRIQGVFFLGPGVW,IGHV1-2,IGHJ2,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAHPRRIQGVFFLGPGVW,IGHV1-2,IGHJ3,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAHPRRIQGVFFLGPGVW,IGHV1-2,IGHJ4,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAHPRRIQGVFFLGPGVW,IGHV1-2,IGHJ5,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAHPRRIQGVFFLGPGVW,IGHV1-2,IGHJ6,CAAWDDSLNGVVF,IGLV1-44,COV107_Plate1_HC_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ1,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_79-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ2,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_79-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ3,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_79-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ4,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_79-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ5,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_79-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ6,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_79-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ1,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ2,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ3,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ4,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ5,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARANHETTMDTYYYYYYMDVW,IGHV1-46,IGHJ6,CSSYTSSSTSVVF,IGLV2-14,COV107_Plate1_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSSTSCFDAFDIW,IGHV1-58,IGHJ1,CQQYGNSPWTF,IGKV3-20,COV107_Plate1_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSSTSCFDAFDIW,IGHV1-58,IGHJ2,CQQYGNSPWTF,IGKV3-20,COV107_Plate1_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSSTSCFDAFDIW,IGHV1-58,IGHJ3,CQQYGNSPWTF,IGKV3-20,COV107_Plate1_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSSTSCFDAFDIW,IGHV1-58,IGHJ4,CQQYGNSPWTF,IGKV3-20,COV107_Plate1_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSSTSCFDAFDIW,IGHV1-58,IGHJ5,CQQYGNSPWTF,IGKV3-20,COV107_Plate1_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSSTSCFDAFDIW,IGHV1-58,IGHJ6,CQQYGNSPWTF,IGKV3-20,COV107_Plate1_HC_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCSDAFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,COV107_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCSDAFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,COV107_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCSDAFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,COV107_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCSDAFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,COV107_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCSDAFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,COV107_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPYCSGGSCSDAFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,COV107_Plate2_HC_81-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ1,CGTWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ2,CGTWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ3,CGTWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ4,CGTWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ5,CGTWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ6,CGTWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_42-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ1,CGAWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ2,CGAWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ3,CGAWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ4,CGAWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ5,CGAWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPIWFGELLSPPFVHFDYW,IGHV3-30-3,IGHJ6,CGAWDSSLSAGGVYVF,IGLV1-51,COV107_Plate2_HC_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ1,CSSYTSSSTWVF,IGLV2-14,COV107_Plate1_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ2,CSSYTSSSTWVF,IGLV2-14,COV107_Plate1_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ3,CSSYTSSSTWVF,IGLV2-14,COV107_Plate1_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ4,CSSYTSSSTWVF,IGLV2-14,COV107_Plate1_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ5,CSSYTSSSTWVF,IGLV2-14,COV107_Plate1_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ6,CSSYTSSSTWVF,IGLV2-14,COV107_Plate1_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ1,CSSYTSSSTWVF,IGLV2-14,COV107_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ2,CSSYTSSSTWVF,IGLV2-14,COV107_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ3,CSSYTSSSTWVF,IGLV2-14,COV107_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ4,CSSYTSSSTWVF,IGLV2-14,COV107_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ5,CSSYTSSSTWVF,IGLV2-14,COV107_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREDYYDSSGSFDYW,IGHV3-30-3,IGHJ6,CSSYTSSSTWVF,IGLV2-14,COV107_Plate2_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVRGDYYGLDVW,IGHV3-30-3,IGHJ1,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVRGDYYGLDVW,IGHV3-30-3,IGHJ2,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVRGDYYGLDVW,IGHV3-30-3,IGHJ3,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVRGDYYGLDVW,IGHV3-30-3,IGHJ4,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVRGDYYGLDVW,IGHV3-30-3,IGHJ5,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVRGDYYGLDVW,IGHV3-30-3,IGHJ6,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVGGDYYGMDVW,IGHV3-30-3,IGHJ1,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVGGDYYGMDVW,IGHV3-30-3,IGHJ2,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVGGDYYGMDVW,IGHV3-30-3,IGHJ3,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVGGDYYGMDVW,IGHV3-30-3,IGHJ4,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVGGDYYGMDVW,IGHV3-30-3,IGHJ5,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGYTGYDYFVGGDYYGMDVW,IGHV3-30-3,IGHJ6,CQTWGTGILVF,IGLV4-69,COV107_Plate2_HC_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ1,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_19-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ2,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_19-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ3,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_19-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ4,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_19-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ5,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_19-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ6,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_19-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ1,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ2,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ3,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ4,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ5,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVNPDDILTGVDAFDIW,IGHV3-33,IGHJ6,CQQHNSSPLTF,IGKV1-5,COV107_Plate1_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ1,CMQVLQIPYTF,IGKV2-28,COV107_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ2,CMQVLQIPYTF,IGKV2-28,COV107_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ3,CMQVLQIPYTF,IGKV2-28,COV107_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ4,CMQVLQIPYTF,IGKV2-28,COV107_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ5,CMQVLQIPYTF,IGKV2-28,COV107_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ6,CMQVLQIPYTF,IGKV2-28,COV107_Plate2_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ1,CMQVLQVPYTF,IGKV2-28,COV107_Plate2_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ2,CMQVLQVPYTF,IGKV2-28,COV107_Plate2_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ3,CMQVLQVPYTF,IGKV2-28,COV107_Plate2_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ4,CMQVLQVPYTF,IGKV2-28,COV107_Plate2_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ5,CMQVLQVPYTF,IGKV2-28,COV107_Plate2_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRWDGWSQHDYW,IGHV3-49,IGHJ6,CMQVLQVPYTF,IGKV2-28,COV107_Plate2_HC_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGMAAAGTW,IGHV3-53,IGHJ1,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGMAAAGTW,IGHV3-53,IGHJ2,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGMAAAGTW,IGHV3-53,IGHJ3,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGMAAAGTW,IGHV3-53,IGHJ4,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGMAAAGTW,IGHV3-53,IGHJ5,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGMAAAGTW,IGHV3-53,IGHJ6,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGIAAAGTW,IGHV3-53,IGHJ1,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGIAAAGTW,IGHV3-53,IGHJ2,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGIAAAGTW,IGHV3-53,IGHJ3,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGIAAAGTW,IGHV3-53,IGHJ4,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGIAAAGTW,IGHV3-53,IGHJ5,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGMGIAAAGTW,IGHV3-53,IGHJ6,CQQYDNLPQTF,IGKV1-33,COV107_Plate2_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDHW,IGHV3-53,IGHJ1,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_62-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDHW,IGHV3-53,IGHJ2,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_62-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDHW,IGHV3-53,IGHJ3,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_62-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDHW,IGHV3-53,IGHJ4,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_62-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDHW,IGHV3-53,IGHJ5,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_62-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDHW,IGHV3-53,IGHJ6,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_62-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDQW,IGHV3-53,IGHJ1,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDQW,IGHV3-53,IGHJ2,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDQW,IGHV3-53,IGHJ3,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDQW,IGHV3-53,IGHJ4,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDQW,IGHV3-53,IGHJ5,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDGELFFDQW,IGHV3-53,IGHJ6,CQSYDSSLYAVF,IGLV1-40,COV107_Plate1_HC_73-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ1,CNSYTSSSTRVF,IGLV2-14,COV107_Plate1_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ2,CNSYTSSSTRVF,IGLV2-14,COV107_Plate1_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ3,CNSYTSSSTRVF,IGLV2-14,COV107_Plate1_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ4,CNSYTSSSTRVF,IGLV2-14,COV107_Plate1_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ5,CNSYTSSSTRVF,IGLV2-14,COV107_Plate1_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ6,CNSYTSSSTRVF,IGLV2-14,COV107_Plate1_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ1,CNSYTSSSTRVF,IGLV2-14,COV107_Plate2_HC_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ2,CNSYTSSSTRVF,IGLV2-14,COV107_Plate2_HC_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ3,CNSYTSSSTRVF,IGLV2-14,COV107_Plate2_HC_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ4,CNSYTSSSTRVF,IGLV2-14,COV107_Plate2_HC_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ5,CNSYTSSSTRVF,IGLV2-14,COV107_Plate2_HC_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRDGGRPGDAFDIW,IGHV4-4,IGHJ6,CNSYTSSSTRVF,IGLV2-14,COV107_Plate2_HC_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ1,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ2,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ3,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ4,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ5,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ6,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ1,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ2,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ3,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ4,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ5,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVEDWGYCSSTNCYSGAFDIW,IGHV4-59,IGHJ6,CAAWDDSLNGAWVF,IGLV1-36,COV107_Plate2_HC_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ1,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate1_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ2,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate1_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ3,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate1_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ4,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate1_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ5,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate1_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ6,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate1_HC_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ1,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ2,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ3,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ4,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ5,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERPGGTYSNTWYTPTDTNWFDTW,IGHV4-61,IGHJ6,CQVWDSSRDHVVF,IGLV3-21,COV107_Plate2_HC_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ1,CQQYNSYPYTF,IGKV1-5,COV107_Plate1_HC_75-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ2,CQQYNSYPYTF,IGKV1-5,COV107_Plate1_HC_75-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ3,CQQYNSYPYTF,IGKV1-5,COV107_Plate1_HC_75-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ4,CQQYNSYPYTF,IGKV1-5,COV107_Plate1_HC_75-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ5,CQQYNSYPYTF,IGKV1-5,COV107_Plate1_HC_75-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ6,CQQYNSYPYTF,IGKV1-5,COV107_Plate1_HC_75-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ1,CQQYNSYPYTF,IGKV1-5,COV107_Plate2_HC_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ2,CQQYNSYPYTF,IGKV1-5,COV107_Plate2_HC_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ3,CQQYNSYPYTF,IGKV1-5,COV107_Plate2_HC_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ4,CQQYNSYPYTF,IGKV1-5,COV107_Plate2_HC_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ5,CQQYNSYPYTF,IGKV1-5,COV107_Plate2_HC_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSFRDDPRIAVAGPADAFDIW,IGHV5-51,IGHJ6,CQQYNSYPYTF,IGKV1-5,COV107_Plate2_HC_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAIAVAGTSGEFDYW,IGHV1-18,IGHJ1,CAAWDDSLNGHVVF,IGLV1-44,COV107_Plate1_HC_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAIAVAGTSGEFDYW,IGHV1-18,IGHJ2,CAAWDDSLNGHVVF,IGLV1-44,COV107_Plate1_HC_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAIAVAGTSGEFDYW,IGHV1-18,IGHJ3,CAAWDDSLNGHVVF,IGLV1-44,COV107_Plate1_HC_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAIAVAGTSGEFDYW,IGHV1-18,IGHJ4,CAAWDDSLNGHVVF,IGLV1-44,COV107_Plate1_HC_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAIAVAGTSGEFDYW,IGHV1-18,IGHJ5,CAAWDDSLNGHVVF,IGLV1-44,COV107_Plate1_HC_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAIAVAGTSGEFDYW,IGHV1-18,IGHJ6,CAAWDDSLNGHVVF,IGLV1-44,COV107_Plate1_HC_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSQGWLQLNDYW,IGHV1-18,IGHJ1,CQSYDSSTPNCVF,IGLV6-57,COV107_Plate1_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSQGWLQLNDYW,IGHV1-18,IGHJ2,CQSYDSSTPNCVF,IGLV6-57,COV107_Plate1_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSQGWLQLNDYW,IGHV1-18,IGHJ3,CQSYDSSTPNCVF,IGLV6-57,COV107_Plate1_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSQGWLQLNDYW,IGHV1-18,IGHJ4,CQSYDSSTPNCVF,IGLV6-57,COV107_Plate1_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSQGWLQLNDYW,IGHV1-18,IGHJ5,CQSYDSSTPNCVF,IGLV6-57,COV107_Plate1_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSQGWLQLNDYW,IGHV1-18,IGHJ6,CQSYDSSTPNCVF,IGLV6-57,COV107_Plate1_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGHARGVITGGDYFYYGMDVW,IGHV1-18,IGHJ1,CQQYGSSPTF,IGKV3-20,COV107_Plate1_HC_7-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGHARGVITGGDYFYYGMDVW,IGHV1-18,IGHJ2,CQQYGSSPTF,IGKV3-20,COV107_Plate1_HC_7-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGHARGVITGGDYFYYGMDVW,IGHV1-18,IGHJ3,CQQYGSSPTF,IGKV3-20,COV107_Plate1_HC_7-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGHARGVITGGDYFYYGMDVW,IGHV1-18,IGHJ4,CQQYGSSPTF,IGKV3-20,COV107_Plate1_HC_7-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGHARGVITGGDYFYYGMDVW,IGHV1-18,IGHJ5,CQQYGSSPTF,IGKV3-20,COV107_Plate1_HC_7-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGHARGVITGGDYFYYGMDVW,IGHV1-18,IGHJ6,CQQYGSSPTF,IGKV3-20,COV107_Plate1_HC_7-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPQINPYYDILTGYRAFDYW,IGHV1-2,IGHJ1,CQQYGSSLTF,IGKV3-20,COV107_Plate2_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPQINPYYDILTGYRAFDYW,IGHV1-2,IGHJ2,CQQYGSSLTF,IGKV3-20,COV107_Plate2_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPQINPYYDILTGYRAFDYW,IGHV1-2,IGHJ3,CQQYGSSLTF,IGKV3-20,COV107_Plate2_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPQINPYYDILTGYRAFDYW,IGHV1-2,IGHJ4,CQQYGSSLTF,IGKV3-20,COV107_Plate2_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPQINPYYDILTGYRAFDYW,IGHV1-2,IGHJ5,CQQYGSSLTF,IGKV3-20,COV107_Plate2_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPQINPYYDILTGYRAFDYW,IGHV1-2,IGHJ6,CQQYGSSLTF,IGKV3-20,COV107_Plate2_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGHDYVWGSYRYHNVW,IGHV1-2,IGHJ1,CSSYTSSSTLLF,IGLV2-14,COV107_Plate2_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGHDYVWGSYRYHNVW,IGHV1-2,IGHJ2,CSSYTSSSTLLF,IGLV2-14,COV107_Plate2_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGHDYVWGSYRYHNVW,IGHV1-2,IGHJ3,CSSYTSSSTLLF,IGLV2-14,COV107_Plate2_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGHDYVWGSYRYHNVW,IGHV1-2,IGHJ4,CSSYTSSSTLLF,IGLV2-14,COV107_Plate2_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGHDYVWGSYRYHNVW,IGHV1-2,IGHJ5,CSSYTSSSTLLF,IGLV2-14,COV107_Plate2_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGHDYVWGSYRYHNVW,IGHV1-2,IGHJ6,CSSYTSSSTLLF,IGLV2-14,COV107_Plate2_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAFSMVRAPGDYW,IGHV1-2,IGHJ1,CCSYAGSSTWVF,IGLV2-23,COV107_Plate1_HC_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAFSMVRAPGDYW,IGHV1-2,IGHJ2,CCSYAGSSTWVF,IGLV2-23,COV107_Plate1_HC_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAFSMVRAPGDYW,IGHV1-2,IGHJ3,CCSYAGSSTWVF,IGLV2-23,COV107_Plate1_HC_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAFSMVRAPGDYW,IGHV1-2,IGHJ4,CCSYAGSSTWVF,IGLV2-23,COV107_Plate1_HC_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAFSMVRAPGDYW,IGHV1-2,IGHJ5,CCSYAGSSTWVF,IGLV2-23,COV107_Plate1_HC_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLAFSMVRAPGDYW,IGHV1-2,IGHJ6,CCSYAGSSTWVF,IGLV2-23,COV107_Plate1_HC_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARELIAVAGIFDYW,IGHV1-2,IGHJ1,CQVWDSSWVF,IGLV3-21,COV107_Plate1_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARELIAVAGIFDYW,IGHV1-2,IGHJ2,CQVWDSSWVF,IGLV3-21,COV107_Plate1_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARELIAVAGIFDYW,IGHV1-2,IGHJ3,CQVWDSSWVF,IGLV3-21,COV107_Plate1_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARELIAVAGIFDYW,IGHV1-2,IGHJ4,CQVWDSSWVF,IGLV3-21,COV107_Plate1_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARELIAVAGIFDYW,IGHV1-2,IGHJ5,CQVWDSSWVF,IGLV3-21,COV107_Plate1_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARELIAVAGIFDYW,IGHV1-2,IGHJ6,CQVWDSSWVF,IGLV3-21,COV107_Plate1_HC_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPLFPTGVLAGDYYYYGMDVW,IGHV1-2,IGHJ1,CCSYAGSSTLVF,IGLV2-23,COV107_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPLFPTGVLAGDYYYYGMDVW,IGHV1-2,IGHJ2,CCSYAGSSTLVF,IGLV2-23,COV107_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPLFPTGVLAGDYYYYGMDVW,IGHV1-2,IGHJ3,CCSYAGSSTLVF,IGLV2-23,COV107_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPLFPTGVLAGDYYYYGMDVW,IGHV1-2,IGHJ4,CCSYAGSSTLVF,IGLV2-23,COV107_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPLFPTGVLAGDYYYYGMDVW,IGHV1-2,IGHJ5,CCSYAGSSTLVF,IGLV2-23,COV107_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPLFPTGVLAGDYYYYGMDVW,IGHV1-2,IGHJ6,CCSYAGSSTLVF,IGLV2-23,COV107_Plate2_HC_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYKGTTVNTNYYYGMDVW,IGHV1-2,IGHJ1,CQAWDSSTVVF,IGLV3-1,COV107_Plate1_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYKGTTVNTNYYYGMDVW,IGHV1-2,IGHJ2,CQAWDSSTVVF,IGLV3-1,COV107_Plate1_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYKGTTVNTNYYYGMDVW,IGHV1-2,IGHJ3,CQAWDSSTVVF,IGLV3-1,COV107_Plate1_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYKGTTVNTNYYYGMDVW,IGHV1-2,IGHJ4,CQAWDSSTVVF,IGLV3-1,COV107_Plate1_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYKGTTVNTNYYYGMDVW,IGHV1-2,IGHJ5,CQAWDSSTVVF,IGLV3-1,COV107_Plate1_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYKGTTVNTNYYYGMDVW,IGHV1-2,IGHJ6,CQAWDSSTVVF,IGLV3-1,COV107_Plate1_HC_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPRSPSDWCSGGSCYDDQNWFDPW,IGHV1-46,IGHJ1,CQQSYSTLITF,IGKV1-39,COV107_Plate1_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPRSPSDWCSGGSCYDDQNWFDPW,IGHV1-46,IGHJ2,CQQSYSTLITF,IGKV1-39,COV107_Plate1_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPRSPSDWCSGGSCYDDQNWFDPW,IGHV1-46,IGHJ3,CQQSYSTLITF,IGKV1-39,COV107_Plate1_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPRSPSDWCSGGSCYDDQNWFDPW,IGHV1-46,IGHJ4,CQQSYSTLITF,IGKV1-39,COV107_Plate1_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPRSPSDWCSGGSCYDDQNWFDPW,IGHV1-46,IGHJ5,CQQSYSTLITF,IGKV1-39,COV107_Plate1_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPRSPSDWCSGGSCYDDQNWFDPW,IGHV1-46,IGHJ6,CQQSYSTLITF,IGKV1-39,COV107_Plate1_HC_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFELWFGELRGWFDPW,IGHV1-46,IGHJ1,CQQYNNWPPITF,IGKV3-15,COV107_Plate1_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFELWFGELRGWFDPW,IGHV1-46,IGHJ2,CQQYNNWPPITF,IGKV3-15,COV107_Plate1_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFELWFGELRGWFDPW,IGHV1-46,IGHJ3,CQQYNNWPPITF,IGKV3-15,COV107_Plate1_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFELWFGELRGWFDPW,IGHV1-46,IGHJ4,CQQYNNWPPITF,IGKV3-15,COV107_Plate1_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFELWFGELRGWFDPW,IGHV1-46,IGHJ5,CQQYNNWPPITF,IGKV3-15,COV107_Plate1_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFELWFGELRGWFDPW,IGHV1-46,IGHJ6,CQQYNNWPPITF,IGKV3-15,COV107_Plate1_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSPIIARPGMGYWFDPW,IGHV1-46,IGHJ1,CQSYDSSLSAVVF,IGLV1-40,COV107_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSPIIARPGMGYWFDPW,IGHV1-46,IGHJ2,CQSYDSSLSAVVF,IGLV1-40,COV107_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSPIIARPGMGYWFDPW,IGHV1-46,IGHJ3,CQSYDSSLSAVVF,IGLV1-40,COV107_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSPIIARPGMGYWFDPW,IGHV1-46,IGHJ4,CQSYDSSLSAVVF,IGLV1-40,COV107_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSPIIARPGMGYWFDPW,IGHV1-46,IGHJ5,CQSYDSSLSAVVF,IGLV1-40,COV107_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSPIIARPGMGYWFDPW,IGHV1-46,IGHJ6,CQSYDSSLSAVVF,IGLV1-40,COV107_Plate2_HC_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASFHVAYGDYIPFDYW,IGHV1-69,IGHJ1,CQQYGRSPTWTF,IGKV3-20,COV107_Plate2_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASFHVAYGDYIPFDYW,IGHV1-69,IGHJ2,CQQYGRSPTWTF,IGKV3-20,COV107_Plate2_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASFHVAYGDYIPFDYW,IGHV1-69,IGHJ3,CQQYGRSPTWTF,IGKV3-20,COV107_Plate2_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASFHVAYGDYIPFDYW,IGHV1-69,IGHJ4,CQQYGRSPTWTF,IGKV3-20,COV107_Plate2_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASFHVAYGDYIPFDYW,IGHV1-69,IGHJ5,CQQYGRSPTWTF,IGKV3-20,COV107_Plate2_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASFHVAYGDYIPFDYW,IGHV1-69,IGHJ6,CQQYGRSPTWTF,IGKV3-20,COV107_Plate2_HC_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGLLTKNIVATIGCFDPW,IGHV1-69,IGHJ1,CQQYYSTPLTF,IGKV4-1,COV107_Plate1_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGLLTKNIVATIGCFDPW,IGHV1-69,IGHJ2,CQQYYSTPLTF,IGKV4-1,COV107_Plate1_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGLLTKNIVATIGCFDPW,IGHV1-69,IGHJ3,CQQYYSTPLTF,IGKV4-1,COV107_Plate1_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGLLTKNIVATIGCFDPW,IGHV1-69,IGHJ4,CQQYYSTPLTF,IGKV4-1,COV107_Plate1_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGLLTKNIVATIGCFDPW,IGHV1-69,IGHJ5,CQQYYSTPLTF,IGKV4-1,COV107_Plate1_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGLLTKNIVATIGCFDPW,IGHV1-69,IGHJ6,CQQYYSTPLTF,IGKV4-1,COV107_Plate1_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSGYYYVSNWFDPW,IGHV1-69,IGHJ1,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate1_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSGYYYVSNWFDPW,IGHV1-69,IGHJ2,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate1_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSGYYYVSNWFDPW,IGHV1-69,IGHJ3,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate1_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSGYYYVSNWFDPW,IGHV1-69,IGHJ4,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate1_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSGYYYVSNWFDPW,IGHV1-69,IGHJ5,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate1_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSGYYYVSNWFDPW,IGHV1-69,IGHJ6,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate1_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSSTSCYSHVGFDPW,IGHV1-8,IGHJ1,CQQLNSYPITF,IGKV1-9,COV107_Plate1_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSSTSCYSHVGFDPW,IGHV1-8,IGHJ2,CQQLNSYPITF,IGKV1-9,COV107_Plate1_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSSTSCYSHVGFDPW,IGHV1-8,IGHJ3,CQQLNSYPITF,IGKV1-9,COV107_Plate1_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSSTSCYSHVGFDPW,IGHV1-8,IGHJ4,CQQLNSYPITF,IGKV1-9,COV107_Plate1_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSSTSCYSHVGFDPW,IGHV1-8,IGHJ5,CQQLNSYPITF,IGKV1-9,COV107_Plate1_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSSTSCYSHVGFDPW,IGHV1-8,IGHJ6,CQQLNSYPITF,IGKV1-9,COV107_Plate1_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATYRSYLPLVQVDYW,IGHV3-11,IGHJ1,CQSYDSSKHAVF,IGLV6-57,COV107_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATYRSYLPLVQVDYW,IGHV3-11,IGHJ2,CQSYDSSKHAVF,IGLV6-57,COV107_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATYRSYLPLVQVDYW,IGHV3-11,IGHJ3,CQSYDSSKHAVF,IGLV6-57,COV107_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATYRSYLPLVQVDYW,IGHV3-11,IGHJ4,CQSYDSSKHAVF,IGLV6-57,COV107_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATYRSYLPLVQVDYW,IGHV3-11,IGHJ5,CQSYDSSKHAVF,IGLV6-57,COV107_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATYRSYLPLVQVDYW,IGHV3-11,IGHJ6,CQSYDSSKHAVF,IGLV6-57,COV107_Plate2_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRYDSSGYFWSLDYW,IGHV3-13,IGHJ1,CQQSYSTPQYTF,IGKV1-39,COV107_Plate2_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRYDSSGYFWSLDYW,IGHV3-13,IGHJ2,CQQSYSTPQYTF,IGKV1-39,COV107_Plate2_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRYDSSGYFWSLDYW,IGHV3-13,IGHJ3,CQQSYSTPQYTF,IGKV1-39,COV107_Plate2_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRYDSSGYFWSLDYW,IGHV3-13,IGHJ4,CQQSYSTPQYTF,IGKV1-39,COV107_Plate2_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRYDSSGYFWSLDYW,IGHV3-13,IGHJ5,CQQSYSTPQYTF,IGKV1-39,COV107_Plate2_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVRYDSSGYFWSLDYW,IGHV3-13,IGHJ6,CQQSYSTPQYTF,IGKV1-39,COV107_Plate2_HC_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVSGVVRGVIRSFYYYGLDVW,IGHV3-13,IGHJ1,CQQSYITPGWTF,IGKV1-39,COV107_Plate2_HC_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVSGVVRGVIRSFYYYGLDVW,IGHV3-13,IGHJ2,CQQSYITPGWTF,IGKV1-39,COV107_Plate2_HC_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVSGVVRGVIRSFYYYGLDVW,IGHV3-13,IGHJ3,CQQSYITPGWTF,IGKV1-39,COV107_Plate2_HC_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVSGVVRGVIRSFYYYGLDVW,IGHV3-13,IGHJ4,CQQSYITPGWTF,IGKV1-39,COV107_Plate2_HC_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVSGVVRGVIRSFYYYGLDVW,IGHV3-13,IGHJ5,CQQSYITPGWTF,IGKV1-39,COV107_Plate2_HC_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGVSGVVRGVIRSFYYYGLDVW,IGHV3-13,IGHJ6,CQQSYITPGWTF,IGKV1-39,COV107_Plate2_HC_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGQLLPFADYW,IGHV3-21,IGHJ1,CQSYDSSKSWVF,IGLV6-57,COV107_Plate2_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGQLLPFADYW,IGHV3-21,IGHJ2,CQSYDSSKSWVF,IGLV6-57,COV107_Plate2_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGQLLPFADYW,IGHV3-21,IGHJ3,CQSYDSSKSWVF,IGLV6-57,COV107_Plate2_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGQLLPFADYW,IGHV3-21,IGHJ4,CQSYDSSKSWVF,IGLV6-57,COV107_Plate2_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGQLLPFADYW,IGHV3-21,IGHJ5,CQSYDSSKSWVF,IGLV6-57,COV107_Plate2_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGQLLPFADYW,IGHV3-21,IGHJ6,CQSYDSSKSWVF,IGLV6-57,COV107_Plate2_HC_55-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRGSRGYYDRSGYYTPLDPYYGMDVW,IGHV3-21,IGHJ1,CQSYDSSLSGSYVF,IGLV1-40,COV107_Plate2_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRGSRGYYDRSGYYTPLDPYYGMDVW,IGHV3-21,IGHJ2,CQSYDSSLSGSYVF,IGLV1-40,COV107_Plate2_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRGSRGYYDRSGYYTPLDPYYGMDVW,IGHV3-21,IGHJ3,CQSYDSSLSGSYVF,IGLV1-40,COV107_Plate2_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRGSRGYYDRSGYYTPLDPYYGMDVW,IGHV3-21,IGHJ4,CQSYDSSLSGSYVF,IGLV1-40,COV107_Plate2_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRGSRGYYDRSGYYTPLDPYYGMDVW,IGHV3-21,IGHJ5,CQSYDSSLSGSYVF,IGLV1-40,COV107_Plate2_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRGSRGYYDRSGYYTPLDPYYGMDVW,IGHV3-21,IGHJ6,CQSYDSSLSGSYVF,IGLV1-40,COV107_Plate2_HC_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEVLPAVEYFQHW,IGHV3-23,IGHJ1,CQVWDGSSDHHVVF,IGLV3-21,COV107_Plate1_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEVLPAVEYFQHW,IGHV3-23,IGHJ2,CQVWDGSSDHHVVF,IGLV3-21,COV107_Plate1_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEVLPAVEYFQHW,IGHV3-23,IGHJ3,CQVWDGSSDHHVVF,IGLV3-21,COV107_Plate1_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEVLPAVEYFQHW,IGHV3-23,IGHJ4,CQVWDGSSDHHVVF,IGLV3-21,COV107_Plate1_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEVLPAVEYFQHW,IGHV3-23,IGHJ5,CQVWDGSSDHHVVF,IGLV3-21,COV107_Plate1_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEVLPAVEYFQHW,IGHV3-23,IGHJ6,CQVWDGSSDHHVVF,IGLV3-21,COV107_Plate1_HC_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVETNLWFGEDNYYYYYGMDVW,IGHV3-23,IGHJ1,CQQYGSSPPWTF,IGKV3-20,COV107_Plate1_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVETNLWFGEDNYYYYYGMDVW,IGHV3-23,IGHJ2,CQQYGSSPPWTF,IGKV3-20,COV107_Plate1_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVETNLWFGEDNYYYYYGMDVW,IGHV3-23,IGHJ3,CQQYGSSPPWTF,IGKV3-20,COV107_Plate1_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVETNLWFGEDNYYYYYGMDVW,IGHV3-23,IGHJ4,CQQYGSSPPWTF,IGKV3-20,COV107_Plate1_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVETNLWFGEDNYYYYYGMDVW,IGHV3-23,IGHJ5,CQQYGSSPPWTF,IGKV3-20,COV107_Plate1_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVETNLWFGEDNYYYYYGMDVW,IGHV3-23,IGHJ6,CQQYGSSPPWTF,IGKV3-20,COV107_Plate1_HC_80-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATGGGSYFSPRIYFDYW,IGHV3-30,IGHJ1,CQQYDNLPPYTF,IGKV1-33,COV107_Plate2_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATGGGSYFSPRIYFDYW,IGHV3-30,IGHJ2,CQQYDNLPPYTF,IGKV1-33,COV107_Plate2_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATGGGSYFSPRIYFDYW,IGHV3-30,IGHJ3,CQQYDNLPPYTF,IGKV1-33,COV107_Plate2_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATGGGSYFSPRIYFDYW,IGHV3-30,IGHJ4,CQQYDNLPPYTF,IGKV1-33,COV107_Plate2_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATGGGSYFSPRIYFDYW,IGHV3-30,IGHJ5,CQQYDNLPPYTF,IGKV1-33,COV107_Plate2_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATGGGSYFSPRIYFDYW,IGHV3-30,IGHJ6,CQQYDNLPPYTF,IGKV1-33,COV107_Plate2_HC_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGTCYPGTLDYW,IGHV3-30,IGHJ1,CQQYDNVPLTF,IGKV1-33,COV107_Plate2_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGTCYPGTLDYW,IGHV3-30,IGHJ2,CQQYDNVPLTF,IGKV1-33,COV107_Plate2_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGTCYPGTLDYW,IGHV3-30,IGHJ3,CQQYDNVPLTF,IGKV1-33,COV107_Plate2_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGTCYPGTLDYW,IGHV3-30,IGHJ4,CQQYDNVPLTF,IGKV1-33,COV107_Plate2_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGTCYPGTLDYW,IGHV3-30,IGHJ5,CQQYDNVPLTF,IGKV1-33,COV107_Plate2_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGTCYPGTLDYW,IGHV3-30,IGHJ6,CQQYDNVPLTF,IGKV1-33,COV107_Plate2_HC_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGYSYGYPQQYFDYW,IGHV3-30,IGHJ1,CQQYNSYSYTF,IGKV1-5,COV107_Plate1_HC_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGYSYGYPQQYFDYW,IGHV3-30,IGHJ2,CQQYNSYSYTF,IGKV1-5,COV107_Plate1_HC_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGYSYGYPQQYFDYW,IGHV3-30,IGHJ3,CQQYNSYSYTF,IGKV1-5,COV107_Plate1_HC_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGYSYGYPQQYFDYW,IGHV3-30,IGHJ4,CQQYNSYSYTF,IGKV1-5,COV107_Plate1_HC_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGYSYGYPQQYFDYW,IGHV3-30,IGHJ5,CQQYNSYSYTF,IGKV1-5,COV107_Plate1_HC_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGYSYGYPQQYFDYW,IGHV3-30,IGHJ6,CQQYNSYSYTF,IGKV1-5,COV107_Plate1_HC_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSLGPYCSGGNCYSSYFDYW,IGHV3-30,IGHJ1,CQQYNSYSTF,IGKV1-5,COV107_Plate2_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSLGPYCSGGNCYSSYFDYW,IGHV3-30,IGHJ2,CQQYNSYSTF,IGKV1-5,COV107_Plate2_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSLGPYCSGGNCYSSYFDYW,IGHV3-30,IGHJ3,CQQYNSYSTF,IGKV1-5,COV107_Plate2_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSLGPYCSGGNCYSSYFDYW,IGHV3-30,IGHJ4,CQQYNSYSTF,IGKV1-5,COV107_Plate2_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSLGPYCSGGNCYSSYFDYW,IGHV3-30,IGHJ5,CQQYNSYSTF,IGKV1-5,COV107_Plate2_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSLGPYCSGGNCYSSYFDYW,IGHV3-30,IGHJ6,CQQYNSYSTF,IGKV1-5,COV107_Plate2_HC_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGGGAYCGGDCYLGEFDYW,IGHV3-30,IGHJ1,CQQYGTSPSTF,IGKV3-20,COV107_Plate2_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGGGAYCGGDCYLGEFDYW,IGHV3-30,IGHJ2,CQQYGTSPSTF,IGKV3-20,COV107_Plate2_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGGGAYCGGDCYLGEFDYW,IGHV3-30,IGHJ3,CQQYGTSPSTF,IGKV3-20,COV107_Plate2_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGGGAYCGGDCYLGEFDYW,IGHV3-30,IGHJ4,CQQYGTSPSTF,IGKV3-20,COV107_Plate2_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGGGAYCGGDCYLGEFDYW,IGHV3-30,IGHJ5,CQQYGTSPSTF,IGKV3-20,COV107_Plate2_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKKGGGAYCGGDCYLGEFDYW,IGHV3-30,IGHJ6,CQQYGTSPSTF,IGKV3-20,COV107_Plate2_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYYYYNSDSYQAEIDYW,IGHV3-30,IGHJ1,CGTWDSSLSAFVF,IGLV1-51,COV107_Plate2_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYYYYNSDSYQAEIDYW,IGHV3-30,IGHJ2,CGTWDSSLSAFVF,IGLV1-51,COV107_Plate2_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYYYYNSDSYQAEIDYW,IGHV3-30,IGHJ3,CGTWDSSLSAFVF,IGLV1-51,COV107_Plate2_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYYYYNSDSYQAEIDYW,IGHV3-30,IGHJ4,CGTWDSSLSAFVF,IGLV1-51,COV107_Plate2_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYYYYNSDSYQAEIDYW,IGHV3-30,IGHJ5,CGTWDSSLSAFVF,IGLV1-51,COV107_Plate2_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYYYYNSDSYQAEIDYW,IGHV3-30,IGHJ6,CGTWDSSLSAFVF,IGLV1-51,COV107_Plate2_HC_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSWWLSENWFDPW,IGHV3-30,IGHJ1,CQQYNNWPLTF,IGKV3-15,COV107_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSWWLSENWFDPW,IGHV3-30,IGHJ2,CQQYNNWPLTF,IGKV3-15,COV107_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSWWLSENWFDPW,IGHV3-30,IGHJ3,CQQYNNWPLTF,IGKV3-15,COV107_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSWWLSENWFDPW,IGHV3-30,IGHJ4,CQQYNNWPLTF,IGKV3-15,COV107_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSWWLSENWFDPW,IGHV3-30,IGHJ5,CQQYNNWPLTF,IGKV3-15,COV107_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSWWLSENWFDPW,IGHV3-30,IGHJ6,CQQYNNWPLTF,IGKV3-15,COV107_Plate2_HC_76-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGLYDSSGYYPHYGMDVW,IGHV3-30,IGHJ1,CQQYDNLPLAF,IGKV1-33,COV107_Plate1_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGLYDSSGYYPHYGMDVW,IGHV3-30,IGHJ2,CQQYDNLPLAF,IGKV1-33,COV107_Plate1_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGLYDSSGYYPHYGMDVW,IGHV3-30,IGHJ3,CQQYDNLPLAF,IGKV1-33,COV107_Plate1_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGLYDSSGYYPHYGMDVW,IGHV3-30,IGHJ4,CQQYDNLPLAF,IGKV1-33,COV107_Plate1_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGLYDSSGYYPHYGMDVW,IGHV3-30,IGHJ5,CQQYDNLPLAF,IGKV1-33,COV107_Plate1_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGLYDSSGYYPHYGMDVW,IGHV3-30,IGHJ6,CQQYDNLPLAF,IGKV1-33,COV107_Plate1_HC_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLPFRDFFYYYMDVW,IGHV3-30,IGHJ1,CSSYTSSSTLGVF,IGLV2-14,COV107_Plate2_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLPFRDFFYYYMDVW,IGHV3-30,IGHJ2,CSSYTSSSTLGVF,IGLV2-14,COV107_Plate2_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLPFRDFFYYYMDVW,IGHV3-30,IGHJ3,CSSYTSSSTLGVF,IGLV2-14,COV107_Plate2_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLPFRDFFYYYMDVW,IGHV3-30,IGHJ4,CSSYTSSSTLGVF,IGLV2-14,COV107_Plate2_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLPFRDFFYYYMDVW,IGHV3-30,IGHJ5,CSSYTSSSTLGVF,IGLV2-14,COV107_Plate2_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPLPFRDFFYYYMDVW,IGHV3-30,IGHJ6,CSSYTSSSTLGVF,IGLV2-14,COV107_Plate2_HC_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQDLDTAMVTLFDYW,IGHV3-30-3,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV107_Plate1_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQDLDTAMVTLFDYW,IGHV3-30-3,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV107_Plate1_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQDLDTAMVTLFDYW,IGHV3-30-3,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV107_Plate1_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQDLDTAMVTLFDYW,IGHV3-30-3,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV107_Plate1_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQDLDTAMVTLFDYW,IGHV3-30-3,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV107_Plate1_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQDLDTAMVTLFDYW,IGHV3-30-3,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV107_Plate1_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPSQIVVVPVFDYW,IGHV3-30-3,IGHJ1,CQQSYSTLALTF,IGKV1-39,COV107_Plate1_HC_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPSQIVVVPVFDYW,IGHV3-30-3,IGHJ2,CQQSYSTLALTF,IGKV1-39,COV107_Plate1_HC_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPSQIVVVPVFDYW,IGHV3-30-3,IGHJ3,CQQSYSTLALTF,IGKV1-39,COV107_Plate1_HC_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPSQIVVVPVFDYW,IGHV3-30-3,IGHJ4,CQQSYSTLALTF,IGKV1-39,COV107_Plate1_HC_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPSQIVVVPVFDYW,IGHV3-30-3,IGHJ5,CQQSYSTLALTF,IGKV1-39,COV107_Plate1_HC_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPSQIVVVPVFDYW,IGHV3-30-3,IGHJ6,CQQSYSTLALTF,IGKV1-39,COV107_Plate1_HC_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETQGGYYGSGSYYASPFDPW,IGHV3-30-3,IGHJ1,CQVWDSSSDHPVVF,IGLV3-21,COV107_Plate2_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETQGGYYGSGSYYASPFDPW,IGHV3-30-3,IGHJ2,CQVWDSSSDHPVVF,IGLV3-21,COV107_Plate2_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETQGGYYGSGSYYASPFDPW,IGHV3-30-3,IGHJ3,CQVWDSSSDHPVVF,IGLV3-21,COV107_Plate2_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETQGGYYGSGSYYASPFDPW,IGHV3-30-3,IGHJ4,CQVWDSSSDHPVVF,IGLV3-21,COV107_Plate2_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETQGGYYGSGSYYASPFDPW,IGHV3-30-3,IGHJ5,CQVWDSSSDHPVVF,IGLV3-21,COV107_Plate2_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETQGGYYGSGSYYASPFDPW,IGHV3-30-3,IGHJ6,CQVWDSSSDHPVVF,IGLV3-21,COV107_Plate2_HC_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFYHNWFDPW,IGHV3-30-3,IGHJ1,CQSYDSSNQWVVF,IGLV6-57,COV107_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFYHNWFDPW,IGHV3-30-3,IGHJ2,CQSYDSSNQWVVF,IGLV6-57,COV107_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFYHNWFDPW,IGHV3-30-3,IGHJ3,CQSYDSSNQWVVF,IGLV6-57,COV107_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFYHNWFDPW,IGHV3-30-3,IGHJ4,CQSYDSSNQWVVF,IGLV6-57,COV107_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFYHNWFDPW,IGHV3-30-3,IGHJ5,CQSYDSSNQWVVF,IGLV6-57,COV107_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFYHNWFDPW,IGHV3-30-3,IGHJ6,CQSYDSSNQWVVF,IGLV6-57,COV107_Plate2_HC_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGLRLGGPKYYFDYW,IGHV3-33,IGHJ1,CSSYTSSSVVF,IGLV2-14,COV107_Plate2_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGLRLGGPKYYFDYW,IGHV3-33,IGHJ2,CSSYTSSSVVF,IGLV2-14,COV107_Plate2_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGLRLGGPKYYFDYW,IGHV3-33,IGHJ3,CSSYTSSSVVF,IGLV2-14,COV107_Plate2_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGLRLGGPKYYFDYW,IGHV3-33,IGHJ4,CSSYTSSSVVF,IGLV2-14,COV107_Plate2_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGLRLGGPKYYFDYW,IGHV3-33,IGHJ5,CSSYTSSSVVF,IGLV2-14,COV107_Plate2_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGLRLGGPKYYFDYW,IGHV3-33,IGHJ6,CSSYTSSSVVF,IGLV2-14,COV107_Plate2_HC_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGARVGATYDTYYFDYW,IGHV3-48,IGHJ1,CQQRNNWPPEWTF,IGKV3-11,COV107_Plate1_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGARVGATYDTYYFDYW,IGHV3-48,IGHJ2,CQQRNNWPPEWTF,IGKV3-11,COV107_Plate1_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGARVGATYDTYYFDYW,IGHV3-48,IGHJ3,CQQRNNWPPEWTF,IGKV3-11,COV107_Plate1_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGARVGATYDTYYFDYW,IGHV3-48,IGHJ4,CQQRNNWPPEWTF,IGKV3-11,COV107_Plate1_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGARVGATYDTYYFDYW,IGHV3-48,IGHJ5,CQQRNNWPPEWTF,IGKV3-11,COV107_Plate1_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGARVGATYDTYYFDYW,IGHV3-48,IGHJ6,CQQRNNWPPEWTF,IGKV3-11,COV107_Plate1_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAIRVVVPSATYYFDYW,IGHV3-48,IGHJ1,CQQRSNWPQGFTF,IGKV3-11,COV107_Plate2_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAIRVVVPSATYYFDYW,IGHV3-48,IGHJ2,CQQRSNWPQGFTF,IGKV3-11,COV107_Plate2_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAIRVVVPSATYYFDYW,IGHV3-48,IGHJ3,CQQRSNWPQGFTF,IGKV3-11,COV107_Plate2_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAIRVVVPSATYYFDYW,IGHV3-48,IGHJ4,CQQRSNWPQGFTF,IGKV3-11,COV107_Plate2_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAIRVVVPSATYYFDYW,IGHV3-48,IGHJ5,CQQRSNWPQGFTF,IGKV3-11,COV107_Plate2_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAIRVVVPSATYYFDYW,IGHV3-48,IGHJ6,CQQRSNWPQGFTF,IGKV3-11,COV107_Plate2_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPQRDPADYFDYW,IGHV3-48,IGHJ1,CQVWDSSRVF,IGLV3-21,COV107_Plate1_HC_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPQRDPADYFDYW,IGHV3-48,IGHJ2,CQVWDSSRVF,IGLV3-21,COV107_Plate1_HC_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPQRDPADYFDYW,IGHV3-48,IGHJ3,CQVWDSSRVF,IGLV3-21,COV107_Plate1_HC_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPQRDPADYFDYW,IGHV3-48,IGHJ4,CQVWDSSRVF,IGLV3-21,COV107_Plate1_HC_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPQRDPADYFDYW,IGHV3-48,IGHJ5,CQVWDSSRVF,IGLV3-21,COV107_Plate1_HC_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPQRDPADYFDYW,IGHV3-48,IGHJ6,CQVWDSSRVF,IGLV3-21,COV107_Plate1_HC_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGYCSSTSCYDGYYYYMDVW,IGHV3-48,IGHJ1,CQQSYSAPWTF,IGKV1-39,COV107_Plate2_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGYCSSTSCYDGYYYYMDVW,IGHV3-48,IGHJ2,CQQSYSAPWTF,IGKV1-39,COV107_Plate2_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGYCSSTSCYDGYYYYMDVW,IGHV3-48,IGHJ3,CQQSYSAPWTF,IGKV1-39,COV107_Plate2_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGYCSSTSCYDGYYYYMDVW,IGHV3-48,IGHJ4,CQQSYSAPWTF,IGKV1-39,COV107_Plate2_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGYCSSTSCYDGYYYYMDVW,IGHV3-48,IGHJ5,CQQSYSAPWTF,IGKV1-39,COV107_Plate2_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGYCSSTSCYDGYYYYMDVW,IGHV3-48,IGHJ6,CQQSYSAPWTF,IGKV1-39,COV107_Plate2_HC_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRGPGTFDIW,IGHV3-53,IGHJ1,CQQYDNLPRVTF,IGKV1-33,COV107_Plate1_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRGPGTFDIW,IGHV3-53,IGHJ2,CQQYDNLPRVTF,IGKV1-33,COV107_Plate1_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRGPGTFDIW,IGHV3-53,IGHJ3,CQQYDNLPRVTF,IGKV1-33,COV107_Plate1_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRGPGTFDIW,IGHV3-53,IGHJ4,CQQYDNLPRVTF,IGKV1-33,COV107_Plate1_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRGPGTFDIW,IGHV3-53,IGHJ5,CQQYDNLPRVTF,IGKV1-33,COV107_Plate1_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRGPGTFDIW,IGHV3-53,IGHJ6,CQQYDNLPRVTF,IGKV1-33,COV107_Plate1_HC_44-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVAAFDIW,IGHV3-53,IGHJ1,CQQLNSYPPGF,IGKV1-9,COV107_Plate1_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVAAFDIW,IGHV3-53,IGHJ2,CQQLNSYPPGF,IGKV1-9,COV107_Plate1_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVAAFDIW,IGHV3-53,IGHJ3,CQQLNSYPPGF,IGKV1-9,COV107_Plate1_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVAAFDIW,IGHV3-53,IGHJ4,CQQLNSYPPGF,IGKV1-9,COV107_Plate1_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVAAFDIW,IGHV3-53,IGHJ5,CQQLNSYPPGF,IGKV1-9,COV107_Plate1_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVAAFDIW,IGHV3-53,IGHJ6,CQQLNSYPPGF,IGKV1-9,COV107_Plate1_HC_88-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSAAFDIW,IGHV3-53,IGHJ1,CQQLNSYPPAF,IGKV1-9,COV107_Plate1_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSAAFDIW,IGHV3-53,IGHJ2,CQQLNSYPPAF,IGKV1-9,COV107_Plate1_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSAAFDIW,IGHV3-53,IGHJ3,CQQLNSYPPAF,IGKV1-9,COV107_Plate1_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSAAFDIW,IGHV3-53,IGHJ4,CQQLNSYPPAF,IGKV1-9,COV107_Plate1_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSAAFDIW,IGHV3-53,IGHJ5,CQQLNSYPPAF,IGKV1-9,COV107_Plate1_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSAAFDIW,IGHV3-53,IGHJ6,CQQLNSYPPAF,IGKV1-9,COV107_Plate1_HC_18-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMDGDYFDYW,IGHV3-53,IGHJ1,CQKYNSAPLTF,IGKV1-27,COV107_Plate1_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMDGDYFDYW,IGHV3-53,IGHJ2,CQKYNSAPLTF,IGKV1-27,COV107_Plate1_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMDGDYFDYW,IGHV3-53,IGHJ3,CQKYNSAPLTF,IGKV1-27,COV107_Plate1_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMDGDYFDYW,IGHV3-53,IGHJ4,CQKYNSAPLTF,IGKV1-27,COV107_Plate1_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMDGDYFDYW,IGHV3-53,IGHJ5,CQKYNSAPLTF,IGKV1-27,COV107_Plate1_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMDGDYFDYW,IGHV3-53,IGHJ6,CQKYNSAPLTF,IGKV1-27,COV107_Plate1_HC_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDIVVVPAARGFYFDYW,IGHV3-53,IGHJ1,CQQYNSYGTF,IGKV1-5,COV107_Plate1_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDIVVVPAARGFYFDYW,IGHV3-53,IGHJ2,CQQYNSYGTF,IGKV1-5,COV107_Plate1_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDIVVVPAARGFYFDYW,IGHV3-53,IGHJ3,CQQYNSYGTF,IGKV1-5,COV107_Plate1_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDIVVVPAARGFYFDYW,IGHV3-53,IGHJ4,CQQYNSYGTF,IGKV1-5,COV107_Plate1_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDIVVVPAARGFYFDYW,IGHV3-53,IGHJ5,CQQYNSYGTF,IGKV1-5,COV107_Plate1_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDIVVVPAARGFYFDYW,IGHV3-53,IGHJ6,CQQYNSYGTF,IGKV1-5,COV107_Plate1_HC_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESGDTTMAFDYW,IGHV3-53,IGHJ1,CQQLNSDSYTF,IGKV1-9,COV107_Plate1_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESGDTTMAFDYW,IGHV3-53,IGHJ2,CQQLNSDSYTF,IGKV1-9,COV107_Plate1_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESGDTTMAFDYW,IGHV3-53,IGHJ3,CQQLNSDSYTF,IGKV1-9,COV107_Plate1_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESGDTTMAFDYW,IGHV3-53,IGHJ4,CQQLNSDSYTF,IGKV1-9,COV107_Plate1_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESGDTTMAFDYW,IGHV3-53,IGHJ5,CQQLNSDSYTF,IGKV1-9,COV107_Plate1_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESGDTTMAFDYW,IGHV3-53,IGHJ6,CQQLNSDSYTF,IGKV1-9,COV107_Plate1_HC_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGTGLFDYW,IGHV3-53,IGHJ1,CQQLDSYPPGTF,IGKV1-9,COV107_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGTGLFDYW,IGHV3-53,IGHJ2,CQQLDSYPPGTF,IGKV1-9,COV107_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGTGLFDYW,IGHV3-53,IGHJ3,CQQLDSYPPGTF,IGKV1-9,COV107_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGTGLFDYW,IGHV3-53,IGHJ4,CQQLDSYPPGTF,IGKV1-9,COV107_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGTGLFDYW,IGHV3-53,IGHJ5,CQQLDSYPPGTF,IGKV1-9,COV107_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGTGLFDYW,IGHV3-53,IGHJ6,CQQLDSYPPGTF,IGKV1-9,COV107_Plate2_HC_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ1,CQQYYNWPRTF,IGKV3-15,COV107_Plate1_HC_82-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ2,CQQYYNWPRTF,IGKV3-15,COV107_Plate1_HC_82-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ3,CQQYYNWPRTF,IGKV3-15,COV107_Plate1_HC_82-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ4,CQQYYNWPRTF,IGKV3-15,COV107_Plate1_HC_82-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ5,CQQYYNWPRTF,IGKV3-15,COV107_Plate1_HC_82-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ6,CQQYYNWPRTF,IGKV3-15,COV107_Plate1_HC_82-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDLYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDLYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDLYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDLYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDLYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDLYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COV107_Plate2_HC_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATDLTSGRGPW,IGHV3-53,IGHJ1,CLQDYNYPKTF,IGKV1-6,COV107_Plate1_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATDLTSGRGPW,IGHV3-53,IGHJ2,CLQDYNYPKTF,IGKV1-6,COV107_Plate1_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATDLTSGRGPW,IGHV3-53,IGHJ3,CLQDYNYPKTF,IGKV1-6,COV107_Plate1_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATDLTSGRGPW,IGHV3-53,IGHJ4,CLQDYNYPKTF,IGKV1-6,COV107_Plate1_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATDLTSGRGPW,IGHV3-53,IGHJ5,CLQDYNYPKTF,IGKV1-6,COV107_Plate1_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATDLTSGRGPW,IGHV3-53,IGHJ6,CLQDYNYPKTF,IGKV1-6,COV107_Plate1_HC_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVWGMDVW,IGHV3-53,IGHJ1,CQLLNSYPYTF,IGKV1-9,COV107_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVWGMDVW,IGHV3-53,IGHJ2,CQLLNSYPYTF,IGKV1-9,COV107_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVWGMDVW,IGHV3-53,IGHJ3,CQLLNSYPYTF,IGKV1-9,COV107_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVWGMDVW,IGHV3-53,IGHJ4,CQLLNSYPYTF,IGKV1-9,COV107_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVWGMDVW,IGHV3-53,IGHJ5,CQLLNSYPYTF,IGKV1-9,COV107_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLVVWGMDVW,IGHV3-53,IGHJ6,CQLLNSYPYTF,IGKV1-9,COV107_Plate2_HC_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAIQLWLRGGYDYW,IGHV3-7,IGHJ1,CSSYAGSNNYVVF,IGLV2-8,COV107_Plate2_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAIQLWLRGGYDYW,IGHV3-7,IGHJ2,CSSYAGSNNYVVF,IGLV2-8,COV107_Plate2_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAIQLWLRGGYDYW,IGHV3-7,IGHJ3,CSSYAGSNNYVVF,IGLV2-8,COV107_Plate2_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAIQLWLRGGYDYW,IGHV3-7,IGHJ4,CSSYAGSNNYVVF,IGLV2-8,COV107_Plate2_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAIQLWLRGGYDYW,IGHV3-7,IGHJ5,CSSYAGSNNYVVF,IGLV2-8,COV107_Plate2_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAIQLWLRGGYDYW,IGHV3-7,IGHJ6,CSSYAGSNNYVVF,IGLV2-8,COV107_Plate2_HC_46-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAVQLWLRGNFDYW,IGHV3-7,IGHJ1,CQSYDSSNHVVF,IGLV6-57,COV107_Plate1_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAVQLWLRGNFDYW,IGHV3-7,IGHJ2,CQSYDSSNHVVF,IGLV6-57,COV107_Plate1_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAVQLWLRGNFDYW,IGHV3-7,IGHJ3,CQSYDSSNHVVF,IGLV6-57,COV107_Plate1_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAVQLWLRGNFDYW,IGHV3-7,IGHJ4,CQSYDSSNHVVF,IGLV6-57,COV107_Plate1_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAVQLWLRGNFDYW,IGHV3-7,IGHJ5,CQSYDSSNHVVF,IGLV6-57,COV107_Plate1_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAVQLWLRGNFDYW,IGHV3-7,IGHJ6,CQSYDSSNHVVF,IGLV6-57,COV107_Plate1_HC_32-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTKPHAHCGGDCYSRDWFDPW,IGHV3-73,IGHJ1,CQQSYSTPPFTF,IGKV1-39,COV107_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTKPHAHCGGDCYSRDWFDPW,IGHV3-73,IGHJ2,CQQSYSTPPFTF,IGKV1-39,COV107_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTKPHAHCGGDCYSRDWFDPW,IGHV3-73,IGHJ3,CQQSYSTPPFTF,IGKV1-39,COV107_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTKPHAHCGGDCYSRDWFDPW,IGHV3-73,IGHJ4,CQQSYSTPPFTF,IGKV1-39,COV107_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTKPHAHCGGDCYSRDWFDPW,IGHV3-73,IGHJ5,CQQSYSTPPFTF,IGKV1-39,COV107_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTKPHAHCGGDCYSRDWFDPW,IGHV3-73,IGHJ6,CQQSYSTPPFTF,IGKV1-39,COV107_Plate2_HC_9-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLIAELVGGGWYFDYW,IGHV3-9,IGHJ1,CQQRSNWPPLTF,IGKV3-11,COV107_Plate2_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLIAELVGGGWYFDYW,IGHV3-9,IGHJ2,CQQRSNWPPLTF,IGKV3-11,COV107_Plate2_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLIAELVGGGWYFDYW,IGHV3-9,IGHJ3,CQQRSNWPPLTF,IGKV3-11,COV107_Plate2_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLIAELVGGGWYFDYW,IGHV3-9,IGHJ4,CQQRSNWPPLTF,IGKV3-11,COV107_Plate2_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLIAELVGGGWYFDYW,IGHV3-9,IGHJ5,CQQRSNWPPLTF,IGKV3-11,COV107_Plate2_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGLIAELVGGGWYFDYW,IGHV3-9,IGHJ6,CQQRSNWPPLTF,IGKV3-11,COV107_Plate2_HC_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKALSSTGFLVVYFDYW,IGHV3-9,IGHJ1,CQQYNNWLSLTF,IGKV3-15,COV107_Plate1_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKALSSTGFLVVYFDYW,IGHV3-9,IGHJ2,CQQYNNWLSLTF,IGKV3-15,COV107_Plate1_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKALSSTGFLVVYFDYW,IGHV3-9,IGHJ3,CQQYNNWLSLTF,IGKV3-15,COV107_Plate1_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKALSSTGFLVVYFDYW,IGHV3-9,IGHJ4,CQQYNNWLSLTF,IGKV3-15,COV107_Plate1_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKALSSTGFLVVYFDYW,IGHV3-9,IGHJ5,CQQYNNWLSLTF,IGKV3-15,COV107_Plate1_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKALSSTGFLVVYFDYW,IGHV3-9,IGHJ6,CQQYNNWLSLTF,IGKV3-15,COV107_Plate1_HC_74-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDREGFGDYFDYW,IGHV3-9,IGHJ1,CQVWDSSSDHYVF,IGLV3-21,COV107_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDREGFGDYFDYW,IGHV3-9,IGHJ2,CQVWDSSSDHYVF,IGLV3-21,COV107_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDREGFGDYFDYW,IGHV3-9,IGHJ3,CQVWDSSSDHYVF,IGLV3-21,COV107_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDREGFGDYFDYW,IGHV3-9,IGHJ4,CQVWDSSSDHYVF,IGLV3-21,COV107_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDREGFGDYFDYW,IGHV3-9,IGHJ5,CQVWDSSSDHYVF,IGLV3-21,COV107_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDREGFGDYFDYW,IGHV3-9,IGHJ6,CQVWDSSSDHYVF,IGLV3-21,COV107_Plate2_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSLVRRNFYYYYMDVW,IGHV3-9,IGHJ1,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSLVRRNFYYYYMDVW,IGHV3-9,IGHJ2,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSLVRRNFYYYYMDVW,IGHV3-9,IGHJ3,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSLVRRNFYYYYMDVW,IGHV3-9,IGHJ4,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSLVRRNFYYYYMDVW,IGHV3-9,IGHJ5,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSLVRRNFYYYYMDVW,IGHV3-9,IGHJ6,CQSYDSSLSGVVF,IGLV1-40,COV107_Plate2_HC_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAWRYSSSWYTVDNKKGDYYFDYW,IGHV4-31,IGHJ1,CMQALQTPRTF,IGKV2-28,COV107_Plate1_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAWRYSSSWYTVDNKKGDYYFDYW,IGHV4-31,IGHJ2,CMQALQTPRTF,IGKV2-28,COV107_Plate1_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAWRYSSSWYTVDNKKGDYYFDYW,IGHV4-31,IGHJ3,CMQALQTPRTF,IGKV2-28,COV107_Plate1_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAWRYSSSWYTVDNKKGDYYFDYW,IGHV4-31,IGHJ4,CMQALQTPRTF,IGKV2-28,COV107_Plate1_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAWRYSSSWYTVDNKKGDYYFDYW,IGHV4-31,IGHJ5,CMQALQTPRTF,IGKV2-28,COV107_Plate1_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAWRYSSSWYTVDNKKGDYYFDYW,IGHV4-31,IGHJ6,CMQALQTPRTF,IGKV2-28,COV107_Plate1_HC_93-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGMYYDILTGYSEGAFDIW,IGHV4-39,IGHJ1,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGMYYDILTGYSEGAFDIW,IGHV4-39,IGHJ2,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGMYYDILTGYSEGAFDIW,IGHV4-39,IGHJ3,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGMYYDILTGYSEGAFDIW,IGHV4-39,IGHJ4,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGMYYDILTGYSEGAFDIW,IGHV4-39,IGHJ5,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGMYYDILTGYSEGAFDIW,IGHV4-39,IGHJ6,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTNPQWLDSTFDYW,IGHV4-39,IGHJ1,CSSYTSSSTYVF,IGLV2-14,COV107_Plate1_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTNPQWLDSTFDYW,IGHV4-39,IGHJ2,CSSYTSSSTYVF,IGLV2-14,COV107_Plate1_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTNPQWLDSTFDYW,IGHV4-39,IGHJ3,CSSYTSSSTYVF,IGLV2-14,COV107_Plate1_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTNPQWLDSTFDYW,IGHV4-39,IGHJ4,CSSYTSSSTYVF,IGLV2-14,COV107_Plate1_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTNPQWLDSTFDYW,IGHV4-39,IGHJ5,CSSYTSSSTYVF,IGLV2-14,COV107_Plate1_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAGGTNPQWLDSTFDYW,IGHV4-39,IGHJ6,CSSYTSSSTYVF,IGLV2-14,COV107_Plate1_HC_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAPYLNWNDWIFDYW,IGHV4-39,IGHJ1,CSSYTSSSTLVF,IGLV2-14,COV107_Plate1_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAPYLNWNDWIFDYW,IGHV4-39,IGHJ2,CSSYTSSSTLVF,IGLV2-14,COV107_Plate1_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAPYLNWNDWIFDYW,IGHV4-39,IGHJ3,CSSYTSSSTLVF,IGLV2-14,COV107_Plate1_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAPYLNWNDWIFDYW,IGHV4-39,IGHJ4,CSSYTSSSTLVF,IGLV2-14,COV107_Plate1_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAPYLNWNDWIFDYW,IGHV4-39,IGHJ5,CSSYTSSSTLVF,IGLV2-14,COV107_Plate1_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAPYLNWNDWIFDYW,IGHV4-39,IGHJ6,CSSYTSSSTLVF,IGLV2-14,COV107_Plate1_HC_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLQWLRGAFDIW,IGHV4-59,IGHJ1,CQSYDSSNLVF,IGLV6-57,COV107_Plate2_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLQWLRGAFDIW,IGHV4-59,IGHJ2,CQSYDSSNLVF,IGLV6-57,COV107_Plate2_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLQWLRGAFDIW,IGHV4-59,IGHJ3,CQSYDSSNLVF,IGLV6-57,COV107_Plate2_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLQWLRGAFDIW,IGHV4-59,IGHJ4,CQSYDSSNLVF,IGLV6-57,COV107_Plate2_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLQWLRGAFDIW,IGHV4-59,IGHJ5,CQSYDSSNLVF,IGLV6-57,COV107_Plate2_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLQWLRGAFDIW,IGHV4-59,IGHJ6,CQSYDSSNLVF,IGLV6-57,COV107_Plate2_HC_28-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGWGYDSSGYYFDYW,IGHV4-59,IGHJ1,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGWGYDSSGYYFDYW,IGHV4-59,IGHJ2,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGWGYDSSGYYFDYW,IGHV4-59,IGHJ3,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGWGYDSSGYYFDYW,IGHV4-59,IGHJ4,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGWGYDSSGYYFDYW,IGHV4-59,IGHJ5,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGWGYDSSGYYFDYW,IGHV4-59,IGHJ6,CCSYAGSSTWVF,IGLV2-23,COV107_Plate2_HC_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATTPFSGVDYW,IGHV4-59,IGHJ1,CQSYDTSNWVF,IGLV6-57,COV107_Plate2_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATTPFSGVDYW,IGHV4-59,IGHJ2,CQSYDTSNWVF,IGLV6-57,COV107_Plate2_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATTPFSGVDYW,IGHV4-59,IGHJ3,CQSYDTSNWVF,IGLV6-57,COV107_Plate2_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATTPFSGVDYW,IGHV4-59,IGHJ4,CQSYDTSNWVF,IGLV6-57,COV107_Plate2_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATTPFSGVDYW,IGHV4-59,IGHJ5,CQSYDTSNWVF,IGLV6-57,COV107_Plate2_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATTPFSGVDYW,IGHV4-59,IGHJ6,CQSYDTSNWVF,IGLV6-57,COV107_Plate2_HC_2-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARILRGVAENWFDPW,IGHV4-59,IGHJ1,CQVWDNNSDHRGVF,IGLV3-21,COV107_Plate2_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARILRGVAENWFDPW,IGHV4-59,IGHJ2,CQVWDNNSDHRGVF,IGLV3-21,COV107_Plate2_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARILRGVAENWFDPW,IGHV4-59,IGHJ3,CQVWDNNSDHRGVF,IGLV3-21,COV107_Plate2_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARILRGVAENWFDPW,IGHV4-59,IGHJ4,CQVWDNNSDHRGVF,IGLV3-21,COV107_Plate2_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARILRGVAENWFDPW,IGHV4-59,IGHJ5,CQVWDNNSDHRGVF,IGLV3-21,COV107_Plate2_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARILRGVAENWFDPW,IGHV4-59,IGHJ6,CQVWDNNSDHRGVF,IGLV3-21,COV107_Plate2_HC_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATRGGYYDSSGYYALAFDIW,IGHV4-61,IGHJ1,CSSYTSSSTVWVF,IGLV2-14,COV107_Plate1_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATRGGYYDSSGYYALAFDIW,IGHV4-61,IGHJ2,CSSYTSSSTVWVF,IGLV2-14,COV107_Plate1_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATRGGYYDSSGYYALAFDIW,IGHV4-61,IGHJ3,CSSYTSSSTVWVF,IGLV2-14,COV107_Plate1_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATRGGYYDSSGYYALAFDIW,IGHV4-61,IGHJ4,CSSYTSSSTVWVF,IGLV2-14,COV107_Plate1_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATRGGYYDSSGYYALAFDIW,IGHV4-61,IGHJ5,CSSYTSSSTVWVF,IGLV2-14,COV107_Plate1_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATRGGYYDSSGYYALAFDIW,IGHV4-61,IGHJ6,CSSYTSSSTVWVF,IGLV2-14,COV107_Plate1_HC_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHISSGWYDYW,IGHV5-10-1,IGHJ1,CQQYDNLPYTF,IGKV1-33,COV107_Plate1_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHISSGWYDYW,IGHV5-10-1,IGHJ2,CQQYDNLPYTF,IGKV1-33,COV107_Plate1_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHISSGWYDYW,IGHV5-10-1,IGHJ3,CQQYDNLPYTF,IGKV1-33,COV107_Plate1_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHISSGWYDYW,IGHV5-10-1,IGHJ4,CQQYDNLPYTF,IGKV1-33,COV107_Plate1_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHISSGWYDYW,IGHV5-10-1,IGHJ5,CQQYDNLPYTF,IGKV1-33,COV107_Plate1_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHISSGWYDYW,IGHV5-10-1,IGHJ6,CQQYDNLPYTF,IGKV1-33,COV107_Plate1_HC_45-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHRHPGITMIVALDYW,IGHV5-10-1,IGHJ1,CQQYDNVPLF,IGKV1-33,COV107_Plate1_HC_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHRHPGITMIVALDYW,IGHV5-10-1,IGHJ2,CQQYDNVPLF,IGKV1-33,COV107_Plate1_HC_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHRHPGITMIVALDYW,IGHV5-10-1,IGHJ3,CQQYDNVPLF,IGKV1-33,COV107_Plate1_HC_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHRHPGITMIVALDYW,IGHV5-10-1,IGHJ4,CQQYDNVPLF,IGKV1-33,COV107_Plate1_HC_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHRHPGITMIVALDYW,IGHV5-10-1,IGHJ5,CQQYDNVPLF,IGKV1-33,COV107_Plate1_HC_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHRHPGITMIVALDYW,IGHV5-10-1,IGHJ6,CQQYDNVPLF,IGKV1-33,COV107_Plate1_HC_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATETNSETTDMFTGYSFDPW,IGHV5-10-1,IGHJ1,CAAWDDSLSGYVF,IGLV1-44,COV107_Plate2_HC_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATETNSETTDMFTGYSFDPW,IGHV5-10-1,IGHJ2,CAAWDDSLSGYVF,IGLV1-44,COV107_Plate2_HC_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATETNSETTDMFTGYSFDPW,IGHV5-10-1,IGHJ3,CAAWDDSLSGYVF,IGLV1-44,COV107_Plate2_HC_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATETNSETTDMFTGYSFDPW,IGHV5-10-1,IGHJ4,CAAWDDSLSGYVF,IGLV1-44,COV107_Plate2_HC_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATETNSETTDMFTGYSFDPW,IGHV5-10-1,IGHJ5,CAAWDDSLSGYVF,IGLV1-44,COV107_Plate2_HC_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATETNSETTDMFTGYSFDPW,IGHV5-10-1,IGHJ6,CAAWDDSLSGYVF,IGLV1-44,COV107_Plate2_HC_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGPPGGVKLELTDYW,IGHV5-51,IGHJ1,CAAWDDSLNGPVVF,IGLV1-44,COV107_Plate2_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGPPGGVKLELTDYW,IGHV5-51,IGHJ2,CAAWDDSLNGPVVF,IGLV1-44,COV107_Plate2_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGPPGGVKLELTDYW,IGHV5-51,IGHJ3,CAAWDDSLNGPVVF,IGLV1-44,COV107_Plate2_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGPPGGVKLELTDYW,IGHV5-51,IGHJ4,CAAWDDSLNGPVVF,IGLV1-44,COV107_Plate2_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGPPGGVKLELTDYW,IGHV5-51,IGHJ5,CAAWDDSLNGPVVF,IGLV1-44,COV107_Plate2_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGPPGGVKLELTDYW,IGHV5-51,IGHJ6,CAAWDDSLNGPVVF,IGLV1-44,COV107_Plate2_HC_1-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLHPTYYDILTGYYIDYW,IGHV5-51,IGHJ1,CCLYAFSSIVF,IGLV2-23,COV107_Plate1_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLHPTYYDILTGYYIDYW,IGHV5-51,IGHJ2,CCLYAFSSIVF,IGLV2-23,COV107_Plate1_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLHPTYYDILTGYYIDYW,IGHV5-51,IGHJ3,CCLYAFSSIVF,IGLV2-23,COV107_Plate1_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLHPTYYDILTGYYIDYW,IGHV5-51,IGHJ4,CCLYAFSSIVF,IGLV2-23,COV107_Plate1_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLHPTYYDILTGYYIDYW,IGHV5-51,IGHJ5,CCLYAFSSIVF,IGLV2-23,COV107_Plate1_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLHPTYYDILTGYYIDYW,IGHV5-51,IGHJ6,CCLYAFSSIVF,IGLV2-23,COV107_Plate1_HC_92-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CALTTVTTGRWFDPW,IGHV5-51,IGHJ1,CMQGTHWLWTF,IGKV2-30,COV107_Plate1_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CALTTVTTGRWFDPW,IGHV5-51,IGHJ2,CMQGTHWLWTF,IGKV2-30,COV107_Plate1_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CALTTVTTGRWFDPW,IGHV5-51,IGHJ3,CMQGTHWLWTF,IGKV2-30,COV107_Plate1_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CALTTVTTGRWFDPW,IGHV5-51,IGHJ4,CMQGTHWLWTF,IGKV2-30,COV107_Plate1_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CALTTVTTGRWFDPW,IGHV5-51,IGHJ5,CMQGTHWLWTF,IGKV2-30,COV107_Plate1_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CALTTVTTGRWFDPW,IGHV5-51,IGHJ6,CMQGTHWLWTF,IGKV2-30,COV107_Plate1_HC_37-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPSSYSGWFDPW,IGHV5-51,IGHJ1,CAAWDDSLNGLVF,IGLV1-44,COV107_Plate1_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPSSYSGWFDPW,IGHV5-51,IGHJ2,CAAWDDSLNGLVF,IGLV1-44,COV107_Plate1_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPSSYSGWFDPW,IGHV5-51,IGHJ3,CAAWDDSLNGLVF,IGLV1-44,COV107_Plate1_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPSSYSGWFDPW,IGHV5-51,IGHJ4,CAAWDDSLNGLVF,IGLV1-44,COV107_Plate1_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPSSYSGWFDPW,IGHV5-51,IGHJ5,CAAWDDSLNGLVF,IGLV1-44,COV107_Plate1_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPSSYSGWFDPW,IGHV5-51,IGHJ6,CAAWDDSLNGLVF,IGLV1-44,COV107_Plate1_HC_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV096_HC_100-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV096_HC_100-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV096_HC_100-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV096_HC_100-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV096_HC_100-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV096_HC_100-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATERIAVAGTRMYNWFDPW,IGHV3-23,IGHJ1,CQQSYSAPPWTF,IGKV1-39,COV096_HC_164-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATERIAVAGTRMYNWFDPW,IGHV3-23,IGHJ2,CQQSYSAPPWTF,IGKV1-39,COV096_HC_164-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATERIAVAGTRMYNWFDPW,IGHV3-23,IGHJ3,CQQSYSAPPWTF,IGKV1-39,COV096_HC_164-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATERIAVAGTRMYNWFDPW,IGHV3-23,IGHJ4,CQQSYSAPPWTF,IGKV1-39,COV096_HC_164-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATERIAVAGTRMYNWFDPW,IGHV3-23,IGHJ5,CQQSYSAPPWTF,IGKV1-39,COV096_HC_164-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATERIAVAGTRMYNWFDPW,IGHV3-23,IGHJ6,CQQSYSAPPWTF,IGKV1-39,COV096_HC_164-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEEDYSNYVGWFDPW,IGHV3-23,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV096_HC_25-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEEDYSNYVGWFDPW,IGHV3-23,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV096_HC_25-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEEDYSNYVGWFDPW,IGHV3-23,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV096_HC_25-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEEDYSNYVGWFDPW,IGHV3-23,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV096_HC_25-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEEDYSNYVGWFDPW,IGHV3-23,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV096_HC_25-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEEDYSNYVGWFDPW,IGHV3-23,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV096_HC_25-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV096_HC_91-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV096_HC_91-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV096_HC_91-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV096_HC_91-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV096_HC_91-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESDCGSTSCYQVGWFDPW,IGHV3-23,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV096_HC_91-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ1,CQQYDNLPRSF,IGKV1-33,COV096_HC_115-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ2,CQQYDNLPRSF,IGKV1-33,COV096_HC_115-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ3,CQQYDNLPRSF,IGKV1-33,COV096_HC_115-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ4,CQQYDNLPRSF,IGKV1-33,COV096_HC_115-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ5,CQQYDNLPRSF,IGKV1-33,COV096_HC_115-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ6,CQQYDNLPRSF,IGKV1-33,COV096_HC_115-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTFGRGGDYW,IGHV3-66,IGHJ1,CQQYDNLPRSF,IGKV1-33,COV096_HC_133-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTFGRGGDYW,IGHV3-66,IGHJ2,CQQYDNLPRSF,IGKV1-33,COV096_HC_133-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTFGRGGDYW,IGHV3-66,IGHJ3,CQQYDNLPRSF,IGKV1-33,COV096_HC_133-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTFGRGGDYW,IGHV3-66,IGHJ4,CQQYDNLPRSF,IGKV1-33,COV096_HC_133-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTFGRGGDYW,IGHV3-66,IGHJ5,CQQYDNLPRSF,IGKV1-33,COV096_HC_133-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTFGRGGDYW,IGHV3-66,IGHJ6,CQQYDNLPRSF,IGKV1-33,COV096_HC_133-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ1,CQQYDNLPRSF,IGKV1-33,COV096_HC_34-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ2,CQQYDNLPRSF,IGKV1-33,COV096_HC_34-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ3,CQQYDNLPRSF,IGKV1-33,COV096_HC_34-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ4,CQQYDNLPRSF,IGKV1-33,COV096_HC_34-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ5,CQQYDNLPRSF,IGKV1-33,COV096_HC_34-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDTLGRGGDYW,IGHV3-66,IGHJ6,CQQYDNLPRSF,IGKV1-33,COV096_HC_34-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGVEYSSSSNFDYW,IGHV3-9,IGHJ1,CQQTNSFPLTF,IGKV1D-12,COV096_HC_106-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGVEYSSSSNFDYW,IGHV3-9,IGHJ2,CQQTNSFPLTF,IGKV1D-12,COV096_HC_106-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGVEYSSSSNFDYW,IGHV3-9,IGHJ3,CQQTNSFPLTF,IGKV1D-12,COV096_HC_106-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGVEYSSSSNFDYW,IGHV3-9,IGHJ4,CQQTNSFPLTF,IGKV1D-12,COV096_HC_106-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGVEYSSSSNFDYW,IGHV3-9,IGHJ5,CQQTNSFPLTF,IGKV1D-12,COV096_HC_106-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGVEYSSSSNFDYW,IGHV3-9,IGHJ6,CQQTNSFPLTF,IGKV1D-12,COV096_HC_106-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ1,CQQTNSFPLTF,IGKV1D-12,COV096_HC_132-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ2,CQQTNSFPLTF,IGKV1D-12,COV096_HC_132-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ3,CQQTNSFPLTF,IGKV1D-12,COV096_HC_132-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ4,CQQTNSFPLTF,IGKV1D-12,COV096_HC_132-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ5,CQQTNSFPLTF,IGKV1D-12,COV096_HC_132-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ6,CQQTNSFPLTF,IGKV1D-12,COV096_HC_132-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ1,CQQANSFPLTF,IGKV1D-12,COV096_HC_6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ2,CQQANSFPLTF,IGKV1D-12,COV096_HC_6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ3,CQQANSFPLTF,IGKV1D-12,COV096_HC_6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ4,CQQANSFPLTF,IGKV1D-12,COV096_HC_6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ5,CQQANSFPLTF,IGKV1D-12,COV096_HC_6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVKGVEYSSSSNFDYW,IGHV3-9,IGHJ6,CQQANSFPLTF,IGKV1D-12,COV096_HC_6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYFDLGGMDVW,IGHV1-2,IGHJ1,CCSYAGSSTRLF,IGLV2-23,COV096_HC_116-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYFDLGGMDVW,IGHV1-2,IGHJ2,CCSYAGSSTRLF,IGLV2-23,COV096_HC_116-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYFDLGGMDVW,IGHV1-2,IGHJ3,CCSYAGSSTRLF,IGLV2-23,COV096_HC_116-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYFDLGGMDVW,IGHV1-2,IGHJ4,CCSYAGSSTRLF,IGLV2-23,COV096_HC_116-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYFDLGGMDVW,IGHV1-2,IGHJ5,CCSYAGSSTRLF,IGLV2-23,COV096_HC_116-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYFDLGGMDVW,IGHV1-2,IGHJ6,CCSYAGSSTRLF,IGLV2-23,COV096_HC_116-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPYFDLGGMDVW,IGHV1-2,IGHJ1,CCSYAGSSTRVF,IGLV2-23,COV096_HC_77-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPYFDLGGMDVW,IGHV1-2,IGHJ2,CCSYAGSSTRVF,IGLV2-23,COV096_HC_77-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPYFDLGGMDVW,IGHV1-2,IGHJ3,CCSYAGSSTRVF,IGLV2-23,COV096_HC_77-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPYFDLGGMDVW,IGHV1-2,IGHJ4,CCSYAGSSTRVF,IGLV2-23,COV096_HC_77-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPYFDLGGMDVW,IGHV1-2,IGHJ5,CCSYAGSSTRVF,IGLV2-23,COV096_HC_77-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREPYFDLGGMDVW,IGHV1-2,IGHJ6,CCSYAGSSTRVF,IGLV2-23,COV096_HC_77-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ1,CQVWDSTGGHPDVVF,IGLV3-21,COV096_HC_138-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ2,CQVWDSTGGHPDVVF,IGLV3-21,COV096_HC_138-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ3,CQVWDSTGGHPDVVF,IGLV3-21,COV096_HC_138-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ4,CQVWDSTGGHPDVVF,IGLV3-21,COV096_HC_138-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ5,CQVWDSTGGHPDVVF,IGLV3-21,COV096_HC_138-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ6,CQVWDSTGGHPDVVF,IGLV3-21,COV096_HC_138-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ1,CQVWDSTSDHPDVVF,IGLV3-21,COV096_HC_176-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ2,CQVWDSTSDHPDVVF,IGLV3-21,COV096_HC_176-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ3,CQVWDSTSDHPDVVF,IGLV3-21,COV096_HC_176-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ4,CQVWDSTSDHPDVVF,IGLV3-21,COV096_HC_176-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ5,CQVWDSTSDHPDVVF,IGLV3-21,COV096_HC_176-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGFSLTWYFDLW,IGHV1-8,IGHJ6,CQVWDSTSDHPDVVF,IGLV3-21,COV096_HC_176-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ1,CQSYDSINWVF,IGLV6-57,COV096_HC_104-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ2,CQSYDSINWVF,IGLV6-57,COV096_HC_104-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ3,CQSYDSINWVF,IGLV6-57,COV096_HC_104-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ4,CQSYDSINWVF,IGLV6-57,COV096_HC_104-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ5,CQSYDSINWVF,IGLV6-57,COV096_HC_104-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ6,CQSYDSINWVF,IGLV6-57,COV096_HC_104-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ1,CQSYDRINWVF,IGLV6-57,COV096_HC_111-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ2,CQSYDRINWVF,IGLV6-57,COV096_HC_111-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ3,CQSYDRINWVF,IGLV6-57,COV096_HC_111-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ4,CQSYDRINWVF,IGLV6-57,COV096_HC_111-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ5,CQSYDRINWVF,IGLV6-57,COV096_HC_111-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVGARGWVDYW,IGHV3-21,IGHJ6,CQSYDRINWVF,IGLV6-57,COV096_HC_111-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ1,CQQRSNWPRGF,IGKV3-11,COV096_HC_158-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ2,CQQRSNWPRGF,IGKV3-11,COV096_HC_158-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ3,CQQRSNWPRGF,IGKV3-11,COV096_HC_158-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ4,CQQRSNWPRGF,IGKV3-11,COV096_HC_158-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ5,CQQRSNWPRGF,IGKV3-11,COV096_HC_158-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ6,CQQRSNWPRGF,IGKV3-11,COV096_HC_158-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ1,CQQRSNWPRGF,IGKV3-11,COV096_HC_78-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ2,CQQRSNWPRGF,IGKV3-11,COV096_HC_78-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ3,CQQRSNWPRGF,IGKV3-11,COV096_HC_78-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ4,CQQRSNWPRGF,IGKV3-11,COV096_HC_78-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ5,CQQRSNWPRGF,IGKV3-11,COV096_HC_78-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEPIGQPLLWWDYW,IGHV3-23,IGHJ6,CQQRSNWPRGF,IGKV3-11,COV096_HC_78-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ1,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_130-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ2,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_130-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ3,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_130-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ4,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_130-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ5,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_130-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ6,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_130-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ1,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_44-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ2,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_44-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ3,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_44-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ4,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_44-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ5,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_44-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSGWTRPLDYW,IGHV3-9,IGHJ6,CQVWDSSSDPVVF,IGLV3-21,COV096_HC_44-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPRDYYDRSGYYYVPGYFDYW,IGHV1-18,IGHJ1,CQQYDNLPLTF,IGKV1-33,COV096_HC_72-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPRDYYDRSGYYYVPGYFDYW,IGHV1-18,IGHJ2,CQQYDNLPLTF,IGKV1-33,COV096_HC_72-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPRDYYDRSGYYYVPGYFDYW,IGHV1-18,IGHJ3,CQQYDNLPLTF,IGKV1-33,COV096_HC_72-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPRDYYDRSGYYYVPGYFDYW,IGHV1-18,IGHJ4,CQQYDNLPLTF,IGKV1-33,COV096_HC_72-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPRDYYDRSGYYYVPGYFDYW,IGHV1-18,IGHJ5,CQQYDNLPLTF,IGKV1-33,COV096_HC_72-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRPRDYYDRSGYYYVPGYFDYW,IGHV1-18,IGHJ6,CQQYDNLPLTF,IGKV1-33,COV096_HC_72-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRVEDNGDDGGDYYYYYGMDVW,IGHV1-18,IGHJ1,CQSADSSGTLVVF,IGLV3-25,COV096_HC_90-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRVEDNGDDGGDYYYYYGMDVW,IGHV1-18,IGHJ2,CQSADSSGTLVVF,IGLV3-25,COV096_HC_90-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRVEDNGDDGGDYYYYYGMDVW,IGHV1-18,IGHJ3,CQSADSSGTLVVF,IGLV3-25,COV096_HC_90-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRVEDNGDDGGDYYYYYGMDVW,IGHV1-18,IGHJ4,CQSADSSGTLVVF,IGLV3-25,COV096_HC_90-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRVEDNGDDGGDYYYYYGMDVW,IGHV1-18,IGHJ5,CQSADSSGTLVVF,IGLV3-25,COV096_HC_90-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRVEDNGDDGGDYYYYYGMDVW,IGHV1-18,IGHJ6,CQSADSSGTLVVF,IGLV3-25,COV096_HC_90-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLEYCSSTSCYTSTTFDYW,IGHV1-2,IGHJ1,CQVWDYGVVF,IGLV3-21,COV096_HC_71-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLEYCSSTSCYTSTTFDYW,IGHV1-2,IGHJ2,CQVWDYGVVF,IGLV3-21,COV096_HC_71-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLEYCSSTSCYTSTTFDYW,IGHV1-2,IGHJ3,CQVWDYGVVF,IGLV3-21,COV096_HC_71-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLEYCSSTSCYTSTTFDYW,IGHV1-2,IGHJ4,CQVWDYGVVF,IGLV3-21,COV096_HC_71-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLEYCSSTSCYTSTTFDYW,IGHV1-2,IGHJ5,CQVWDYGVVF,IGLV3-21,COV096_HC_71-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLEYCSSTSCYTSTTFDYW,IGHV1-2,IGHJ6,CQVWDYGVVF,IGLV3-21,COV096_HC_71-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGIGHNWNYVSTPNGMDVW,IGHV1-2,IGHJ1,CQSYDSGVVF,IGLV6-57,COV096_HC_52-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGIGHNWNYVSTPNGMDVW,IGHV1-2,IGHJ2,CQSYDSGVVF,IGLV6-57,COV096_HC_52-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGIGHNWNYVSTPNGMDVW,IGHV1-2,IGHJ3,CQSYDSGVVF,IGLV6-57,COV096_HC_52-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGIGHNWNYVSTPNGMDVW,IGHV1-2,IGHJ4,CQSYDSGVVF,IGLV6-57,COV096_HC_52-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGIGHNWNYVSTPNGMDVW,IGHV1-2,IGHJ5,CQSYDSGVVF,IGLV6-57,COV096_HC_52-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGIGHNWNYVSTPNGMDVW,IGHV1-2,IGHJ6,CQSYDSGVVF,IGLV6-57,COV096_HC_52-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFAMGTVTGTFVYW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,COV096_HC_10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFAMGTVTGTFVYW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,COV096_HC_10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFAMGTVTGTFVYW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,COV096_HC_10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFAMGTVTGTFVYW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,COV096_HC_10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFAMGTVTGTFVYW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,COV096_HC_10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFAMGTVTGTFVYW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,COV096_HC_10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKVATMFALPPYGMDVW,IGHV1-2,IGHJ1,CQQRSNWPPIAF,IGKV3-11,COV096_HC_4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKVATMFALPPYGMDVW,IGHV1-2,IGHJ2,CQQRSNWPPIAF,IGKV3-11,COV096_HC_4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKVATMFALPPYGMDVW,IGHV1-2,IGHJ3,CQQRSNWPPIAF,IGKV3-11,COV096_HC_4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKVATMFALPPYGMDVW,IGHV1-2,IGHJ4,CQQRSNWPPIAF,IGKV3-11,COV096_HC_4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKVATMFALPPYGMDVW,IGHV1-2,IGHJ5,CQQRSNWPPIAF,IGKV3-11,COV096_HC_4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKVATMFALPPYGMDVW,IGHV1-2,IGHJ6,CQQRSNWPPIAF,IGKV3-11,COV096_HC_4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPLLPGETGSLNRLDYW,IGHV1-46,IGHJ1,CQQSYSTLWTF,IGKV1-39,COV096_HC_127-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPLLPGETGSLNRLDYW,IGHV1-46,IGHJ2,CQQSYSTLWTF,IGKV1-39,COV096_HC_127-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPLLPGETGSLNRLDYW,IGHV1-46,IGHJ3,CQQSYSTLWTF,IGKV1-39,COV096_HC_127-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPLLPGETGSLNRLDYW,IGHV1-46,IGHJ4,CQQSYSTLWTF,IGKV1-39,COV096_HC_127-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPLLPGETGSLNRLDYW,IGHV1-46,IGHJ5,CQQSYSTLWTF,IGKV1-39,COV096_HC_127-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPLLPGETGSLNRLDYW,IGHV1-46,IGHJ6,CQQSYSTLWTF,IGKV1-39,COV096_HC_127-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGVGGTSYFDYW,IGHV1-46,IGHJ1,CQVWDSSSDPYVF,IGLV3-21,COV096_HC_2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGVGGTSYFDYW,IGHV1-46,IGHJ2,CQVWDSSSDPYVF,IGLV3-21,COV096_HC_2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGVGGTSYFDYW,IGHV1-46,IGHJ3,CQVWDSSSDPYVF,IGLV3-21,COV096_HC_2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGVGGTSYFDYW,IGHV1-46,IGHJ4,CQVWDSSSDPYVF,IGLV3-21,COV096_HC_2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGVGGTSYFDYW,IGHV1-46,IGHJ5,CQVWDSSSDPYVF,IGLV3-21,COV096_HC_2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGVGGTSYFDYW,IGHV1-46,IGHJ6,CQVWDSSSDPYVF,IGLV3-21,COV096_HC_2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPERGIVGATDYFDYW,IGHV1-46,IGHJ1,CQQYVSSPWTF,IGKV3-20,COV096_HC_113-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPERGIVGATDYFDYW,IGHV1-46,IGHJ2,CQQYVSSPWTF,IGKV3-20,COV096_HC_113-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPERGIVGATDYFDYW,IGHV1-46,IGHJ3,CQQYVSSPWTF,IGKV3-20,COV096_HC_113-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPERGIVGATDYFDYW,IGHV1-46,IGHJ4,CQQYVSSPWTF,IGKV3-20,COV096_HC_113-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPERGIVGATDYFDYW,IGHV1-46,IGHJ5,CQQYVSSPWTF,IGKV3-20,COV096_HC_113-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPERGIVGATDYFDYW,IGHV1-46,IGHJ6,CQQYVSSPWTF,IGKV3-20,COV096_HC_113-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEWEIFGFDYW,IGHV1-69,IGHJ1,CQQSYSTPWTF,IGKV1-39,COV096_HC_153-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEWEIFGFDYW,IGHV1-69,IGHJ2,CQQSYSTPWTF,IGKV1-39,COV096_HC_153-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEWEIFGFDYW,IGHV1-69,IGHJ3,CQQSYSTPWTF,IGKV1-39,COV096_HC_153-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEWEIFGFDYW,IGHV1-69,IGHJ4,CQQSYSTPWTF,IGKV1-39,COV096_HC_153-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEWEIFGFDYW,IGHV1-69,IGHJ5,CQQSYSTPWTF,IGKV1-39,COV096_HC_153-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASEWEIFGFDYW,IGHV1-69,IGHJ6,CQQSYSTPWTF,IGKV1-39,COV096_HC_153-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSGQGAGVNRGVVITTLGYW,IGHV1-69,IGHJ1,CQQYYSTPCSF,IGKV4-1,COV096_HC_55-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSGQGAGVNRGVVITTLGYW,IGHV1-69,IGHJ2,CQQYYSTPCSF,IGKV4-1,COV096_HC_55-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSGQGAGVNRGVVITTLGYW,IGHV1-69,IGHJ3,CQQYYSTPCSF,IGKV4-1,COV096_HC_55-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSGQGAGVNRGVVITTLGYW,IGHV1-69,IGHJ4,CQQYYSTPCSF,IGKV4-1,COV096_HC_55-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSGQGAGVNRGVVITTLGYW,IGHV1-69,IGHJ5,CQQYYSTPCSF,IGKV4-1,COV096_HC_55-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSGQGAGVNRGVVITTLGYW,IGHV1-69,IGHJ6,CQQYYSTPCSF,IGKV4-1,COV096_HC_55-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDDGQQLWSYFDYW,IGHV1-69,IGHJ1,CQQYYSTLPLTF,IGKV4-1,COV096_HC_42-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDDGQQLWSYFDYW,IGHV1-69,IGHJ2,CQQYYSTLPLTF,IGKV4-1,COV096_HC_42-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDDGQQLWSYFDYW,IGHV1-69,IGHJ3,CQQYYSTLPLTF,IGKV4-1,COV096_HC_42-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDDGQQLWSYFDYW,IGHV1-69,IGHJ4,CQQYYSTLPLTF,IGKV4-1,COV096_HC_42-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDDGQQLWSYFDYW,IGHV1-69,IGHJ5,CQQYYSTLPLTF,IGKV4-1,COV096_HC_42-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDDGQQLWSYFDYW,IGHV1-69,IGHJ6,CQQYYSTLPLTF,IGKV4-1,COV096_HC_42-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLSGHFPHNWFDPW,IGHV1-69,IGHJ1,CQSYDSSLRGVF,IGLV1-40,COV096_HC_30-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLSGHFPHNWFDPW,IGHV1-69,IGHJ2,CQSYDSSLRGVF,IGLV1-40,COV096_HC_30-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLSGHFPHNWFDPW,IGHV1-69,IGHJ3,CQSYDSSLRGVF,IGLV1-40,COV096_HC_30-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLSGHFPHNWFDPW,IGHV1-69,IGHJ4,CQSYDSSLRGVF,IGLV1-40,COV096_HC_30-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLSGHFPHNWFDPW,IGHV1-69,IGHJ5,CQSYDSSLRGVF,IGLV1-40,COV096_HC_30-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLSGHFPHNWFDPW,IGHV1-69,IGHJ6,CQSYDSSLRGVF,IGLV1-40,COV096_HC_30-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARREAYGPRDYYYYYGMDVW,IGHV1-69,IGHJ1,CGADQGSGSNFVGVF,IGLV9-49,COV096_HC_136-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARREAYGPRDYYYYYGMDVW,IGHV1-69,IGHJ2,CGADQGSGSNFVGVF,IGLV9-49,COV096_HC_136-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARREAYGPRDYYYYYGMDVW,IGHV1-69,IGHJ3,CGADQGSGSNFVGVF,IGLV9-49,COV096_HC_136-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARREAYGPRDYYYYYGMDVW,IGHV1-69,IGHJ4,CGADQGSGSNFVGVF,IGLV9-49,COV096_HC_136-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARREAYGPRDYYYYYGMDVW,IGHV1-69,IGHJ5,CGADQGSGSNFVGVF,IGLV9-49,COV096_HC_136-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARREAYGPRDYYYYYGMDVW,IGHV1-69,IGHJ6,CGADQGSGSNFVGVF,IGLV9-49,COV096_HC_136-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGYYDSSGSNDAFDIW,IGHV1-69,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,COV096_HC_99-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGYYDSSGSNDAFDIW,IGHV1-69,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,COV096_HC_99-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGYYDSSGSNDAFDIW,IGHV1-69,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,COV096_HC_99-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGYYDSSGSNDAFDIW,IGHV1-69,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,COV096_HC_99-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGYYDSSGSNDAFDIW,IGHV1-69,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,COV096_HC_99-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLGYYDSSGSNDAFDIW,IGHV1-69,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,COV096_HC_99-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSDVSCYSGTGFDYW,IGHV1-8,IGHJ1,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_152-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSDVSCYSGTGFDYW,IGHV1-8,IGHJ2,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_152-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSDVSCYSGTGFDYW,IGHV1-8,IGHJ3,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_152-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSDVSCYSGTGFDYW,IGHV1-8,IGHJ4,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_152-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSDVSCYSGTGFDYW,IGHV1-8,IGHJ5,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_152-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYCSDVSCYSGTGFDYW,IGHV1-8,IGHJ6,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_152-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLPPRRFDIW,IGHV3-11,IGHJ1,CQQFDNLPITF,IGKV1-33,COV096_HC_156-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLPPRRFDIW,IGHV3-11,IGHJ2,CQQFDNLPITF,IGKV1-33,COV096_HC_156-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLPPRRFDIW,IGHV3-11,IGHJ3,CQQFDNLPITF,IGKV1-33,COV096_HC_156-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLPPRRFDIW,IGHV3-11,IGHJ4,CQQFDNLPITF,IGKV1-33,COV096_HC_156-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLPPRRFDIW,IGHV3-11,IGHJ5,CQQFDNLPITF,IGKV1-33,COV096_HC_156-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLPPRRFDIW,IGHV3-11,IGHJ6,CQQFDNLPITF,IGKV1-33,COV096_HC_156-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDSGSYLGVWYFDLW,IGHV3-13,IGHJ1,CQQSYSSPPITF,IGKV1-39,COV096_HC_137-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDSGSYLGVWYFDLW,IGHV3-13,IGHJ2,CQQSYSSPPITF,IGKV1-39,COV096_HC_137-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDSGSYLGVWYFDLW,IGHV3-13,IGHJ3,CQQSYSSPPITF,IGKV1-39,COV096_HC_137-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDSGSYLGVWYFDLW,IGHV3-13,IGHJ4,CQQSYSSPPITF,IGKV1-39,COV096_HC_137-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDSGSYLGVWYFDLW,IGHV3-13,IGHJ5,CQQSYSSPPITF,IGKV1-39,COV096_HC_137-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDSGSYLGVWYFDLW,IGHV3-13,IGHJ6,CQQSYSSPPITF,IGKV1-39,COV096_HC_137-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGSSGWYGWYFDLW,IGHV3-13,IGHJ1,CQQSYSTPPITF,IGKV1-39,COV096_HC_75-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGSSGWYGWYFDLW,IGHV3-13,IGHJ2,CQQSYSTPPITF,IGKV1-39,COV096_HC_75-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGSSGWYGWYFDLW,IGHV3-13,IGHJ3,CQQSYSTPPITF,IGKV1-39,COV096_HC_75-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGSSGWYGWYFDLW,IGHV3-13,IGHJ4,CQQSYSTPPITF,IGKV1-39,COV096_HC_75-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGSSGWYGWYFDLW,IGHV3-13,IGHJ5,CQQSYSTPPITF,IGKV1-39,COV096_HC_75-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGSSGWYGWYFDLW,IGHV3-13,IGHJ6,CQQSYSTPPITF,IGKV1-39,COV096_HC_75-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYNILTGYYFDYW,IGHV3-13,IGHJ1,CQQSYNTPQVTF,IGKV1-39,COV096_HC_123-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYNILTGYYFDYW,IGHV3-13,IGHJ2,CQQSYNTPQVTF,IGKV1-39,COV096_HC_123-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYNILTGYYFDYW,IGHV3-13,IGHJ3,CQQSYNTPQVTF,IGKV1-39,COV096_HC_123-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYNILTGYYFDYW,IGHV3-13,IGHJ4,CQQSYNTPQVTF,IGKV1-39,COV096_HC_123-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYNILTGYYFDYW,IGHV3-13,IGHJ5,CQQSYNTPQVTF,IGKV1-39,COV096_HC_123-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYNILTGYYFDYW,IGHV3-13,IGHJ6,CQQSYNTPQVTF,IGKV1-39,COV096_HC_123-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRDSSWSFDYW,IGHV3-13,IGHJ1,CQQSYSTPPITF,IGKV1-39,COV096_HC_65-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRDSSWSFDYW,IGHV3-13,IGHJ2,CQQSYSTPPITF,IGKV1-39,COV096_HC_65-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRDSSWSFDYW,IGHV3-13,IGHJ3,CQQSYSTPPITF,IGKV1-39,COV096_HC_65-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRDSSWSFDYW,IGHV3-13,IGHJ4,CQQSYSTPPITF,IGKV1-39,COV096_HC_65-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRDSSWSFDYW,IGHV3-13,IGHJ5,CQQSYSTPPITF,IGKV1-39,COV096_HC_65-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRDSSWSFDYW,IGHV3-13,IGHJ6,CQQSYSTPPITF,IGKV1-39,COV096_HC_65-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTFFYGSGSYNWFDPW,IGHV3-13,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV096_HC_81-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTFFYGSGSYNWFDPW,IGHV3-13,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV096_HC_81-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTFFYGSGSYNWFDPW,IGHV3-13,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV096_HC_81-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTFFYGSGSYNWFDPW,IGHV3-13,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV096_HC_81-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTFFYGSGSYNWFDPW,IGHV3-13,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV096_HC_81-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTFFYGSGSYNWFDPW,IGHV3-13,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV096_HC_81-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTLSDYGDLSSVYW,IGHV3-15,IGHJ1,CQQSYSTPLTF,IGKV1-39,COV096_HC_166-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTLSDYGDLSSVYW,IGHV3-15,IGHJ2,CQQSYSTPLTF,IGKV1-39,COV096_HC_166-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTLSDYGDLSSVYW,IGHV3-15,IGHJ3,CQQSYSTPLTF,IGKV1-39,COV096_HC_166-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTLSDYGDLSSVYW,IGHV3-15,IGHJ4,CQQSYSTPLTF,IGKV1-39,COV096_HC_166-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTLSDYGDLSSVYW,IGHV3-15,IGHJ5,CQQSYSTPLTF,IGKV1-39,COV096_HC_166-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTLSDYGDLSSVYW,IGHV3-15,IGHJ6,CQQSYSTPLTF,IGKV1-39,COV096_HC_166-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDLGYCSSTNCYYYYW,IGHV3-15,IGHJ1,CQVWDSSSDHPVF,IGLV3-21,COV096_HC_50-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDLGYCSSTNCYYYYW,IGHV3-15,IGHJ2,CQVWDSSSDHPVF,IGLV3-21,COV096_HC_50-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDLGYCSSTNCYYYYW,IGHV3-15,IGHJ3,CQVWDSSSDHPVF,IGLV3-21,COV096_HC_50-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDLGYCSSTNCYYYYW,IGHV3-15,IGHJ4,CQVWDSSSDHPVF,IGLV3-21,COV096_HC_50-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDLGYCSSTNCYYYYW,IGHV3-15,IGHJ5,CQVWDSSSDHPVF,IGLV3-21,COV096_HC_50-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDLGYCSSTNCYYYYW,IGHV3-15,IGHJ6,CQVWDSSSDHPVF,IGLV3-21,COV096_HC_50-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDDPGSYYYGMDVW,IGHV3-15,IGHJ1,CLLSYSGARVF,IGLV7-46,COV096_HC_92-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDDPGSYYYGMDVW,IGHV3-15,IGHJ2,CLLSYSGARVF,IGLV7-46,COV096_HC_92-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDDPGSYYYGMDVW,IGHV3-15,IGHJ3,CLLSYSGARVF,IGLV7-46,COV096_HC_92-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDDPGSYYYGMDVW,IGHV3-15,IGHJ4,CLLSYSGARVF,IGLV7-46,COV096_HC_92-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDDPGSYYYGMDVW,IGHV3-15,IGHJ5,CLLSYSGARVF,IGLV7-46,COV096_HC_92-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDDPGSYYYGMDVW,IGHV3-15,IGHJ6,CLLSYSGARVF,IGLV7-46,COV096_HC_92-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEYYGMDVW,IGHV3-21,IGHJ1,CQQANRFPITF,IGKV1-12,COV096_HC_140-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEYYGMDVW,IGHV3-21,IGHJ2,CQQANRFPITF,IGKV1-12,COV096_HC_140-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEYYGMDVW,IGHV3-21,IGHJ3,CQQANRFPITF,IGKV1-12,COV096_HC_140-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEYYGMDVW,IGHV3-21,IGHJ4,CQQANRFPITF,IGKV1-12,COV096_HC_140-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEYYGMDVW,IGHV3-21,IGHJ5,CQQANRFPITF,IGKV1-12,COV096_HC_140-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEEYYGMDVW,IGHV3-21,IGHJ6,CQQANRFPITF,IGKV1-12,COV096_HC_140-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGTTNSDYFDYW,IGHV3-30,IGHJ1,CQVWDSSSALWVF,IGLV3-21,COV096_HC_40-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGTTNSDYFDYW,IGHV3-30,IGHJ2,CQVWDSSSALWVF,IGLV3-21,COV096_HC_40-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGTTNSDYFDYW,IGHV3-30,IGHJ3,CQVWDSSSALWVF,IGLV3-21,COV096_HC_40-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGTTNSDYFDYW,IGHV3-30,IGHJ4,CQVWDSSSALWVF,IGLV3-21,COV096_HC_40-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGTTNSDYFDYW,IGHV3-30,IGHJ5,CQVWDSSSALWVF,IGLV3-21,COV096_HC_40-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGTTNSDYFDYW,IGHV3-30,IGHJ6,CQVWDSSSALWVF,IGLV3-21,COV096_HC_40-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLYYYGSGSYVFDYW,IGHV3-30,IGHJ1,CQQYDNLPLTF,IGKV1-33,COV096_HC_43-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLYYYGSGSYVFDYW,IGHV3-30,IGHJ2,CQQYDNLPLTF,IGKV1-33,COV096_HC_43-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLYYYGSGSYVFDYW,IGHV3-30,IGHJ3,CQQYDNLPLTF,IGKV1-33,COV096_HC_43-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLYYYGSGSYVFDYW,IGHV3-30,IGHJ4,CQQYDNLPLTF,IGKV1-33,COV096_HC_43-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLYYYGSGSYVFDYW,IGHV3-30,IGHJ5,CQQYDNLPLTF,IGKV1-33,COV096_HC_43-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQLYYYGSGSYVFDYW,IGHV3-30,IGHJ6,CQQYDNLPLTF,IGKV1-33,COV096_HC_43-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYSYGYSLYYFDYW,IGHV3-30,IGHJ1,CSSYTSSSTLVF,IGLV2-14,COV096_HC_149-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYSYGYSLYYFDYW,IGHV3-30,IGHJ2,CSSYTSSSTLVF,IGLV2-14,COV096_HC_149-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYSYGYSLYYFDYW,IGHV3-30,IGHJ3,CSSYTSSSTLVF,IGLV2-14,COV096_HC_149-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYSYGYSLYYFDYW,IGHV3-30,IGHJ4,CSSYTSSSTLVF,IGLV2-14,COV096_HC_149-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYSYGYSLYYFDYW,IGHV3-30,IGHJ5,CSSYTSSSTLVF,IGLV2-14,COV096_HC_149-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGYSYGYSLYYFDYW,IGHV3-30,IGHJ6,CSSYTSSSTLVF,IGLV2-14,COV096_HC_149-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAQYSYGYVVYYFDYW,IGHV3-30,IGHJ1,CQSYDSSNVVF,IGLV6-57,COV096_HC_157-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAQYSYGYVVYYFDYW,IGHV3-30,IGHJ2,CQSYDSSNVVF,IGLV6-57,COV096_HC_157-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAQYSYGYVVYYFDYW,IGHV3-30,IGHJ3,CQSYDSSNVVF,IGLV6-57,COV096_HC_157-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAQYSYGYVVYYFDYW,IGHV3-30,IGHJ4,CQSYDSSNVVF,IGLV6-57,COV096_HC_157-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAQYSYGYVVYYFDYW,IGHV3-30,IGHJ5,CQSYDSSNVVF,IGLV6-57,COV096_HC_157-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAQYSYGYVVYYFDYW,IGHV3-30,IGHJ6,CQSYDSSNVVF,IGLV6-57,COV096_HC_157-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTPGGDDILTGWGLYGMDVW,IGHV3-30,IGHJ1,CQQSYSTPWTF,IGKV1-39,COV096_HC_21-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTPGGDDILTGWGLYGMDVW,IGHV3-30,IGHJ2,CQQSYSTPWTF,IGKV1-39,COV096_HC_21-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTPGGDDILTGWGLYGMDVW,IGHV3-30,IGHJ3,CQQSYSTPWTF,IGKV1-39,COV096_HC_21-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTPGGDDILTGWGLYGMDVW,IGHV3-30,IGHJ4,CQQSYSTPWTF,IGKV1-39,COV096_HC_21-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTPGGDDILTGWGLYGMDVW,IGHV3-30,IGHJ5,CQQSYSTPWTF,IGKV1-39,COV096_HC_21-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDTPGGDDILTGWGLYGMDVW,IGHV3-30,IGHJ6,CQQSYSTPWTF,IGKV1-39,COV096_HC_21-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMGTLVTHFDYW,IGHV3-33,IGHJ1,CQQSYSSPPWTF,IGKV1-39,COV096_HC_122-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMGTLVTHFDYW,IGHV3-33,IGHJ2,CQQSYSSPPWTF,IGKV1-39,COV096_HC_122-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMGTLVTHFDYW,IGHV3-33,IGHJ3,CQQSYSSPPWTF,IGKV1-39,COV096_HC_122-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMGTLVTHFDYW,IGHV3-33,IGHJ4,CQQSYSSPPWTF,IGKV1-39,COV096_HC_122-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMGTLVTHFDYW,IGHV3-33,IGHJ5,CQQSYSSPPWTF,IGKV1-39,COV096_HC_122-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMGTLVTHFDYW,IGHV3-33,IGHJ6,CQQSYSSPPWTF,IGKV1-39,COV096_HC_122-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVGRVTTWFDPW,IGHV3-33,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV096_HC_98-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVGRVTTWFDPW,IGHV3-33,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV096_HC_98-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVGRVTTWFDPW,IGHV3-33,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV096_HC_98-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVGRVTTWFDPW,IGHV3-33,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV096_HC_98-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVGRVTTWFDPW,IGHV3-33,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV096_HC_98-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVGRVTTWFDPW,IGHV3-33,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV096_HC_98-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASGLRSYYYYGMDVW,IGHV3-48,IGHJ1,CQQSYSTPATF,IGKV1-39,COV096_HC_48-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASGLRSYYYYGMDVW,IGHV3-48,IGHJ2,CQQSYSTPATF,IGKV1-39,COV096_HC_48-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASGLRSYYYYGMDVW,IGHV3-48,IGHJ3,CQQSYSTPATF,IGKV1-39,COV096_HC_48-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASGLRSYYYYGMDVW,IGHV3-48,IGHJ4,CQQSYSTPATF,IGKV1-39,COV096_HC_48-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASGLRSYYYYGMDVW,IGHV3-48,IGHJ5,CQQSYSTPATF,IGKV1-39,COV096_HC_48-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASGLRSYYYYGMDVW,IGHV3-48,IGHJ6,CQQSYSTPATF,IGKV1-39,COV096_HC_48-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGSGSYYYYGMDVW,IGHV3-48,IGHJ1,CQQSYSTPATF,IGKV1-39,COV096_HC_79-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGSGSYYYYGMDVW,IGHV3-48,IGHJ2,CQQSYSTPATF,IGKV1-39,COV096_HC_79-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGSGSYYYYGMDVW,IGHV3-48,IGHJ3,CQQSYSTPATF,IGKV1-39,COV096_HC_79-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGSGSYYYYGMDVW,IGHV3-48,IGHJ4,CQQSYSTPATF,IGKV1-39,COV096_HC_79-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGSGSYYYYGMDVW,IGHV3-48,IGHJ5,CQQSYSTPATF,IGKV1-39,COV096_HC_79-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGSGSYYYYGMDVW,IGHV3-48,IGHJ6,CQQSYSTPATF,IGKV1-39,COV096_HC_79-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDLSYYYDSSGRGSHLFDYW,IGHV3-49,IGHJ1,CQQYNNWWTF,IGKV3-15,COV096_HC_3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDLSYYYDSSGRGSHLFDYW,IGHV3-49,IGHJ2,CQQYNNWWTF,IGKV3-15,COV096_HC_3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDLSYYYDSSGRGSHLFDYW,IGHV3-49,IGHJ3,CQQYNNWWTF,IGKV3-15,COV096_HC_3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDLSYYYDSSGRGSHLFDYW,IGHV3-49,IGHJ4,CQQYNNWWTF,IGKV3-15,COV096_HC_3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDLSYYYDSSGRGSHLFDYW,IGHV3-49,IGHJ5,CQQYNNWWTF,IGKV3-15,COV096_HC_3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDLSYYYDSSGRGSHLFDYW,IGHV3-49,IGHJ6,CQQYNNWWTF,IGKV3-15,COV096_HC_3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSLWLRGSFQHW,IGHV3-53,IGHJ1,CQSYDSSSWVF,IGLV6-57,COV096_HC_121-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSLWLRGSFQHW,IGHV3-53,IGHJ2,CQSYDSSSWVF,IGLV6-57,COV096_HC_121-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSLWLRGSFQHW,IGHV3-53,IGHJ3,CQSYDSSSWVF,IGLV6-57,COV096_HC_121-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSLWLRGSFQHW,IGHV3-53,IGHJ4,CQSYDSSSWVF,IGLV6-57,COV096_HC_121-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSLWLRGSFQHW,IGHV3-53,IGHJ5,CQSYDSSSWVF,IGLV6-57,COV096_HC_121-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSLWLRGSFQHW,IGHV3-53,IGHJ6,CQSYDSSSWVF,IGLV6-57,COV096_HC_121-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLMAYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPQGTF,IGKV1-9,COV096_HC_134-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLMAYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPQGTF,IGKV1-9,COV096_HC_134-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLMAYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPQGTF,IGKV1-9,COV096_HC_134-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLMAYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPQGTF,IGKV1-9,COV096_HC_134-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLMAYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPQGTF,IGKV1-9,COV096_HC_134-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLMAYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPQGTF,IGKV1-9,COV096_HC_134-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGGHYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPPAF,IGKV1-9,COV096_HC_68-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGGHYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPPAF,IGKV1-9,COV096_HC_68-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGGHYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPPAF,IGKV1-9,COV096_HC_68-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGGHYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPPAF,IGKV1-9,COV096_HC_68-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGGHYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPPAF,IGKV1-9,COV096_HC_68-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGGHYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPPAF,IGKV1-9,COV096_HC_68-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESYGMDVW,IGHV3-53,IGHJ1,CQQYVTSPWTF,IGKV3-20,COV096_HC_183-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESYGMDVW,IGHV3-53,IGHJ2,CQQYVTSPWTF,IGKV3-20,COV096_HC_183-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESYGMDVW,IGHV3-53,IGHJ3,CQQYVTSPWTF,IGKV3-20,COV096_HC_183-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESYGMDVW,IGHV3-53,IGHJ4,CQQYVTSPWTF,IGKV3-20,COV096_HC_183-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESYGMDVW,IGHV3-53,IGHJ5,CQQYVTSPWTF,IGKV3-20,COV096_HC_183-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARESYGMDVW,IGHV3-53,IGHJ6,CQQYVTSPWTF,IGKV3-20,COV096_HC_183-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ1,CQQYNNWPRTF,IGKV3-15,COV096_HC_74-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ2,CQQYNNWPRTF,IGKV3-15,COV096_HC_74-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ3,CQQYNNWPRTF,IGKV3-15,COV096_HC_74-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ4,CQQYNNWPRTF,IGKV3-15,COV096_HC_74-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ5,CQQYNNWPRTF,IGKV3-15,COV096_HC_74-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ6,CQQYNNWPRTF,IGKV3-15,COV096_HC_74-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYDFWSGYYDYW,IGHV3-7,IGHJ1,CQSADSSSWVF,IGLV3-25,COV096_HC_27-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYDFWSGYYDYW,IGHV3-7,IGHJ2,CQSADSSSWVF,IGLV3-25,COV096_HC_27-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYDFWSGYYDYW,IGHV3-7,IGHJ3,CQSADSSSWVF,IGLV3-25,COV096_HC_27-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYDFWSGYYDYW,IGHV3-7,IGHJ4,CQSADSSSWVF,IGLV3-25,COV096_HC_27-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYDFWSGYYDYW,IGHV3-7,IGHJ5,CQSADSSSWVF,IGLV3-25,COV096_HC_27-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGDYDFWSGYYDYW,IGHV3-7,IGHJ6,CQSADSSSWVF,IGLV3-25,COV096_HC_27-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAPWLRGGFDYW,IGHV3-7,IGHJ1,CQSFDSTNLWVF,IGLV6-57,COV096_HC_142-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAPWLRGGFDYW,IGHV3-7,IGHJ2,CQSFDSTNLWVF,IGLV6-57,COV096_HC_142-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAPWLRGGFDYW,IGHV3-7,IGHJ3,CQSFDSTNLWVF,IGLV6-57,COV096_HC_142-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAPWLRGGFDYW,IGHV3-7,IGHJ4,CQSFDSTNLWVF,IGLV6-57,COV096_HC_142-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAPWLRGGFDYW,IGHV3-7,IGHJ5,CQSFDSTNLWVF,IGLV6-57,COV096_HC_142-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATAPWLRGGFDYW,IGHV3-7,IGHJ6,CQSFDSTNLWVF,IGLV6-57,COV096_HC_142-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ1,CQQYDNLPPKLTF,IGKV1-33,COV096_HC_45-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ2,CQQYDNLPPKLTF,IGKV1-33,COV096_HC_45-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ3,CQQYDNLPPKLTF,IGKV1-33,COV096_HC_45-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ4,CQQYDNLPPKLTF,IGKV1-33,COV096_HC_45-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ5,CQQYDNLPPKLTF,IGKV1-33,COV096_HC_45-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ6,CQQYDNLPPKLTF,IGKV1-33,COV096_HC_45-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ1,CQQSYISPYTF,IGKV1-39,COV096_HC_126-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ2,CQQSYISPYTF,IGKV1-39,COV096_HC_126-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ3,CQQSYISPYTF,IGKV1-39,COV096_HC_126-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ4,CQQSYISPYTF,IGKV1-39,COV096_HC_126-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ5,CQQSYISPYTF,IGKV1-39,COV096_HC_126-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ6,CQQSYISPYTF,IGKV1-39,COV096_HC_126-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKIADIVRAYDFWSGQHFDAFDIW,IGHV3-9,IGHJ1,CAAWDDSLVVF,IGLV1-44,COV096_HC_1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKIADIVRAYDFWSGQHFDAFDIW,IGHV3-9,IGHJ2,CAAWDDSLVVF,IGLV1-44,COV096_HC_1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKIADIVRAYDFWSGQHFDAFDIW,IGHV3-9,IGHJ3,CAAWDDSLVVF,IGLV1-44,COV096_HC_1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKIADIVRAYDFWSGQHFDAFDIW,IGHV3-9,IGHJ4,CAAWDDSLVVF,IGLV1-44,COV096_HC_1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKIADIVRAYDFWSGQHFDAFDIW,IGHV3-9,IGHJ5,CAAWDDSLVVF,IGLV1-44,COV096_HC_1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKIADIVRAYDFWSGQHFDAFDIW,IGHV3-9,IGHJ6,CAAWDDSLVVF,IGLV1-44,COV096_HC_1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGSGTTEYEAYYFDYW,IGHV3-9,IGHJ1,CAAWDDSLNGVVF,IGLV1-44,COV096_HC_15-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGSGTTEYEAYYFDYW,IGHV3-9,IGHJ2,CAAWDDSLNGVVF,IGLV1-44,COV096_HC_15-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGSGTTEYEAYYFDYW,IGHV3-9,IGHJ3,CAAWDDSLNGVVF,IGLV1-44,COV096_HC_15-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGSGTTEYEAYYFDYW,IGHV3-9,IGHJ4,CAAWDDSLNGVVF,IGLV1-44,COV096_HC_15-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGSGTTEYEAYYFDYW,IGHV3-9,IGHJ5,CAAWDDSLNGVVF,IGLV1-44,COV096_HC_15-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGSGTTEYEAYYFDYW,IGHV3-9,IGHJ6,CAAWDDSLNGVVF,IGLV1-44,COV096_HC_15-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMGRDDSSGSLLFDYW,IGHV3-9,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,COV096_HC_20-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMGRDDSSGSLLFDYW,IGHV3-9,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,COV096_HC_20-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMGRDDSSGSLLFDYW,IGHV3-9,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,COV096_HC_20-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMGRDDSSGSLLFDYW,IGHV3-9,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,COV096_HC_20-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMGRDDSSGSLLFDYW,IGHV3-9,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,COV096_HC_20-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMGRDDSSGSLLFDYW,IGHV3-9,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,COV096_HC_20-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDIGSKRSTSENYGMDVW,IGHV3-9,IGHJ1,CQVWDSSSDSVVF,IGLV3-21,COV096_HC_159-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDIGSKRSTSENYGMDVW,IGHV3-9,IGHJ2,CQVWDSSSDSVVF,IGLV3-21,COV096_HC_159-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDIGSKRSTSENYGMDVW,IGHV3-9,IGHJ3,CQVWDSSSDSVVF,IGLV3-21,COV096_HC_159-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDIGSKRSTSENYGMDVW,IGHV3-9,IGHJ4,CQVWDSSSDSVVF,IGLV3-21,COV096_HC_159-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDIGSKRSTSENYGMDVW,IGHV3-9,IGHJ5,CQVWDSSSDSVVF,IGLV3-21,COV096_HC_159-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDIGSKRSTSENYGMDVW,IGHV3-9,IGHJ6,CQVWDSSSDSVVF,IGLV3-21,COV096_HC_159-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASLRGAYYDFWSGPRDGGWFDPW,IGHV4-39,IGHJ1,CCSYAGSSLWVF,IGLV2-23,COV096_HC_103-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASLRGAYYDFWSGPRDGGWFDPW,IGHV4-39,IGHJ2,CCSYAGSSLWVF,IGLV2-23,COV096_HC_103-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASLRGAYYDFWSGPRDGGWFDPW,IGHV4-39,IGHJ3,CCSYAGSSLWVF,IGLV2-23,COV096_HC_103-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASLRGAYYDFWSGPRDGGWFDPW,IGHV4-39,IGHJ4,CCSYAGSSLWVF,IGLV2-23,COV096_HC_103-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASLRGAYYDFWSGPRDGGWFDPW,IGHV4-39,IGHJ5,CCSYAGSSLWVF,IGLV2-23,COV096_HC_103-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASLRGAYYDFWSGPRDGGWFDPW,IGHV4-39,IGHJ6,CCSYAGSSLWVF,IGLV2-23,COV096_HC_103-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPSTWYFDLW,IGHV4-61,IGHJ1,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_23-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPSTWYFDLW,IGHV4-61,IGHJ2,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_23-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPSTWYFDLW,IGHV4-61,IGHJ3,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_23-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPSTWYFDLW,IGHV4-61,IGHJ4,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_23-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPSTWYFDLW,IGHV4-61,IGHJ5,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_23-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREIPSTWYFDLW,IGHV4-61,IGHJ6,CAAWDDSLSGYWVF,IGLV1-47,COV096_HC_23-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIPPTWYFDLW,IGHV4-61,IGHJ1,CQVWDSTSDHLFWVF,IGLV3-21,COV096_HC_101-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIPPTWYFDLW,IGHV4-61,IGHJ2,CQVWDSTSDHLFWVF,IGLV3-21,COV096_HC_101-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIPPTWYFDLW,IGHV4-61,IGHJ3,CQVWDSTSDHLFWVF,IGLV3-21,COV096_HC_101-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIPPTWYFDLW,IGHV4-61,IGHJ4,CQVWDSTSDHLFWVF,IGLV3-21,COV096_HC_101-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIPPTWYFDLW,IGHV4-61,IGHJ5,CQVWDSTSDHLFWVF,IGLV3-21,COV096_HC_101-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDIPPTWYFDLW,IGHV4-61,IGHJ6,CQVWDSTSDHLFWVF,IGLV3-21,COV096_HC_101-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPVTYDWYFDLW,IGHV5-51,IGHJ1,CQQANSFPITF,IGKV1-12,COV096_HC_8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPVTYDWYFDLW,IGHV5-51,IGHJ2,CQQANSFPITF,IGKV1-12,COV096_HC_8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPVTYDWYFDLW,IGHV5-51,IGHJ3,CQQANSFPITF,IGKV1-12,COV096_HC_8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPVTYDWYFDLW,IGHV5-51,IGHJ4,CQQANSFPITF,IGKV1-12,COV096_HC_8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPVTYDWYFDLW,IGHV5-51,IGHJ5,CQQANSFPITF,IGKV1-12,COV096_HC_8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPVTYDWYFDLW,IGHV5-51,IGHJ6,CQQANSFPITF,IGKV1-12,COV096_HC_8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSSSDYGDYGGFEYW,IGHV5-51,IGHJ1,CQQSYSTPCSF,IGKV1-39,COV096_HC_124-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSSSDYGDYGGFEYW,IGHV5-51,IGHJ2,CQQSYSTPCSF,IGKV1-39,COV096_HC_124-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSSSDYGDYGGFEYW,IGHV5-51,IGHJ3,CQQSYSTPCSF,IGKV1-39,COV096_HC_124-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSSSDYGDYGGFEYW,IGHV5-51,IGHJ4,CQQSYSTPCSF,IGKV1-39,COV096_HC_124-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSSSDYGDYGGFEYW,IGHV5-51,IGHJ5,CQQSYSTPCSF,IGKV1-39,COV096_HC_124-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSSSDYGDYGGFEYW,IGHV5-51,IGHJ6,CQQSYSTPCSF,IGKV1-39,COV096_HC_124-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMVTSGTYYYDNSGYSSSGPFDYW,IGHV5-51,IGHJ1,CQQFNNF,IGKV1D-13,COV096_HC_28-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMVTSGTYYYDNSGYSSSGPFDYW,IGHV5-51,IGHJ2,CQQFNNF,IGKV1D-13,COV096_HC_28-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMVTSGTYYYDNSGYSSSGPFDYW,IGHV5-51,IGHJ3,CQQFNNF,IGKV1D-13,COV096_HC_28-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMVTSGTYYYDNSGYSSSGPFDYW,IGHV5-51,IGHJ4,CQQFNNF,IGKV1D-13,COV096_HC_28-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMVTSGTYYYDNSGYSSSGPFDYW,IGHV5-51,IGHJ5,CQQFNNF,IGKV1D-13,COV096_HC_28-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARMVTSGTYYYDNSGYSSSGPFDYW,IGHV5-51,IGHJ6,CQQFNNF,IGKV1D-13,COV096_HC_28-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ1,CQQYNNWPPGGFTF,IGKV3-15,COV096_HC_12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ2,CQQYNNWPPGGFTF,IGKV3-15,COV096_HC_12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ3,CQQYNNWPPGGFTF,IGKV3-15,COV096_HC_12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ4,CQQYNNWPPGGFTF,IGKV3-15,COV096_HC_12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ5,CQQYNNWPPGGFTF,IGKV3-15,COV096_HC_12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ6,CQQYNNWPPGGFTF,IGKV3-15,COV096_HC_12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPSGRYNWFDPW,IGHV5-51,IGHJ1,CAAWDDSLNGHVVF,IGLV1-44,COV096_HC_174-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPSGRYNWFDPW,IGHV5-51,IGHJ2,CAAWDDSLNGHVVF,IGLV1-44,COV096_HC_174-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPSGRYNWFDPW,IGHV5-51,IGHJ3,CAAWDDSLNGHVVF,IGLV1-44,COV096_HC_174-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPSGRYNWFDPW,IGHV5-51,IGHJ4,CAAWDDSLNGHVVF,IGLV1-44,COV096_HC_174-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPSGRYNWFDPW,IGHV5-51,IGHJ5,CAAWDDSLNGHVVF,IGLV1-44,COV096_HC_174-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPSGRYNWFDPW,IGHV5-51,IGHJ6,CAAWDDSLNGHVVF,IGLV1-44,COV096_HC_174-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPQEEKRFLEWLPPANVRKQIPYYYGMDVW,IGHV5-51,IGHJ1,CQSYDSSLSGPYWVF,IGLV1-40,COV096_HC_189-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPQEEKRFLEWLPPANVRKQIPYYYGMDVW,IGHV5-51,IGHJ2,CQSYDSSLSGPYWVF,IGLV1-40,COV096_HC_189-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPQEEKRFLEWLPPANVRKQIPYYYGMDVW,IGHV5-51,IGHJ3,CQSYDSSLSGPYWVF,IGLV1-40,COV096_HC_189-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPQEEKRFLEWLPPANVRKQIPYYYGMDVW,IGHV5-51,IGHJ4,CQSYDSSLSGPYWVF,IGLV1-40,COV096_HC_189-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPQEEKRFLEWLPPANVRKQIPYYYGMDVW,IGHV5-51,IGHJ5,CQSYDSSLSGPYWVF,IGLV1-40,COV096_HC_189-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLPQEEKRFLEWLPPANVRKQIPYYYGMDVW,IGHV5-51,IGHJ6,CQSYDSSLSGPYWVF,IGLV1-40,COV096_HC_189-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYNDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ1,CSSYTSSSTRVF,IGLV2-14,COV047_P3_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYNDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ2,CSSYTSSSTRVF,IGLV2-14,COV047_P3_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYNDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ3,CSSYTSSSTRVF,IGLV2-14,COV047_P3_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYNDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ4,CSSYTSSSTRVF,IGLV2-14,COV047_P3_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYNDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ5,CSSYTSSSTRVF,IGLV2-14,COV047_P3_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYNDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ6,CSSYTSSSTRVF,IGLV2-14,COV047_P3_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ1,CSSYTSSTTRVF,IGLV2-14,COV047_P4_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ2,CSSYTSSTTRVF,IGLV2-14,COV047_P4_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ3,CSSYTSSTTRVF,IGLV2-14,COV047_P4_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ4,CSSYTSSTTRVF,IGLV2-14,COV047_P4_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ5,CSSYTSSTTRVF,IGLV2-14,COV047_P4_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ6,CSSYTSSTTRVF,IGLV2-14,COV047_P4_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ1,CSSYTSISTRVF,IGLV2-14,COV047_P4_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ2,CSSYTSISTRVF,IGLV2-14,COV047_P4_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ3,CSSYTSISTRVF,IGLV2-14,COV047_P4_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ4,CSSYTSISTRVF,IGLV2-14,COV047_P4_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ5,CSSYTSISTRVF,IGLV2-14,COV047_P4_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ6,CSSYTSISTRVF,IGLV2-14,COV047_P4_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGDVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ1,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGDVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ2,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGDVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ3,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGDVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ4,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGDVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ5,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGDVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ6,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_26-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ1,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ2,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ3,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ4,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ5,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ6,CSSYTSSSTRVF,IGLV2-14,COV047_P5_IgG_41-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ1,CSSYTSSTTRVF,IGLV2-14,COV047_P5_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ2,CSSYTSSTTRVF,IGLV2-14,COV047_P5_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ3,CSSYTSSTTRVF,IGLV2-14,COV047_P5_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ4,CSSYTSSTTRVF,IGLV2-14,COV047_P5_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ5,CSSYTSSTTRVF,IGLV2-14,COV047_P5_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREGEVEGYYDFWSGYSRDRYYFDYW,IGHV3-53,IGHJ6,CSSYTSSTTRVF,IGLV2-14,COV047_P5_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CCSYAGASTFVF,IGLV2-23,COV047_P3_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CCSYAGASTFVF,IGLV2-23,COV047_P3_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CCSYAGASTFVF,IGLV2-23,COV047_P3_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CCSYAGASTFVF,IGLV2-23,COV047_P3_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CCSYAGASTFVF,IGLV2-23,COV047_P3_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CCSYAGASTFVF,IGLV2-23,COV047_P3_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_12-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CCSYAGASTFVF,IGLV2-23,COV047_P5_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CCSYAGASTFVF,IGLV2-23,COV047_P5_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CCSYAGASTFVF,IGLV2-23,COV047_P5_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CCSYAGASTFVF,IGLV2-23,COV047_P5_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CCSYAGASTFVF,IGLV2-23,COV047_P5_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CCSYAGASTFVF,IGLV2-23,COV047_P5_IgG_57-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHDFWSGYGFYYYYGMDVW,IGHV1-18,IGHJ1,CQKYNSAPRTF,IGKV1-27,COV047_P3_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHDFWSGYGFYYYYGMDVW,IGHV1-18,IGHJ2,CQKYNSAPRTF,IGKV1-27,COV047_P3_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHDFWSGYGFYYYYGMDVW,IGHV1-18,IGHJ3,CQKYNSAPRTF,IGKV1-27,COV047_P3_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHDFWSGYGFYYYYGMDVW,IGHV1-18,IGHJ4,CQKYNSAPRTF,IGKV1-27,COV047_P3_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHDFWSGYGFYYYYGMDVW,IGHV1-18,IGHJ5,CQKYNSAPRTF,IGKV1-27,COV047_P3_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHDFWSGYGFYYYYGMDVW,IGHV1-18,IGHJ6,CQKYNSAPRTF,IGKV1-27,COV047_P3_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHNFWSGYGYYYYYGMDVW,IGHV1-18,IGHJ1,CQKYNSAPRTF,IGKV1-27,COV047_P5_IgG_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHNFWSGYGYYYYYGMDVW,IGHV1-18,IGHJ2,CQKYNSAPRTF,IGKV1-27,COV047_P5_IgG_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHNFWSGYGYYYYYGMDVW,IGHV1-18,IGHJ3,CQKYNSAPRTF,IGKV1-27,COV047_P5_IgG_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHNFWSGYGYYYYYGMDVW,IGHV1-18,IGHJ4,CQKYNSAPRTF,IGKV1-27,COV047_P5_IgG_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHNFWSGYGYYYYYGMDVW,IGHV1-18,IGHJ5,CQKYNSAPRTF,IGKV1-27,COV047_P5_IgG_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRGGHNFWSGYGYYYYYGMDVW,IGHV1-18,IGHJ6,CQKYNSAPRTF,IGKV1-27,COV047_P5_IgG_95-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYYGGKTPPFLW,IGHV3-21,IGHJ1,CQSYDSSNYWVF,IGLV6-57,COV047_P4_IgG_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYYGGKTPPFLW,IGHV3-21,IGHJ2,CQSYDSSNYWVF,IGLV6-57,COV047_P4_IgG_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYYGGKTPPFLW,IGHV3-21,IGHJ3,CQSYDSSNYWVF,IGLV6-57,COV047_P4_IgG_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYYGGKTPPFLW,IGHV3-21,IGHJ4,CQSYDSSNYWVF,IGLV6-57,COV047_P4_IgG_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYYGGKTPPFLW,IGHV3-21,IGHJ5,CQSYDSSNYWVF,IGLV6-57,COV047_P4_IgG_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYYGGKTPPFLW,IGHV3-21,IGHJ6,CQSYDSSNYWVF,IGLV6-57,COV047_P4_IgG_34-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYDGGKTPPFLW,IGHV3-21,IGHJ1,CQSYDSSNYWVF,IGLV6-57,COV047_P5_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYDGGKTPPFLW,IGHV3-21,IGHJ2,CQSYDSSNYWVF,IGLV6-57,COV047_P5_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYDGGKTPPFLW,IGHV3-21,IGHJ3,CQSYDSSNYWVF,IGLV6-57,COV047_P5_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYDGGKTPPFLW,IGHV3-21,IGHJ4,CQSYDSSNYWVF,IGLV6-57,COV047_P5_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYDGGKTPPFLW,IGHV3-21,IGHJ5,CQSYDSSNYWVF,IGLV6-57,COV047_P5_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERGYDGGKTPPFLW,IGHV3-21,IGHJ6,CQSYDSSNYWVF,IGLV6-57,COV047_P5_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNVGTGYNVMYYFDYW,IGHV3-30,IGHJ1,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNVGTGYNVMYYFDYW,IGHV3-30,IGHJ2,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNVGTGYNVMYYFDYW,IGHV3-30,IGHJ3,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNVGTGYNVMYYFDYW,IGHV3-30,IGHJ4,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNVGTGYNVMYYFDYW,IGHV3-30,IGHJ5,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNVGTGYNVMYYFDYW,IGHV3-30,IGHJ6,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGSCYSAPFDYW,IGHV3-30,IGHJ1,CQQYDNLPITF,IGKV1-33,COV047_P5_IgG_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGSCYSAPFDYW,IGHV3-30,IGHJ2,CQQYDNLPITF,IGKV1-33,COV047_P5_IgG_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGSCYSAPFDYW,IGHV3-30,IGHJ3,CQQYDNLPITF,IGKV1-33,COV047_P5_IgG_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGSCYSAPFDYW,IGHV3-30,IGHJ4,CQQYDNLPITF,IGKV1-33,COV047_P5_IgG_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGSCYSAPFDYW,IGHV3-30,IGHJ5,CQQYDNLPITF,IGKV1-33,COV047_P5_IgG_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKQAGPYCSGGSCYSAPFDYW,IGHV3-30,IGHJ6,CQQYDNLPITF,IGKV1-33,COV047_P5_IgG_87-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGLGYSSGWYGEEIDYW,IGHV3-30,IGHJ1,CQQSYRTPLTF,IGKV1-39,COV047_P4_IgG_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGLGYSSGWYGEEIDYW,IGHV3-30,IGHJ2,CQQSYRTPLTF,IGKV1-39,COV047_P4_IgG_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGLGYSSGWYGEEIDYW,IGHV3-30,IGHJ3,CQQSYRTPLTF,IGKV1-39,COV047_P4_IgG_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGLGYSSGWYGEEIDYW,IGHV3-30,IGHJ4,CQQSYRTPLTF,IGKV1-39,COV047_P4_IgG_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGLGYSSGWYGEEIDYW,IGHV3-30,IGHJ5,CQQSYRTPLTF,IGKV1-39,COV047_P4_IgG_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGLGYSSGWYGEEIDYW,IGHV3-30,IGHJ6,CQQSYRTPLTF,IGKV1-39,COV047_P4_IgG_69-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGMEYSSGWYGEEIDFW,IGHV3-30,IGHJ1,CQQSYRTPLTF,IGKV1-39,COV047_P5_IgG_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGMEYSSGWYGEEIDFW,IGHV3-30,IGHJ2,CQQSYRTPLTF,IGKV1-39,COV047_P5_IgG_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGMEYSSGWYGEEIDFW,IGHV3-30,IGHJ3,CQQSYRTPLTF,IGKV1-39,COV047_P5_IgG_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGMEYSSGWYGEEIDFW,IGHV3-30,IGHJ4,CQQSYRTPLTF,IGKV1-39,COV047_P5_IgG_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGMEYSSGWYGEEIDFW,IGHV3-30,IGHJ5,CQQSYRTPLTF,IGKV1-39,COV047_P5_IgG_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVGMEYSSGWYGEEIDFW,IGHV3-30,IGHJ6,CQQSYRTPLTF,IGKV1-39,COV047_P5_IgG_68-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPFPLAVAGTGYFDYW,IGHV3-30,IGHJ1,CQVWDSSSDPWVF,IGLV3-21,COV047_P3_IgG_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPFPLAVAGTGYFDYW,IGHV3-30,IGHJ2,CQVWDSSSDPWVF,IGLV3-21,COV047_P3_IgG_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPFPLAVAGTGYFDYW,IGHV3-30,IGHJ3,CQVWDSSSDPWVF,IGLV3-21,COV047_P3_IgG_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPFPLAVAGTGYFDYW,IGHV3-30,IGHJ4,CQVWDSSSDPWVF,IGLV3-21,COV047_P3_IgG_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPFPLAVAGTGYFDYW,IGHV3-30,IGHJ5,CQVWDSSSDPWVF,IGLV3-21,COV047_P3_IgG_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPFPLAVAGTGYFDYW,IGHV3-30,IGHJ6,CQVWDSSSDPWVF,IGLV3-21,COV047_P3_IgG_64-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPWELRQGNYFDYW,IGHV3-30,IGHJ1,CQVWDSSSDPWVF,IGLV3-21,COV047_P5_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPWELRQGNYFDYW,IGHV3-30,IGHJ2,CQVWDSSSDPWVF,IGLV3-21,COV047_P5_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPWELRQGNYFDYW,IGHV3-30,IGHJ3,CQVWDSSSDPWVF,IGLV3-21,COV047_P5_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPWELRQGNYFDYW,IGHV3-30,IGHJ4,CQVWDSSSDPWVF,IGLV3-21,COV047_P5_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPWELRQGNYFDYW,IGHV3-30,IGHJ5,CQVWDSSSDPWVF,IGLV3-21,COV047_P5_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDPWELRQGNYFDYW,IGHV3-30,IGHJ6,CQVWDSSSDPWVF,IGLV3-21,COV047_P5_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ1,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ2,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ3,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ4,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ5,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDYYFDYW,IGHV3-53,IGHJ6,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_65-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFGEFYFDYW,IGHV3-53,IGHJ1,CQQYNNWPRTF,IGKV3-15,COV047_P5_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFGEFYFDYW,IGHV3-53,IGHJ2,CQQYNNWPRTF,IGKV3-15,COV047_P5_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFGEFYFDYW,IGHV3-53,IGHJ3,CQQYNNWPRTF,IGKV3-15,COV047_P5_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFGEFYFDYW,IGHV3-53,IGHJ4,CQQYNNWPRTF,IGKV3-15,COV047_P5_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFGEFYFDYW,IGHV3-53,IGHJ5,CQQYNNWPRTF,IGKV3-15,COV047_P5_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDFGEFYFDYW,IGHV3-53,IGHJ6,CQQYNNWPRTF,IGKV3-15,COV047_P5_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CCSYAGASTFVF,IGLV2-23,COV047_P4_IgG_3-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CCSYAGTSTFVF,IGLV2-23,COV047_P5_IgG_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CCSYAGTSTFVF,IGLV2-23,COV047_P5_IgG_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CCSYAGTSTFVF,IGLV2-23,COV047_P5_IgG_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CCSYAGTSTFVF,IGLV2-23,COV047_P5_IgG_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CCSYAGTSTFVF,IGLV2-23,COV047_P5_IgG_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CCSYAGTSTFVF,IGLV2-23,COV047_P5_IgG_90-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ1,CQQYNNWPPLTF,IGKV3-15,COV047_P3_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ2,CQQYNNWPPLTF,IGKV3-15,COV047_P3_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ3,CQQYNNWPPLTF,IGKV3-15,COV047_P3_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ4,CQQYNNWPPLTF,IGKV3-15,COV047_P3_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ5,CQQYNNWPPLTF,IGKV3-15,COV047_P3_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ6,CQQYNNWPPLTF,IGKV3-15,COV047_P3_IgG_24-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ1,CQQYNNWPPLTF,IGKV3-15,COV047_P5_IgG_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ2,CQQYNNWPPLTF,IGKV3-15,COV047_P5_IgG_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ3,CQQYNNWPPLTF,IGKV3-15,COV047_P5_IgG_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ4,CQQYNNWPPLTF,IGKV3-15,COV047_P5_IgG_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ5,CQQYNNWPPLTF,IGKV3-15,COV047_P5_IgG_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARIANYMDVW,IGHV3-66,IGHJ6,CQQYNNWPPLTF,IGKV3-15,COV047_P5_IgG_94-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ1,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ2,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ3,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ4,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ5,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ6,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ1,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ2,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ3,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ4,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ5,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLSDRWYSPFDPW,IGHV5-51,IGHJ6,CLLSYSGARPVF,IGLV7-46,COV047_P3_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPRGYYDRSGYYYLPHYLDYW,IGHV1-18,IGHJ1,CQQYDSLPGCSF,IGKV1-33,COV047_P3_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPRGYYDRSGYYYLPHYLDYW,IGHV1-18,IGHJ2,CQQYDSLPGCSF,IGKV1-33,COV047_P3_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPRGYYDRSGYYYLPHYLDYW,IGHV1-18,IGHJ3,CQQYDSLPGCSF,IGKV1-33,COV047_P3_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPRGYYDRSGYYYLPHYLDYW,IGHV1-18,IGHJ4,CQQYDSLPGCSF,IGKV1-33,COV047_P3_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPRGYYDRSGYYYLPHYLDYW,IGHV1-18,IGHJ5,CQQYDSLPGCSF,IGKV1-33,COV047_P3_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPRGYYDRSGYYYLPHYLDYW,IGHV1-18,IGHJ6,CQQYDSLPGCSF,IGKV1-33,COV047_P3_IgG_77-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSAYSGYDFFEAPRDYW,IGHV1-18,IGHJ1,CQQSYRTPPLF,IGKV1-39,COV047_P5_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSAYSGYDFFEAPRDYW,IGHV1-18,IGHJ2,CQQSYRTPPLF,IGKV1-39,COV047_P5_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSAYSGYDFFEAPRDYW,IGHV1-18,IGHJ3,CQQSYRTPPLF,IGKV1-39,COV047_P5_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSAYSGYDFFEAPRDYW,IGHV1-18,IGHJ4,CQQSYRTPPLF,IGKV1-39,COV047_P5_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSAYSGYDFFEAPRDYW,IGHV1-18,IGHJ5,CQQSYRTPPLF,IGKV1-39,COV047_P5_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSAYSGYDFFEAPRDYW,IGHV1-18,IGHJ6,CQQSYRTPPLF,IGKV1-39,COV047_P5_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPSSSLTSYFDYW,IGHV1-18,IGHJ1,CQVWDSSSDRHWVF,IGLV3-21,COV047_P5_IgG_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPSSSLTSYFDYW,IGHV1-18,IGHJ2,CQVWDSSSDRHWVF,IGLV3-21,COV047_P5_IgG_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPSSSLTSYFDYW,IGHV1-18,IGHJ3,CQVWDSSSDRHWVF,IGLV3-21,COV047_P5_IgG_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPSSSLTSYFDYW,IGHV1-18,IGHJ4,CQVWDSSSDRHWVF,IGLV3-21,COV047_P5_IgG_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPSSSLTSYFDYW,IGHV1-18,IGHJ5,CQVWDSSSDRHWVF,IGLV3-21,COV047_P5_IgG_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPSSSLTSYFDYW,IGHV1-18,IGHJ6,CQVWDSSSDRHWVF,IGLV3-21,COV047_P5_IgG_21-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPASYGDDDYYYYYGMDVW,IGHV1-18,IGHJ1,CQSADSSGTLWVF,IGLV3-25,COV047_P3_IgG_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPASYGDDDYYYYYGMDVW,IGHV1-18,IGHJ2,CQSADSSGTLWVF,IGLV3-25,COV047_P3_IgG_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPASYGDDDYYYYYGMDVW,IGHV1-18,IGHJ3,CQSADSSGTLWVF,IGLV3-25,COV047_P3_IgG_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPASYGDDDYYYYYGMDVW,IGHV1-18,IGHJ4,CQSADSSGTLWVF,IGLV3-25,COV047_P3_IgG_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPASYGDDDYYYYYGMDVW,IGHV1-18,IGHJ5,CQSADSSGTLWVF,IGLV3-25,COV047_P3_IgG_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPASYGDDDYYYYYGMDVW,IGHV1-18,IGHJ6,CQSADSSGTLWVF,IGLV3-25,COV047_P3_IgG_53-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPLFHRLVYDFWSGYHDGFDMW,IGHV1-2,IGHJ1,CNSYTSSSTWVF,IGLV2-14,COV047_P4_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPLFHRLVYDFWSGYHDGFDMW,IGHV1-2,IGHJ2,CNSYTSSSTWVF,IGLV2-14,COV047_P4_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPLFHRLVYDFWSGYHDGFDMW,IGHV1-2,IGHJ3,CNSYTSSSTWVF,IGLV2-14,COV047_P4_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPLFHRLVYDFWSGYHDGFDMW,IGHV1-2,IGHJ4,CNSYTSSSTWVF,IGLV2-14,COV047_P4_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPLFHRLVYDFWSGYHDGFDMW,IGHV1-2,IGHJ5,CNSYTSSSTWVF,IGLV2-14,COV047_P4_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPLFHRLVYDFWSGYHDGFDMW,IGHV1-2,IGHJ6,CNSYTSSSTWVF,IGLV2-14,COV047_P4_IgG_27-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTPRVYDPTLPNQWLVGEYYCDYW,IGHV1-2,IGHJ1,CCSYAGSYTWVF,IGLV2-11,COV047_P5_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTPRVYDPTLPNQWLVGEYYCDYW,IGHV1-2,IGHJ2,CCSYAGSYTWVF,IGLV2-11,COV047_P5_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTPRVYDPTLPNQWLVGEYYCDYW,IGHV1-2,IGHJ3,CCSYAGSYTWVF,IGLV2-11,COV047_P5_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTPRVYDPTLPNQWLVGEYYCDYW,IGHV1-2,IGHJ4,CCSYAGSYTWVF,IGLV2-11,COV047_P5_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTPRVYDPTLPNQWLVGEYYCDYW,IGHV1-2,IGHJ5,CCSYAGSYTWVF,IGLV2-11,COV047_P5_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTPRVYDPTLPNQWLVGEYYCDYW,IGHV1-2,IGHJ6,CCSYAGSYTWVF,IGLV2-11,COV047_P5_IgG_10-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTEYNWNSAHFDPW,IGHV1-2,IGHJ1,CSSYTSSSTSWVF,IGLV2-14,COV047_P4_IgG_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTEYNWNSAHFDPW,IGHV1-2,IGHJ2,CSSYTSSSTSWVF,IGLV2-14,COV047_P4_IgG_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTEYNWNSAHFDPW,IGHV1-2,IGHJ3,CSSYTSSSTSWVF,IGLV2-14,COV047_P4_IgG_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTEYNWNSAHFDPW,IGHV1-2,IGHJ4,CSSYTSSSTSWVF,IGLV2-14,COV047_P4_IgG_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTEYNWNSAHFDPW,IGHV1-2,IGHJ5,CSSYTSSSTSWVF,IGLV2-14,COV047_P4_IgG_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGTEYNWNSAHFDPW,IGHV1-2,IGHJ6,CSSYTSSSTSWVF,IGLV2-14,COV047_P4_IgG_60-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRGGTWNYVGGEVW,IGHV1-2,IGHJ1,CTSFTSSSDSWIF,IGLV2-14,COV047_P5_IgG_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRGGTWNYVGGEVW,IGHV1-2,IGHJ2,CTSFTSSSDSWIF,IGLV2-14,COV047_P5_IgG_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRGGTWNYVGGEVW,IGHV1-2,IGHJ3,CTSFTSSSDSWIF,IGLV2-14,COV047_P5_IgG_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRGGTWNYVGGEVW,IGHV1-2,IGHJ4,CTSFTSSSDSWIF,IGLV2-14,COV047_P5_IgG_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRGGTWNYVGGEVW,IGHV1-2,IGHJ5,CTSFTSSSDSWIF,IGLV2-14,COV047_P5_IgG_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CVRGGTWNYVGGEVW,IGHV1-2,IGHJ6,CTSFTSSSDSWIF,IGLV2-14,COV047_P5_IgG_29-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSSTPDYYGMDVW,IGHV1-46,IGHJ1,CQQLNSYPLCSF,IGKV1-9,COV047_P3_IgG_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSSTPDYYGMDVW,IGHV1-46,IGHJ2,CQQLNSYPLCSF,IGKV1-9,COV047_P3_IgG_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSSTPDYYGMDVW,IGHV1-46,IGHJ3,CQQLNSYPLCSF,IGKV1-9,COV047_P3_IgG_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSSTPDYYGMDVW,IGHV1-46,IGHJ4,CQQLNSYPLCSF,IGKV1-9,COV047_P3_IgG_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSSTPDYYGMDVW,IGHV1-46,IGHJ5,CQQLNSYPLCSF,IGKV1-9,COV047_P3_IgG_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASSSSTPDYYGMDVW,IGHV1-46,IGHJ6,CQQLNSYPLCSF,IGKV1-9,COV047_P3_IgG_61-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASTSTTNWNDALSLGCW,IGHV1-46,IGHJ1,CQSYDSGLSGSGVVF,IGLV1-40,COV047_P4_IgG_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASTSTTNWNDALSLGCW,IGHV1-46,IGHJ2,CQSYDSGLSGSGVVF,IGLV1-40,COV047_P4_IgG_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASTSTTNWNDALSLGCW,IGHV1-46,IGHJ3,CQSYDSGLSGSGVVF,IGLV1-40,COV047_P4_IgG_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASTSTTNWNDALSLGCW,IGHV1-46,IGHJ4,CQSYDSGLSGSGVVF,IGLV1-40,COV047_P4_IgG_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASTSTTNWNDALSLGCW,IGHV1-46,IGHJ5,CQSYDSGLSGSGVVF,IGLV1-40,COV047_P4_IgG_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARASTSTTNWNDALSLGCW,IGHV1-46,IGHJ6,CQSYDSGLSGSGVVF,IGLV1-40,COV047_P4_IgG_48-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGSSRYCSSTSCYSFGVDNFDYW,IGHV1-46,IGHJ1,CQVWDSSSDHYYVF,IGLV3-21,COV047_P3_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGSSRYCSSTSCYSFGVDNFDYW,IGHV1-46,IGHJ2,CQVWDSSSDHYYVF,IGLV3-21,COV047_P3_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGSSRYCSSTSCYSFGVDNFDYW,IGHV1-46,IGHJ3,CQVWDSSSDHYYVF,IGLV3-21,COV047_P3_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGSSRYCSSTSCYSFGVDNFDYW,IGHV1-46,IGHJ4,CQVWDSSSDHYYVF,IGLV3-21,COV047_P3_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGSSRYCSSTSCYSFGVDNFDYW,IGHV1-46,IGHJ5,CQVWDSSSDHYYVF,IGLV3-21,COV047_P3_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGSSRYCSSTSCYSFGVDNFDYW,IGHV1-46,IGHJ6,CQVWDSSSDHYYVF,IGLV3-21,COV047_P3_IgG_78-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYGYYFDYW,IGHV1-69,IGHJ1,CQQRSNWPSF,IGKV3-11,COV047_P4_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYGYYFDYW,IGHV1-69,IGHJ2,CQQRSNWPSF,IGKV3-11,COV047_P4_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYGYYFDYW,IGHV1-69,IGHJ3,CQQRSNWPSF,IGKV3-11,COV047_P4_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYGYYFDYW,IGHV1-69,IGHJ4,CQQRSNWPSF,IGKV3-11,COV047_P4_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYGYYFDYW,IGHV1-69,IGHJ5,CQQRSNWPSF,IGKV3-11,COV047_P4_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYGYYFDYW,IGHV1-69,IGHJ6,CQQRSNWPSF,IGKV3-11,COV047_P4_IgG_43-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRYCSGGRCLWWFDPW,IGHV1-69,IGHJ1,CQQSYSTPRTF,IGKV1-39,COV047_P4_IgG_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRYCSGGRCLWWFDPW,IGHV1-69,IGHJ2,CQQSYSTPRTF,IGKV1-39,COV047_P4_IgG_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRYCSGGRCLWWFDPW,IGHV1-69,IGHJ3,CQQSYSTPRTF,IGKV1-39,COV047_P4_IgG_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRYCSGGRCLWWFDPW,IGHV1-69,IGHJ4,CQQSYSTPRTF,IGKV1-39,COV047_P4_IgG_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRYCSGGRCLWWFDPW,IGHV1-69,IGHJ5,CQQSYSTPRTF,IGKV1-39,COV047_P4_IgG_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRYCSGGRCLWWFDPW,IGHV1-69,IGHJ6,CQQSYSTPRTF,IGKV1-39,COV047_P4_IgG_89-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYTYYYDRSGYYRPDYFDYW,IGHV1-69,IGHJ1,CQQFNSYQLTF,IGKV1-13,COV047_P5_IgG_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYTYYYDRSGYYRPDYFDYW,IGHV1-69,IGHJ2,CQQFNSYQLTF,IGKV1-13,COV047_P5_IgG_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYTYYYDRSGYYRPDYFDYW,IGHV1-69,IGHJ3,CQQFNSYQLTF,IGKV1-13,COV047_P5_IgG_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYTYYYDRSGYYRPDYFDYW,IGHV1-69,IGHJ4,CQQFNSYQLTF,IGKV1-13,COV047_P5_IgG_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYTYYYDRSGYYRPDYFDYW,IGHV1-69,IGHJ5,CQQFNSYQLTF,IGKV1-13,COV047_P5_IgG_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYTYYYDRSGYYRPDYFDYW,IGHV1-69,IGHJ6,CQQFNSYQLTF,IGKV1-13,COV047_P5_IgG_15-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTTNDYGDYSPAYW,IGHV3-15,IGHJ1,CQQSYSTPLTF,IGKV1-39,COV047_P3_IgG_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTTNDYGDYSPAYW,IGHV3-15,IGHJ2,CQQSYSTPLTF,IGKV1-39,COV047_P3_IgG_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTTNDYGDYSPAYW,IGHV3-15,IGHJ3,CQQSYSTPLTF,IGKV1-39,COV047_P3_IgG_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTTNDYGDYSPAYW,IGHV3-15,IGHJ4,CQQSYSTPLTF,IGKV1-39,COV047_P3_IgG_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTTNDYGDYSPAYW,IGHV3-15,IGHJ5,CQQSYSTPLTF,IGKV1-39,COV047_P3_IgG_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTTNDYGDYSPAYW,IGHV3-15,IGHJ6,CQQSYSTPLTF,IGKV1-39,COV047_P3_IgG_54-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSQVWLRGPGDYW,IGHV3-15,IGHJ1,CQSYDSSLNWVF,IGLV6-57,COV047_P5_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSQVWLRGPGDYW,IGHV3-15,IGHJ2,CQSYDSSLNWVF,IGLV6-57,COV047_P5_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSQVWLRGPGDYW,IGHV3-15,IGHJ3,CQSYDSSLNWVF,IGLV6-57,COV047_P5_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSQVWLRGPGDYW,IGHV3-15,IGHJ4,CQSYDSSLNWVF,IGLV6-57,COV047_P5_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSQVWLRGPGDYW,IGHV3-15,IGHJ5,CQSYDSSLNWVF,IGLV6-57,COV047_P5_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTSQVWLRGPGDYW,IGHV3-15,IGHJ6,CQSYDSSLNWVF,IGLV6-57,COV047_P5_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAEWEAFDIW,IGHV3-21,IGHJ1,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAEWEAFDIW,IGHV3-21,IGHJ2,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAEWEAFDIW,IGHV3-21,IGHJ3,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAEWEAFDIW,IGHV3-21,IGHJ4,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAEWEAFDIW,IGHV3-21,IGHJ5,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAEWEAFDIW,IGHV3-21,IGHJ6,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_17-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ1,CQQSYSTPPLTF,IGKV1-39,COV047_P5_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ2,CQQSYSTPPLTF,IGKV1-39,COV047_P5_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ3,CQQSYSTPPLTF,IGKV1-39,COV047_P5_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ4,CQQSYSTPPLTF,IGKV1-39,COV047_P5_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ5,CQQSYSTPPLTF,IGKV1-39,COV047_P5_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDVASNYAYFDLW,IGHV3-21,IGHJ6,CQQSYSTPPLTF,IGKV1-39,COV047_P5_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYGDNW,IGHV3-21,IGHJ1,CQTWGPWVF,IGLV4-69,COV047_P4_IgG_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYGDNW,IGHV3-21,IGHJ2,CQTWGPWVF,IGLV4-69,COV047_P4_IgG_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYGDNW,IGHV3-21,IGHJ3,CQTWGPWVF,IGLV4-69,COV047_P4_IgG_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYGDNW,IGHV3-21,IGHJ4,CQTWGPWVF,IGLV4-69,COV047_P4_IgG_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYGDNW,IGHV3-21,IGHJ5,CQTWGPWVF,IGLV4-69,COV047_P4_IgG_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARERYGDNW,IGHV3-21,IGHJ6,CQTWGPWVF,IGLV4-69,COV047_P4_IgG_67-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVANWFDPW,IGHV3-21,IGHJ1,CQQYYSTPQPSWTF,IGKV4-1,COV047_P3_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVANWFDPW,IGHV3-21,IGHJ2,CQQYYSTPQPSWTF,IGKV4-1,COV047_P3_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVANWFDPW,IGHV3-21,IGHJ3,CQQYYSTPQPSWTF,IGKV4-1,COV047_P3_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVANWFDPW,IGHV3-21,IGHJ4,CQQYYSTPQPSWTF,IGKV4-1,COV047_P3_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVANWFDPW,IGHV3-21,IGHJ5,CQQYYSTPQPSWTF,IGKV4-1,COV047_P3_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVANWFDPW,IGHV3-21,IGHJ6,CQQYYSTPQPSWTF,IGKV4-1,COV047_P3_IgG_84-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAARRYDFWSGLNWFDPW,IGHV3-21,IGHJ1,CQQYYSTMLTF,IGKV4-1,COV047_P3_IgG_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAARRYDFWSGLNWFDPW,IGHV3-21,IGHJ2,CQQYYSTMLTF,IGKV4-1,COV047_P3_IgG_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAARRYDFWSGLNWFDPW,IGHV3-21,IGHJ3,CQQYYSTMLTF,IGKV4-1,COV047_P3_IgG_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAARRYDFWSGLNWFDPW,IGHV3-21,IGHJ4,CQQYYSTMLTF,IGKV4-1,COV047_P3_IgG_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAARRYDFWSGLNWFDPW,IGHV3-21,IGHJ5,CQQYYSTMLTF,IGKV4-1,COV047_P3_IgG_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAARRYDFWSGLNWFDPW,IGHV3-21,IGHJ6,CQQYYSTMLTF,IGKV4-1,COV047_P3_IgG_40-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSGGRHYYDSSGYYRLPLDDAFDIW,IGHV3-23,IGHJ1,CQSYDSSLSGSWVF,IGLV1-40,COV047_P4_IgG_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSGGRHYYDSSGYYRLPLDDAFDIW,IGHV3-23,IGHJ2,CQSYDSSLSGSWVF,IGLV1-40,COV047_P4_IgG_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSGGRHYYDSSGYYRLPLDDAFDIW,IGHV3-23,IGHJ3,CQSYDSSLSGSWVF,IGLV1-40,COV047_P4_IgG_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSGGRHYYDSSGYYRLPLDDAFDIW,IGHV3-23,IGHJ4,CQSYDSSLSGSWVF,IGLV1-40,COV047_P4_IgG_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSGGRHYYDSSGYYRLPLDDAFDIW,IGHV3-23,IGHJ5,CQSYDSSLSGSWVF,IGLV1-40,COV047_P4_IgG_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSGGRHYYDSSGYYRLPLDDAFDIW,IGHV3-23,IGHJ6,CQSYDSSLSGSWVF,IGLV1-40,COV047_P4_IgG_36-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAEWLRGAFDIW,IGHV3-30,IGHJ1,CQSYDSTNHWVF,IGLV6-57,COV047_P4_IgG_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAEWLRGAFDIW,IGHV3-30,IGHJ2,CQSYDSTNHWVF,IGLV6-57,COV047_P4_IgG_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAEWLRGAFDIW,IGHV3-30,IGHJ3,CQSYDSTNHWVF,IGLV6-57,COV047_P4_IgG_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAEWLRGAFDIW,IGHV3-30,IGHJ4,CQSYDSTNHWVF,IGLV6-57,COV047_P4_IgG_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAEWLRGAFDIW,IGHV3-30,IGHJ5,CQSYDSTNHWVF,IGLV6-57,COV047_P4_IgG_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAEWLRGAFDIW,IGHV3-30,IGHJ6,CQSYDSTNHWVF,IGLV6-57,COV047_P4_IgG_52-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGWELLRIRYYFDFW,IGHV3-30,IGHJ1,CQQYDNLPPTF,IGKV1-33,COV047_P3_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGWELLRIRYYFDFW,IGHV3-30,IGHJ2,CQQYDNLPPTF,IGKV1-33,COV047_P3_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGWELLRIRYYFDFW,IGHV3-30,IGHJ3,CQQYDNLPPTF,IGKV1-33,COV047_P3_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGWELLRIRYYFDFW,IGHV3-30,IGHJ4,CQQYDNLPPTF,IGKV1-33,COV047_P3_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGWELLRIRYYFDFW,IGHV3-30,IGHJ5,CQQYDNLPPTF,IGKV1-33,COV047_P3_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAGWELLRIRYYFDFW,IGHV3-30,IGHJ6,CQQYDNLPPTF,IGKV1-33,COV047_P3_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CYALFERGNWNDAEYW,IGHV3-30,IGHJ1,CMQGTHWPRTF,IGKV2-30,COV047_P4_IgG_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CYALFERGNWNDAEYW,IGHV3-30,IGHJ2,CMQGTHWPRTF,IGKV2-30,COV047_P4_IgG_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CYALFERGNWNDAEYW,IGHV3-30,IGHJ3,CMQGTHWPRTF,IGKV2-30,COV047_P4_IgG_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CYALFERGNWNDAEYW,IGHV3-30,IGHJ4,CMQGTHWPRTF,IGKV2-30,COV047_P4_IgG_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CYALFERGNWNDAEYW,IGHV3-30,IGHJ5,CMQGTHWPRTF,IGKV2-30,COV047_P4_IgG_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CYALFERGNWNDAEYW,IGHV3-30,IGHJ6,CMQGTHWPRTF,IGKV2-30,COV047_P4_IgG_31-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLGSSLYYDAFDIW,IGHV3-30,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV047_P5_IgG_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLGSSLYYDAFDIW,IGHV3-30,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV047_P5_IgG_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLGSSLYYDAFDIW,IGHV3-30,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV047_P5_IgG_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLGSSLYYDAFDIW,IGHV3-30,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV047_P5_IgG_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLGSSLYYDAFDIW,IGHV3-30,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV047_P5_IgG_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLGSSLYYDAFDIW,IGHV3-30,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV047_P5_IgG_30-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDGSYYYYYYGMDVW,IGHV3-30,IGHJ1,CSSYTSSSTAWVF,IGLV2-14,COV047_P4_IgG_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDGSYYYYYYGMDVW,IGHV3-30,IGHJ2,CSSYTSSSTAWVF,IGLV2-14,COV047_P4_IgG_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDGSYYYYYYGMDVW,IGHV3-30,IGHJ3,CSSYTSSSTAWVF,IGLV2-14,COV047_P4_IgG_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDGSYYYYYYGMDVW,IGHV3-30,IGHJ4,CSSYTSSSTAWVF,IGLV2-14,COV047_P4_IgG_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDGSYYYYYYGMDVW,IGHV3-30,IGHJ5,CSSYTSSSTAWVF,IGLV2-14,COV047_P4_IgG_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVDGSYYYYYYGMDVW,IGHV3-30,IGHJ6,CSSYTSSSTAWVF,IGLV2-14,COV047_P4_IgG_20-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREQEANYYDISGYYHWGESLGYW,IGHV3-33,IGHJ1,CQKVNSHPPGLTF,IGKV1-9,COV047_P4_IgG_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREQEANYYDISGYYHWGESLGYW,IGHV3-33,IGHJ2,CQKVNSHPPGLTF,IGKV1-9,COV047_P4_IgG_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREQEANYYDISGYYHWGESLGYW,IGHV3-33,IGHJ3,CQKVNSHPPGLTF,IGKV1-9,COV047_P4_IgG_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREQEANYYDISGYYHWGESLGYW,IGHV3-33,IGHJ4,CQKVNSHPPGLTF,IGKV1-9,COV047_P4_IgG_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREQEANYYDISGYYHWGESLGYW,IGHV3-33,IGHJ5,CQKVNSHPPGLTF,IGKV1-9,COV047_P4_IgG_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREQEANYYDISGYYHWGESLGYW,IGHV3-33,IGHJ6,CQKVNSHPPGLTF,IGKV1-9,COV047_P4_IgG_22-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYYDSSGYNGTYEFDYW,IGHV3-33,IGHJ1,CQQYNNWPPVTF,IGKV3-15,COV047_P4_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYYDSSGYNGTYEFDYW,IGHV3-33,IGHJ2,CQQYNNWPPVTF,IGKV3-15,COV047_P4_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYYDSSGYNGTYEFDYW,IGHV3-33,IGHJ3,CQQYNNWPPVTF,IGKV3-15,COV047_P4_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYYDSSGYNGTYEFDYW,IGHV3-33,IGHJ4,CQQYNNWPPVTF,IGKV3-15,COV047_P4_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYYDSSGYNGTYEFDYW,IGHV3-33,IGHJ5,CQQYNNWPPVTF,IGKV3-15,COV047_P4_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGRYYDSSGYNGTYEFDYW,IGHV3-33,IGHJ6,CQQYNNWPPVTF,IGKV3-15,COV047_P4_IgG_70-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRKYSSGWSVVNFDYW,IGHV3-33,IGHJ1,CAAWDDSLNGWVF,IGLV1-36,COV047_P4_IgG_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRKYSSGWSVVNFDYW,IGHV3-33,IGHJ2,CAAWDDSLNGWVF,IGLV1-36,COV047_P4_IgG_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRKYSSGWSVVNFDYW,IGHV3-33,IGHJ3,CAAWDDSLNGWVF,IGLV1-36,COV047_P4_IgG_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRKYSSGWSVVNFDYW,IGHV3-33,IGHJ4,CAAWDDSLNGWVF,IGLV1-36,COV047_P4_IgG_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRKYSSGWSVVNFDYW,IGHV3-33,IGHJ5,CAAWDDSLNGWVF,IGLV1-36,COV047_P4_IgG_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRKYSSGWSVVNFDYW,IGHV3-33,IGHJ6,CAAWDDSLNGWVF,IGLV1-36,COV047_P4_IgG_50-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLNWNVPHYGMDVW,IGHV3-33,IGHJ1,CQQANSFPPLTF,IGKV1-12,COV047_P5_IgG_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLNWNVPHYGMDVW,IGHV3-33,IGHJ2,CQQANSFPPLTF,IGKV1-12,COV047_P5_IgG_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLNWNVPHYGMDVW,IGHV3-33,IGHJ3,CQQANSFPPLTF,IGKV1-12,COV047_P5_IgG_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLNWNVPHYGMDVW,IGHV3-33,IGHJ4,CQQANSFPPLTF,IGKV1-12,COV047_P5_IgG_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLNWNVPHYGMDVW,IGHV3-33,IGHJ5,CQQANSFPPLTF,IGKV1-12,COV047_P5_IgG_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGLNWNVPHYGMDVW,IGHV3-33,IGHJ6,CQQANSFPPLTF,IGKV1-12,COV047_P5_IgG_59-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGGAHSGYDGSFDYW,IGHV3-53,IGHJ1,CCSYAGSSTWVF,IGLV2-23,COV047_P5_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGGAHSGYDGSFDYW,IGHV3-53,IGHJ2,CCSYAGSSTWVF,IGLV2-23,COV047_P5_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGGAHSGYDGSFDYW,IGHV3-53,IGHJ3,CCSYAGSSTWVF,IGLV2-23,COV047_P5_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGGAHSGYDGSFDYW,IGHV3-53,IGHJ4,CCSYAGSSTWVF,IGLV2-23,COV047_P5_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGGAHSGYDGSFDYW,IGHV3-53,IGHJ5,CCSYAGSSTWVF,IGLV2-23,COV047_P5_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGGAHSGYDGSFDYW,IGHV3-53,IGHJ6,CCSYAGSSTWVF,IGLV2-23,COV047_P5_IgG_58-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRVIYGMDVW,IGHV3-53,IGHJ1,CQQYDNLPQTF,IGKV1-33,COV047_P5_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRVIYGMDVW,IGHV3-53,IGHJ2,CQQYDNLPQTF,IGKV1-33,COV047_P5_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRVIYGMDVW,IGHV3-53,IGHJ3,CQQYDNLPQTF,IGKV1-33,COV047_P5_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRVIYGMDVW,IGHV3-53,IGHJ4,CQQYDNLPQTF,IGKV1-33,COV047_P5_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRVIYGMDVW,IGHV3-53,IGHJ5,CQQYDNLPQTF,IGKV1-33,COV047_P5_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRVIYGMDVW,IGHV3-53,IGHJ6,CQQYDNLPQTF,IGKV1-33,COV047_P5_IgG_8-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAISESPRYGVYW,IGHV3-53,IGHJ1,CQQYDNLPLTF,IGKV1-33,COV047_P4_IgG_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAISESPRYGVYW,IGHV3-53,IGHJ2,CQQYDNLPLTF,IGKV1-33,COV047_P4_IgG_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAISESPRYGVYW,IGHV3-53,IGHJ3,CQQYDNLPLTF,IGKV1-33,COV047_P4_IgG_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAISESPRYGVYW,IGHV3-53,IGHJ4,CQQYDNLPLTF,IGKV1-33,COV047_P4_IgG_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAISESPRYGVYW,IGHV3-53,IGHJ5,CQQYDNLPLTF,IGKV1-33,COV047_P4_IgG_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAISESPRYGVYW,IGHV3-53,IGHJ6,CQQYDNLPLTF,IGKV1-33,COV047_P4_IgG_11-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLPFGDYFDYW,IGHV3-53,IGHJ1,CQSYDINLSAWVF,IGLV1-40,COV047_P3_IgG_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLPFGDYFDYW,IGHV3-53,IGHJ2,CQSYDINLSAWVF,IGLV1-40,COV047_P3_IgG_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLPFGDYFDYW,IGHV3-53,IGHJ3,CQSYDINLSAWVF,IGLV1-40,COV047_P3_IgG_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLPFGDYFDYW,IGHV3-53,IGHJ4,CQSYDINLSAWVF,IGLV1-40,COV047_P3_IgG_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLPFGDYFDYW,IGHV3-53,IGHJ5,CQSYDINLSAWVF,IGLV1-40,COV047_P3_IgG_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLPFGDYFDYW,IGHV3-53,IGHJ6,CQSYDINLSAWVF,IGLV1-40,COV047_P3_IgG_14-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ1,CQQYYSTPLTF,IGKV4-1,COV047_P5_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ2,CQQYYSTPLTF,IGKV4-1,COV047_P5_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ3,CQQYYSTPLTF,IGKV4-1,COV047_P5_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ4,CQQYYSTPLTF,IGKV4-1,COV047_P5_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ5,CQQYYSTPLTF,IGKV4-1,COV047_P5_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSSEVRDHPGHPGRSVGAFDIW,IGHV3-66,IGHJ6,CQQYYSTPLTF,IGKV4-1,COV047_P5_IgG_91-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSTPGYGDYW,IGHV3-66,IGHJ1,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSTPGYGDYW,IGHV3-66,IGHJ2,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSTPGYGDYW,IGHV3-66,IGHJ3,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSTPGYGDYW,IGHV3-66,IGHJ4,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSTPGYGDYW,IGHV3-66,IGHJ5,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSTPGYGDYW,IGHV3-66,IGHJ6,CQQYDNLPITF,IGKV1-33,COV047_P4_IgG_51-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ1,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ2,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ3,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ4,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ5,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-66,IGHJ6,CQQYNNWPRTF,IGKV3-15,COV047_P3_IgG_47-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRDQDGYSYGAFDYW,IGHV3-66,IGHJ1,CSSYTSSSSWVF,IGLV2-14,COV047_P5_IgG_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRDQDGYSYGAFDYW,IGHV3-66,IGHJ2,CSSYTSSSSWVF,IGLV2-14,COV047_P5_IgG_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRDQDGYSYGAFDYW,IGHV3-66,IGHJ3,CSSYTSSSSWVF,IGLV2-14,COV047_P5_IgG_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRDQDGYSYGAFDYW,IGHV3-66,IGHJ4,CSSYTSSSSWVF,IGLV2-14,COV047_P5_IgG_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRDQDGYSYGAFDYW,IGHV3-66,IGHJ5,CSSYTSSSSWVF,IGLV2-14,COV047_P5_IgG_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLRDQDGYSYGAFDYW,IGHV3-66,IGHJ6,CSSYTSSSSWVF,IGLV2-14,COV047_P5_IgG_71-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAFWQRGNFDYW,IGHV3-74,IGHJ1,CQSYDSSILWVF,IGLV6-57,COV047_P5_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAFWQRGNFDYW,IGHV3-74,IGHJ2,CQSYDSSILWVF,IGLV6-57,COV047_P5_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAFWQRGNFDYW,IGHV3-74,IGHJ3,CQSYDSSILWVF,IGLV6-57,COV047_P5_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAFWQRGNFDYW,IGHV3-74,IGHJ4,CQSYDSSILWVF,IGLV6-57,COV047_P5_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAFWQRGNFDYW,IGHV3-74,IGHJ5,CQSYDSSILWVF,IGLV6-57,COV047_P5_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASAFWQRGNFDYW,IGHV3-74,IGHJ6,CQSYDSSILWVF,IGLV6-57,COV047_P5_IgG_16-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPTAVAAAGNYFYYYGMDVW,IGHV3-74,IGHJ1,CSSYRSSSTLVF,IGLV2-14,COV047_P3_IgG_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPTAVAAAGNYFYYYGMDVW,IGHV3-74,IGHJ2,CSSYRSSSTLVF,IGLV2-14,COV047_P3_IgG_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPTAVAAAGNYFYYYGMDVW,IGHV3-74,IGHJ3,CSSYRSSSTLVF,IGLV2-14,COV047_P3_IgG_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPTAVAAAGNYFYYYGMDVW,IGHV3-74,IGHJ4,CSSYRSSSTLVF,IGLV2-14,COV047_P3_IgG_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPTAVAAAGNYFYYYGMDVW,IGHV3-74,IGHJ5,CSSYRSSSTLVF,IGLV2-14,COV047_P3_IgG_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARPTAVAAAGNYFYYYGMDVW,IGHV3-74,IGHJ6,CSSYRSSSTLVF,IGLV2-14,COV047_P3_IgG_25-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFTNPNYYDSSGYYGFDYW,IGHV4-30-2,IGHJ1,CTSYAGSNNWVF,IGLV2-8,COV047_P4_IgG_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFTNPNYYDSSGYYGFDYW,IGHV4-30-2,IGHJ2,CTSYAGSNNWVF,IGLV2-8,COV047_P4_IgG_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFTNPNYYDSSGYYGFDYW,IGHV4-30-2,IGHJ3,CTSYAGSNNWVF,IGLV2-8,COV047_P4_IgG_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFTNPNYYDSSGYYGFDYW,IGHV4-30-2,IGHJ4,CTSYAGSNNWVF,IGLV2-8,COV047_P4_IgG_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFTNPNYYDSSGYYGFDYW,IGHV4-30-2,IGHJ5,CTSYAGSNNWVF,IGLV2-8,COV047_P4_IgG_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARFTNPNYYDSSGYYGFDYW,IGHV4-30-2,IGHJ6,CTSYAGSNNWVF,IGLV2-8,COV047_P4_IgG_86-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVKGWLRGYFDYW,IGHV4-31,IGHJ1,CQSYDSGSHVVF,IGLV6-57,COV047_P4_IgG_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVKGWLRGYFDYW,IGHV4-31,IGHJ2,CQSYDSGSHVVF,IGLV6-57,COV047_P4_IgG_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVKGWLRGYFDYW,IGHV4-31,IGHJ3,CQSYDSGSHVVF,IGLV6-57,COV047_P4_IgG_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVKGWLRGYFDYW,IGHV4-31,IGHJ4,CQSYDSGSHVVF,IGLV6-57,COV047_P4_IgG_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVKGWLRGYFDYW,IGHV4-31,IGHJ5,CQSYDSGSHVVF,IGLV6-57,COV047_P4_IgG_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVKGWLRGYFDYW,IGHV4-31,IGHJ6,CQSYDSGSHVVF,IGLV6-57,COV047_P4_IgG_39-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAAFLDYW,IGHV4-4,IGHJ1,CQQYYSTRTF,IGKV1-NL1,COV047_P4_IgG_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAAFLDYW,IGHV4-4,IGHJ2,CQQYYSTRTF,IGKV1-NL1,COV047_P4_IgG_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAAFLDYW,IGHV4-4,IGHJ3,CQQYYSTRTF,IGKV1-NL1,COV047_P4_IgG_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAAFLDYW,IGHV4-4,IGHJ4,CQQYYSTRTF,IGKV1-NL1,COV047_P4_IgG_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAAFLDYW,IGHV4-4,IGHJ5,CQQYYSTRTF,IGKV1-NL1,COV047_P4_IgG_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVAAFLDYW,IGHV4-4,IGHJ6,CQQYYSTRTF,IGKV1-NL1,COV047_P4_IgG_83-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTWIQPHNWFDPW,IGHV4-4,IGHJ1,CQQYNSYPLFTF,IGKV1-16,COV047_P3_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTWIQPHNWFDPW,IGHV4-4,IGHJ2,CQQYNSYPLFTF,IGKV1-16,COV047_P3_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTWIQPHNWFDPW,IGHV4-4,IGHJ3,CQQYNSYPLFTF,IGKV1-16,COV047_P3_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTWIQPHNWFDPW,IGHV4-4,IGHJ4,CQQYNSYPLFTF,IGKV1-16,COV047_P3_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTWIQPHNWFDPW,IGHV4-4,IGHJ5,CQQYNSYPLFTF,IGKV1-16,COV047_P3_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTWIQPHNWFDPW,IGHV4-4,IGHJ6,CQQYNSYPLFTF,IGKV1-16,COV047_P3_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPPRLLWFGESPPTYWYFNLW,IGHV4-4,IGHJ1,CQQYYSTPLTF,IGKV4-1,COV047_P4_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPPRLLWFGESPPTYWYFNLW,IGHV4-4,IGHJ2,CQQYYSTPLTF,IGKV4-1,COV047_P4_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPPRLLWFGESPPTYWYFNLW,IGHV4-4,IGHJ3,CQQYYSTPLTF,IGKV4-1,COV047_P4_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPPRLLWFGESPPTYWYFNLW,IGHV4-4,IGHJ4,CQQYYSTPLTF,IGKV4-1,COV047_P4_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPPRLLWFGESPPTYWYFNLW,IGHV4-4,IGHJ5,CQQYYSTPLTF,IGKV4-1,COV047_P4_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPPRLLWFGESPPTYWYFNLW,IGHV4-4,IGHJ6,CQQYYSTPLTF,IGKV4-1,COV047_P4_IgG_72-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYQLAPGSGSYYNWGGYPRESEYYFDYW,IGHV4-59,IGHJ1,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYQLAPGSGSYYNWGGYPRESEYYFDYW,IGHV4-59,IGHJ2,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYQLAPGSGSYYNWGGYPRESEYYFDYW,IGHV4-59,IGHJ3,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYQLAPGSGSYYNWGGYPRESEYYFDYW,IGHV4-59,IGHJ4,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYQLAPGSGSYYNWGGYPRESEYYFDYW,IGHV4-59,IGHJ5,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYQLAPGSGSYYNWGGYPRESEYYFDYW,IGHV4-59,IGHJ6,CCSYAGSYTWVF,IGLV2-11,COV047_P4_IgG_38-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHDTIFGVGQYYFDYW,IGHV4-59,IGHJ1,CCSYAGSSTWVF,IGLV2-23,COV047_P3_IgG_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHDTIFGVGQYYFDYW,IGHV4-59,IGHJ2,CCSYAGSSTWVF,IGLV2-23,COV047_P3_IgG_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHDTIFGVGQYYFDYW,IGHV4-59,IGHJ3,CCSYAGSSTWVF,IGLV2-23,COV047_P3_IgG_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHDTIFGVGQYYFDYW,IGHV4-59,IGHJ4,CCSYAGSSTWVF,IGLV2-23,COV047_P3_IgG_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHDTIFGVGQYYFDYW,IGHV4-59,IGHJ5,CCSYAGSSTWVF,IGLV2-23,COV047_P3_IgG_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHDTIFGVGQYYFDYW,IGHV4-59,IGHJ6,CCSYAGSSTWVF,IGLV2-23,COV047_P3_IgG_5-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHSWLRGMADYW,IGHV4-59,IGHJ1,CQSYDSSIWVF,IGLV6-57,COV047_P3_IgG_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHSWLRGMADYW,IGHV4-59,IGHJ2,CQSYDSSIWVF,IGLV6-57,COV047_P3_IgG_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHSWLRGMADYW,IGHV4-59,IGHJ3,CQSYDSSIWVF,IGLV6-57,COV047_P3_IgG_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHSWLRGMADYW,IGHV4-59,IGHJ4,CQSYDSSIWVF,IGLV6-57,COV047_P3_IgG_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHSWLRGMADYW,IGHV4-59,IGHJ5,CQSYDSSIWVF,IGLV6-57,COV047_P3_IgG_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHSWLRGMADYW,IGHV4-59,IGHJ6,CQSYDSSIWVF,IGLV6-57,COV047_P3_IgG_35-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLKQQLVGFGWFDPW,IGHV4-59,IGHJ1,CQSYDHSLNWVF,IGLV1-40,COV047_P3_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLKQQLVGFGWFDPW,IGHV4-59,IGHJ2,CQSYDHSLNWVF,IGLV1-40,COV047_P3_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLKQQLVGFGWFDPW,IGHV4-59,IGHJ3,CQSYDHSLNWVF,IGLV1-40,COV047_P3_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLKQQLVGFGWFDPW,IGHV4-59,IGHJ4,CQSYDHSLNWVF,IGLV1-40,COV047_P3_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLKQQLVGFGWFDPW,IGHV4-59,IGHJ5,CQSYDHSLNWVF,IGLV1-40,COV047_P3_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLKQQLVGFGWFDPW,IGHV4-59,IGHJ6,CQSYDHSLNWVF,IGLV1-40,COV047_P3_IgG_49-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDILRDTSWPHDAFDIW,IGHV6-1,IGHJ1,CSSYTSSSTPFYVF,IGLV2-14,COV047_P4_IgG_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDILRDTSWPHDAFDIW,IGHV6-1,IGHJ2,CSSYTSSSTPFYVF,IGLV2-14,COV047_P4_IgG_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDILRDTSWPHDAFDIW,IGHV6-1,IGHJ3,CSSYTSSSTPFYVF,IGLV2-14,COV047_P4_IgG_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDILRDTSWPHDAFDIW,IGHV6-1,IGHJ4,CSSYTSSSTPFYVF,IGLV2-14,COV047_P4_IgG_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDILRDTSWPHDAFDIW,IGHV6-1,IGHJ5,CSSYTSSSTPFYVF,IGLV2-14,COV047_P4_IgG_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDILRDTSWPHDAFDIW,IGHV6-1,IGHJ6,CSSYTSSSTPFYVF,IGLV2-14,COV047_P4_IgG_23-P1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P2_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_B9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_E11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_F6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_F6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_F6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_F6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_F6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P1_HC_F6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_A6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_A6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_A6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_A6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_A6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_A6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ1,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ2,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ3,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ4,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ5,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKEGRPSDIVVVVAFDYW,IGHV3-30,IGHJ6,CQQSYSTPRTF,IGKV1-39,COVD21_P3_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ1,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ2,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ3,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ4,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ5,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ6,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ1,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ2,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ3,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ4,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ5,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ6,CQQYDNLPITF,IGKV1-33,COVD21_P2_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ1,CQQYDNLPITF,IGKV1-33,COVD21_P1_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ2,CQQYDNLPITF,IGKV1-33,COVD21_P1_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ3,CQQYDNLPITF,IGKV1-33,COVD21_P1_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ4,CQQYDNLPITF,IGKV1-33,COVD21_P1_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ5,CQQYDNLPITF,IGKV1-33,COVD21_P1_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASPASRGYSGYDHGYYYYMDVW,IGHV1-2,IGHJ6,CQQYDNLPITF,IGKV1-33,COVD21_P1_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ1,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_E5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ2,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_E5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ3,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_E5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ4,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_E5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ5,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_E5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ6,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_E5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ1,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ2,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ3,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ4,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ5,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ6,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ1,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ2,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ3,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ4,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ5,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARRGDGSSSIYYYNYMDVW,IGHV3-11,IGHJ6,CAAWDDSLNGPVF,IGLV1-44,COVD21_P1_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTAMVTWFDYW,IGHV3-30-3,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_A11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTAMVTWFDYW,IGHV3-30-3,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_A11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTAMVTWFDYW,IGHV3-30-3,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_A11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTAMVTWFDYW,IGHV3-30-3,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_A11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTAMVTWFDYW,IGHV3-30-3,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_A11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTAMVTWFDYW,IGHV3-30-3,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_A11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGMATTYFDYW,IGHV3-30-3,IGHJ1,CQQSYNTPPWTF,IGKV1-39,COVD21_P2_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGMATTYFDYW,IGHV3-30-3,IGHJ2,CQQSYNTPPWTF,IGKV1-39,COVD21_P2_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGMATTYFDYW,IGHV3-30-3,IGHJ3,CQQSYNTPPWTF,IGKV1-39,COVD21_P2_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGMATTYFDYW,IGHV3-30-3,IGHJ4,CQQSYNTPPWTF,IGKV1-39,COVD21_P2_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGMATTYFDYW,IGHV3-30-3,IGHJ5,CQQSYNTPPWTF,IGKV1-39,COVD21_P2_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDQGMATTYFDYW,IGHV3-30-3,IGHJ6,CQQSYNTPPWTF,IGKV1-39,COVD21_P2_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTALVTWFDYW,IGHV3-30-3,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTALVTWFDYW,IGHV3-30-3,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTALVTWFDYW,IGHV3-30-3,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTALVTWFDYW,IGHV3-30-3,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTALVTWFDYW,IGHV3-30-3,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGIVDTALVTWFDYW,IGHV3-30-3,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COVD21_P2_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSGLGASNDYW,IGHV1-2,IGHJ1,CSSDAGSNNVVF,IGLV2-8,COVD21_P1_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSGLGASNDYW,IGHV1-2,IGHJ2,CSSDAGSNNVVF,IGLV2-8,COVD21_P1_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSGLGASNDYW,IGHV1-2,IGHJ3,CSSDAGSNNVVF,IGLV2-8,COVD21_P1_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSGLGASNDYW,IGHV1-2,IGHJ4,CSSDAGSNNVVF,IGLV2-8,COVD21_P1_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSGLGASNDYW,IGHV1-2,IGHJ5,CSSDAGSNNVVF,IGLV2-8,COVD21_P1_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSGLGASNDYW,IGHV1-2,IGHJ6,CSSDAGSNNVVF,IGLV2-8,COVD21_P1_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSALGASNDYW,IGHV1-2,IGHJ1,CSSDAGSNNVVF,IGLV2-8,COVD21_P3_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSALGASNDYW,IGHV1-2,IGHJ2,CSSDAGSNNVVF,IGLV2-8,COVD21_P3_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSALGASNDYW,IGHV1-2,IGHJ3,CSSDAGSNNVVF,IGLV2-8,COVD21_P3_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSALGASNDYW,IGHV1-2,IGHJ4,CSSDAGSNNVVF,IGLV2-8,COVD21_P3_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSALGASNDYW,IGHV1-2,IGHJ5,CSSDAGSNNVVF,IGLV2-8,COVD21_P3_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSPFSALGASNDYW,IGHV1-2,IGHJ6,CSSDAGSNNVVF,IGLV2-8,COVD21_P3_HC_B5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCLDAFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,COVD21_P2_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCLDAFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,COVD21_P2_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCLDAFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,COVD21_P2_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCLDAFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,COVD21_P2_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCLDAFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,COVD21_P2_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCLDAFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,COVD21_P2_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCYDAFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,COVD21_P1_HC_F10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCYDAFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,COVD21_P1_HC_F10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCYDAFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,COVD21_P1_HC_F10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCYDAFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,COVD21_P1_HC_F10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCYDAFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,COVD21_P1_HC_F10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAAPHCSGGSCYDAFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,COVD21_P1_HC_F10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDSSGYSYTVDSW,IGHV3-15,IGHJ1,CMQGLQTPLTF,IGKV2-28,COVD21_P2_HC_E9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDSSGYSYTVDSW,IGHV3-15,IGHJ2,CMQGLQTPLTF,IGKV2-28,COVD21_P2_HC_E9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDSSGYSYTVDSW,IGHV3-15,IGHJ3,CMQGLQTPLTF,IGKV2-28,COVD21_P2_HC_E9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDSSGYSYTVDSW,IGHV3-15,IGHJ4,CMQGLQTPLTF,IGKV2-28,COVD21_P2_HC_E9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDSSGYSYTVDSW,IGHV3-15,IGHJ5,CMQGLQTPLTF,IGKV2-28,COVD21_P2_HC_E9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDSSGYSYTVDSW,IGHV3-15,IGHJ6,CMQGLQTPLTF,IGKV2-28,COVD21_P2_HC_E9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDDSGYSYTVDYW,IGHV3-15,IGHJ1,CMQALQTPLTF,IGKV2-28,COVD21_P2_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDDSGYSYTVDYW,IGHV3-15,IGHJ2,CMQALQTPLTF,IGKV2-28,COVD21_P2_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDDSGYSYTVDYW,IGHV3-15,IGHJ3,CMQALQTPLTF,IGKV2-28,COVD21_P2_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDDSGYSYTVDYW,IGHV3-15,IGHJ4,CMQALQTPLTF,IGKV2-28,COVD21_P2_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDDSGYSYTVDYW,IGHV3-15,IGHJ5,CMQALQTPLTF,IGKV2-28,COVD21_P2_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPHYDDSGYSYTVDYW,IGHV3-15,IGHJ6,CMQALQTPLTF,IGKV2-28,COVD21_P2_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGDCYSYYFDYW,IGHV3-30,IGHJ1,CQQYNSYSTF,IGKV1-5,COVD21_P2_HC_G4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGDCYSYYFDYW,IGHV3-30,IGHJ2,CQQYNSYSTF,IGKV1-5,COVD21_P2_HC_G4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGDCYSYYFDYW,IGHV3-30,IGHJ3,CQQYNSYSTF,IGKV1-5,COVD21_P2_HC_G4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGDCYSYYFDYW,IGHV3-30,IGHJ4,CQQYNSYSTF,IGKV1-5,COVD21_P2_HC_G4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGDCYSYYFDYW,IGHV3-30,IGHJ5,CQQYNSYSTF,IGKV1-5,COVD21_P2_HC_G4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGDCYSYYFDYW,IGHV3-30,IGHJ6,CQQYNSYSTF,IGKV1-5,COVD21_P2_HC_G4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGNCYSYYFDYW,IGHV3-30,IGHJ1,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGNCYSYYFDYW,IGHV3-30,IGHJ2,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGNCYSYYFDYW,IGHV3-30,IGHJ3,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGNCYSYYFDYW,IGHV3-30,IGHJ4,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGNCYSYYFDYW,IGHV3-30,IGHJ5,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGIYCSGGNCYSYYFDYW,IGHV3-30,IGHJ6,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGRVVYAIDPDSVSPFDYW,IGHV3-9,IGHJ1,CSSYTSRSTLGVF,IGLV2-14,COVD21_P2_HC_F2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGRVVYAIDPDSVSPFDYW,IGHV3-9,IGHJ2,CSSYTSRSTLGVF,IGLV2-14,COVD21_P2_HC_F2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGRVVYAIDPDSVSPFDYW,IGHV3-9,IGHJ3,CSSYTSRSTLGVF,IGLV2-14,COVD21_P2_HC_F2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGRVVYAIDPDSVSPFDYW,IGHV3-9,IGHJ4,CSSYTSRSTLGVF,IGLV2-14,COVD21_P2_HC_F2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGRVVYAIDPDSVSPFDYW,IGHV3-9,IGHJ5,CSSYTSRSTLGVF,IGLV2-14,COVD21_P2_HC_F2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGRVVYAIDPDSVSPFDYW,IGHV3-9,IGHJ6,CSSYTSRSTLGVF,IGLV2-14,COVD21_P2_HC_F2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKPRKRGDYYGSGSYDYW,IGHV3-9,IGHJ1,CSSYTSSSTVVF,IGLV2-14,COVD21_P1_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKPRKRGDYYGSGSYDYW,IGHV3-9,IGHJ2,CSSYTSSSTVVF,IGLV2-14,COVD21_P1_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKPRKRGDYYGSGSYDYW,IGHV3-9,IGHJ3,CSSYTSSSTVVF,IGLV2-14,COVD21_P1_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKPRKRGDYYGSGSYDYW,IGHV3-9,IGHJ4,CSSYTSSSTVVF,IGLV2-14,COVD21_P1_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKPRKRGDYYGSGSYDYW,IGHV3-9,IGHJ5,CSSYTSSSTVVF,IGLV2-14,COVD21_P1_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKPRKRGDYYGSGSYDYW,IGHV3-9,IGHJ6,CSSYTSSSTVVF,IGLV2-14,COVD21_P1_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ1,CQQYNNYRYTF,IGKV1-5,COVD21_P2_HC_B10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ2,CQQYNNYRYTF,IGKV1-5,COVD21_P2_HC_B10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ3,CQQYNNYRYTF,IGKV1-5,COVD21_P2_HC_B10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ4,CQQYNNYRYTF,IGKV1-5,COVD21_P2_HC_B10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ5,CQQYNNYRYTF,IGKV1-5,COVD21_P2_HC_B10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ6,CQQYNNYRYTF,IGKV1-5,COVD21_P2_HC_B10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ1,CQKYNSYRYTF,IGKV1-5,COVD21_P2_HC_H11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ2,CQKYNSYRYTF,IGKV1-5,COVD21_P2_HC_H11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ3,CQKYNSYRYTF,IGKV1-5,COVD21_P2_HC_H11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ4,CQKYNSYRYTF,IGKV1-5,COVD21_P2_HC_H11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ5,CQKYNSYRYTF,IGKV1-5,COVD21_P2_HC_H11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHAAAYYDRSGYYFIEYFQHW,IGHV4-39,IGHJ6,CQKYNSYRYTF,IGKV1-5,COVD21_P2_HC_H11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDGTPAEYFQYW,IGHV1-18,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDGTPAEYFQYW,IGHV1-18,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDGTPAEYFQYW,IGHV1-18,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDGTPAEYFQYW,IGHV1-18,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDGTPAEYFQYW,IGHV1-18,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTDGTPAEYFQYW,IGHV1-18,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGQDELTGAFDIW,IGHV1-2,IGHJ1,CQVWDSGWVF,IGLV3-21,COVD21_P2_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGQDELTGAFDIW,IGHV1-2,IGHJ2,CQVWDSGWVF,IGLV3-21,COVD21_P2_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGQDELTGAFDIW,IGHV1-2,IGHJ3,CQVWDSGWVF,IGLV3-21,COVD21_P2_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGQDELTGAFDIW,IGHV1-2,IGHJ4,CQVWDSGWVF,IGLV3-21,COVD21_P2_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGQDELTGAFDIW,IGHV1-2,IGHJ5,CQVWDSGWVF,IGLV3-21,COVD21_P2_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGQDELTGAFDIW,IGHV1-2,IGHJ6,CQVWDSGWVF,IGLV3-21,COVD21_P2_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPYYYDSSGYLGGFDYW,IGHV1-2,IGHJ1,CCSYAASSTYVF,IGLV2-23,COVD21_P1_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPYYYDSSGYLGGFDYW,IGHV1-2,IGHJ2,CCSYAASSTYVF,IGLV2-23,COVD21_P1_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPYYYDSSGYLGGFDYW,IGHV1-2,IGHJ3,CCSYAASSTYVF,IGLV2-23,COVD21_P1_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPYYYDSSGYLGGFDYW,IGHV1-2,IGHJ4,CCSYAASSTYVF,IGLV2-23,COVD21_P1_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPYYYDSSGYLGGFDYW,IGHV1-2,IGHJ5,CCSYAASSTYVF,IGLV2-23,COVD21_P1_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKSPYYYDSSGYLGGFDYW,IGHV1-2,IGHJ6,CCSYAASSTYVF,IGLV2-23,COVD21_P1_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYSYVQGYFDYW,IGHV1-2,IGHJ1,CCSYAGSNTWVF,IGLV2-23,COVD21_P1_HC_C7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYSYVQGYFDYW,IGHV1-2,IGHJ2,CCSYAGSNTWVF,IGLV2-23,COVD21_P1_HC_C7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYSYVQGYFDYW,IGHV1-2,IGHJ3,CCSYAGSNTWVF,IGLV2-23,COVD21_P1_HC_C7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYSYVQGYFDYW,IGHV1-2,IGHJ4,CCSYAGSNTWVF,IGLV2-23,COVD21_P1_HC_C7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYSYVQGYFDYW,IGHV1-2,IGHJ5,CCSYAGSNTWVF,IGLV2-23,COVD21_P1_HC_C7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGYSYVQGYFDYW,IGHV1-2,IGHJ6,CCSYAGSNTWVF,IGLV2-23,COVD21_P1_HC_C7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGFSRLQFLFDYW,IGHV1-2,IGHJ1,CCSYAGSSIVVF,IGLV2-23,COVD21_P2_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGFSRLQFLFDYW,IGHV1-2,IGHJ2,CCSYAGSSIVVF,IGLV2-23,COVD21_P2_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGFSRLQFLFDYW,IGHV1-2,IGHJ3,CCSYAGSSIVVF,IGLV2-23,COVD21_P2_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGFSRLQFLFDYW,IGHV1-2,IGHJ4,CCSYAGSSIVVF,IGLV2-23,COVD21_P2_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGFSRLQFLFDYW,IGHV1-2,IGHJ5,CCSYAGSSIVVF,IGLV2-23,COVD21_P2_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGFSRLQFLFDYW,IGHV1-2,IGHJ6,CCSYAGSSIVVF,IGLV2-23,COVD21_P2_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASTGYYILTGYEFGAMDVW,IGHV1-2,IGHJ1,CSSYTSSSTVF,IGLV2-14,COVD21_P1_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASTGYYILTGYEFGAMDVW,IGHV1-2,IGHJ2,CSSYTSSSTVF,IGLV2-14,COVD21_P1_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASTGYYILTGYEFGAMDVW,IGHV1-2,IGHJ3,CSSYTSSSTVF,IGLV2-14,COVD21_P1_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASTGYYILTGYEFGAMDVW,IGHV1-2,IGHJ4,CSSYTSSSTVF,IGLV2-14,COVD21_P1_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASTGYYILTGYEFGAMDVW,IGHV1-2,IGHJ5,CSSYTSSSTVF,IGLV2-14,COVD21_P1_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASTGYYILTGYEFGAMDVW,IGHV1-2,IGHJ6,CSSYTSSSTVF,IGLV2-14,COVD21_P1_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRPLWFGVEYGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTLVF,IGLV2-14,COVD21_P1_HC_D7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRPLWFGVEYGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTLVF,IGLV2-14,COVD21_P1_HC_D7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRPLWFGVEYGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTLVF,IGLV2-14,COVD21_P1_HC_D7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRPLWFGVEYGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTLVF,IGLV2-14,COVD21_P1_HC_D7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRPLWFGVEYGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTLVF,IGLV2-14,COVD21_P1_HC_D7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRPLWFGVEYGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTLVF,IGLV2-14,COVD21_P1_HC_D7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATTEGQQLPHPPYYYYYYYMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,COVD21_P1_HC_C1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATTEGQQLPHPPYYYYYYYMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,COVD21_P1_HC_C1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATTEGQQLPHPPYYYYYYYMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,COVD21_P1_HC_C1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATTEGQQLPHPPYYYYYYYMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,COVD21_P1_HC_C1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATTEGQQLPHPPYYYYYYYMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,COVD21_P1_HC_C1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATTEGQQLPHPPYYYYYYYMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,COVD21_P1_HC_C1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRAETEGSETYYYDSSGYYLLGYW,IGHV1-46,IGHJ1,CQQSYSTPPSF,IGKV1-39,COVD21_P2_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRAETEGSETYYYDSSGYYLLGYW,IGHV1-46,IGHJ2,CQQSYSTPPSF,IGKV1-39,COVD21_P2_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRAETEGSETYYYDSSGYYLLGYW,IGHV1-46,IGHJ3,CQQSYSTPPSF,IGKV1-39,COVD21_P2_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRAETEGSETYYYDSSGYYLLGYW,IGHV1-46,IGHJ4,CQQSYSTPPSF,IGKV1-39,COVD21_P2_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRAETEGSETYYYDSSGYYLLGYW,IGHV1-46,IGHJ5,CQQSYSTPPSF,IGKV1-39,COVD21_P2_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRAETEGSETYYYDSSGYYLLGYW,IGHV1-46,IGHJ6,CQQSYSTPPSF,IGKV1-39,COVD21_P2_HC_G5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSSVTGTPPFDYW,IGHV1-46,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSSVTGTPPFDYW,IGHV1-46,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSSVTGTPPFDYW,IGHV1-46,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSSVTGTPPFDYW,IGHV1-46,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSSVTGTPPFDYW,IGHV1-46,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSSVTGTPPFDYW,IGHV1-46,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPREGTPGFDPW,IGHV1-46,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,COVD21_P2_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPREGTPGFDPW,IGHV1-46,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,COVD21_P2_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPREGTPGFDPW,IGHV1-46,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,COVD21_P2_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPREGTPGFDPW,IGHV1-46,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,COVD21_P2_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPREGTPGFDPW,IGHV1-46,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,COVD21_P2_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPREGTPGFDPW,IGHV1-46,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,COVD21_P2_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CLVGISTIVVVRPAVWTSW,IGHV1-46,IGHJ1,CGTWHSNSRVF,IGLV5-52,COVD21_P1_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CLVGISTIVVVRPAVWTSW,IGHV1-46,IGHJ2,CGTWHSNSRVF,IGLV5-52,COVD21_P1_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CLVGISTIVVVRPAVWTSW,IGHV1-46,IGHJ3,CGTWHSNSRVF,IGLV5-52,COVD21_P1_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CLVGISTIVVVRPAVWTSW,IGHV1-46,IGHJ4,CGTWHSNSRVF,IGLV5-52,COVD21_P1_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CLVGISTIVVVRPAVWTSW,IGHV1-46,IGHJ5,CGTWHSNSRVF,IGLV5-52,COVD21_P1_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CLVGISTIVVVRPAVWTSW,IGHV1-46,IGHJ6,CGTWHSNSRVF,IGLV5-52,COVD21_P1_HC_E4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLYYYDSSGYPNLEYFQHW,IGHV1-69,IGHJ1,CQQYDNLPSFTF,IGKV1-33,COVD21_P1_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLYYYDSSGYPNLEYFQHW,IGHV1-69,IGHJ2,CQQYDNLPSFTF,IGKV1-33,COVD21_P1_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLYYYDSSGYPNLEYFQHW,IGHV1-69,IGHJ3,CQQYDNLPSFTF,IGKV1-33,COVD21_P1_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLYYYDSSGYPNLEYFQHW,IGHV1-69,IGHJ4,CQQYDNLPSFTF,IGKV1-33,COVD21_P1_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLYYYDSSGYPNLEYFQHW,IGHV1-69,IGHJ5,CQQYDNLPSFTF,IGKV1-33,COVD21_P1_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVLYYYDSSGYPNLEYFQHW,IGHV1-69,IGHJ6,CQQYDNLPSFTF,IGKV1-33,COVD21_P1_HC_F12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ1,CASWDDSLNGPLF,IGLV1-44,COVD21_P2_HC_B3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ2,CASWDDSLNGPLF,IGLV1-44,COVD21_P2_HC_B3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ3,CASWDDSLNGPLF,IGLV1-44,COVD21_P2_HC_B3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ4,CASWDDSLNGPLF,IGLV1-44,COVD21_P2_HC_B3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ5,CASWDDSLNGPLF,IGLV1-44,COVD21_P2_HC_B3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ6,CASWDDSLNGPLF,IGLV1-44,COVD21_P2_HC_B3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYYYDRSGFPRTEDYFDYW,IGHV1-69,IGHJ1,CQSYDSSLSGVVF,IGLV1-40,COVD21_P3_HC_C11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYYYDRSGFPRTEDYFDYW,IGHV1-69,IGHJ2,CQSYDSSLSGVVF,IGLV1-40,COVD21_P3_HC_C11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYYYDRSGFPRTEDYFDYW,IGHV1-69,IGHJ3,CQSYDSSLSGVVF,IGLV1-40,COVD21_P3_HC_C11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYYYDRSGFPRTEDYFDYW,IGHV1-69,IGHJ4,CQSYDSSLSGVVF,IGLV1-40,COVD21_P3_HC_C11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYYYDRSGFPRTEDYFDYW,IGHV1-69,IGHJ5,CQSYDSSLSGVVF,IGLV1-40,COVD21_P3_HC_C11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYYYDRSGFPRTEDYFDYW,IGHV1-69,IGHJ6,CQSYDSSLSGVVF,IGLV1-40,COVD21_P3_HC_C11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDEGYCSGGSCYGYYYGMDVW,IGHV1-69,IGHJ1,CQQYDNLPMYTF,IGKV1-33,COVD21_P1_HC_G6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDEGYCSGGSCYGYYYGMDVW,IGHV1-69,IGHJ2,CQQYDNLPMYTF,IGKV1-33,COVD21_P1_HC_G6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDEGYCSGGSCYGYYYGMDVW,IGHV1-69,IGHJ3,CQQYDNLPMYTF,IGKV1-33,COVD21_P1_HC_G6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDEGYCSGGSCYGYYYGMDVW,IGHV1-69,IGHJ4,CQQYDNLPMYTF,IGKV1-33,COVD21_P1_HC_G6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDEGYCSGGSCYGYYYGMDVW,IGHV1-69,IGHJ5,CQQYDNLPMYTF,IGKV1-33,COVD21_P1_HC_G6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDEGYCSGGSCYGYYYGMDVW,IGHV1-69,IGHJ6,CQQYDNLPMYTF,IGKV1-33,COVD21_P1_HC_G6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ1,CQQRSNWPLTF,IGKV3-11,COVD21_P2_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ2,CQQRSNWPLTF,IGKV3-11,COVD21_P2_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ3,CQQRSNWPLTF,IGKV3-11,COVD21_P2_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ4,CQQRSNWPLTF,IGKV3-11,COVD21_P2_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ5,CQQRSNWPLTF,IGKV3-11,COVD21_P2_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGNRLLYCSSTSCYLDAVRQGYYYYYYMDVW,IGHV1-69,IGHJ6,CQQRSNWPLTF,IGKV3-11,COVD21_P2_HC_B2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGLVYTPYRFGYW,IGHV3-11,IGHJ1,CQQHDNVVTF,IGKV1-33,COVD21_P1_HC_D2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGLVYTPYRFGYW,IGHV3-11,IGHJ2,CQQHDNVVTF,IGKV1-33,COVD21_P1_HC_D2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGLVYTPYRFGYW,IGHV3-11,IGHJ3,CQQHDNVVTF,IGKV1-33,COVD21_P1_HC_D2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGLVYTPYRFGYW,IGHV3-11,IGHJ4,CQQHDNVVTF,IGKV1-33,COVD21_P1_HC_D2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGLVYTPYRFGYW,IGHV3-11,IGHJ5,CQQHDNVVTF,IGKV1-33,COVD21_P1_HC_D2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGLVYTPYRFGYW,IGHV3-11,IGHJ6,CQQHDNVVTF,IGKV1-33,COVD21_P1_HC_D2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRTWELVDYW,IGHV3-11,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_B4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRTWELVDYW,IGHV3-11,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_B4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRTWELVDYW,IGHV3-11,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_B4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRTWELVDYW,IGHV3-11,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_B4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRTWELVDYW,IGHV3-11,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_B4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGRTWELVDYW,IGHV3-11,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_B4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGKWLRGSFDYW,IGHV3-11,IGHJ1,CQSYDSSNHWVF,IGLV6-57,COVD21_P1_HC_A12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGKWLRGSFDYW,IGHV3-11,IGHJ2,CQSYDSSNHWVF,IGLV6-57,COVD21_P1_HC_A12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGKWLRGSFDYW,IGHV3-11,IGHJ3,CQSYDSSNHWVF,IGLV6-57,COVD21_P1_HC_A12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGKWLRGSFDYW,IGHV3-11,IGHJ4,CQSYDSSNHWVF,IGLV6-57,COVD21_P1_HC_A12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGKWLRGSFDYW,IGHV3-11,IGHJ5,CQSYDSSNHWVF,IGLV6-57,COVD21_P1_HC_A12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGKWLRGSFDYW,IGHV3-11,IGHJ6,CQSYDSSNHWVF,IGLV6-57,COVD21_P1_HC_A12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYDSSGYSGWYFDLW,IGHV3-13,IGHJ1,CQQSYSTPPLTF,IGKV1-39,COVD21_P2_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYDSSGYSGWYFDLW,IGHV3-13,IGHJ2,CQQSYSTPPLTF,IGKV1-39,COVD21_P2_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYDSSGYSGWYFDLW,IGHV3-13,IGHJ3,CQQSYSTPPLTF,IGKV1-39,COVD21_P2_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYDSSGYSGWYFDLW,IGHV3-13,IGHJ4,CQQSYSTPPLTF,IGKV1-39,COVD21_P2_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYDSSGYSGWYFDLW,IGHV3-13,IGHJ5,CQQSYSTPPLTF,IGKV1-39,COVD21_P2_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVGYDSSGYSGWYFDLW,IGHV3-13,IGHJ6,CQQSYSTPPLTF,IGKV1-39,COVD21_P2_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGGETITTVFDYW,IGHV3-13,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGGETITTVFDYW,IGHV3-13,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGGETITTVFDYW,IGHV3-13,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGGETITTVFDYW,IGHV3-13,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGGETITTVFDYW,IGHV3-13,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGGETITTVFDYW,IGHV3-13,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYVGYMDVW,IGHV3-13,IGHJ1,CQQSYSTPGLTF,IGKV1-39,COVD21_P2_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYVGYMDVW,IGHV3-13,IGHJ2,CQQSYSTPGLTF,IGKV1-39,COVD21_P2_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYVGYMDVW,IGHV3-13,IGHJ3,CQQSYSTPGLTF,IGKV1-39,COVD21_P2_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYVGYMDVW,IGHV3-13,IGHJ4,CQQSYSTPGLTF,IGKV1-39,COVD21_P2_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYVGYMDVW,IGHV3-13,IGHJ5,CQQSYSTPGLTF,IGKV1-39,COVD21_P2_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYVGYMDVW,IGHV3-13,IGHJ6,CQQSYSTPGLTF,IGKV1-39,COVD21_P2_HC_D3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDQIYGDYLRMPVPFDYW,IGHV3-15,IGHJ1,CATWDDSLSGPVF,IGLV1-47,COVD21_P2_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDQIYGDYLRMPVPFDYW,IGHV3-15,IGHJ2,CATWDDSLSGPVF,IGLV1-47,COVD21_P2_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDQIYGDYLRMPVPFDYW,IGHV3-15,IGHJ3,CATWDDSLSGPVF,IGLV1-47,COVD21_P2_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDQIYGDYLRMPVPFDYW,IGHV3-15,IGHJ4,CATWDDSLSGPVF,IGLV1-47,COVD21_P2_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDQIYGDYLRMPVPFDYW,IGHV3-15,IGHJ5,CATWDDSLSGPVF,IGLV1-47,COVD21_P2_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTDQIYGDYLRMPVPFDYW,IGHV3-15,IGHJ6,CATWDDSLSGPVF,IGLV1-47,COVD21_P2_HC_D10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPQYDDNGYSYTVDYW,IGHV3-15,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_H6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPQYDDNGYSYTVDYW,IGHV3-15,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_H6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPQYDDNGYSYTVDYW,IGHV3-15,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_H6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPQYDDNGYSYTVDYW,IGHV3-15,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_H6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPQYDDNGYSYTVDYW,IGHV3-15,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_H6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTTGPQYDDNGYSYTVDYW,IGHV3-15,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_H6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ1,CAEWDDSLSTWVF,IGLV1-44,COVD21_P3_HC_D12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ2,CAEWDDSLSTWVF,IGLV1-44,COVD21_P3_HC_D12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ3,CAEWDDSLSTWVF,IGLV1-44,COVD21_P3_HC_D12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ4,CAEWDDSLSTWVF,IGLV1-44,COVD21_P3_HC_D12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ5,CAEWDDSLSTWVF,IGLV1-44,COVD21_P3_HC_D12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ6,CAEWDDSLSTWVF,IGLV1-44,COVD21_P3_HC_D12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREVKRVVAAPEYYFDYW,IGHV3-21,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRNRYDFWSGYYRLVGFDPW,IGHV3-21,IGHJ1,CSSYAGSNNHVF,IGLV2-8,COVD21_P2_HC_C3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRNRYDFWSGYYRLVGFDPW,IGHV3-21,IGHJ2,CSSYAGSNNHVF,IGLV2-8,COVD21_P2_HC_C3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRNRYDFWSGYYRLVGFDPW,IGHV3-21,IGHJ3,CSSYAGSNNHVF,IGLV2-8,COVD21_P2_HC_C3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRNRYDFWSGYYRLVGFDPW,IGHV3-21,IGHJ4,CSSYAGSNNHVF,IGLV2-8,COVD21_P2_HC_C3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRNRYDFWSGYYRLVGFDPW,IGHV3-21,IGHJ5,CSSYAGSNNHVF,IGLV2-8,COVD21_P2_HC_C3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDRNRYDFWSGYYRLVGFDPW,IGHV3-21,IGHJ6,CSSYAGSNNHVF,IGLV2-8,COVD21_P2_HC_C3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVWSISLDAFDIW,IGHV3-23,IGHJ1,CQVWDSSSDLF,IGLV3-21,COVD21_P1_HC_F11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVWSISLDAFDIW,IGHV3-23,IGHJ2,CQVWDSSSDLF,IGLV3-21,COVD21_P1_HC_F11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVWSISLDAFDIW,IGHV3-23,IGHJ3,CQVWDSSSDLF,IGLV3-21,COVD21_P1_HC_F11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVWSISLDAFDIW,IGHV3-23,IGHJ4,CQVWDSSSDLF,IGLV3-21,COVD21_P1_HC_F11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVWSISLDAFDIW,IGHV3-23,IGHJ5,CQVWDSSSDLF,IGLV3-21,COVD21_P1_HC_F11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVWSISLDAFDIW,IGHV3-23,IGHJ6,CQVWDSSSDLF,IGLV3-21,COVD21_P1_HC_F11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGRQWLVELLDYW,IGHV3-23,IGHJ1,CQQSYSSPPTF,IGKV1-39,COVD21_P2_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGRQWLVELLDYW,IGHV3-23,IGHJ2,CQQSYSSPPTF,IGKV1-39,COVD21_P2_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGRQWLVELLDYW,IGHV3-23,IGHJ3,CQQSYSSPPTF,IGKV1-39,COVD21_P2_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGRQWLVELLDYW,IGHV3-23,IGHJ4,CQQSYSSPPTF,IGKV1-39,COVD21_P2_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGRQWLVELLDYW,IGHV3-23,IGHJ5,CQQSYSSPPTF,IGKV1-39,COVD21_P2_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGGRQWLVELLDYW,IGHV3-23,IGHJ6,CQQSYSSPPTF,IGKV1-39,COVD21_P2_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDRAAAHWATDYW,IGHV3-23,IGHJ1,CQQYDNRLFTF,IGKV1-33,COVD21_P2_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDRAAAHWATDYW,IGHV3-23,IGHJ2,CQQYDNRLFTF,IGKV1-33,COVD21_P2_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDRAAAHWATDYW,IGHV3-23,IGHJ3,CQQYDNRLFTF,IGKV1-33,COVD21_P2_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDRAAAHWATDYW,IGHV3-23,IGHJ4,CQQYDNRLFTF,IGKV1-33,COVD21_P2_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDRAAAHWATDYW,IGHV3-23,IGHJ5,CQQYDNRLFTF,IGKV1-33,COVD21_P2_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDRAAAHWATDYW,IGHV3-23,IGHJ6,CQQYDNRLFTF,IGKV1-33,COVD21_P2_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDSSGYHYYFDYW,IGHV3-23,IGHJ1,CQQSYNTPPITF,IGKV1-39,COVD21_P1_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDSSGYHYYFDYW,IGHV3-23,IGHJ2,CQQSYNTPPITF,IGKV1-39,COVD21_P1_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDSSGYHYYFDYW,IGHV3-23,IGHJ3,CQQSYNTPPITF,IGKV1-39,COVD21_P1_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDSSGYHYYFDYW,IGHV3-23,IGHJ4,CQQSYNTPPITF,IGKV1-39,COVD21_P1_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDSSGYHYYFDYW,IGHV3-23,IGHJ5,CQQSYNTPPITF,IGKV1-39,COVD21_P1_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDDSSGYHYYFDYW,IGHV3-23,IGHJ6,CQQSYNTPPITF,IGKV1-39,COVD21_P1_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSGTAMVEIFDYW,IGHV3-23,IGHJ1,CQQSYSSTLTF,IGKV1-39,COVD21_P1_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSGTAMVEIFDYW,IGHV3-23,IGHJ2,CQQSYSSTLTF,IGKV1-39,COVD21_P1_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSGTAMVEIFDYW,IGHV3-23,IGHJ3,CQQSYSSTLTF,IGKV1-39,COVD21_P1_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSGTAMVEIFDYW,IGHV3-23,IGHJ4,CQQSYSSTLTF,IGKV1-39,COVD21_P1_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSGTAMVEIFDYW,IGHV3-23,IGHJ5,CQQSYSSTLTF,IGKV1-39,COVD21_P1_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDSGTAMVEIFDYW,IGHV3-23,IGHJ6,CQQSYSSTLTF,IGKV1-39,COVD21_P1_HC_D1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLRSTTFYVYYFDYW,IGHV3-23,IGHJ1,CSSYTSSSTPDVF,IGLV2-14,COVD21_P3_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLRSTTFYVYYFDYW,IGHV3-23,IGHJ2,CSSYTSSSTPDVF,IGLV2-14,COVD21_P3_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLRSTTFYVYYFDYW,IGHV3-23,IGHJ3,CSSYTSSSTPDVF,IGLV2-14,COVD21_P3_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLRSTTFYVYYFDYW,IGHV3-23,IGHJ4,CSSYTSSSTPDVF,IGLV2-14,COVD21_P3_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLRSTTFYVYYFDYW,IGHV3-23,IGHJ5,CSSYTSSSTPDVF,IGLV2-14,COVD21_P3_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDLRSTTFYVYYFDYW,IGHV3-23,IGHJ6,CSSYTSSSTPDVF,IGLV2-14,COVD21_P3_HC_E1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVPIHYCSNGVCYFDYW,IGHV3-23,IGHJ1,CQSYDSSNRWVF,IGLV6-57,COVD21_P2_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVPIHYCSNGVCYFDYW,IGHV3-23,IGHJ2,CQSYDSSNRWVF,IGLV6-57,COVD21_P2_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVPIHYCSNGVCYFDYW,IGHV3-23,IGHJ3,CQSYDSSNRWVF,IGLV6-57,COVD21_P2_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVPIHYCSNGVCYFDYW,IGHV3-23,IGHJ4,CQSYDSSNRWVF,IGLV6-57,COVD21_P2_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVPIHYCSNGVCYFDYW,IGHV3-23,IGHJ5,CQSYDSSNRWVF,IGLV6-57,COVD21_P2_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVPIHYCSNGVCYFDYW,IGHV3-23,IGHJ6,CQSYDSSNRWVF,IGLV6-57,COVD21_P2_HC_F8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVVGSGTPPDYYYYYYMDVW,IGHV3-23,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVVGSGTPPDYYYYYYMDVW,IGHV3-23,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVVGSGTPPDYYYYYYMDVW,IGHV3-23,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVVGSGTPPDYYYYYYMDVW,IGHV3-23,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVVGSGTPPDYYYYYYMDVW,IGHV3-23,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVVGSGTPPDYYYYYYMDVW,IGHV3-23,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATCSGGSCLFGQNAFDIW,IGHV3-30,IGHJ1,CMQGTHWPPYTF,IGKV2-30,COVD21_P1_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATCSGGSCLFGQNAFDIW,IGHV3-30,IGHJ2,CMQGTHWPPYTF,IGKV2-30,COVD21_P1_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATCSGGSCLFGQNAFDIW,IGHV3-30,IGHJ3,CMQGTHWPPYTF,IGKV2-30,COVD21_P1_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATCSGGSCLFGQNAFDIW,IGHV3-30,IGHJ4,CMQGTHWPPYTF,IGKV2-30,COVD21_P1_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATCSGGSCLFGQNAFDIW,IGHV3-30,IGHJ5,CMQGTHWPPYTF,IGKV2-30,COVD21_P1_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARATCSGGSCLFGQNAFDIW,IGHV3-30,IGHJ6,CMQGTHWPPYTF,IGKV2-30,COVD21_P1_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGSSWYQVPDYW,IGHV3-30,IGHJ1,CQQSYSTPPLTF,IGKV1-39,COVD21_P1_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGSSWYQVPDYW,IGHV3-30,IGHJ2,CQQSYSTPPLTF,IGKV1-39,COVD21_P1_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGSSWYQVPDYW,IGHV3-30,IGHJ3,CQQSYSTPPLTF,IGKV1-39,COVD21_P1_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGSSWYQVPDYW,IGHV3-30,IGHJ4,CQQSYSTPPLTF,IGKV1-39,COVD21_P1_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGSSWYQVPDYW,IGHV3-30,IGHJ5,CQQSYSTPPLTF,IGKV1-39,COVD21_P1_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGSSWYQVPDYW,IGHV3-30,IGHJ6,CQQSYSTPPLTF,IGKV1-39,COVD21_P1_HC_G9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREFGDPEWYFDYW,IGHV3-30,IGHJ1,CQQYNSYWTF,IGKV1-5,COVD21_P2_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREFGDPEWYFDYW,IGHV3-30,IGHJ2,CQQYNSYWTF,IGKV1-5,COVD21_P2_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREFGDPEWYFDYW,IGHV3-30,IGHJ3,CQQYNSYWTF,IGKV1-5,COVD21_P2_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREFGDPEWYFDYW,IGHV3-30,IGHJ4,CQQYNSYWTF,IGKV1-5,COVD21_P2_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREFGDPEWYFDYW,IGHV3-30,IGHJ5,CQQYNSYWTF,IGKV1-5,COVD21_P2_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREFGDPEWYFDYW,IGHV3-30,IGHJ6,CQQYNSYWTF,IGKV1-5,COVD21_P2_HC_H9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNQNSYGYLSYFDYW,IGHV3-30,IGHJ1,CQQYDNLPRTF,IGKV1-33,COVD21_P1_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNQNSYGYLSYFDYW,IGHV3-30,IGHJ2,CQQYDNLPRTF,IGKV1-33,COVD21_P1_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNQNSYGYLSYFDYW,IGHV3-30,IGHJ3,CQQYDNLPRTF,IGKV1-33,COVD21_P1_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNQNSYGYLSYFDYW,IGHV3-30,IGHJ4,CQQYDNLPRTF,IGKV1-33,COVD21_P1_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNQNSYGYLSYFDYW,IGHV3-30,IGHJ5,CQQYDNLPRTF,IGKV1-33,COVD21_P1_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKNQNSYGYLSYFDYW,IGHV3-30,IGHJ6,CQQYDNLPRTF,IGKV1-33,COVD21_P1_HC_G8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGEYCGGGSCYRGVFDYW,IGHV3-30,IGHJ1,CQQYDNLPLTF,IGKV1-33,COVD21_P1_HC_E12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGEYCGGGSCYRGVFDYW,IGHV3-30,IGHJ2,CQQYDNLPLTF,IGKV1-33,COVD21_P1_HC_E12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGEYCGGGSCYRGVFDYW,IGHV3-30,IGHJ3,CQQYDNLPLTF,IGKV1-33,COVD21_P1_HC_E12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGEYCGGGSCYRGVFDYW,IGHV3-30,IGHJ4,CQQYDNLPLTF,IGKV1-33,COVD21_P1_HC_E12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGEYCGGGSCYRGVFDYW,IGHV3-30,IGHJ5,CQQYDNLPLTF,IGKV1-33,COVD21_P1_HC_E12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKASGEYCGGGSCYRGVFDYW,IGHV3-30,IGHJ6,CQQYDNLPLTF,IGKV1-33,COVD21_P1_HC_E12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVMGPYCSGGSCYSGYFDYW,IGHV3-30,IGHJ1,CQQRSNWPLTF,IGKV3-11,COVD21_P3_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVMGPYCSGGSCYSGYFDYW,IGHV3-30,IGHJ2,CQQRSNWPLTF,IGKV3-11,COVD21_P3_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVMGPYCSGGSCYSGYFDYW,IGHV3-30,IGHJ3,CQQRSNWPLTF,IGKV3-11,COVD21_P3_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVMGPYCSGGSCYSGYFDYW,IGHV3-30,IGHJ4,CQQRSNWPLTF,IGKV3-11,COVD21_P3_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVMGPYCSGGSCYSGYFDYW,IGHV3-30,IGHJ5,CQQRSNWPLTF,IGKV3-11,COVD21_P3_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKVMGPYCSGGSCYSGYFDYW,IGHV3-30,IGHJ6,CQQRSNWPLTF,IGKV3-11,COVD21_P3_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGPYCSGGSCYSSYFDYW,IGHV3-30,IGHJ1,CQQYGSSPAITF,IGKV3-20,COVD21_P1_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGPYCSGGSCYSSYFDYW,IGHV3-30,IGHJ2,CQQYGSSPAITF,IGKV3-20,COVD21_P1_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGPYCSGGSCYSSYFDYW,IGHV3-30,IGHJ3,CQQYGSSPAITF,IGKV3-20,COVD21_P1_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGPYCSGGSCYSSYFDYW,IGHV3-30,IGHJ4,CQQYGSSPAITF,IGKV3-20,COVD21_P1_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGPYCSGGSCYSSYFDYW,IGHV3-30,IGHJ5,CQQYGSSPAITF,IGKV3-20,COVD21_P1_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGGPYCSGGSCYSSYFDYW,IGHV3-30,IGHJ6,CQQYGSSPAITF,IGKV3-20,COVD21_P1_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDCGGDCYPTTDAFDIW,IGHV3-30-3,IGHJ1,CQQSYSTPWTF,IGKV1-39,COVD21_P1_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDCGGDCYPTTDAFDIW,IGHV3-30-3,IGHJ2,CQQSYSTPWTF,IGKV1-39,COVD21_P1_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDCGGDCYPTTDAFDIW,IGHV3-30-3,IGHJ3,CQQSYSTPWTF,IGKV1-39,COVD21_P1_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDCGGDCYPTTDAFDIW,IGHV3-30-3,IGHJ4,CQQSYSTPWTF,IGKV1-39,COVD21_P1_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDCGGDCYPTTDAFDIW,IGHV3-30-3,IGHJ5,CQQSYSTPWTF,IGKV1-39,COVD21_P1_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDCGGDCYPTTDAFDIW,IGHV3-30-3,IGHJ6,CQQSYSTPWTF,IGKV1-39,COVD21_P1_HC_G2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHDYGEIVDAFDIW,IGHV3-30-3,IGHJ1,CQQSYSTLMYTF,IGKV1-39,COVD21_P2_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHDYGEIVDAFDIW,IGHV3-30-3,IGHJ2,CQQSYSTLMYTF,IGKV1-39,COVD21_P2_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHDYGEIVDAFDIW,IGHV3-30-3,IGHJ3,CQQSYSTLMYTF,IGKV1-39,COVD21_P2_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHDYGEIVDAFDIW,IGHV3-30-3,IGHJ4,CQQSYSTLMYTF,IGKV1-39,COVD21_P2_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHDYGEIVDAFDIW,IGHV3-30-3,IGHJ5,CQQSYSTLMYTF,IGKV1-39,COVD21_P2_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHDYGEIVDAFDIW,IGHV3-30-3,IGHJ6,CQQSYSTLMYTF,IGKV1-39,COVD21_P2_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEDCSSTSCYLDYW,IGHV3-30-3,IGHJ1,CQQYYSTPFTF,IGKV4-1,COVD21_P1_HC_B1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEDCSSTSCYLDYW,IGHV3-30-3,IGHJ2,CQQYYSTPFTF,IGKV4-1,COVD21_P1_HC_B1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEDCSSTSCYLDYW,IGHV3-30-3,IGHJ3,CQQYYSTPFTF,IGKV4-1,COVD21_P1_HC_B1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEDCSSTSCYLDYW,IGHV3-30-3,IGHJ4,CQQYYSTPFTF,IGKV4-1,COVD21_P1_HC_B1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEDCSSTSCYLDYW,IGHV3-30-3,IGHJ5,CQQYYSTPFTF,IGKV4-1,COVD21_P1_HC_B1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSEDCSSTSCYLDYW,IGHV3-30-3,IGHJ6,CQQYYSTPFTF,IGKV4-1,COVD21_P1_HC_B1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPGWQWPELDYW,IGHV3-30-3,IGHJ1,CAAWDDSLNGPVF,IGLV1-44,COVD21_P3_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPGWQWPELDYW,IGHV3-30-3,IGHJ2,CAAWDDSLNGPVF,IGLV1-44,COVD21_P3_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPGWQWPELDYW,IGHV3-30-3,IGHJ3,CAAWDDSLNGPVF,IGLV1-44,COVD21_P3_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPGWQWPELDYW,IGHV3-30-3,IGHJ4,CAAWDDSLNGPVF,IGLV1-44,COVD21_P3_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPGWQWPELDYW,IGHV3-30-3,IGHJ5,CAAWDDSLNGPVF,IGLV1-44,COVD21_P3_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGPGWQWPELDYW,IGHV3-30-3,IGHJ6,CAAWDDSLNGPVF,IGLV1-44,COVD21_P3_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATEDYYDSSGSFDYW,IGHV3-30-3,IGHJ1,CCSYAGSFWVF,IGLV2-11,COVD21_P3_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATEDYYDSSGSFDYW,IGHV3-30-3,IGHJ2,CCSYAGSFWVF,IGLV2-11,COVD21_P3_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATEDYYDSSGSFDYW,IGHV3-30-3,IGHJ3,CCSYAGSFWVF,IGLV2-11,COVD21_P3_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATEDYYDSSGSFDYW,IGHV3-30-3,IGHJ4,CCSYAGSFWVF,IGLV2-11,COVD21_P3_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATEDYYDSSGSFDYW,IGHV3-30-3,IGHJ5,CCSYAGSFWVF,IGLV2-11,COVD21_P3_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CATEDYYDSSGSFDYW,IGHV3-30-3,IGHJ6,CCSYAGSFWVF,IGLV2-11,COVD21_P3_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSKSYTSWGYYHMDVW,IGHV3-30-3,IGHJ1,CSSYTSSSTWVF,IGLV2-14,COVD21_P3_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSKSYTSWGYYHMDVW,IGHV3-30-3,IGHJ2,CSSYTSSSTWVF,IGLV2-14,COVD21_P3_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSKSYTSWGYYHMDVW,IGHV3-30-3,IGHJ3,CSSYTSSSTWVF,IGLV2-14,COVD21_P3_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSKSYTSWGYYHMDVW,IGHV3-30-3,IGHJ4,CSSYTSSSTWVF,IGLV2-14,COVD21_P3_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSKSYTSWGYYHMDVW,IGHV3-30-3,IGHJ5,CSSYTSSSTWVF,IGLV2-14,COVD21_P3_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSKSYTSWGYYHMDVW,IGHV3-30-3,IGHJ6,CSSYTSSSTWVF,IGLV2-14,COVD21_P3_HC_C12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTSITLITEGDAFDIW,IGHV3-33,IGHJ1,CQQANSLPLTF,IGKV1-12,COVD21_P1_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTSITLITEGDAFDIW,IGHV3-33,IGHJ2,CQQANSLPLTF,IGKV1-12,COVD21_P1_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTSITLITEGDAFDIW,IGHV3-33,IGHJ3,CQQANSLPLTF,IGKV1-12,COVD21_P1_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTSITLITEGDAFDIW,IGHV3-33,IGHJ4,CQQANSLPLTF,IGKV1-12,COVD21_P1_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTSITLITEGDAFDIW,IGHV3-33,IGHJ5,CQQANSLPLTF,IGKV1-12,COVD21_P1_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGTSITLITEGDAFDIW,IGHV3-33,IGHJ6,CQQANSLPLTF,IGKV1-12,COVD21_P1_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSVVVTAIDFDYW,IGHV3-33,IGHJ1,CMQGTHWPWTF,IGKV2-30,COVD21_P2_HC_B11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSVVVTAIDFDYW,IGHV3-33,IGHJ2,CMQGTHWPWTF,IGKV2-30,COVD21_P2_HC_B11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSVVVTAIDFDYW,IGHV3-33,IGHJ3,CMQGTHWPWTF,IGKV2-30,COVD21_P2_HC_B11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSVVVTAIDFDYW,IGHV3-33,IGHJ4,CMQGTHWPWTF,IGKV2-30,COVD21_P2_HC_B11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSVVVTAIDFDYW,IGHV3-33,IGHJ5,CMQGTHWPWTF,IGKV2-30,COVD21_P2_HC_B11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDPSVVVTAIDFDYW,IGHV3-33,IGHJ6,CMQGTHWPWTF,IGKV2-30,COVD21_P2_HC_B11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREHTPTDIVVVNVEYW,IGHV3-33,IGHJ1,CMQGTHWPYTF,IGKV2-30,COVD21_P2_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREHTPTDIVVVNVEYW,IGHV3-33,IGHJ2,CMQGTHWPYTF,IGKV2-30,COVD21_P2_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREHTPTDIVVVNVEYW,IGHV3-33,IGHJ3,CMQGTHWPYTF,IGKV2-30,COVD21_P2_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREHTPTDIVVVNVEYW,IGHV3-33,IGHJ4,CMQGTHWPYTF,IGKV2-30,COVD21_P2_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREHTPTDIVVVNVEYW,IGHV3-33,IGHJ5,CMQGTHWPYTF,IGKV2-30,COVD21_P2_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREHTPTDIVVVNVEYW,IGHV3-33,IGHJ6,CMQGTHWPYTF,IGKV2-30,COVD21_P2_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKDIVATDFDYW,IGHV3-33,IGHJ1,CQSYDSSLSGPYVF,IGLV1-40,COVD21_P3_HC_H8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKDIVATDFDYW,IGHV3-33,IGHJ2,CQSYDSSLSGPYVF,IGLV1-40,COVD21_P3_HC_H8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKDIVATDFDYW,IGHV3-33,IGHJ3,CQSYDSSLSGPYVF,IGLV1-40,COVD21_P3_HC_H8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKDIVATDFDYW,IGHV3-33,IGHJ4,CQSYDSSLSGPYVF,IGLV1-40,COVD21_P3_HC_H8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKDIVATDFDYW,IGHV3-33,IGHJ5,CQSYDSSLSGPYVF,IGLV1-40,COVD21_P3_HC_H8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREKDIVATDFDYW,IGHV3-33,IGHJ6,CQSYDSSLSGPYVF,IGLV1-40,COVD21_P3_HC_H8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYFYDSSDYYFEYYFDYW,IGHV3-33,IGHJ1,CCSYAGSYTYVF,IGLV2-11,COVD21_P1_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYFYDSSDYYFEYYFDYW,IGHV3-33,IGHJ2,CCSYAGSYTYVF,IGLV2-11,COVD21_P1_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYFYDSSDYYFEYYFDYW,IGHV3-33,IGHJ3,CCSYAGSYTYVF,IGLV2-11,COVD21_P1_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYFYDSSDYYFEYYFDYW,IGHV3-33,IGHJ4,CCSYAGSYTYVF,IGLV2-11,COVD21_P1_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYFYDSSDYYFEYYFDYW,IGHV3-33,IGHJ5,CCSYAGSYTYVF,IGLV2-11,COVD21_P1_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREYFYDSSDYYFEYYFDYW,IGHV3-33,IGHJ6,CCSYAGSYTYVF,IGLV2-11,COVD21_P1_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHSLGVRGDGYGMDVW,IGHV3-33,IGHJ1,CQQFNNYPLTF,IGKV1D-13,COVD21_P1_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHSLGVRGDGYGMDVW,IGHV3-33,IGHJ2,CQQFNNYPLTF,IGKV1D-13,COVD21_P1_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHSLGVRGDGYGMDVW,IGHV3-33,IGHJ3,CQQFNNYPLTF,IGKV1D-13,COVD21_P1_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHSLGVRGDGYGMDVW,IGHV3-33,IGHJ4,CQQFNNYPLTF,IGKV1D-13,COVD21_P1_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHSLGVRGDGYGMDVW,IGHV3-33,IGHJ5,CQQFNNYPLTF,IGKV1D-13,COVD21_P1_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDHSLGVRGDGYGMDVW,IGHV3-33,IGHJ6,CQQFNNYPLTF,IGKV1D-13,COVD21_P1_HC_A4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGAVVRFLEWPTVGYYYYYMDVW,IGHV3-33,IGHJ1,CMQALQTPITF,IGKV2-28,COVD21_P1_HC_G11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGAVVRFLEWPTVGYYYYYMDVW,IGHV3-33,IGHJ2,CMQALQTPITF,IGKV2-28,COVD21_P1_HC_G11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGAVVRFLEWPTVGYYYYYMDVW,IGHV3-33,IGHJ3,CMQALQTPITF,IGKV2-28,COVD21_P1_HC_G11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGAVVRFLEWPTVGYYYYYMDVW,IGHV3-33,IGHJ4,CMQALQTPITF,IGKV2-28,COVD21_P1_HC_G11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGAVVRFLEWPTVGYYYYYMDVW,IGHV3-33,IGHJ5,CMQALQTPITF,IGKV2-28,COVD21_P1_HC_G11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDGAVVRFLEWPTVGYYYYYMDVW,IGHV3-33,IGHJ6,CMQALQTPITF,IGKV2-28,COVD21_P1_HC_G11-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMMIRGVAWYYYMDVW,IGHV3-33,IGHJ1,CSSYISSNTVF,IGLV2-14,COVD21_P3_HC_G10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMMIRGVAWYYYMDVW,IGHV3-33,IGHJ2,CSSYISSNTVF,IGLV2-14,COVD21_P3_HC_G10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMMIRGVAWYYYMDVW,IGHV3-33,IGHJ3,CSSYISSNTVF,IGLV2-14,COVD21_P3_HC_G10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMMIRGVAWYYYMDVW,IGHV3-33,IGHJ4,CSSYISSNTVF,IGLV2-14,COVD21_P3_HC_G10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMMIRGVAWYYYMDVW,IGHV3-33,IGHJ5,CSSYISSNTVF,IGLV2-14,COVD21_P3_HC_G10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDMMIRGVAWYYYMDVW,IGHV3-33,IGHJ6,CSSYISSNTVF,IGLV2-14,COVD21_P3_HC_G10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGGDIVVIPAVNGFDYW,IGHV3-48,IGHJ1,CQSADSRGVF,IGLV3-25,COVD21_P2_HC_H2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGGDIVVIPAVNGFDYW,IGHV3-48,IGHJ2,CQSADSRGVF,IGLV3-25,COVD21_P2_HC_H2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGGDIVVIPAVNGFDYW,IGHV3-48,IGHJ3,CQSADSRGVF,IGLV3-25,COVD21_P2_HC_H2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGGDIVVIPAVNGFDYW,IGHV3-48,IGHJ4,CQSADSRGVF,IGLV3-25,COVD21_P2_HC_H2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGGDIVVIPAVNGFDYW,IGHV3-48,IGHJ5,CQSADSRGVF,IGLV3-25,COVD21_P2_HC_H2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDSGGDIVVIPAVNGFDYW,IGHV3-48,IGHJ6,CQSADSRGVF,IGLV3-25,COVD21_P2_HC_H2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAHDGALTDYGDYLNWFDPW,IGHV3-48,IGHJ1,CQVWDSSSDHLYWVF,IGLV3-21,COVD21_P2_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAHDGALTDYGDYLNWFDPW,IGHV3-48,IGHJ2,CQVWDSSSDHLYWVF,IGLV3-21,COVD21_P2_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAHDGALTDYGDYLNWFDPW,IGHV3-48,IGHJ3,CQVWDSSSDHLYWVF,IGLV3-21,COVD21_P2_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAHDGALTDYGDYLNWFDPW,IGHV3-48,IGHJ4,CQVWDSSSDHLYWVF,IGLV3-21,COVD21_P2_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAHDGALTDYGDYLNWFDPW,IGHV3-48,IGHJ5,CQVWDSSSDHLYWVF,IGLV3-21,COVD21_P2_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAREAHDGALTDYGDYLNWFDPW,IGHV3-48,IGHJ6,CQVWDSSSDHLYWVF,IGLV3-21,COVD21_P2_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ1,CQQYGSSPGTF,IGKV3-20,COVD21_P1_HC_A3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ2,CQQYGSSPGTF,IGKV3-20,COVD21_P1_HC_A3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ3,CQQYGSSPGTF,IGKV3-20,COVD21_P1_HC_A3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ4,CQQYGSSPGTF,IGKV3-20,COVD21_P1_HC_A3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ5,CQQYGSSPGTF,IGKV3-20,COVD21_P1_HC_A3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ6,CQQYGSSPGTF,IGKV3-20,COVD21_P1_HC_A3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLYSSGGTDIW,IGHV3-53,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGYGDYYFDYW,IGHV3-53,IGHJ1,CQHLNGF,IGKV1-9,COVD21_P1_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGYGDYYFDYW,IGHV3-53,IGHJ2,CQHLNGF,IGKV1-9,COVD21_P1_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGYGDYYFDYW,IGHV3-53,IGHJ3,CQHLNGF,IGKV1-9,COVD21_P1_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGYGDYYFDYW,IGHV3-53,IGHJ4,CQHLNGF,IGKV1-9,COVD21_P1_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGYGDYYFDYW,IGHV3-53,IGHJ5,CQHLNGF,IGKV1-9,COVD21_P1_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGYGDYYFDYW,IGHV3-53,IGHJ6,CQHLNGF,IGKV1-9,COVD21_P1_HC_A2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ1,CQQYYSTPRTF,IGKV1-NL1,COVD21_P2_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ2,CQQYYSTPRTF,IGKV1-NL1,COVD21_P2_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ3,CQQYYSTPRTF,IGKV1-NL1,COVD21_P2_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ4,CQQYYSTPRTF,IGKV1-NL1,COVD21_P2_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ5,CQQYYSTPRTF,IGKV1-NL1,COVD21_P2_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ6,CQQYYSTPRTF,IGKV1-NL1,COVD21_P2_HC_F7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGDYYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGDYYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGDYYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGDYYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGDYYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDWGDYYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_C8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ1,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ2,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ3,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ4,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ5,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDYGDFYFDYW,IGHV3-53,IGHJ6,CQQYGSSPRTF,IGKV3-20,COVD21_P1_HC_A10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSVFGMDVW,IGHV3-53,IGHJ1,CQQVNSYSHF,IGKV1-9,COVD21_P1_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSVFGMDVW,IGHV3-53,IGHJ2,CQQVNSYSHF,IGKV1-9,COVD21_P1_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSVFGMDVW,IGHV3-53,IGHJ3,CQQVNSYSHF,IGKV1-9,COVD21_P1_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSVFGMDVW,IGHV3-53,IGHJ4,CQQVNSYSHF,IGKV1-9,COVD21_P1_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSVFGMDVW,IGHV3-53,IGHJ5,CQQVNSYSHF,IGKV1-9,COVD21_P1_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLSVFGMDVW,IGHV3-53,IGHJ6,CQQVNSYSHF,IGKV1-9,COVD21_P1_HC_B12-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGERGMDVW,IGHV3-53,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGERGMDVW,IGHV3-53,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGERGMDVW,IGHV3-53,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGERGMDVW,IGHV3-53,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGERGMDVW,IGHV3-53,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDLGERGMDVW,IGHV3-53,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_C9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYCSGGSCHPPGQWLSDAFDIW,IGHV3-7,IGHJ1,CQQSYSTWTF,IGKV1-39,COVD21_P1_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYCSGGSCHPPGQWLSDAFDIW,IGHV3-7,IGHJ2,CQQSYSTWTF,IGKV1-39,COVD21_P1_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYCSGGSCHPPGQWLSDAFDIW,IGHV3-7,IGHJ3,CQQSYSTWTF,IGKV1-39,COVD21_P1_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYCSGGSCHPPGQWLSDAFDIW,IGHV3-7,IGHJ4,CQQSYSTWTF,IGKV1-39,COVD21_P1_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYCSGGSCHPPGQWLSDAFDIW,IGHV3-7,IGHJ5,CQQSYSTWTF,IGKV1-39,COVD21_P1_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYCSGGSCHPPGQWLSDAFDIW,IGHV3-7,IGHJ6,CQQSYSTWTF,IGKV1-39,COVD21_P1_HC_H7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLRWLRADFDYW,IGHV3-7,IGHJ1,CQSYDSGNVVF,IGLV6-57,COVD21_P1_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLRWLRADFDYW,IGHV3-7,IGHJ2,CQSYDSGNVVF,IGLV6-57,COVD21_P1_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLRWLRADFDYW,IGHV3-7,IGHJ3,CQSYDSGNVVF,IGLV6-57,COVD21_P1_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLRWLRADFDYW,IGHV3-7,IGHJ4,CQSYDSGNVVF,IGLV6-57,COVD21_P1_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLRWLRADFDYW,IGHV3-7,IGHJ5,CQSYDSGNVVF,IGLV6-57,COVD21_P1_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARLRWLRADFDYW,IGHV3-7,IGHJ6,CQSYDSGNVVF,IGLV6-57,COVD21_P1_HC_F1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYYDILTGYYVDYYYMDVW,IGHV3-7,IGHJ1,CQSADSSGTYVVF,IGLV3-25,COVD21_P1_HC_C10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYYDILTGYYVDYYYMDVW,IGHV3-7,IGHJ2,CQSADSSGTYVVF,IGLV3-25,COVD21_P1_HC_C10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYYDILTGYYVDYYYMDVW,IGHV3-7,IGHJ3,CQSADSSGTYVVF,IGLV3-25,COVD21_P1_HC_C10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYYDILTGYYVDYYYMDVW,IGHV3-7,IGHJ4,CQSADSSGTYVVF,IGLV3-25,COVD21_P1_HC_C10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYYDILTGYYVDYYYMDVW,IGHV3-7,IGHJ5,CQSADSSGTYVVF,IGLV3-25,COVD21_P1_HC_C10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYYDILTGYYVDYYYMDVW,IGHV3-7,IGHJ6,CQSADSSGTYVVF,IGLV3-25,COVD21_P1_HC_C10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ1,CQQSYSTRTF,IGKV1-39,COVD21_P3_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ2,CQQSYSTRTF,IGKV1-39,COVD21_P3_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ3,CQQSYSTRTF,IGKV1-39,COVD21_P3_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ4,CQQSYSTRTF,IGKV1-39,COVD21_P3_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ5,CQQSYSTRTF,IGKV1-39,COVD21_P3_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CTRDDSSWPHFFDNW,IGHV3-74,IGHJ6,CQQSYSTRTF,IGKV1-39,COVD21_P3_HC_H10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ1,CQQYGSSPYTF,IGKV3-20,COVD21_P2_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ2,CQQYGSSPYTF,IGKV3-20,COVD21_P2_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ3,CQQYGSSPYTF,IGKV3-20,COVD21_P2_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ4,CQQYGSSPYTF,IGKV3-20,COVD21_P2_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ5,CQQYGSSPYTF,IGKV3-20,COVD21_P2_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ6,CQQYGSSPYTF,IGKV3-20,COVD21_P2_HC_D8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ1,CQSADSRKVVF,IGLV3-25,COVD21_P2_HC_D9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ2,CQSADSRKVVF,IGLV3-25,COVD21_P2_HC_D9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ3,CQSADSRKVVF,IGLV3-25,COVD21_P2_HC_D9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ4,CQSADSRKVVF,IGLV3-25,COVD21_P2_HC_D9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ5,CQSADSRKVVF,IGLV3-25,COVD21_P2_HC_D9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAWAMRQTTLTPEWIDYW,IGHV3-74,IGHJ6,CQSADSRKVVF,IGLV3-25,COVD21_P2_HC_D9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGEGFRNWNDGLDYFDYW,IGHV3-9,IGHJ1,CAAWDDSLNGYVF,IGLV1-44,COVD21_P3_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGEGFRNWNDGLDYFDYW,IGHV3-9,IGHJ2,CAAWDDSLNGYVF,IGLV1-44,COVD21_P3_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGEGFRNWNDGLDYFDYW,IGHV3-9,IGHJ3,CAAWDDSLNGYVF,IGLV1-44,COVD21_P3_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGEGFRNWNDGLDYFDYW,IGHV3-9,IGHJ4,CAAWDDSLNGYVF,IGLV1-44,COVD21_P3_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGEGFRNWNDGLDYFDYW,IGHV3-9,IGHJ5,CAAWDDSLNGYVF,IGLV1-44,COVD21_P3_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGGEGFRNWNDGLDYFDYW,IGHV3-9,IGHJ6,CAAWDDSLNGYVF,IGLV1-44,COVD21_P3_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGRSGDQWPELYYFDYW,IGHV3-9,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGRSGDQWPELYYFDYW,IGHV3-9,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGRSGDQWPELYYFDYW,IGHV3-9,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGRSGDQWPELYYFDYW,IGHV3-9,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGRSGDQWPELYYFDYW,IGHV3-9,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGRSGDQWPELYYFDYW,IGHV3-9,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,COVD21_P1_HC_A5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGVRGIAAAGPDLNFDHW,IGHV3-9,IGHJ1,CQQRITF,IGKV3-11,COVD21_P2_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGVRGIAAAGPDLNFDHW,IGHV3-9,IGHJ2,CQQRITF,IGKV3-11,COVD21_P2_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGVRGIAAAGPDLNFDHW,IGHV3-9,IGHJ3,CQQRITF,IGKV3-11,COVD21_P2_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGVRGIAAAGPDLNFDHW,IGHV3-9,IGHJ4,CQQRITF,IGKV3-11,COVD21_P2_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGVRGIAAAGPDLNFDHW,IGHV3-9,IGHJ5,CQQRITF,IGKV3-11,COVD21_P2_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKAGVRGIAAAGPDLNFDHW,IGHV3-9,IGHJ6,CQQRITF,IGKV3-11,COVD21_P2_HC_E10-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSSYHNWFDPW,IGHV3-9,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSSYHNWFDPW,IGHV3-9,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSSYHNWFDPW,IGHV3-9,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSSYHNWFDPW,IGHV3-9,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSSYHNWFDPW,IGHV3-9,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKGSSSSYHNWFDPW,IGHV3-9,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_F9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGAGTENWFDPW,IGHV3-9,IGHJ1,CQVWDSSSDPHVVF,IGLV3-21,COVD21_P1_HC_D6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGAGTENWFDPW,IGHV3-9,IGHJ2,CQVWDSSSDPHVVF,IGLV3-21,COVD21_P1_HC_D6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGAGTENWFDPW,IGHV3-9,IGHJ3,CQVWDSSSDPHVVF,IGLV3-21,COVD21_P1_HC_D6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGAGTENWFDPW,IGHV3-9,IGHJ4,CQVWDSSSDPHVVF,IGLV3-21,COVD21_P1_HC_D6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGAGTENWFDPW,IGHV3-9,IGHJ5,CQVWDSSSDPHVVF,IGLV3-21,COVD21_P1_HC_D6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDGAGTENWFDPW,IGHV3-9,IGHJ6,CQVWDSSSDPHVVF,IGLV3-21,COVD21_P1_HC_D6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMLGNYYYYAMVVW,IGHV3-9,IGHJ1,CSSYTSSSTLEGVF,IGLV2-14,COVD21_P2_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMLGNYYYYAMVVW,IGHV3-9,IGHJ2,CSSYTSSSTLEGVF,IGLV2-14,COVD21_P2_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMLGNYYYYAMVVW,IGHV3-9,IGHJ3,CSSYTSSSTLEGVF,IGLV2-14,COVD21_P2_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMLGNYYYYAMVVW,IGHV3-9,IGHJ4,CSSYTSSSTLEGVF,IGLV2-14,COVD21_P2_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMLGNYYYYAMVVW,IGHV3-9,IGHJ5,CSSYTSSSTLEGVF,IGLV2-14,COVD21_P2_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CAKDMLGNYYYYAMVVW,IGHV3-9,IGHJ6,CSSYTSSSTLEGVF,IGLV2-14,COVD21_P2_HC_G3-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMYYYDSSGSFDYW,IGHV4-31,IGHJ1,CMQALQTPHTF,IGKV2-28,COVD21_P1_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMYYYDSSGSFDYW,IGHV4-31,IGHJ2,CMQALQTPHTF,IGKV2-28,COVD21_P1_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMYYYDSSGSFDYW,IGHV4-31,IGHJ3,CMQALQTPHTF,IGKV2-28,COVD21_P1_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMYYYDSSGSFDYW,IGHV4-31,IGHJ4,CMQALQTPHTF,IGKV2-28,COVD21_P1_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMYYYDSSGSFDYW,IGHV4-31,IGHJ5,CMQALQTPHTF,IGKV2-28,COVD21_P1_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARTMYYYDSSGSFDYW,IGHV4-31,IGHJ6,CMQALQTPHTF,IGKV2-28,COVD21_P1_HC_E6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGELSAFGELFPHDYW,IGHV4-31,IGHJ1,CQQRSNWLFTF,IGKV3-11,COVD21_P1_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGELSAFGELFPHDYW,IGHV4-31,IGHJ2,CQQRSNWLFTF,IGKV3-11,COVD21_P1_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGELSAFGELFPHDYW,IGHV4-31,IGHJ3,CQQRSNWLFTF,IGKV3-11,COVD21_P1_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGELSAFGELFPHDYW,IGHV4-31,IGHJ4,CQQRSNWLFTF,IGKV3-11,COVD21_P1_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGELSAFGELFPHDYW,IGHV4-31,IGHJ5,CQQRSNWLFTF,IGKV3-11,COVD21_P1_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CASGELSAFGELFPHDYW,IGHV4-31,IGHJ6,CQQRSNWLFTF,IGKV3-11,COVD21_P1_HC_G1-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVHVVRGVANYPYFDYW,IGHV4-31,IGHJ1,CCSYAGSYTPWVF,IGLV2-11,COVD21_P3_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVHVVRGVANYPYFDYW,IGHV4-31,IGHJ2,CCSYAGSYTPWVF,IGLV2-11,COVD21_P3_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVHVVRGVANYPYFDYW,IGHV4-31,IGHJ3,CCSYAGSYTPWVF,IGLV2-11,COVD21_P3_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVHVVRGVANYPYFDYW,IGHV4-31,IGHJ4,CCSYAGSYTPWVF,IGLV2-11,COVD21_P3_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVHVVRGVANYPYFDYW,IGHV4-31,IGHJ5,CCSYAGSYTPWVF,IGLV2-11,COVD21_P3_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVHVVRGVANYPYFDYW,IGHV4-31,IGHJ6,CCSYAGSYTPWVF,IGLV2-11,COVD21_P3_HC_G7-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYNGGLDYW,IGHV4-31,IGHJ1,CSSYAGSNNWVF,IGLV2-8,COVD21_P1_HC_D5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYNGGLDYW,IGHV4-31,IGHJ2,CSSYAGSNNWVF,IGLV2-8,COVD21_P1_HC_D5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYNGGLDYW,IGHV4-31,IGHJ3,CSSYAGSNNWVF,IGLV2-8,COVD21_P1_HC_D5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYNGGLDYW,IGHV4-31,IGHJ4,CSSYAGSNNWVF,IGLV2-8,COVD21_P1_HC_D5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYNGGLDYW,IGHV4-31,IGHJ5,CSSYAGSNNWVF,IGLV2-8,COVD21_P1_HC_D5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGSYSNYNGGLDYW,IGHV4-31,IGHJ6,CSSYAGSNNWVF,IGLV2-8,COVD21_P1_HC_D5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVATDYGDSFDYW,IGHV4-31,IGHJ1,CLLYYGGAWVF,IGLV7-43,COVD21_P2_HC_A9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVATDYGDSFDYW,IGHV4-31,IGHJ2,CLLYYGGAWVF,IGLV7-43,COVD21_P2_HC_A9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVATDYGDSFDYW,IGHV4-31,IGHJ3,CLLYYGGAWVF,IGLV7-43,COVD21_P2_HC_A9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVATDYGDSFDYW,IGHV4-31,IGHJ4,CLLYYGGAWVF,IGLV7-43,COVD21_P2_HC_A9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVATDYGDSFDYW,IGHV4-31,IGHJ5,CLLYYGGAWVF,IGLV7-43,COVD21_P2_HC_A9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVATDYGDSFDYW,IGHV4-31,IGHJ6,CLLYYGGAWVF,IGLV7-43,COVD21_P2_HC_A9-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPPGDFYDSSGYFSAFDIW,IGHV4-4,IGHJ1,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPPGDFYDSSGYFSAFDIW,IGHV4-4,IGHJ2,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPPGDFYDSSGYFSAFDIW,IGHV4-4,IGHJ3,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPPGDFYDSSGYFSAFDIW,IGHV4-4,IGHJ4,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPPGDFYDSSGYFSAFDIW,IGHV4-4,IGHJ5,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARAPPGDFYDSSGYFSAFDIW,IGHV4-4,IGHJ6,CSSYRGSSTPYVF,IGLV2-14,COVD21_P3_HC_A8-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNGYVWGSYRPDAFDIW,IGHV4-4,IGHJ1,CQSYDSRNVVF,IGLV6-57,COVD21_P1_HC_B6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNGYVWGSYRPDAFDIW,IGHV4-4,IGHJ2,CQSYDSRNVVF,IGLV6-57,COVD21_P1_HC_B6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNGYVWGSYRPDAFDIW,IGHV4-4,IGHJ3,CQSYDSRNVVF,IGLV6-57,COVD21_P1_HC_B6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNGYVWGSYRPDAFDIW,IGHV4-4,IGHJ4,CQSYDSRNVVF,IGLV6-57,COVD21_P1_HC_B6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNGYVWGSYRPDAFDIW,IGHV4-4,IGHJ5,CQSYDSRNVVF,IGLV6-57,COVD21_P1_HC_B6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARDNGYVWGSYRPDAFDIW,IGHV4-4,IGHJ6,CQSYDSRNVVF,IGLV6-57,COVD21_P1_HC_B6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYSSRGANYYMDVW,IGHV4-4,IGHJ1,CQSYDSSLSDSLF,IGLV1-40,COVD21_P2_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYSSRGANYYMDVW,IGHV4-4,IGHJ2,CQSYDSSLSDSLF,IGLV1-40,COVD21_P2_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYSSRGANYYMDVW,IGHV4-4,IGHJ3,CQSYDSSLSDSLF,IGLV1-40,COVD21_P2_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYSSRGANYYMDVW,IGHV4-4,IGHJ4,CQSYDSSLSDSLF,IGLV1-40,COVD21_P2_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYSSRGANYYMDVW,IGHV4-4,IGHJ5,CQSYDSSLSDSLF,IGLV1-40,COVD21_P2_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVVGYSSRGANYYMDVW,IGHV4-4,IGHJ6,CQSYDSSLSDSLF,IGLV1-40,COVD21_P2_HC_D4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSVGDCSSTSCLYWYFDLW,IGHV4-59,IGHJ1,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_H5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSVGDCSSTSCLYWYFDLW,IGHV4-59,IGHJ2,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_H5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSVGDCSSTSCLYWYFDLW,IGHV4-59,IGHJ3,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_H5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSVGDCSSTSCLYWYFDLW,IGHV4-59,IGHJ4,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_H5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSVGDCSSTSCLYWYFDLW,IGHV4-59,IGHJ5,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_H5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVPSVGDCSSTSCLYWYFDLW,IGHV4-59,IGHJ6,CQQYNSYSTF,IGKV1-5,COVD21_P1_HC_H5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGMGELLTLRSEYYFDYW,IGHV4-59,IGHJ1,CYSYAGSYTFVF,IGLV2-11,COVD21_P2_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGMGELLTLRSEYYFDYW,IGHV4-59,IGHJ2,CYSYAGSYTFVF,IGLV2-11,COVD21_P2_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGMGELLTLRSEYYFDYW,IGHV4-59,IGHJ3,CYSYAGSYTFVF,IGLV2-11,COVD21_P2_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGMGELLTLRSEYYFDYW,IGHV4-59,IGHJ4,CYSYAGSYTFVF,IGLV2-11,COVD21_P2_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGMGELLTLRSEYYFDYW,IGHV4-59,IGHJ5,CYSYAGSYTFVF,IGLV2-11,COVD21_P2_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARYGMGELLTLRSEYYFDYW,IGHV4-59,IGHJ6,CYSYAGSYTFVF,IGLV2-11,COVD21_P2_HC_F4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSYDSSGLSYNWFDPW,IGHV4-59,IGHJ1,CQSYDSSLSGYVVF,IGLV1-40,COVD21_P3_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSYDSSGLSYNWFDPW,IGHV4-59,IGHJ2,CQSYDSSLSGYVVF,IGLV1-40,COVD21_P3_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSYDSSGLSYNWFDPW,IGHV4-59,IGHJ3,CQSYDSSLSGYVVF,IGLV1-40,COVD21_P3_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSYDSSGLSYNWFDPW,IGHV4-59,IGHJ4,CQSYDSSLSGYVVF,IGLV1-40,COVD21_P3_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSYDSSGLSYNWFDPW,IGHV4-59,IGHJ5,CQSYDSSLSGYVVF,IGLV1-40,COVD21_P3_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARSYDSSGLSYNWFDPW,IGHV4-59,IGHJ6,CQSYDSSLSGYVVF,IGLV1-40,COVD21_P3_HC_C4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYYYDSSGYEYYYYYGMDVW,IGHV4-59,IGHJ1,CAAWDDSLSGYWVF,IGLV1-47,COVD21_P2_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYYYDSSGYEYYYYYGMDVW,IGHV4-59,IGHJ2,CAAWDDSLSGYWVF,IGLV1-47,COVD21_P2_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYYYDSSGYEYYYYYGMDVW,IGHV4-59,IGHJ3,CAAWDDSLSGYWVF,IGLV1-47,COVD21_P2_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYYYDSSGYEYYYYYGMDVW,IGHV4-59,IGHJ4,CAAWDDSLSGYWVF,IGLV1-47,COVD21_P2_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYYYDSSGYEYYYYYGMDVW,IGHV4-59,IGHJ5,CAAWDDSLSGYWVF,IGLV1-47,COVD21_P2_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARGGYYYDSSGYEYYYYYGMDVW,IGHV4-59,IGHJ6,CAAWDDSLSGYWVF,IGLV1-47,COVD21_P2_HC_E2-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETYYYDSSGYYISDAFDIW,IGHV4-61,IGHJ1,CQQYNSFSYTF,IGKV1-5,COVD21_P1_HC_C5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETYYYDSSGYYISDAFDIW,IGHV4-61,IGHJ2,CQQYNSFSYTF,IGKV1-5,COVD21_P1_HC_C5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETYYYDSSGYYISDAFDIW,IGHV4-61,IGHJ3,CQQYNSFSYTF,IGKV1-5,COVD21_P1_HC_C5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETYYYDSSGYYISDAFDIW,IGHV4-61,IGHJ4,CQQYNSFSYTF,IGKV1-5,COVD21_P1_HC_C5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETYYYDSSGYYISDAFDIW,IGHV4-61,IGHJ5,CQQYNSFSYTF,IGKV1-5,COVD21_P1_HC_C5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARETYYYDSSGYYISDAFDIW,IGHV4-61,IGHJ6,CQQYNSFSYTF,IGKV1-5,COVD21_P1_HC_C5-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQWRGYYDRSGYYHFDAFDIW,IGHV5-51,IGHJ1,CQQYNNWLGTF,IGKV3-15,COVD21_P2_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQWRGYYDRSGYYHFDAFDIW,IGHV5-51,IGHJ2,CQQYNNWLGTF,IGKV3-15,COVD21_P2_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQWRGYYDRSGYYHFDAFDIW,IGHV5-51,IGHJ3,CQQYNNWLGTF,IGKV3-15,COVD21_P2_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQWRGYYDRSGYYHFDAFDIW,IGHV5-51,IGHJ4,CQQYNNWLGTF,IGKV3-15,COVD21_P2_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQWRGYYDRSGYYHFDAFDIW,IGHV5-51,IGHJ5,CQQYNNWLGTF,IGKV3-15,COVD21_P2_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARQWRGYYDRSGYYHFDAFDIW,IGHV5-51,IGHJ6,CQQYNNWLGTF,IGKV3-15,COVD21_P2_HC_H4-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWYYGDYGNYSYYYLDVW,IGHV5-51,IGHJ1,CQQYNNWPLTF,IGKV3-15,COVD21_P1_HC_C6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWYYGDYGNYSYYYLDVW,IGHV5-51,IGHJ2,CQQYNNWPLTF,IGKV3-15,COVD21_P1_HC_C6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWYYGDYGNYSYYYLDVW,IGHV5-51,IGHJ3,CQQYNNWPLTF,IGKV3-15,COVD21_P1_HC_C6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWYYGDYGNYSYYYLDVW,IGHV5-51,IGHJ4,CQQYNNWPLTF,IGKV3-15,COVD21_P1_HC_C6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWYYGDYGNYSYYYLDVW,IGHV5-51,IGHJ5,CQQYNNWPLTF,IGKV3-15,COVD21_P1_HC_C6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARHWYYGDYGNYSYYYLDVW,IGHV5-51,IGHJ6,CQQYNNWPLTF,IGKV3-15,COVD21_P1_HC_C6-p1369,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ1,CQQTYSTPRTF,IGKV1-39,81E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ2,CQQTYSTPRTF,IGKV1-39,81E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ3,CQQTYSTPRTF,IGKV1-39,81E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ4,CQQTYSTPRTF,IGKV1-39,81E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ5,CQQTYSTPRTF,IGKV1-39,81E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ6,CQQTYSTPRTF,IGKV1-39,81E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFRYGDYPDYW,IGHV3-53,IGHJ1,CQQYDNLPSFTF,IGKV1-33,81D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFRYGDYPDYW,IGHV3-53,IGHJ2,CQQYDNLPSFTF,IGKV1-33,81D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFRYGDYPDYW,IGHV3-53,IGHJ3,CQQYDNLPSFTF,IGKV1-33,81D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFRYGDYPDYW,IGHV3-53,IGHJ4,CQQYDNLPSFTF,IGKV1-33,81D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFRYGDYPDYW,IGHV3-53,IGHJ5,CQQYDNLPSFTF,IGKV1-33,81D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFRYGDYPDYW,IGHV3-53,IGHJ6,CQQYDNLPSFTF,IGKV1-33,81D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGVPYCSSSSCYRYYGMDVW,IGHV4-34,IGHJ1,CQQLNSYPQATF,IGKV1-9,81A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGVPYCSSSSCYRYYGMDVW,IGHV4-34,IGHJ2,CQQLNSYPQATF,IGKV1-9,81A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGVPYCSSSSCYRYYGMDVW,IGHV4-34,IGHJ3,CQQLNSYPQATF,IGKV1-9,81A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGVPYCSSSSCYRYYGMDVW,IGHV4-34,IGHJ4,CQQLNSYPQATF,IGKV1-9,81A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGVPYCSSSSCYRYYGMDVW,IGHV4-34,IGHJ5,CQQLNSYPQATF,IGKV1-9,81A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGVPYCSSSSCYRYYGMDVW,IGHV4-34,IGHJ6,CQQLNSYPQATF,IGKV1-9,81A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ1,CQQSYNTPPWTF,IGKV1-39,81C8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ2,CQQSYNTPPWTF,IGKV1-39,81C8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ3,CQQSYNTPPWTF,IGKV1-39,81C8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ4,CQQSYNTPPWTF,IGKV1-39,81C8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ5,CQQSYNTPPWTF,IGKV1-39,81C8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ6,CQQSYNTPPWTF,IGKV1-39,81C8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQGYSSGWNDAFDIW,IGHV4-59,IGHJ1,CCSYAGSRFWVF,IGLV2-23,81A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQGYSSGWNDAFDIW,IGHV4-59,IGHJ2,CCSYAGSRFWVF,IGLV2-23,81A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQGYSSGWNDAFDIW,IGHV4-59,IGHJ3,CCSYAGSRFWVF,IGLV2-23,81A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQGYSSGWNDAFDIW,IGHV4-59,IGHJ4,CCSYAGSRFWVF,IGLV2-23,81A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQGYSSGWNDAFDIW,IGHV4-59,IGHJ5,CCSYAGSRFWVF,IGLV2-23,81A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQGYSSGWNDAFDIW,IGHV4-59,IGHJ6,CCSYAGSRFWVF,IGLV2-23,81A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAGTTDWYFDLW,IGHV1-69,IGHJ1,CQSYDSSLSVVVF,IGLV1-40,81A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAGTTDWYFDLW,IGHV1-69,IGHJ2,CQSYDSSLSVVVF,IGLV1-40,81A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAGTTDWYFDLW,IGHV1-69,IGHJ3,CQSYDSSLSVVVF,IGLV1-40,81A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAGTTDWYFDLW,IGHV1-69,IGHJ4,CQSYDSSLSVVVF,IGLV1-40,81A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAGTTDWYFDLW,IGHV1-69,IGHJ5,CQSYDSSLSVVVF,IGLV1-40,81A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAGTTDWYFDLW,IGHV1-69,IGHJ6,CQSYDSSLSVVVF,IGLV1-40,81A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPRFSWRGNDSGYFDYW,IGHV4-39,IGHJ1,CSSFTSSSTPYVF,IGLV2-14,81C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPRFSWRGNDSGYFDYW,IGHV4-39,IGHJ2,CSSFTSSSTPYVF,IGLV2-14,81C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPRFSWRGNDSGYFDYW,IGHV4-39,IGHJ3,CSSFTSSSTPYVF,IGLV2-14,81C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPRFSWRGNDSGYFDYW,IGHV4-39,IGHJ4,CSSFTSSSTPYVF,IGLV2-14,81C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPRFSWRGNDSGYFDYW,IGHV4-39,IGHJ5,CSSFTSSSTPYVF,IGLV2-14,81C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPRFSWRGNDSGYFDYW,IGHV4-39,IGHJ6,CSSFTSSSTPYVF,IGLV2-14,81C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSMVRGVLFGADFDYW,IGHV2-5,IGHJ1,CAAWDDSLNGPVF,IGLV1-36,81C7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSMVRGVLFGADFDYW,IGHV2-5,IGHJ2,CAAWDDSLNGPVF,IGLV1-36,81C7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSMVRGVLFGADFDYW,IGHV2-5,IGHJ3,CAAWDDSLNGPVF,IGLV1-36,81C7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSMVRGVLFGADFDYW,IGHV2-5,IGHJ4,CAAWDDSLNGPVF,IGLV1-36,81C7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSMVRGVLFGADFDYW,IGHV2-5,IGHJ5,CAAWDDSLNGPVF,IGLV1-36,81C7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSMVRGVLFGADFDYW,IGHV2-5,IGHJ6,CAAWDDSLNGPVF,IGLV1-36,81C7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRWDGVGFDIW,IGHV5-51,IGHJ1,CNSRDSSINHYVF,IGLV3-19,81D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRWDGVGFDIW,IGHV5-51,IGHJ2,CNSRDSSINHYVF,IGLV3-19,81D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRWDGVGFDIW,IGHV5-51,IGHJ3,CNSRDSSINHYVF,IGLV3-19,81D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRWDGVGFDIW,IGHV5-51,IGHJ4,CNSRDSSINHYVF,IGLV3-19,81D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRWDGVGFDIW,IGHV5-51,IGHJ5,CNSRDSSINHYVF,IGLV3-19,81D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRWDGVGFDIW,IGHV5-51,IGHJ6,CNSRDSSINHYVF,IGLV3-19,81D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGWTVPPLWVLNWFDPW,IGHV4-34,IGHJ1,CMQALQTPRTF,IGKV2-28,81F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGWTVPPLWVLNWFDPW,IGHV4-34,IGHJ2,CMQALQTPRTF,IGKV2-28,81F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGWTVPPLWVLNWFDPW,IGHV4-34,IGHJ3,CMQALQTPRTF,IGKV2-28,81F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGWTVPPLWVLNWFDPW,IGHV4-34,IGHJ4,CMQALQTPRTF,IGKV2-28,81F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGWTVPPLWVLNWFDPW,IGHV4-34,IGHJ5,CMQALQTPRTF,IGKV2-28,81F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGWTVPPLWVLNWFDPW,IGHV4-34,IGHJ6,CMQALQTPRTF,IGKV2-28,81F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARSPHYYGGFDYW,IGHV3-7,IGHJ1,CQSYHNSVWVF,IGLV6-57,81G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARSPHYYGGFDYW,IGHV3-7,IGHJ2,CQSYHNSVWVF,IGLV6-57,81G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARSPHYYGGFDYW,IGHV3-7,IGHJ3,CQSYHNSVWVF,IGLV6-57,81G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARSPHYYGGFDYW,IGHV3-7,IGHJ4,CQSYHNSVWVF,IGLV6-57,81G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARSPHYYGGFDYW,IGHV3-7,IGHJ5,CQSYHNSVWVF,IGLV6-57,81G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARSPHYYGGFDYW,IGHV3-7,IGHJ6,CQSYHNSVWVF,IGLV6-57,81G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSVARGLRGYFDTW,IGHV1-24,IGHJ1,CAAWDDSLSRVVF,IGLV1-47,81E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSVARGLRGYFDTW,IGHV1-24,IGHJ2,CAAWDDSLSRVVF,IGLV1-47,81E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSVARGLRGYFDTW,IGHV1-24,IGHJ3,CAAWDDSLSRVVF,IGLV1-47,81E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSVARGLRGYFDTW,IGHV1-24,IGHJ4,CAAWDDSLSRVVF,IGLV1-47,81E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSVARGLRGYFDTW,IGHV1-24,IGHJ5,CAAWDDSLSRVVF,IGLV1-47,81E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSVARGLRGYFDTW,IGHV1-24,IGHJ6,CAAWDDSLSRVVF,IGLV1-47,81E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSLARGLKGYFDSW,IGHV1-24,IGHJ1,CAAWDDSLSGVIF,IGLV1-47,81E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSLARGLKGYFDSW,IGHV1-24,IGHJ2,CAAWDDSLSGVIF,IGLV1-47,81E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSLARGLKGYFDSW,IGHV1-24,IGHJ3,CAAWDDSLSGVIF,IGLV1-47,81E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSLARGLKGYFDSW,IGHV1-24,IGHJ4,CAAWDDSLSGVIF,IGLV1-47,81E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSLARGLKGYFDSW,IGHV1-24,IGHJ5,CAAWDDSLSGVIF,IGLV1-47,81E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAITSLARGLKGYFDSW,IGHV1-24,IGHJ6,CAAWDDSLSGVIF,IGLV1-47,81E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGCSSTSCSYYHYYGMDVW,IGHV3-9,IGHJ1,CMQALQTPTF,IGKV2-28,81A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGCSSTSCSYYHYYGMDVW,IGHV3-9,IGHJ2,CMQALQTPTF,IGKV2-28,81A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGCSSTSCSYYHYYGMDVW,IGHV3-9,IGHJ3,CMQALQTPTF,IGKV2-28,81A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGCSSTSCSYYHYYGMDVW,IGHV3-9,IGHJ4,CMQALQTPTF,IGKV2-28,81A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGCSSTSCSYYHYYGMDVW,IGHV3-9,IGHJ5,CMQALQTPTF,IGKV2-28,81A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGCSSTSCSYYHYYGMDVW,IGHV3-9,IGHJ6,CMQALQTPTF,IGKV2-28,81A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGRAVAGTDW,IGHV3-66,IGHJ1,CHQYDNLPRTF,IGKV1-33,81B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGRAVAGTDW,IGHV3-66,IGHJ2,CHQYDNLPRTF,IGKV1-33,81B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGRAVAGTDW,IGHV3-66,IGHJ3,CHQYDNLPRTF,IGKV1-33,81B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGRAVAGTDW,IGHV3-66,IGHJ4,CHQYDNLPRTF,IGKV1-33,81B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGRAVAGTDW,IGHV3-66,IGHJ5,CHQYDNLPRTF,IGKV1-33,81B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGRAVAGTDW,IGHV3-66,IGHJ6,CHQYDNLPRTF,IGKV1-33,81B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ1,CQQRRDFTF,IGKV3-11,81B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ2,CQQRRDFTF,IGKV3-11,81B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ3,CQQRRDFTF,IGKV3-11,81B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ4,CQQRRDFTF,IGKV3-11,81B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ5,CQQRRDFTF,IGKV3-11,81B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ6,CQQRRDFTF,IGKV3-11,81B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ1,CQQSYSTPRLTF,IGKV1-39,82A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ2,CQQSYSTPRLTF,IGKV1-39,82A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ3,CQQSYSTPRLTF,IGKV1-39,82A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ4,CQQSYSTPRLTF,IGKV1-39,82A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ5,CQQSYSTPRLTF,IGKV1-39,82A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ6,CQQSYSTPRLTF,IGKV1-39,82A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAADRMRIVGGKGYYYGMDVW,IGHV1-58,IGHJ1,CQQYNSYSPGDTF,IGKV1-5,82C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAADRMRIVGGKGYYYGMDVW,IGHV1-58,IGHJ2,CQQYNSYSPGDTF,IGKV1-5,82C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAADRMRIVGGKGYYYGMDVW,IGHV1-58,IGHJ3,CQQYNSYSPGDTF,IGKV1-5,82C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAADRMRIVGGKGYYYGMDVW,IGHV1-58,IGHJ4,CQQYNSYSPGDTF,IGKV1-5,82C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAADRMRIVGGKGYYYGMDVW,IGHV1-58,IGHJ5,CQQYNSYSPGDTF,IGKV1-5,82C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAADRMRIVGGKGYYYGMDVW,IGHV1-58,IGHJ6,CQQYNSYSPGDTF,IGKV1-5,82C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRSMGYCSGGNCYSGFDPW,IGHV4-59,IGHJ1,CQQSYSTPLTF,IGKV1-39,82G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRSMGYCSGGNCYSGFDPW,IGHV4-59,IGHJ2,CQQSYSTPLTF,IGKV1-39,82G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRSMGYCSGGNCYSGFDPW,IGHV4-59,IGHJ3,CQQSYSTPLTF,IGKV1-39,82G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRSMGYCSGGNCYSGFDPW,IGHV4-59,IGHJ4,CQQSYSTPLTF,IGKV1-39,82G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRSMGYCSGGNCYSGFDPW,IGHV4-59,IGHJ5,CQQSYSTPLTF,IGKV1-39,82G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARRSMGYCSGGNCYSGFDPW,IGHV4-59,IGHJ6,CQQSYSTPLTF,IGKV1-39,82G8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAMTYYDYIWGRVDPQFDPW,IGHV4-61,IGHJ1,CCMQGTHWPPTF,IGKV2-30,82B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAMTYYDYIWGRVDPQFDPW,IGHV4-61,IGHJ2,CCMQGTHWPPTF,IGKV2-30,82B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAMTYYDYIWGRVDPQFDPW,IGHV4-61,IGHJ3,CCMQGTHWPPTF,IGKV2-30,82B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAMTYYDYIWGRVDPQFDPW,IGHV4-61,IGHJ4,CCMQGTHWPPTF,IGKV2-30,82B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAMTYYDYIWGRVDPQFDPW,IGHV4-61,IGHJ5,CCMQGTHWPPTF,IGKV2-30,82B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAMTYYDYIWGRVDPQFDPW,IGHV4-61,IGHJ6,CCMQGTHWPPTF,IGKV2-30,82B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ1,CHQYASSPRTF,IGKV3-20,82B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ2,CHQYASSPRTF,IGKV3-20,82B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ3,CHQYASSPRTF,IGKV3-20,82B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ4,CHQYASSPRTF,IGKV3-20,82B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ5,CHQYASSPRTF,IGKV3-20,82B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGWFGELSTEGQFDYW,IGHV1-18,IGHJ6,CHQYASSPRTF,IGKV3-20,82B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ1,CMQGTHWPMYTF,IGKV2-30,82C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ2,CMQGTHWPMYTF,IGKV2-30,82C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ3,CMQGTHWPMYTF,IGKV2-30,82C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ4,CMQGTHWPMYTF,IGKV2-30,82C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ5,CMQGTHWPMYTF,IGKV2-30,82C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFITDGYSSGSDSW,IGHV4-39,IGHJ6,CMQGTHWPMYTF,IGKV2-30,82C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQASPYCSGGSCYSGNFDYW,IGHV3-30,IGHJ1,CQQHDNVPLTF,IGKV1-33,82F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQASPYCSGGSCYSGNFDYW,IGHV3-30,IGHJ2,CQQHDNVPLTF,IGKV1-33,82F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQASPYCSGGSCYSGNFDYW,IGHV3-30,IGHJ3,CQQHDNVPLTF,IGKV1-33,82F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQASPYCSGGSCYSGNFDYW,IGHV3-30,IGHJ4,CQQHDNVPLTF,IGKV1-33,82F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQASPYCSGGSCYSGNFDYW,IGHV3-30,IGHJ5,CQQHDNVPLTF,IGKV1-33,82F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQASPYCSGGSCYSGNFDYW,IGHV3-30,IGHJ6,CQQHDNVPLTF,IGKV1-33,82F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQWLRLDYW,IGHV1-18,IGHJ1,CQQAKGFPLTF,IGKV1-12,82A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQWLRLDYW,IGHV1-18,IGHJ2,CQQAKGFPLTF,IGKV1-12,82A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQWLRLDYW,IGHV1-18,IGHJ3,CQQAKGFPLTF,IGKV1-12,82A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQWLRLDYW,IGHV1-18,IGHJ4,CQQAKGFPLTF,IGKV1-12,82A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQWLRLDYW,IGHV1-18,IGHJ5,CQQAKGFPLTF,IGKV1-12,82A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQWLRLDYW,IGHV1-18,IGHJ6,CQQAKGFPLTF,IGKV1-12,82A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRPAGFWSAHFDYW,IGHV2-5,IGHJ1,CQQSYSTPAWTF,IGKV1-39,82C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRPAGFWSAHFDYW,IGHV2-5,IGHJ2,CQQSYSTPAWTF,IGKV1-39,82C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRPAGFWSAHFDYW,IGHV2-5,IGHJ3,CQQSYSTPAWTF,IGKV1-39,82C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRPAGFWSAHFDYW,IGHV2-5,IGHJ4,CQQSYSTPAWTF,IGKV1-39,82C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRPAGFWSAHFDYW,IGHV2-5,IGHJ5,CQQSYSTPAWTF,IGKV1-39,82C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRPAGFWSAHFDYW,IGHV2-5,IGHJ6,CQQSYSTPAWTF,IGKV1-39,82C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLLVGPTGRGLGMDVW,IGHV3-66,IGHJ1,CQQYADLPYTF,IGKV1-33,51D3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLLVGPTGRGLGMDVW,IGHV3-66,IGHJ2,CQQYADLPYTF,IGKV1-33,51D3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLLVGPTGRGLGMDVW,IGHV3-66,IGHJ3,CQQYADLPYTF,IGKV1-33,51D3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLLVGPTGRGLGMDVW,IGHV3-66,IGHJ4,CQQYADLPYTF,IGKV1-33,51D3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLLVGPTGRGLGMDVW,IGHV3-66,IGHJ5,CQQYADLPYTF,IGKV1-33,51D3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLLVGPTGRGLGMDVW,IGHV3-66,IGHJ6,CQQYADLPYTF,IGKV1-33,51D3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMVVRGVMLDYW,IGHV2-70,IGHJ1,CQQSYSPPHSF,IGKV1-39,51D4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMVVRGVMLDYW,IGHV2-70,IGHJ2,CQQSYSPPHSF,IGKV1-39,51D4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMVVRGVMLDYW,IGHV2-70,IGHJ3,CQQSYSPPHSF,IGKV1-39,51D4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMVVRGVMLDYW,IGHV2-70,IGHJ4,CQQSYSPPHSF,IGKV1-39,51D4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMVVRGVMLDYW,IGHV2-70,IGHJ5,CQQSYSPPHSF,IGKV1-39,51D4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMVVRGVMLDYW,IGHV2-70,IGHJ6,CQQSYSPPHSF,IGKV1-39,51D4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLAWFGELSESPIEYW,IGHV1-18,IGHJ1,CQQRGNSITF,IGKV3-11,51A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLAWFGELSESPIEYW,IGHV1-18,IGHJ2,CQQRGNSITF,IGKV3-11,51A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLAWFGELSESPIEYW,IGHV1-18,IGHJ3,CQQRGNSITF,IGKV3-11,51A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLAWFGELSESPIEYW,IGHV1-18,IGHJ4,CQQRGNSITF,IGKV3-11,51A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLAWFGELSESPIEYW,IGHV1-18,IGHJ5,CQQRGNSITF,IGKV3-11,51A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLAWFGELSESPIEYW,IGHV1-18,IGHJ6,CQQRGNSITF,IGKV3-11,51A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRLAPDYDFLTGYYNGDDAFDVW,IGHV2-5,IGHJ1,CQQSYNTLALSF,IGKV1-39,51D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRLAPDYDFLTGYYNGDDAFDVW,IGHV2-5,IGHJ2,CQQSYNTLALSF,IGKV1-39,51D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRLAPDYDFLTGYYNGDDAFDVW,IGHV2-5,IGHJ3,CQQSYNTLALSF,IGKV1-39,51D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRLAPDYDFLTGYYNGDDAFDVW,IGHV2-5,IGHJ4,CQQSYNTLALSF,IGKV1-39,51D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRLAPDYDFLTGYYNGDDAFDVW,IGHV2-5,IGHJ5,CQQSYNTLALSF,IGKV1-39,51D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHRLAPDYDFLTGYYNGDDAFDVW,IGHV2-5,IGHJ6,CQQSYNTLALSF,IGKV1-39,51D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLNIAGGFDIW,IGHV3-66,IGHJ1,CQHLNIDPITF,IGKV1-9,51A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLNIAGGFDIW,IGHV3-66,IGHJ2,CQHLNIDPITF,IGKV1-9,51A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLNIAGGFDIW,IGHV3-66,IGHJ3,CQHLNIDPITF,IGKV1-9,51A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLNIAGGFDIW,IGHV3-66,IGHJ4,CQHLNIDPITF,IGKV1-9,51A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLNIAGGFDIW,IGHV3-66,IGHJ5,CQHLNIDPITF,IGKV1-9,51A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLNIAGGFDIW,IGHV3-66,IGHJ6,CQHLNIDPITF,IGKV1-9,51A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLMYYYGNFDYW,IGHV3-7,IGHJ1,CQQYYGYPTF,IGKV1-8,51E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLMYYYGNFDYW,IGHV3-7,IGHJ2,CQQYYGYPTF,IGKV1-8,51E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLMYYYGNFDYW,IGHV3-7,IGHJ3,CQQYYGYPTF,IGKV1-8,51E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLMYYYGNFDYW,IGHV3-7,IGHJ4,CQQYYGYPTF,IGKV1-8,51E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLMYYYGNFDYW,IGHV3-7,IGHJ5,CQQYYGYPTF,IGKV1-8,51E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLMYYYGNFDYW,IGHV3-7,IGHJ6,CQQYYGYPTF,IGKV1-8,51E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPFCDSASCGRAHYYYGMDVW,IGHV5-10-1,IGHJ1,CQQYNNWPETF,IGKV3-15,51D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPFCDSASCGRAHYYYGMDVW,IGHV5-10-1,IGHJ2,CQQYNNWPETF,IGKV3-15,51D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPFCDSASCGRAHYYYGMDVW,IGHV5-10-1,IGHJ3,CQQYNNWPETF,IGKV3-15,51D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPFCDSASCGRAHYYYGMDVW,IGHV5-10-1,IGHJ4,CQQYNNWPETF,IGKV3-15,51D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPFCDSASCGRAHYYYGMDVW,IGHV5-10-1,IGHJ5,CQQYNNWPETF,IGKV3-15,51D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPFCDSASCGRAHYYYGMDVW,IGHV5-10-1,IGHJ6,CQQYNNWPETF,IGKV3-15,51D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ1,CQQYGSSRTF,IGKV3-20,51F11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ2,CQQYGSSRTF,IGKV3-20,51F11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ3,CQQYGSSRTF,IGKV3-20,51F11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ4,CQQYGSSRTF,IGKV3-20,51F11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ5,CQQYGSSRTF,IGKV3-20,51F11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ6,CQQYGSSRTF,IGKV3-20,51F11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARARQLVLNWYFDLW,IGHV1-18,IGHJ1,CQQYYITPQLTF,IGKV4-1,51E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARARQLVLNWYFDLW,IGHV1-18,IGHJ2,CQQYYITPQLTF,IGKV4-1,51E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARARQLVLNWYFDLW,IGHV1-18,IGHJ3,CQQYYITPQLTF,IGKV4-1,51E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARARQLVLNWYFDLW,IGHV1-18,IGHJ4,CQQYYITPQLTF,IGKV4-1,51E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARARQLVLNWYFDLW,IGHV1-18,IGHJ5,CQQYYITPQLTF,IGKV4-1,51E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARARQLVLNWYFDLW,IGHV1-18,IGHJ6,CQQYYITPQLTF,IGKV4-1,51E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYYGSGSYPLYWYFDLW,IGHV3-13,IGHJ1,CQQSYSAPPWTF,IGKV1-39,51E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYYGSGSYPLYWYFDLW,IGHV3-13,IGHJ2,CQQSYSAPPWTF,IGKV1-39,51E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYYGSGSYPLYWYFDLW,IGHV3-13,IGHJ3,CQQSYSAPPWTF,IGKV1-39,51E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYYGSGSYPLYWYFDLW,IGHV3-13,IGHJ4,CQQSYSAPPWTF,IGKV1-39,51E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYYGSGSYPLYWYFDLW,IGHV3-13,IGHJ5,CQQSYSAPPWTF,IGKV1-39,51E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYYGSGSYPLYWYFDLW,IGHV3-13,IGHJ6,CQQSYSAPPWTF,IGKV1-39,51E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATRTGWTNDAFDIW,IGHV5-51,IGHJ1,CQQSYSTPCTF,IGKV1-39,51D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATRTGWTNDAFDIW,IGHV5-51,IGHJ2,CQQSYSTPCTF,IGKV1-39,51D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATRTGWTNDAFDIW,IGHV5-51,IGHJ3,CQQSYSTPCTF,IGKV1-39,51D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATRTGWTNDAFDIW,IGHV5-51,IGHJ4,CQQSYSTPCTF,IGKV1-39,51D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATRTGWTNDAFDIW,IGHV5-51,IGHJ5,CQQSYSTPCTF,IGKV1-39,51D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATRTGWTNDAFDIW,IGHV5-51,IGHJ6,CQQSYSTPCTF,IGKV1-39,51D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALGRAGTMDYW,IGHV2-70,IGHJ1,CQQSYSPPYTF,IGKV1-39,51F5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALGRAGTMDYW,IGHV2-70,IGHJ2,CQQSYSPPYTF,IGKV1-39,51F5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALGRAGTMDYW,IGHV2-70,IGHJ3,CQQSYSPPYTF,IGKV1-39,51F5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALGRAGTMDYW,IGHV2-70,IGHJ4,CQQSYSPPYTF,IGKV1-39,51F5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALGRAGTMDYW,IGHV2-70,IGHJ5,CQQSYSPPYTF,IGKV1-39,51F5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALGRAGTMDYW,IGHV2-70,IGHJ6,CQQSYSPPYTF,IGKV1-39,51F5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDMVAGPHYYGMDVW,IGHV3-9,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,51E3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDMVAGPHYYGMDVW,IGHV3-9,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,51E3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDMVAGPHYYGMDVW,IGHV3-9,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,51E3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDMVAGPHYYGMDVW,IGHV3-9,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,51E3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDMVAGPHYYGMDVW,IGHV3-9,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,51E3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDMVAGPHYYGMDVW,IGHV3-9,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,51E3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPSNFYDSGGDYYAMDVW,IGHV5-51,IGHJ1,CCSYAGSSSWVF,IGLV2-23,51B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPSNFYDSGGDYYAMDVW,IGHV5-51,IGHJ2,CCSYAGSSSWVF,IGLV2-23,51B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPSNFYDSGGDYYAMDVW,IGHV5-51,IGHJ3,CCSYAGSSSWVF,IGLV2-23,51B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPSNFYDSGGDYYAMDVW,IGHV5-51,IGHJ4,CCSYAGSSSWVF,IGLV2-23,51B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPSNFYDSGGDYYAMDVW,IGHV5-51,IGHJ5,CCSYAGSSSWVF,IGLV2-23,51B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPSNFYDSGGDYYAMDVW,IGHV5-51,IGHJ6,CCSYAGSSSWVF,IGLV2-23,51B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLASDGSGSYLDYFDYW,IGHV3-66,IGHJ1,CQSYDSSLSGSWVF,IGLV1-40,52C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLASDGSGSYLDYFDYW,IGHV3-66,IGHJ2,CQSYDSSLSGSWVF,IGLV1-40,52C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLASDGSGSYLDYFDYW,IGHV3-66,IGHJ3,CQSYDSSLSGSWVF,IGLV1-40,52C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLASDGSGSYLDYFDYW,IGHV3-66,IGHJ4,CQSYDSSLSGSWVF,IGLV1-40,52C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLASDGSGSYLDYFDYW,IGHV3-66,IGHJ5,CQSYDSSLSGSWVF,IGLV1-40,52C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLASDGSGSYLDYFDYW,IGHV3-66,IGHJ6,CQSYDSSLSGSWVF,IGLV1-40,52C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDLSSGWDLFDYW,IGHV3-9,IGHJ1,CQVWDTSGDPLVF,IGLV3-21,52G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDLSSGWDLFDYW,IGHV3-9,IGHJ2,CQVWDTSGDPLVF,IGLV3-21,52G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDLSSGWDLFDYW,IGHV3-9,IGHJ3,CQVWDTSGDPLVF,IGLV3-21,52G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDLSSGWDLFDYW,IGHV3-9,IGHJ4,CQVWDTSGDPLVF,IGLV3-21,52G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDLSSGWDLFDYW,IGHV3-9,IGHJ5,CQVWDTSGDPLVF,IGLV3-21,52G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDLSSGWDLFDYW,IGHV3-9,IGHJ6,CQVWDTSGDPLVF,IGLV3-21,52G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDGGGGSYYYAHYYYGMDVW,IGHV1-69,IGHJ1,CVLYMGSGIVVF,IGLV8-61,52C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDGGGGSYYYAHYYYGMDVW,IGHV1-69,IGHJ2,CVLYMGSGIVVF,IGLV8-61,52C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDGGGGSYYYAHYYYGMDVW,IGHV1-69,IGHJ3,CVLYMGSGIVVF,IGLV8-61,52C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDGGGGSYYYAHYYYGMDVW,IGHV1-69,IGHJ4,CVLYMGSGIVVF,IGLV8-61,52C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDGGGGSYYYAHYYYGMDVW,IGHV1-69,IGHJ5,CVLYMGSGIVVF,IGLV8-61,52C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDGGGGSYYYAHYYYGMDVW,IGHV1-69,IGHJ6,CVLYMGSGIVVF,IGLV8-61,52C6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRSDGDYVIGHDYW,IGHV5-51,IGHJ1,CATWDDSLNGRVF,IGLV1-44,52E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRSDGDYVIGHDYW,IGHV5-51,IGHJ2,CATWDDSLNGRVF,IGLV1-44,52E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRSDGDYVIGHDYW,IGHV5-51,IGHJ3,CATWDDSLNGRVF,IGLV1-44,52E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRSDGDYVIGHDYW,IGHV5-51,IGHJ4,CATWDDSLNGRVF,IGLV1-44,52E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRSDGDYVIGHDYW,IGHV5-51,IGHJ5,CATWDDSLNGRVF,IGLV1-44,52E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRSDGDYVIGHDYW,IGHV5-51,IGHJ6,CATWDDSLNGRVF,IGLV1-44,52E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRDDYGDYRGGDFDYW,IGHV3-48,IGHJ1,CQQRSNWPPITF,IGKV3-11,52B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRDDYGDYRGGDFDYW,IGHV3-48,IGHJ2,CQQRSNWPPITF,IGKV3-11,52B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRDDYGDYRGGDFDYW,IGHV3-48,IGHJ3,CQQRSNWPPITF,IGKV3-11,52B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRDDYGDYRGGDFDYW,IGHV3-48,IGHJ4,CQQRSNWPPITF,IGKV3-11,52B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRDDYGDYRGGDFDYW,IGHV3-48,IGHJ5,CQQRSNWPPITF,IGKV3-11,52B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRDDYGDYRGGDFDYW,IGHV3-48,IGHJ6,CQQRSNWPPITF,IGKV3-11,52B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGVMVPGVTPYGMDVW,IGHV3-9,IGHJ1,CMQGTHWPPGTF,IGKV2D-30,52F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGVMVPGVTPYGMDVW,IGHV3-9,IGHJ2,CMQGTHWPPGTF,IGKV2D-30,52F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGVMVPGVTPYGMDVW,IGHV3-9,IGHJ3,CMQGTHWPPGTF,IGKV2D-30,52F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGVMVPGVTPYGMDVW,IGHV3-9,IGHJ4,CMQGTHWPPGTF,IGKV2D-30,52F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGVMVPGVTPYGMDVW,IGHV3-9,IGHJ5,CMQGTHWPPGTF,IGKV2D-30,52F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDIGVMVPGVTPYGMDVW,IGHV3-9,IGHJ6,CMQGTHWPPGTF,IGKV2D-30,52F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPAYVSGTYYWNAFDIW,IGHV1-69,IGHJ1,CQHYNNWPLYTF,IGKV3-15,52B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPAYVSGTYYWNAFDIW,IGHV1-69,IGHJ2,CQHYNNWPLYTF,IGKV3-15,52B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPAYVSGTYYWNAFDIW,IGHV1-69,IGHJ3,CQHYNNWPLYTF,IGKV3-15,52B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPAYVSGTYYWNAFDIW,IGHV1-69,IGHJ4,CQHYNNWPLYTF,IGKV3-15,52B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPAYVSGTYYWNAFDIW,IGHV1-69,IGHJ5,CQHYNNWPLYTF,IGKV3-15,52B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPAYVSGTYYWNAFDIW,IGHV1-69,IGHJ6,CQHYNNWPLYTF,IGKV3-15,52B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPPGNMGSMAQHLVLLVVFDIW,IGHV3-30,IGHJ1,CQQSYTTLALTF,IGKV1-39,52E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPPGNMGSMAQHLVLLVVFDIW,IGHV3-30,IGHJ2,CQQSYTTLALTF,IGKV1-39,52E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPPGNMGSMAQHLVLLVVFDIW,IGHV3-30,IGHJ3,CQQSYTTLALTF,IGKV1-39,52E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPPGNMGSMAQHLVLLVVFDIW,IGHV3-30,IGHJ4,CQQSYTTLALTF,IGKV1-39,52E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPPGNMGSMAQHLVLLVVFDIW,IGHV3-30,IGHJ5,CQQSYTTLALTF,IGKV1-39,52E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPPGNMGSMAQHLVLLVVFDIW,IGHV3-30,IGHJ6,CQQSYTTLALTF,IGKV1-39,52E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPMRPGMDVW,IGHV3-66,IGHJ1,CQQYDNLPRTF,IGKV1-33,52G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPMRPGMDVW,IGHV3-66,IGHJ2,CQQYDNLPRTF,IGKV1-33,52G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPMRPGMDVW,IGHV3-66,IGHJ3,CQQYDNLPRTF,IGKV1-33,52G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPMRPGMDVW,IGHV3-66,IGHJ4,CQQYDNLPRTF,IGKV1-33,52G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPMRPGMDVW,IGHV3-66,IGHJ5,CQQYDNLPRTF,IGKV1-33,52G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPMRPGMDVW,IGHV3-66,IGHJ6,CQQYDNLPRTF,IGKV1-33,52G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPQGRAFDIW,IGHV3-66,IGHJ1,CQQYDNLPLTF,IGKV1-33,53H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPQGRAFDIW,IGHV3-66,IGHJ2,CQQYDNLPLTF,IGKV1-33,53H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPQGRAFDIW,IGHV3-66,IGHJ3,CQQYDNLPLTF,IGKV1-33,53H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPQGRAFDIW,IGHV3-66,IGHJ4,CQQYDNLPLTF,IGKV1-33,53H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPQGRAFDIW,IGHV3-66,IGHJ5,CQQYDNLPLTF,IGKV1-33,53H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPQGRAFDIW,IGHV3-66,IGHJ6,CQQYDNLPLTF,IGKV1-33,53H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRYTYGTEGYFDNW,IGHV1-69,IGHJ1,CQQYNNLYTF,IGKV1-5,53C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRYTYGTEGYFDNW,IGHV1-69,IGHJ2,CQQYNNLYTF,IGKV1-5,53C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRYTYGTEGYFDNW,IGHV1-69,IGHJ3,CQQYNNLYTF,IGKV1-5,53C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRYTYGTEGYFDNW,IGHV1-69,IGHJ4,CQQYNNLYTF,IGKV1-5,53C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRYTYGTEGYFDNW,IGHV1-69,IGHJ5,CQQYNNLYTF,IGKV1-5,53C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGRYTYGTEGYFDNW,IGHV1-69,IGHJ6,CQQYNNLYTF,IGKV1-5,53C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGFGYASGWYYLDYW,IGHV3-33,IGHJ1,CQQYGNLPPIAF,IGKV1-33,53G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGFGYASGWYYLDYW,IGHV3-33,IGHJ2,CQQYGNLPPIAF,IGKV1-33,53G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGFGYASGWYYLDYW,IGHV3-33,IGHJ3,CQQYGNLPPIAF,IGKV1-33,53G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGFGYASGWYYLDYW,IGHV3-33,IGHJ4,CQQYGNLPPIAF,IGKV1-33,53G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGFGYASGWYYLDYW,IGHV3-33,IGHJ5,CQQYGNLPPIAF,IGKV1-33,53G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGFGYASGWYYLDYW,IGHV3-33,IGHJ6,CQQYGNLPPIAF,IGKV1-33,53G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAYYDTSGYYNYFDHW,IGHV3-13,IGHJ1,CQHYNNWPLYTF,IGKV3-15,53B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAYYDTSGYYNYFDHW,IGHV3-13,IGHJ2,CQHYNNWPLYTF,IGKV3-15,53B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAYYDTSGYYNYFDHW,IGHV3-13,IGHJ3,CQHYNNWPLYTF,IGKV3-15,53B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAYYDTSGYYNYFDHW,IGHV3-13,IGHJ4,CQHYNNWPLYTF,IGKV3-15,53B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAYYDTSGYYNYFDHW,IGHV3-13,IGHJ5,CQHYNNWPLYTF,IGKV3-15,53B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAYYDTSGYYNYFDHW,IGHV3-13,IGHJ6,CQHYNNWPLYTF,IGKV3-15,53B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGYGSGSYGWFDPW,IGHV3-53,IGHJ1,CQHYNNWPLYTF,IGKV3-15,53H5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGYGSGSYGWFDPW,IGHV3-53,IGHJ2,CQHYNNWPLYTF,IGKV3-15,53H5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGYGSGSYGWFDPW,IGHV3-53,IGHJ3,CQHYNNWPLYTF,IGKV3-15,53H5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGYGSGSYGWFDPW,IGHV3-53,IGHJ4,CQHYNNWPLYTF,IGKV3-15,53H5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGYGSGSYGWFDPW,IGHV3-53,IGHJ5,CQHYNNWPLYTF,IGKV3-15,53H5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGYGSGSYGWFDPW,IGHV3-53,IGHJ6,CQHYNNWPLYTF,IGKV3-15,53H5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLGMDVW,IGHV3-53,IGHJ1,CQHYNNWPLYTF,IGKV3-15,53H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLGMDVW,IGHV3-53,IGHJ2,CQHYNNWPLYTF,IGKV3-15,53H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLGMDVW,IGHV3-53,IGHJ3,CQHYNNWPLYTF,IGKV3-15,53H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLGMDVW,IGHV3-53,IGHJ4,CQHYNNWPLYTF,IGKV3-15,53H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLGMDVW,IGHV3-53,IGHJ5,CQHYNNWPLYTF,IGKV3-15,53H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLGMDVW,IGHV3-53,IGHJ6,CQHYNNWPLYTF,IGKV3-15,53H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTTLTFDYW,IGHV3-53,IGHJ1,CMQGTHWPPGTF,IGKV2D-30,53F9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTTLTFDYW,IGHV3-53,IGHJ2,CMQGTHWPPGTF,IGKV2D-30,53F9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTTLTFDYW,IGHV3-53,IGHJ3,CMQGTHWPPGTF,IGKV2D-30,53F9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTTLTFDYW,IGHV3-53,IGHJ4,CMQGTHWPPGTF,IGKV2D-30,53F9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTTLTFDYW,IGHV3-53,IGHJ5,CMQGTHWPPGTF,IGKV2D-30,53F9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTTLTFDYW,IGHV3-53,IGHJ6,CMQGTHWPPGTF,IGKV2D-30,53F9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFLVGGFKAWFDPW,IGHV2-70,IGHJ1,CGTWDTSLNVWVF,IGLV1-51,53G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFLVGGFKAWFDPW,IGHV2-70,IGHJ2,CGTWDTSLNVWVF,IGLV1-51,53G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFLVGGFKAWFDPW,IGHV2-70,IGHJ3,CGTWDTSLNVWVF,IGLV1-51,53G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFLVGGFKAWFDPW,IGHV2-70,IGHJ4,CGTWDTSLNVWVF,IGLV1-51,53G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFLVGGFKAWFDPW,IGHV2-70,IGHJ5,CGTWDTSLNVWVF,IGLV1-51,53G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARFLVGGFKAWFDPW,IGHV2-70,IGHJ6,CGTWDTSLNVWVF,IGLV1-51,53G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARESPKLTGYFDYW,IGHV3-43,IGHJ1,CQVWDSSSDPYVF,IGLV3-21,53C10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARESPKLTGYFDYW,IGHV3-43,IGHJ2,CQVWDSSSDPYVF,IGLV3-21,53C10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARESPKLTGYFDYW,IGHV3-43,IGHJ3,CQVWDSSSDPYVF,IGLV3-21,53C10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARESPKLTGYFDYW,IGHV3-43,IGHJ4,CQVWDSSSDPYVF,IGLV3-21,53C10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARESPKLTGYFDYW,IGHV3-43,IGHJ5,CQVWDSSSDPYVF,IGLV3-21,53C10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARESPKLTGYFDYW,IGHV3-43,IGHJ6,CQVWDSSSDPYVF,IGLV3-21,53C10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQAFIVATLGPDYW,IGHV1-46,IGHJ1,CVLYMGSGIWVF,IGLV8-61,53E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQAFIVATLGPDYW,IGHV1-46,IGHJ2,CVLYMGSGIWVF,IGLV8-61,53E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQAFIVATLGPDYW,IGHV1-46,IGHJ3,CVLYMGSGIWVF,IGLV8-61,53E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQAFIVATLGPDYW,IGHV1-46,IGHJ4,CVLYMGSGIWVF,IGLV8-61,53E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQAFIVATLGPDYW,IGHV1-46,IGHJ5,CVLYMGSGIWVF,IGLV8-61,53E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDQAFIVATLGPDYW,IGHV1-46,IGHJ6,CVLYMGSGIWVF,IGLV8-61,53E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKMLWLRGWFDPW,IGHV3-53,IGHJ1,CQSYDTSNHWVF,IGLV6-57,53E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKMLWLRGWFDPW,IGHV3-53,IGHJ2,CQSYDTSNHWVF,IGLV6-57,53E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKMLWLRGWFDPW,IGHV3-53,IGHJ3,CQSYDTSNHWVF,IGLV6-57,53E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKMLWLRGWFDPW,IGHV3-53,IGHJ4,CQSYDTSNHWVF,IGLV6-57,53E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKMLWLRGWFDPW,IGHV3-53,IGHJ5,CQSYDTSNHWVF,IGLV6-57,53E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKMLWLRGWFDPW,IGHV3-53,IGHJ6,CQSYDTSNHWVF,IGLV6-57,53E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDAVGSYYYGMEVW,IGHV3-66,IGHJ1,CQHYNNWPLYTF,IGKV3-15,53F12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDAVGSYYYGMEVW,IGHV3-66,IGHJ2,CQHYNNWPLYTF,IGKV3-15,53F12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDAVGSYYYGMEVW,IGHV3-66,IGHJ3,CQHYNNWPLYTF,IGKV3-15,53F12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDAVGSYYYGMEVW,IGHV3-66,IGHJ4,CQHYNNWPLYTF,IGKV3-15,53F12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDAVGSYYYGMEVW,IGHV3-66,IGHJ5,CQHYNNWPLYTF,IGKV3-15,53F12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDAVGSYYYGMEVW,IGHV3-66,IGHJ6,CQHYNNWPLYTF,IGKV3-15,53F12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ1,CQQSYSTPRTF,IGKV1-39,54H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ2,CQQSYSTPRTF,IGKV1-39,54H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ3,CQQSYSTPRTF,IGKV1-39,54H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ4,CQQSYSTPRTF,IGKV1-39,54H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ5,CQQSYSTPRTF,IGKV1-39,54H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ6,CQQSYSTPRTF,IGKV1-39,54H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLEERGAMDVW,IGHV3-53,IGHJ1,CQQYGSSLWTF,IGKV3-20,54F10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLEERGAMDVW,IGHV3-53,IGHJ2,CQQYGSSLWTF,IGKV3-20,54F10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLEERGAMDVW,IGHV3-53,IGHJ3,CQQYGSSLWTF,IGKV3-20,54F10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLEERGAMDVW,IGHV3-53,IGHJ4,CQQYGSSLWTF,IGKV3-20,54F10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLEERGAMDVW,IGHV3-53,IGHJ5,CQQYGSSLWTF,IGKV3-20,54F10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLEERGAMDVW,IGHV3-53,IGHJ6,CQQYGSSLWTF,IGKV3-20,54F10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWLRGRFDPW,IGHV3-66,IGHJ1,CQVWDSTTDLPHWVF,IGLV3-21,54G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWLRGRFDPW,IGHV3-66,IGHJ2,CQVWDSTTDLPHWVF,IGLV3-21,54G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWLRGRFDPW,IGHV3-66,IGHJ3,CQVWDSTTDLPHWVF,IGLV3-21,54G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWLRGRFDPW,IGHV3-66,IGHJ4,CQVWDSTTDLPHWVF,IGLV3-21,54G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWLRGRFDPW,IGHV3-66,IGHJ5,CQVWDSTTDLPHWVF,IGLV3-21,54G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWLRGRFDPW,IGHV3-66,IGHJ6,CQVWDSTTDLPHWVF,IGLV3-21,54G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTRLGITAFDIW,IGHV2-70,IGHJ1,CQQSYTTPRTF,IGKV1-39,55G3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTRLGITAFDIW,IGHV2-70,IGHJ2,CQQSYTTPRTF,IGKV1-39,55G3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTRLGITAFDIW,IGHV2-70,IGHJ3,CQQSYTTPRTF,IGKV1-39,55G3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTRLGITAFDIW,IGHV2-70,IGHJ4,CQQSYTTPRTF,IGKV1-39,55G3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTRLGITAFDIW,IGHV2-70,IGHJ5,CQQSYTTPRTF,IGKV1-39,55G3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTRLGITAFDIW,IGHV2-70,IGHJ6,CQQSYTTPRTF,IGKV1-39,55G3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTEYGDYDVSHDW,IGHV1-69,IGHJ1,CQQYNSYSHTF,IGKV1-5,55A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTEYGDYDVSHDW,IGHV1-69,IGHJ2,CQQYNSYSHTF,IGKV1-5,55A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTEYGDYDVSHDW,IGHV1-69,IGHJ3,CQQYNSYSHTF,IGKV1-5,55A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTEYGDYDVSHDW,IGHV1-69,IGHJ4,CQQYNSYSHTF,IGKV1-5,55A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTEYGDYDVSHDW,IGHV1-69,IGHJ5,CQQYNSYSHTF,IGKV1-5,55A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTEYGDYDVSHDW,IGHV1-69,IGHJ6,CQQYNSYSHTF,IGKV1-5,55A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTALAFDYW,IGHV3-53,IGHJ1,CQQSYSTPPYTF,IGKV1-39,55C9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTALAFDYW,IGHV3-53,IGHJ2,CQQSYSTPPYTF,IGKV1-39,55C9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTALAFDYW,IGHV3-53,IGHJ3,CQQSYSTPPYTF,IGKV1-39,55C9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTALAFDYW,IGHV3-53,IGHJ4,CQQSYSTPPYTF,IGKV1-39,55C9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTALAFDYW,IGHV3-53,IGHJ5,CQQSYSTPPYTF,IGKV1-39,55C9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGLVGTALAFDYW,IGHV3-53,IGHJ6,CQQSYSTPPYTF,IGKV1-39,55C9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYDSSGYYWYLDLW,IGHV3-13,IGHJ1,CQQSYTTPLFTF,IGKV1-39,55G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYDSSGYYWYLDLW,IGHV3-13,IGHJ2,CQQSYTTPLFTF,IGKV1-39,55G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYDSSGYYWYLDLW,IGHV3-13,IGHJ3,CQQSYTTPLFTF,IGKV1-39,55G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYDSSGYYWYLDLW,IGHV3-13,IGHJ4,CQQSYTTPLFTF,IGKV1-39,55G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYDSSGYYWYLDLW,IGHV3-13,IGHJ5,CQQSYTTPLFTF,IGKV1-39,55G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGYDSSGYYWYLDLW,IGHV3-13,IGHJ6,CQQSYTTPLFTF,IGKV1-39,55G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGKGAGPYCGGGSCYPTKVDYW,IGHV3-30,IGHJ1,CQQYDNLLWTF,IGKV1-33,55G11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGKGAGPYCGGGSCYPTKVDYW,IGHV3-30,IGHJ2,CQQYDNLLWTF,IGKV1-33,55G11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGKGAGPYCGGGSCYPTKVDYW,IGHV3-30,IGHJ3,CQQYDNLLWTF,IGKV1-33,55G11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGKGAGPYCGGGSCYPTKVDYW,IGHV3-30,IGHJ4,CQQYDNLLWTF,IGKV1-33,55G11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGKGAGPYCGGGSCYPTKVDYW,IGHV3-30,IGHJ5,CQQYDNLLWTF,IGKV1-33,55G11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CGKGAGPYCGGGSCYPTKVDYW,IGHV3-30,IGHJ6,CQQYDNLLWTF,IGKV1-33,55G11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDGSGSYYNSGALDYW,IGHV3-33,IGHJ1,CQQYDNLPPYTF,IGKV1-33,56C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDGSGSYYNSGALDYW,IGHV3-33,IGHJ2,CQQYDNLPPYTF,IGKV1-33,56C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDGSGSYYNSGALDYW,IGHV3-33,IGHJ3,CQQYDNLPPYTF,IGKV1-33,56C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDGSGSYYNSGALDYW,IGHV3-33,IGHJ4,CQQYDNLPPYTF,IGKV1-33,56C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDGSGSYYNSGALDYW,IGHV3-33,IGHJ5,CQQYDNLPPYTF,IGKV1-33,56C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDGSGSYYNSGALDYW,IGHV3-33,IGHJ6,CQQYDNLPPYTF,IGKV1-33,56C3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGDYYFDYW,IGHV3-66,IGHJ1,CQQYGSSPRTF,IGKV3-20,56H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGDYYFDYW,IGHV3-66,IGHJ2,CQQYGSSPRTF,IGKV3-20,56H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGDYYFDYW,IGHV3-66,IGHJ3,CQQYGSSPRTF,IGKV3-20,56H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGDYYFDYW,IGHV3-66,IGHJ4,CQQYGSSPRTF,IGKV3-20,56H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGDYYFDYW,IGHV3-66,IGHJ5,CQQYGSSPRTF,IGKV3-20,56H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGDYYFDYW,IGHV3-66,IGHJ6,CQQYGSSPRTF,IGKV3-20,56H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDDPDIVLVPAAMSLDYW,IGHV1-18,IGHJ1,CQQSYNTLALSF,IGKV1-39,56B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDDPDIVLVPAAMSLDYW,IGHV1-18,IGHJ2,CQQSYNTLALSF,IGKV1-39,56B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDDPDIVLVPAAMSLDYW,IGHV1-18,IGHJ3,CQQSYNTLALSF,IGKV1-39,56B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDDPDIVLVPAAMSLDYW,IGHV1-18,IGHJ4,CQQSYNTLALSF,IGKV1-39,56B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDDPDIVLVPAAMSLDYW,IGHV1-18,IGHJ5,CQQSYNTLALSF,IGKV1-39,56B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDDPDIVLVPAAMSLDYW,IGHV1-18,IGHJ6,CQQSYNTLALSF,IGKV1-39,56B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDYYGMDVW,IGHV3-66,IGHJ1,CQQLNSYPPITF,IGKV1-9,56D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDYYGMDVW,IGHV3-66,IGHJ2,CQQLNSYPPITF,IGKV1-9,56D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDYYGMDVW,IGHV3-66,IGHJ3,CQQLNSYPPITF,IGKV1-9,56D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDYYGMDVW,IGHV3-66,IGHJ4,CQQLNSYPPITF,IGKV1-9,56D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDYYGMDVW,IGHV3-66,IGHJ5,CQQLNSYPPITF,IGKV1-9,56D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDYYGMDVW,IGHV3-66,IGHJ6,CQQLNSYPPITF,IGKV1-9,56D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDYYDSSGYRYGMDVW,IGHV4-59,IGHJ1,CQQANSFPLTF,IGKV1D-12,56H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDYYDSSGYRYGMDVW,IGHV4-59,IGHJ2,CQQANSFPLTF,IGKV1D-12,56H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDYYDSSGYRYGMDVW,IGHV4-59,IGHJ3,CQQANSFPLTF,IGKV1D-12,56H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDYYDSSGYRYGMDVW,IGHV4-59,IGHJ4,CQQANSFPLTF,IGKV1D-12,56H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDYYDSSGYRYGMDVW,IGHV4-59,IGHJ5,CQQANSFPLTF,IGKV1D-12,56H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATDYYDSSGYRYGMDVW,IGHV4-59,IGHJ6,CQQANSFPLTF,IGKV1D-12,56H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASFGSLWDLRDYW,IGHV1-69,IGHJ1,CQQYGTSRTF,IGKV3-20,56A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASFGSLWDLRDYW,IGHV1-69,IGHJ2,CQQYGTSRTF,IGKV3-20,56A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASFGSLWDLRDYW,IGHV1-69,IGHJ3,CQQYGTSRTF,IGKV3-20,56A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASFGSLWDLRDYW,IGHV1-69,IGHJ4,CQQYGTSRTF,IGKV3-20,56A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASFGSLWDLRDYW,IGHV1-69,IGHJ5,CQQYGTSRTF,IGKV3-20,56A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASFGSLWDLRDYW,IGHV1-69,IGHJ6,CQQYGTSRTF,IGKV3-20,56A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDVGSRLIYDVFDYW,IGHV3-23,IGHJ1,CQQSYSTPPYSF,IGKV1-39,56E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDVGSRLIYDVFDYW,IGHV3-23,IGHJ2,CQQSYSTPPYSF,IGKV1-39,56E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDVGSRLIYDVFDYW,IGHV3-23,IGHJ3,CQQSYSTPPYSF,IGKV1-39,56E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDVGSRLIYDVFDYW,IGHV3-23,IGHJ4,CQQSYSTPPYSF,IGKV1-39,56E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDVGSRLIYDVFDYW,IGHV3-23,IGHJ5,CQQSYSTPPYSF,IGKV1-39,56E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDVGSRLIYDVFDYW,IGHV3-23,IGHJ6,CQQSYSTPPYSF,IGKV1-39,56E8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CTRTATVVKDYW,IGHV2-70,IGHJ1,CQQSYSTPRTF,IGKV1-39,56A10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CTRTATVVKDYW,IGHV2-70,IGHJ2,CQQSYSTPRTF,IGKV1-39,56A10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CTRTATVVKDYW,IGHV2-70,IGHJ3,CQQSYSTPRTF,IGKV1-39,56A10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CTRTATVVKDYW,IGHV2-70,IGHJ4,CQQSYSTPRTF,IGKV1-39,56A10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CTRTATVVKDYW,IGHV2-70,IGHJ5,CQQSYSTPRTF,IGKV1-39,56A10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CTRTATVVKDYW,IGHV2-70,IGHJ6,CQQSYSTPRTF,IGKV1-39,56A10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMIPIPALDYW,IGHV2-70,IGHJ1,CQQSYSTPHTF,IGKV1-39,56B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMIPIPALDYW,IGHV2-70,IGHJ2,CQQSYSTPHTF,IGKV1-39,56B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMIPIPALDYW,IGHV2-70,IGHJ3,CQQSYSTPHTF,IGKV1-39,56B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMIPIPALDYW,IGHV2-70,IGHJ4,CQQSYSTPHTF,IGKV1-39,56B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMIPIPALDYW,IGHV2-70,IGHJ5,CQQSYSTPHTF,IGKV1-39,56B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARMIPIPALDYW,IGHV2-70,IGHJ6,CQQSYSTPHTF,IGKV1-39,56B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREEAAGTKLDYW,IGHV2-70,IGHJ1,CQQSYSTPRTF,IGKV1-39,56B12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREEAAGTKLDYW,IGHV2-70,IGHJ2,CQQSYSTPRTF,IGKV1-39,56B12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREEAAGTKLDYW,IGHV2-70,IGHJ3,CQQSYSTPRTF,IGKV1-39,56B12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREEAAGTKLDYW,IGHV2-70,IGHJ4,CQQSYSTPRTF,IGKV1-39,56B12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREEAAGTKLDYW,IGHV2-70,IGHJ5,CQQSYSTPRTF,IGKV1-39,56B12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREEAAGTKLDYW,IGHV2-70,IGHJ6,CQQSYSTPRTF,IGKV1-39,56B12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDPTSLYCSGGSCYNNWFDPW,IGHV3-30,IGHJ1,CQQTYSTPRTF,IGKV1-39,56C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDPTSLYCSGGSCYNNWFDPW,IGHV3-30,IGHJ2,CQQTYSTPRTF,IGKV1-39,56C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDPTSLYCSGGSCYNNWFDPW,IGHV3-30,IGHJ3,CQQTYSTPRTF,IGKV1-39,56C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDPTSLYCSGGSCYNNWFDPW,IGHV3-30,IGHJ4,CQQTYSTPRTF,IGKV1-39,56C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDPTSLYCSGGSCYNNWFDPW,IGHV3-30,IGHJ5,CQQTYSTPRTF,IGKV1-39,56C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDPTSLYCSGGSCYNNWFDPW,IGHV3-30,IGHJ6,CQQTYSTPRTF,IGKV1-39,56C12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,56E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,56E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,56E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,56E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,56E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,56E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKRGGTYCSGGICYGGYFDYW,IGHV3-30,IGHJ1,CQSYDSSLSDWGVF,IGLV1-40,56A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKRGGTYCSGGICYGGYFDYW,IGHV3-30,IGHJ2,CQSYDSSLSDWGVF,IGLV1-40,56A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKRGGTYCSGGICYGGYFDYW,IGHV3-30,IGHJ3,CQSYDSSLSDWGVF,IGLV1-40,56A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKRGGTYCSGGICYGGYFDYW,IGHV3-30,IGHJ4,CQSYDSSLSDWGVF,IGLV1-40,56A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKRGGTYCSGGICYGGYFDYW,IGHV3-30,IGHJ5,CQSYDSSLSDWGVF,IGLV1-40,56A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKRGGTYCSGGICYGGYFDYW,IGHV3-30,IGHJ6,CQSYDSSLSDWGVF,IGLV1-40,56A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYSRITMIRGAGDYW,IGHV1-46,IGHJ1,CGTWDSSLSAQVF,IGLV1-51,56F3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYSRITMIRGAGDYW,IGHV1-46,IGHJ2,CGTWDSSLSAQVF,IGLV1-51,56F3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYSRITMIRGAGDYW,IGHV1-46,IGHJ3,CGTWDSSLSAQVF,IGLV1-51,56F3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYSRITMIRGAGDYW,IGHV1-46,IGHJ4,CGTWDSSLSAQVF,IGLV1-51,56F3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYSRITMIRGAGDYW,IGHV1-46,IGHJ5,CGTWDSSLSAQVF,IGLV1-51,56F3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYSRITMIRGAGDYW,IGHV1-46,IGHJ6,CGTWDSSLSAQVF,IGLV1-51,56F3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPYPSSSWAW,IGHV3-53,IGHJ1,CSSFTSSSTPYVF,IGLV2-14,56H9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPYPSSSWAW,IGHV3-53,IGHJ2,CSSFTSSSTPYVF,IGLV2-14,56H9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPYPSSSWAW,IGHV3-53,IGHJ3,CSSFTSSSTPYVF,IGLV2-14,56H9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPYPSSSWAW,IGHV3-53,IGHJ4,CSSFTSSSTPYVF,IGLV2-14,56H9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPYPSSSWAW,IGHV3-53,IGHJ5,CSSFTSSSTPYVF,IGLV2-14,56H9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGPYPSSSWAW,IGHV3-53,IGHJ6,CSSFTSSSTPYVF,IGLV2-14,56H9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGEQHIVTTIIDYW,IGHV4-4,IGHJ1,CATWDDSLNGRVF,IGLV1-44,56H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGEQHIVTTIIDYW,IGHV4-4,IGHJ2,CATWDDSLNGRVF,IGLV1-44,56H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGEQHIVTTIIDYW,IGHV4-4,IGHJ3,CATWDDSLNGRVF,IGLV1-44,56H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGEQHIVTTIIDYW,IGHV4-4,IGHJ4,CATWDDSLNGRVF,IGLV1-44,56H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGEQHIVTTIIDYW,IGHV4-4,IGHJ5,CATWDDSLNGRVF,IGLV1-44,56H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGEQHIVTTIIDYW,IGHV4-4,IGHJ6,CATWDDSLNGRVF,IGLV1-44,56H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ1,CQQSDNVPVTF,IGKV1-33,57B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ2,CQQSDNVPVTF,IGKV1-33,57B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ3,CQQSDNVPVTF,IGKV1-33,57B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ4,CQQSDNVPVTF,IGKV1-33,57B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ5,CQQSDNVPVTF,IGKV1-33,57B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGGGVLVTSDPDAFDIW,IGHV3-30,IGHJ6,CQQSDNVPVTF,IGKV1-33,57B2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CSTTNDYGDYSANYW,IGHV3-15,IGHJ1,CQQSYSTPLTF,IGKV1-39,57C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CSTTNDYGDYSANYW,IGHV3-15,IGHJ2,CQQSYSTPLTF,IGKV1-39,57C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CSTTNDYGDYSANYW,IGHV3-15,IGHJ3,CQQSYSTPLTF,IGKV1-39,57C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CSTTNDYGDYSANYW,IGHV3-15,IGHJ4,CQQSYSTPLTF,IGKV1-39,57C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CSTTNDYGDYSANYW,IGHV3-15,IGHJ5,CQQSYSTPLTF,IGKV1-39,57C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CSTTNDYGDYSANYW,IGHV3-15,IGHJ6,CQQSYSTPLTF,IGKV1-39,57C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIEYYNDSSGYYQFW,IGHV5-51,IGHJ1,CQQYGSSWTF,IGKV3-20,57E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIEYYNDSSGYYQFW,IGHV5-51,IGHJ2,CQQYGSSWTF,IGKV3-20,57E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIEYYNDSSGYYQFW,IGHV5-51,IGHJ3,CQQYGSSWTF,IGKV3-20,57E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIEYYNDSSGYYQFW,IGHV5-51,IGHJ4,CQQYGSSWTF,IGKV3-20,57E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIEYYNDSSGYYQFW,IGHV5-51,IGHJ5,CQQYGSSWTF,IGKV3-20,57E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIEYYNDSSGYYQFW,IGHV5-51,IGHJ6,CQQYGSSWTF,IGKV3-20,57E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ1,CQQFNNFLLTF,IGKV1D-13,57H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ2,CQQFNNFLLTF,IGKV1D-13,57H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ3,CQQFNNFLLTF,IGKV1D-13,57H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ4,CQQFNNFLLTF,IGKV1D-13,57H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ5,CQQFNNFLLTF,IGKV1D-13,57H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ6,CQQFNNFLLTF,IGKV1D-13,57H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGQRGSPDFFDYW,IGHV3-23,IGHJ1,CQQYNSYSPLTF,IGKV1-5,57A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGQRGSPDFFDYW,IGHV3-23,IGHJ2,CQQYNSYSPLTF,IGKV1-5,57A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGQRGSPDFFDYW,IGHV3-23,IGHJ3,CQQYNSYSPLTF,IGKV1-5,57A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGQRGSPDFFDYW,IGHV3-23,IGHJ4,CQQYNSYSPLTF,IGKV1-5,57A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGQRGSPDFFDYW,IGHV3-23,IGHJ5,CQQYNSYSPLTF,IGKV1-5,57A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGQRGSPDFFDYW,IGHV3-23,IGHJ6,CQQYNSYSPLTF,IGKV1-5,57A8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLVTWGLDYW,IGHV3-53,IGHJ1,CQLLNTDPITF,IGKV1-9,57B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLVTWGLDYW,IGHV3-53,IGHJ2,CQLLNTDPITF,IGKV1-9,57B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLVTWGLDYW,IGHV3-53,IGHJ3,CQLLNTDPITF,IGKV1-9,57B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLVTWGLDYW,IGHV3-53,IGHJ4,CQLLNTDPITF,IGKV1-9,57B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLVTWGLDYW,IGHV3-53,IGHJ5,CQLLNTDPITF,IGKV1-9,57B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLVTWGLDYW,IGHV3-53,IGHJ6,CQLLNTDPITF,IGKV1-9,57B8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWELNYW,IGHV1-3,IGHJ1,CQQYYSFWAF,IGKV4-1,57A9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWELNYW,IGHV1-3,IGHJ2,CQQYYSFWAF,IGKV4-1,57A9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWELNYW,IGHV1-3,IGHJ3,CQQYYSFWAF,IGKV4-1,57A9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWELNYW,IGHV1-3,IGHJ4,CQQYYSFWAF,IGKV4-1,57A9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWELNYW,IGHV1-3,IGHJ5,CQQYYSFWAF,IGKV4-1,57A9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARAGWELNYW,IGHV1-3,IGHJ6,CQQYYSFWAF,IGKV4-1,57A9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARITPHLVYDYW,IGHV2-70,IGHJ1,CQQSYSIPRTF,IGKV1-39,57G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARITPHLVYDYW,IGHV2-70,IGHJ2,CQQSYSIPRTF,IGKV1-39,57G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARITPHLVYDYW,IGHV2-70,IGHJ3,CQQSYSIPRTF,IGKV1-39,57G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARITPHLVYDYW,IGHV2-70,IGHJ4,CQQSYSIPRTF,IGKV1-39,57G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARITPHLVYDYW,IGHV2-70,IGHJ5,CQQSYSIPRTF,IGKV1-39,57G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARITPHLVYDYW,IGHV2-70,IGHJ6,CQQSYSIPRTF,IGKV1-39,57G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ1,CNSRDSSGNHWVF,IGLV3-19,57A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ2,CNSRDSSGNHWVF,IGLV3-19,57A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ3,CNSRDSSGNHWVF,IGLV3-19,57A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ4,CNSRDSSGNHWVF,IGLV3-19,57A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ5,CNSRDSSGNHWVF,IGLV3-19,57A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARQESGWSFDYW,IGHV5-51,IGHJ6,CNSRDSSGNHWVF,IGLV3-19,57A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDDSSSSGVGTGMDVW,IGHV4-34,IGHJ1,CAVWDDSLNGWVF,IGLV1-44,57F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDDSSSSGVGTGMDVW,IGHV4-34,IGHJ2,CAVWDDSLNGWVF,IGLV1-44,57F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDDSSSSGVGTGMDVW,IGHV4-34,IGHJ3,CAVWDDSLNGWVF,IGLV1-44,57F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDDSSSSGVGTGMDVW,IGHV4-34,IGHJ4,CAVWDDSLNGWVF,IGLV1-44,57F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDDSSSSGVGTGMDVW,IGHV4-34,IGHJ5,CAVWDDSLNGWVF,IGLV1-44,57F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDDSSSSGVGTGMDVW,IGHV4-34,IGHJ6,CAVWDDSLNGWVF,IGLV1-44,57F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHTTWYYYGSGWFDPW,IGHV2-5,IGHJ1,CAAWDDSLNGHVF,IGLV1-44,57F8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHTTWYYYGSGWFDPW,IGHV2-5,IGHJ2,CAAWDDSLNGHVF,IGLV1-44,57F8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHTTWYYYGSGWFDPW,IGHV2-5,IGHJ3,CAAWDDSLNGHVF,IGLV1-44,57F8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHTTWYYYGSGWFDPW,IGHV2-5,IGHJ4,CAAWDDSLNGHVF,IGLV1-44,57F8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHTTWYYYGSGWFDPW,IGHV2-5,IGHJ5,CAAWDDSLNGHVF,IGLV1-44,57F8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHTTWYYYGSGWFDPW,IGHV2-5,IGHJ6,CAAWDDSLNGHVF,IGLV1-44,57F8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQEFWLDPW,IGHV1-18,IGHJ1,CQVWDSSSDHPLF,IGLV3-21,57A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQEFWLDPW,IGHV1-18,IGHJ2,CQVWDSSSDHPLF,IGLV3-21,57A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQEFWLDPW,IGHV1-18,IGHJ3,CQVWDSSSDHPLF,IGLV3-21,57A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQEFWLDPW,IGHV1-18,IGHJ4,CQVWDSSSDHPLF,IGLV3-21,57A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQEFWLDPW,IGHV1-18,IGHJ5,CQVWDSSSDHPLF,IGLV3-21,57A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQEFWLDPW,IGHV1-18,IGHJ6,CQVWDSSSDHPLF,IGLV3-21,57A11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,57E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,57E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,57E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,57E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,57E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,57E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLENGGLDVW,IGHV3-53,IGHJ1,CQQTNSFPTF,IGKV1D-12,58G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLENGGLDVW,IGHV3-53,IGHJ2,CQQTNSFPTF,IGKV1D-12,58G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLENGGLDVW,IGHV3-53,IGHJ3,CQQTNSFPTF,IGKV1D-12,58G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLENGGLDVW,IGHV3-53,IGHJ4,CQQTNSFPTF,IGKV1D-12,58G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLENGGLDVW,IGHV3-53,IGHJ5,CQQTNSFPTF,IGKV1D-12,58G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLENGGLDVW,IGHV3-53,IGHJ6,CQQTNSFPTF,IGKV1D-12,58G1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASPLLSHNYGSGSYYNVYWYFELW,IGHV3-11,IGHJ1,CQQLGTF,IGKV3-11,58D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASPLLSHNYGSGSYYNVYWYFELW,IGHV3-11,IGHJ2,CQQLGTF,IGKV3-11,58D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASPLLSHNYGSGSYYNVYWYFELW,IGHV3-11,IGHJ3,CQQLGTF,IGKV3-11,58D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASPLLSHNYGSGSYYNVYWYFELW,IGHV3-11,IGHJ4,CQQLGTF,IGKV3-11,58D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASPLLSHNYGSGSYYNVYWYFELW,IGHV3-11,IGHJ5,CQQLGTF,IGKV3-11,58D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASPLLSHNYGSGSYYNVYWYFELW,IGHV3-11,IGHJ6,CQQLGTF,IGKV3-11,58D2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTLGAYYDILTGFRTPGGWFAPW,IGHV4-59,IGHJ1,CQQYGSSPWTF,IGKV3-20,58A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTLGAYYDILTGFRTPGGWFAPW,IGHV4-59,IGHJ2,CQQYGSSPWTF,IGKV3-20,58A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTLGAYYDILTGFRTPGGWFAPW,IGHV4-59,IGHJ3,CQQYGSSPWTF,IGKV3-20,58A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTLGAYYDILTGFRTPGGWFAPW,IGHV4-59,IGHJ4,CQQYGSSPWTF,IGKV3-20,58A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTLGAYYDILTGFRTPGGWFAPW,IGHV4-59,IGHJ5,CQQYGSSPWTF,IGKV3-20,58A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTLGAYYDILTGFRTPGGWFAPW,IGHV4-59,IGHJ6,CQQYGSSPWTF,IGKV3-20,58A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKEPSFGLWFGELSGW,IGHV3-23,IGHJ1,CQQYGSSLPYTF,IGKV3-20,58B5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKEPSFGLWFGELSGW,IGHV3-23,IGHJ2,CQQYGSSLPYTF,IGKV3-20,58B5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKEPSFGLWFGELSGW,IGHV3-23,IGHJ3,CQQYGSSLPYTF,IGKV3-20,58B5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKEPSFGLWFGELSGW,IGHV3-23,IGHJ4,CQQYGSSLPYTF,IGKV3-20,58B5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKEPSFGLWFGELSGW,IGHV3-23,IGHJ5,CQQYGSSLPYTF,IGKV3-20,58B5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKEPSFGLWFGELSGW,IGHV3-23,IGHJ6,CQQYGSSLPYTF,IGKV3-20,58B5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPNCNSTTCHDGFDIW,IGHV1-58,IGHJ1,CQQYDNSPWTF,IGKV3-20,58G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPNCNSTTCHDGFDIW,IGHV1-58,IGHJ2,CQQYDNSPWTF,IGKV3-20,58G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPNCNSTTCHDGFDIW,IGHV1-58,IGHJ3,CQQYDNSPWTF,IGKV3-20,58G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPNCNSTTCHDGFDIW,IGHV1-58,IGHJ4,CQQYDNSPWTF,IGKV3-20,58G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPNCNSTTCHDGFDIW,IGHV1-58,IGHJ5,CQQYDNSPWTF,IGKV3-20,58G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPNCNSTTCHDGFDIW,IGHV1-58,IGHJ6,CQQYDNSPWTF,IGKV3-20,58G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSLRGGILSGYAFDIW,IGHV3-13,IGHJ1,CQQSYSSPPWTF,IGKV1-39,58G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSLRGGILSGYAFDIW,IGHV3-13,IGHJ2,CQQSYSSPPWTF,IGKV1-39,58G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSLRGGILSGYAFDIW,IGHV3-13,IGHJ3,CQQSYSSPPWTF,IGKV1-39,58G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSLRGGILSGYAFDIW,IGHV3-13,IGHJ4,CQQSYSSPPWTF,IGKV1-39,58G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSLRGGILSGYAFDIW,IGHV3-13,IGHJ5,CQQSYSSPPWTF,IGKV1-39,58G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSLRGGILSGYAFDIW,IGHV3-13,IGHJ6,CQQSYSSPPWTF,IGKV1-39,58G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPGTYYDAFDIW,IGHV4-39,IGHJ1,CSSYTSSSTWVF,IGLV2-14,58E2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPGTYYDAFDIW,IGHV4-39,IGHJ2,CSSYTSSSTWVF,IGLV2-14,58E2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPGTYYDAFDIW,IGHV4-39,IGHJ3,CSSYTSSSTWVF,IGLV2-14,58E2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPGTYYDAFDIW,IGHV4-39,IGHJ4,CSSYTSSSTWVF,IGLV2-14,58E2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPGTYYDAFDIW,IGHV4-39,IGHJ5,CSSYTSSSTWVF,IGLV2-14,58E2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARYYGPGTYYDAFDIW,IGHV4-39,IGHJ6,CSSYTSSSTWVF,IGLV2-14,58E2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDWVHYGSGSYPPDYW,IGHV3-30,IGHJ1,CSSYTSSSTWVF,IGLV2-18,58A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDWVHYGSGSYPPDYW,IGHV3-30,IGHJ2,CSSYTSSSTWVF,IGLV2-18,58A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDWVHYGSGSYPPDYW,IGHV3-30,IGHJ3,CSSYTSSSTWVF,IGLV2-18,58A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDWVHYGSGSYPPDYW,IGHV3-30,IGHJ4,CSSYTSSSTWVF,IGLV2-18,58A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDWVHYGSGSYPPDYW,IGHV3-30,IGHJ5,CSSYTSSSTWVF,IGLV2-18,58A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDWVHYGSGSYPPDYW,IGHV3-30,IGHJ6,CSSYTSSSTWVF,IGLV2-18,58A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPVLRGNIDYW,IGHV5-51,IGHJ1,CQSYDSSLRGSVF,IGLV1-40,58H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPVLRGNIDYW,IGHV5-51,IGHJ2,CQSYDSSLRGSVF,IGLV1-40,58H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPVLRGNIDYW,IGHV5-51,IGHJ3,CQSYDSSLRGSVF,IGLV1-40,58H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPVLRGNIDYW,IGHV5-51,IGHJ4,CQSYDSSLRGSVF,IGLV1-40,58H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPVLRGNIDYW,IGHV5-51,IGHJ5,CQSYDSSLRGSVF,IGLV1-40,58H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHPVLRGNIDYW,IGHV5-51,IGHJ6,CQSYDSSLRGSVF,IGLV1-40,58H3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDKWEGTFDYW,IGHV3-66,IGHJ1,CQQLNSYPRMTF,IGKV1-9,510H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDKWEGTFDYW,IGHV3-66,IGHJ2,CQQLNSYPRMTF,IGKV1-9,510H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDKWEGTFDYW,IGHV3-66,IGHJ3,CQQLNSYPRMTF,IGKV1-9,510H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDKWEGTFDYW,IGHV3-66,IGHJ4,CQQLNSYPRMTF,IGKV1-9,510H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDKWEGTFDYW,IGHV3-66,IGHJ5,CQQLNSYPRMTF,IGKV1-9,510H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDKWEGTFDYW,IGHV3-66,IGHJ6,CQQLNSYPRMTF,IGKV1-9,510H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ1,CMQALQMGTF,IGKV2-28,510A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ2,CMQALQMGTF,IGKV2-28,510A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ3,CMQALQMGTF,IGKV2-28,510A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ4,CMQALQMGTF,IGKV2-28,510A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ5,CMQALQMGTF,IGKV2-28,510A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQVAAAGSPYDYW,IGHV2-70,IGHJ6,CMQALQMGTF,IGKV2-28,510A4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGGNSNYFHYW,IGHV4-31,IGHJ1,CQQYDTLPLTF,IGKV1-33,510G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGGNSNYFHYW,IGHV4-31,IGHJ2,CQQYDTLPLTF,IGKV1-33,510G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGGNSNYFHYW,IGHV4-31,IGHJ3,CQQYDTLPLTF,IGKV1-33,510G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGGNSNYFHYW,IGHV4-31,IGHJ4,CQQYDTLPLTF,IGKV1-33,510G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGGNSNYFHYW,IGHV4-31,IGHJ5,CQQYDTLPLTF,IGKV1-33,510G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDYGGNSNYFHYW,IGHV4-31,IGHJ6,CQQYDTLPLTF,IGKV1-33,510G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAETGWDGMDVW,IGHV3-66,IGHJ1,CQQRSNWPGTF,IGKV3-11,510H4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAETGWDGMDVW,IGHV3-66,IGHJ2,CQQRSNWPGTF,IGKV3-11,510H4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAETGWDGMDVW,IGHV3-66,IGHJ3,CQQRSNWPGTF,IGKV3-11,510H4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAETGWDGMDVW,IGHV3-66,IGHJ4,CQQRSNWPGTF,IGKV3-11,510H4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAETGWDGMDVW,IGHV3-66,IGHJ5,CQQRSNWPGTF,IGKV3-11,510H4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAETGWDGMDVW,IGHV3-66,IGHJ6,CQQRSNWPGTF,IGKV3-11,510H4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDRGYEILTPASFDYW,IGHV3-9,IGHJ1,CQQSYSTPPYTF,IGKV1-39,510A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDRGYEILTPASFDYW,IGHV3-9,IGHJ2,CQQSYSTPPYTF,IGKV1-39,510A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDRGYEILTPASFDYW,IGHV3-9,IGHJ3,CQQSYSTPPYTF,IGKV1-39,510A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDRGYEILTPASFDYW,IGHV3-9,IGHJ4,CQQSYSTPPYTF,IGKV1-39,510A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDRGYEILTPASFDYW,IGHV3-9,IGHJ5,CQQSYSTPPYTF,IGKV1-39,510A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKDRGYEILTPASFDYW,IGHV3-9,IGHJ6,CQQSYSTPPYTF,IGKV1-39,510A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSLPSKYSYSYGSFDYW,IGHV2-5,IGHJ1,CQQSYSAPYTF,IGKV1-39,510F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSLPSKYSYSYGSFDYW,IGHV2-5,IGHJ2,CQQSYSAPYTF,IGKV1-39,510F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSLPSKYSYSYGSFDYW,IGHV2-5,IGHJ3,CQQSYSAPYTF,IGKV1-39,510F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSLPSKYSYSYGSFDYW,IGHV2-5,IGHJ4,CQQSYSAPYTF,IGKV1-39,510F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSLPSKYSYSYGSFDYW,IGHV2-5,IGHJ5,CQQSYSAPYTF,IGKV1-39,510F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSLPSKYSYSYGSFDYW,IGHV2-5,IGHJ6,CQQSYSAPYTF,IGKV1-39,510F6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ1,CQQYGSSRTF,IGKV3-20,510D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ2,CQQYGSSRTF,IGKV3-20,510D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ3,CQQYGSSRTF,IGKV3-20,510D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ4,CQQYGSSRTF,IGKV3-20,510D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ5,CQQYGSSRTF,IGKV3-20,510D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CATGRYTYGYGYYFDYW,IGHV1-69,IGHJ6,CQQYGSSRTF,IGKV3-20,510D7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGELLWFGELLENWFDPW,IGHV3-23,IGHJ1,CQQADSFPWTF,IGKV1-12,510E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGELLWFGELLENWFDPW,IGHV3-23,IGHJ2,CQQADSFPWTF,IGKV1-12,510E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGELLWFGELLENWFDPW,IGHV3-23,IGHJ3,CQQADSFPWTF,IGKV1-12,510E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGELLWFGELLENWFDPW,IGHV3-23,IGHJ4,CQQADSFPWTF,IGKV1-12,510E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGELLWFGELLENWFDPW,IGHV3-23,IGHJ5,CQQADSFPWTF,IGKV1-12,510E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGELLWFGELLENWFDPW,IGHV3-23,IGHJ6,CQQADSFPWTF,IGKV1-12,510E10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIQRGIAADYW,IGHV2-70,IGHJ1,CQQSYSTPRTF,IGKV1-39,510H10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIQRGIAADYW,IGHV2-70,IGHJ2,CQQSYSTPRTF,IGKV1-39,510H10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIQRGIAADYW,IGHV2-70,IGHJ3,CQQSYSTPRTF,IGKV1-39,510H10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIQRGIAADYW,IGHV2-70,IGHJ4,CQQSYSTPRTF,IGKV1-39,510H10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIQRGIAADYW,IGHV2-70,IGHJ5,CQQSYSTPRTF,IGKV1-39,510H10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIQRGIAADYW,IGHV2-70,IGHJ6,CQQSYSTPRTF,IGKV1-39,510H10,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPPHFGSGSYYGNAFDIW,IGHV5-51,IGHJ1,CATWDDSLTGPVF,IGLV1-47,510B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPPHFGSGSYYGNAFDIW,IGHV5-51,IGHJ2,CATWDDSLTGPVF,IGLV1-47,510B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPPHFGSGSYYGNAFDIW,IGHV5-51,IGHJ3,CATWDDSLTGPVF,IGLV1-47,510B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPPHFGSGSYYGNAFDIW,IGHV5-51,IGHJ4,CATWDDSLTGPVF,IGLV1-47,510B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPPHFGSGSYYGNAFDIW,IGHV5-51,IGHJ5,CATWDDSLTGPVF,IGLV1-47,510B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARLPPHFGSGSYYGNAFDIW,IGHV5-51,IGHJ6,CATWDDSLTGPVF,IGLV1-47,510B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTVGRGSGTYYYGNYYSYSMDVW,IGHV7-4-1,IGHJ1,CTSYTGSSTSVVF,IGLV2-14,510G2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTVGRGSGTYYYGNYYSYSMDVW,IGHV7-4-1,IGHJ2,CTSYTGSSTSVVF,IGLV2-14,510G2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTVGRGSGTYYYGNYYSYSMDVW,IGHV7-4-1,IGHJ3,CTSYTGSSTSVVF,IGLV2-14,510G2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTVGRGSGTYYYGNYYSYSMDVW,IGHV7-4-1,IGHJ4,CTSYTGSSTSVVF,IGLV2-14,510G2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTVGRGSGTYYYGNYYSYSMDVW,IGHV7-4-1,IGHJ5,CTSYTGSSTSVVF,IGLV2-14,510G2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTVGRGSGTYYYGNYYSYSMDVW,IGHV7-4-1,IGHJ6,CTSYTGSSTSVVF,IGLV2-14,510G2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHCPWQQLVSNWFDPW,IGHV4-59,IGHJ1,CQQFNNFLLTF,IGKV1D-13,510H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHCPWQQLVSNWFDPW,IGHV4-59,IGHJ2,CQQFNNFLLTF,IGKV1D-13,510H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHCPWQQLVSNWFDPW,IGHV4-59,IGHJ3,CQQFNNFLLTF,IGKV1D-13,510H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHCPWQQLVSNWFDPW,IGHV4-59,IGHJ4,CQQFNNFLLTF,IGKV1D-13,510H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHCPWQQLVSNWFDPW,IGHV4-59,IGHJ5,CQQFNNFLLTF,IGKV1D-13,510H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHCPWQQLVSNWFDPW,IGHV4-59,IGHJ6,CQQFNNFLLTF,IGKV1D-13,510H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTGFLIPSKGGGMDVW,IGHV1-46,IGHJ1,CSSYTSSSSLQIF,IGLV2-14,510H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTGFLIPSKGGGMDVW,IGHV1-46,IGHJ2,CSSYTSSSSLQIF,IGLV2-14,510H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTGFLIPSKGGGMDVW,IGHV1-46,IGHJ3,CSSYTSSSSLQIF,IGLV2-14,510H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTGFLIPSKGGGMDVW,IGHV1-46,IGHJ4,CSSYTSSSSLQIF,IGLV2-14,510H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTGFLIPSKGGGMDVW,IGHV1-46,IGHJ5,CSSYTSSSSLQIF,IGLV2-14,510H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTGFLIPSKGGGMDVW,IGHV1-46,IGHJ6,CSSYTSSSSLQIF,IGLV2-14,510H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPGEWESLDLDYW,IGHV3-48,IGHJ1,CQSYDSSLSGNWVF,IGLV1-40,510C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPGEWESLDLDYW,IGHV3-48,IGHJ2,CQSYDSSLSGNWVF,IGLV1-40,510C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPGEWESLDLDYW,IGHV3-48,IGHJ3,CQSYDSSLSGNWVF,IGLV1-40,510C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPGEWESLDLDYW,IGHV3-48,IGHJ4,CQSYDSSLSGNWVF,IGLV1-40,510C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPGEWESLDLDYW,IGHV3-48,IGHJ5,CQSYDSSLSGNWVF,IGLV1-40,510C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPGEWESLDLDYW,IGHV3-48,IGHJ6,CQSYDSSLSGNWVF,IGLV1-40,510C4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREKIRSIAAAGTVYYYGMDVW,IGHV4-31,IGHJ1,CQQYNNWPPWTF,IGKV3-15,511A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREKIRSIAAAGTVYYYGMDVW,IGHV4-31,IGHJ2,CQQYNNWPPWTF,IGKV3-15,511A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREKIRSIAAAGTVYYYGMDVW,IGHV4-31,IGHJ3,CQQYNNWPPWTF,IGKV3-15,511A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREKIRSIAAAGTVYYYGMDVW,IGHV4-31,IGHJ4,CQQYNNWPPWTF,IGKV3-15,511A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREKIRSIAAAGTVYYYGMDVW,IGHV4-31,IGHJ5,CQQYNNWPPWTF,IGKV3-15,511A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREKIRSIAAAGTVYYYGMDVW,IGHV4-31,IGHJ6,CQQYNNWPPWTF,IGKV3-15,511A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTYWDSSGYYYGVDYW,IGHV4-59,IGHJ1,CQQANSFRLTF,IGKV1D-12,511B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTYWDSSGYYYGVDYW,IGHV4-59,IGHJ2,CQQANSFRLTF,IGKV1D-12,511B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTYWDSSGYYYGVDYW,IGHV4-59,IGHJ3,CQQANSFRLTF,IGKV1D-12,511B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTYWDSSGYYYGVDYW,IGHV4-59,IGHJ4,CQQANSFRLTF,IGKV1D-12,511B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTYWDSSGYYYGVDYW,IGHV4-59,IGHJ5,CQQANSFRLTF,IGKV1D-12,511B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASTYWDSSGYYYGVDYW,IGHV4-59,IGHJ6,CQQANSFRLTF,IGKV1D-12,511B4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALAVGRGIPTSYFDYW,IGHV5-51,IGHJ1,CQQYHNLPITF,IGKV1-33,511E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALAVGRGIPTSYFDYW,IGHV5-51,IGHJ2,CQQYHNLPITF,IGKV1-33,511E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALAVGRGIPTSYFDYW,IGHV5-51,IGHJ3,CQQYHNLPITF,IGKV1-33,511E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALAVGRGIPTSYFDYW,IGHV5-51,IGHJ4,CQQYHNLPITF,IGKV1-33,511E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALAVGRGIPTSYFDYW,IGHV5-51,IGHJ5,CQQYHNLPITF,IGKV1-33,511E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CALAVGRGIPTSYFDYW,IGHV5-51,IGHJ6,CQQYHNLPITF,IGKV1-33,511E7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGNYGDYLRGFDYW,IGHV3-33,IGHJ1,CQQYHNVPPAF,IGKV1-33,511G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGNYGDYLRGFDYW,IGHV3-33,IGHJ2,CQQYHNVPPAF,IGKV1-33,511G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGNYGDYLRGFDYW,IGHV3-33,IGHJ3,CQQYHNVPPAF,IGKV1-33,511G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGNYGDYLRGFDYW,IGHV3-33,IGHJ4,CQQYHNVPPAF,IGKV1-33,511G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGNYGDYLRGFDYW,IGHV3-33,IGHJ5,CQQYHNVPPAF,IGKV1-33,511G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGNYGDYLRGFDYW,IGHV3-33,IGHJ6,CQQYHNVPPAF,IGKV1-33,511G7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGAGLIIAYDYW,IGHV1-18,IGHJ1,CHQSSSLPYTF,IGKV6-21,511E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGAGLIIAYDYW,IGHV1-18,IGHJ2,CHQSSSLPYTF,IGKV6-21,511E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGAGLIIAYDYW,IGHV1-18,IGHJ3,CHQSSSLPYTF,IGKV6-21,511E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGAGLIIAYDYW,IGHV1-18,IGHJ4,CHQSSSLPYTF,IGKV6-21,511E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGAGLIIAYDYW,IGHV1-18,IGHJ5,CHQSSSLPYTF,IGKV6-21,511E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREGAGLIIAYDYW,IGHV1-18,IGHJ6,CHQSSSLPYTF,IGKV6-21,511E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLDYCSGGSSSSGYYNYGMDVW,IGHV1-18,IGHJ1,CQQYGRSPYTF,IGKV3-20,511D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLDYCSGGSSSSGYYNYGMDVW,IGHV1-18,IGHJ2,CQQYGRSPYTF,IGKV3-20,511D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLDYCSGGSSSSGYYNYGMDVW,IGHV1-18,IGHJ3,CQQYGRSPYTF,IGKV3-20,511D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLDYCSGGSSSSGYYNYGMDVW,IGHV1-18,IGHJ4,CQQYGRSPYTF,IGKV3-20,511D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLDYCSGGSSSSGYYNYGMDVW,IGHV1-18,IGHJ5,CQQYGRSPYTF,IGKV3-20,511D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLDYCSGGSSSSGYYNYGMDVW,IGHV1-18,IGHJ6,CQQYGRSPYTF,IGKV3-20,511D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRGDHSSGWYGTYYYYMDVW,IGHV3-13,IGHJ1,CQQSYSSPPWTF,IGKV1-39,511H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRGDHSSGWYGTYYYYMDVW,IGHV3-13,IGHJ2,CQQSYSSPPWTF,IGKV1-39,511H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRGDHSSGWYGTYYYYMDVW,IGHV3-13,IGHJ3,CQQSYSSPPWTF,IGKV1-39,511H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRGDHSSGWYGTYYYYMDVW,IGHV3-13,IGHJ4,CQQSYSSPPWTF,IGKV1-39,511H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRGDHSSGWYGTYYYYMDVW,IGHV3-13,IGHJ5,CQQSYSSPPWTF,IGKV1-39,511H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CVRGDHSSGWYGTYYYYMDVW,IGHV3-13,IGHJ6,CQQSYSSPPWTF,IGKV1-39,511H11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDIAGAFDIW,IGHV3-66,IGHJ1,CQLLNSFPITF,IGKV1-9,511D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDIAGAFDIW,IGHV3-66,IGHJ2,CQLLNSFPITF,IGKV1-9,511D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDIAGAFDIW,IGHV3-66,IGHJ3,CQLLNSFPITF,IGKV1-9,511D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDIAGAFDIW,IGHV3-66,IGHJ4,CQLLNSFPITF,IGKV1-9,511D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDIAGAFDIW,IGHV3-66,IGHJ5,CQLLNSFPITF,IGKV1-9,511D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLDIAGAFDIW,IGHV3-66,IGHJ6,CQLLNSFPITF,IGKV1-9,511D12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIYRGTMVVVFSDLHWYFDLW,IGHV4-31,IGHJ1,CQVWDSSADHYVF,IGLV3-21,511A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIYRGTMVVVFSDLHWYFDLW,IGHV4-31,IGHJ2,CQVWDSSADHYVF,IGLV3-21,511A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIYRGTMVVVFSDLHWYFDLW,IGHV4-31,IGHJ3,CQVWDSSADHYVF,IGLV3-21,511A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIYRGTMVVVFSDLHWYFDLW,IGHV4-31,IGHJ4,CQVWDSSADHYVF,IGLV3-21,511A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIYRGTMVVVFSDLHWYFDLW,IGHV4-31,IGHJ5,CQVWDSSADHYVF,IGLV3-21,511A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIYRGTMVVVFSDLHWYFDLW,IGHV4-31,IGHJ6,CQVWDSSADHYVF,IGLV3-21,511A5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDSLFSRVDWYFDLW,IGHV1-2,IGHJ1,CNSRDSSGNTVVF,IGLV1-40,511E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDSLFSRVDWYFDLW,IGHV1-2,IGHJ2,CNSRDSSGNTVVF,IGLV1-40,511E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDSLFSRVDWYFDLW,IGHV1-2,IGHJ3,CNSRDSSGNTVVF,IGLV1-40,511E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDSLFSRVDWYFDLW,IGHV1-2,IGHJ4,CNSRDSSGNTVVF,IGLV1-40,511E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDSLFSRVDWYFDLW,IGHV1-2,IGHJ5,CNSRDSSGNTVVF,IGLV1-40,511E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDSLFSRVDWYFDLW,IGHV1-2,IGHJ6,CNSRDSSGNTVVF,IGLV1-40,511E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGALYSNSPTEFDYW,IGHV1-46,IGHJ1,CTTWDASRGGWVF,IGLV1-47,511G5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGALYSNSPTEFDYW,IGHV1-46,IGHJ2,CTTWDASRGGWVF,IGLV1-47,511G5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGALYSNSPTEFDYW,IGHV1-46,IGHJ3,CTTWDASRGGWVF,IGLV1-47,511G5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGALYSNSPTEFDYW,IGHV1-46,IGHJ4,CTTWDASRGGWVF,IGLV1-47,511G5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGALYSNSPTEFDYW,IGHV1-46,IGHJ5,CTTWDASRGGWVF,IGLV1-47,511G5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGALYSNSPTEFDYW,IGHV1-46,IGHJ6,CTTWDASRGGWVF,IGLV1-47,511G5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGLVPAVMPALDYW,IGHV1-46,IGHJ1,CAAWDDSLSGPVF,IGLV1-47,511B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGLVPAVMPALDYW,IGHV1-46,IGHJ2,CAAWDDSLSGPVF,IGLV1-47,511B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGLVPAVMPALDYW,IGHV1-46,IGHJ3,CAAWDDSLSGPVF,IGLV1-47,511B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGLVPAVMPALDYW,IGHV1-46,IGHJ4,CAAWDDSLSGPVF,IGLV1-47,511B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGLVPAVMPALDYW,IGHV1-46,IGHJ5,CAAWDDSLSGPVF,IGLV1-47,511B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGLVPAVMPALDYW,IGHV1-46,IGHJ6,CAAWDDSLSGPVF,IGLV1-47,511B7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLQYYYDTSGYYKDSYYYGVDVW,IGHV3-23,IGHJ1,CAAWDDSLSGPVF,IGLV1-47,511H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLQYYYDTSGYYKDSYYYGVDVW,IGHV3-23,IGHJ2,CAAWDDSLSGPVF,IGLV1-47,511H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLQYYYDTSGYYKDSYYYGVDVW,IGHV3-23,IGHJ3,CAAWDDSLSGPVF,IGLV1-47,511H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLQYYYDTSGYYKDSYYYGVDVW,IGHV3-23,IGHJ4,CAAWDDSLSGPVF,IGLV1-47,511H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLQYYYDTSGYYKDSYYYGVDVW,IGHV3-23,IGHJ5,CAAWDDSLSGPVF,IGLV1-47,511H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLQYYYDTSGYYKDSYYYGVDVW,IGHV3-23,IGHJ6,CAAWDDSLSGPVF,IGLV1-47,511H7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGLFWYGGYFDYW,IGHV3-7,IGHJ1,CQSYDRSLSVLYVF,IGLV1-40,511B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGLFWYGGYFDYW,IGHV3-7,IGHJ2,CQSYDRSLSVLYVF,IGLV1-40,511B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGLFWYGGYFDYW,IGHV3-7,IGHJ3,CQSYDRSLSVLYVF,IGLV1-40,511B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGLFWYGGYFDYW,IGHV3-7,IGHJ4,CQSYDRSLSVLYVF,IGLV1-40,511B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGLFWYGGYFDYW,IGHV3-7,IGHJ5,CQSYDRSLSVLYVF,IGLV1-40,511B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAGLFWYGGYFDYW,IGHV3-7,IGHJ6,CQSYDRSLSVLYVF,IGLV1-40,511B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTQDRVELMVGSPYYYYYMDVW,IGHV3-13,IGHJ1,CQQSYITTMYTF,IGKV1-39,59B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTQDRVELMVGSPYYYYYMDVW,IGHV3-13,IGHJ2,CQQSYITTMYTF,IGKV1-39,59B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTQDRVELMVGSPYYYYYMDVW,IGHV3-13,IGHJ3,CQQSYITTMYTF,IGKV1-39,59B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTQDRVELMVGSPYYYYYMDVW,IGHV3-13,IGHJ4,CQQSYITTMYTF,IGKV1-39,59B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTQDRVELMVGSPYYYYYMDVW,IGHV3-13,IGHJ5,CQQSYITTMYTF,IGKV1-39,59B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGTQDRVELMVGSPYYYYYMDVW,IGHV3-13,IGHJ6,CQQSYITTMYTF,IGKV1-39,59B11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHRRDYITMIVRPTRLWAFDYW,IGHV4-34,IGHJ1,CQSYDSALVVF,IGLV1-40,59D6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHRRDYITMIVRPTRLWAFDYW,IGHV4-34,IGHJ2,CQSYDSALVVF,IGLV1-40,59D6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHRRDYITMIVRPTRLWAFDYW,IGHV4-34,IGHJ3,CQSYDSALVVF,IGLV1-40,59D6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHRRDYITMIVRPTRLWAFDYW,IGHV4-34,IGHJ4,CQSYDSALVVF,IGLV1-40,59D6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHRRDYITMIVRPTRLWAFDYW,IGHV4-34,IGHJ5,CQSYDSALVVF,IGLV1-40,59D6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARHRRDYITMIVRPTRLWAFDYW,IGHV4-34,IGHJ6,CQSYDSALVVF,IGLV1-40,59D6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARELGPVGGTDQW,IGHV3-66,IGHJ1,CQQSHSTPYTF,IGKV1-39,59A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARELGPVGGTDQW,IGHV3-66,IGHJ2,CQQSHSTPYTF,IGKV1-39,59A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARELGPVGGTDQW,IGHV3-66,IGHJ3,CQQSHSTPYTF,IGKV1-39,59A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARELGPVGGTDQW,IGHV3-66,IGHJ4,CQQSHSTPYTF,IGKV1-39,59A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARELGPVGGTDQW,IGHV3-66,IGHJ5,CQQSHSTPYTF,IGKV1-39,59A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARELGPVGGTDQW,IGHV3-66,IGHJ6,CQQSHSTPYTF,IGKV1-39,59A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLPLHGDYFDYW,IGHV3-66,IGHJ1,CQQSDNVPVTF,IGKV1-33,59A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLPLHGDYFDYW,IGHV3-66,IGHJ2,CQQSDNVPVTF,IGKV1-33,59A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLPLHGDYFDYW,IGHV3-66,IGHJ3,CQQSDNVPVTF,IGKV1-33,59A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLPLHGDYFDYW,IGHV3-66,IGHJ4,CQQSDNVPVTF,IGKV1-33,59A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLPLHGDYFDYW,IGHV3-66,IGHJ5,CQQSDNVPVTF,IGKV1-33,59A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLPLHGDYFDYW,IGHV3-66,IGHJ6,CQQSDNVPVTF,IGKV1-33,59A2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARETLGGYCNGGSCYDAGYFDYW,IGHV3-30,IGHJ1,CQQYGSSPWTF,IGKV3-20,59H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARETLGGYCNGGSCYDAGYFDYW,IGHV3-30,IGHJ2,CQQYGSSPWTF,IGKV3-20,59H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARETLGGYCNGGSCYDAGYFDYW,IGHV3-30,IGHJ3,CQQYGSSPWTF,IGKV3-20,59H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARETLGGYCNGGSCYDAGYFDYW,IGHV3-30,IGHJ4,CQQYGSSPWTF,IGKV3-20,59H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARETLGGYCNGGSCYDAGYFDYW,IGHV3-30,IGHJ5,CQQYGSSPWTF,IGKV3-20,59H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARETLGGYCNGGSCYDAGYFDYW,IGHV3-30,IGHJ6,CQQYGSSPWTF,IGKV3-20,59H6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ1,CQQSYNTPPWTF,IGKV1-39,59G12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ2,CQQSYNTPPWTF,IGKV1-39,59G12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ3,CQQSYNTPPWTF,IGKV1-39,59G12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ4,CQQSYNTPPWTF,IGKV1-39,59G12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ5,CQQSYNTPPWTF,IGKV1-39,59G12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGVDFGMVTLFDYW,IGHV3-33,IGHJ6,CQQSYNTPPWTF,IGKV1-39,59G12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQGLIDYW,IGHV4-4,IGHJ1,CQQYYSTPPRTF,IGKV1-NL1,8B1E6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQGLIDYW,IGHV4-4,IGHJ2,CQQYYSTPPRTF,IGKV1-NL1,8B1E6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQGLIDYW,IGHV4-4,IGHJ3,CQQYYSTPPRTF,IGKV1-NL1,8B1E6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQGLIDYW,IGHV4-4,IGHJ4,CQQYYSTPPRTF,IGKV1-NL1,8B1E6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQGLIDYW,IGHV4-4,IGHJ5,CQQYYSTPPRTF,IGKV1-NL1,8B1E6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVQGLIDYW,IGHV4-4,IGHJ6,CQQYYSTPPRTF,IGKV1-NL1,8B1E6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASQAAAGYYYYMDVW,IGHV5-51,IGHJ1,CQQSYNILWTF,IGKV1-39,8B1B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASQAAAGYYYYMDVW,IGHV5-51,IGHJ2,CQQSYNILWTF,IGKV1-39,8B1B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASQAAAGYYYYMDVW,IGHV5-51,IGHJ3,CQQSYNILWTF,IGKV1-39,8B1B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASQAAAGYYYYMDVW,IGHV5-51,IGHJ4,CQQSYNILWTF,IGKV1-39,8B1B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASQAAAGYYYYMDVW,IGHV5-51,IGHJ5,CQQSYNILWTF,IGKV1-39,8B1B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CASQAAAGYYYYMDVW,IGHV5-51,IGHJ6,CQQSYNILWTF,IGKV1-39,8B1B1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQTDYGVGWFDPW,IGHV3-23,IGHJ1,CQQYDNFSLTF,IGKV1-33,8B1H12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQTDYGVGWFDPW,IGHV3-23,IGHJ2,CQQYDNFSLTF,IGKV1-33,8B1H12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQTDYGVGWFDPW,IGHV3-23,IGHJ3,CQQYDNFSLTF,IGKV1-33,8B1H12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQTDYGVGWFDPW,IGHV3-23,IGHJ4,CQQYDNFSLTF,IGKV1-33,8B1H12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQTDYGVGWFDPW,IGHV3-23,IGHJ5,CQQYDNFSLTF,IGKV1-33,8B1H12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKQTDYGVGWFDPW,IGHV3-23,IGHJ6,CQQYDNFSLTF,IGKV1-33,8B1H12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLPLHSSYNWYYFDYW,IGHV1-69,IGHJ1,CQQRSNWPPGMYTF,IGKV3-11,8B1E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLPLHSSYNWYYFDYW,IGHV1-69,IGHJ2,CQQRSNWPPGMYTF,IGKV3-11,8B1E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLPLHSSYNWYYFDYW,IGHV1-69,IGHJ3,CQQRSNWPPGMYTF,IGKV3-11,8B1E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLPLHSSYNWYYFDYW,IGHV1-69,IGHJ4,CQQRSNWPPGMYTF,IGKV3-11,8B1E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLPLHSSYNWYYFDYW,IGHV1-69,IGHJ5,CQQRSNWPPGMYTF,IGKV3-11,8B1E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAVLPLHSSYNWYYFDYW,IGHV1-69,IGHJ6,CQQRSNWPPGMYTF,IGKV3-11,8B1E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHQRHSNSWYVSAWFDPW,IGHV2-5,IGHJ1,CQSYDSSLSGNFVF,IGLV1-40,8B2F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHQRHSNSWYVSAWFDPW,IGHV2-5,IGHJ2,CQSYDSSLSGNFVF,IGLV1-40,8B2F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHQRHSNSWYVSAWFDPW,IGHV2-5,IGHJ3,CQSYDSSLSGNFVF,IGLV1-40,8B2F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHQRHSNSWYVSAWFDPW,IGHV2-5,IGHJ4,CQSYDSSLSGNFVF,IGLV1-40,8B2F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHQRHSNSWYVSAWFDPW,IGHV2-5,IGHJ5,CQSYDSSLSGNFVF,IGLV1-40,8B2F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHQRHSNSWYVSAWFDPW,IGHV2-5,IGHJ6,CQSYDSSLSGNFVF,IGLV1-40,8B2F2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ1,CMQALQMGTF,IGKV2-28,8B5A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ2,CMQALQMGTF,IGKV2-28,8B5A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ3,CMQALQMGTF,IGKV2-28,8B5A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ4,CMQALQMGTF,IGKV2-28,8B5A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ5,CMQALQMGTF,IGKV2-28,8B5A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ6,CMQALQMGTF,IGKV2-28,8B5A6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSDTVTTAFDIW,IGHV3-13,IGHJ1,CQQSYTTPGLTF,IGKV1-39,8B2D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSDTVTTAFDIW,IGHV3-13,IGHJ2,CQQSYTTPGLTF,IGKV1-39,8B2D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSDTVTTAFDIW,IGHV3-13,IGHJ3,CQQSYTTPGLTF,IGKV1-39,8B2D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSDTVTTAFDIW,IGHV3-13,IGHJ4,CQQSYTTPGLTF,IGKV1-39,8B2D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSDTVTTAFDIW,IGHV3-13,IGHJ5,CQQSYTTPGLTF,IGKV1-39,8B2D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSDTVTTAFDIW,IGHV3-13,IGHJ6,CQQSYTTPGLTF,IGKV1-39,8B2D5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAPNSRGSGTNFDYW,IGHV3-53,IGHJ1,CQQSYSTPPYTF,IGKV1-39,8B2H8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAPNSRGSGTNFDYW,IGHV3-53,IGHJ2,CQQSYSTPPYTF,IGKV1-39,8B2H8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAPNSRGSGTNFDYW,IGHV3-53,IGHJ3,CQQSYSTPPYTF,IGKV1-39,8B2H8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAPNSRGSGTNFDYW,IGHV3-53,IGHJ4,CQQSYSTPPYTF,IGKV1-39,8B2H8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAPNSRGSGTNFDYW,IGHV3-53,IGHJ5,CQQSYSTPPYTF,IGKV1-39,8B2H8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREAPNSRGSGTNFDYW,IGHV3-53,IGHJ6,CQQSYSTPPYTF,IGKV1-39,8B2H8,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKNGYSYAYPRQYFDYW,IGHV3-33,IGHJ1,CQHYDNLKVTF,IGKV1-33,8B2D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKNGYSYAYPRQYFDYW,IGHV3-33,IGHJ2,CQHYDNLKVTF,IGKV1-33,8B2D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKNGYSYAYPRQYFDYW,IGHV3-33,IGHJ3,CQHYDNLKVTF,IGKV1-33,8B2D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKNGYSYAYPRQYFDYW,IGHV3-33,IGHJ4,CQHYDNLKVTF,IGKV1-33,8B2D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKNGYSYAYPRQYFDYW,IGHV3-33,IGHJ5,CQHYDNLKVTF,IGKV1-33,8B2D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKNGYSYAYPRQYFDYW,IGHV3-33,IGHJ6,CQHYDNLKVTF,IGKV1-33,8B2D11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVSRYTMVRGVIFDYW,IGHV4-31,IGHJ1,CCLYAGHSTYVVF,IGLV2-23,8B2E4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVSRYTMVRGVIFDYW,IGHV4-31,IGHJ2,CCLYAGHSTYVVF,IGLV2-23,8B2E4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVSRYTMVRGVIFDYW,IGHV4-31,IGHJ3,CCLYAGHSTYVVF,IGLV2-23,8B2E4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVSRYTMVRGVIFDYW,IGHV4-31,IGHJ4,CCLYAGHSTYVVF,IGLV2-23,8B2E4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVSRYTMVRGVIFDYW,IGHV4-31,IGHJ5,CCLYAGHSTYVVF,IGLV2-23,8B2E4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVSRYTMVRGVIFDYW,IGHV4-31,IGHJ6,CCLYAGHSTYVVF,IGLV2-23,8B2E4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGVATILGVDYW,IGHV4-38-2,IGHJ1,CQSYDSSWVF,IGLV6-57,8B2G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGVATILGVDYW,IGHV4-38-2,IGHJ2,CQSYDSSWVF,IGLV6-57,8B2G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGVATILGVDYW,IGHV4-38-2,IGHJ3,CQSYDSSWVF,IGLV6-57,8B2G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGVATILGVDYW,IGHV4-38-2,IGHJ4,CQSYDSSWVF,IGLV6-57,8B2G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGVATILGVDYW,IGHV4-38-2,IGHJ5,CQSYDSSWVF,IGLV6-57,8B2G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGVATILGVDYW,IGHV4-38-2,IGHJ6,CQSYDSSWVF,IGLV6-57,8B2G6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGGYISAWSTRYYAMDVW,IGHV3-30,IGHJ1,CSSYTSSSTWVF,IGLV2-14,8B2E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGGYISAWSTRYYAMDVW,IGHV3-30,IGHJ2,CSSYTSSSTWVF,IGLV2-14,8B2E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGGYISAWSTRYYAMDVW,IGHV3-30,IGHJ3,CSSYTSSSTWVF,IGLV2-14,8B2E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGGYISAWSTRYYAMDVW,IGHV3-30,IGHJ4,CSSYTSSSTWVF,IGLV2-14,8B2E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGGYISAWSTRYYAMDVW,IGHV3-30,IGHJ5,CSSYTSSSTWVF,IGLV2-14,8B2E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGGYISAWSTRYYAMDVW,IGHV3-30,IGHJ6,CSSYTSSSTWVF,IGLV2-14,8B2E12,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAESSSLTGNFNYW,IGHV3-23,IGHJ1,CQVWDTAWVF,IGLV3-21,8B3E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAESSSLTGNFNYW,IGHV3-23,IGHJ2,CQVWDTAWVF,IGLV3-21,8B3E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAESSSLTGNFNYW,IGHV3-23,IGHJ3,CQVWDTAWVF,IGLV3-21,8B3E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAESSSLTGNFNYW,IGHV3-23,IGHJ4,CQVWDTAWVF,IGLV3-21,8B3E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAESSSLTGNFNYW,IGHV3-23,IGHJ5,CQVWDTAWVF,IGLV3-21,8B3E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAESSSLTGNFNYW,IGHV3-23,IGHJ6,CQVWDTAWVF,IGLV3-21,8B3E9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGFDTTTGFYFDYW,IGHV3-13,IGHJ1,CQQDYNFPWTF,IGKV1-NL1,8B5A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGFDTTTGFYFDYW,IGHV3-13,IGHJ2,CQQDYNFPWTF,IGKV1-NL1,8B5A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGFDTTTGFYFDYW,IGHV3-13,IGHJ3,CQQDYNFPWTF,IGKV1-NL1,8B5A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGFDTTTGFYFDYW,IGHV3-13,IGHJ4,CQQDYNFPWTF,IGKV1-NL1,8B5A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGFDTTTGFYFDYW,IGHV3-13,IGHJ5,CQQDYNFPWTF,IGKV1-NL1,8B5A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGFDTTTGFYFDYW,IGHV3-13,IGHJ6,CQQDYNFPWTF,IGKV1-NL1,8B5A1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTEYSYDSGSSRAYSMDVW,IGHV1-69,IGHJ1,CQQTHSTPRTF,IGKV1-39,8B5B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTEYSYDSGSSRAYSMDVW,IGHV1-69,IGHJ2,CQQTHSTPRTF,IGKV1-39,8B5B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTEYSYDSGSSRAYSMDVW,IGHV1-69,IGHJ3,CQQTHSTPRTF,IGKV1-39,8B5B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTEYSYDSGSSRAYSMDVW,IGHV1-69,IGHJ4,CQQTHSTPRTF,IGKV1-39,8B5B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTEYSYDSGSSRAYSMDVW,IGHV1-69,IGHJ5,CQQTHSTPRTF,IGKV1-39,8B5B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARTEYSYDSGSSRAYSMDVW,IGHV1-69,IGHJ6,CQQTHSTPRTF,IGKV1-39,8B5B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGPSSSWPSW,IGHV7-4-1,IGHJ1,CQQSYSTPRTF,IGKV1-39,8B5E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGPSSSWPSW,IGHV7-4-1,IGHJ2,CQQSYSTPRTF,IGKV1-39,8B5E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGPSSSWPSW,IGHV7-4-1,IGHJ3,CQQSYSTPRTF,IGKV1-39,8B5E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGPSSSWPSW,IGHV7-4-1,IGHJ4,CQQSYSTPRTF,IGKV1-39,8B5E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGPSSSWPSW,IGHV7-4-1,IGHJ5,CQQSYSTPRTF,IGKV1-39,8B5E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARVGPSSSWPSW,IGHV7-4-1,IGHJ6,CQQSYSTPRTF,IGKV1-39,8B5E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ1,CMQALQMGTF,IGKV2-28,8B5C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ2,CMQALQMGTF,IGKV2-28,8B5C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ3,CMQALQMGTF,IGKV2-28,8B5C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ4,CMQALQMGTF,IGKV2-28,8B5C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ5,CMQALQMGTF,IGKV2-28,8B5C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKGGWYSSKWYYFDYW,IGHV3-33,IGHJ6,CMQALQMGTF,IGKV2-28,8B5C1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDPYW,IGHV3-7,IGHJ1,CQQYYSAPRTF,IGKV1-NL1,8B5F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDPYW,IGHV3-7,IGHJ2,CQQYYSAPRTF,IGKV1-NL1,8B5F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDPYW,IGHV3-7,IGHJ3,CQQYYSAPRTF,IGKV1-NL1,8B5F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDPYW,IGHV3-7,IGHJ4,CQQYYSAPRTF,IGKV1-NL1,8B5F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDPYW,IGHV3-7,IGHJ5,CQQYYSAPRTF,IGKV1-NL1,8B5F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDPYW,IGHV3-7,IGHJ6,CQQYYSAPRTF,IGKV1-NL1,8B5F7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSPDHRYFDVLTGYFNSERFYFDYW,IGHV2-5,IGHJ1,CGTWDSSLSAGVF,IGLV1-51,8B4G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSPDHRYFDVLTGYFNSERFYFDYW,IGHV2-5,IGHJ2,CGTWDSSLSAGVF,IGLV1-51,8B4G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSPDHRYFDVLTGYFNSERFYFDYW,IGHV2-5,IGHJ3,CGTWDSSLSAGVF,IGLV1-51,8B4G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSPDHRYFDVLTGYFNSERFYFDYW,IGHV2-5,IGHJ4,CGTWDSSLSAGVF,IGLV1-51,8B4G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSPDHRYFDVLTGYFNSERFYFDYW,IGHV2-5,IGHJ5,CGTWDSSLSAGVF,IGLV1-51,8B4G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAHSPDHRYFDVLTGYFNSERFYFDYW,IGHV2-5,IGHJ6,CGTWDSSLSAGVF,IGLV1-51,8B4G4,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIPRHLGQDHYYYVMDVW,IGHV4-39,IGHJ1,CCSYAGIFVF,IGLV2-23,8B4A7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIPRHLGQDHYYYVMDVW,IGHV4-39,IGHJ2,CCSYAGIFVF,IGLV2-23,8B4A7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIPRHLGQDHYYYVMDVW,IGHV4-39,IGHJ3,CCSYAGIFVF,IGLV2-23,8B4A7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIPRHLGQDHYYYVMDVW,IGHV4-39,IGHJ4,CCSYAGIFVF,IGLV2-23,8B4A7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIPRHLGQDHYYYVMDVW,IGHV4-39,IGHJ5,CCSYAGIFVF,IGLV2-23,8B4A7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARIPRHLGQDHYYYVMDVW,IGHV4-39,IGHJ6,CCSYAGIFVF,IGLV2-23,8B4A7,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKAAGGGYSYIYWGGDYW,IGHV3-30,IGHJ1,CQSYDSSNLWVF,IGLV6-57,8B4D9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKAAGGGYSYIYWGGDYW,IGHV3-30,IGHJ2,CQSYDSSNLWVF,IGLV6-57,8B4D9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKAAGGGYSYIYWGGDYW,IGHV3-30,IGHJ3,CQSYDSSNLWVF,IGLV6-57,8B4D9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKAAGGGYSYIYWGGDYW,IGHV3-30,IGHJ4,CQSYDSSNLWVF,IGLV6-57,8B4D9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKAAGGGYSYIYWGGDYW,IGHV3-30,IGHJ5,CQSYDSSNLWVF,IGLV6-57,8B4D9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAKAAGGGYSYIYWGGDYW,IGHV3-30,IGHJ6,CQSYDSSNLWVF,IGLV6-57,8B4D9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREYFVSLPAAQTLYYYGIDVW,IGHV4-61,IGHJ1,CQQYKNWPPWTF,IGKV3-15,8B4E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREYFVSLPAAQTLYYYGIDVW,IGHV4-61,IGHJ2,CQQYKNWPPWTF,IGKV3-15,8B4E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREYFVSLPAAQTLYYYGIDVW,IGHV4-61,IGHJ3,CQQYKNWPPWTF,IGKV3-15,8B4E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREYFVSLPAAQTLYYYGIDVW,IGHV4-61,IGHJ4,CQQYKNWPPWTF,IGKV3-15,8B4E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREYFVSLPAAQTLYYYGIDVW,IGHV4-61,IGHJ5,CQQYKNWPPWTF,IGKV3-15,8B4E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREYFVSLPAAQTLYYYGIDVW,IGHV4-61,IGHJ6,CQQYKNWPPWTF,IGKV3-15,8B4E1,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ1,CHQYDSSPLTF,IGKV3-20,8B4H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ2,CHQYDSSPLTF,IGKV3-20,8B4H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ3,CHQYDSSPLTF,IGKV3-20,8B4H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ4,CHQYDSSPLTF,IGKV3-20,8B4H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ5,CHQYDSSPLTF,IGKV3-20,8B4H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGLWFGDLTRTKYNWFDPW,IGHV1-8,IGHJ6,CHQYDSSPLTF,IGKV3-20,8B4H2,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPSGNYDNIDEWTRSENHYNYGMDAW,IGHV1-46,IGHJ1,CQQRSNWPYLTF,IGKV3-11,8B4A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPSGNYDNIDEWTRSENHYNYGMDAW,IGHV1-46,IGHJ2,CQQRSNWPYLTF,IGKV3-11,8B4A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPSGNYDNIDEWTRSENHYNYGMDAW,IGHV1-46,IGHJ3,CQQRSNWPYLTF,IGKV3-11,8B4A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPSGNYDNIDEWTRSENHYNYGMDAW,IGHV1-46,IGHJ4,CQQRSNWPYLTF,IGKV3-11,8B4A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPSGNYDNIDEWTRSENHYNYGMDAW,IGHV1-46,IGHJ5,CQQRSNWPYLTF,IGKV3-11,8B4A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDPPSGNYDNIDEWTRSENHYNYGMDAW,IGHV1-46,IGHJ6,CQQRSNWPYLTF,IGKV3-11,8B4A3,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGSAVAGPMSYFDYW,IGHV3-11,IGHJ1,CQQYYSIPRTF,IGKV1-NL1,8B4C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGSAVAGPMSYFDYW,IGHV3-11,IGHJ2,CQQYYSIPRTF,IGKV1-NL1,8B4C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGSAVAGPMSYFDYW,IGHV3-11,IGHJ3,CQQYYSIPRTF,IGKV1-NL1,8B4C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGSAVAGPMSYFDYW,IGHV3-11,IGHJ4,CQQYYSIPRTF,IGKV1-NL1,8B4C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGSAVAGPMSYFDYW,IGHV3-11,IGHJ5,CQQYYSIPRTF,IGKV1-NL1,8B4C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDGSAVAGPMSYFDYW,IGHV3-11,IGHJ6,CQQYYSIPRTF,IGKV1-NL1,8B4C5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREVAGAVHLDYW,IGHV2-70,IGHJ1,CQQSFSTPRTF,IGKV1-39,8B4E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREVAGAVHLDYW,IGHV2-70,IGHJ2,CQQSFSTPRTF,IGKV1-39,8B4E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREVAGAVHLDYW,IGHV2-70,IGHJ3,CQQSFSTPRTF,IGKV1-39,8B4E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREVAGAVHLDYW,IGHV2-70,IGHJ4,CQQSFSTPRTF,IGKV1-39,8B4E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREVAGAVHLDYW,IGHV2-70,IGHJ5,CQQSFSTPRTF,IGKV1-39,8B4E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAREVAGAVHLDYW,IGHV2-70,IGHJ6,CQQSFSTPRTF,IGKV1-39,8B4E5,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDLLFW,IGHV3-7,IGHJ1,CQQYYSDPPRTF,IGKV1-NL1,8B4B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDLLFW,IGHV3-7,IGHJ2,CQQYYSDPPRTF,IGKV1-NL1,8B4B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDLLFW,IGHV3-7,IGHJ3,CQQYYSDPPRTF,IGKV1-NL1,8B4B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDLLFW,IGHV3-7,IGHJ4,CQQYYSDPPRTF,IGKV1-NL1,8B4B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDLLFW,IGHV3-7,IGHJ5,CQQYYSDPPRTF,IGKV1-NL1,8B4B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARDLGVLWFGDLLFW,IGHV3-7,IGHJ6,CQQYYSDPPRTF,IGKV1-NL1,8B4B6,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGYYYGPPRDFDYW,IGHV4-59,IGHJ1,CQHYGSSPQYTF,IGKV3-20,8B4E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGYYYGPPRDFDYW,IGHV4-59,IGHJ2,CQHYGSSPQYTF,IGKV3-20,8B4E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGYYYGPPRDFDYW,IGHV4-59,IGHJ3,CQHYGSSPQYTF,IGKV3-20,8B4E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGYYYGPPRDFDYW,IGHV4-59,IGHJ4,CQHYGSSPQYTF,IGKV3-20,8B4E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGYYYGPPRDFDYW,IGHV4-59,IGHJ5,CQHYGSSPQYTF,IGKV3-20,8B4E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGGYYYGPPRDFDYW,IGHV4-59,IGHJ6,CQHYGSSPQYTF,IGKV3-20,8B4E11,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPYCSSTSCRDGFDIW,IGHV1-58,IGHJ1,CQQYGRSPWTF,IGKV3-20,13G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPYCSSTSCRDGFDIW,IGHV1-58,IGHJ2,CQQYGRSPWTF,IGKV3-20,13G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPYCSSTSCRDGFDIW,IGHV1-58,IGHJ3,CQQYGRSPWTF,IGKV3-20,13G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPYCSSTSCRDGFDIW,IGHV1-58,IGHJ4,CQQYGRSPWTF,IGKV3-20,13G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPYCSSTSCRDGFDIW,IGHV1-58,IGHJ5,CQQYGRSPWTF,IGKV3-20,13G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CAAPYCSSTSCRDGFDIW,IGHV1-58,IGHJ6,CQQYGRSPWTF,IGKV3-20,13G9,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
CARGSSNLFDIW,IGHV3-74,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,HL CV01-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSSNLFDIW,IGHV3-74,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,HL CV01-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSSNLFDIW,IGHV3-74,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,HL CV01-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSSNLFDIW,IGHV3-74,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,HL CV01-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSSNLFDIW,IGHV3-74,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,HL CV01-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSSNLFDIW,IGHV3-74,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,HL CV01-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSGGYSGYDYSHRIDYW,IGHV3-21,IGHJ1,CSSYTLDSTVVF,IGLV2-14,HL CV01-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSGGYSGYDYSHRIDYW,IGHV3-21,IGHJ2,CSSYTLDSTVVF,IGLV2-14,HL CV01-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSGGYSGYDYSHRIDYW,IGHV3-21,IGHJ3,CSSYTLDSTVVF,IGLV2-14,HL CV01-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSGGYSGYDYSHRIDYW,IGHV3-21,IGHJ4,CSSYTLDSTVVF,IGLV2-14,HL CV01-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSGGYSGYDYSHRIDYW,IGHV3-21,IGHJ5,CSSYTLDSTVVF,IGLV2-14,HL CV01-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSGGYSGYDYSHRIDYW,IGHV3-21,IGHJ6,CSSYTLDSTVVF,IGLV2-14,HL CV01-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGWGMEYSSSSADYW,IGHV1-69,IGHJ1,CQQRSNWPPYTF,IGKV3-11,HK CV01-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGWGMEYSSSSADYW,IGHV1-69,IGHJ2,CQQRSNWPPYTF,IGKV3-11,HK CV01-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGWGMEYSSSSADYW,IGHV1-69,IGHJ3,CQQRSNWPPYTF,IGKV3-11,HK CV01-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGWGMEYSSSSADYW,IGHV1-69,IGHJ4,CQQRSNWPPYTF,IGKV3-11,HK CV01-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGWGMEYSSSSADYW,IGHV1-69,IGHJ5,CQQRSNWPPYTF,IGKV3-11,HK CV01-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGWGMEYSSSSADYW,IGHV1-69,IGHJ6,CQQRSNWPPYTF,IGKV3-11,HK CV01-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADETMVQGVIPNFDYW,IGHV1-18,IGHJ1,CSSYAGSNNVVF,IGLV2-8,HL CV01-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADETMVQGVIPNFDYW,IGHV1-18,IGHJ2,CSSYAGSNNVVF,IGLV2-8,HL CV01-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADETMVQGVIPNFDYW,IGHV1-18,IGHJ3,CSSYAGSNNVVF,IGLV2-8,HL CV01-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADETMVQGVIPNFDYW,IGHV1-18,IGHJ4,CSSYAGSNNVVF,IGLV2-8,HL CV01-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADETMVQGVIPNFDYW,IGHV1-18,IGHJ5,CSSYAGSNNVVF,IGLV2-8,HL CV01-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADETMVQGVIPNFDYW,IGHV1-18,IGHJ6,CSSYAGSNNVVF,IGLV2-8,HL CV01-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDCGGSSCYGYPYYGMDVW,IGHV3-74,IGHJ1,CMQALHTPYTF,IGKV2-28,HK CV01-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDCGGSSCYGYPYYGMDVW,IGHV3-74,IGHJ2,CMQALHTPYTF,IGKV2-28,HK CV01-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDCGGSSCYGYPYYGMDVW,IGHV3-74,IGHJ3,CMQALHTPYTF,IGKV2-28,HK CV01-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDCGGSSCYGYPYYGMDVW,IGHV3-74,IGHJ4,CMQALHTPYTF,IGKV2-28,HK CV01-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDCGGSSCYGYPYYGMDVW,IGHV3-74,IGHJ5,CMQALHTPYTF,IGKV2-28,HK CV01-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDCGGSSCYGYPYYGMDVW,IGHV3-74,IGHJ6,CMQALHTPYTF,IGKV2-28,HK CV01-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGVVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGVVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGVVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGVVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGVVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGVVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDRGYCVGDVCYTVLDYW,IGHV3-7,IGHJ1,CLHDYNYPPTF,IGKV1-6,HK CV01-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDRGYCVGDVCYTVLDYW,IGHV3-7,IGHJ2,CLHDYNYPPTF,IGKV1-6,HK CV01-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDRGYCVGDVCYTVLDYW,IGHV3-7,IGHJ3,CLHDYNYPPTF,IGKV1-6,HK CV01-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDRGYCVGDVCYTVLDYW,IGHV3-7,IGHJ4,CLHDYNYPPTF,IGKV1-6,HK CV01-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDRGYCVGDVCYTVLDYW,IGHV3-7,IGHJ5,CLHDYNYPPTF,IGKV1-6,HK CV01-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDRGYCVGDVCYTVLDYW,IGHV3-7,IGHJ6,CLHDYNYPPTF,IGKV1-6,HK CV01-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWFYYDIRDHW,IGHV3-15,IGHJ1,CQQRSNWPPFTF,IGKV3-11,HK CV01-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWFYYDIRDHW,IGHV3-15,IGHJ2,CQQRSNWPPFTF,IGKV3-11,HK CV01-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWFYYDIRDHW,IGHV3-15,IGHJ3,CQQRSNWPPFTF,IGKV3-11,HK CV01-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWFYYDIRDHW,IGHV3-15,IGHJ4,CQQRSNWPPFTF,IGKV3-11,HK CV01-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWFYYDIRDHW,IGHV3-15,IGHJ5,CQQRSNWPPFTF,IGKV3-11,HK CV01-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWFYYDIRDHW,IGHV3-15,IGHJ6,CQQRSNWPPFTF,IGKV3-11,HK CV01-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ1,CSSYAGSNNVVF,IGLV2-8,HL CV01-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ2,CSSYAGSNNVVF,IGLV2-8,HL CV01-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ3,CSSYAGSNNVVF,IGLV2-8,HL CV01-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ4,CSSYAGSNNVVF,IGLV2-8,HL CV01-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ5,CSSYAGSNNVVF,IGLV2-8,HL CV01-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ6,CSSYAGSNNVVF,IGLV2-8,HL CV01-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIYYDFW,IGHV3-15,IGHJ1,CLHYNSVPYTF,IGKV1-17,HK CV01-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIYYDFW,IGHV3-15,IGHJ2,CLHYNSVPYTF,IGKV1-17,HK CV01-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIYYDFW,IGHV3-15,IGHJ3,CLHYNSVPYTF,IGKV1-17,HK CV01-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIYYDFW,IGHV3-15,IGHJ4,CLHYNSVPYTF,IGKV1-17,HK CV01-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIYYDFW,IGHV3-15,IGHJ5,CLHYNSVPYTF,IGKV1-17,HK CV01-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIYYDFW,IGHV3-15,IGHJ6,CLHYNSVPYTF,IGKV1-17,HK CV01-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDAVARTLNLDYW,IGHV1-2,IGHJ1,CAAWDDSLNGVF,IGLV1-44,HL CV01-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDAVARTLNLDYW,IGHV1-2,IGHJ2,CAAWDDSLNGVF,IGLV1-44,HL CV01-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDAVARTLNLDYW,IGHV1-2,IGHJ3,CAAWDDSLNGVF,IGLV1-44,HL CV01-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDAVARTLNLDYW,IGHV1-2,IGHJ4,CAAWDDSLNGVF,IGLV1-44,HL CV01-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDAVARTLNLDYW,IGHV1-2,IGHJ5,CAAWDDSLNGVF,IGLV1-44,HL CV01-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDAVARTLNLDYW,IGHV1-2,IGHJ6,CAAWDDSLNGVF,IGLV1-44,HL CV01-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNIGAVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNIGAVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNIGAVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNIGAVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNIGAVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNIGAVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGLSYYYDNGGYYSVPPIDVW,IGHV3-49,IGHJ1,CSSYADSNNLVF,IGLV2-8,HL CV01-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGLSYYYDNGGYYSVPPIDVW,IGHV3-49,IGHJ2,CSSYADSNNLVF,IGLV2-8,HL CV01-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGLSYYYDNGGYYSVPPIDVW,IGHV3-49,IGHJ3,CSSYADSNNLVF,IGLV2-8,HL CV01-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGLSYYYDNGGYYSVPPIDVW,IGHV3-49,IGHJ4,CSSYADSNNLVF,IGLV2-8,HL CV01-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGLSYYYDNGGYYSVPPIDVW,IGHV3-49,IGHJ5,CSSYADSNNLVF,IGLV2-8,HL CV01-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGLSYYYDNGGYYSVPPIDVW,IGHV3-49,IGHJ6,CSSYADSNNLVF,IGLV2-8,HL CV01-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSPSCADAVCYFDVW,IGHV3-9,IGHJ1,CQQYYSAPRTF,IGKV4-1,HK CV01-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSPSCADAVCYFDVW,IGHV3-9,IGHJ2,CQQYYSAPRTF,IGKV4-1,HK CV01-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSPSCADAVCYFDVW,IGHV3-9,IGHJ3,CQQYYSAPRTF,IGKV4-1,HK CV01-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSPSCADAVCYFDVW,IGHV3-9,IGHJ4,CQQYYSAPRTF,IGKV4-1,HK CV01-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSPSCADAVCYFDVW,IGHV3-9,IGHJ5,CQQYYSAPRTF,IGKV4-1,HK CV01-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSPSCADAVCYFDVW,IGHV3-9,IGHJ6,CQQYYSAPRTF,IGKV4-1,HK CV01-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGVLITIFGVARDAFDIW,IGHV4-30-4,IGHJ1,CQQYGSSPRTF,IGKV3-20,HK CV01-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGVLITIFGVARDAFDIW,IGHV4-30-4,IGHJ2,CQQYGSSPRTF,IGKV3-20,HK CV01-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGVLITIFGVARDAFDIW,IGHV4-30-4,IGHJ3,CQQYGSSPRTF,IGKV3-20,HK CV01-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGVLITIFGVARDAFDIW,IGHV4-30-4,IGHJ4,CQQYGSSPRTF,IGKV3-20,HK CV01-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGVLITIFGVARDAFDIW,IGHV4-30-4,IGHJ5,CQQYGSSPRTF,IGKV3-20,HK CV01-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGVLITIFGVARDAFDIW,IGHV4-30-4,IGHJ6,CQQYGSSPRTF,IGKV3-20,HK CV01-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSIWGGVQGVLQDYW,IGHV4-38-2,IGHJ1,CQQYNDWPRTF,IGKV3-15,HK CV01-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSIWGGVQGVLQDYW,IGHV4-38-2,IGHJ2,CQQYNDWPRTF,IGKV3-15,HK CV01-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSIWGGVQGVLQDYW,IGHV4-38-2,IGHJ3,CQQYNDWPRTF,IGKV3-15,HK CV01-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSIWGGVQGVLQDYW,IGHV4-38-2,IGHJ4,CQQYNDWPRTF,IGKV3-15,HK CV01-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSIWGGVQGVLQDYW,IGHV4-38-2,IGHJ5,CQQYNDWPRTF,IGKV3-15,HK CV01-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSIWGGVQGVLQDYW,IGHV4-38-2,IGHJ6,CQQYNDWPRTF,IGKV3-15,HK CV01-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSIASVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSIASVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSIASVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSIASVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSIASVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSIASVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGWRYFDYW,IGHV3-7,IGHJ1,CQQRSSWPLTF,IGKV3-11,HK CV01-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGWRYFDYW,IGHV3-7,IGHJ2,CQQRSSWPLTF,IGKV3-11,HK CV01-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGWRYFDYW,IGHV3-7,IGHJ3,CQQRSSWPLTF,IGKV3-11,HK CV01-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGWRYFDYW,IGHV3-7,IGHJ4,CQQRSSWPLTF,IGKV3-11,HK CV01-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGWRYFDYW,IGHV3-7,IGHJ5,CQQRSSWPLTF,IGKV3-11,HK CV01-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGWRYFDYW,IGHV3-7,IGHJ6,CQQRSSWPLTF,IGKV3-11,HK CV01-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKYGSITIFGVVIIGYFYFDYW,IGHV3-23,IGHJ1,CQQYGSSPATF,IGKV3-20,HK CV01-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKYGSITIFGVVIIGYFYFDYW,IGHV3-23,IGHJ2,CQQYGSSPATF,IGKV3-20,HK CV01-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKYGSITIFGVVIIGYFYFDYW,IGHV3-23,IGHJ3,CQQYGSSPATF,IGKV3-20,HK CV01-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKYGSITIFGVVIIGYFYFDYW,IGHV3-23,IGHJ4,CQQYGSSPATF,IGKV3-20,HK CV01-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKYGSITIFGVVIIGYFYFDYW,IGHV3-23,IGHJ5,CQQYGSSPATF,IGKV3-20,HK CV01-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKYGSITIFGVVIIGYFYFDYW,IGHV3-23,IGHJ6,CQQYGSSPATF,IGKV3-20,HK CV01-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ1,CSSYAGSNNVLF,IGLV2-8,HL CV01-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ2,CSSYAGSNNVLF,IGLV2-8,HL CV01-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ3,CSSYAGSNNVLF,IGLV2-8,HL CV01-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ4,CSSYAGSNNVLF,IGLV2-8,HL CV01-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ5,CSSYAGSNNVLF,IGLV2-8,HL CV01-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ6,CSSYAGSNNVLF,IGLV2-8,HL CV01-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGHVRYCISTNCYHYGMDVW,IGHV5-51,IGHJ1,CMIWHTSAWVF,IGLV5-45,HL CV01-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGHVRYCISTNCYHYGMDVW,IGHV5-51,IGHJ2,CMIWHTSAWVF,IGLV5-45,HL CV01-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGHVRYCISTNCYHYGMDVW,IGHV5-51,IGHJ3,CMIWHTSAWVF,IGLV5-45,HL CV01-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGHVRYCISTNCYHYGMDVW,IGHV5-51,IGHJ4,CMIWHTSAWVF,IGLV5-45,HL CV01-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGHVRYCISTNCYHYGMDVW,IGHV5-51,IGHJ5,CMIWHTSAWVF,IGLV5-45,HL CV01-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGHVRYCISTNCYHYGMDVW,IGHV5-51,IGHJ6,CMIWHTSAWVF,IGLV5-45,HL CV01-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ1,CSSYAGSNNVVF,IGLV2-8,HL CV01-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ2,CSSYAGSNNVVF,IGLV2-8,HL CV01-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ3,CSSYAGSNNVVF,IGLV2-8,HL CV01-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ4,CSSYAGSNNVVF,IGLV2-8,HL CV01-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ5,CSSYAGSNNVVF,IGLV2-8,HL CV01-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADYTMVQGVIPNFDYW,IGHV1-18,IGHJ6,CSSYAGSNNVVF,IGLV2-8,HL CV01-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPGYSGNNWGEAFDIW,IGHV3-7,IGHJ1,CQQYYDTLWTF,IGKV4-1,HK CV01-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPGYSGNNWGEAFDIW,IGHV3-7,IGHJ2,CQQYYDTLWTF,IGKV4-1,HK CV01-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPGYSGNNWGEAFDIW,IGHV3-7,IGHJ3,CQQYYDTLWTF,IGKV4-1,HK CV01-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPGYSGNNWGEAFDIW,IGHV3-7,IGHJ4,CQQYYDTLWTF,IGKV4-1,HK CV01-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPGYSGNNWGEAFDIW,IGHV3-7,IGHJ5,CQQYYDTLWTF,IGKV4-1,HK CV01-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPGYSGNNWGEAFDIW,IGHV3-7,IGHJ6,CQQYYDTLWTF,IGKV4-1,HK CV01-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYNWNYYYYYGMDVW,IGHV4-59,IGHJ1,CQQYGSSPSTF,IGKV3-20,HK CV01-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYNWNYYYYYGMDVW,IGHV4-59,IGHJ2,CQQYGSSPSTF,IGKV3-20,HK CV01-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYNWNYYYYYGMDVW,IGHV4-59,IGHJ3,CQQYGSSPSTF,IGKV3-20,HK CV01-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYNWNYYYYYGMDVW,IGHV4-59,IGHJ4,CQQYGSSPSTF,IGKV3-20,HK CV01-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYNWNYYYYYGMDVW,IGHV4-59,IGHJ5,CQQYGSSPSTF,IGKV3-20,HK CV01-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYNWNYYYYYGMDVW,IGHV4-59,IGHJ6,CQQYGSSPSTF,IGKV3-20,HK CV01-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSRGSVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSRGSVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSRGSVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSRGSVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSRGSVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSRGSVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKLDCSSTSCYFGFIYYYYYMDVW,IGHV3-30,IGHJ1,CQQANSFPLTF,IGKV1-12,HK CV01-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKLDCSSTSCYFGFIYYYYYMDVW,IGHV3-30,IGHJ2,CQQANSFPLTF,IGKV1-12,HK CV01-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKLDCSSTSCYFGFIYYYYYMDVW,IGHV3-30,IGHJ3,CQQANSFPLTF,IGKV1-12,HK CV01-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKLDCSSTSCYFGFIYYYYYMDVW,IGHV3-30,IGHJ4,CQQANSFPLTF,IGKV1-12,HK CV01-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKLDCSSTSCYFGFIYYYYYMDVW,IGHV3-30,IGHJ5,CQQANSFPLTF,IGKV1-12,HK CV01-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKLDCSSTSCYFGFIYYYYYMDVW,IGHV3-30,IGHJ6,CQQANSFPLTF,IGKV1-12,HK CV01-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESYEGSSFDYW,IGHV3-11,IGHJ1,CQSYDSSNRRVF,IGLV6-57,HL CV01-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESYEGSSFDYW,IGHV3-11,IGHJ2,CQSYDSSNRRVF,IGLV6-57,HL CV01-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESYEGSSFDYW,IGHV3-11,IGHJ3,CQSYDSSNRRVF,IGLV6-57,HL CV01-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESYEGSSFDYW,IGHV3-11,IGHJ4,CQSYDSSNRRVF,IGLV6-57,HL CV01-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESYEGSSFDYW,IGHV3-11,IGHJ5,CQSYDSSNRRVF,IGLV6-57,HL CV01-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESYEGSSFDYW,IGHV3-11,IGHJ6,CQSYDSSNRRVF,IGLV6-57,HL CV01-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGRCGDYW,IGHV3-7,IGHJ1,CQQGGNWPRTF,IGKV3-11,HK CV01-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGRCGDYW,IGHV3-7,IGHJ2,CQQGGNWPRTF,IGKV3-11,HK CV01-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGRCGDYW,IGHV3-7,IGHJ3,CQQGGNWPRTF,IGKV3-11,HK CV01-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGRCGDYW,IGHV3-7,IGHJ4,CQQGGNWPRTF,IGKV3-11,HK CV01-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGRCGDYW,IGHV3-7,IGHJ5,CQQGGNWPRTF,IGKV3-11,HK CV01-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGRCGDYW,IGHV3-7,IGHJ6,CQQGGNWPRTF,IGKV3-11,HK CV01-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGYITIFGVVIIPGWFDPW,IGHV4-39,IGHJ1,CQQYNNWPPWTF,IGKV3-15,HK CV01-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGYITIFGVVIIPGWFDPW,IGHV4-39,IGHJ2,CQQYNNWPPWTF,IGKV3-15,HK CV01-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGYITIFGVVIIPGWFDPW,IGHV4-39,IGHJ3,CQQYNNWPPWTF,IGKV3-15,HK CV01-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGYITIFGVVIIPGWFDPW,IGHV4-39,IGHJ4,CQQYNNWPPWTF,IGKV3-15,HK CV01-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGYITIFGVVIIPGWFDPW,IGHV4-39,IGHJ5,CQQYNNWPPWTF,IGKV3-15,HK CV01-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGYITIFGVVIIPGWFDPW,IGHV4-39,IGHJ6,CQQYNNWPPWTF,IGKV3-15,HK CV01-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPDNELLPFDYW,IGHV4-39,IGHJ1,CQVWDSSSDSYVF,IGLV3-21,HL CV01-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPDNELLPFDYW,IGHV4-39,IGHJ2,CQVWDSSSDSYVF,IGLV3-21,HL CV01-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPDNELLPFDYW,IGHV4-39,IGHJ3,CQVWDSSSDSYVF,IGLV3-21,HL CV01-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPDNELLPFDYW,IGHV4-39,IGHJ4,CQVWDSSSDSYVF,IGLV3-21,HL CV01-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPDNELLPFDYW,IGHV4-39,IGHJ5,CQVWDSSSDSYVF,IGLV3-21,HL CV01-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPDNELLPFDYW,IGHV4-39,IGHJ6,CQVWDSSSDSYVF,IGLV3-21,HL CV01-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPRNYCHSNTCPVWYFDLW,IGHV3-30-3,IGHJ1,CQQYGSSPRTF,IGKV3-20,HK CV01-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPRNYCHSNTCPVWYFDLW,IGHV3-30-3,IGHJ2,CQQYGSSPRTF,IGKV3-20,HK CV01-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPRNYCHSNTCPVWYFDLW,IGHV3-30-3,IGHJ3,CQQYGSSPRTF,IGKV3-20,HK CV01-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPRNYCHSNTCPVWYFDLW,IGHV3-30-3,IGHJ4,CQQYGSSPRTF,IGKV3-20,HK CV01-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPRNYCHSNTCPVWYFDLW,IGHV3-30-3,IGHJ5,CQQYGSSPRTF,IGKV3-20,HK CV01-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPRNYCHSNTCPVWYFDLW,IGHV3-30-3,IGHJ6,CQQYGSSPRTF,IGKV3-20,HK CV01-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGNYGDYGGSFDYW,IGHV3-33,IGHJ1,CYSTDSSGNHRVF,IGLV3-10,HL CV01-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGNYGDYGGSFDYW,IGHV3-33,IGHJ2,CYSTDSSGNHRVF,IGLV3-10,HL CV01-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGNYGDYGGSFDYW,IGHV3-33,IGHJ3,CYSTDSSGNHRVF,IGLV3-10,HL CV01-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGNYGDYGGSFDYW,IGHV3-33,IGHJ4,CYSTDSSGNHRVF,IGLV3-10,HL CV01-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGNYGDYGGSFDYW,IGHV3-33,IGHJ5,CYSTDSSGNHRVF,IGLV3-10,HL CV01-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGNYGDYGGSFDYW,IGHV3-33,IGHJ6,CYSTDSSGNHRVF,IGLV3-10,HL CV01-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPRITIFGVVIYWYFDLW,IGHV4-30-4,IGHJ1,CQSYDSSLSGSGVF,IGLV1-40,HL CV01-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPRITIFGVVIYWYFDLW,IGHV4-30-4,IGHJ2,CQSYDSSLSGSGVF,IGLV1-40,HL CV01-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPRITIFGVVIYWYFDLW,IGHV4-30-4,IGHJ3,CQSYDSSLSGSGVF,IGLV1-40,HL CV01-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPRITIFGVVIYWYFDLW,IGHV4-30-4,IGHJ4,CQSYDSSLSGSGVF,IGLV1-40,HL CV01-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPRITIFGVVIYWYFDLW,IGHV4-30-4,IGHJ5,CQSYDSSLSGSGVF,IGLV1-40,HL CV01-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPRITIFGVVIYWYFDLW,IGHV4-30-4,IGHJ6,CQSYDSSLSGSGVF,IGLV1-40,HL CV01-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRDRIFEFGATREALDFW,IGHV3-30,IGHJ1,CQSYDSSLSGYVF,IGLV1-40,HL CV01-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRDRIFEFGATREALDFW,IGHV3-30,IGHJ2,CQSYDSSLSGYVF,IGLV1-40,HL CV01-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRDRIFEFGATREALDFW,IGHV3-30,IGHJ3,CQSYDSSLSGYVF,IGLV1-40,HL CV01-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRDRIFEFGATREALDFW,IGHV3-30,IGHJ4,CQSYDSSLSGYVF,IGLV1-40,HL CV01-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRDRIFEFGATREALDFW,IGHV3-30,IGHJ5,CQSYDSSLSGYVF,IGLV1-40,HL CV01-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRDRIFEFGATREALDFW,IGHV3-30,IGHJ6,CQSYDSSLSGYVF,IGLV1-40,HL CV01-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTWTTTGDSW,IGHV3-23,IGHJ1,CQQYNSYPWTF,IGKV1-5,HK CV01-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTWTTTGDSW,IGHV3-23,IGHJ2,CQQYNSYPWTF,IGKV1-5,HK CV01-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTWTTTGDSW,IGHV3-23,IGHJ3,CQQYNSYPWTF,IGKV1-5,HK CV01-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTWTTTGDSW,IGHV3-23,IGHJ4,CQQYNSYPWTF,IGKV1-5,HK CV01-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTWTTTGDSW,IGHV3-23,IGHJ5,CQQYNSYPWTF,IGKV1-5,HK CV01-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTWTTTGDSW,IGHV3-23,IGHJ6,CQQYNSYPWTF,IGKV1-5,HK CV01-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ1,CMQGTQWPWTF,IGKV2-30,HK CV01-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ2,CMQGTQWPWTF,IGKV2-30,HK CV01-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ3,CMQGTQWPWTF,IGKV2-30,HK CV01-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ4,CMQGTQWPWTF,IGKV2-30,HK CV01-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ5,CMQGTQWPWTF,IGKV2-30,HK CV01-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ6,CMQGTQWPWTF,IGKV2-30,HK CV01-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERVNGRWLQLLTPW,IGHV3-30-3,IGHJ1,CQQYDAYLSF,IGKV1-5,HK CV01-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERVNGRWLQLLTPW,IGHV3-30-3,IGHJ2,CQQYDAYLSF,IGKV1-5,HK CV01-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERVNGRWLQLLTPW,IGHV3-30-3,IGHJ3,CQQYDAYLSF,IGKV1-5,HK CV01-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERVNGRWLQLLTPW,IGHV3-30-3,IGHJ4,CQQYDAYLSF,IGKV1-5,HK CV01-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERVNGRWLQLLTPW,IGHV3-30-3,IGHJ5,CQQYDAYLSF,IGKV1-5,HK CV01-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERVNGRWLQLLTPW,IGHV3-30-3,IGHJ6,CQQYDAYLSF,IGKV1-5,HK CV01-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDRGAVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYPRYNWNYDNRYYFDFW,IGHV1-18,IGHJ1,CQQSYSAPITF,IGKV1-39,HK CV01-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYPRYNWNYDNRYYFDFW,IGHV1-18,IGHJ2,CQQSYSAPITF,IGKV1-39,HK CV01-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYPRYNWNYDNRYYFDFW,IGHV1-18,IGHJ3,CQQSYSAPITF,IGKV1-39,HK CV01-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYPRYNWNYDNRYYFDFW,IGHV1-18,IGHJ4,CQQSYSAPITF,IGKV1-39,HK CV01-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYPRYNWNYDNRYYFDFW,IGHV1-18,IGHJ5,CQQSYSAPITF,IGKV1-39,HK CV01-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYPRYNWNYDNRYYFDFW,IGHV1-18,IGHJ6,CQQSYSAPITF,IGKV1-39,HK CV01-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ1,CSSYAGSNNVVF,IGLV2-8,HL CV01-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ2,CSSYAGSNNVVF,IGLV2-8,HL CV01-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ3,CSSYAGSNNVVF,IGLV2-8,HL CV01-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ4,CSSYAGSNNVVF,IGLV2-8,HL CV01-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ5,CSSYAGSNNVVF,IGLV2-8,HL CV01-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADDTMVQGVIPNFDYW,IGHV1-18,IGHJ6,CSSYAGSNNVVF,IGLV2-8,HL CV01-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVGATIPYYYYYYMDVW,IGHV1-3,IGHJ1,CQQYNSYSWTF,IGKV1-5,HK CV01-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVGATIPYYYYYYMDVW,IGHV1-3,IGHJ2,CQQYNSYSWTF,IGKV1-5,HK CV01-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVGATIPYYYYYYMDVW,IGHV1-3,IGHJ3,CQQYNSYSWTF,IGKV1-5,HK CV01-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVGATIPYYYYYYMDVW,IGHV1-3,IGHJ4,CQQYNSYSWTF,IGKV1-5,HK CV01-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVGATIPYYYYYYMDVW,IGHV1-3,IGHJ5,CQQYNSYSWTF,IGKV1-5,HK CV01-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVGATIPYYYYYYMDVW,IGHV1-3,IGHJ6,CQQYNSYSWTF,IGKV1-5,HK CV01-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGGGNADHGPGYYYYYMDVW,IGHV4-4,IGHJ1,CQELNRYPRTF,IGKV1-9,HK CV01-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGGGNADHGPGYYYYYMDVW,IGHV4-4,IGHJ2,CQELNRYPRTF,IGKV1-9,HK CV01-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGGGNADHGPGYYYYYMDVW,IGHV4-4,IGHJ3,CQELNRYPRTF,IGKV1-9,HK CV01-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGGGNADHGPGYYYYYMDVW,IGHV4-4,IGHJ4,CQELNRYPRTF,IGKV1-9,HK CV01-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGGGNADHGPGYYYYYMDVW,IGHV4-4,IGHJ5,CQELNRYPRTF,IGKV1-9,HK CV01-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGGGNADHGPGYYYYYMDVW,IGHV4-4,IGHJ6,CQELNRYPRTF,IGKV1-9,HK CV01-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSASCADDLCYFDIW,IGHV3-9,IGHJ1,CQQYYSGPRTF,IGKV4-1,HK CV01-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSASCADDLCYFDIW,IGHV3-9,IGHJ2,CQQYYSGPRTF,IGKV4-1,HK CV01-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSASCADDLCYFDIW,IGHV3-9,IGHJ3,CQQYYSGPRTF,IGKV4-1,HK CV01-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSASCADDLCYFDIW,IGHV3-9,IGHJ4,CQQYYSGPRTF,IGKV4-1,HK CV01-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSASCADDLCYFDIW,IGHV3-9,IGHJ5,CQQYYSGPRTF,IGKV4-1,HK CV01-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKNSASCADDLCYFDIW,IGHV3-9,IGHJ6,CQQYYSGPRTF,IGKV4-1,HK CV01-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALPGGITIFGVVITEYYFDYW,IGHV3-11,IGHJ1,CQQYGSSSYTF,IGKV3-20,HK CV01-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALPGGITIFGVVITEYYFDYW,IGHV3-11,IGHJ2,CQQYGSSSYTF,IGKV3-20,HK CV01-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALPGGITIFGVVITEYYFDYW,IGHV3-11,IGHJ3,CQQYGSSSYTF,IGKV3-20,HK CV01-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALPGGITIFGVVITEYYFDYW,IGHV3-11,IGHJ4,CQQYGSSSYTF,IGKV3-20,HK CV01-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALPGGITIFGVVITEYYFDYW,IGHV3-11,IGHJ5,CQQYGSSSYTF,IGKV3-20,HK CV01-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALPGGITIFGVVITEYYFDYW,IGHV3-11,IGHJ6,CQQYGSSSYTF,IGKV3-20,HK CV01-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDDYGEYTGAFDAW,IGHV3-21,IGHJ1,CQAWDSSTVVF,IGLV3-1,HL CV01-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDDYGEYTGAFDAW,IGHV3-21,IGHJ2,CQAWDSSTVVF,IGLV3-1,HL CV01-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDDYGEYTGAFDAW,IGHV3-21,IGHJ3,CQAWDSSTVVF,IGLV3-1,HL CV01-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDDYGEYTGAFDAW,IGHV3-21,IGHJ4,CQAWDSSTVVF,IGLV3-1,HL CV01-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDDYGEYTGAFDAW,IGHV3-21,IGHJ5,CQAWDSSTVVF,IGLV3-1,HL CV01-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDDYGEYTGAFDAW,IGHV3-21,IGHJ6,CQAWDSSTVVF,IGLV3-1,HL CV01-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGETQQRLVWDQKTDDW,IGHV1-46,IGHJ1,CLQYNSYPLTF,IGKV1-17,HK CV01-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGETQQRLVWDQKTDDW,IGHV1-46,IGHJ2,CLQYNSYPLTF,IGKV1-17,HK CV01-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGETQQRLVWDQKTDDW,IGHV1-46,IGHJ3,CLQYNSYPLTF,IGKV1-17,HK CV01-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGETQQRLVWDQKTDDW,IGHV1-46,IGHJ4,CLQYNSYPLTF,IGKV1-17,HK CV01-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGETQQRLVWDQKTDDW,IGHV1-46,IGHJ5,CLQYNSYPLTF,IGKV1-17,HK CV01-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGETQQRLVWDQKTDDW,IGHV1-46,IGHJ6,CLQYNSYPLTF,IGKV1-17,HK CV01-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGTVDYW,IGHV3-7,IGHJ1,CMQGTHWPWTF,IGKV2-30,HK CV01-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGTVDYW,IGHV3-7,IGHJ2,CMQGTHWPWTF,IGKV2-30,HK CV01-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGTVDYW,IGHV3-7,IGHJ3,CMQGTHWPWTF,IGKV2-30,HK CV01-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGTVDYW,IGHV3-7,IGHJ4,CMQGTHWPWTF,IGKV2-30,HK CV01-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGTVDYW,IGHV3-7,IGHJ5,CMQGTHWPWTF,IGKV2-30,HK CV01-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGSVGTVDYW,IGHV3-7,IGHJ6,CMQGTHWPWTF,IGKV2-30,HK CV01-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTEKGRYHLGGVFANW,IGHV3-15,IGHJ1,CQQYYSTPLTF,IGKV4-1,HK CV01-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTEKGRYHLGGVFANW,IGHV3-15,IGHJ2,CQQYYSTPLTF,IGKV4-1,HK CV01-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTEKGRYHLGGVFANW,IGHV3-15,IGHJ3,CQQYYSTPLTF,IGKV4-1,HK CV01-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTEKGRYHLGGVFANW,IGHV3-15,IGHJ4,CQQYYSTPLTF,IGKV4-1,HK CV01-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTEKGRYHLGGVFANW,IGHV3-15,IGHJ5,CQQYYSTPLTF,IGKV4-1,HK CV01-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTEKGRYHLGGVFANW,IGHV3-15,IGHJ6,CQQYYSTPLTF,IGKV4-1,HK CV01-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVWTSRGYFDHW,IGHV5-51,IGHJ1,CLFYYGGAWVF,IGLV7-43,HL CV01-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVWTSRGYFDHW,IGHV5-51,IGHJ2,CLFYYGGAWVF,IGLV7-43,HL CV01-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVWTSRGYFDHW,IGHV5-51,IGHJ3,CLFYYGGAWVF,IGLV7-43,HL CV01-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVWTSRGYFDHW,IGHV5-51,IGHJ4,CLFYYGGAWVF,IGLV7-43,HL CV01-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVWTSRGYFDHW,IGHV5-51,IGHJ5,CLFYYGGAWVF,IGLV7-43,HL CV01-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVWTSRGYFDHW,IGHV5-51,IGHJ6,CLFYYGGAWVF,IGLV7-43,HL CV01-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSGWSLDSW,IGHV3-30,IGHJ1,CSSYTSSNTWVF,IGLV2-14,HL CV01-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSGWSLDSW,IGHV3-30,IGHJ2,CSSYTSSNTWVF,IGLV2-14,HL CV01-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSGWSLDSW,IGHV3-30,IGHJ3,CSSYTSSNTWVF,IGLV2-14,HL CV01-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSGWSLDSW,IGHV3-30,IGHJ4,CSSYTSSNTWVF,IGLV2-14,HL CV01-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSGWSLDSW,IGHV3-30,IGHJ5,CSSYTSSNTWVF,IGLV2-14,HL CV01-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSGWSLDSW,IGHV3-30,IGHJ6,CSSYTSSNTWVF,IGLV2-14,HL CV01-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYCSSTSCYGYYYYGMDVW,IGHV4-4,IGHJ1,CSSYAGSISYVF,IGLV2-8,HL CV01-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYCSSTSCYGYYYYGMDVW,IGHV4-4,IGHJ2,CSSYAGSISYVF,IGLV2-8,HL CV01-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYCSSTSCYGYYYYGMDVW,IGHV4-4,IGHJ3,CSSYAGSISYVF,IGLV2-8,HL CV01-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYCSSTSCYGYYYYGMDVW,IGHV4-4,IGHJ4,CSSYAGSISYVF,IGLV2-8,HL CV01-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYCSSTSCYGYYYYGMDVW,IGHV4-4,IGHJ5,CSSYAGSISYVF,IGLV2-8,HL CV01-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYCSSTSCYGYYYYGMDVW,IGHV4-4,IGHJ6,CSSYAGSISYVF,IGLV2-8,HL CV01-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGSGWYYDAFDIW,IGHV4-4,IGHJ1,CQQYNNWLRTF,IGKV3-15,HK CV01-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGSGWYYDAFDIW,IGHV4-4,IGHJ2,CQQYNNWLRTF,IGKV3-15,HK CV01-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGSGWYYDAFDIW,IGHV4-4,IGHJ3,CQQYNNWLRTF,IGKV3-15,HK CV01-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGSGWYYDAFDIW,IGHV4-4,IGHJ4,CQQYNNWLRTF,IGKV3-15,HK CV01-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGSGWYYDAFDIW,IGHV4-4,IGHJ5,CQQYNNWLRTF,IGKV3-15,HK CV01-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGSGWYYDAFDIW,IGHV4-4,IGHJ6,CQQYNNWLRTF,IGKV3-15,HK CV01-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDDWNYARGNFDYW,IGHV1-18,IGHJ1,CSSYTSSSSVVF,IGLV2-14,HL CV01-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDDWNYARGNFDYW,IGHV1-18,IGHJ2,CSSYTSSSSVVF,IGLV2-14,HL CV01-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDDWNYARGNFDYW,IGHV1-18,IGHJ3,CSSYTSSSSVVF,IGLV2-14,HL CV01-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDDWNYARGNFDYW,IGHV1-18,IGHJ4,CSSYTSSSSVVF,IGLV2-14,HL CV01-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDDWNYARGNFDYW,IGHV1-18,IGHJ5,CSSYTSSSSVVF,IGLV2-14,HL CV01-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDDWNYARGNFDYW,IGHV1-18,IGHJ6,CSSYTSSSSVVF,IGLV2-14,HL CV01-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGGVGTVDYW,IGHV3-7,IGHJ1,CMQGTLWPWTF,IGKV2-30,HK CV01-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGGVGTVDYW,IGHV3-7,IGHJ2,CMQGTLWPWTF,IGKV2-30,HK CV01-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGGVGTVDYW,IGHV3-7,IGHJ3,CMQGTLWPWTF,IGKV2-30,HK CV01-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGGVGTVDYW,IGHV3-7,IGHJ4,CMQGTLWPWTF,IGKV2-30,HK CV01-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGGVGTVDYW,IGHV3-7,IGHJ5,CMQGTLWPWTF,IGKV2-30,HK CV01-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGGVGTVDYW,IGHV3-7,IGHJ6,CMQGTLWPWTF,IGKV2-30,HK CV01-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADHTMVQGVIPNFDYW,IGHV1-18,IGHJ1,CSSYTGRKNVVF,IGKV2-28,HL CV01-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADHTMVQGVIPNFDYW,IGHV1-18,IGHJ2,CSSYTGRKNVVF,IGKV2-28,HL CV01-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADHTMVQGVIPNFDYW,IGHV1-18,IGHJ3,CSSYTGRKNVVF,IGKV2-28,HL CV01-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADHTMVQGVIPNFDYW,IGHV1-18,IGHJ4,CSSYTGRKNVVF,IGKV2-28,HL CV01-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADHTMVQGVIPNFDYW,IGHV1-18,IGHJ5,CSSYTGRKNVVF,IGKV2-28,HL CV01-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARADHTMVQGVIPNFDYW,IGHV1-18,IGHJ6,CSSYTGRKNVVF,IGKV2-28,HL CV01-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCDMAGTTDYW,IGHV3-7,IGHJ1,CMQGTLWPWTF,IGKV2-30,HK CV01-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCDMAGTTDYW,IGHV3-7,IGHJ2,CMQGTLWPWTF,IGKV2-30,HK CV01-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCDMAGTTDYW,IGHV3-7,IGHJ3,CMQGTLWPWTF,IGKV2-30,HK CV01-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCDMAGTTDYW,IGHV3-7,IGHJ4,CMQGTLWPWTF,IGKV2-30,HK CV01-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCDMAGTTDYW,IGHV3-7,IGHJ5,CMQGTLWPWTF,IGKV2-30,HK CV01-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCDMAGTTDYW,IGHV3-7,IGHJ6,CMQGTLWPWTF,IGKV2-30,HK CV01-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLEGVETIFGVVIIPAYWYFDLW,IGHV3-21,IGHJ1,CMQALQTRLTF,IGKV2-28,HK CV01-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLEGVETIFGVVIIPAYWYFDLW,IGHV3-21,IGHJ2,CMQALQTRLTF,IGKV2-28,HK CV01-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLEGVETIFGVVIIPAYWYFDLW,IGHV3-21,IGHJ3,CMQALQTRLTF,IGKV2-28,HK CV01-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLEGVETIFGVVIIPAYWYFDLW,IGHV3-21,IGHJ4,CMQALQTRLTF,IGKV2-28,HK CV01-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLEGVETIFGVVIIPAYWYFDLW,IGHV3-21,IGHJ5,CMQALQTRLTF,IGKV2-28,HK CV01-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLEGVETIFGVVIIPAYWYFDLW,IGHV3-21,IGHJ6,CMQALQTRLTF,IGKV2-28,HK CV01-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDLKIGTLGWYYDFWSGYLPDPSNKIFDYW,IGHV3-23,IGHJ1,CQSYDSSLSGWVF,IGLV1-40,HL CV01-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDLKIGTLGWYYDFWSGYLPDPSNKIFDYW,IGHV3-23,IGHJ2,CQSYDSSLSGWVF,IGLV1-40,HL CV01-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDLKIGTLGWYYDFWSGYLPDPSNKIFDYW,IGHV3-23,IGHJ3,CQSYDSSLSGWVF,IGLV1-40,HL CV01-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDLKIGTLGWYYDFWSGYLPDPSNKIFDYW,IGHV3-23,IGHJ4,CQSYDSSLSGWVF,IGLV1-40,HL CV01-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDLKIGTLGWYYDFWSGYLPDPSNKIFDYW,IGHV3-23,IGHJ5,CQSYDSSLSGWVF,IGLV1-40,HL CV01-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDLKIGTLGWYYDFWSGYLPDPSNKIFDYW,IGHV3-23,IGHJ6,CQSYDSSLSGWVF,IGLV1-40,HL CV01-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRVNPIQGAFYDALDIW,IGHV3-73,IGHJ1,CGTWDSSLSVVVF,IGLV1-51,HL CV01-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRVNPIQGAFYDALDIW,IGHV3-73,IGHJ2,CGTWDSSLSVVVF,IGLV1-51,HL CV01-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRVNPIQGAFYDALDIW,IGHV3-73,IGHJ3,CGTWDSSLSVVVF,IGLV1-51,HL CV01-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRVNPIQGAFYDALDIW,IGHV3-73,IGHJ4,CGTWDSSLSVVVF,IGLV1-51,HL CV01-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRVNPIQGAFYDALDIW,IGHV3-73,IGHJ5,CGTWDSSLSVVVF,IGLV1-51,HL CV01-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRVNPIQGAFYDALDIW,IGHV3-73,IGHJ6,CGTWDSSLSVVVF,IGLV1-51,HL CV01-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSSAAGVWALDHW,IGHV4-59,IGHJ1,CQQYYTTPFTF,IGKV4-1,HK CV01-184,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSSAAGVWALDHW,IGHV4-59,IGHJ2,CQQYYTTPFTF,IGKV4-1,HK CV01-184,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSSAAGVWALDHW,IGHV4-59,IGHJ3,CQQYYTTPFTF,IGKV4-1,HK CV01-184,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSSAAGVWALDHW,IGHV4-59,IGHJ4,CQQYYTTPFTF,IGKV4-1,HK CV01-184,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSSAAGVWALDHW,IGHV4-59,IGHJ5,CQQYYTTPFTF,IGKV4-1,HK CV01-184,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSSAAGVWALDHW,IGHV4-59,IGHJ6,CQQYYTTPFTF,IGKV4-1,HK CV01-184,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CACDMVQGVAVLDVW,IGHV1-69,IGHJ1,CSSYTSSSTVVF,IGLV2-14,HL CV01-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CACDMVQGVAVLDVW,IGHV1-69,IGHJ2,CSSYTSSSTVVF,IGLV2-14,HL CV01-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CACDMVQGVAVLDVW,IGHV1-69,IGHJ3,CSSYTSSSTVVF,IGLV2-14,HL CV01-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CACDMVQGVAVLDVW,IGHV1-69,IGHJ4,CSSYTSSSTVVF,IGLV2-14,HL CV01-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CACDMVQGVAVLDVW,IGHV1-69,IGHJ5,CSSYTSSSTVVF,IGLV2-14,HL CV01-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CACDMVQGVAVLDVW,IGHV1-69,IGHJ6,CSSYTSSSTVVF,IGLV2-14,HL CV01-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGKSIPYSNYDWFDPW,IGHV4-59,IGHJ1,CQQSYSTLPFTF,IGKV1-39,HK CV01-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGKSIPYSNYDWFDPW,IGHV4-59,IGHJ2,CQQSYSTLPFTF,IGKV1-39,HK CV01-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGKSIPYSNYDWFDPW,IGHV4-59,IGHJ3,CQQSYSTLPFTF,IGKV1-39,HK CV01-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGKSIPYSNYDWFDPW,IGHV4-59,IGHJ4,CQQSYSTLPFTF,IGKV1-39,HK CV01-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGKSIPYSNYDWFDPW,IGHV4-59,IGHJ5,CQQSYSTLPFTF,IGKV1-39,HK CV01-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHGKSIPYSNYDWFDPW,IGHV4-59,IGHJ6,CQQSYSTLPFTF,IGKV1-39,HK CV01-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGANGDRFGNW,IGHV3-72,IGHJ1,CQQYYSTPLTF,IGKV4-1,HK CV01-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGANGDRFGNW,IGHV3-72,IGHJ2,CQQYYSTPLTF,IGKV4-1,HK CV01-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGANGDRFGNW,IGHV3-72,IGHJ3,CQQYYSTPLTF,IGKV4-1,HK CV01-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGANGDRFGNW,IGHV3-72,IGHJ4,CQQYYSTPLTF,IGKV4-1,HK CV01-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGANGDRFGNW,IGHV3-72,IGHJ5,CQQYYSTPLTF,IGKV4-1,HK CV01-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGANGDRFGNW,IGHV3-72,IGHJ6,CQQYYSTPLTF,IGKV4-1,HK CV01-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDLGDYGDYMRSW,IGHV3-15,IGHJ1,CQQANSFPYTF,IGKV1-12,HK CV01-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDLGDYGDYMRSW,IGHV3-15,IGHJ2,CQQANSFPYTF,IGKV1-12,HK CV01-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDLGDYGDYMRSW,IGHV3-15,IGHJ3,CQQANSFPYTF,IGKV1-12,HK CV01-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDLGDYGDYMRSW,IGHV3-15,IGHJ4,CQQANSFPYTF,IGKV1-12,HK CV01-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDLGDYGDYMRSW,IGHV3-15,IGHJ5,CQQANSFPYTF,IGKV1-12,HK CV01-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDLGDYGDYMRSW,IGHV3-15,IGHJ6,CQQANSFPYTF,IGKV1-12,HK CV01-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKADPHSAFDYW,IGHV4-59,IGHJ1,CCSYAGSYTYVF,IGLV2-11,HL CV01-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKADPHSAFDYW,IGHV4-59,IGHJ2,CCSYAGSYTYVF,IGLV2-11,HL CV01-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKADPHSAFDYW,IGHV4-59,IGHJ3,CCSYAGSYTYVF,IGLV2-11,HL CV01-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKADPHSAFDYW,IGHV4-59,IGHJ4,CCSYAGSYTYVF,IGLV2-11,HL CV01-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKADPHSAFDYW,IGHV4-59,IGHJ5,CCSYAGSYTYVF,IGLV2-11,HL CV01-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKADPHSAFDYW,IGHV4-59,IGHJ6,CCSYAGSYTYVF,IGLV2-11,HL CV01-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRELVVGRAEYFQDW,IGHV3-7,IGHJ1,CAAWDDSLNGRVF,IGLV1-44,HL CV01-195,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRELVVGRAEYFQDW,IGHV3-7,IGHJ2,CAAWDDSLNGRVF,IGLV1-44,HL CV01-195,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRELVVGRAEYFQDW,IGHV3-7,IGHJ3,CAAWDDSLNGRVF,IGLV1-44,HL CV01-195,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRELVVGRAEYFQDW,IGHV3-7,IGHJ4,CAAWDDSLNGRVF,IGLV1-44,HL CV01-195,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRELVVGRAEYFQDW,IGHV3-7,IGHJ5,CAAWDDSLNGRVF,IGLV1-44,HL CV01-195,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRELVVGRAEYFQDW,IGHV3-7,IGHJ6,CAAWDDSLNGRVF,IGLV1-44,HL CV01-195,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPGMLYPSAFDMW,IGHV3-30,IGHJ1,CQQYNNWPPLTF,IGKV3-15,HK CV01-196,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPGMLYPSAFDMW,IGHV3-30,IGHJ2,CQQYNNWPPLTF,IGKV3-15,HK CV01-196,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPGMLYPSAFDMW,IGHV3-30,IGHJ3,CQQYNNWPPLTF,IGKV3-15,HK CV01-196,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPGMLYPSAFDMW,IGHV3-30,IGHJ4,CQQYNNWPPLTF,IGKV3-15,HK CV01-196,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPGMLYPSAFDMW,IGHV3-30,IGHJ5,CQQYNNWPPLTF,IGKV3-15,HK CV01-196,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPGMLYPSAFDMW,IGHV3-30,IGHJ6,CQQYNNWPPLTF,IGKV3-15,HK CV01-196,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQDGHYGGNPDMDHW,IGHV3-23,IGHJ1,CSSYAGSNKMVF,IGLV2-8,HL CV01-197,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQDGHYGGNPDMDHW,IGHV3-23,IGHJ2,CSSYAGSNKMVF,IGLV2-8,HL CV01-197,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQDGHYGGNPDMDHW,IGHV3-23,IGHJ3,CSSYAGSNKMVF,IGLV2-8,HL CV01-197,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQDGHYGGNPDMDHW,IGHV3-23,IGHJ4,CSSYAGSNKMVF,IGLV2-8,HL CV01-197,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQDGHYGGNPDMDHW,IGHV3-23,IGHJ5,CSSYAGSNKMVF,IGLV2-8,HL CV01-197,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQDGHYGGNPDMDHW,IGHV3-23,IGHJ6,CSSYAGSNKMVF,IGLV2-8,HL CV01-197,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLTYGYSPYW,IGHV3-15,IGHJ1,CSSYTSSTTYVF,IGLV2-14,HL CV01-198,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLTYGYSPYW,IGHV3-15,IGHJ2,CSSYTSSTTYVF,IGLV2-14,HL CV01-198,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLTYGYSPYW,IGHV3-15,IGHJ3,CSSYTSSTTYVF,IGLV2-14,HL CV01-198,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLTYGYSPYW,IGHV3-15,IGHJ4,CSSYTSSTTYVF,IGLV2-14,HL CV01-198,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLTYGYSPYW,IGHV3-15,IGHJ5,CSSYTSSTTYVF,IGLV2-14,HL CV01-198,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLTYGYSPYW,IGHV3-15,IGHJ6,CSSYTSSTTYVF,IGLV2-14,HL CV01-198,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASNFNRNDGYW,IGHV3-74,IGHJ1,CIQSTHWPPNF,IGKV2-30,HK CV01-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASNFNRNDGYW,IGHV3-74,IGHJ2,CIQSTHWPPNF,IGKV2-30,HK CV01-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASNFNRNDGYW,IGHV3-74,IGHJ3,CIQSTHWPPNF,IGKV2-30,HK CV01-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASNFNRNDGYW,IGHV3-74,IGHJ4,CIQSTHWPPNF,IGKV2-30,HK CV01-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASNFNRNDGYW,IGHV3-74,IGHJ5,CIQSTHWPPNF,IGKV2-30,HK CV01-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASNFNRNDGYW,IGHV3-74,IGHJ6,CIQSTHWPPNF,IGKV2-30,HK CV01-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMGNMFGYSVVDFW,IGHV4-30-4,IGHJ1,CLQTYSAPYTF,IGKV1-39,HK CV01-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMGNMFGYSVVDFW,IGHV4-30-4,IGHJ2,CLQTYSAPYTF,IGKV1-39,HK CV01-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMGNMFGYSVVDFW,IGHV4-30-4,IGHJ3,CLQTYSAPYTF,IGKV1-39,HK CV01-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMGNMFGYSVVDFW,IGHV4-30-4,IGHJ4,CLQTYSAPYTF,IGKV1-39,HK CV01-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMGNMFGYSVVDFW,IGHV4-30-4,IGHJ5,CLQTYSAPYTF,IGKV1-39,HK CV01-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMGNMFGYSVVDFW,IGHV4-30-4,IGHJ6,CLQTYSAPYTF,IGKV1-39,HK CV01-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSEGKFYFYGVDVW,IGHV3-30,IGHJ1,CAACDDSLSGHVF,IGLV1-47,HL CV01-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSEGKFYFYGVDVW,IGHV3-30,IGHJ2,CAACDDSLSGHVF,IGLV1-47,HL CV01-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSEGKFYFYGVDVW,IGHV3-30,IGHJ3,CAACDDSLSGHVF,IGLV1-47,HL CV01-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSEGKFYFYGVDVW,IGHV3-30,IGHJ4,CAACDDSLSGHVF,IGLV1-47,HL CV01-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSEGKFYFYGVDVW,IGHV3-30,IGHJ5,CAACDDSLSGHVF,IGLV1-47,HL CV01-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSEGKFYFYGVDVW,IGHV3-30,IGHJ6,CAACDDSLSGHVF,IGLV1-47,HL CV01-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREARWSFPSWFDPW,IGHV5-51,IGHJ1,CQQYNNWPRFF,IGKV3-15,HK CV01-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREARWSFPSWFDPW,IGHV5-51,IGHJ2,CQQYNNWPRFF,IGKV3-15,HK CV01-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREARWSFPSWFDPW,IGHV5-51,IGHJ3,CQQYNNWPRFF,IGKV3-15,HK CV01-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREARWSFPSWFDPW,IGHV5-51,IGHJ4,CQQYNNWPRFF,IGKV3-15,HK CV01-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREARWSFPSWFDPW,IGHV5-51,IGHJ5,CQQYNNWPRFF,IGKV3-15,HK CV01-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREARWSFPSWFDPW,IGHV5-51,IGHJ6,CQQYNNWPRFF,IGKV3-15,HK CV01-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSSGWYGGFNFDYW,IGHV5-51,IGHJ1,CQQYGSSPVYTF,IGKV3-20,HK CV01-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSSGWYGGFNFDYW,IGHV5-51,IGHJ2,CQQYGSSPVYTF,IGKV3-20,HK CV01-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSSGWYGGFNFDYW,IGHV5-51,IGHJ3,CQQYGSSPVYTF,IGKV3-20,HK CV01-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSSGWYGGFNFDYW,IGHV5-51,IGHJ4,CQQYGSSPVYTF,IGKV3-20,HK CV01-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSSGWYGGFNFDYW,IGHV5-51,IGHJ5,CQQYGSSPVYTF,IGKV3-20,HK CV01-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSSGWYGGFNFDYW,IGHV5-51,IGHJ6,CQQYGSSPVYTF,IGKV3-20,HK CV01-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCSYTSICKGWDGAHW,IGHV3-30,IGHJ1,CSSFTTSYTLVF,IGLV2-14,HL CV01-212,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCSYTSICKGWDGAHW,IGHV3-30,IGHJ2,CSSFTTSYTLVF,IGLV2-14,HL CV01-212,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCSYTSICKGWDGAHW,IGHV3-30,IGHJ3,CSSFTTSYTLVF,IGLV2-14,HL CV01-212,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCSYTSICKGWDGAHW,IGHV3-30,IGHJ4,CSSFTTSYTLVF,IGLV2-14,HL CV01-212,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCSYTSICKGWDGAHW,IGHV3-30,IGHJ5,CSSFTTSYTLVF,IGLV2-14,HL CV01-212,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCSYTSICKGWDGAHW,IGHV3-30,IGHJ6,CSSFTTSYTLVF,IGLV2-14,HL CV01-212,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLQGTGYLDYW,IGHV3-64,IGHJ1,CHQYGSSPRTF,IGKV3-20,HK CV01-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLQGTGYLDYW,IGHV3-64,IGHJ2,CHQYGSSPRTF,IGKV3-20,HK CV01-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLQGTGYLDYW,IGHV3-64,IGHJ3,CHQYGSSPRTF,IGKV3-20,HK CV01-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLQGTGYLDYW,IGHV3-64,IGHJ4,CHQYGSSPRTF,IGKV3-20,HK CV01-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLQGTGYLDYW,IGHV3-64,IGHJ5,CHQYGSSPRTF,IGKV3-20,HK CV01-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLQGTGYLDYW,IGHV3-64,IGHJ6,CHQYGSSPRTF,IGKV3-20,HK CV01-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQWAVNWFVPW,IGHV3-48,IGHJ1,CSSHTSSSTVVF,IGLV2-14,HL CV01-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQWAVNWFVPW,IGHV3-48,IGHJ2,CSSHTSSSTVVF,IGLV2-14,HL CV01-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQWAVNWFVPW,IGHV3-48,IGHJ3,CSSHTSSSTVVF,IGLV2-14,HL CV01-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQWAVNWFVPW,IGHV3-48,IGHJ4,CSSHTSSSTVVF,IGLV2-14,HL CV01-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQWAVNWFVPW,IGHV3-48,IGHJ5,CSSHTSSSTVVF,IGLV2-14,HL CV01-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQWAVNWFVPW,IGHV3-48,IGHJ6,CSSHTSSSTVVF,IGLV2-14,HL CV01-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVGTYESTSTGMDVW,IGHV3-48,IGHJ1,CQQRGNWPPATF,IGKV3-11,HK CV01-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVGTYESTSTGMDVW,IGHV3-48,IGHJ2,CQQRGNWPPATF,IGKV3-11,HK CV01-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVGTYESTSTGMDVW,IGHV3-48,IGHJ3,CQQRGNWPPATF,IGKV3-11,HK CV01-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVGTYESTSTGMDVW,IGHV3-48,IGHJ4,CQQRGNWPPATF,IGKV3-11,HK CV01-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVGTYESTSTGMDVW,IGHV3-48,IGHJ5,CQQRGNWPPATF,IGKV3-11,HK CV01-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVGTYESTSTGMDVW,IGHV3-48,IGHJ6,CQQRGNWPPATF,IGKV3-11,HK CV01-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPVDYW,IGHV3-30-3,IGHJ1,,IGLV2-8,HL CV01-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPVDYW,IGHV3-30-3,IGHJ2,,IGLV2-8,HL CV01-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPVDYW,IGHV3-30-3,IGHJ3,,IGLV2-8,HL CV01-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPVDYW,IGHV3-30-3,IGHJ4,,IGLV2-8,HL CV01-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPVDYW,IGHV3-30-3,IGHJ5,,IGLV2-8,HL CV01-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPVDYW,IGHV3-30-3,IGHJ6,,IGLV2-8,HL CV01-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPGGEWYSSGWRFDYW,IGHV3-23,IGHJ1,CAAWDDSLSGPVF,IGLV1-47,HL CV01-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPGGEWYSSGWRFDYW,IGHV3-23,IGHJ2,CAAWDDSLSGPVF,IGLV1-47,HL CV01-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPGGEWYSSGWRFDYW,IGHV3-23,IGHJ3,CAAWDDSLSGPVF,IGLV1-47,HL CV01-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPGGEWYSSGWRFDYW,IGHV3-23,IGHJ4,CAAWDDSLSGPVF,IGLV1-47,HL CV01-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPGGEWYSSGWRFDYW,IGHV3-23,IGHJ5,CAAWDDSLSGPVF,IGLV1-47,HL CV01-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPGGEWYSSGWRFDYW,IGHV3-23,IGHJ6,CAAWDDSLSGPVF,IGLV1-47,HL CV01-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCGRTSCRVDAFDIW,IGHV3-23,IGHJ1,CVLSMGGGVWVF,IGLV8-61,HL CV01-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCGRTSCRVDAFDIW,IGHV3-23,IGHJ2,CVLSMGGGVWVF,IGLV8-61,HL CV01-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCGRTSCRVDAFDIW,IGHV3-23,IGHJ3,CVLSMGGGVWVF,IGLV8-61,HL CV01-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCGRTSCRVDAFDIW,IGHV3-23,IGHJ4,CVLSMGGGVWVF,IGLV8-61,HL CV01-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCGRTSCRVDAFDIW,IGHV3-23,IGHJ5,CVLSMGGGVWVF,IGLV8-61,HL CV01-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKCGRTSCRVDAFDIW,IGHV3-23,IGHJ6,CVLSMGGGVWVF,IGLV8-61,HL CV01-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGGGSYPHRAFDIW,IGHV3-53,IGHJ1,CSSYTSSSTSDVVF,IGLV2-14,HL CV01-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGGGSYPHRAFDIW,IGHV3-53,IGHJ2,CSSYTSSSTSDVVF,IGLV2-14,HL CV01-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGGGSYPHRAFDIW,IGHV3-53,IGHJ3,CSSYTSSSTSDVVF,IGLV2-14,HL CV01-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGGGSYPHRAFDIW,IGHV3-53,IGHJ4,CSSYTSSSTSDVVF,IGLV2-14,HL CV01-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGGGSYPHRAFDIW,IGHV3-53,IGHJ5,CSSYTSSSTSDVVF,IGLV2-14,HL CV01-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGGGSYPHRAFDIW,IGHV3-53,IGHJ6,CSSYTSSSTSDVVF,IGLV2-14,HL CV01-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHATGTPPYYYYYMDVW,IGHV4-39,IGHJ1,CQAWDSSTACVF,IGLV3-1,HL CV01-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHATGTPPYYYYYMDVW,IGHV4-39,IGHJ2,CQAWDSSTACVF,IGLV3-1,HL CV01-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHATGTPPYYYYYMDVW,IGHV4-39,IGHJ3,CQAWDSSTACVF,IGLV3-1,HL CV01-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHATGTPPYYYYYMDVW,IGHV4-39,IGHJ4,CQAWDSSTACVF,IGLV3-1,HL CV01-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHATGTPPYYYYYMDVW,IGHV4-39,IGHJ5,CQAWDSSTACVF,IGLV3-1,HL CV01-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHATGTPPYYYYYMDVW,IGHV4-39,IGHJ6,CQAWDSSTACVF,IGLV3-1,HL CV01-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGSPLLGFGGVDYW,IGHV3-30,IGHJ1,CAIWYSSSLVF,IGLV5-39,HL CV01-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGSPLLGFGGVDYW,IGHV3-30,IGHJ2,CAIWYSSSLVF,IGLV5-39,HL CV01-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGSPLLGFGGVDYW,IGHV3-30,IGHJ3,CAIWYSSSLVF,IGLV5-39,HL CV01-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGSPLLGFGGVDYW,IGHV3-30,IGHJ4,CAIWYSSSLVF,IGLV5-39,HL CV01-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGSPLLGFGGVDYW,IGHV3-30,IGHJ5,CAIWYSSSLVF,IGLV5-39,HL CV01-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGSPLLGFGGVDYW,IGHV3-30,IGHJ6,CAIWYSSSLVF,IGLV5-39,HL CV01-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGASDYDYVWGTRTLDSW,IGHV3-7,IGHJ1,CQQCLTTPPWTF,IGKV4-1,HK CV01-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGASDYDYVWGTRTLDSW,IGHV3-7,IGHJ2,CQQCLTTPPWTF,IGKV4-1,HK CV01-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGASDYDYVWGTRTLDSW,IGHV3-7,IGHJ3,CQQCLTTPPWTF,IGKV4-1,HK CV01-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGASDYDYVWGTRTLDSW,IGHV3-7,IGHJ4,CQQCLTTPPWTF,IGKV4-1,HK CV01-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGASDYDYVWGTRTLDSW,IGHV3-7,IGHJ5,CQQCLTTPPWTF,IGKV4-1,HK CV01-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGASDYDYVWGTRTLDSW,IGHV3-7,IGHJ6,CQQCLTTPPWTF,IGKV4-1,HK CV01-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPYGAGTAHYFDYW,IGHV5-51,IGHJ1,CQQYYGTPHTF,IGKV4-1,HK CV01-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPYGAGTAHYFDYW,IGHV5-51,IGHJ2,CQQYYGTPHTF,IGKV4-1,HK CV01-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPYGAGTAHYFDYW,IGHV5-51,IGHJ3,CQQYYGTPHTF,IGKV4-1,HK CV01-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPYGAGTAHYFDYW,IGHV5-51,IGHJ4,CQQYYGTPHTF,IGKV4-1,HK CV01-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPYGAGTAHYFDYW,IGHV5-51,IGHJ5,CQQYYGTPHTF,IGKV4-1,HK CV01-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARPYGAGTAHYFDYW,IGHV5-51,IGHJ6,CQQYYGTPHTF,IGKV4-1,HK CV01-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFHPGNYYYYYMDVW,IGHV4-39,IGHJ1,CQAWDSSTYVVF,IGLV3-1,HL CV01-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFHPGNYYYYYMDVW,IGHV4-39,IGHJ2,CQAWDSSTYVVF,IGLV3-1,HL CV01-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFHPGNYYYYYMDVW,IGHV4-39,IGHJ3,CQAWDSSTYVVF,IGLV3-1,HL CV01-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFHPGNYYYYYMDVW,IGHV4-39,IGHJ4,CQAWDSSTYVVF,IGLV3-1,HL CV01-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFHPGNYYYYYMDVW,IGHV4-39,IGHJ5,CQAWDSSTYVVF,IGLV3-1,HL CV01-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFHPGNYYYYYMDVW,IGHV4-39,IGHJ6,CQAWDSSTYVVF,IGLV3-1,HL CV01-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKYGDLHFDYW,IGHV4-39,IGHJ1,CVLYMGSGISVF,IGLV8-61,HL CV01-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKYGDLHFDYW,IGHV4-39,IGHJ2,CVLYMGSGISVF,IGLV8-61,HL CV01-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKYGDLHFDYW,IGHV4-39,IGHJ3,CVLYMGSGISVF,IGLV8-61,HL CV01-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKYGDLHFDYW,IGHV4-39,IGHJ4,CVLYMGSGISVF,IGLV8-61,HL CV01-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKYGDLHFDYW,IGHV4-39,IGHJ5,CVLYMGSGISVF,IGLV8-61,HL CV01-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKYGDLHFDYW,IGHV4-39,IGHJ6,CVLYMGSGISVF,IGLV8-61,HL CV01-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDARFLEWLFPDAFDIW,IGHV4-39,IGHJ1,CCSYAGSTTFVVF,IGLV2-23,HL CV01-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDARFLEWLFPDAFDIW,IGHV4-39,IGHJ2,CCSYAGSTTFVVF,IGLV2-23,HL CV01-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDARFLEWLFPDAFDIW,IGHV4-39,IGHJ3,CCSYAGSTTFVVF,IGLV2-23,HL CV01-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDARFLEWLFPDAFDIW,IGHV4-39,IGHJ4,CCSYAGSTTFVVF,IGLV2-23,HL CV01-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDARFLEWLFPDAFDIW,IGHV4-39,IGHJ5,CCSYAGSTTFVVF,IGLV2-23,HL CV01-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDARFLEWLFPDAFDIW,IGHV4-39,IGHJ6,CCSYAGSTTFVVF,IGLV2-23,HL CV01-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSPFGGIRSGLGPW,IGHV3-30,IGHJ1,CQKYNSAPWTF,IGKV1-27,HL CV01-234,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSPFGGIRSGLGPW,IGHV3-30,IGHJ2,CQKYNSAPWTF,IGKV1-27,HL CV01-234,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSPFGGIRSGLGPW,IGHV3-30,IGHJ3,CQKYNSAPWTF,IGKV1-27,HL CV01-234,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSPFGGIRSGLGPW,IGHV3-30,IGHJ4,CQKYNSAPWTF,IGKV1-27,HL CV01-234,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSPFGGIRSGLGPW,IGHV3-30,IGHJ5,CQKYNSAPWTF,IGKV1-27,HL CV01-234,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSPFGGIRSGLGPW,IGHV3-30,IGHJ6,CQKYNSAPWTF,IGKV1-27,HL CV01-234,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPTGSGSYQYYYYYIDVW,IGHV4-39,IGHJ1,CQAWDSSTVVF,IGLV3-1,HL CV01-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPTGSGSYQYYYYYIDVW,IGHV4-39,IGHJ2,CQAWDSSTVVF,IGLV3-1,HL CV01-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPTGSGSYQYYYYYIDVW,IGHV4-39,IGHJ3,CQAWDSSTVVF,IGLV3-1,HL CV01-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPTGSGSYQYYYYYIDVW,IGHV4-39,IGHJ4,CQAWDSSTVVF,IGLV3-1,HL CV01-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPTGSGSYQYYYYYIDVW,IGHV4-39,IGHJ5,CQAWDSSTVVF,IGLV3-1,HL CV01-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPTGSGSYQYYYYYIDVW,IGHV4-39,IGHJ6,CQAWDSSTVVF,IGLV3-1,HL CV01-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYDSSGYTAADAFDIW,IGHV3-66,IGHJ1,CQQYNSYSTF,IGKV1-5,HL CV01-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYDSSGYTAADAFDIW,IGHV3-66,IGHJ2,CQQYNSYSTF,IGKV1-5,HL CV01-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYDSSGYTAADAFDIW,IGHV3-66,IGHJ3,CQQYNSYSTF,IGKV1-5,HL CV01-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYDSSGYTAADAFDIW,IGHV3-66,IGHJ4,CQQYNSYSTF,IGKV1-5,HL CV01-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYDSSGYTAADAFDIW,IGHV3-66,IGHJ5,CQQYNSYSTF,IGKV1-5,HL CV01-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGYDSSGYTAADAFDIW,IGHV3-66,IGHJ6,CQQYNSYSTF,IGKV1-5,HL CV01-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYRNWFDPW,IGHV4-31,IGHJ1,CCSYAGSYTWVF,IGLV2-11,HL CV01-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYRNWFDPW,IGHV4-31,IGHJ2,CCSYAGSYTWVF,IGLV2-11,HL CV01-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYRNWFDPW,IGHV4-31,IGHJ3,CCSYAGSYTWVF,IGLV2-11,HL CV01-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYRNWFDPW,IGHV4-31,IGHJ4,CCSYAGSYTWVF,IGLV2-11,HL CV01-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYRNWFDPW,IGHV4-31,IGHJ5,CCSYAGSYTWVF,IGLV2-11,HL CV01-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYRNWFDPW,IGHV4-31,IGHJ6,CCSYAGSYTWVF,IGLV2-11,HL CV01-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLKGSVPPYYYNYMDVW,IGHV5-10-1,IGHJ1,CMQGLQTPFIF,IGKV2-28,HK CV01-244,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLKGSVPPYYYNYMDVW,IGHV5-10-1,IGHJ2,CMQGLQTPFIF,IGKV2-28,HK CV01-244,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLKGSVPPYYYNYMDVW,IGHV5-10-1,IGHJ3,CMQGLQTPFIF,IGKV2-28,HK CV01-244,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLKGSVPPYYYNYMDVW,IGHV5-10-1,IGHJ4,CMQGLQTPFIF,IGKV2-28,HK CV01-244,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLKGSVPPYYYNYMDVW,IGHV5-10-1,IGHJ5,CMQGLQTPFIF,IGKV2-28,HK CV01-244,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLKGSVPPYYYNYMDVW,IGHV5-10-1,IGHJ6,CMQGLQTPFIF,IGKV2-28,HK CV01-244,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHNRAQGPSFDVW,IGHV3-30-3,IGHJ1,CQQTYSVPTTF,IGKV1-39,HK CV01-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHNRAQGPSFDVW,IGHV3-30-3,IGHJ2,CQQTYSVPTTF,IGKV1-39,HK CV01-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHNRAQGPSFDVW,IGHV3-30-3,IGHJ3,CQQTYSVPTTF,IGKV1-39,HK CV01-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHNRAQGPSFDVW,IGHV3-30-3,IGHJ4,CQQTYSVPTTF,IGKV1-39,HK CV01-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHNRAQGPSFDVW,IGHV3-30-3,IGHJ5,CQQTYSVPTTF,IGKV1-39,HK CV01-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHNRAQGPSFDVW,IGHV3-30-3,IGHJ6,CQQTYSVPTTF,IGKV1-39,HK CV01-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLLGGTVVNDYW,IGHV3-7,IGHJ1,CQQYYSTQYTF,IGKV4-1,HK CV01-254,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLLGGTVVNDYW,IGHV3-7,IGHJ2,CQQYYSTQYTF,IGKV4-1,HK CV01-254,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLLGGTVVNDYW,IGHV3-7,IGHJ3,CQQYYSTQYTF,IGKV4-1,HK CV01-254,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLLGGTVVNDYW,IGHV3-7,IGHJ4,CQQYYSTQYTF,IGKV4-1,HK CV01-254,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLLGGTVVNDYW,IGHV3-7,IGHJ5,CQQYYSTQYTF,IGKV4-1,HK CV01-254,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLLGGTVVNDYW,IGHV3-7,IGHJ6,CQQYYSTQYTF,IGKV4-1,HK CV01-254,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPWDDYGDYYYYYMDVW,IGHV3-48,IGHJ1,CQQYGSSLNTF,IGKV3-20,HK CV01-257,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPWDDYGDYYYYYMDVW,IGHV3-48,IGHJ2,CQQYGSSLNTF,IGKV3-20,HK CV01-257,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPWDDYGDYYYYYMDVW,IGHV3-48,IGHJ3,CQQYGSSLNTF,IGKV3-20,HK CV01-257,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPWDDYGDYYYYYMDVW,IGHV3-48,IGHJ4,CQQYGSSLNTF,IGKV3-20,HK CV01-257,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPWDDYGDYYYYYMDVW,IGHV3-48,IGHJ5,CQQYGSSLNTF,IGKV3-20,HK CV01-257,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPWDDYGDYYYYYMDVW,IGHV3-48,IGHJ6,CQQYGSSLNTF,IGKV3-20,HK CV01-257,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAVHGVDTGMVTYYYHYYMDVW,IGHV4-59,IGHJ1,CQVWDNSIDHVVF,IGLV3-21,HL CV01-258,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAVHGVDTGMVTYYYHYYMDVW,IGHV4-59,IGHJ2,CQVWDNSIDHVVF,IGLV3-21,HL CV01-258,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAVHGVDTGMVTYYYHYYMDVW,IGHV4-59,IGHJ3,CQVWDNSIDHVVF,IGLV3-21,HL CV01-258,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAVHGVDTGMVTYYYHYYMDVW,IGHV4-59,IGHJ4,CQVWDNSIDHVVF,IGLV3-21,HL CV01-258,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAVHGVDTGMVTYYYHYYMDVW,IGHV4-59,IGHJ5,CQVWDNSIDHVVF,IGLV3-21,HL CV01-258,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAVHGVDTGMVTYYYHYYMDVW,IGHV4-59,IGHJ6,CQVWDNSIDHVVF,IGLV3-21,HL CV01-258,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGREYYDFWSGYYNW,IGHV1-8,IGHJ1,CSSYTRSNTVVF,IGLV2-14,HL CV01-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGREYYDFWSGYYNW,IGHV1-8,IGHJ2,CSSYTRSNTVVF,IGLV2-14,HL CV01-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGREYYDFWSGYYNW,IGHV1-8,IGHJ3,CSSYTRSNTVVF,IGLV2-14,HL CV01-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGREYYDFWSGYYNW,IGHV1-8,IGHJ4,CSSYTRSNTVVF,IGLV2-14,HL CV01-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGREYYDFWSGYYNW,IGHV1-8,IGHJ5,CSSYTRSNTVVF,IGLV2-14,HL CV01-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGREYYDFWSGYYNW,IGHV1-8,IGHJ6,CSSYTRSNTVVF,IGLV2-14,HL CV01-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTSERWLDAFDIW,IGHV3-15,IGHJ1,CQQSYRSPPITF,IGKV1-39,HK CV01-266,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTSERWLDAFDIW,IGHV3-15,IGHJ2,CQQSYRSPPITF,IGKV1-39,HK CV01-266,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTSERWLDAFDIW,IGHV3-15,IGHJ3,CQQSYRSPPITF,IGKV1-39,HK CV01-266,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTSERWLDAFDIW,IGHV3-15,IGHJ4,CQQSYRSPPITF,IGKV1-39,HK CV01-266,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTSERWLDAFDIW,IGHV3-15,IGHJ5,CQQSYRSPPITF,IGKV1-39,HK CV01-266,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTSERWLDAFDIW,IGHV3-15,IGHJ6,CQQSYRSPPITF,IGKV1-39,HK CV01-266,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGKGPPLGYW,IGHV4-4,IGHJ1,CYSYAGSSTWVF,IGLV2-23,HL CV01-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGKGPPLGYW,IGHV4-4,IGHJ2,CYSYAGSSTWVF,IGLV2-23,HL CV01-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGKGPPLGYW,IGHV4-4,IGHJ3,CYSYAGSSTWVF,IGLV2-23,HL CV01-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGKGPPLGYW,IGHV4-4,IGHJ4,CYSYAGSSTWVF,IGLV2-23,HL CV01-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGKGPPLGYW,IGHV4-4,IGHJ5,CYSYAGSSTWVF,IGLV2-23,HL CV01-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGKGPPLGYW,IGHV4-4,IGHJ6,CYSYAGSSTWVF,IGLV2-23,HL CV01-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDNGDYACFDYW,IGHV3-30,IGHJ1,CQQYYSTPLTF,IGKV4-1,HK CV01-274,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDNGDYACFDYW,IGHV3-30,IGHJ2,CQQYYSTPLTF,IGKV4-1,HK CV01-274,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDNGDYACFDYW,IGHV3-30,IGHJ3,CQQYYSTPLTF,IGKV4-1,HK CV01-274,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDNGDYACFDYW,IGHV3-30,IGHJ4,CQQYYSTPLTF,IGKV4-1,HK CV01-274,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDNGDYACFDYW,IGHV3-30,IGHJ5,CQQYYSTPLTF,IGKV4-1,HK CV01-274,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDNGDYACFDYW,IGHV3-30,IGHJ6,CQQYYSTPLTF,IGKV4-1,HK CV01-274,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPFEYYDFWSGYYRGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTRVF,IGLV2-14,HL CV01-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPFEYYDFWSGYYRGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTRVF,IGLV2-14,HL CV01-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPFEYYDFWSGYYRGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTRVF,IGLV2-14,HL CV01-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPFEYYDFWSGYYRGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTRVF,IGLV2-14,HL CV01-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPFEYYDFWSGYYRGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTRVF,IGLV2-14,HL CV01-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPFEYYDFWSGYYRGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTRVF,IGLV2-14,HL CV01-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLITWYYYYDSSAVDYW,IGHV1-2,IGHJ1,CQQYGSSPWTF,IGKV3-20,HK CV03-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLITWYYYYDSSAVDYW,IGHV1-2,IGHJ2,CQQYGSSPWTF,IGKV3-20,HK CV03-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLITWYYYYDSSAVDYW,IGHV1-2,IGHJ3,CQQYGSSPWTF,IGKV3-20,HK CV03-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLITWYYYYDSSAVDYW,IGHV1-2,IGHJ4,CQQYGSSPWTF,IGKV3-20,HK CV03-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLITWYYYYDSSAVDYW,IGHV1-2,IGHJ5,CQQYGSSPWTF,IGKV3-20,HK CV03-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLITWYYYYDSSAVDYW,IGHV1-2,IGHJ6,CQQYGSSPWTF,IGKV3-20,HK CV03-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPDGHRSGWFDWFDPW,IGHV3-21,IGHJ1,CQQANSFPITF,IGKV1D-12,HK CV03-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPDGHRSGWFDWFDPW,IGHV3-21,IGHJ2,CQQANSFPITF,IGKV1D-12,HK CV03-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPDGHRSGWFDWFDPW,IGHV3-21,IGHJ3,CQQANSFPITF,IGKV1D-12,HK CV03-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPDGHRSGWFDWFDPW,IGHV3-21,IGHJ4,CQQANSFPITF,IGKV1D-12,HK CV03-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPDGHRSGWFDWFDPW,IGHV3-21,IGHJ5,CQQANSFPITF,IGKV1D-12,HK CV03-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPDGHRSGWFDWFDPW,IGHV3-21,IGHJ6,CQQANSFPITF,IGKV1D-12,HK CV03-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSHYYDSSGYYYLYYYYGTDVW,IGHV1-18,IGHJ1,CQSADSSGTYVF,IGLV3-25,HL CV03-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSHYYDSSGYYYLYYYYGTDVW,IGHV1-18,IGHJ2,CQSADSSGTYVF,IGLV3-25,HL CV03-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSHYYDSSGYYYLYYYYGTDVW,IGHV1-18,IGHJ3,CQSADSSGTYVF,IGLV3-25,HL CV03-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSHYYDSSGYYYLYYYYGTDVW,IGHV1-18,IGHJ4,CQSADSSGTYVF,IGLV3-25,HL CV03-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSHYYDSSGYYYLYYYYGTDVW,IGHV1-18,IGHJ5,CQSADSSGTYVF,IGLV3-25,HL CV03-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSHYYDSSGYYYLYYYYGTDVW,IGHV1-18,IGHJ6,CQSADSSGTYVF,IGLV3-25,HL CV03-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ1,CQQYGSSPLTF,IGKV3-20,HK CV03-106,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ2,CQQYGSSPLTF,IGKV3-20,HK CV03-106,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ3,CQQYGSSPLTF,IGKV3-20,HK CV03-106,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ4,CQQYGSSPLTF,IGKV3-20,HK CV03-106,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ5,CQQYGSSPLTF,IGKV3-20,HK CV03-106,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ6,CQQYGSSPLTF,IGKV3-20,HK CV03-106,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ1,CQQYGSSPLTF,IGKV3-20,HK CV03-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ2,CQQYGSSPLTF,IGKV3-20,HK CV03-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ3,CQQYGSSPLTF,IGKV3-20,HK CV03-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ4,CQQYGSSPLTF,IGKV3-20,HK CV03-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ5,CQQYGSSPLTF,IGKV3-20,HK CV03-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRTIFGVVSGAFDIW,IGHV4-31,IGHJ6,CQQYGSSPLTF,IGKV3-20,HK CV03-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTKTKNPPAYDFWSGYYRGRPPYYKYGMDVW,IGHV3-15,IGHJ1,CQSYDNSLSEYDDVF,IGLV1-40,HL CV03-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTKTKNPPAYDFWSGYYRGRPPYYKYGMDVW,IGHV3-15,IGHJ2,CQSYDNSLSEYDDVF,IGLV1-40,HL CV03-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTKTKNPPAYDFWSGYYRGRPPYYKYGMDVW,IGHV3-15,IGHJ3,CQSYDNSLSEYDDVF,IGLV1-40,HL CV03-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTKTKNPPAYDFWSGYYRGRPPYYKYGMDVW,IGHV3-15,IGHJ4,CQSYDNSLSEYDDVF,IGLV1-40,HL CV03-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTKTKNPPAYDFWSGYYRGRPPYYKYGMDVW,IGHV3-15,IGHJ5,CQSYDNSLSEYDDVF,IGLV1-40,HL CV03-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTKTKNPPAYDFWSGYYRGRPPYYKYGMDVW,IGHV3-15,IGHJ6,CQSYDNSLSEYDDVF,IGLV1-40,HL CV03-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVGVGATHSPPFDYW,IGHV5-10-1,IGHJ1,CQSYDSSLSGPTVF,IGLV1-40,HL CV03-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVGVGATHSPPFDYW,IGHV5-10-1,IGHJ2,CQSYDSSLSGPTVF,IGLV1-40,HL CV03-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVGVGATHSPPFDYW,IGHV5-10-1,IGHJ3,CQSYDSSLSGPTVF,IGLV1-40,HL CV03-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVGVGATHSPPFDYW,IGHV5-10-1,IGHJ4,CQSYDSSLSGPTVF,IGLV1-40,HL CV03-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVGVGATHSPPFDYW,IGHV5-10-1,IGHJ5,CQSYDSSLSGPTVF,IGLV1-40,HL CV03-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVGVGATHSPPFDYW,IGHV5-10-1,IGHJ6,CQSYDSSLSGPTVF,IGLV1-40,HL CV03-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGSWYYLLDFDYW,IGHV3-48,IGHJ1,CQQYNSYPRTF,IGKV1-5,HK CV03-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGSWYYLLDFDYW,IGHV3-48,IGHJ2,CQQYNSYPRTF,IGKV1-5,HK CV03-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGSWYYLLDFDYW,IGHV3-48,IGHJ3,CQQYNSYPRTF,IGKV1-5,HK CV03-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGSWYYLLDFDYW,IGHV3-48,IGHJ4,CQQYNSYPRTF,IGKV1-5,HK CV03-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGSWYYLLDFDYW,IGHV3-48,IGHJ5,CQQYNSYPRTF,IGKV1-5,HK CV03-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGSWYYLLDFDYW,IGHV3-48,IGHJ6,CQQYNSYPRTF,IGKV1-5,HK CV03-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGRSSSWRYNWFDPW,IGHV3-48,IGHJ1,CQQYNNWPPWTF,IGKV3-15,HK CV03-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGRSSSWRYNWFDPW,IGHV3-48,IGHJ2,CQQYNNWPPWTF,IGKV3-15,HK CV03-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGRSSSWRYNWFDPW,IGHV3-48,IGHJ3,CQQYNNWPPWTF,IGKV3-15,HK CV03-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGRSSSWRYNWFDPW,IGHV3-48,IGHJ4,CQQYNNWPPWTF,IGKV3-15,HK CV03-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGRSSSWRYNWFDPW,IGHV3-48,IGHJ5,CQQYNNWPPWTF,IGKV3-15,HK CV03-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CGRSSSWRYNWFDPW,IGHV3-48,IGHJ6,CQQYNNWPPWTF,IGKV3-15,HK CV03-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPYYEISSGYSPDYW,IGHV3-15,IGHJ1,,IGLV2-11,HL CV03-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPYYEISSGYSPDYW,IGHV3-15,IGHJ2,,IGLV2-11,HL CV03-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPYYEISSGYSPDYW,IGHV3-15,IGHJ3,,IGLV2-11,HL CV03-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPYYEISSGYSPDYW,IGHV3-15,IGHJ4,,IGLV2-11,HL CV03-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPYYEISSGYSPDYW,IGHV3-15,IGHJ5,,IGLV2-11,HL CV03-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPYYEISSGYSPDYW,IGHV3-15,IGHJ6,,IGLV2-11,HL CV03-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVQGRGSGSYYSAYYYGMDVW,IGHV4-59,IGHJ1,CQSYDSSLSGVF,IGLV1-40,HL CV03-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVQGRGSGSYYSAYYYGMDVW,IGHV4-59,IGHJ2,CQSYDSSLSGVF,IGLV1-40,HL CV03-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVQGRGSGSYYSAYYYGMDVW,IGHV4-59,IGHJ3,CQSYDSSLSGVF,IGLV1-40,HL CV03-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVQGRGSGSYYSAYYYGMDVW,IGHV4-59,IGHJ4,CQSYDSSLSGVF,IGLV1-40,HL CV03-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVQGRGSGSYYSAYYYGMDVW,IGHV4-59,IGHJ5,CQSYDSSLSGVF,IGLV1-40,HL CV03-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVQGRGSGSYYSAYYYGMDVW,IGHV4-59,IGHJ6,CQSYDSSLSGVF,IGLV1-40,HL CV03-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLRDGISTFGVVNHYYAMDVW,IGHV1-46,IGHJ1,CSSYTSSSTVVF,IGLV2-14,HL CV03-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLRDGISTFGVVNHYYAMDVW,IGHV1-46,IGHJ2,CSSYTSSSTVVF,IGLV2-14,HL CV03-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLRDGISTFGVVNHYYAMDVW,IGHV1-46,IGHJ3,CSSYTSSSTVVF,IGLV2-14,HL CV03-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLRDGISTFGVVNHYYAMDVW,IGHV1-46,IGHJ4,CSSYTSSSTVVF,IGLV2-14,HL CV03-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLRDGISTFGVVNHYYAMDVW,IGHV1-46,IGHJ5,CSSYTSSSTVVF,IGLV2-14,HL CV03-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLRDGISTFGVVNHYYAMDVW,IGHV1-46,IGHJ6,CSSYTSSSTVVF,IGLV2-14,HL CV03-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGISTFGVVKHYYAMDVW,IGHV1-46,IGHJ1,CSSYTTTTTLVF,IGLV2-14,HL CV03-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGISTFGVVKHYYAMDVW,IGHV1-46,IGHJ2,CSSYTTTTTLVF,IGLV2-14,HL CV03-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGISTFGVVKHYYAMDVW,IGHV1-46,IGHJ3,CSSYTTTTTLVF,IGLV2-14,HL CV03-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGISTFGVVKHYYAMDVW,IGHV1-46,IGHJ4,CSSYTTTTTLVF,IGLV2-14,HL CV03-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGISTFGVVKHYYAMDVW,IGHV1-46,IGHJ5,CSSYTTTTTLVF,IGLV2-14,HL CV03-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGISTFGVVKHYYAMDVW,IGHV1-46,IGHJ6,CSSYTTTTTLVF,IGLV2-14,HL CV03-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSLITIFGVVIEAPDDYGMDVW,IGHV3-21,IGHJ1,CSSYTSSSTVVF,IGLV2-14,HL CV03-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSLITIFGVVIEAPDDYGMDVW,IGHV3-21,IGHJ2,CSSYTSSSTVVF,IGLV2-14,HL CV03-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSLITIFGVVIEAPDDYGMDVW,IGHV3-21,IGHJ3,CSSYTSSSTVVF,IGLV2-14,HL CV03-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSLITIFGVVIEAPDDYGMDVW,IGHV3-21,IGHJ4,CSSYTSSSTVVF,IGLV2-14,HL CV03-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSLITIFGVVIEAPDDYGMDVW,IGHV3-21,IGHJ5,CSSYTSSSTVVF,IGLV2-14,HL CV03-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSLITIFGVVIEAPDDYGMDVW,IGHV3-21,IGHJ6,CSSYTSSSTVVF,IGLV2-14,HL CV03-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYFVIPPAALYDYW,IGHV3-23,IGHJ1,CGTWDSSLSAGVF,IGLV1-51,HL CV03-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYFVIPPAALYDYW,IGHV3-23,IGHJ2,CGTWDSSLSAGVF,IGLV1-51,HL CV03-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYFVIPPAALYDYW,IGHV3-23,IGHJ3,CGTWDSSLSAGVF,IGLV1-51,HL CV03-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYFVIPPAALYDYW,IGHV3-23,IGHJ4,CGTWDSSLSAGVF,IGLV1-51,HL CV03-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYFVIPPAALYDYW,IGHV3-23,IGHJ5,CGTWDSSLSAGVF,IGLV1-51,HL CV03-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYFVIPPAALYDYW,IGHV3-23,IGHJ6,CGTWDSSLSAGVF,IGLV1-51,HL CV03-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKELDDQLTLGGWFDPW,IGHV3-23,IGHJ1,CCSYVGTATVVF,IGLV2-23,HL CV03-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKELDDQLTLGGWFDPW,IGHV3-23,IGHJ2,CCSYVGTATVVF,IGLV2-23,HL CV03-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKELDDQLTLGGWFDPW,IGHV3-23,IGHJ3,CCSYVGTATVVF,IGLV2-23,HL CV03-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKELDDQLTLGGWFDPW,IGHV3-23,IGHJ4,CCSYVGTATVVF,IGLV2-23,HL CV03-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKELDDQLTLGGWFDPW,IGHV3-23,IGHJ5,CCSYVGTATVVF,IGLV2-23,HL CV03-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKELDDQLTLGGWFDPW,IGHV3-23,IGHJ6,CCSYVGTATVVF,IGLV2-23,HL CV03-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSVRYFDWFDFDYW,IGHV5-51,IGHJ1,CAAWDDSLNGYVF,IGLV1-44,HL CV03-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSVRYFDWFDFDYW,IGHV5-51,IGHJ2,CAAWDDSLNGYVF,IGLV1-44,HL CV03-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSVRYFDWFDFDYW,IGHV5-51,IGHJ3,CAAWDDSLNGYVF,IGLV1-44,HL CV03-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSVRYFDWFDFDYW,IGHV5-51,IGHJ4,CAAWDDSLNGYVF,IGLV1-44,HL CV03-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSVRYFDWFDFDYW,IGHV5-51,IGHJ5,CAAWDDSLNGYVF,IGLV1-44,HL CV03-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSVRYFDWFDFDYW,IGHV5-51,IGHJ6,CAAWDDSLNGYVF,IGLV1-44,HL CV03-124,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARRPTYSSSWGTFDYW,IGHV1-69,IGHJ1,CQQSYSTPWTF,IGKV1-39,HK CV03-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARRPTYSSSWGTFDYW,IGHV1-69,IGHJ2,CQQSYSTPWTF,IGKV1-39,HK CV03-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARRPTYSSSWGTFDYW,IGHV1-69,IGHJ3,CQQSYSTPWTF,IGKV1-39,HK CV03-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARRPTYSSSWGTFDYW,IGHV1-69,IGHJ4,CQQSYSTPWTF,IGKV1-39,HK CV03-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARRPTYSSSWGTFDYW,IGHV1-69,IGHJ5,CQQSYSTPWTF,IGKV1-39,HK CV03-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARRPTYSSSWGTFDYW,IGHV1-69,IGHJ6,CQQSYSTPWTF,IGKV1-39,HK CV03-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYGGPYLFDYW,IGHV4-59,IGHJ1,CQKYNTYPGTF,IGKV1-5,HK CV03-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYGGPYLFDYW,IGHV4-59,IGHJ2,CQKYNTYPGTF,IGKV1-5,HK CV03-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYGGPYLFDYW,IGHV4-59,IGHJ3,CQKYNTYPGTF,IGKV1-5,HK CV03-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYGGPYLFDYW,IGHV4-59,IGHJ4,CQKYNTYPGTF,IGKV1-5,HK CV03-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYGGPYLFDYW,IGHV4-59,IGHJ5,CQKYNTYPGTF,IGKV1-5,HK CV03-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYGGPYLFDYW,IGHV4-59,IGHJ6,CQKYNTYPGTF,IGKV1-5,HK CV03-130,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDMIVVAAFDYW,IGHV3-11,IGHJ1,CQQYGSSPLTF,IGKV3-20,HK CV03-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDMIVVAAFDYW,IGHV3-11,IGHJ2,CQQYGSSPLTF,IGKV3-20,HK CV03-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDMIVVAAFDYW,IGHV3-11,IGHJ3,CQQYGSSPLTF,IGKV3-20,HK CV03-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDMIVVAAFDYW,IGHV3-11,IGHJ4,CQQYGSSPLTF,IGKV3-20,HK CV03-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDMIVVAAFDYW,IGHV3-11,IGHJ5,CQQYGSSPLTF,IGKV3-20,HK CV03-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGDMIVVAAFDYW,IGHV3-11,IGHJ6,CQQYGSSPLTF,IGKV3-20,HK CV03-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPQMVYALFPYYYYYGMDVW,IGHV3-7,IGHJ1,CQKYNSAPWTF,IGKV1-27,HK CV03-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPQMVYALFPYYYYYGMDVW,IGHV3-7,IGHJ2,CQKYNSAPWTF,IGKV1-27,HK CV03-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPQMVYALFPYYYYYGMDVW,IGHV3-7,IGHJ3,CQKYNSAPWTF,IGKV1-27,HK CV03-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPQMVYALFPYYYYYGMDVW,IGHV3-7,IGHJ4,CQKYNSAPWTF,IGKV1-27,HK CV03-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPQMVYALFPYYYYYGMDVW,IGHV3-7,IGHJ5,CQKYNSAPWTF,IGKV1-27,HK CV03-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPQMVYALFPYYYYYGMDVW,IGHV3-7,IGHJ6,CQKYNSAPWTF,IGKV1-27,HK CV03-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVMELYGSDVFDLW,IGHV3-64,IGHJ1,CQQSYSTSWTF,IGKV1-39,HK CV03-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVMELYGSDVFDLW,IGHV3-64,IGHJ2,CQQSYSTSWTF,IGKV1-39,HK CV03-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVMELYGSDVFDLW,IGHV3-64,IGHJ3,CQQSYSTSWTF,IGKV1-39,HK CV03-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVMELYGSDVFDLW,IGHV3-64,IGHJ4,CQQSYSTSWTF,IGKV1-39,HK CV03-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVMELYGSDVFDLW,IGHV3-64,IGHJ5,CQQSYSTSWTF,IGKV1-39,HK CV03-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVMELYGSDVFDLW,IGHV3-64,IGHJ6,CQQSYSTSWTF,IGKV1-39,HK CV03-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASYTWGRIW,IGHV3-74,IGHJ1,CSSYTRSSTLVVF,IGLV2-14,HL CV03-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASYTWGRIW,IGHV3-74,IGHJ2,CSSYTRSSTLVVF,IGLV2-14,HL CV03-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASYTWGRIW,IGHV3-74,IGHJ3,CSSYTRSSTLVVF,IGLV2-14,HL CV03-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASYTWGRIW,IGHV3-74,IGHJ4,CSSYTRSSTLVVF,IGLV2-14,HL CV03-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASYTWGRIW,IGHV3-74,IGHJ5,CSSYTRSSTLVVF,IGLV2-14,HL CV03-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASYTWGRIW,IGHV3-74,IGHJ6,CSSYTRSSTLVVF,IGLV2-14,HL CV03-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQGPLPPILYDILTGYYLGDYYYGMDVW,IGHV4-39,IGHJ1,CMQALQTPLTF,IGKV2-28,HK CV03-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQGPLPPILYDILTGYYLGDYYYGMDVW,IGHV4-39,IGHJ2,CMQALQTPLTF,IGKV2-28,HK CV03-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQGPLPPILYDILTGYYLGDYYYGMDVW,IGHV4-39,IGHJ3,CMQALQTPLTF,IGKV2-28,HK CV03-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQGPLPPILYDILTGYYLGDYYYGMDVW,IGHV4-39,IGHJ4,CMQALQTPLTF,IGKV2-28,HK CV03-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQGPLPPILYDILTGYYLGDYYYGMDVW,IGHV4-39,IGHJ5,CMQALQTPLTF,IGKV2-28,HK CV03-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQGPLPPILYDILTGYYLGDYYYGMDVW,IGHV4-39,IGHJ6,CMQALQTPLTF,IGKV2-28,HK CV03-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDAYYYGSGSYSEGGHW,IGHV3-49,IGHJ1,CQQRSNWPPLFTF,IGKV3-11,HK CV03-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDAYYYGSGSYSEGGHW,IGHV3-49,IGHJ2,CQQRSNWPPLFTF,IGKV3-11,HK CV03-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDAYYYGSGSYSEGGHW,IGHV3-49,IGHJ3,CQQRSNWPPLFTF,IGKV3-11,HK CV03-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDAYYYGSGSYSEGGHW,IGHV3-49,IGHJ4,CQQRSNWPPLFTF,IGKV3-11,HK CV03-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDAYYYGSGSYSEGGHW,IGHV3-49,IGHJ5,CQQRSNWPPLFTF,IGKV3-11,HK CV03-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDAYYYGSGSYSEGGHW,IGHV3-49,IGHJ6,CQQRSNWPPLFTF,IGKV3-11,HK CV03-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVTGYDNEDYYYYYGLDVW,IGHV4-38-2,IGHJ1,CQQYYSSPRTF,IGKV4-1,HK CV03-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVTGYDNEDYYYYYGLDVW,IGHV4-38-2,IGHJ2,CQQYYSSPRTF,IGKV4-1,HK CV03-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVTGYDNEDYYYYYGLDVW,IGHV4-38-2,IGHJ3,CQQYYSSPRTF,IGKV4-1,HK CV03-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVTGYDNEDYYYYYGLDVW,IGHV4-38-2,IGHJ4,CQQYYSSPRTF,IGKV4-1,HK CV03-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVTGYDNEDYYYYYGLDVW,IGHV4-38-2,IGHJ5,CQQYYSSPRTF,IGKV4-1,HK CV03-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDVTGYDNEDYYYYYGLDVW,IGHV4-38-2,IGHJ6,CQQYYSSPRTF,IGKV4-1,HK CV03-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGPDSGYLDYW,IGHV3-53,IGHJ1,CQTWGTGIRVF,IGLV4-69,HL CV03-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGPDSGYLDYW,IGHV3-53,IGHJ2,CQTWGTGIRVF,IGLV4-69,HL CV03-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGPDSGYLDYW,IGHV3-53,IGHJ3,CQTWGTGIRVF,IGLV4-69,HL CV03-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGPDSGYLDYW,IGHV3-53,IGHJ4,CQTWGTGIRVF,IGLV4-69,HL CV03-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGPDSGYLDYW,IGHV3-53,IGHJ5,CQTWGTGIRVF,IGLV4-69,HL CV03-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGPDSGYLDYW,IGHV3-53,IGHJ6,CQTWGTGIRVF,IGLV4-69,HL CV03-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSGFWSGYYPGNFNYW,IGHV3-48,IGHJ1,CQQYDNLPPLTF,IGKV1-33,HK CV03-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSGFWSGYYPGNFNYW,IGHV3-48,IGHJ2,CQQYDNLPPLTF,IGKV1-33,HK CV03-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSGFWSGYYPGNFNYW,IGHV3-48,IGHJ3,CQQYDNLPPLTF,IGKV1-33,HK CV03-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSGFWSGYYPGNFNYW,IGHV3-48,IGHJ4,CQQYDNLPPLTF,IGKV1-33,HK CV03-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSGFWSGYYPGNFNYW,IGHV3-48,IGHJ5,CQQYDNLPPLTF,IGKV1-33,HK CV03-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSGFWSGYYPGNFNYW,IGHV3-48,IGHJ6,CQQYDNLPPLTF,IGKV1-33,HK CV03-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWIELRPPRNYYYNGMDVW,IGHV1-18,IGHJ1,CMQALQTPRTF,IGKV2-28,HK CV03-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWIELRPPRNYYYNGMDVW,IGHV1-18,IGHJ2,CMQALQTPRTF,IGKV2-28,HK CV03-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWIELRPPRNYYYNGMDVW,IGHV1-18,IGHJ3,CMQALQTPRTF,IGKV2-28,HK CV03-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWIELRPPRNYYYNGMDVW,IGHV1-18,IGHJ4,CMQALQTPRTF,IGKV2-28,HK CV03-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWIELRPPRNYYYNGMDVW,IGHV1-18,IGHJ5,CMQALQTPRTF,IGKV2-28,HK CV03-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWIELRPPRNYYYNGMDVW,IGHV1-18,IGHJ6,CMQALQTPRTF,IGKV2-28,HK CV03-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSDCSGGSCYRFDYW,IGHV1-46,IGHJ1,CAAWDDSLNGYVF,IGLV1-44,HL CV03-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSDCSGGSCYRFDYW,IGHV1-46,IGHJ2,CAAWDDSLNGYVF,IGLV1-44,HL CV03-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSDCSGGSCYRFDYW,IGHV1-46,IGHJ3,CAAWDDSLNGYVF,IGLV1-44,HL CV03-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSDCSGGSCYRFDYW,IGHV1-46,IGHJ4,CAAWDDSLNGYVF,IGLV1-44,HL CV03-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSDCSGGSCYRFDYW,IGHV1-46,IGHJ5,CAAWDDSLNGYVF,IGLV1-44,HL CV03-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSDCSGGSCYRFDYW,IGHV1-46,IGHJ6,CAAWDDSLNGYVF,IGLV1-44,HL CV03-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRTVTKTGLFYLDDCW,IGHV3-23,IGHJ1,CQQSYSTPITF,IGKV1-39,HK CV03-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRTVTKTGLFYLDDCW,IGHV3-23,IGHJ2,CQQSYSTPITF,IGKV1-39,HK CV03-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRTVTKTGLFYLDDCW,IGHV3-23,IGHJ3,CQQSYSTPITF,IGKV1-39,HK CV03-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRTVTKTGLFYLDDCW,IGHV3-23,IGHJ4,CQQSYSTPITF,IGKV1-39,HK CV03-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRTVTKTGLFYLDDCW,IGHV3-23,IGHJ5,CQQSYSTPITF,IGKV1-39,HK CV03-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRTVTKTGLFYLDDCW,IGHV3-23,IGHJ6,CQQSYSTPITF,IGKV1-39,HK CV03-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQTGTGEVDYW,IGHV3-23,IGHJ1,CQAWDSSTGVF,IGLV3-1,HL CV03-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQTGTGEVDYW,IGHV3-23,IGHJ2,CQAWDSSTGVF,IGLV3-1,HL CV03-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQTGTGEVDYW,IGHV3-23,IGHJ3,CQAWDSSTGVF,IGLV3-1,HL CV03-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQTGTGEVDYW,IGHV3-23,IGHJ4,CQAWDSSTGVF,IGLV3-1,HL CV03-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQTGTGEVDYW,IGHV3-23,IGHJ5,CQAWDSSTGVF,IGLV3-1,HL CV03-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASQTGTGEVDYW,IGHV3-23,IGHJ6,CQAWDSSTGVF,IGLV3-1,HL CV03-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGPRLLWFGELSPFDYW,IGHV3-23,IGHJ1,CGTWDSSLSALVF,IGLV1-51,HL CV03-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGPRLLWFGELSPFDYW,IGHV3-23,IGHJ2,CGTWDSSLSALVF,IGLV1-51,HL CV03-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGPRLLWFGELSPFDYW,IGHV3-23,IGHJ3,CGTWDSSLSALVF,IGLV1-51,HL CV03-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGPRLLWFGELSPFDYW,IGHV3-23,IGHJ4,CGTWDSSLSALVF,IGLV1-51,HL CV03-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGPRLLWFGELSPFDYW,IGHV3-23,IGHJ5,CGTWDSSLSALVF,IGLV1-51,HL CV03-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGPRLLWFGELSPFDYW,IGHV3-23,IGHJ6,CGTWDSSLSALVF,IGLV1-51,HL CV03-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLEVW,IGHV3-23,IGHJ1,CAVWDDSLSAWVF,IGLV1-47,HL CV03-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLEVW,IGHV3-23,IGHJ2,CAVWDDSLSAWVF,IGLV1-47,HL CV03-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLEVW,IGHV3-23,IGHJ3,CAVWDDSLSAWVF,IGLV1-47,HL CV03-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLEVW,IGHV3-23,IGHJ4,CAVWDDSLSAWVF,IGLV1-47,HL CV03-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLEVW,IGHV3-23,IGHJ5,CAVWDDSLSAWVF,IGLV1-47,HL CV03-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLEVW,IGHV3-23,IGHJ6,CAVWDDSLSAWVF,IGLV1-47,HL CV03-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ1,CAVWDDSLSAWVF,IGLV1-47,HL CV03-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ2,CAVWDDSLSAWVF,IGLV1-47,HL CV03-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ3,CAVWDDSLSAWVF,IGLV1-47,HL CV03-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ4,CAVWDDSLSAWVF,IGLV1-47,HL CV03-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ5,CAVWDDSLSAWVF,IGLV1-47,HL CV03-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ6,CAVWDDSLSAWVF,IGLV1-47,HL CV03-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSGEVFWFGRFRRDYLDYW,IGHV3-30,IGHJ1,CAAWDDRLNGVVF,IGLV1-44,HL CV03-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSGEVFWFGRFRRDYLDYW,IGHV3-30,IGHJ2,CAAWDDRLNGVVF,IGLV1-44,HL CV03-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSGEVFWFGRFRRDYLDYW,IGHV3-30,IGHJ3,CAAWDDRLNGVVF,IGLV1-44,HL CV03-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSGEVFWFGRFRRDYLDYW,IGHV3-30,IGHJ4,CAAWDDRLNGVVF,IGLV1-44,HL CV03-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSGEVFWFGRFRRDYLDYW,IGHV3-30,IGHJ5,CAAWDDRLNGVVF,IGLV1-44,HL CV03-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSGEVFWFGRFRRDYLDYW,IGHV3-30,IGHJ6,CAAWDDRLNGVVF,IGLV1-44,HL CV03-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSCTSTSCYESMKW,IGHV3-74,IGHJ1,CQHYNSYPWMF,IGKV1-5,HK CV03-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSCTSTSCYESMKW,IGHV3-74,IGHJ2,CQHYNSYPWMF,IGKV1-5,HK CV03-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSCTSTSCYESMKW,IGHV3-74,IGHJ3,CQHYNSYPWMF,IGKV1-5,HK CV03-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSCTSTSCYESMKW,IGHV3-74,IGHJ4,CQHYNSYPWMF,IGKV1-5,HK CV03-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSCTSTSCYESMKW,IGHV3-74,IGHJ5,CQHYNSYPWMF,IGKV1-5,HK CV03-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSCTSTSCYESMKW,IGHV3-74,IGHJ6,CQHYNSYPWMF,IGKV1-5,HK CV03-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTVIAAAGTVHYYYYYGMDVW,IGHV1-24,IGHJ1,CMQATQFPYTF,IGKV2-24,HK CV03-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTVIAAAGTVHYYYYYGMDVW,IGHV1-24,IGHJ2,CMQATQFPYTF,IGKV2-24,HK CV03-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTVIAAAGTVHYYYYYGMDVW,IGHV1-24,IGHJ3,CMQATQFPYTF,IGKV2-24,HK CV03-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTVIAAAGTVHYYYYYGMDVW,IGHV1-24,IGHJ4,CMQATQFPYTF,IGKV2-24,HK CV03-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTVIAAAGTVHYYYYYGMDVW,IGHV1-24,IGHJ5,CMQATQFPYTF,IGKV2-24,HK CV03-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTVIAAAGTVHYYYYYGMDVW,IGHV1-24,IGHJ6,CMQATQFPYTF,IGKV2-24,HK CV03-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEKAYDFWSGYLSYYYYGMDVW,IGHV3-33,IGHJ1,CMQGTHWPPYTF,IGKV2-30,HK CV03-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEKAYDFWSGYLSYYYYGMDVW,IGHV3-33,IGHJ2,CMQGTHWPPYTF,IGKV2-30,HK CV03-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEKAYDFWSGYLSYYYYGMDVW,IGHV3-33,IGHJ3,CMQGTHWPPYTF,IGKV2-30,HK CV03-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEKAYDFWSGYLSYYYYGMDVW,IGHV3-33,IGHJ4,CMQGTHWPPYTF,IGKV2-30,HK CV03-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEKAYDFWSGYLSYYYYGMDVW,IGHV3-33,IGHJ5,CMQGTHWPPYTF,IGKV2-30,HK CV03-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEKAYDFWSGYLSYYYYGMDVW,IGHV3-33,IGHJ6,CMQGTHWPPYTF,IGKV2-30,HK CV03-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLYYYDSSGYYLPSPIDYW,IGHV5-10-1,IGHJ1,CQQYDNLLLTF,IGKV1-33,HK CV03-156,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLYYYDSSGYYLPSPIDYW,IGHV5-10-1,IGHJ2,CQQYDNLLLTF,IGKV1-33,HK CV03-156,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLYYYDSSGYYLPSPIDYW,IGHV5-10-1,IGHJ3,CQQYDNLLLTF,IGKV1-33,HK CV03-156,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLYYYDSSGYYLPSPIDYW,IGHV5-10-1,IGHJ4,CQQYDNLLLTF,IGKV1-33,HK CV03-156,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLYYYDSSGYYLPSPIDYW,IGHV5-10-1,IGHJ5,CQQYDNLLLTF,IGKV1-33,HK CV03-156,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLYYYDSSGYYLPSPIDYW,IGHV5-10-1,IGHJ6,CQQYDNLLLTF,IGKV1-33,HK CV03-156,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ1,CAVWDDSLSAWVF,IGLV1-47,HL CV03-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ2,CAVWDDSLSAWVF,IGLV1-47,HL CV03-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ3,CAVWDDSLSAWVF,IGLV1-47,HL CV03-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ4,CAVWDDSLSAWVF,IGLV1-47,HL CV03-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ5,CAVWDDSLSAWVF,IGLV1-47,HL CV03-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ6,CAVWDDSLSAWVF,IGLV1-47,HL CV03-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGADSSGYYLPSGGIGYW,IGHV5-10-1,IGHJ1,CQSYDSSLSGSKVF,IGLV1-40,HL CV03-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGADSSGYYLPSGGIGYW,IGHV5-10-1,IGHJ2,CQSYDSSLSGSKVF,IGLV1-40,HL CV03-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGADSSGYYLPSGGIGYW,IGHV5-10-1,IGHJ3,CQSYDSSLSGSKVF,IGLV1-40,HL CV03-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGADSSGYYLPSGGIGYW,IGHV5-10-1,IGHJ4,CQSYDSSLSGSKVF,IGLV1-40,HL CV03-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGADSSGYYLPSGGIGYW,IGHV5-10-1,IGHJ5,CQSYDSSLSGSKVF,IGLV1-40,HL CV03-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGADSSGYYLPSGGIGYW,IGHV5-10-1,IGHJ6,CQSYDSSLSGSKVF,IGLV1-40,HL CV03-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRKGWLQLRGNWYFDLW,IGHV4-39,IGHJ1,CYSTDSSGNQVVF,IGLV3-10,HL CV03-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRKGWLQLRGNWYFDLW,IGHV4-39,IGHJ2,CYSTDSSGNQVVF,IGLV3-10,HL CV03-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRKGWLQLRGNWYFDLW,IGHV4-39,IGHJ3,CYSTDSSGNQVVF,IGLV3-10,HL CV03-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRKGWLQLRGNWYFDLW,IGHV4-39,IGHJ4,CYSTDSSGNQVVF,IGLV3-10,HL CV03-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRKGWLQLRGNWYFDLW,IGHV4-39,IGHJ5,CYSTDSSGNQVVF,IGLV3-10,HL CV03-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRKGWLQLRGNWYFDLW,IGHV4-39,IGHJ6,CYSTDSSGNQVVF,IGLV3-10,HL CV03-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGGTVVTPGPDYW,IGHV3-74,IGHJ1,CQTWGIGTHDVIF,IGLV4-69,HL CV03-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGGTVVTPGPDYW,IGHV3-74,IGHJ2,CQTWGIGTHDVIF,IGLV4-69,HL CV03-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGGTVVTPGPDYW,IGHV3-74,IGHJ3,CQTWGIGTHDVIF,IGLV4-69,HL CV03-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGGTVVTPGPDYW,IGHV3-74,IGHJ4,CQTWGIGTHDVIF,IGLV4-69,HL CV03-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGGTVVTPGPDYW,IGHV3-74,IGHJ5,CQTWGIGTHDVIF,IGLV4-69,HL CV03-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGGTVVTPGPDYW,IGHV3-74,IGHJ6,CQTWGIGTHDVIF,IGLV4-69,HL CV03-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVDALRYYFYGMDVW,IGHV3-23,IGHJ1,CAAWDDSLSAWVF,IGLV1-47,HL CV03-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVDALRYYFYGMDVW,IGHV3-23,IGHJ2,CAAWDDSLSAWVF,IGLV1-47,HL CV03-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVDALRYYFYGMDVW,IGHV3-23,IGHJ3,CAAWDDSLSAWVF,IGLV1-47,HL CV03-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVDALRYYFYGMDVW,IGHV3-23,IGHJ4,CAAWDDSLSAWVF,IGLV1-47,HL CV03-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVDALRYYFYGMDVW,IGHV3-23,IGHJ5,CAAWDDSLSAWVF,IGLV1-47,HL CV03-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVDALRYYFYGMDVW,IGHV3-23,IGHJ6,CAAWDDSLSAWVF,IGLV1-47,HL CV03-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRLYCSSGACYLGPW,IGHV4-4,IGHJ1,CQQYGRSPTF,IGKV3-20,HK CV03-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRLYCSSGACYLGPW,IGHV4-4,IGHJ2,CQQYGRSPTF,IGKV3-20,HK CV03-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRLYCSSGACYLGPW,IGHV4-4,IGHJ3,CQQYGRSPTF,IGKV3-20,HK CV03-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRLYCSSGACYLGPW,IGHV4-4,IGHJ4,CQQYGRSPTF,IGKV3-20,HK CV03-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRLYCSSGACYLGPW,IGHV4-4,IGHJ5,CQQYGRSPTF,IGKV3-20,HK CV03-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRLYCSSGACYLGPW,IGHV4-4,IGHJ6,CQQYGRSPTF,IGKV3-20,HK CV03-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDWFDPW,IGHV1-46,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV03-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDWFDPW,IGHV1-46,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV03-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDWFDPW,IGHV1-46,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV03-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDWFDPW,IGHV1-46,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV03-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDWFDPW,IGHV1-46,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV03-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDWFDPW,IGHV1-46,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV03-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREAFYDILTGYSSTPNHYYYGMDVW,IGHV1-69,IGHJ1,CMQALQTPWTF,IGKV2-28,HK CV03-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREAFYDILTGYSSTPNHYYYGMDVW,IGHV1-69,IGHJ2,CMQALQTPWTF,IGKV2-28,HK CV03-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREAFYDILTGYSSTPNHYYYGMDVW,IGHV1-69,IGHJ3,CMQALQTPWTF,IGKV2-28,HK CV03-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREAFYDILTGYSSTPNHYYYGMDVW,IGHV1-69,IGHJ4,CMQALQTPWTF,IGKV2-28,HK CV03-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREAFYDILTGYSSTPNHYYYGMDVW,IGHV1-69,IGHJ5,CMQALQTPWTF,IGKV2-28,HK CV03-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREAFYDILTGYSSTPNHYYYGMDVW,IGHV1-69,IGHJ6,CMQALQTPWTF,IGKV2-28,HK CV03-168,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFYYDSSGFDYW,IGHV3-74,IGHJ1,CQQSYSTPPWTF,IGKV1-39,HK CV03-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFYYDSSGFDYW,IGHV3-74,IGHJ2,CQQSYSTPPWTF,IGKV1-39,HK CV03-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFYYDSSGFDYW,IGHV3-74,IGHJ3,CQQSYSTPPWTF,IGKV1-39,HK CV03-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFYYDSSGFDYW,IGHV3-74,IGHJ4,CQQSYSTPPWTF,IGKV1-39,HK CV03-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFYYDSSGFDYW,IGHV3-74,IGHJ5,CQQSYSTPPWTF,IGKV1-39,HK CV03-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFYYDSSGFDYW,IGHV3-74,IGHJ6,CQQSYSTPPWTF,IGKV1-39,HK CV03-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTIGGHAFDIW,IGHV4-4,IGHJ1,CQVWDSSSDHRVF,IGLV3-21,HL CV03-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTIGGHAFDIW,IGHV4-4,IGHJ2,CQVWDSSSDHRVF,IGLV3-21,HL CV03-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTIGGHAFDIW,IGHV4-4,IGHJ3,CQVWDSSSDHRVF,IGLV3-21,HL CV03-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTIGGHAFDIW,IGHV4-4,IGHJ4,CQVWDSSSDHRVF,IGLV3-21,HL CV03-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTIGGHAFDIW,IGHV4-4,IGHJ5,CQVWDSSSDHRVF,IGLV3-21,HL CV03-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTIGGHAFDIW,IGHV4-4,IGHJ6,CQVWDSSSDHRVF,IGLV3-21,HL CV03-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTLFSSVVPASWFDPW,IGHV1-24,IGHJ1,CSSYTSSSTPVVF,IGLV2-14,HL CV03-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTLFSSVVPASWFDPW,IGHV1-24,IGHJ2,CSSYTSSSTPVVF,IGLV2-14,HL CV03-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTLFSSVVPASWFDPW,IGHV1-24,IGHJ3,CSSYTSSSTPVVF,IGLV2-14,HL CV03-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTLFSSVVPASWFDPW,IGHV1-24,IGHJ4,CSSYTSSSTPVVF,IGLV2-14,HL CV03-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTLFSSVVPASWFDPW,IGHV1-24,IGHJ5,CSSYTSSSTPVVF,IGLV2-14,HL CV03-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSTLFSSVVPASWFDPW,IGHV1-24,IGHJ6,CSSYTSSSTPVVF,IGLV2-14,HL CV03-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARILPSDYFWSGYYSIQETDAFDIW,IGHV1-2,IGHJ1,CQQYNSYSSSF,IGKV1-5,HK CV03-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARILPSDYFWSGYYSIQETDAFDIW,IGHV1-2,IGHJ2,CQQYNSYSSSF,IGKV1-5,HK CV03-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARILPSDYFWSGYYSIQETDAFDIW,IGHV1-2,IGHJ3,CQQYNSYSSSF,IGKV1-5,HK CV03-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARILPSDYFWSGYYSIQETDAFDIW,IGHV1-2,IGHJ4,CQQYNSYSSSF,IGKV1-5,HK CV03-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARILPSDYFWSGYYSIQETDAFDIW,IGHV1-2,IGHJ5,CQQYNSYSSSF,IGKV1-5,HK CV03-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARILPSDYFWSGYYSIQETDAFDIW,IGHV1-2,IGHJ6,CQQYNSYSSSF,IGKV1-5,HK CV03-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQVFIAVAGTGFDYW,IGHV5-51,IGHJ1,CMQALQTPWTF,IGKV2-28,HK CV03-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQVFIAVAGTGFDYW,IGHV5-51,IGHJ2,CMQALQTPWTF,IGKV2-28,HK CV03-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQVFIAVAGTGFDYW,IGHV5-51,IGHJ3,CMQALQTPWTF,IGKV2-28,HK CV03-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQVFIAVAGTGFDYW,IGHV5-51,IGHJ4,CMQALQTPWTF,IGKV2-28,HK CV03-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQVFIAVAGTGFDYW,IGHV5-51,IGHJ5,CMQALQTPWTF,IGKV2-28,HK CV03-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQVFIAVAGTGFDYW,IGHV5-51,IGHJ6,CMQALQTPWTF,IGKV2-28,HK CV03-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFVSGPLMTENVPIYDSSGYYLTRYNWFDPW,IGHV4-31,IGHJ1,CGTWDSSLSAVVF,IGLV1-51,HL CV03-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFVSGPLMTENVPIYDSSGYYLTRYNWFDPW,IGHV4-31,IGHJ2,CGTWDSSLSAVVF,IGLV1-51,HL CV03-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFVSGPLMTENVPIYDSSGYYLTRYNWFDPW,IGHV4-31,IGHJ3,CGTWDSSLSAVVF,IGLV1-51,HL CV03-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFVSGPLMTENVPIYDSSGYYLTRYNWFDPW,IGHV4-31,IGHJ4,CGTWDSSLSAVVF,IGLV1-51,HL CV03-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFVSGPLMTENVPIYDSSGYYLTRYNWFDPW,IGHV4-31,IGHJ5,CGTWDSSLSAVVF,IGLV1-51,HL CV03-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDFVSGPLMTENVPIYDSSGYYLTRYNWFDPW,IGHV4-31,IGHJ6,CGTWDSSLSAVVF,IGLV1-51,HL CV03-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSGSYLLNW,IGHV3-23,IGHJ1,CQAWDSSTYVF,IGLV3-1,HL CV03-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSGSYLLNW,IGHV3-23,IGHJ2,CQAWDSSTYVF,IGLV3-1,HL CV03-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSGSYLLNW,IGHV3-23,IGHJ3,CQAWDSSTYVF,IGLV3-1,HL CV03-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSGSYLLNW,IGHV3-23,IGHJ4,CQAWDSSTYVF,IGLV3-1,HL CV03-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSGSYLLNW,IGHV3-23,IGHJ5,CQAWDSSTYVF,IGLV3-1,HL CV03-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSGSYLLNW,IGHV3-23,IGHJ6,CQAWDSSTYVF,IGLV3-1,HL CV03-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDGSSPLGGGMDVW,IGHV1-2,IGHJ1,CQAWDSSTYVF,IGLV3-1,HL CV03-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDGSSPLGGGMDVW,IGHV1-2,IGHJ2,CQAWDSSTYVF,IGLV3-1,HL CV03-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDGSSPLGGGMDVW,IGHV1-2,IGHJ3,CQAWDSSTYVF,IGLV3-1,HL CV03-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDGSSPLGGGMDVW,IGHV1-2,IGHJ4,CQAWDSSTYVF,IGLV3-1,HL CV03-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDGSSPLGGGMDVW,IGHV1-2,IGHJ5,CQAWDSSTYVF,IGLV3-1,HL CV03-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDGSSPLGGGMDVW,IGHV1-2,IGHJ6,CQAWDSSTYVF,IGLV3-1,HL CV03-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ1,CAVWDDSLSAWVF,IGLV1-47,HL CV03-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ2,CAVWDDSLSAWVF,IGLV1-47,HL CV03-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ3,CAVWDDSLSAWVF,IGLV1-47,HL CV03-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ4,CAVWDDSLSAWVF,IGLV1-47,HL CV03-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ5,CAVWDDSLSAWVF,IGLV1-47,HL CV03-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ6,CAVWDDSLSAWVF,IGLV1-47,HL CV03-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASTGHHQDASDYW,IGHV1-69,IGHJ1,CQQRSNWPPRVTF,IGKV3-11,HK CV03-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASTGHHQDASDYW,IGHV1-69,IGHJ2,CQQRSNWPPRVTF,IGKV3-11,HK CV03-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASTGHHQDASDYW,IGHV1-69,IGHJ3,CQQRSNWPPRVTF,IGKV3-11,HK CV03-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASTGHHQDASDYW,IGHV1-69,IGHJ4,CQQRSNWPPRVTF,IGKV3-11,HK CV03-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASTGHHQDASDYW,IGHV1-69,IGHJ5,CQQRSNWPPRVTF,IGKV3-11,HK CV03-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASTGHHQDASDYW,IGHV1-69,IGHJ6,CQQRSNWPPRVTF,IGKV3-11,HK CV03-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERLAAAGTDFDYW,IGHV1-2,IGHJ1,CQSYDSSLSDYVF,IGLV1-40,HL CV03-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERLAAAGTDFDYW,IGHV1-2,IGHJ2,CQSYDSSLSDYVF,IGLV1-40,HL CV03-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERLAAAGTDFDYW,IGHV1-2,IGHJ3,CQSYDSSLSDYVF,IGLV1-40,HL CV03-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERLAAAGTDFDYW,IGHV1-2,IGHJ4,CQSYDSSLSDYVF,IGLV1-40,HL CV03-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERLAAAGTDFDYW,IGHV1-2,IGHJ5,CQSYDSSLSDYVF,IGLV1-40,HL CV03-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARERLAAAGTDFDYW,IGHV1-2,IGHJ6,CQSYDSSLSDYVF,IGLV1-40,HL CV03-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ1,CAVWDDSLSAWVF,IGLV1-47,HL CV03-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ2,CAVWDDSLSAWVF,IGLV1-47,HL CV03-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ3,CAVWDDSLSAWVF,IGLV1-47,HL CV03-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ4,CAVWDDSLSAWVF,IGLV1-47,HL CV03-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ5,CAVWDDSLSAWVF,IGLV1-47,HL CV03-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSSLRYYFYGLDVW,IGHV3-23,IGHJ6,CAVWDDSLSAWVF,IGLV1-47,HL CV03-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRGHTLLWYYYYGMDVW,IGHV4-4,IGHJ1,CGTWDSSLSAGAVF,IGLV1-51,HL CV03-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRGHTLLWYYYYGMDVW,IGHV4-4,IGHJ2,CGTWDSSLSAGAVF,IGLV1-51,HL CV03-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRGHTLLWYYYYGMDVW,IGHV4-4,IGHJ3,CGTWDSSLSAGAVF,IGLV1-51,HL CV03-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRGHTLLWYYYYGMDVW,IGHV4-4,IGHJ4,CGTWDSSLSAGAVF,IGLV1-51,HL CV03-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRGHTLLWYYYYGMDVW,IGHV4-4,IGHJ5,CGTWDSSLSAGAVF,IGLV1-51,HL CV03-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRGHTLLWYYYYGMDVW,IGHV4-4,IGHJ6,CGTWDSSLSAGAVF,IGLV1-51,HL CV03-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGQRGLPFYYYYGMDVW,IGHV3-48,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,HL CV03-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGQRGLPFYYYYGMDVW,IGHV3-48,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,HL CV03-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGQRGLPFYYYYGMDVW,IGHV3-48,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,HL CV03-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGQRGLPFYYYYGMDVW,IGHV3-48,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,HL CV03-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGQRGLPFYYYYGMDVW,IGHV3-48,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,HL CV03-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGQRGLPFYYYYGMDVW,IGHV3-48,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,HL CV03-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ1,CAVWDDSLSAWVF,IGLV1-47,HL CV03-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ2,CAVWDDSLSAWVF,IGLV1-47,HL CV03-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ3,CAVWDDSLSAWVF,IGLV1-47,HL CV03-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ4,CAVWDDSLSAWVF,IGLV1-47,HL CV03-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ5,CAVWDDSLSAWVF,IGLV1-47,HL CV03-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGSGDIERMVSTLRYYFYGLDVW,IGHV3-23,IGHJ6,CAVWDDSLSAWVF,IGLV1-47,HL CV03-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGMGYDFWSGYSSYYGMDVW,IGHV4-4,IGHJ1,CQQYNSYPLTF,IGKV1-16,HK CV03-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGMGYDFWSGYSSYYGMDVW,IGHV4-4,IGHJ2,CQQYNSYPLTF,IGKV1-16,HK CV03-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGMGYDFWSGYSSYYGMDVW,IGHV4-4,IGHJ3,CQQYNSYPLTF,IGKV1-16,HK CV03-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGMGYDFWSGYSSYYGMDVW,IGHV4-4,IGHJ4,CQQYNSYPLTF,IGKV1-16,HK CV03-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGMGYDFWSGYSSYYGMDVW,IGHV4-4,IGHJ5,CQQYNSYPLTF,IGKV1-16,HK CV03-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGMGYDFWSGYSSYYGMDVW,IGHV4-4,IGHJ6,CQQYNSYPLTF,IGKV1-16,HK CV03-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYNRRFDYW,IGHV3-11,IGHJ1,CQQYDNLPLTF,IGKV1-33,HK CV03-191,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYNRRFDYW,IGHV3-11,IGHJ2,CQQYDNLPLTF,IGKV1-33,HK CV03-191,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYNRRFDYW,IGHV3-11,IGHJ3,CQQYDNLPLTF,IGKV1-33,HK CV03-191,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYNRRFDYW,IGHV3-11,IGHJ4,CQQYDNLPLTF,IGKV1-33,HK CV03-191,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYNRRFDYW,IGHV3-11,IGHJ5,CQQYDNLPLTF,IGKV1-33,HK CV03-191,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYNRRFDYW,IGHV3-11,IGHJ6,CQQYDNLPLTF,IGKV1-33,HK CV03-191,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPLRYYDSSGYLYYGMDVW,IGHV3-15,IGHJ1,CMQALLTPSTF,IGKV2-28,HK CV03-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPLRYYDSSGYLYYGMDVW,IGHV3-15,IGHJ2,CMQALLTPSTF,IGKV2-28,HK CV03-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPLRYYDSSGYLYYGMDVW,IGHV3-15,IGHJ3,CMQALLTPSTF,IGKV2-28,HK CV03-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPLRYYDSSGYLYYGMDVW,IGHV3-15,IGHJ4,CMQALLTPSTF,IGKV2-28,HK CV03-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPLRYYDSSGYLYYGMDVW,IGHV3-15,IGHJ5,CMQALLTPSTF,IGKV2-28,HK CV03-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDPLRYYDSSGYLYYGMDVW,IGHV3-15,IGHJ6,CMQALLTPSTF,IGKV2-28,HK CV03-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGSWPNVFDIW,IGHV3-53,IGHJ1,CVLYMGSGIWVF,IGLV8-61,HL CV03-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGSWPNVFDIW,IGHV3-53,IGHJ2,CVLYMGSGIWVF,IGLV8-61,HL CV03-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGSWPNVFDIW,IGHV3-53,IGHJ3,CVLYMGSGIWVF,IGLV8-61,HL CV03-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGSWPNVFDIW,IGHV3-53,IGHJ4,CVLYMGSGIWVF,IGLV8-61,HL CV03-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGSWPNVFDIW,IGHV3-53,IGHJ5,CVLYMGSGIWVF,IGLV8-61,HL CV03-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGSWPNVFDIW,IGHV3-53,IGHJ6,CVLYMGSGIWVF,IGLV8-61,HL CV03-193,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLRVRGVIKYYYYGMDVW,IGHV1-18,IGHJ1,CQSADSSGTHWVF,IGLV3-25,HL CV03-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLRVRGVIKYYYYGMDVW,IGHV1-18,IGHJ2,CQSADSSGTHWVF,IGLV3-25,HL CV03-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLRVRGVIKYYYYGMDVW,IGHV1-18,IGHJ3,CQSADSSGTHWVF,IGLV3-25,HL CV03-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLRVRGVIKYYYYGMDVW,IGHV1-18,IGHJ4,CQSADSSGTHWVF,IGLV3-25,HL CV03-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLRVRGVIKYYYYGMDVW,IGHV1-18,IGHJ5,CQSADSSGTHWVF,IGLV3-25,HL CV03-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLRVRGVIKYYYYGMDVW,IGHV1-18,IGHJ6,CQSADSSGTHWVF,IGLV3-25,HL CV03-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGYSSSWFSYLDSW,IGHV3-30,IGHJ1,CQQYGSLRLTF,IGKV3-20,HK CV05-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGYSSSWFSYLDSW,IGHV3-30,IGHJ2,CQQYGSLRLTF,IGKV3-20,HK CV05-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGYSSSWFSYLDSW,IGHV3-30,IGHJ3,CQQYGSLRLTF,IGKV3-20,HK CV05-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGYSSSWFSYLDSW,IGHV3-30,IGHJ4,CQQYGSLRLTF,IGKV3-20,HK CV05-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGYSSSWFSYLDSW,IGHV3-30,IGHJ5,CQQYGSLRLTF,IGKV3-20,HK CV05-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGYSSSWFSYLDSW,IGHV3-30,IGHJ6,CQQYGSLRLTF,IGKV3-20,HK CV05-101,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ1,CQQYGVSPRTF,IGKV3-20,HK CV05-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ2,CQQYGVSPRTF,IGKV3-20,HK CV05-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ3,CQQYGVSPRTF,IGKV3-20,HK CV05-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ4,CQQYGVSPRTF,IGKV3-20,HK CV05-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ5,CQQYGVSPRTF,IGKV3-20,HK CV05-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ6,CQQYGVSPRTF,IGKV3-20,HK CV05-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGRSLQPNLGFDLW,IGHV5-51,IGHJ1,CMQGSHWPLTF,IGKV2-30,HK CV05-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGRSLQPNLGFDLW,IGHV5-51,IGHJ2,CMQGSHWPLTF,IGKV2-30,HK CV05-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGRSLQPNLGFDLW,IGHV5-51,IGHJ3,CMQGSHWPLTF,IGKV2-30,HK CV05-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGRSLQPNLGFDLW,IGHV5-51,IGHJ4,CMQGSHWPLTF,IGKV2-30,HK CV05-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGRSLQPNLGFDLW,IGHV5-51,IGHJ5,CMQGSHWPLTF,IGKV2-30,HK CV05-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGRSLQPNLGFDLW,IGHV5-51,IGHJ6,CMQGSHWPLTF,IGKV2-30,HK CV05-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSESAWNRIGNFYFDLW,IGHV3-21,IGHJ1,CQQYNDWLITF,IGKV3-15,HK CV05-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSESAWNRIGNFYFDLW,IGHV3-21,IGHJ2,CQQYNDWLITF,IGKV3-15,HK CV05-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSESAWNRIGNFYFDLW,IGHV3-21,IGHJ3,CQQYNDWLITF,IGKV3-15,HK CV05-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSESAWNRIGNFYFDLW,IGHV3-21,IGHJ4,CQQYNDWLITF,IGKV3-15,HK CV05-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSESAWNRIGNFYFDLW,IGHV3-21,IGHJ5,CQQYNDWLITF,IGKV3-15,HK CV05-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSESAWNRIGNFYFDLW,IGHV3-21,IGHJ6,CQQYNDWLITF,IGKV3-15,HK CV05-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHHLKRGYATRYGMDVW,IGHV5-10-1,IGHJ1,CQQSYSTPWTF,IGKV1-39,HK CV05-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHHLKRGYATRYGMDVW,IGHV5-10-1,IGHJ2,CQQSYSTPWTF,IGKV1-39,HK CV05-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHHLKRGYATRYGMDVW,IGHV5-10-1,IGHJ3,CQQSYSTPWTF,IGKV1-39,HK CV05-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHHLKRGYATRYGMDVW,IGHV5-10-1,IGHJ4,CQQSYSTPWTF,IGKV1-39,HK CV05-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHHLKRGYATRYGMDVW,IGHV5-10-1,IGHJ5,CQQSYSTPWTF,IGKV1-39,HK CV05-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHHLKRGYATRYGMDVW,IGHV5-10-1,IGHJ6,CQQSYSTPWTF,IGKV1-39,HK CV05-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLEGPYCSDTTCYEGGQGLDYW,IGHV4-31,IGHJ1,CHQRGNWWTF,IGKV3-11,HK CV05-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLEGPYCSDTTCYEGGQGLDYW,IGHV4-31,IGHJ2,CHQRGNWWTF,IGKV3-11,HK CV05-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLEGPYCSDTTCYEGGQGLDYW,IGHV4-31,IGHJ3,CHQRGNWWTF,IGKV3-11,HK CV05-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLEGPYCSDTTCYEGGQGLDYW,IGHV4-31,IGHJ4,CHQRGNWWTF,IGKV3-11,HK CV05-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLEGPYCSDTTCYEGGQGLDYW,IGHV4-31,IGHJ5,CHQRGNWWTF,IGKV3-11,HK CV05-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASLEGPYCSDTTCYEGGQGLDYW,IGHV4-31,IGHJ6,CHQRGNWWTF,IGKV3-11,HK CV05-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ1,CQQYGVSPRTF,IGKV3-20,HK CV05-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ2,CQQYGVSPRTF,IGKV3-20,HK CV05-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ3,CQQYGVSPRTF,IGKV3-20,HK CV05-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ4,CQQYGVSPRTF,IGKV3-20,HK CV05-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ5,CQQYGVSPRTF,IGKV3-20,HK CV05-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ6,CQQYGVSPRTF,IGKV3-20,HK CV05-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLDGDYVTYYYGMDVW,IGHV3-33,IGHJ1,CSSYTSSSTPVVF,IGLV2-14,HL CV05-111,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLDGDYVTYYYGMDVW,IGHV3-33,IGHJ2,CSSYTSSSTPVVF,IGLV2-14,HL CV05-111,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLDGDYVTYYYGMDVW,IGHV3-33,IGHJ3,CSSYTSSSTPVVF,IGLV2-14,HL CV05-111,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLDGDYVTYYYGMDVW,IGHV3-33,IGHJ4,CSSYTSSSTPVVF,IGLV2-14,HL CV05-111,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLDGDYVTYYYGMDVW,IGHV3-33,IGHJ5,CSSYTSSSTPVVF,IGLV2-14,HL CV05-111,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLDGDYVTYYYGMDVW,IGHV3-33,IGHJ6,CSSYTSSSTPVVF,IGLV2-14,HL CV05-111,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGDGYRNFWYFDIW,IGHV3-30,IGHJ1,CMQALQTPTF,IGKV2-28,HK CV05-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGDGYRNFWYFDIW,IGHV3-30,IGHJ2,CMQALQTPTF,IGKV2-28,HK CV05-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGDGYRNFWYFDIW,IGHV3-30,IGHJ3,CMQALQTPTF,IGKV2-28,HK CV05-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGDGYRNFWYFDIW,IGHV3-30,IGHJ4,CMQALQTPTF,IGKV2-28,HK CV05-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGDGYRNFWYFDIW,IGHV3-30,IGHJ5,CMQALQTPTF,IGKV2-28,HK CV05-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGDGYRNFWYFDIW,IGHV3-30,IGHJ6,CMQALQTPTF,IGKV2-28,HK CV05-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTVGDYGDYW,IGHV3-30-3,IGHJ1,CQAWDSSTVVF,IGLV3-1,HL CV05-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTVGDYGDYW,IGHV3-30-3,IGHJ2,CQAWDSSTVVF,IGLV3-1,HL CV05-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTVGDYGDYW,IGHV3-30-3,IGHJ3,CQAWDSSTVVF,IGLV3-1,HL CV05-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTVGDYGDYW,IGHV3-30-3,IGHJ4,CQAWDSSTVVF,IGLV3-1,HL CV05-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTVGDYGDYW,IGHV3-30-3,IGHJ5,CQAWDSSTVVF,IGLV3-1,HL CV05-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTVGDYGDYW,IGHV3-30-3,IGHJ6,CQAWDSSTVVF,IGLV3-1,HL CV05-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGGYSGYGPYYYGMDVW,IGHV3-48,IGHJ1,CQQSYSTPWTF,IGKV1-39,HK CV05-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGGYSGYGPYYYGMDVW,IGHV3-48,IGHJ2,CQQSYSTPWTF,IGKV1-39,HK CV05-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGGYSGYGPYYYGMDVW,IGHV3-48,IGHJ3,CQQSYSTPWTF,IGKV1-39,HK CV05-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGGYSGYGPYYYGMDVW,IGHV3-48,IGHJ4,CQQSYSTPWTF,IGKV1-39,HK CV05-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGGYSGYGPYYYGMDVW,IGHV3-48,IGHJ5,CQQSYSTPWTF,IGKV1-39,HK CV05-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGGYSGYGPYYYGMDVW,IGHV3-48,IGHJ6,CQQSYSTPWTF,IGKV1-39,HK CV05-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKTSWLVAYYYGLDVW,IGHV3-23,IGHJ1,CQQVNSHPHTF,IGKV1-9,HK CV05-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKTSWLVAYYYGLDVW,IGHV3-23,IGHJ2,CQQVNSHPHTF,IGKV1-9,HK CV05-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKTSWLVAYYYGLDVW,IGHV3-23,IGHJ3,CQQVNSHPHTF,IGKV1-9,HK CV05-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKTSWLVAYYYGLDVW,IGHV3-23,IGHJ4,CQQVNSHPHTF,IGKV1-9,HK CV05-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKTSWLVAYYYGLDVW,IGHV3-23,IGHJ5,CQQVNSHPHTF,IGKV1-9,HK CV05-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEKTSWLVAYYYGLDVW,IGHV3-23,IGHJ6,CQQVNSHPHTF,IGKV1-9,HK CV05-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ1,CQQYSNWPRTF,IGKV3-15,HK CV05-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ2,CQQYSNWPRTF,IGKV3-15,HK CV05-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ3,CQQYSNWPRTF,IGKV3-15,HK CV05-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ4,CQQYSNWPRTF,IGKV3-15,HK CV05-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ5,CQQYSNWPRTF,IGKV3-15,HK CV05-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ6,CQQYSNWPRTF,IGKV3-15,HK CV05-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ1,CQQYNSYWTF,IGKV1-5,HK CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ2,CQQYNSYWTF,IGKV1-5,HK CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ3,CQQYNSYWTF,IGKV1-5,HK CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ4,CQQYNSYWTF,IGKV1-5,HK CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ5,CQQYNSYWTF,IGKV1-5,HK CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ6,CQQYNSYWTF,IGKV1-5,HK CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ1,CQVWDSSSDHWVF,IGLV3-21,HL CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ2,CQVWDSSSDHWVF,IGLV3-21,HL CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ3,CQVWDSSSDHWVF,IGLV3-21,HL CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ4,CQVWDSSSDHWVF,IGLV3-21,HL CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ5,CQVWDSSSDHWVF,IGLV3-21,HL CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKPVGSSGYYEGGKPIDYW,IGHV3-30,IGHJ6,CQVWDSSSDHWVF,IGLV3-21,HL CV05-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNRAGVIDYW,IGHV5-51,IGHJ1,CQSYDSSNLWVF,IGLV6-57,HL CV05-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNRAGVIDYW,IGHV5-51,IGHJ2,CQSYDSSNLWVF,IGLV6-57,HL CV05-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNRAGVIDYW,IGHV5-51,IGHJ3,CQSYDSSNLWVF,IGLV6-57,HL CV05-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNRAGVIDYW,IGHV5-51,IGHJ4,CQSYDSSNLWVF,IGLV6-57,HL CV05-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNRAGVIDYW,IGHV5-51,IGHJ5,CQSYDSSNLWVF,IGLV6-57,HL CV05-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNRAGVIDYW,IGHV5-51,IGHJ6,CQSYDSSNLWVF,IGLV6-57,HL CV05-120,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRERIDYDHSGVSTSAFEFW,IGHV1-8,IGHJ1,CGGWDDSLNGYVF,IGLV1-44,HL CV05-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRERIDYDHSGVSTSAFEFW,IGHV1-8,IGHJ2,CGGWDDSLNGYVF,IGLV1-44,HL CV05-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRERIDYDHSGVSTSAFEFW,IGHV1-8,IGHJ3,CGGWDDSLNGYVF,IGLV1-44,HL CV05-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRERIDYDHSGVSTSAFEFW,IGHV1-8,IGHJ4,CGGWDDSLNGYVF,IGLV1-44,HL CV05-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRERIDYDHSGVSTSAFEFW,IGHV1-8,IGHJ5,CGGWDDSLNGYVF,IGLV1-44,HL CV05-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRERIDYDHSGVSTSAFEFW,IGHV1-8,IGHJ6,CGGWDDSLNGYVF,IGLV1-44,HL CV05-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGYCSGGNCKMAHSYYGLDVW,IGHV3-23,IGHJ1,CAAWDDSLSGHWVF,IGLV1-47,HL CV05-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGYCSGGNCKMAHSYYGLDVW,IGHV3-23,IGHJ2,CAAWDDSLSGHWVF,IGLV1-47,HL CV05-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGYCSGGNCKMAHSYYGLDVW,IGHV3-23,IGHJ3,CAAWDDSLSGHWVF,IGLV1-47,HL CV05-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGYCSGGNCKMAHSYYGLDVW,IGHV3-23,IGHJ4,CAAWDDSLSGHWVF,IGLV1-47,HL CV05-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGYCSGGNCKMAHSYYGLDVW,IGHV3-23,IGHJ5,CAAWDDSLSGHWVF,IGLV1-47,HL CV05-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGYCSGGNCKMAHSYYGLDVW,IGHV3-23,IGHJ6,CAAWDDSLSGHWVF,IGLV1-47,HL CV05-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSNTASTMIVVVVQRNWFDPW,IGHV4-39,IGHJ1,CQQYNNWPPITF,IGKV3-15,HK CV05-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSNTASTMIVVVVQRNWFDPW,IGHV4-39,IGHJ2,CQQYNNWPPITF,IGKV3-15,HK CV05-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSNTASTMIVVVVQRNWFDPW,IGHV4-39,IGHJ3,CQQYNNWPPITF,IGKV3-15,HK CV05-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSNTASTMIVVVVQRNWFDPW,IGHV4-39,IGHJ4,CQQYNNWPPITF,IGKV3-15,HK CV05-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSNTASTMIVVVVQRNWFDPW,IGHV4-39,IGHJ5,CQQYNNWPPITF,IGKV3-15,HK CV05-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSNTASTMIVVVVQRNWFDPW,IGHV4-39,IGHJ6,CQQYNNWPPITF,IGKV3-15,HK CV05-125,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRARAKWLAYSNYFDYW,IGHV3-48,IGHJ1,CQQYNNWPLF,IGKV3-15,HK CV05-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRARAKWLAYSNYFDYW,IGHV3-48,IGHJ2,CQQYNNWPLF,IGKV3-15,HK CV05-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRARAKWLAYSNYFDYW,IGHV3-48,IGHJ3,CQQYNNWPLF,IGKV3-15,HK CV05-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRARAKWLAYSNYFDYW,IGHV3-48,IGHJ4,CQQYNNWPLF,IGKV3-15,HK CV05-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRARAKWLAYSNYFDYW,IGHV3-48,IGHJ5,CQQYNNWPLF,IGKV3-15,HK CV05-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRARAKWLAYSNYFDYW,IGHV3-48,IGHJ6,CQQYNNWPLF,IGKV3-15,HK CV05-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSSWEYYFDYW,IGHV3-33,IGHJ1,CYSTDSSGNHRGVF,IGLV3-10,HL CV05-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSSWEYYFDYW,IGHV3-33,IGHJ2,CYSTDSSGNHRGVF,IGLV3-10,HL CV05-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSSWEYYFDYW,IGHV3-33,IGHJ3,CYSTDSSGNHRGVF,IGLV3-10,HL CV05-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSSWEYYFDYW,IGHV3-33,IGHJ4,CYSTDSSGNHRGVF,IGLV3-10,HL CV05-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSSWEYYFDYW,IGHV3-33,IGHJ5,CYSTDSSGNHRGVF,IGLV3-10,HL CV05-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSSWEYYFDYW,IGHV3-33,IGHJ6,CYSTDSSGNHRGVF,IGLV3-10,HL CV05-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,HL CV05-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,HL CV05-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,HL CV05-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,HL CV05-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,HL CV05-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,HL CV05-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYIGYCSGSTCTTNGGGDYW,IGHV3-23,IGHJ1,CVTWDSSLSAGVF,IGLV1-51,HL CV05-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYIGYCSGSTCTTNGGGDYW,IGHV3-23,IGHJ2,CVTWDSSLSAGVF,IGLV1-51,HL CV05-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYIGYCSGSTCTTNGGGDYW,IGHV3-23,IGHJ3,CVTWDSSLSAGVF,IGLV1-51,HL CV05-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYIGYCSGSTCTTNGGGDYW,IGHV3-23,IGHJ4,CVTWDSSLSAGVF,IGLV1-51,HL CV05-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYIGYCSGSTCTTNGGGDYW,IGHV3-23,IGHJ5,CVTWDSSLSAGVF,IGLV1-51,HL CV05-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYIGYCSGSTCTTNGGGDYW,IGHV3-23,IGHJ6,CVTWDSSLSAGVF,IGLV1-51,HL CV05-131,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAGIRGGISMVRAHFDIW,IGHV3-23,IGHJ1,CSSYAGSNNFVF,IGLV2-8,HL CV05-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAGIRGGISMVRAHFDIW,IGHV3-23,IGHJ2,CSSYAGSNNFVF,IGLV2-8,HL CV05-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAGIRGGISMVRAHFDIW,IGHV3-23,IGHJ3,CSSYAGSNNFVF,IGLV2-8,HL CV05-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAGIRGGISMVRAHFDIW,IGHV3-23,IGHJ4,CSSYAGSNNFVF,IGLV2-8,HL CV05-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAGIRGGISMVRAHFDIW,IGHV3-23,IGHJ5,CSSYAGSNNFVF,IGLV2-8,HL CV05-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAGIRGGISMVRAHFDIW,IGHV3-23,IGHJ6,CSSYAGSNNFVF,IGLV2-8,HL CV05-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ1,CQQSYSTHTF,IGKV1-39,HK CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ2,CQQSYSTHTF,IGKV1-39,HK CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ3,CQQSYSTHTF,IGKV1-39,HK CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ4,CQQSYSTHTF,IGKV1-39,HK CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ5,CQQSYSTHTF,IGKV1-39,HK CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ6,CQQSYSTHTF,IGKV1-39,HK CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ1,CQAWDSSNVVF,IGLV3-1,HL CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ2,CQAWDSSNVVF,IGLV3-1,HL CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ3,CQAWDSSNVVF,IGLV3-1,HL CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ4,CQAWDSSNVVF,IGLV3-1,HL CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ5,CQAWDSSNVVF,IGLV3-1,HL CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTAMVQRFDYW,IGHV3-33,IGHJ6,CQAWDSSNVVF,IGLV3-1,HL CV05-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDIVVESTDQDPMDVW,IGHV1-69,IGHJ1,CQQYYSTSSITF,IGKV4-1,HK CV05-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDIVVESTDQDPMDVW,IGHV1-69,IGHJ2,CQQYYSTSSITF,IGKV4-1,HK CV05-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDIVVESTDQDPMDVW,IGHV1-69,IGHJ3,CQQYYSTSSITF,IGKV4-1,HK CV05-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDIVVESTDQDPMDVW,IGHV1-69,IGHJ4,CQQYYSTSSITF,IGKV4-1,HK CV05-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDIVVESTDQDPMDVW,IGHV1-69,IGHJ5,CQQYYSTSSITF,IGKV4-1,HK CV05-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRDIVVESTDQDPMDVW,IGHV1-69,IGHJ6,CQQYYSTSSITF,IGKV4-1,HK CV05-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ1,CQQYNNWPRTF,IGKV3-15,HK CV05-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ2,CQQYNNWPRTF,IGKV3-15,HK CV05-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ3,CQQYNNWPRTF,IGKV3-15,HK CV05-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ4,CQQYNNWPRTF,IGKV3-15,HK CV05-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ5,CQQYNNWPRTF,IGKV3-15,HK CV05-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ6,CQQYNNWPRTF,IGKV3-15,HK CV05-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFSGANGDYYYYGMDVW,IGHV3-23,IGHJ1,CQSADSSGTWVF,IGLV3-25,HL CV05-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFSGANGDYYYYGMDVW,IGHV3-23,IGHJ2,CQSADSSGTWVF,IGLV3-25,HL CV05-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFSGANGDYYYYGMDVW,IGHV3-23,IGHJ3,CQSADSSGTWVF,IGLV3-25,HL CV05-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFSGANGDYYYYGMDVW,IGHV3-23,IGHJ4,CQSADSSGTWVF,IGLV3-25,HL CV05-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFSGANGDYYYYGMDVW,IGHV3-23,IGHJ5,CQSADSSGTWVF,IGLV3-25,HL CV05-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFSGANGDYYYYGMDVW,IGHV3-23,IGHJ6,CQSADSSGTWVF,IGLV3-25,HL CV05-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGGGSGFYYFW,IGHV4-59,IGHJ1,CQQYKSSSSTF,IGKV1-5,HK CV05-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGGGSGFYYFW,IGHV4-59,IGHJ2,CQQYKSSSSTF,IGKV1-5,HK CV05-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGGGSGFYYFW,IGHV4-59,IGHJ3,CQQYKSSSSTF,IGKV1-5,HK CV05-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGGGSGFYYFW,IGHV4-59,IGHJ4,CQQYKSSSSTF,IGKV1-5,HK CV05-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGGGSGFYYFW,IGHV4-59,IGHJ5,CQQYKSSSSTF,IGKV1-5,HK CV05-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGGGSGFYYFW,IGHV4-59,IGHJ6,CQQYKSSSSTF,IGKV1-5,HK CV05-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVAAGVDYW,IGHV4-59,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,HL CV05-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVAAGVDYW,IGHV4-59,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,HL CV05-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVAAGVDYW,IGHV4-59,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,HL CV05-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVAAGVDYW,IGHV4-59,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,HL CV05-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVAAGVDYW,IGHV4-59,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,HL CV05-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVAAGVDYW,IGHV4-59,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,HL CV05-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTPGDGMDVW,IGHV3-30-3,IGHJ1,,IGLV3-10,HL CV05-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTPGDGMDVW,IGHV3-30-3,IGHJ2,,IGLV3-10,HL CV05-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTPGDGMDVW,IGHV3-30-3,IGHJ3,,IGLV3-10,HL CV05-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTPGDGMDVW,IGHV3-30-3,IGHJ4,,IGLV3-10,HL CV05-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTPGDGMDVW,IGHV3-30-3,IGHJ5,,IGLV3-10,HL CV05-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTPGDGMDVW,IGHV3-30-3,IGHJ6,,IGLV3-10,HL CV05-144,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHAIYCSGGSCYAYFDYW,IGHV5-10-1,IGHJ1,,IGLV1-41,HL CV05-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHAIYCSGGSCYAYFDYW,IGHV5-10-1,IGHJ2,,IGLV1-41,HL CV05-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHAIYCSGGSCYAYFDYW,IGHV5-10-1,IGHJ3,,IGLV1-41,HL CV05-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHAIYCSGGSCYAYFDYW,IGHV5-10-1,IGHJ4,,IGLV1-41,HL CV05-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHAIYCSGGSCYAYFDYW,IGHV5-10-1,IGHJ5,,IGLV1-41,HL CV05-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHAIYCSGGSCYAYFDYW,IGHV5-10-1,IGHJ6,,IGLV1-41,HL CV05-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ1,CQQYNNWPRTF,IGKV3-15,HK CV05-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ2,CQQYNNWPRTF,IGKV3-15,HK CV05-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ3,CQQYNNWPRTF,IGKV3-15,HK CV05-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ4,CQQYNNWPRTF,IGKV3-15,HK CV05-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ5,CQQYNNWPRTF,IGKV3-15,HK CV05-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCPWVDVFDIW,IGHV4-31,IGHJ6,CQQYNNWPRTF,IGKV3-15,HK CV05-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ1,CQQYYSTPWTF,IGKV4-1,HK CV05-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ2,CQQYYSTPWTF,IGKV4-1,HK CV05-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ3,CQQYYSTPWTF,IGKV4-1,HK CV05-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ4,CQQYYSTPWTF,IGKV4-1,HK CV05-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ5,CQQYYSTPWTF,IGKV4-1,HK CV05-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ6,CQQYYSTPWTF,IGKV4-1,HK CV05-148,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGFPGSTNVHFYFYGLDVW,IGHV4-59,IGHJ1,CQQLNSYRTF,IGKV1-9,HK CV05-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGFPGSTNVHFYFYGLDVW,IGHV4-59,IGHJ2,CQQLNSYRTF,IGKV1-9,HK CV05-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGFPGSTNVHFYFYGLDVW,IGHV4-59,IGHJ3,CQQLNSYRTF,IGKV1-9,HK CV05-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGFPGSTNVHFYFYGLDVW,IGHV4-59,IGHJ4,CQQLNSYRTF,IGKV1-9,HK CV05-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGFPGSTNVHFYFYGLDVW,IGHV4-59,IGHJ5,CQQLNSYRTF,IGKV1-9,HK CV05-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGFPGSTNVHFYFYGLDVW,IGHV4-59,IGHJ6,CQQLNSYRTF,IGKV1-9,HK CV05-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGEVVTAISYYYYGMDVW,IGHV4-59,IGHJ1,CQAWDSSSVVF,IGLV3-1,HL CV05-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGEVVTAISYYYYGMDVW,IGHV4-59,IGHJ2,CQAWDSSSVVF,IGLV3-1,HL CV05-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGEVVTAISYYYYGMDVW,IGHV4-59,IGHJ3,CQAWDSSSVVF,IGLV3-1,HL CV05-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGEVVTAISYYYYGMDVW,IGHV4-59,IGHJ4,CQAWDSSSVVF,IGLV3-1,HL CV05-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGEVVTAISYYYYGMDVW,IGHV4-59,IGHJ5,CQAWDSSSVVF,IGLV3-1,HL CV05-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGEVVTAISYYYYGMDVW,IGHV4-59,IGHJ6,CQAWDSSSVVF,IGLV3-1,HL CV05-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTERIYDYVWGSYRYSDYW,IGHV3-15,IGHJ1,CQQYGSSPVTF,IGKV3-20,HK CV05-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTERIYDYVWGSYRYSDYW,IGHV3-15,IGHJ2,CQQYGSSPVTF,IGKV3-20,HK CV05-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTERIYDYVWGSYRYSDYW,IGHV3-15,IGHJ3,CQQYGSSPVTF,IGKV3-20,HK CV05-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTERIYDYVWGSYRYSDYW,IGHV3-15,IGHJ4,CQQYGSSPVTF,IGKV3-20,HK CV05-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTERIYDYVWGSYRYSDYW,IGHV3-15,IGHJ5,CQQYGSSPVTF,IGKV3-20,HK CV05-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTERIYDYVWGSYRYSDYW,IGHV3-15,IGHJ6,CQQYGSSPVTF,IGKV3-20,HK CV05-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLNVW,IGHV4-4,IGHJ1,CQQYVNWPFTF,IGKV3-15,HK CV05-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLNVW,IGHV4-4,IGHJ2,CQQYVNWPFTF,IGKV3-15,HK CV05-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLNVW,IGHV4-4,IGHJ3,CQQYVNWPFTF,IGKV3-15,HK CV05-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLNVW,IGHV4-4,IGHJ4,CQQYVNWPFTF,IGKV3-15,HK CV05-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLNVW,IGHV4-4,IGHJ5,CQQYVNWPFTF,IGKV3-15,HK CV05-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLNVW,IGHV4-4,IGHJ6,CQQYVNWPFTF,IGKV3-15,HK CV05-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALRITMIVVVTHYGMDVW,IGHV1-2,IGHJ1,CQQYGSSPYTF,IGKV3-20,HK CV05-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALRITMIVVVTHYGMDVW,IGHV1-2,IGHJ2,CQQYGSSPYTF,IGKV3-20,HK CV05-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALRITMIVVVTHYGMDVW,IGHV1-2,IGHJ3,CQQYGSSPYTF,IGKV3-20,HK CV05-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALRITMIVVVTHYGMDVW,IGHV1-2,IGHJ4,CQQYGSSPYTF,IGKV3-20,HK CV05-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALRITMIVVVTHYGMDVW,IGHV1-2,IGHJ5,CQQYGSSPYTF,IGKV3-20,HK CV05-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALRITMIVVVTHYGMDVW,IGHV1-2,IGHJ6,CQQYGSSPYTF,IGKV3-20,HK CV05-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKSDFWSGNFDYW,IGHV3-48,IGHJ1,CQQYDNLLVTF,IGKV1-33,HK CV05-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKSDFWSGNFDYW,IGHV3-48,IGHJ2,CQQYDNLLVTF,IGKV1-33,HK CV05-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKSDFWSGNFDYW,IGHV3-48,IGHJ3,CQQYDNLLVTF,IGKV1-33,HK CV05-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKSDFWSGNFDYW,IGHV3-48,IGHJ4,CQQYDNLLVTF,IGKV1-33,HK CV05-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKSDFWSGNFDYW,IGHV3-48,IGHJ5,CQQYDNLLVTF,IGKV1-33,HK CV05-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKSDFWSGNFDYW,IGHV3-48,IGHJ6,CQQYDNLLVTF,IGKV1-33,HK CV05-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKVDYYPYYFDYW,IGHV4-38-2,IGHJ1,CQVWDSSSDHRVF,IGLV3-21,HL CV05-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKVDYYPYYFDYW,IGHV4-38-2,IGHJ2,CQVWDSSSDHRVF,IGLV3-21,HL CV05-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKVDYYPYYFDYW,IGHV4-38-2,IGHJ3,CQVWDSSSDHRVF,IGLV3-21,HL CV05-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKVDYYPYYFDYW,IGHV4-38-2,IGHJ4,CQVWDSSSDHRVF,IGLV3-21,HL CV05-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKVDYYPYYFDYW,IGHV4-38-2,IGHJ5,CQVWDSSSDHRVF,IGLV3-21,HL CV05-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKVDYYPYYFDYW,IGHV4-38-2,IGHJ6,CQVWDSSSDHRVF,IGLV3-21,HL CV05-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQWSGTTVTSMGHW,IGHV3-21,IGHJ1,CQQYDSNWYTF,IGKV1-5,HK CV05-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQWSGTTVTSMGHW,IGHV3-21,IGHJ2,CQQYDSNWYTF,IGKV1-5,HK CV05-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQWSGTTVTSMGHW,IGHV3-21,IGHJ3,CQQYDSNWYTF,IGKV1-5,HK CV05-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQWSGTTVTSMGHW,IGHV3-21,IGHJ4,CQQYDSNWYTF,IGKV1-5,HK CV05-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQWSGTTVTSMGHW,IGHV3-21,IGHJ5,CQQYDSNWYTF,IGKV1-5,HK CV05-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQWSGTTVTSMGHW,IGHV3-21,IGHJ6,CQQYDSNWYTF,IGKV1-5,HK CV05-162,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREVMVRGALPPYGMDVW,IGHV1-2,IGHJ1,CQQRSNWPPVTF,IGKV3-11,HK CV05-163,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREVMVRGALPPYGMDVW,IGHV1-2,IGHJ2,CQQRSNWPPVTF,IGKV3-11,HK CV05-163,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREVMVRGALPPYGMDVW,IGHV1-2,IGHJ3,CQQRSNWPPVTF,IGKV3-11,HK CV05-163,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREVMVRGALPPYGMDVW,IGHV1-2,IGHJ4,CQQRSNWPPVTF,IGKV3-11,HK CV05-163,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREVMVRGALPPYGMDVW,IGHV1-2,IGHJ5,CQQRSNWPPVTF,IGKV3-11,HK CV05-163,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREVMVRGALPPYGMDVW,IGHV1-2,IGHJ6,CQQRSNWPPVTF,IGKV3-11,HK CV05-163,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCSWVDVFDIW,IGHV4-31,IGHJ1,CQQYNNWPRTF,IGKV3-15,HK CV05-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCSWVDVFDIW,IGHV4-31,IGHJ2,CQQYNNWPRTF,IGKV3-15,HK CV05-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCSWVDVFDIW,IGHV4-31,IGHJ3,CQQYNNWPRTF,IGKV3-15,HK CV05-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCSWVDVFDIW,IGHV4-31,IGHJ4,CQQYNNWPRTF,IGKV3-15,HK CV05-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCSWVDVFDIW,IGHV4-31,IGHJ5,CQQYNNWPRTF,IGKV3-15,HK CV05-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYPFCGADCSWVDVFDIW,IGHV4-31,IGHJ6,CQQYNNWPRTF,IGKV3-15,HK CV05-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGGDGFDYW,IGHV3-74,IGHJ1,CQQYQSYPLAF,IGKV1-5,HK CV05-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGGDGFDYW,IGHV3-74,IGHJ2,CQQYQSYPLAF,IGKV1-5,HK CV05-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGGDGFDYW,IGHV3-74,IGHJ3,CQQYQSYPLAF,IGKV1-5,HK CV05-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGGDGFDYW,IGHV3-74,IGHJ4,CQQYQSYPLAF,IGKV1-5,HK CV05-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGGDGFDYW,IGHV3-74,IGHJ5,CQQYQSYPLAF,IGKV1-5,HK CV05-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGGDGFDYW,IGHV3-74,IGHJ6,CQQYQSYPLAF,IGKV1-5,HK CV05-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVEMATILPDDAFDIW,IGHV1-69,IGHJ1,CQQYNNWPPVTF,IGKV3-15,HK CV05-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVEMATILPDDAFDIW,IGHV1-69,IGHJ2,CQQYNNWPPVTF,IGKV3-15,HK CV05-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVEMATILPDDAFDIW,IGHV1-69,IGHJ3,CQQYNNWPPVTF,IGKV3-15,HK CV05-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVEMATILPDDAFDIW,IGHV1-69,IGHJ4,CQQYNNWPPVTF,IGKV3-15,HK CV05-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVEMATILPDDAFDIW,IGHV1-69,IGHJ5,CQQYNNWPPVTF,IGKV3-15,HK CV05-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVEMATILPDDAFDIW,IGHV1-69,IGHJ6,CQQYNNWPPVTF,IGKV3-15,HK CV05-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSTHNNLFVMDYW,IGHV1-69,IGHJ1,CFLSYSGVRGLFVVF,IGLV7-46,HL CV05-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSTHNNLFVMDYW,IGHV1-69,IGHJ2,CFLSYSGVRGLFVVF,IGLV7-46,HL CV05-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSTHNNLFVMDYW,IGHV1-69,IGHJ3,CFLSYSGVRGLFVVF,IGLV7-46,HL CV05-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSTHNNLFVMDYW,IGHV1-69,IGHJ4,CFLSYSGVRGLFVVF,IGLV7-46,HL CV05-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSTHNNLFVMDYW,IGHV1-69,IGHJ5,CFLSYSGVRGLFVVF,IGLV7-46,HL CV05-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGSTHNNLFVMDYW,IGHV1-69,IGHJ6,CFLSYSGVRGLFVVF,IGLV7-46,HL CV05-169,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ1,CQAWDSSTALVVF,IGLV3-1,HL CV05-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ2,CQAWDSSTALVVF,IGLV3-1,HL CV05-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ3,CQAWDSSTALVVF,IGLV3-1,HL CV05-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ4,CQAWDSSTALVVF,IGLV3-1,HL CV05-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ5,CQAWDSSTALVVF,IGLV3-1,HL CV05-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ6,CQAWDSSTALVVF,IGLV3-1,HL CV05-170,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ1,CQQSYSTHTF,IGKV1-39,HK CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ2,CQQSYSTHTF,IGKV1-39,HK CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ3,CQQSYSTHTF,IGKV1-39,HK CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ4,CQQSYSTHTF,IGKV1-39,HK CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ5,CQQSYSTHTF,IGKV1-39,HK CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ6,CQQSYSTHTF,IGKV1-39,HK CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ1,CQAWDSSVVF,IGLV3-1,HL CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ2,CQAWDSSVVF,IGLV3-1,HL CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ3,CQAWDSSVVF,IGLV3-1,HL CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ4,CQAWDSSVVF,IGLV3-1,HL CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ5,CQAWDSSVVF,IGLV3-1,HL CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLHGDYYYFDYW,IGHV4-30-4,IGHJ6,CQAWDSSVVF,IGLV3-1,HL CV05-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ1,CQQSYSTHTF,IGKV1-39,HK CV05-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ2,CQQSYSTHTF,IGKV1-39,HK CV05-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ3,CQQSYSTHTF,IGKV1-39,HK CV05-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ4,CQQSYSTHTF,IGKV1-39,HK CV05-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ5,CQQSYSTHTF,IGKV1-39,HK CV05-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ6,CQQSYSTHTF,IGKV1-39,HK CV05-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSNSGSSFDYW,IGHV1-2,IGHJ1,CQAWDSSTADVVF,IGLV3-1,HL CV05-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSNSGSSFDYW,IGHV1-2,IGHJ2,CQAWDSSTADVVF,IGLV3-1,HL CV05-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSNSGSSFDYW,IGHV1-2,IGHJ3,CQAWDSSTADVVF,IGLV3-1,HL CV05-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSNSGSSFDYW,IGHV1-2,IGHJ4,CQAWDSSTADVVF,IGLV3-1,HL CV05-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSNSGSSFDYW,IGHV1-2,IGHJ5,CQAWDSSTADVVF,IGLV3-1,HL CV05-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSNSGSSFDYW,IGHV1-2,IGHJ6,CQAWDSSTADVVF,IGLV3-1,HL CV05-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVQDLGVRGGRRALDVW,IGHV1-46,IGHJ1,CFQALQTPYTF,IGKV2-28,HK CV05-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVQDLGVRGGRRALDVW,IGHV1-46,IGHJ2,CFQALQTPYTF,IGKV2-28,HK CV05-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVQDLGVRGGRRALDVW,IGHV1-46,IGHJ3,CFQALQTPYTF,IGKV2-28,HK CV05-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVQDLGVRGGRRALDVW,IGHV1-46,IGHJ4,CFQALQTPYTF,IGKV2-28,HK CV05-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVQDLGVRGGRRALDVW,IGHV1-46,IGHJ5,CFQALQTPYTF,IGKV2-28,HK CV05-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVQDLGVRGGRRALDVW,IGHV1-46,IGHJ6,CFQALQTPYTF,IGKV2-28,HK CV05-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYPGGPW,IGHV3-53,IGHJ1,CQQYDNLLTF,IGKV1-33,HK CV05-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYPGGPW,IGHV3-53,IGHJ2,CQQYDNLLTF,IGKV1-33,HK CV05-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYPGGPW,IGHV3-53,IGHJ3,CQQYDNLLTF,IGKV1-33,HK CV05-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYPGGPW,IGHV3-53,IGHJ4,CQQYDNLLTF,IGKV1-33,HK CV05-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYPGGPW,IGHV3-53,IGHJ5,CQQYDNLLTF,IGKV1-33,HK CV05-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYPGGPW,IGHV3-53,IGHJ6,CQQYDNLLTF,IGKV1-33,HK CV05-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ1,CQQYNSYPYTF,IGKV1-5,HK CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ2,CQQYNSYPYTF,IGKV1-5,HK CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ3,CQQYNSYPYTF,IGKV1-5,HK CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ4,CQQYNSYPYTF,IGKV1-5,HK CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ5,CQQYNSYPYTF,IGKV1-5,HK CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ6,CQQYNSYPYTF,IGKV1-5,HK CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDALGFCSGTSCYGEGAFDIW,IGHV3-23,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV05-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLQYYDFWSGYLGTPGRYYYYGMDVW,IGHV3-30-3,IGHJ1,CQQYGSSPPWTF,IGKV3-20,HK CV05-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLQYYDFWSGYLGTPGRYYYYGMDVW,IGHV3-30-3,IGHJ2,CQQYGSSPPWTF,IGKV3-20,HK CV05-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLQYYDFWSGYLGTPGRYYYYGMDVW,IGHV3-30-3,IGHJ3,CQQYGSSPPWTF,IGKV3-20,HK CV05-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLQYYDFWSGYLGTPGRYYYYGMDVW,IGHV3-30-3,IGHJ4,CQQYGSSPPWTF,IGKV3-20,HK CV05-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLQYYDFWSGYLGTPGRYYYYGMDVW,IGHV3-30-3,IGHJ5,CQQYGSSPPWTF,IGKV3-20,HK CV05-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLQYYDFWSGYLGTPGRYYYYGMDVW,IGHV3-30-3,IGHJ6,CQQYGSSPPWTF,IGKV3-20,HK CV05-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ1,CQVWDSSSDHVVF,IGLV3-21,HL CV05-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ2,CQVWDSSSDHVVF,IGLV3-21,HL CV05-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ3,CQVWDSSSDHVVF,IGLV3-21,HL CV05-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ4,CQVWDSSSDHVVF,IGLV3-21,HL CV05-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ5,CQVWDSSSDHVVF,IGLV3-21,HL CV05-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRVSGGMDVW,IGHV4-59,IGHJ6,CQVWDSSSDHVVF,IGLV3-21,HL CV05-182,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ1,CQQLNSYPYTF,IGKV1-9,HK CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ2,CQQLNSYPYTF,IGKV1-9,HK CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ3,CQQLNSYPYTF,IGKV1-9,HK CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ4,CQQLNSYPYTF,IGKV1-9,HK CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ5,CQQLNSYPYTF,IGKV1-9,HK CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ6,CQQLNSYPYTF,IGKV1-9,HK CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ1,CCSFAGGITLVF,IGLV2-23,HL CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ2,CCSFAGGITLVF,IGLV2-23,HL CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ3,CCSFAGGITLVF,IGLV2-23,HL CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ4,CCSFAGGITLVF,IGLV2-23,HL CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ5,CCSFAGGITLVF,IGLV2-23,HL CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLRFLEWLFNVPYYYYYGMDVW,IGHV3-30-3,IGHJ6,CCSFAGGITLVF,IGLV2-23,HL CV05-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ1,CQQSYSTLPRTF,IGKV1-39,HK CV05-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ2,CQQSYSTLPRTF,IGKV1-39,HK CV05-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ3,CQQSYSTLPRTF,IGKV1-39,HK CV05-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ4,CQQSYSTLPRTF,IGKV1-39,HK CV05-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ5,CQQSYSTLPRTF,IGKV1-39,HK CV05-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ6,CQQSYSTLPRTF,IGKV1-39,HK CV05-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ1,CQQSYSTHTF,IGKV1-39,HK CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ2,CQQSYSTHTF,IGKV1-39,HK CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ3,CQQSYSTHTF,IGKV1-39,HK CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ4,CQQSYSTHTF,IGKV1-39,HK CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ5,CQQSYSTHTF,IGKV1-39,HK CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ6,CQQSYSTHTF,IGKV1-39,HK CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ1,CCSYGGTYVLF,IGLV2-11,HL CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ2,CCSYGGTYVLF,IGLV2-11,HL CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ3,CCSYGGTYVLF,IGLV2-11,HL CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ4,CCSYGGTYVLF,IGLV2-11,HL CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ5,CCSYGGTYVLF,IGLV2-11,HL CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTIGSGYGFGHW,IGHV3-73,IGHJ6,CCSYGGTYVLF,IGLV2-11,HL CV05-187,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAHSDPNYDFWSPDYYGMDVW,IGHV3-9,IGHJ1,CSSYSTSSTKEVF,IGLV2-14,HL CV05-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAHSDPNYDFWSPDYYGMDVW,IGHV3-9,IGHJ2,CSSYSTSSTKEVF,IGLV2-14,HL CV05-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAHSDPNYDFWSPDYYGMDVW,IGHV3-9,IGHJ3,CSSYSTSSTKEVF,IGLV2-14,HL CV05-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAHSDPNYDFWSPDYYGMDVW,IGHV3-9,IGHJ4,CSSYSTSSTKEVF,IGLV2-14,HL CV05-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAHSDPNYDFWSPDYYGMDVW,IGHV3-9,IGHJ5,CSSYSTSSTKEVF,IGLV2-14,HL CV05-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKAHSDPNYDFWSPDYYGMDVW,IGHV3-9,IGHJ6,CSSYSTSSTKEVF,IGLV2-14,HL CV05-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVYGDSGVDYW,IGHV3-30-3,IGHJ1,CQVWDSSSDHLYVF,IGLV3-21,HL CV05-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVYGDSGVDYW,IGHV3-30-3,IGHJ2,CQVWDSSSDHLYVF,IGLV3-21,HL CV05-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVYGDSGVDYW,IGHV3-30-3,IGHJ3,CQVWDSSSDHLYVF,IGLV3-21,HL CV05-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVYGDSGVDYW,IGHV3-30-3,IGHJ4,CQVWDSSSDHLYVF,IGLV3-21,HL CV05-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVYGDSGVDYW,IGHV3-30-3,IGHJ5,CQVWDSSSDHLYVF,IGLV3-21,HL CV05-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGVYGDSGVDYW,IGHV3-30-3,IGHJ6,CQVWDSSSDHLYVF,IGLV3-21,HL CV05-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTSQSHMDVW,IGHV3-11,IGHJ1,CMQGTHWPPYTF,IGKV2-30,HK CV05-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTSQSHMDVW,IGHV3-11,IGHJ2,CMQGTHWPPYTF,IGKV2-30,HK CV05-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTSQSHMDVW,IGHV3-11,IGHJ3,CMQGTHWPPYTF,IGKV2-30,HK CV05-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTSQSHMDVW,IGHV3-11,IGHJ4,CMQGTHWPPYTF,IGKV2-30,HK CV05-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTSQSHMDVW,IGHV3-11,IGHJ5,CMQGTHWPPYTF,IGKV2-30,HK CV05-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTSQSHMDVW,IGHV3-11,IGHJ6,CMQGTHWPPYTF,IGKV2-30,HK CV05-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ1,CQQYGVSPRTF,IGKV3-20,HK CV05-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ2,CQQYGVSPRTF,IGKV3-20,HK CV05-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ3,CQQYGVSPRTF,IGKV3-20,HK CV05-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ4,CQQYGVSPRTF,IGKV3-20,HK CV05-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ5,CQQYGVSPRTF,IGKV3-20,HK CV05-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDTFSVFGVVTRGNAYDVW,IGHV1-3,IGHJ6,CQQYGVSPRTF,IGKV3-20,HK CV05-192,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRHTYSLEYFQHW,IGHV3-74,IGHJ1,CQSYDSSNQVF,IGLV6-57,HL CV05-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRHTYSLEYFQHW,IGHV3-74,IGHJ2,CQSYDSSNQVF,IGLV6-57,HL CV05-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRHTYSLEYFQHW,IGHV3-74,IGHJ3,CQSYDSSNQVF,IGLV6-57,HL CV05-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRHTYSLEYFQHW,IGHV3-74,IGHJ4,CQSYDSSNQVF,IGLV6-57,HL CV05-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRHTYSLEYFQHW,IGHV3-74,IGHJ5,CQSYDSSNQVF,IGLV6-57,HL CV05-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRHTYSLEYFQHW,IGHV3-74,IGHJ6,CQSYDSSNQVF,IGLV6-57,HL CV05-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ1,CQSADSSGTYQVF,IGLV3-25,HL CV05-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ2,CQSADSSGTYQVF,IGLV3-25,HL CV05-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ3,CQSADSSGTYQVF,IGLV3-25,HL CV05-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ4,CQSADSSGTYQVF,IGLV3-25,HL CV05-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ5,CQSADSSGTYQVF,IGLV3-25,HL CV05-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ6,CQSADSSGTYQVF,IGLV3-25,HL CV05-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLARVGWTWWYYYYGMDVW,IGHV1-18,IGHJ1,CMQGTHWPRTF,IGKV2-30,HK CV07-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLARVGWTWWYYYYGMDVW,IGHV1-18,IGHJ2,CMQGTHWPRTF,IGKV2-30,HK CV07-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLARVGWTWWYYYYGMDVW,IGHV1-18,IGHJ3,CMQGTHWPRTF,IGKV2-30,HK CV07-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLARVGWTWWYYYYGMDVW,IGHV1-18,IGHJ4,CMQGTHWPRTF,IGKV2-30,HK CV07-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLARVGWTWWYYYYGMDVW,IGHV1-18,IGHJ5,CMQGTHWPRTF,IGKV2-30,HK CV07-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLARVGWTWWYYYYGMDVW,IGHV1-18,IGHJ6,CMQGTHWPRTF,IGKV2-30,HK CV07-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVYGSNTHTPVDYW,IGHV3-23,IGHJ1,CSSYAGSNNVVF,IGLV2-8,HL CV07-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVYGSNTHTPVDYW,IGHV3-23,IGHJ2,CSSYAGSNNVVF,IGLV2-8,HL CV07-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVYGSNTHTPVDYW,IGHV3-23,IGHJ3,CSSYAGSNNVVF,IGLV2-8,HL CV07-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVYGSNTHTPVDYW,IGHV3-23,IGHJ4,CSSYAGSNNVVF,IGLV2-8,HL CV07-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVYGSNTHTPVDYW,IGHV3-23,IGHJ5,CSSYAGSNNVVF,IGLV2-8,HL CV07-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVYGSNTHTPVDYW,IGHV3-23,IGHJ6,CSSYAGSNNVVF,IGLV2-8,HL CV07-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDAARYYGMDVW,IGHV3-7,IGHJ1,CQQSYSTPRTF,IGKV1-39,HK CV07-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDAARYYGMDVW,IGHV3-7,IGHJ2,CQQSYSTPRTF,IGKV1-39,HK CV07-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDAARYYGMDVW,IGHV3-7,IGHJ3,CQQSYSTPRTF,IGKV1-39,HK CV07-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDAARYYGMDVW,IGHV3-7,IGHJ4,CQQSYSTPRTF,IGKV1-39,HK CV07-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDAARYYGMDVW,IGHV3-7,IGHJ5,CQQSYSTPRTF,IGKV1-39,HK CV07-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDAARYYGMDVW,IGHV3-7,IGHJ6,CQQSYSTPRTF,IGKV1-39,HK CV07-104,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRTMIVVVITNKYYYGMDVW,IGHV3-23,IGHJ1,CQQYNSYPLTF,IGKV1-5,HK CV07-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRTMIVVVITNKYYYGMDVW,IGHV3-23,IGHJ2,CQQYNSYPLTF,IGKV1-5,HK CV07-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRTMIVVVITNKYYYGMDVW,IGHV3-23,IGHJ3,CQQYNSYPLTF,IGKV1-5,HK CV07-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRTMIVVVITNKYYYGMDVW,IGHV3-23,IGHJ4,CQQYNSYPLTF,IGKV1-5,HK CV07-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRTMIVVVITNKYYYGMDVW,IGHV3-23,IGHJ5,CQQYNSYPLTF,IGKV1-5,HK CV07-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRTMIVVVITNKYYYGMDVW,IGHV3-23,IGHJ6,CQQYNSYPLTF,IGKV1-5,HK CV07-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDADTSPVVW,IGHV3-15,IGHJ1,CQTWDTGIRVF,IGLV4-69,HL CV07-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDADTSPVVW,IGHV3-15,IGHJ2,CQTWDTGIRVF,IGLV4-69,HL CV07-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDADTSPVVW,IGHV3-15,IGHJ3,CQTWDTGIRVF,IGLV4-69,HL CV07-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDADTSPVVW,IGHV3-15,IGHJ4,CQTWDTGIRVF,IGLV4-69,HL CV07-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDADTSPVVW,IGHV3-15,IGHJ5,CQTWDTGIRVF,IGLV4-69,HL CV07-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDADTSPVVW,IGHV3-15,IGHJ6,CQTWDTGIRVF,IGLV4-69,HL CV07-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLRMGW,IGHV3-48,IGHJ1,CHQYGSIPRTF,IGKV3-20,HK CV07-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLRMGW,IGHV3-48,IGHJ2,CHQYGSIPRTF,IGKV3-20,HK CV07-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLRMGW,IGHV3-48,IGHJ3,CHQYGSIPRTF,IGKV3-20,HK CV07-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLRMGW,IGHV3-48,IGHJ4,CHQYGSIPRTF,IGKV3-20,HK CV07-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLRMGW,IGHV3-48,IGHJ5,CHQYGSIPRTF,IGKV3-20,HK CV07-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLRMGW,IGHV3-48,IGHJ6,CHQYGSIPRTF,IGKV3-20,HK CV07-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASFKMGTNYHYGMDVW,IGHV4-59,IGHJ1,CQNYNSVPFTF,IGKV1-27,HK CV07-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASFKMGTNYHYGMDVW,IGHV4-59,IGHJ2,CQNYNSVPFTF,IGKV1-27,HK CV07-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASFKMGTNYHYGMDVW,IGHV4-59,IGHJ3,CQNYNSVPFTF,IGKV1-27,HK CV07-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASFKMGTNYHYGMDVW,IGHV4-59,IGHJ4,CQNYNSVPFTF,IGKV1-27,HK CV07-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASFKMGTNYHYGMDVW,IGHV4-59,IGHJ5,CQNYNSVPFTF,IGKV1-27,HK CV07-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASFKMGTNYHYGMDVW,IGHV4-59,IGHJ6,CQNYNSVPFTF,IGKV1-27,HK CV07-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLTAVVTPLGYW,IGHV1-2,IGHJ1,CMQGTHWPRTF,IGKV2-30,HK CV07-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLTAVVTPLGYW,IGHV1-2,IGHJ2,CMQGTHWPRTF,IGKV2-30,HK CV07-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLTAVVTPLGYW,IGHV1-2,IGHJ3,CMQGTHWPRTF,IGKV2-30,HK CV07-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLTAVVTPLGYW,IGHV1-2,IGHJ4,CMQGTHWPRTF,IGKV2-30,HK CV07-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLTAVVTPLGYW,IGHV1-2,IGHJ5,CMQGTHWPRTF,IGKV2-30,HK CV07-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLTAVVTPLGYW,IGHV1-2,IGHJ6,CMQGTHWPRTF,IGKV2-30,HK CV07-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDEQRNYCTSPNCRGGAFDIW,IGHV3-15,IGHJ1,CQTWGTGIRVF,IGLV4-69,HL CV07-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDEQRNYCTSPNCRGGAFDIW,IGHV3-15,IGHJ2,CQTWGTGIRVF,IGLV4-69,HL CV07-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDEQRNYCTSPNCRGGAFDIW,IGHV3-15,IGHJ3,CQTWGTGIRVF,IGLV4-69,HL CV07-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDEQRNYCTSPNCRGGAFDIW,IGHV3-15,IGHJ4,CQTWGTGIRVF,IGLV4-69,HL CV07-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDEQRNYCTSPNCRGGAFDIW,IGHV3-15,IGHJ5,CQTWGTGIRVF,IGLV4-69,HL CV07-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDEQRNYCTSPNCRGGAFDIW,IGHV3-15,IGHJ6,CQTWGTGIRVF,IGLV4-69,HL CV07-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CMRQGDWNYSYYFDAW,IGHV4-39,IGHJ1,CVQGTLWPLTF,IGKV2-30,HK CV07-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CMRQGDWNYSYYFDAW,IGHV4-39,IGHJ2,CVQGTLWPLTF,IGKV2-30,HK CV07-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CMRQGDWNYSYYFDAW,IGHV4-39,IGHJ3,CVQGTLWPLTF,IGKV2-30,HK CV07-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CMRQGDWNYSYYFDAW,IGHV4-39,IGHJ4,CVQGTLWPLTF,IGKV2-30,HK CV07-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CMRQGDWNYSYYFDAW,IGHV4-39,IGHJ5,CVQGTLWPLTF,IGKV2-30,HK CV07-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CMRQGDWNYSYYFDAW,IGHV4-39,IGHJ6,CVQGTLWPLTF,IGKV2-30,HK CV07-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPLALITIFGVSRQYGMDVW,IGHV4-39,IGHJ1,CQQANSFPWTF,IGKV1-12,HK CV07-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPLALITIFGVSRQYGMDVW,IGHV4-39,IGHJ2,CQQANSFPWTF,IGKV1-12,HK CV07-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPLALITIFGVSRQYGMDVW,IGHV4-39,IGHJ3,CQQANSFPWTF,IGKV1-12,HK CV07-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPLALITIFGVSRQYGMDVW,IGHV4-39,IGHJ4,CQQANSFPWTF,IGKV1-12,HK CV07-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPLALITIFGVSRQYGMDVW,IGHV4-39,IGHJ5,CQQANSFPWTF,IGKV1-12,HK CV07-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHPLALITIFGVSRQYGMDVW,IGHV4-39,IGHJ6,CQQANSFPWTF,IGKV1-12,HK CV07-127,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGTSGTLDSW,IGHV3-30-3,IGHJ1,CLSHSTFTTPQWVF,IGLV2-14,HL CV07-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGTSGTLDSW,IGHV3-30-3,IGHJ2,CLSHSTFTTPQWVF,IGLV2-14,HL CV07-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGTSGTLDSW,IGHV3-30-3,IGHJ3,CLSHSTFTTPQWVF,IGLV2-14,HL CV07-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGTSGTLDSW,IGHV3-30-3,IGHJ4,CLSHSTFTTPQWVF,IGLV2-14,HL CV07-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGTSGTLDSW,IGHV3-30-3,IGHJ5,CLSHSTFTTPQWVF,IGLV2-14,HL CV07-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGTSGTLDSW,IGHV3-30-3,IGHJ6,CLSHSTFTTPQWVF,IGLV2-14,HL CV07-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIASYDYVWGTNRPNDAFDIW,IGHV3-48,IGHJ1,CCSYGGPRNLYVF,IGLV2-23,HL CV07-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIASYDYVWGTNRPNDAFDIW,IGHV3-48,IGHJ2,CCSYGGPRNLYVF,IGLV2-23,HL CV07-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIASYDYVWGTNRPNDAFDIW,IGHV3-48,IGHJ3,CCSYGGPRNLYVF,IGLV2-23,HL CV07-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIASYDYVWGTNRPNDAFDIW,IGHV3-48,IGHJ4,CCSYGGPRNLYVF,IGLV2-23,HL CV07-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIASYDYVWGTNRPNDAFDIW,IGHV3-48,IGHJ5,CCSYGGPRNLYVF,IGLV2-23,HL CV07-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASIASYDYVWGTNRPNDAFDIW,IGHV3-48,IGHJ6,CCSYGGPRNLYVF,IGLV2-23,HL CV07-129,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRQYRGSDYNYYFDYW,IGHV4-4,IGHJ1,CATWDDSLNGRVF,IGLV1-44,HL CV07-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRQYRGSDYNYYFDYW,IGHV4-4,IGHJ2,CATWDDSLNGRVF,IGLV1-44,HL CV07-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRQYRGSDYNYYFDYW,IGHV4-4,IGHJ3,CATWDDSLNGRVF,IGLV1-44,HL CV07-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRQYRGSDYNYYFDYW,IGHV4-4,IGHJ4,CATWDDSLNGRVF,IGLV1-44,HL CV07-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRQYRGSDYNYYFDYW,IGHV4-4,IGHJ5,CATWDDSLNGRVF,IGLV1-44,HL CV07-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRQYRGSDYNYYFDYW,IGHV4-4,IGHJ6,CATWDDSLNGRVF,IGLV1-44,HL CV07-132,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQRPVTTFIDYW,IGHV4-39,IGHJ1,CQHYKDWPPFFTF,IGKV3-15,HK CV07-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQRPVTTFIDYW,IGHV4-39,IGHJ2,CQHYKDWPPFFTF,IGKV3-15,HK CV07-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQRPVTTFIDYW,IGHV4-39,IGHJ3,CQHYKDWPPFFTF,IGKV3-15,HK CV07-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQRPVTTFIDYW,IGHV4-39,IGHJ4,CQHYKDWPPFFTF,IGKV3-15,HK CV07-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQRPVTTFIDYW,IGHV4-39,IGHJ5,CQHYKDWPPFFTF,IGKV3-15,HK CV07-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQRPVTTFIDYW,IGHV4-39,IGHJ6,CQHYKDWPPFFTF,IGKV3-15,HK CV07-133,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVMRDDFWSGYYNDYYYGMDVW,IGHV3-23,IGHJ1,CQQYGRTF,IGKV3-20,HK CV07-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVMRDDFWSGYYNDYYYGMDVW,IGHV3-23,IGHJ2,CQQYGRTF,IGKV3-20,HK CV07-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVMRDDFWSGYYNDYYYGMDVW,IGHV3-23,IGHJ3,CQQYGRTF,IGKV3-20,HK CV07-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVMRDDFWSGYYNDYYYGMDVW,IGHV3-23,IGHJ4,CQQYGRTF,IGKV3-20,HK CV07-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVMRDDFWSGYYNDYYYGMDVW,IGHV3-23,IGHJ5,CQQYGRTF,IGKV3-20,HK CV07-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVMRDDFWSGYYNDYYYGMDVW,IGHV3-23,IGHJ6,CQQYGRTF,IGKV3-20,HK CV07-134,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNYSSRRYYYYYGMDVW,IGHV4-59,IGHJ1,CQQYGSSPTWTF,IGKV3-20,HK CV07-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNYSSRRYYYYYGMDVW,IGHV4-59,IGHJ2,CQQYGSSPTWTF,IGKV3-20,HK CV07-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNYSSRRYYYYYGMDVW,IGHV4-59,IGHJ3,CQQYGSSPTWTF,IGKV3-20,HK CV07-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNYSSRRYYYYYGMDVW,IGHV4-59,IGHJ4,CQQYGSSPTWTF,IGKV3-20,HK CV07-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNYSSRRYYYYYGMDVW,IGHV4-59,IGHJ5,CQQYGSSPTWTF,IGKV3-20,HK CV07-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNYSSRRYYYYYGMDVW,IGHV4-59,IGHJ6,CQQYGSSPTWTF,IGKV3-20,HK CV07-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ1,CAAWDDSLSGWVF,IGLV1-47,HL CV07-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ2,CAAWDDSLSGWVF,IGLV1-47,HL CV07-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ3,CAAWDDSLSGWVF,IGLV1-47,HL CV07-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ4,CAAWDDSLSGWVF,IGLV1-47,HL CV07-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ5,CAAWDDSLSGWVF,IGLV1-47,HL CV07-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLSMTTVTRGNWFDPW,IGHV4-30-4,IGHJ6,CAAWDDSLSGWVF,IGLV1-47,HL CV07-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDFPFGGCTSTTTNCDLFFALW,IGHV3-23,IGHJ1,CMQATQFPRAF,IGKV2-24,HK CV07-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDFPFGGCTSTTTNCDLFFALW,IGHV3-23,IGHJ2,CMQATQFPRAF,IGKV2-24,HK CV07-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDFPFGGCTSTTTNCDLFFALW,IGHV3-23,IGHJ3,CMQATQFPRAF,IGKV2-24,HK CV07-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDFPFGGCTSTTTNCDLFFALW,IGHV3-23,IGHJ4,CMQATQFPRAF,IGKV2-24,HK CV07-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDFPFGGCTSTTTNCDLFFALW,IGHV3-23,IGHJ5,CMQATQFPRAF,IGKV2-24,HK CV07-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDFPFGGCTSTTTNCDLFFALW,IGHV3-23,IGHJ6,CMQATQFPRAF,IGKV2-24,HK CV07-138,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYLRNDNLDPW,IGHV4-59,IGHJ1,CQQRSDWPLTF,IGKV3-11,HK CV07-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYLRNDNLDPW,IGHV4-59,IGHJ2,CQQRSDWPLTF,IGKV3-11,HK CV07-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYLRNDNLDPW,IGHV4-59,IGHJ3,CQQRSDWPLTF,IGKV3-11,HK CV07-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYLRNDNLDPW,IGHV4-59,IGHJ4,CQQRSDWPLTF,IGKV3-11,HK CV07-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYLRNDNLDPW,IGHV4-59,IGHJ5,CQQRSDWPLTF,IGKV3-11,HK CV07-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGYLRNDNLDPW,IGHV4-59,IGHJ6,CQQRSDWPLTF,IGKV3-11,HK CV07-139,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYYGLLTGYYLDLW,IGHV3-64,IGHJ1,CQQSYSIPWTF,IGKV1-39,HK CV07-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYYGLLTGYYLDLW,IGHV3-64,IGHJ2,CQQSYSIPWTF,IGKV1-39,HK CV07-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYYGLLTGYYLDLW,IGHV3-64,IGHJ3,CQQSYSIPWTF,IGKV1-39,HK CV07-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYYGLLTGYYLDLW,IGHV3-64,IGHJ4,CQQSYSIPWTF,IGKV1-39,HK CV07-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYYGLLTGYYLDLW,IGHV3-64,IGHJ5,CQQSYSIPWTF,IGKV1-39,HK CV07-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYYGLLTGYYLDLW,IGHV3-64,IGHJ6,CQQSYSIPWTF,IGKV1-39,HK CV07-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDSW,IGHV3-23,IGHJ1,CQQRNNWPVTF,IGKV3-11,HK CV07-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDSW,IGHV3-23,IGHJ2,CQQRNNWPVTF,IGKV3-11,HK CV07-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDSW,IGHV3-23,IGHJ3,CQQRNNWPVTF,IGKV3-11,HK CV07-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDSW,IGHV3-23,IGHJ4,CQQRNNWPVTF,IGKV3-11,HK CV07-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDSW,IGHV3-23,IGHJ5,CQQRNNWPVTF,IGKV3-11,HK CV07-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDSW,IGHV3-23,IGHJ6,CQQRNNWPVTF,IGKV3-11,HK CV07-143,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYDILTGYYMPMDVW,IGHV1-2,IGHJ1,CQQRGNWPPITF,IGKV3-11,HK CV07-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYDILTGYYMPMDVW,IGHV1-2,IGHJ2,CQQRGNWPPITF,IGKV3-11,HK CV07-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYDILTGYYMPMDVW,IGHV1-2,IGHJ3,CQQRGNWPPITF,IGKV3-11,HK CV07-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYDILTGYYMPMDVW,IGHV1-2,IGHJ4,CQQRGNWPPITF,IGKV3-11,HK CV07-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYDILTGYYMPMDVW,IGHV1-2,IGHJ5,CQQRGNWPPITF,IGKV3-11,HK CV07-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYDILTGYYMPMDVW,IGHV1-2,IGHJ6,CQQRGNWPPITF,IGKV3-11,HK CV07-147,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAADPGGVGYCSGGSCYRAFDIW,IGHV1-58,IGHJ1,CQQYNNWPPALTF,IGKV3D-15,HK CV07-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAADPGGVGYCSGGSCYRAFDIW,IGHV1-58,IGHJ2,CQQYNNWPPALTF,IGKV3D-15,HK CV07-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAADPGGVGYCSGGSCYRAFDIW,IGHV1-58,IGHJ3,CQQYNNWPPALTF,IGKV3D-15,HK CV07-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAADPGGVGYCSGGSCYRAFDIW,IGHV1-58,IGHJ4,CQQYNNWPPALTF,IGKV3D-15,HK CV07-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAADPGGVGYCSGGSCYRAFDIW,IGHV1-58,IGHJ5,CQQYNNWPPALTF,IGKV3D-15,HK CV07-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAADPGGVGYCSGGSCYRAFDIW,IGHV1-58,IGHJ6,CQQYNNWPPALTF,IGKV3D-15,HK CV07-151,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRVPLTAHDAFDIW,IGHV1-69,IGHJ1,CQSYDSSVGVF,IGLV1-40,HL CV07-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRVPLTAHDAFDIW,IGHV1-69,IGHJ2,CQSYDSSVGVF,IGLV1-40,HL CV07-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRVPLTAHDAFDIW,IGHV1-69,IGHJ3,CQSYDSSVGVF,IGLV1-40,HL CV07-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRVPLTAHDAFDIW,IGHV1-69,IGHJ4,CQSYDSSVGVF,IGLV1-40,HL CV07-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRVPLTAHDAFDIW,IGHV1-69,IGHJ5,CQSYDSSVGVF,IGLV1-40,HL CV07-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRVPLTAHDAFDIW,IGHV1-69,IGHJ6,CQSYDSSVGVF,IGLV1-40,HL CV07-152,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYCSGGSCYSYYYGMDVW,IGHV1-69,IGHJ1,CQAWDSSTAF,IGLV3-1,HL CV07-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYCSGGSCYSYYYGMDVW,IGHV1-69,IGHJ2,CQAWDSSTAF,IGLV3-1,HL CV07-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYCSGGSCYSYYYGMDVW,IGHV1-69,IGHJ3,CQAWDSSTAF,IGLV3-1,HL CV07-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYCSGGSCYSYYYGMDVW,IGHV1-69,IGHJ4,CQAWDSSTAF,IGLV3-1,HL CV07-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYCSGGSCYSYYYGMDVW,IGHV1-69,IGHJ5,CQAWDSSTAF,IGLV3-1,HL CV07-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYCSGGSCYSYYYGMDVW,IGHV1-69,IGHJ6,CQAWDSSTAF,IGLV3-1,HL CV07-154,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPREWLSPLYYGW,IGHV4-59,IGHJ1,CQQYNSYQWTF,IGKV1-5,HK CV07-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPREWLSPLYYGW,IGHV4-59,IGHJ2,CQQYNSYQWTF,IGKV1-5,HK CV07-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPREWLSPLYYGW,IGHV4-59,IGHJ3,CQQYNSYQWTF,IGKV1-5,HK CV07-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPREWLSPLYYGW,IGHV4-59,IGHJ4,CQQYNSYQWTF,IGKV1-5,HK CV07-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPREWLSPLYYGW,IGHV4-59,IGHJ5,CQQYNSYQWTF,IGKV1-5,HK CV07-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPREWLSPLYYGW,IGHV4-59,IGHJ6,CQQYNSYQWTF,IGKV1-5,HK CV07-155,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDNARTRRGSFDYW,IGHV3-9,IGHJ1,CCSYAGSNTYVF,IGLV2-23,HL CV07-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDNARTRRGSFDYW,IGHV3-9,IGHJ2,CCSYAGSNTYVF,IGLV2-23,HL CV07-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDNARTRRGSFDYW,IGHV3-9,IGHJ3,CCSYAGSNTYVF,IGLV2-23,HL CV07-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDNARTRRGSFDYW,IGHV3-9,IGHJ4,CCSYAGSNTYVF,IGLV2-23,HL CV07-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDNARTRRGSFDYW,IGHV3-9,IGHJ5,CCSYAGSNTYVF,IGLV2-23,HL CV07-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDNARTRRGSFDYW,IGHV3-9,IGHJ6,CCSYAGSNTYVF,IGLV2-23,HL CV07-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGELSNYDAFDIW,IGHV3-48,IGHJ1,CCSYAGTHSYVF,IGLV2-11,HL CV07-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGELSNYDAFDIW,IGHV3-48,IGHJ2,CCSYAGTHSYVF,IGLV2-11,HL CV07-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGELSNYDAFDIW,IGHV3-48,IGHJ3,CCSYAGTHSYVF,IGLV2-11,HL CV07-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGELSNYDAFDIW,IGHV3-48,IGHJ4,CCSYAGTHSYVF,IGLV2-11,HL CV07-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGELSNYDAFDIW,IGHV3-48,IGHJ5,CCSYAGTHSYVF,IGLV2-11,HL CV07-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGELSNYDAFDIW,IGHV3-48,IGHJ6,CCSYAGTHSYVF,IGLV2-11,HL CV07-159,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ1,CMQAFEPPAITF,IGKV2-28,HK CV07-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ2,CMQAFEPPAITF,IGKV2-28,HK CV07-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ3,CMQAFEPPAITF,IGKV2-28,HK CV07-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ4,CMQAFEPPAITF,IGKV2-28,HK CV07-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ5,CMQAFEPPAITF,IGKV2-28,HK CV07-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWLQSSCYFDYW,IGHV3-30,IGHJ6,CMQAFEPPAITF,IGKV2-28,HK CV07-161,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWAVAGNFDYW,IGHV3-33,IGHJ1,CQQYGASPPTTF,IGKV3-20,HK CV07-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWAVAGNFDYW,IGHV3-33,IGHJ2,CQQYGASPPTTF,IGKV3-20,HK CV07-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWAVAGNFDYW,IGHV3-33,IGHJ3,CQQYGASPPTTF,IGKV3-20,HK CV07-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWAVAGNFDYW,IGHV3-33,IGHJ4,CQQYGASPPTTF,IGKV3-20,HK CV07-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWAVAGNFDYW,IGHV3-33,IGHJ5,CQQYGASPPTTF,IGKV3-20,HK CV07-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWAVAGNFDYW,IGHV3-33,IGHJ6,CQQYGASPPTTF,IGKV3-20,HK CV07-163,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGSHWDFDYW,IGHV1-46,IGHJ1,CSSYVSSDAWVF,IGLV2-14,HL CV07-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGSHWDFDYW,IGHV1-46,IGHJ2,CSSYVSSDAWVF,IGLV2-14,HL CV07-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGSHWDFDYW,IGHV1-46,IGHJ3,CSSYVSSDAWVF,IGLV2-14,HL CV07-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGSHWDFDYW,IGHV1-46,IGHJ4,CSSYVSSDAWVF,IGLV2-14,HL CV07-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGSHWDFDYW,IGHV1-46,IGHJ5,CSSYVSSDAWVF,IGLV2-14,HL CV07-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGSHWDFDYW,IGHV1-46,IGHJ6,CSSYVSSDAWVF,IGLV2-14,HL CV07-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAASGWNFDYW,IGHV3-53,IGHJ1,CCSYLGSATYVF,IGLV2-23,HL CV07-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAASGWNFDYW,IGHV3-53,IGHJ2,CCSYLGSATYVF,IGLV2-23,HL CV07-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAASGWNFDYW,IGHV3-53,IGHJ3,CCSYLGSATYVF,IGLV2-23,HL CV07-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAASGWNFDYW,IGHV3-53,IGHJ4,CCSYLGSATYVF,IGLV2-23,HL CV07-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAASGWNFDYW,IGHV3-53,IGHJ5,CCSYLGSATYVF,IGLV2-23,HL CV07-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAASGWNFDYW,IGHV3-53,IGHJ6,CCSYLGSATYVF,IGLV2-23,HL CV07-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTWDIVIVPAASAYYGMDVW,IGHV1-18,IGHJ1,CMQALQTHTF,IGKV2-28,HK CV07-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTWDIVIVPAASAYYGMDVW,IGHV1-18,IGHJ2,CMQALQTHTF,IGKV2-28,HK CV07-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTWDIVIVPAASAYYGMDVW,IGHV1-18,IGHJ3,CMQALQTHTF,IGKV2-28,HK CV07-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTWDIVIVPAASAYYGMDVW,IGHV1-18,IGHJ4,CMQALQTHTF,IGKV2-28,HK CV07-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTWDIVIVPAASAYYGMDVW,IGHV1-18,IGHJ5,CMQALQTHTF,IGKV2-28,HK CV07-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTWDIVIVPAASAYYGMDVW,IGHV1-18,IGHJ6,CMQALQTHTF,IGKV2-28,HK CV07-166,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ1,CQQTFSSPPWTF,IGKV1-39,HK CV07-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ2,CQQTFSSPPWTF,IGKV1-39,HK CV07-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ3,CQQTFSSPPWTF,IGKV1-39,HK CV07-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ4,CQQTFSSPPWTF,IGKV1-39,HK CV07-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ5,CQQTFSSPPWTF,IGKV1-39,HK CV07-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRTYDYVWGSYRYRDYW,IGHV3-15,IGHJ6,CQQTFSSPPWTF,IGKV1-39,HK CV07-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSKGFLEWLLRRYYYGMDVW,IGHV3-30,IGHJ1,CQQLNSYPFTF,IGKV1-9,HK CV07-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSKGFLEWLLRRYYYGMDVW,IGHV3-30,IGHJ2,CQQLNSYPFTF,IGKV1-9,HK CV07-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSKGFLEWLLRRYYYGMDVW,IGHV3-30,IGHJ3,CQQLNSYPFTF,IGKV1-9,HK CV07-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSKGFLEWLLRRYYYGMDVW,IGHV3-30,IGHJ4,CQQLNSYPFTF,IGKV1-9,HK CV07-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSKGFLEWLLRRYYYGMDVW,IGHV3-30,IGHJ5,CQQLNSYPFTF,IGKV1-9,HK CV07-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSKGFLEWLLRRYYYGMDVW,IGHV3-30,IGHJ6,CQQLNSYPFTF,IGKV1-9,HK CV07-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ1,CMQARQTPPLTF,IGKV2-28,HK CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ2,CMQARQTPPLTF,IGKV2-28,HK CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ3,CMQARQTPPLTF,IGKV2-28,HK CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ4,CMQARQTPPLTF,IGKV2-28,HK CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ5,CMQARQTPPLTF,IGKV2-28,HK CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ6,CMQARQTPPLTF,IGKV2-28,HK CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ1,CSSYAGSTNLVF,IGLV2-8,HL CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ2,CSSYAGSTNLVF,IGLV2-8,HL CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ3,CSSYAGSTNLVF,IGLV2-8,HL CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ4,CSSYAGSTNLVF,IGLV2-8,HL CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ5,CSSYAGSTNLVF,IGLV2-8,HL CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHFGGSGSYYNGHWIPAYYYHGMDVW,IGHV5-51,IGHJ6,CSSYAGSTNLVF,IGLV2-8,HL CV07-176,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTMVVWNAFDIW,IGHV4-31,IGHJ1,CQQSHSPSRTF,IGKV1-39,HK CV07-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTMVVWNAFDIW,IGHV4-31,IGHJ2,CQQSHSPSRTF,IGKV1-39,HK CV07-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTMVVWNAFDIW,IGHV4-31,IGHJ3,CQQSHSPSRTF,IGKV1-39,HK CV07-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTMVVWNAFDIW,IGHV4-31,IGHJ4,CQQSHSPSRTF,IGKV1-39,HK CV07-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTMVVWNAFDIW,IGHV4-31,IGHJ5,CQQSHSPSRTF,IGKV1-39,HK CV07-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTMVVWNAFDIW,IGHV4-31,IGHJ6,CQQSHSPSRTF,IGKV1-39,HK CV07-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESRLGIAIFDRRLRSWFGAW,IGHV3-7,IGHJ1,CSSYTSSSTRVF,IGLV2-14,HL CV07-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESRLGIAIFDRRLRSWFGAW,IGHV3-7,IGHJ2,CSSYTSSSTRVF,IGLV2-14,HL CV07-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESRLGIAIFDRRLRSWFGAW,IGHV3-7,IGHJ3,CSSYTSSSTRVF,IGLV2-14,HL CV07-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESRLGIAIFDRRLRSWFGAW,IGHV3-7,IGHJ4,CSSYTSSSTRVF,IGLV2-14,HL CV07-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESRLGIAIFDRRLRSWFGAW,IGHV3-7,IGHJ5,CSSYTSSSTRVF,IGLV2-14,HL CV07-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARESRLGIAIFDRRLRSWFGAW,IGHV3-7,IGHJ6,CSSYTSSSTRVF,IGLV2-14,HL CV07-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTQHYDFWSGNYKPFAFW,IGHV3-15,IGHJ1,CMQALQTLTF,IGKV2-28,HK CV07-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTQHYDFWSGNYKPFAFW,IGHV3-15,IGHJ2,CMQALQTLTF,IGKV2-28,HK CV07-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTQHYDFWSGNYKPFAFW,IGHV3-15,IGHJ3,CMQALQTLTF,IGKV2-28,HK CV07-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTQHYDFWSGNYKPFAFW,IGHV3-15,IGHJ4,CMQALQTLTF,IGKV2-28,HK CV07-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTQHYDFWSGNYKPFAFW,IGHV3-15,IGHJ5,CMQALQTLTF,IGKV2-28,HK CV07-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTQHYDFWSGNYKPFAFW,IGHV3-15,IGHJ6,CMQALQTLTF,IGKV2-28,HK CV07-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEAAEYYFDYW,IGHV3-33,IGHJ1,CQSADSSGTFWVF,IGLV3-25,HL CV07-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEAAEYYFDYW,IGHV3-33,IGHJ2,CQSADSSGTFWVF,IGLV3-25,HL CV07-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEAAEYYFDYW,IGHV3-33,IGHJ3,CQSADSSGTFWVF,IGLV3-25,HL CV07-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEAAEYYFDYW,IGHV3-33,IGHJ4,CQSADSSGTFWVF,IGLV3-25,HL CV07-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEAAEYYFDYW,IGHV3-33,IGHJ5,CQSADSSGTFWVF,IGLV3-25,HL CV07-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEAAEYYFDYW,IGHV3-33,IGHJ6,CQSADSSGTFWVF,IGLV3-25,HL CV07-181,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWIQNSCYFDYW,IGHV3-30,IGHJ1,CQQYYSTPPTF,IGKV4-1,HK CV07-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWIQNSCYFDYW,IGHV3-30,IGHJ2,CQQYYSTPPTF,IGKV4-1,HK CV07-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWIQNSCYFDYW,IGHV3-30,IGHJ3,CQQYYSTPPTF,IGKV4-1,HK CV07-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWIQNSCYFDYW,IGHV3-30,IGHJ4,CQQYYSTPPTF,IGKV4-1,HK CV07-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWIQNSCYFDYW,IGHV3-30,IGHJ5,CQQYYSTPPTF,IGKV4-1,HK CV07-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEGSKGWIQNSCYFDYW,IGHV3-30,IGHJ6,CQQYYSTPPTF,IGKV4-1,HK CV07-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDPNWANGYW,IGHV3-23,IGHJ1,CVQGTHWPLTF,IGKV2-30,HK CV07-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDPNWANGYW,IGHV3-23,IGHJ2,CVQGTHWPLTF,IGKV2-30,HK CV07-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDPNWANGYW,IGHV3-23,IGHJ3,CVQGTHWPLTF,IGKV2-30,HK CV07-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDPNWANGYW,IGHV3-23,IGHJ4,CVQGTHWPLTF,IGKV2-30,HK CV07-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDPNWANGYW,IGHV3-23,IGHJ5,CVQGTHWPLTF,IGKV2-30,HK CV07-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKDPNWANGYW,IGHV3-23,IGHJ6,CVQGTHWPLTF,IGKV2-30,HK CV07-185,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRSTIFGVIVNQGDCYDYW,IGHV1-46,IGHJ1,CQKYNSAPLTF,IGKV1-27,HK CV07-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRSTIFGVIVNQGDCYDYW,IGHV1-46,IGHJ2,CQKYNSAPLTF,IGKV1-27,HK CV07-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRSTIFGVIVNQGDCYDYW,IGHV1-46,IGHJ3,CQKYNSAPLTF,IGKV1-27,HK CV07-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRSTIFGVIVNQGDCYDYW,IGHV1-46,IGHJ4,CQKYNSAPLTF,IGKV1-27,HK CV07-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRSTIFGVIVNQGDCYDYW,IGHV1-46,IGHJ5,CQKYNSAPLTF,IGKV1-27,HK CV07-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRSTIFGVIVNQGDCYDYW,IGHV1-46,IGHJ6,CQKYNSAPLTF,IGKV1-27,HK CV07-186,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPHFDFWSGNYFDYW,IGHV3-23,IGHJ1,CQQANSFPLTF,IGKV1D-12,HK CV07-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPHFDFWSGNYFDYW,IGHV3-23,IGHJ2,CQQANSFPLTF,IGKV1D-12,HK CV07-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPHFDFWSGNYFDYW,IGHV3-23,IGHJ3,CQQANSFPLTF,IGKV1D-12,HK CV07-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPHFDFWSGNYFDYW,IGHV3-23,IGHJ4,CQQANSFPLTF,IGKV1D-12,HK CV07-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPHFDFWSGNYFDYW,IGHV3-23,IGHJ5,CQQANSFPLTF,IGKV1D-12,HK CV07-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPHFDFWSGNYFDYW,IGHV3-23,IGHJ6,CQQANSFPLTF,IGKV1D-12,HK CV07-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGVTIFGVVIIDAFDIW,IGHV4-31,IGHJ1,CQQYGSSPLTF,IGKV3-20,HK CV07-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGVTIFGVVIIDAFDIW,IGHV4-31,IGHJ2,CQQYGSSPLTF,IGKV3-20,HK CV07-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGVTIFGVVIIDAFDIW,IGHV4-31,IGHJ3,CQQYGSSPLTF,IGKV3-20,HK CV07-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGVTIFGVVIIDAFDIW,IGHV4-31,IGHJ4,CQQYGSSPLTF,IGKV3-20,HK CV07-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGVTIFGVVIIDAFDIW,IGHV4-31,IGHJ5,CQQYGSSPLTF,IGKV3-20,HK CV07-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGVTIFGVVIIDAFDIW,IGHV4-31,IGHJ6,CQQYGSSPLTF,IGKV3-20,HK CV07-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSREGDLTIFGSVTNAYYYFGMDFW,IGHV1-18,IGHJ1,CQQSYSTPITF,IGKV1-39,HK CV07-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSREGDLTIFGSVTNAYYYFGMDFW,IGHV1-18,IGHJ2,CQQSYSTPITF,IGKV1-39,HK CV07-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSREGDLTIFGSVTNAYYYFGMDFW,IGHV1-18,IGHJ3,CQQSYSTPITF,IGKV1-39,HK CV07-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSREGDLTIFGSVTNAYYYFGMDFW,IGHV1-18,IGHJ4,CQQSYSTPITF,IGKV1-39,HK CV07-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSREGDLTIFGSVTNAYYYFGMDFW,IGHV1-18,IGHJ5,CQQSYSTPITF,IGKV1-39,HK CV07-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSREGDLTIFGSVTNAYYYFGMDFW,IGHV1-18,IGHJ6,CQQSYSTPITF,IGKV1-39,HK CV07-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-196,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-196,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-196,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-196,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-196,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-196,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRDSSGWYPNWFDPW,IGHV4-59,IGHJ1,CQQYNSYPRTF,IGKV1D-16,HK CV07-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRDSSGWYPNWFDPW,IGHV4-59,IGHJ2,CQQYNSYPRTF,IGKV1D-16,HK CV07-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRDSSGWYPNWFDPW,IGHV4-59,IGHJ3,CQQYNSYPRTF,IGKV1D-16,HK CV07-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRDSSGWYPNWFDPW,IGHV4-59,IGHJ4,CQQYNSYPRTF,IGKV1D-16,HK CV07-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRDSSGWYPNWFDPW,IGHV4-59,IGHJ5,CQQYNSYPRTF,IGKV1D-16,HK CV07-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRDSSGWYPNWFDPW,IGHV4-59,IGHJ6,CQQYNSYPRTF,IGKV1D-16,HK CV07-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-200,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-200,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-200,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-200,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-200,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-200,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ1,CCSYGGSSDYVF,IGLV2-23,HL CV07-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ2,CCSYGGSSDYVF,IGLV2-23,HL CV07-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ3,CCSYGGSSDYVF,IGLV2-23,HL CV07-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ4,CCSYGGSSDYVF,IGLV2-23,HL CV07-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ5,CCSYGGSSDYVF,IGLV2-23,HL CV07-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ6,CCSYGGSSDYVF,IGLV2-23,HL CV07-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYGMDVW,IGHV3-53,IGHJ1,CQQLNNYSVTF,IGKV1-9,HK CV07-202,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYGMDVW,IGHV3-53,IGHJ2,CQQLNNYSVTF,IGKV1-9,HK CV07-202,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYGMDVW,IGHV3-53,IGHJ3,CQQLNNYSVTF,IGKV1-9,HK CV07-202,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYGMDVW,IGHV3-53,IGHJ4,CQQLNNYSVTF,IGKV1-9,HK CV07-202,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYGMDVW,IGHV3-53,IGHJ5,CQQLNNYSVTF,IGKV1-9,HK CV07-202,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYGMDVW,IGHV3-53,IGHJ6,CQQLNNYSVTF,IGKV1-9,HK CV07-202,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKQQPSSLSYYYYGMDVW,IGHV1-2,IGHJ1,CQSYDSSLSGSWVF,IGLV1-40,HL CV07-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKQQPSSLSYYYYGMDVW,IGHV1-2,IGHJ2,CQSYDSSLSGSWVF,IGLV1-40,HL CV07-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKQQPSSLSYYYYGMDVW,IGHV1-2,IGHJ3,CQSYDSSLSGSWVF,IGLV1-40,HL CV07-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKQQPSSLSYYYYGMDVW,IGHV1-2,IGHJ4,CQSYDSSLSGSWVF,IGLV1-40,HL CV07-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKQQPSSLSYYYYGMDVW,IGHV1-2,IGHJ5,CQSYDSSLSGSWVF,IGLV1-40,HL CV07-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKQQPSSLSYYYYGMDVW,IGHV1-2,IGHJ6,CQSYDSSLSGSWVF,IGLV1-40,HL CV07-203,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CALCGYSYGSNYYYYGMDVW,IGHV4-39,IGHJ1,CQSYDSSIWVF,IGLV6-57,HL CV07-204,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CALCGYSYGSNYYYYGMDVW,IGHV4-39,IGHJ2,CQSYDSSIWVF,IGLV6-57,HL CV07-204,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CALCGYSYGSNYYYYGMDVW,IGHV4-39,IGHJ3,CQSYDSSIWVF,IGLV6-57,HL CV07-204,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CALCGYSYGSNYYYYGMDVW,IGHV4-39,IGHJ4,CQSYDSSIWVF,IGLV6-57,HL CV07-204,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CALCGYSYGSNYYYYGMDVW,IGHV4-39,IGHJ5,CQSYDSSIWVF,IGLV6-57,HL CV07-204,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CALCGYSYGSNYYYYGMDVW,IGHV4-39,IGHJ6,CQSYDSSIWVF,IGLV6-57,HL CV07-204,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ1,CQQSYSTPNTF,IGKV1-39,HK CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ2,CQQSYSTPNTF,IGKV1-39,HK CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ3,CQQSYSTPNTF,IGKV1-39,HK CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ4,CQQSYSTPNTF,IGKV1-39,HK CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ5,CQQSYSTPNTF,IGKV1-39,HK CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ6,CQQSYSTPNTF,IGKV1-39,HK CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEYGYDSSGSGGDYW,IGHV3-23,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV07-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ1,CQQYNSYWTF,IGKV1-5,HK CV07-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ2,CQQYNSYWTF,IGKV1-5,HK CV07-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ3,CQQYNSYWTF,IGKV1-5,HK CV07-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ4,CQQYNSYWTF,IGKV1-5,HK CV07-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ5,CQQYNSYWTF,IGKV1-5,HK CV07-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ6,CQQYNSYWTF,IGKV1-5,HK CV07-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTRVF,IGLV2-14,HL CV07-206,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTRVF,IGLV2-14,HL CV07-206,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTRVF,IGLV2-14,HL CV07-206,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTRVF,IGLV2-14,HL CV07-206,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTRVF,IGLV2-14,HL CV07-206,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGYYDFWSGYYTVYYYGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTRVF,IGLV2-14,HL CV07-206,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSRNTYVF,IGLV2-14,HL CV07-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSRNTYVF,IGLV2-14,HL CV07-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSRNTYVF,IGLV2-14,HL CV07-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSRNTYVF,IGLV2-14,HL CV07-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSRNTYVF,IGLV2-14,HL CV07-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSRNTYVF,IGLV2-14,HL CV07-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGVIPPRFDYW,IGHV3-11,IGHJ1,CQQYDNLPLTF,IGKV1-33,HK CV07-209,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGVIPPRFDYW,IGHV3-11,IGHJ2,CQQYDNLPLTF,IGKV1-33,HK CV07-209,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGVIPPRFDYW,IGHV3-11,IGHJ3,CQQYDNLPLTF,IGKV1-33,HK CV07-209,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGVIPPRFDYW,IGHV3-11,IGHJ4,CQQYDNLPLTF,IGKV1-33,HK CV07-209,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGVIPPRFDYW,IGHV3-11,IGHJ5,CQQYDNLPLTF,IGKV1-33,HK CV07-209,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGVIPPRFDYW,IGHV3-11,IGHJ6,CQQYDNLPLTF,IGKV1-33,HK CV07-209,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSSGNYRFHYW,IGHV3-21,IGHJ1,CSSYMSSSTPYVF,IGLV2-14,HL CV07-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSSGNYRFHYW,IGHV3-21,IGHJ2,CSSYMSSSTPYVF,IGLV2-14,HL CV07-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSSGNYRFHYW,IGHV3-21,IGHJ3,CSSYMSSSTPYVF,IGLV2-14,HL CV07-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSSGNYRFHYW,IGHV3-21,IGHJ4,CSSYMSSSTPYVF,IGLV2-14,HL CV07-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSSGNYRFHYW,IGHV3-21,IGHJ5,CSSYMSSSTPYVF,IGLV2-14,HL CV07-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSSGNYRFHYW,IGHV3-21,IGHJ6,CSSYMSSSTPYVF,IGLV2-14,HL CV07-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ1,CASWDDRLNGVVF,IGLV1-44,HL CV07-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ2,CASWDDRLNGVVF,IGLV1-44,HL CV07-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ3,CASWDDRLNGVVF,IGLV1-44,HL CV07-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ4,CASWDDRLNGVVF,IGLV1-44,HL CV07-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ5,CASWDDRLNGVVF,IGLV1-44,HL CV07-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ6,CASWDDRLNGVVF,IGLV1-44,HL CV07-213,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREENAFDIW,IGHV6-1,IGHJ1,CQQYSNWLLYTF,IGKV3-15,HK CV07-214,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREENAFDIW,IGHV6-1,IGHJ2,CQQYSNWLLYTF,IGKV3-15,HK CV07-214,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREENAFDIW,IGHV6-1,IGHJ3,CQQYSNWLLYTF,IGKV3-15,HK CV07-214,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREENAFDIW,IGHV6-1,IGHJ4,CQQYSNWLLYTF,IGKV3-15,HK CV07-214,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREENAFDIW,IGHV6-1,IGHJ5,CQQYSNWLLYTF,IGKV3-15,HK CV07-214,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREENAFDIW,IGHV6-1,IGHJ6,CQQYSNWLLYTF,IGKV3-15,HK CV07-214,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGHAFDIW,IGHV3-48,IGHJ1,CQQYGSSPSWTF,IGKV3-20,HK CV07-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGHAFDIW,IGHV3-48,IGHJ2,CQQYGSSPSWTF,IGKV3-20,HK CV07-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGHAFDIW,IGHV3-48,IGHJ3,CQQYGSSPSWTF,IGKV3-20,HK CV07-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGHAFDIW,IGHV3-48,IGHJ4,CQQYGSSPSWTF,IGKV3-20,HK CV07-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGHAFDIW,IGHV3-48,IGHJ5,CQQYGSSPSWTF,IGKV3-20,HK CV07-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREGHAFDIW,IGHV3-48,IGHJ6,CQQYGSSPSWTF,IGKV3-20,HK CV07-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVAWGTTPLGTSENNW,IGHV3-7,IGHJ1,CMQHTHWPHTF,IGKV2-30,HK CV07-216,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVAWGTTPLGTSENNW,IGHV3-7,IGHJ2,CMQHTHWPHTF,IGKV2-30,HK CV07-216,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVAWGTTPLGTSENNW,IGHV3-7,IGHJ3,CMQHTHWPHTF,IGKV2-30,HK CV07-216,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVAWGTTPLGTSENNW,IGHV3-7,IGHJ4,CMQHTHWPHTF,IGKV2-30,HK CV07-216,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVAWGTTPLGTSENNW,IGHV3-7,IGHJ5,CMQHTHWPHTF,IGKV2-30,HK CV07-216,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVAWGTTPLGTSENNW,IGHV3-7,IGHJ6,CMQHTHWPHTF,IGKV2-30,HK CV07-216,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ1,CASWDDSLNGVVF,IGLV1-44,HL CV07-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ2,CASWDDSLNGVVF,IGLV1-44,HL CV07-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ3,CASWDDSLNGVVF,IGLV1-44,HL CV07-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ4,CASWDDSLNGVVF,IGLV1-44,HL CV07-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ5,CASWDDSLNGVVF,IGLV1-44,HL CV07-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPSWNGYYYYFDYW,IGHV1-8,IGHJ6,CASWDDSLNGVVF,IGLV1-44,HL CV07-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKRMGGNRFNPPVEYW,IGHV3-23,IGHJ1,CHSYDSSLSASVF,IGLV1-40,HL CV07-218,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKRMGGNRFNPPVEYW,IGHV3-23,IGHJ2,CHSYDSSLSASVF,IGLV1-40,HL CV07-218,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKRMGGNRFNPPVEYW,IGHV3-23,IGHJ3,CHSYDSSLSASVF,IGLV1-40,HL CV07-218,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKRMGGNRFNPPVEYW,IGHV3-23,IGHJ4,CHSYDSSLSASVF,IGLV1-40,HL CV07-218,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKRMGGNRFNPPVEYW,IGHV3-23,IGHJ5,CHSYDSSLSASVF,IGLV1-40,HL CV07-218,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKRMGGNRFNPPVEYW,IGHV3-23,IGHJ6,CHSYDSSLSASVF,IGLV1-40,HL CV07-218,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGIGQLWDDSYYYGLDVW,IGHV3-11,IGHJ1,CMQGAHWPPYTF,IGKV2-30,HK CV07-219,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGIGQLWDDSYYYGLDVW,IGHV3-11,IGHJ2,CMQGAHWPPYTF,IGKV2-30,HK CV07-219,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGIGQLWDDSYYYGLDVW,IGHV3-11,IGHJ3,CMQGAHWPPYTF,IGKV2-30,HK CV07-219,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGIGQLWDDSYYYGLDVW,IGHV3-11,IGHJ4,CMQGAHWPPYTF,IGKV2-30,HK CV07-219,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGIGQLWDDSYYYGLDVW,IGHV3-11,IGHJ5,CMQGAHWPPYTF,IGKV2-30,HK CV07-219,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGIGQLWDDSYYYGLDVW,IGHV3-11,IGHJ6,CMQGAHWPPYTF,IGKV2-30,HK CV07-219,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ1,CQSYDSSLRGVF,IGLV1-40,HL CV07-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ2,CQSYDSSLRGVF,IGLV1-40,HL CV07-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ3,CQSYDSSLRGVF,IGLV1-40,HL CV07-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ4,CQSYDSSLRGVF,IGLV1-40,HL CV07-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ5,CQSYDSSLRGVF,IGLV1-40,HL CV07-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ6,CQSYDSSLRGVF,IGLV1-40,HL CV07-221,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPYYYDSSGSLGAFDIW,IGHV1-2,IGHJ1,CCSYAGGSTSYVF,IGLV2-23,HL CV07-222,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPYYYDSSGSLGAFDIW,IGHV1-2,IGHJ2,CCSYAGGSTSYVF,IGLV2-23,HL CV07-222,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPYYYDSSGSLGAFDIW,IGHV1-2,IGHJ3,CCSYAGGSTSYVF,IGLV2-23,HL CV07-222,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPYYYDSSGSLGAFDIW,IGHV1-2,IGHJ4,CCSYAGGSTSYVF,IGLV2-23,HL CV07-222,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPYYYDSSGSLGAFDIW,IGHV1-2,IGHJ5,CCSYAGGSTSYVF,IGLV2-23,HL CV07-222,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPYYYDSSGSLGAFDIW,IGHV1-2,IGHJ6,CCSYAGGSTSYVF,IGLV2-23,HL CV07-222,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPSWNGYYYYFDYW,IGHV1-8,IGHJ1,CASWDDSLNGVVF,IGLV1-44,HL CV07-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPSWNGYYYYFDYW,IGHV1-8,IGHJ2,CASWDDSLNGVVF,IGLV1-44,HL CV07-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPSWNGYYYYFDYW,IGHV1-8,IGHJ3,CASWDDSLNGVVF,IGLV1-44,HL CV07-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPSWNGYYYYFDYW,IGHV1-8,IGHJ4,CASWDDSLNGVVF,IGLV1-44,HL CV07-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPSWNGYYYYFDYW,IGHV1-8,IGHJ5,CASWDDSLNGVVF,IGLV1-44,HL CV07-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPSWNGYYYYFDYW,IGHV1-8,IGHJ6,CASWDDSLNGVVF,IGLV1-44,HL CV07-223,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGPYYSSSSNGMDVW,IGHV5-51,IGHJ1,CCSYAGSSTRVF,IGLV2-23,HL CV07-224,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGPYYSSSSNGMDVW,IGHV5-51,IGHJ2,CCSYAGSSTRVF,IGLV2-23,HL CV07-224,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGPYYSSSSNGMDVW,IGHV5-51,IGHJ3,CCSYAGSSTRVF,IGLV2-23,HL CV07-224,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGPYYSSSSNGMDVW,IGHV5-51,IGHJ4,CCSYAGSSTRVF,IGLV2-23,HL CV07-224,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGPYYSSSSNGMDVW,IGHV5-51,IGHJ5,CCSYAGSSTRVF,IGLV2-23,HL CV07-224,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLGPYYSSSSNGMDVW,IGHV5-51,IGHJ6,CCSYAGSSTRVF,IGLV2-23,HL CV07-224,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTPPGYNWNYGPYGMDVW,IGHV4-31,IGHJ1,CQQYNNWPPGYTF,IGKV3-15,HK CV07-225,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTPPGYNWNYGPYGMDVW,IGHV4-31,IGHJ2,CQQYNNWPPGYTF,IGKV3-15,HK CV07-225,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTPPGYNWNYGPYGMDVW,IGHV4-31,IGHJ3,CQQYNNWPPGYTF,IGKV3-15,HK CV07-225,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTPPGYNWNYGPYGMDVW,IGHV4-31,IGHJ4,CQQYNNWPPGYTF,IGKV3-15,HK CV07-225,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTPPGYNWNYGPYGMDVW,IGHV4-31,IGHJ5,CQQYNNWPPGYTF,IGKV3-15,HK CV07-225,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTPPGYNWNYGPYGMDVW,IGHV4-31,IGHJ6,CQQYNNWPPGYTF,IGKV3-15,HK CV07-225,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ1,CSSYTASNRGF,IGLV2-8,HL CV07-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ2,CSSYTASNRGF,IGLV2-8,HL CV07-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ3,CSSYTASNRGF,IGLV2-8,HL CV07-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ4,CSSYTASNRGF,IGLV2-8,HL CV07-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ5,CSSYTASNRGF,IGLV2-8,HL CV07-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ6,CSSYTASNRGF,IGLV2-8,HL CV07-226,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEISGYYFDYW,IGHV3-9,IGHJ1,CQTWGTGIHWVF,IGLV4-69,HL CV07-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEISGYYFDYW,IGHV3-9,IGHJ2,CQTWGTGIHWVF,IGLV4-69,HL CV07-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEISGYYFDYW,IGHV3-9,IGHJ3,CQTWGTGIHWVF,IGLV4-69,HL CV07-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEISGYYFDYW,IGHV3-9,IGHJ4,CQTWGTGIHWVF,IGLV4-69,HL CV07-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEISGYYFDYW,IGHV3-9,IGHJ5,CQTWGTGIHWVF,IGLV4-69,HL CV07-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEISGYYFDYW,IGHV3-9,IGHJ6,CQTWGTGIHWVF,IGLV4-69,HL CV07-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ1,CQSYDSSLRGVF,IGLV1-40,HL CV07-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ2,CQSYDSSLRGVF,IGLV1-40,HL CV07-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ3,CQSYDSSLRGVF,IGLV1-40,HL CV07-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ4,CQSYDSSLRGVF,IGLV1-40,HL CV07-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ5,CQSYDSSLRGVF,IGLV1-40,HL CV07-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKKAGYSSGWYTDYYYNGMDVW,IGHV3-30,IGHJ6,CQSYDSSLRGVF,IGLV1-40,HL CV07-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSTYGDYYYYYGMDVW,IGHV3-23,IGHJ1,CNSYTSNSSLGVF,IGLV2-14,HL CV07-235,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSTYGDYYYYYGMDVW,IGHV3-23,IGHJ2,CNSYTSNSSLGVF,IGLV2-14,HL CV07-235,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSTYGDYYYYYGMDVW,IGHV3-23,IGHJ3,CNSYTSNSSLGVF,IGLV2-14,HL CV07-235,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSTYGDYYYYYGMDVW,IGHV3-23,IGHJ4,CNSYTSNSSLGVF,IGLV2-14,HL CV07-235,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSTYGDYYYYYGMDVW,IGHV3-23,IGHJ5,CNSYTSNSSLGVF,IGLV2-14,HL CV07-235,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSTYGDYYYYYGMDVW,IGHV3-23,IGHJ6,CNSYTSNSSLGVF,IGLV2-14,HL CV07-235,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYSSGWYDYW,IGHV3-53,IGHJ1,CQQYNNWPLTF,IGKV3-15,HK CV07-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYSSGWYDYW,IGHV3-53,IGHJ2,CQQYNNWPLTF,IGKV3-15,HK CV07-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYSSGWYDYW,IGHV3-53,IGHJ3,CQQYNNWPLTF,IGKV3-15,HK CV07-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYSSGWYDYW,IGHV3-53,IGHJ4,CQQYNNWPLTF,IGKV3-15,HK CV07-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYSSGWYDYW,IGHV3-53,IGHJ5,CQQYNNWPLTF,IGKV3-15,HK CV07-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYSSGWYDYW,IGHV3-53,IGHJ6,CQQYNNWPLTF,IGKV3-15,HK CV07-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-237,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-237,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-237,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-237,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-237,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-237,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTNWNYYYYYYGMDVW,IGHV1-8,IGHJ1,CAAWDDSLNGYVF,IGLV1-44,HL CV07-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTNWNYYYYYYGMDVW,IGHV1-8,IGHJ2,CAAWDDSLNGYVF,IGLV1-44,HL CV07-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTNWNYYYYYYGMDVW,IGHV1-8,IGHJ3,CAAWDDSLNGYVF,IGLV1-44,HL CV07-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTNWNYYYYYYGMDVW,IGHV1-8,IGHJ4,CAAWDDSLNGYVF,IGLV1-44,HL CV07-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTNWNYYYYYYGMDVW,IGHV1-8,IGHJ5,CAAWDDSLNGYVF,IGLV1-44,HL CV07-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTNWNYYYYYYGMDVW,IGHV1-8,IGHJ6,CAAWDDSLNGYVF,IGLV1-44,HL CV07-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRWYHDNNGYRSDAFDVW,IGHV4-34,IGHJ1,CAAWDDSLNEVF,IGLV1-44,HL CV07-239,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRWYHDNNGYRSDAFDVW,IGHV4-34,IGHJ2,CAAWDDSLNEVF,IGLV1-44,HL CV07-239,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRWYHDNNGYRSDAFDVW,IGHV4-34,IGHJ3,CAAWDDSLNEVF,IGLV1-44,HL CV07-239,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRWYHDNNGYRSDAFDVW,IGHV4-34,IGHJ4,CAAWDDSLNEVF,IGLV1-44,HL CV07-239,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRWYHDNNGYRSDAFDVW,IGHV4-34,IGHJ5,CAAWDDSLNEVF,IGLV1-44,HL CV07-239,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRWYHDNNGYRSDAFDVW,IGHV4-34,IGHJ6,CAAWDDSLNEVF,IGLV1-44,HL CV07-239,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CITSMFNNGFYW,IGHV3-74,IGHJ1,CSSYAGSYTVF,IGLV2-11,HL CV07-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CITSMFNNGFYW,IGHV3-74,IGHJ2,CSSYAGSYTVF,IGLV2-11,HL CV07-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CITSMFNNGFYW,IGHV3-74,IGHJ3,CSSYAGSYTVF,IGLV2-11,HL CV07-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CITSMFNNGFYW,IGHV3-74,IGHJ4,CSSYAGSYTVF,IGLV2-11,HL CV07-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CITSMFNNGFYW,IGHV3-74,IGHJ5,CSSYAGSYTVF,IGLV2-11,HL CV07-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CITSMFNNGFYW,IGHV3-74,IGHJ6,CSSYAGSYTVF,IGLV2-11,HL CV07-241,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLWRLDPW,IGHV3-15,IGHJ1,CLLTHTDSRVF,IGLV7-46,HL CV07-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLWRLDPW,IGHV3-15,IGHJ2,CLLTHTDSRVF,IGLV7-46,HL CV07-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLWRLDPW,IGHV3-15,IGHJ3,CLLTHTDSRVF,IGLV7-46,HL CV07-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLWRLDPW,IGHV3-15,IGHJ4,CLLTHTDSRVF,IGLV7-46,HL CV07-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLWRLDPW,IGHV3-15,IGHJ5,CLLTHTDSRVF,IGLV7-46,HL CV07-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTLWRLDPW,IGHV3-15,IGHJ6,CLLTHTDSRVF,IGLV7-46,HL CV07-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-249,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-249,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-249,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-249,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-249,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-249,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGSDNYGFPYNGMDVW,IGHV1-18,IGHJ1,CSSYAGNNDFVF,IGLV2-8,HL CV07-250,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGSDNYGFPYNGMDVW,IGHV1-18,IGHJ2,CSSYAGNNDFVF,IGLV2-8,HL CV07-250,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGSDNYGFPYNGMDVW,IGHV1-18,IGHJ3,CSSYAGNNDFVF,IGLV2-8,HL CV07-250,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGSDNYGFPYNGMDVW,IGHV1-18,IGHJ4,CSSYAGNNDFVF,IGLV2-8,HL CV07-250,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGSDNYGFPYNGMDVW,IGHV1-18,IGHJ5,CSSYAGNNDFVF,IGLV2-8,HL CV07-250,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAGSDNYGFPYNGMDVW,IGHV1-18,IGHJ6,CSSYAGNNDFVF,IGLV2-8,HL CV07-250,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDYW,IGHV3-23,IGHJ1,CQQRNNWPVTF,IGKV3-11,HK CV07-251,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDYW,IGHV3-23,IGHJ2,CQQRNNWPVTF,IGKV3-11,HK CV07-251,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDYW,IGHV3-23,IGHJ3,CQQRNNWPVTF,IGKV3-11,HK CV07-251,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDYW,IGHV3-23,IGHJ4,CQQRNNWPVTF,IGKV3-11,HK CV07-251,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDYW,IGHV3-23,IGHJ5,CQQRNNWPVTF,IGKV3-11,HK CV07-251,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEFSIGWGLFDYW,IGHV3-23,IGHJ6,CQQRNNWPVTF,IGKV3-11,HK CV07-251,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKHWNNANYYYYGMDVW,IGHV1-46,IGHJ1,CQQYNSYLF,IGKV1-5,HK CV07-252,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKHWNNANYYYYGMDVW,IGHV1-46,IGHJ2,CQQYNSYLF,IGKV1-5,HK CV07-252,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKHWNNANYYYYGMDVW,IGHV1-46,IGHJ3,CQQYNSYLF,IGKV1-5,HK CV07-252,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKHWNNANYYYYGMDVW,IGHV1-46,IGHJ4,CQQYNSYLF,IGKV1-5,HK CV07-252,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKHWNNANYYYYGMDVW,IGHV1-46,IGHJ5,CQQYNSYLF,IGKV1-5,HK CV07-252,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDKHWNNANYYYYGMDVW,IGHV1-46,IGHJ6,CQQYNSYLF,IGKV1-5,HK CV07-252,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGGAALVGHSNYW,IGHV1-2,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV07-254,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGGAALVGHSNYW,IGHV1-2,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV07-254,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGGAALVGHSNYW,IGHV1-2,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV07-254,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGGAALVGHSNYW,IGHV1-2,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV07-254,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGGAALVGHSNYW,IGHV1-2,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV07-254,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGGAALVGHSNYW,IGHV1-2,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV07-254,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSRFSYVNGEFDYW,IGHV1-2,IGHJ1,CCSYAGHSTWVF,IGLV2-23,HL CV07-255,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSRFSYVNGEFDYW,IGHV1-2,IGHJ2,CCSYAGHSTWVF,IGLV2-23,HL CV07-255,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSRFSYVNGEFDYW,IGHV1-2,IGHJ3,CCSYAGHSTWVF,IGLV2-23,HL CV07-255,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSRFSYVNGEFDYW,IGHV1-2,IGHJ4,CCSYAGHSTWVF,IGLV2-23,HL CV07-255,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSRFSYVNGEFDYW,IGHV1-2,IGHJ5,CCSYAGHSTWVF,IGLV2-23,HL CV07-255,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSRFSYVNGEFDYW,IGHV1-2,IGHJ6,CCSYAGHSTWVF,IGLV2-23,HL CV07-255,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGWYDFGTPGDYYYYYGMDVW,IGHV1-2,IGHJ1,CCSYAGTSTFVF,IGLV2-23,HL CV07-262,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGWYDFGTPGDYYYYYGMDVW,IGHV1-2,IGHJ2,CCSYAGTSTFVF,IGLV2-23,HL CV07-262,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGWYDFGTPGDYYYYYGMDVW,IGHV1-2,IGHJ3,CCSYAGTSTFVF,IGLV2-23,HL CV07-262,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGWYDFGTPGDYYYYYGMDVW,IGHV1-2,IGHJ4,CCSYAGTSTFVF,IGLV2-23,HL CV07-262,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGWYDFGTPGDYYYYYGMDVW,IGHV1-2,IGHJ5,CCSYAGTSTFVF,IGLV2-23,HL CV07-262,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVGWYDFGTPGDYYYYYGMDVW,IGHV1-2,IGHJ6,CCSYAGTSTFVF,IGLV2-23,HL CV07-262,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CADSGYWGSHYYYGMDVW,IGHV1-2,IGHJ1,CMQSIQLPLTF,IGKV2D-29,HK CV07-263,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CADSGYWGSHYYYGMDVW,IGHV1-2,IGHJ2,CMQSIQLPLTF,IGKV2D-29,HK CV07-263,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CADSGYWGSHYYYGMDVW,IGHV1-2,IGHJ3,CMQSIQLPLTF,IGKV2D-29,HK CV07-263,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CADSGYWGSHYYYGMDVW,IGHV1-2,IGHJ4,CMQSIQLPLTF,IGKV2D-29,HK CV07-263,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CADSGYWGSHYYYGMDVW,IGHV1-2,IGHJ5,CMQSIQLPLTF,IGKV2D-29,HK CV07-263,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CADSGYWGSHYYYGMDVW,IGHV1-2,IGHJ6,CMQSIQLPLTF,IGKV2D-29,HK CV07-263,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-264,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-264,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-264,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-264,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-264,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-264,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRRYSSSWYYYYGMDVW,IGHV3-48,IGHJ1,CQQLNSYPLTF,IGKV1-9,HK CV07-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRRYSSSWYYYYGMDVW,IGHV3-48,IGHJ2,CQQLNSYPLTF,IGKV1-9,HK CV07-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRRYSSSWYYYYGMDVW,IGHV3-48,IGHJ3,CQQLNSYPLTF,IGKV1-9,HK CV07-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRRYSSSWYYYYGMDVW,IGHV3-48,IGHJ4,CQQLNSYPLTF,IGKV1-9,HK CV07-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRRYSSSWYYYYGMDVW,IGHV3-48,IGHJ5,CQQLNSYPLTF,IGKV1-9,HK CV07-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRRYSSSWYYYYGMDVW,IGHV3-48,IGHJ6,CQQLNSYPLTF,IGKV1-9,HK CV07-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ1,CCSYGGSSDYVF,IGLV2-23,HL CV07-266,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ2,CCSYGGSSDYVF,IGLV2-23,HL CV07-266,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ3,CCSYGGSSDYVF,IGLV2-23,HL CV07-266,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ4,CCSYGGSSDYVF,IGLV2-23,HL CV07-266,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ5,CCSYGGSSDYVF,IGLV2-23,HL CV07-266,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ6,CCSYGGSSDYVF,IGLV2-23,HL CV07-266,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ1,CCSYAGSSSWVF,IGLV2-23,HL CV07-267,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ2,CCSYAGSSSWVF,IGLV2-23,HL CV07-267,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ3,CCSYAGSSSWVF,IGLV2-23,HL CV07-267,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ4,CCSYAGSSSWVF,IGLV2-23,HL CV07-267,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ5,CCSYAGSSSWVF,IGLV2-23,HL CV07-267,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ6,CCSYAGSSSWVF,IGLV2-23,HL CV07-267,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARGSSGWYRIGTRWGNWFDPW,IGHV3-11,IGHJ1,CSSYTSSSNVVF,IGLV2-14,HL CV07-270,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARGSSGWYRIGTRWGNWFDPW,IGHV3-11,IGHJ2,CSSYTSSSNVVF,IGLV2-14,HL CV07-270,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARGSSGWYRIGTRWGNWFDPW,IGHV3-11,IGHJ3,CSSYTSSSNVVF,IGLV2-14,HL CV07-270,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARGSSGWYRIGTRWGNWFDPW,IGHV3-11,IGHJ4,CSSYTSSSNVVF,IGLV2-14,HL CV07-270,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARGSSGWYRIGTRWGNWFDPW,IGHV3-11,IGHJ5,CSSYTSSSNVVF,IGLV2-14,HL CV07-270,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARARGSSGWYRIGTRWGNWFDPW,IGHV3-11,IGHJ6,CSSYTSSSNVVF,IGLV2-14,HL CV07-270,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPFAYCSSTSCDRGTPYYYYYGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTLVF,IGLV2-14,HL CV07-271,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPFAYCSSTSCDRGTPYYYYYGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTLVF,IGLV2-14,HL CV07-271,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPFAYCSSTSCDRGTPYYYYYGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTLVF,IGLV2-14,HL CV07-271,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPFAYCSSTSCDRGTPYYYYYGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTLVF,IGLV2-14,HL CV07-271,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPFAYCSSTSCDRGTPYYYYYGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTLVF,IGLV2-14,HL CV07-271,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVPFAYCSSTSCDRGTPYYYYYGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTLVF,IGLV2-14,HL CV07-271,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLDNNGYYSGYW,IGHV3-64,IGHJ1,CQQYGSSPRTF,IGKV3-20,HK CV07-272,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLDNNGYYSGYW,IGHV3-64,IGHJ2,CQQYGSSPRTF,IGKV3-20,HK CV07-272,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLDNNGYYSGYW,IGHV3-64,IGHJ3,CQQYGSSPRTF,IGKV3-20,HK CV07-272,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLDNNGYYSGYW,IGHV3-64,IGHJ4,CQQYGSSPRTF,IGKV3-20,HK CV07-272,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLDNNGYYSGYW,IGHV3-64,IGHJ5,CQQYGSSPRTF,IGKV3-20,HK CV07-272,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLDNNGYYSGYW,IGHV3-64,IGHJ6,CQQYGSSPRTF,IGKV3-20,HK CV07-272,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-274,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-274,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-274,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-274,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-274,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-274,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYYDSSGYYSSGGLGYW,IGHV3-66,IGHJ1,CSSYAGSNNFVF,IGLV2-8,HL CV07-275,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYYDSSGYYSSGGLGYW,IGHV3-66,IGHJ2,CSSYAGSNNFVF,IGLV2-8,HL CV07-275,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYYDSSGYYSSGGLGYW,IGHV3-66,IGHJ3,CSSYAGSNNFVF,IGLV2-8,HL CV07-275,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYYDSSGYYSSGGLGYW,IGHV3-66,IGHJ4,CSSYAGSNNFVF,IGLV2-8,HL CV07-275,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYYDSSGYYSSGGLGYW,IGHV3-66,IGHJ5,CSSYAGSNNFVF,IGLV2-8,HL CV07-275,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYYDSSGYYSSGGLGYW,IGHV3-66,IGHJ6,CSSYAGSNNFVF,IGLV2-8,HL CV07-275,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-280,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-280,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-280,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-280,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-280,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-280,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-281,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-281,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-281,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-281,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-281,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-281,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPFYYDSSGPLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-283,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPFYYDSSGPLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-283,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPFYYDSSGPLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-283,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPFYYDSSGPLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-283,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPFYYDSSGPLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-283,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRGPFYYDSSGPLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-283,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGGDYPYGMDVW,IGHV5-51,IGHJ1,CAAWDDSLSAWVF,IGLV1-44,HL CV07-284,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGGDYPYGMDVW,IGHV5-51,IGHJ2,CAAWDDSLSAWVF,IGLV1-44,HL CV07-284,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGGDYPYGMDVW,IGHV5-51,IGHJ3,CAAWDDSLSAWVF,IGLV1-44,HL CV07-284,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGGDYPYGMDVW,IGHV5-51,IGHJ4,CAAWDDSLSAWVF,IGLV1-44,HL CV07-284,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGGDYPYGMDVW,IGHV5-51,IGHJ5,CAAWDDSLSAWVF,IGLV1-44,HL CV07-284,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGGDYPYGMDVW,IGHV5-51,IGHJ6,CAAWDDSLSAWVF,IGLV1-44,HL CV07-284,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-285,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-285,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-285,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-285,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-285,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-285,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGRYCSGTNCYEYYFFAMDVW,IGHV3-9,IGHJ1,CSSYAGSNNNVVF,IGLV2-8,HL CV07-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGRYCSGTNCYEYYFFAMDVW,IGHV3-9,IGHJ2,CSSYAGSNNNVVF,IGLV2-8,HL CV07-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGRYCSGTNCYEYYFFAMDVW,IGHV3-9,IGHJ3,CSSYAGSNNNVVF,IGLV2-8,HL CV07-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGRYCSGTNCYEYYFFAMDVW,IGHV3-9,IGHJ4,CSSYAGSNNNVVF,IGLV2-8,HL CV07-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGRYCSGTNCYEYYFFAMDVW,IGHV3-9,IGHJ5,CSSYAGSNNNVVF,IGLV2-8,HL CV07-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGRYCSGTNCYEYYFFAMDVW,IGHV3-9,IGHJ6,CSSYAGSNNNVVF,IGLV2-8,HL CV07-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAPYCSSTNCYDAFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,HK CV07-287,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAPYCSSTNCYDAFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,HK CV07-287,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAPYCSSTNCYDAFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,HK CV07-287,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAPYCSSTNCYDAFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,HK CV07-287,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAPYCSSTNCYDAFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,HK CV07-287,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAPYCSSTNCYDAFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,HK CV07-287,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAAMVTGYTYYYGLDVW,IGHV1-2,IGHJ1,CQQYGSSPITF,IGKV3-20,HK CV07-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAAMVTGYTYYYGLDVW,IGHV1-2,IGHJ2,CQQYGSSPITF,IGKV3-20,HK CV07-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAAMVTGYTYYYGLDVW,IGHV1-2,IGHJ3,CQQYGSSPITF,IGKV3-20,HK CV07-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAAMVTGYTYYYGLDVW,IGHV1-2,IGHJ4,CQQYGSSPITF,IGKV3-20,HK CV07-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAAMVTGYTYYYGLDVW,IGHV1-2,IGHJ5,CQQYGSSPITF,IGKV3-20,HK CV07-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAAMVTGYTYYYGLDVW,IGHV1-2,IGHJ6,CQQYGSSPITF,IGKV3-20,HK CV07-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-290,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-290,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-290,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-290,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-290,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-290,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-292,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-292,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-292,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-292,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-292,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGDYW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-292,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ1,CQQYYSTLTF,IGKV4-1,HK CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ2,CQQYYSTLTF,IGKV4-1,HK CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ3,CQQYYSTLTF,IGKV4-1,HK CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ4,CQQYYSTLTF,IGKV4-1,HK CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ5,CQQYYSTLTF,IGKV4-1,HK CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ6,CQQYYSTLTF,IGKV4-1,HK CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ1,CSSYTISSTWVF,IGLV2-14,HL CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ2,CSSYTISSTWVF,IGLV2-14,HL CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ3,CSSYTISSTWVF,IGLV2-14,HL CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ4,CSSYTISSTWVF,IGLV2-14,HL CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ5,CSSYTISSTWVF,IGLV2-14,HL CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARCNGGGACFYGMDVW,IGHV3-11,IGHJ6,CSSYTISSTWVF,IGLV2-14,HL CV07-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-294,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-294,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-294,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-294,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-294,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-294,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSASGWNFDYW,IGHV3-53,IGHJ1,CSSYAGSNNLVF,IGLV2-8,HL CV07-297,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSASGWNFDYW,IGHV3-53,IGHJ2,CSSYAGSNNLVF,IGLV2-8,HL CV07-297,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSASGWNFDYW,IGHV3-53,IGHJ3,CSSYAGSNNLVF,IGLV2-8,HL CV07-297,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSASGWNFDYW,IGHV3-53,IGHJ4,CSSYAGSNNLVF,IGLV2-8,HL CV07-297,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSASGWNFDYW,IGHV3-53,IGHJ5,CSSYAGSNNLVF,IGLV2-8,HL CV07-297,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSASGWNFDYW,IGHV3-53,IGHJ6,CSSYAGSNNLVF,IGLV2-8,HL CV07-297,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSHGYSGYELGYW,IGHV5-51,IGHJ1,CSSYTSSSTVWVF,IGLV2-14,HL CV07-299,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSHGYSGYELGYW,IGHV5-51,IGHJ2,CSSYTSSSTVWVF,IGLV2-14,HL CV07-299,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSHGYSGYELGYW,IGHV5-51,IGHJ3,CSSYTSSSTVWVF,IGLV2-14,HL CV07-299,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSHGYSGYELGYW,IGHV5-51,IGHJ4,CSSYTSSSTVWVF,IGLV2-14,HL CV07-299,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSHGYSGYELGYW,IGHV5-51,IGHJ5,CSSYTSSSTVWVF,IGLV2-14,HL CV07-299,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSHGYSGYELGYW,IGHV5-51,IGHJ6,CSSYTSSSTVWVF,IGLV2-14,HL CV07-299,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ1,,IGKV2D-29,HK CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ2,,IGKV2D-29,HK CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ3,,IGKV2D-29,HK CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ4,,IGKV2D-29,HK CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ5,,IGKV2D-29,HK CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ6,,IGKV2D-29,HK CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVDTTGTTFWLYYYYGMDVW,IGHV1-2,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV07-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDKGPYYYYGMDVW,IGHV3-9,IGHJ1,CMQSIQLPQTF,IGKV2D-29,HK CV07-302,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDKGPYYYYGMDVW,IGHV3-9,IGHJ2,CMQSIQLPQTF,IGKV2D-29,HK CV07-302,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDKGPYYYYGMDVW,IGHV3-9,IGHJ3,CMQSIQLPQTF,IGKV2D-29,HK CV07-302,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDKGPYYYYGMDVW,IGHV3-9,IGHJ4,CMQSIQLPQTF,IGKV2D-29,HK CV07-302,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDKGPYYYYGMDVW,IGHV3-9,IGHJ5,CMQSIQLPQTF,IGKV2D-29,HK CV07-302,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDKGPYYYYGMDVW,IGHV3-9,IGHJ6,CMQSIQLPQTF,IGKV2D-29,HK CV07-302,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-303,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-303,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-303,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-303,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-303,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-303,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ1,CCSYAGSNSWVF,IGLV2-23,HL CV07-304,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ2,CCSYAGSNSWVF,IGLV2-23,HL CV07-304,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ3,CCSYAGSNSWVF,IGLV2-23,HL CV07-304,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ4,CCSYAGSNSWVF,IGLV2-23,HL CV07-304,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ5,CCSYAGSNSWVF,IGLV2-23,HL CV07-304,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ6,CCSYAGSNSWVF,IGLV2-23,HL CV07-304,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-305,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-305,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-305,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-305,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-305,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGIGVAGNLDHW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-305,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTLYYDILTGSPNPPKLDYW,IGHV1-2,IGHJ1,CQQSYSTPWTF,IGKV1-39,HK CV07-306,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTLYYDILTGSPNPPKLDYW,IGHV1-2,IGHJ2,CQQSYSTPWTF,IGKV1-39,HK CV07-306,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTLYYDILTGSPNPPKLDYW,IGHV1-2,IGHJ3,CQQSYSTPWTF,IGKV1-39,HK CV07-306,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTLYYDILTGSPNPPKLDYW,IGHV1-2,IGHJ4,CQQSYSTPWTF,IGKV1-39,HK CV07-306,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTLYYDILTGSPNPPKLDYW,IGHV1-2,IGHJ5,CQQSYSTPWTF,IGKV1-39,HK CV07-306,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTLYYDILTGSPNPPKLDYW,IGHV1-2,IGHJ6,CQQSYSTPWTF,IGKV1-39,HK CV07-306,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-307,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-307,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-307,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-307,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-307,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-307,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-309,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-309,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-309,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-309,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-309,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDNSGTLGGLDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-309,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-310,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-310,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-310,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-310,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-310,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-310,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIPIFGVVSTPGQYYYYGMDVW,IGHV1-2,IGHJ1,CISYTSSSTWVF,IGLV2-14,HL CV07-312,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIPIFGVVSTPGQYYYYGMDVW,IGHV1-2,IGHJ2,CISYTSSSTWVF,IGLV2-14,HL CV07-312,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIPIFGVVSTPGQYYYYGMDVW,IGHV1-2,IGHJ3,CISYTSSSTWVF,IGLV2-14,HL CV07-312,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIPIFGVVSTPGQYYYYGMDVW,IGHV1-2,IGHJ4,CISYTSSSTWVF,IGLV2-14,HL CV07-312,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIPIFGVVSTPGQYYYYGMDVW,IGHV1-2,IGHJ5,CISYTSSSTWVF,IGLV2-14,HL CV07-312,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIPIFGVVSTPGQYYYYGMDVW,IGHV1-2,IGHJ6,CISYTSSSTWVF,IGLV2-14,HL CV07-312,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ1,CCSYGGSSDYVF,IGLV2-23,HL CV07-313,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ2,CCSYGGSSDYVF,IGLV2-23,HL CV07-313,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ3,CCSYGGSSDYVF,IGLV2-23,HL CV07-313,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ4,CCSYGGSSDYVF,IGLV2-23,HL CV07-313,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ5,CCSYGGSSDYVF,IGLV2-23,HL CV07-313,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATDRLVNTGVYTTGSMDVW,IGHV1-2,IGHJ6,CCSYGGSSDYVF,IGLV2-23,HL CV07-313,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ1,CQQSYSTHAF,IGKV1-39,HK CV07-315,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ2,CQQSYSTHAF,IGKV1-39,HK CV07-315,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ3,CQQSYSTHAF,IGKV1-39,HK CV07-315,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ4,CQQSYSTHAF,IGKV1-39,HK CV07-315,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ5,CQQSYSTHAF,IGKV1-39,HK CV07-315,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ6,CQQSYSTHAF,IGKV1-39,HK CV07-315,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ1,CGTWDSSLNGVF,IGLV1-51,HL CV07-315,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ2,CGTWDSSLNGVF,IGLV1-51,HL CV07-315,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ3,CGTWDSSLNGVF,IGLV1-51,HL CV07-315,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ4,CGTWDSSLNGVF,IGLV1-51,HL CV07-315,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ5,CGTWDSSLNGVF,IGLV1-51,HL CV07-315,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDFLWDLHPPRYYGMDVW,IGHV3-9,IGHJ6,CGTWDSSLNGVF,IGLV1-51,HL CV07-315,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-316,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-316,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-316,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-316,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-316,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSGTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-316,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGHYW,IGHV1-2,IGHJ1,CSSYAGSNNWVF,IGLV2-8,HL CV07-317,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGHYW,IGHV1-2,IGHJ2,CSSYAGSNNWVF,IGLV2-8,HL CV07-317,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGHYW,IGHV1-2,IGHJ3,CSSYAGSNNWVF,IGLV2-8,HL CV07-317,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGHYW,IGHV1-2,IGHJ4,CSSYAGSNNWVF,IGLV2-8,HL CV07-317,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGHYW,IGHV1-2,IGHJ5,CSSYAGSNNWVF,IGLV2-8,HL CV07-317,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQKNDILTGLGHYW,IGHV1-2,IGHJ6,CSSYAGSNNWVF,IGLV2-8,HL CV07-317,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ1,CQQYNNWPPITF,IGKV3-15,HK CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ2,CQQYNNWPPITF,IGKV3-15,HK CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ3,CQQYNNWPPITF,IGKV3-15,HK CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ4,CQQYNNWPPITF,IGKV3-15,HK CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ5,CQQYNNWPPITF,IGKV3-15,HK CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ6,CQQYNNWPPITF,IGKV3-15,HK CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ1,CSSYAGSNVYVF,IGLV2-8,HL CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ2,CSSYAGSNVYVF,IGLV2-8,HL CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ3,CSSYAGSNVYVF,IGLV2-8,HL CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ4,CSSYAGSNVYVF,IGLV2-8,HL CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ5,CSSYAGSNVYVF,IGLV2-8,HL CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFFFEVVVAEGFGWFDPW,IGHV1-2,IGHJ6,CSSYAGSNVYVF,IGLV2-8,HL CV07-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ1,CCSYAGSSSWVF,IGLV2-23,HL CV07-323,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ2,CCSYAGSSSWVF,IGLV2-23,HL CV07-323,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ3,CCSYAGSSSWVF,IGLV2-23,HL CV07-323,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ4,CCSYAGSSSWVF,IGLV2-23,HL CV07-323,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ5,CCSYAGSSSWVF,IGLV2-23,HL CV07-323,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFGPGLDCSSTSCYTYGMDVW,IGHV1-2,IGHJ6,CCSYAGSSSWVF,IGLV2-23,HL CV07-323,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSSTLGGMDVW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV07-324,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSSTLGGMDVW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV07-324,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSSTLGGMDVW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV07-324,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSSTLGGMDVW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV07-324,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSSTLGGMDVW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV07-324,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPFYYDSSSTLGGMDVW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV07-324,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWEYYGSGTKAFDYW,IGHV3-30,IGHJ1,CQHFNSYPLTF,IGKV1-13,HK CV23-101,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWEYYGSGTKAFDYW,IGHV3-30,IGHJ2,CQHFNSYPLTF,IGKV1-13,HK CV23-101,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWEYYGSGTKAFDYW,IGHV3-30,IGHJ3,CQHFNSYPLTF,IGKV1-13,HK CV23-101,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWEYYGSGTKAFDYW,IGHV3-30,IGHJ4,CQHFNSYPLTF,IGKV1-13,HK CV23-101,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWEYYGSGTKAFDYW,IGHV3-30,IGHJ5,CQHFNSYPLTF,IGKV1-13,HK CV23-101,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWEYYGSGTKAFDYW,IGHV3-30,IGHJ6,CQHFNSYPLTF,IGKV1-13,HK CV23-101,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATTRGYSDYEFAYW,IGHV5-51,IGHJ1,CSSYAGSNNFPWVF,IGLV2-8,HL CV23-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATTRGYSDYEFAYW,IGHV5-51,IGHJ2,CSSYAGSNNFPWVF,IGLV2-8,HL CV23-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATTRGYSDYEFAYW,IGHV5-51,IGHJ3,CSSYAGSNNFPWVF,IGLV2-8,HL CV23-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATTRGYSDYEFAYW,IGHV5-51,IGHJ4,CSSYAGSNNFPWVF,IGLV2-8,HL CV23-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATTRGYSDYEFAYW,IGHV5-51,IGHJ5,CSSYAGSNNFPWVF,IGLV2-8,HL CV23-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATTRGYSDYEFAYW,IGHV5-51,IGHJ6,CSSYAGSNNFPWVF,IGLV2-8,HL CV23-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGPRSDFGSGSGVGVIDPW,IGHV4-31,IGHJ1,CQQYHNWPPWTF,IGKV3-15,HK CV23-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGPRSDFGSGSGVGVIDPW,IGHV4-31,IGHJ2,CQQYHNWPPWTF,IGKV3-15,HK CV23-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGPRSDFGSGSGVGVIDPW,IGHV4-31,IGHJ3,CQQYHNWPPWTF,IGKV3-15,HK CV23-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGPRSDFGSGSGVGVIDPW,IGHV4-31,IGHJ4,CQQYHNWPPWTF,IGKV3-15,HK CV23-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGPRSDFGSGSGVGVIDPW,IGHV4-31,IGHJ5,CQQYHNWPPWTF,IGKV3-15,HK CV23-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGPRSDFGSGSGVGVIDPW,IGHV4-31,IGHJ6,CQQYHNWPPWTF,IGKV3-15,HK CV23-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYYDILIGYATTHDAFDLW,IGHV1-2,IGHJ1,CSSYTDSSTWVF,IGLV2-14,HL CV23-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYYDILIGYATTHDAFDLW,IGHV1-2,IGHJ2,CSSYTDSSTWVF,IGLV2-14,HL CV23-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYYDILIGYATTHDAFDLW,IGHV1-2,IGHJ3,CSSYTDSSTWVF,IGLV2-14,HL CV23-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYYDILIGYATTHDAFDLW,IGHV1-2,IGHJ4,CSSYTDSSTWVF,IGLV2-14,HL CV23-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYYDILIGYATTHDAFDLW,IGHV1-2,IGHJ5,CSSYTDSSTWVF,IGLV2-14,HL CV23-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGYYDILIGYATTHDAFDLW,IGHV1-2,IGHJ6,CSSYTDSSTWVF,IGLV2-14,HL CV23-115,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ1,CQQRSNWPLTF,IGKV3-11,HK CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ2,CQQRSNWPLTF,IGKV3-11,HK CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ3,CQQRSNWPLTF,IGKV3-11,HK CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ4,CQQRSNWPLTF,IGKV3-11,HK CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ5,CQQRSNWPLTF,IGKV3-11,HK CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ6,CQQRSNWPLTF,IGKV3-11,HK CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ1,CCSYAGSRVF,IGLV2-23,HL CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ2,CCSYAGSRVF,IGLV2-23,HL CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ3,CCSYAGSRVF,IGLV2-23,HL CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ4,CCSYAGSRVF,IGLV2-23,HL CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ5,CCSYAGSRVF,IGLV2-23,HL CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASLVTMVRGAGNYMDVW,IGHV3-21,IGHJ6,CCSYAGSRVF,IGLV2-23,HL CV23-116,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGSWDGRFDYW,IGHV1-2,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV23-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGSWDGRFDYW,IGHV1-2,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV23-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGSWDGRFDYW,IGHV1-2,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV23-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGSWDGRFDYW,IGHV1-2,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV23-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGSWDGRFDYW,IGHV1-2,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV23-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARELGSWDGRFDYW,IGHV1-2,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV23-121,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTTSYCSGGSCYYNYGMDVW,IGHV4-59,IGHJ1,CMQALQTPRTF,IGKV2-28,HK CV23-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTTSYCSGGSCYYNYGMDVW,IGHV4-59,IGHJ2,CMQALQTPRTF,IGKV2-28,HK CV23-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTTSYCSGGSCYYNYGMDVW,IGHV4-59,IGHJ3,CMQALQTPRTF,IGKV2-28,HK CV23-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTTSYCSGGSCYYNYGMDVW,IGHV4-59,IGHJ4,CMQALQTPRTF,IGKV2-28,HK CV23-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTTSYCSGGSCYYNYGMDVW,IGHV4-59,IGHJ5,CMQALQTPRTF,IGKV2-28,HK CV23-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDTTSYCSGGSCYYNYGMDVW,IGHV4-59,IGHJ6,CMQALQTPRTF,IGKV2-28,HK CV23-126,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ1,CCSYAGSNTWVF,IGLV2-23,HL CV24-198,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ2,CCSYAGSNTWVF,IGLV2-23,HL CV24-198,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ3,CCSYAGSNTWVF,IGLV2-23,HL CV24-198,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ4,CCSYAGSNTWVF,IGLV2-23,HL CV24-198,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ5,CCSYAGSNTWVF,IGLV2-23,HL CV24-198,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ6,CCSYAGSNTWVF,IGLV2-23,HL CV24-198,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ1,CCSYAGSNTWVF,IGLV2-23,HL CV24-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ2,CCSYAGSNTWVF,IGLV2-23,HL CV24-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ3,CCSYAGSNTWVF,IGLV2-23,HL CV24-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ4,CCSYAGSNTWVF,IGLV2-23,HL CV24-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ5,CCSYAGSNTWVF,IGLV2-23,HL CV24-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLAYSMVRGISGIW,IGHV1-2,IGHJ6,CCSYAGSNTWVF,IGLV2-23,HL CV24-201,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGSGWSLDESYFDHW,IGHV3-48,IGHJ1,CQQSKSIPYTF,IGKV1-39,HK CV24-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGSGWSLDESYFDHW,IGHV3-48,IGHJ2,CQQSKSIPYTF,IGKV1-39,HK CV24-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGSGWSLDESYFDHW,IGHV3-48,IGHJ3,CQQSKSIPYTF,IGKV1-39,HK CV24-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGSGWSLDESYFDHW,IGHV3-48,IGHJ4,CQQSKSIPYTF,IGKV1-39,HK CV24-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGSGWSLDESYFDHW,IGHV3-48,IGHJ5,CQQSKSIPYTF,IGKV1-39,HK CV24-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRGSGWSLDESYFDHW,IGHV3-48,IGHJ6,CQQSKSIPYTF,IGKV1-39,HK CV24-220,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ1,CQSYDSSTYWVF,IGLV6-57,HL CV24-223,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ2,CQSYDSSTYWVF,IGLV6-57,HL CV24-223,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ3,CQSYDSSTYWVF,IGLV6-57,HL CV24-223,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ4,CQSYDSSTYWVF,IGLV6-57,HL CV24-223,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ5,CQSYDSSTYWVF,IGLV6-57,HL CV24-223,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ6,CQSYDSSTYWVF,IGLV6-57,HL CV24-223,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ1,CQSYDSSTYWVF,IGLV6-57,HL CV24-226,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ2,CQSYDSSTYWVF,IGLV6-57,HL CV24-226,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ3,CQSYDSSTYWVF,IGLV6-57,HL CV24-226,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ4,CQSYDSSTYWVF,IGLV6-57,HL CV24-226,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ5,CQSYDSSTYWVF,IGLV6-57,HL CV24-226,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLRWLRGEFDYW,IGHV4-39,IGHJ6,CQSYDSSTYWVF,IGLV6-57,HL CV24-226,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRGGYGGNSGFDYW,IGHV3-49,IGHJ1,CGTWDSSLSAVVF,IGLV1-51,HL CV24-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRGGYGGNSGFDYW,IGHV3-49,IGHJ2,CGTWDSSLSAVVF,IGLV1-51,HL CV24-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRGGYGGNSGFDYW,IGHV3-49,IGHJ3,CGTWDSSLSAVVF,IGLV1-51,HL CV24-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRGGYGGNSGFDYW,IGHV3-49,IGHJ4,CGTWDSSLSAVVF,IGLV1-51,HL CV24-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRGGYGGNSGFDYW,IGHV3-49,IGHJ5,CGTWDSSLSAVVF,IGLV1-51,HL CV24-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRGGYGGNSGFDYW,IGHV3-49,IGHJ6,CGTWDSSLSAVVF,IGLV1-51,HL CV24-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLYSGNYFDYW,IGHV3-7,IGHJ1,CQTWDTAIWVF,IGLV4-69,HL CV24-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLYSGNYFDYW,IGHV3-7,IGHJ2,CQTWDTAIWVF,IGLV4-69,HL CV24-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLYSGNYFDYW,IGHV3-7,IGHJ3,CQTWDTAIWVF,IGLV4-69,HL CV24-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLYSGNYFDYW,IGHV3-7,IGHJ4,CQTWDTAIWVF,IGLV4-69,HL CV24-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLYSGNYFDYW,IGHV3-7,IGHJ5,CQTWDTAIWVF,IGLV4-69,HL CV24-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLYSGNYFDYW,IGHV3-7,IGHJ6,CQTWDTAIWVF,IGLV4-69,HL CV24-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFYDILTGYYSFHFDLW,IGHV3-48,IGHJ1,CQQYNTYWTF,IGKV1-5,HK CV24-247,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFYDILTGYYSFHFDLW,IGHV3-48,IGHJ2,CQQYNTYWTF,IGKV1-5,HK CV24-247,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFYDILTGYYSFHFDLW,IGHV3-48,IGHJ3,CQQYNTYWTF,IGKV1-5,HK CV24-247,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFYDILTGYYSFHFDLW,IGHV3-48,IGHJ4,CQQYNTYWTF,IGKV1-5,HK CV24-247,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFYDILTGYYSFHFDLW,IGHV3-48,IGHJ5,CQQYNTYWTF,IGKV1-5,HK CV24-247,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFYDILTGYYSFHFDLW,IGHV3-48,IGHJ6,CQQYNTYWTF,IGKV1-5,HK CV24-247,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYYYYYGMDVW,IGHV3-33,IGHJ1,CLQVYNYPWTF,IGKV1-6,HK CV24-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYYYYYGMDVW,IGHV3-33,IGHJ2,CLQVYNYPWTF,IGKV1-6,HK CV24-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYYYYYGMDVW,IGHV3-33,IGHJ3,CLQVYNYPWTF,IGKV1-6,HK CV24-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYYYYYGMDVW,IGHV3-33,IGHJ4,CLQVYNYPWTF,IGKV1-6,HK CV24-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYYYYYGMDVW,IGHV3-33,IGHJ5,CLQVYNYPWTF,IGKV1-6,HK CV24-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYYYYYGMDVW,IGHV3-33,IGHJ6,CLQVYNYPWTF,IGKV1-6,HK CV24-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYDYSNPNYYYYYGMDVW,IGHV1-18,IGHJ1,CYSAADNMGVF,IGLV3-27,HL CV24-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYDYSNPNYYYYYGMDVW,IGHV1-18,IGHJ2,CYSAADNMGVF,IGLV3-27,HL CV24-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYDYSNPNYYYYYGMDVW,IGHV1-18,IGHJ3,CYSAADNMGVF,IGLV3-27,HL CV24-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYDYSNPNYYYYYGMDVW,IGHV1-18,IGHJ4,CYSAADNMGVF,IGLV3-27,HL CV24-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYDYSNPNYYYYYGMDVW,IGHV1-18,IGHJ5,CYSAADNMGVF,IGLV3-27,HL CV24-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREYDYSNPNYYYYYGMDVW,IGHV1-18,IGHJ6,CYSAADNMGVF,IGLV3-27,HL CV24-249,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRVSGPFHDYFLYAMDVW,IGHV3-74,IGHJ1,CQHYSAATWTF,IGKV3-20,HK CV24-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRVSGPFHDYFLYAMDVW,IGHV3-74,IGHJ2,CQHYSAATWTF,IGKV3-20,HK CV24-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRVSGPFHDYFLYAMDVW,IGHV3-74,IGHJ3,CQHYSAATWTF,IGKV3-20,HK CV24-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRVSGPFHDYFLYAMDVW,IGHV3-74,IGHJ4,CQHYSAATWTF,IGKV3-20,HK CV24-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRVSGPFHDYFLYAMDVW,IGHV3-74,IGHJ5,CQHYSAATWTF,IGKV3-20,HK CV24-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRVSGPFHDYFLYAMDVW,IGHV3-74,IGHJ6,CQHYSAATWTF,IGKV3-20,HK CV24-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDYW,IGHV1-2,IGHJ1,CMIWPSSAVVF,IGLV5-37,HL CV24-253,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDYW,IGHV1-2,IGHJ2,CMIWPSSAVVF,IGLV5-37,HL CV24-253,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDYW,IGHV1-2,IGHJ3,CMIWPSSAVVF,IGLV5-37,HL CV24-253,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDYW,IGHV1-2,IGHJ4,CMIWPSSAVVF,IGLV5-37,HL CV24-253,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDYW,IGHV1-2,IGHJ5,CMIWPSSAVVF,IGLV5-37,HL CV24-253,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDYW,IGHV1-2,IGHJ6,CMIWPSSAVVF,IGLV5-37,HL CV24-253,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRLGFEELFRGVFFYYFDYW,IGHV4-34,IGHJ1,CQQTFNSPRTF,IGKV1-39,HK CV24-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRLGFEELFRGVFFYYFDYW,IGHV4-34,IGHJ2,CQQTFNSPRTF,IGKV1-39,HK CV24-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRLGFEELFRGVFFYYFDYW,IGHV4-34,IGHJ3,CQQTFNSPRTF,IGKV1-39,HK CV24-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRLGFEELFRGVFFYYFDYW,IGHV4-34,IGHJ4,CQQTFNSPRTF,IGKV1-39,HK CV24-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRLGFEELFRGVFFYYFDYW,IGHV4-34,IGHJ5,CQQTFNSPRTF,IGKV1-39,HK CV24-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGRLGFEELFRGVFFYYFDYW,IGHV4-34,IGHJ6,CQQTFNSPRTF,IGKV1-39,HK CV24-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ1,CQQYGSSPITF,IGKV3-20,HK CV24-256,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ2,CQQYGSSPITF,IGKV3-20,HK CV24-256,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ3,CQQYGSSPITF,IGKV3-20,HK CV24-256,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ4,CQQYGSSPITF,IGKV3-20,HK CV24-256,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ5,CQQYGSSPITF,IGKV3-20,HK CV24-256,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ6,CQQYGSSPITF,IGKV3-20,HK CV24-256,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLKSCTGGICQTYFYYAMDVW,IGHV4-59,IGHJ1,CQSYDGSLSESAVF,IGLV1-40,HL CV24-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLKSCTGGICQTYFYYAMDVW,IGHV4-59,IGHJ2,CQSYDGSLSESAVF,IGLV1-40,HL CV24-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLKSCTGGICQTYFYYAMDVW,IGHV4-59,IGHJ3,CQSYDGSLSESAVF,IGLV1-40,HL CV24-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLKSCTGGICQTYFYYAMDVW,IGHV4-59,IGHJ4,CQSYDGSLSESAVF,IGLV1-40,HL CV24-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLKSCTGGICQTYFYYAMDVW,IGHV4-59,IGHJ5,CQSYDGSLSESAVF,IGLV1-40,HL CV24-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLLKSCTGGICQTYFYYAMDVW,IGHV4-59,IGHJ6,CQSYDGSLSESAVF,IGLV1-40,HL CV24-260,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTTYTIFGVVISPFDYW,IGHV4-31,IGHJ1,CQQYGSSPLTF,IGKV3-20,HK CV24-262,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTTYTIFGVVISPFDYW,IGHV4-31,IGHJ2,CQQYGSSPLTF,IGKV3-20,HK CV24-262,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTTYTIFGVVISPFDYW,IGHV4-31,IGHJ3,CQQYGSSPLTF,IGKV3-20,HK CV24-262,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTTYTIFGVVISPFDYW,IGHV4-31,IGHJ4,CQQYGSSPLTF,IGKV3-20,HK CV24-262,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTTYTIFGVVISPFDYW,IGHV4-31,IGHJ5,CQQYGSSPLTF,IGKV3-20,HK CV24-262,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGTTYTIFGVVISPFDYW,IGHV4-31,IGHJ6,CQQYGSSPLTF,IGKV3-20,HK CV24-262,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPGTW,IGHV4-34,IGHJ1,CQHYSTFPYTF,IGKV1-5,HK CV24-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPGTW,IGHV4-34,IGHJ2,CQHYSTFPYTF,IGKV1-5,HK CV24-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPGTW,IGHV4-34,IGHJ3,CQHYSTFPYTF,IGKV1-5,HK CV24-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPGTW,IGHV4-34,IGHJ4,CQHYSTFPYTF,IGKV1-5,HK CV24-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPGTW,IGHV4-34,IGHJ5,CQHYSTFPYTF,IGKV1-5,HK CV24-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAPGTW,IGHV4-34,IGHJ6,CQHYSTFPYTF,IGKV1-5,HK CV24-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTGYCRSNNCLTFYAFW,IGHV3-9,IGHJ1,CQQSYRAPVTF,IGKV1-39,HK CV24-268,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTGYCRSNNCLTFYAFW,IGHV3-9,IGHJ2,CQQSYRAPVTF,IGKV1-39,HK CV24-268,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTGYCRSNNCLTFYAFW,IGHV3-9,IGHJ3,CQQSYRAPVTF,IGKV1-39,HK CV24-268,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTGYCRSNNCLTFYAFW,IGHV3-9,IGHJ4,CQQSYRAPVTF,IGKV1-39,HK CV24-268,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTGYCRSNNCLTFYAFW,IGHV3-9,IGHJ5,CQQSYRAPVTF,IGKV1-39,HK CV24-268,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTGYCRSNNCLTFYAFW,IGHV3-9,IGHJ6,CQQSYRAPVTF,IGKV1-39,HK CV24-268,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYFGRSGSGSSLYYYYGMDVW,IGHV4-31,IGHJ1,CQAWDSSTVF,IGLV3-1,HL CV24-269,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYFGRSGSGSSLYYYYGMDVW,IGHV4-31,IGHJ2,CQAWDSSTVF,IGLV3-1,HL CV24-269,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYFGRSGSGSSLYYYYGMDVW,IGHV4-31,IGHJ3,CQAWDSSTVF,IGLV3-1,HL CV24-269,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYFGRSGSGSSLYYYYGMDVW,IGHV4-31,IGHJ4,CQAWDSSTVF,IGLV3-1,HL CV24-269,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYFGRSGSGSSLYYYYGMDVW,IGHV4-31,IGHJ5,CQAWDSSTVF,IGLV3-1,HL CV24-269,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYFGRSGSGSSLYYYYGMDVW,IGHV4-31,IGHJ6,CQAWDSSTVF,IGLV3-1,HL CV24-269,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVAAAGQKYYFDYW,IGHV3-21,IGHJ1,CQQLNSF,IGKV1-9,HK CV24-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVAAAGQKYYFDYW,IGHV3-21,IGHJ2,CQQLNSF,IGKV1-9,HK CV24-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVAAAGQKYYFDYW,IGHV3-21,IGHJ3,CQQLNSF,IGKV1-9,HK CV24-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVAAAGQKYYFDYW,IGHV3-21,IGHJ4,CQQLNSF,IGKV1-9,HK CV24-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVAAAGQKYYFDYW,IGHV3-21,IGHJ5,CQQLNSF,IGKV1-9,HK CV24-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVAAAGQKYYFDYW,IGHV3-21,IGHJ6,CQQLNSF,IGKV1-9,HK CV24-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVANVFMLYPRGSWGMDVW,IGHV3-30,IGHJ1,CAAWDDSLSGWVF,IGLV1-47,HL CV24-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVANVFMLYPRGSWGMDVW,IGHV3-30,IGHJ2,CAAWDDSLSGWVF,IGLV1-47,HL CV24-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVANVFMLYPRGSWGMDVW,IGHV3-30,IGHJ3,CAAWDDSLSGWVF,IGLV1-47,HL CV24-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVANVFMLYPRGSWGMDVW,IGHV3-30,IGHJ4,CAAWDDSLSGWVF,IGLV1-47,HL CV24-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVANVFMLYPRGSWGMDVW,IGHV3-30,IGHJ5,CAAWDDSLSGWVF,IGLV1-47,HL CV24-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVANVFMLYPRGSWGMDVW,IGHV3-30,IGHJ6,CAAWDDSLSGWVF,IGLV1-47,HL CV24-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGSSTSPSPVW,IGHV3-48,IGHJ1,CQQYNNWPRTF,IGKV3-15,HK CV24-280,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGSSTSPSPVW,IGHV3-48,IGHJ2,CQQYNNWPRTF,IGKV3-15,HK CV24-280,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGSSTSPSPVW,IGHV3-48,IGHJ3,CQQYNNWPRTF,IGKV3-15,HK CV24-280,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGSSTSPSPVW,IGHV3-48,IGHJ4,CQQYNNWPRTF,IGKV3-15,HK CV24-280,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGSSTSPSPVW,IGHV3-48,IGHJ5,CQQYNNWPRTF,IGKV3-15,HK CV24-280,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAGSSTSPSPVW,IGHV3-48,IGHJ6,CQQYNNWPRTF,IGKV3-15,HK CV24-280,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGRRLTHLGVAPDVW,IGHV3-23,IGHJ1,CQQSYTTPYTF,IGKV1-39,HK CV24-282,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGRRLTHLGVAPDVW,IGHV3-23,IGHJ2,CQQSYTTPYTF,IGKV1-39,HK CV24-282,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGRRLTHLGVAPDVW,IGHV3-23,IGHJ3,CQQSYTTPYTF,IGKV1-39,HK CV24-282,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGRRLTHLGVAPDVW,IGHV3-23,IGHJ4,CQQSYTTPYTF,IGKV1-39,HK CV24-282,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGRRLTHLGVAPDVW,IGHV3-23,IGHJ5,CQQSYTTPYTF,IGKV1-39,HK CV24-282,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRGRRLTHLGVAPDVW,IGHV3-23,IGHJ6,CQQSYTTPYTF,IGKV1-39,HK CV24-282,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CCGGYGSSWYLDYW,IGHV3-66,IGHJ1,CQQRSNWPYTF,IGKV3-11,HK CV24-283,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CCGGYGSSWYLDYW,IGHV3-66,IGHJ2,CQQRSNWPYTF,IGKV3-11,HK CV24-283,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CCGGYGSSWYLDYW,IGHV3-66,IGHJ3,CQQRSNWPYTF,IGKV3-11,HK CV24-283,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CCGGYGSSWYLDYW,IGHV3-66,IGHJ4,CQQRSNWPYTF,IGKV3-11,HK CV24-283,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CCGGYGSSWYLDYW,IGHV3-66,IGHJ5,CQQRSNWPYTF,IGKV3-11,HK CV24-283,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CCGGYGSSWYLDYW,IGHV3-66,IGHJ6,CQQRSNWPYTF,IGKV3-11,HK CV24-283,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGLSSRNGGNRSYSSSSFPLGRQDYW,IGHV4-31,IGHJ1,CSSYTSSSTLYVF,IGLV2-14,HL CV24-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGLSSRNGGNRSYSSSSFPLGRQDYW,IGHV4-31,IGHJ2,CSSYTSSSTLYVF,IGLV2-14,HL CV24-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGLSSRNGGNRSYSSSSFPLGRQDYW,IGHV4-31,IGHJ3,CSSYTSSSTLYVF,IGLV2-14,HL CV24-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGLSSRNGGNRSYSSSSFPLGRQDYW,IGHV4-31,IGHJ4,CSSYTSSSTLYVF,IGLV2-14,HL CV24-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGLSSRNGGNRSYSSSSFPLGRQDYW,IGHV4-31,IGHJ5,CSSYTSSSTLYVF,IGLV2-14,HL CV24-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGLSSRNGGNRSYSSSSFPLGRQDYW,IGHV4-31,IGHJ6,CSSYTSSSTLYVF,IGLV2-14,HL CV24-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFLSFVTSPTRYDYW,IGHV5-51,IGHJ1,CSSYTSSSTLVF,IGLV2-14,HL CV24-285,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFLSFVTSPTRYDYW,IGHV5-51,IGHJ2,CSSYTSSSTLVF,IGLV2-14,HL CV24-285,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFLSFVTSPTRYDYW,IGHV5-51,IGHJ3,CSSYTSSSTLVF,IGLV2-14,HL CV24-285,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFLSFVTSPTRYDYW,IGHV5-51,IGHJ4,CSSYTSSSTLVF,IGLV2-14,HL CV24-285,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFLSFVTSPTRYDYW,IGHV5-51,IGHJ5,CSSYTSSSTLVF,IGLV2-14,HL CV24-285,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFLSFVTSPTRYDYW,IGHV5-51,IGHJ6,CSSYTSSSTLVF,IGLV2-14,HL CV24-285,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLPLSGYYAFDVW,IGHV1-69,IGHJ1,CQQYGSSPYTF,IGKV3-20,HK CV24-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLPLSGYYAFDVW,IGHV1-69,IGHJ2,CQQYGSSPYTF,IGKV3-20,HK CV24-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLPLSGYYAFDVW,IGHV1-69,IGHJ3,CQQYGSSPYTF,IGKV3-20,HK CV24-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLPLSGYYAFDVW,IGHV1-69,IGHJ4,CQQYGSSPYTF,IGKV3-20,HK CV24-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLPLSGYYAFDVW,IGHV1-69,IGHJ5,CQQYGSSPYTF,IGKV3-20,HK CV24-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLPLSGYYAFDVW,IGHV1-69,IGHJ6,CQQYGSSPYTF,IGKV3-20,HK CV24-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRSGGILAGGSGGALDIW,IGHV3-23,IGHJ1,CQQYSSYSRTF,IGKV1-5,HK CV24-287,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRSGGILAGGSGGALDIW,IGHV3-23,IGHJ2,CQQYSSYSRTF,IGKV1-5,HK CV24-287,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRSGGILAGGSGGALDIW,IGHV3-23,IGHJ3,CQQYSSYSRTF,IGKV1-5,HK CV24-287,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRSGGILAGGSGGALDIW,IGHV3-23,IGHJ4,CQQYSSYSRTF,IGKV1-5,HK CV24-287,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRSGGILAGGSGGALDIW,IGHV3-23,IGHJ5,CQQYSSYSRTF,IGKV1-5,HK CV24-287,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRSGGILAGGSGGALDIW,IGHV3-23,IGHJ6,CQQYSSYSRTF,IGKV1-5,HK CV24-287,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASEDISLERAYNYGLTIDFW,IGHV4-39,IGHJ1,CQVWDSSTVVF,IGLV3-9,HL CV24-290,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASEDISLERAYNYGLTIDFW,IGHV4-39,IGHJ2,CQVWDSSTVVF,IGLV3-9,HL CV24-290,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASEDISLERAYNYGLTIDFW,IGHV4-39,IGHJ3,CQVWDSSTVVF,IGLV3-9,HL CV24-290,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASEDISLERAYNYGLTIDFW,IGHV4-39,IGHJ4,CQVWDSSTVVF,IGLV3-9,HL CV24-290,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASEDISLERAYNYGLTIDFW,IGHV4-39,IGHJ5,CQVWDSSTVVF,IGLV3-9,HL CV24-290,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARASEDISLERAYNYGLTIDFW,IGHV4-39,IGHJ6,CQVWDSSTVVF,IGLV3-9,HL CV24-290,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARENYDSSGYYYAYYYYGMDVW,IGHV3-7,IGHJ1,CQSADSSGTYVF,IGLV3-25,HL CV24-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARENYDSSGYYYAYYYYGMDVW,IGHV3-7,IGHJ2,CQSADSSGTYVF,IGLV3-25,HL CV24-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARENYDSSGYYYAYYYYGMDVW,IGHV3-7,IGHJ3,CQSADSSGTYVF,IGLV3-25,HL CV24-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARENYDSSGYYYAYYYYGMDVW,IGHV3-7,IGHJ4,CQSADSSGTYVF,IGLV3-25,HL CV24-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARENYDSSGYYYAYYYYGMDVW,IGHV3-7,IGHJ5,CQSADSSGTYVF,IGLV3-25,HL CV24-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARENYDSSGYYYAYYYYGMDVW,IGHV3-7,IGHJ6,CQSADSSGTYVF,IGLV3-25,HL CV24-293,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ1,CQQYNNWPPITF,IGKV3-15,HK CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ2,CQQYNNWPPITF,IGKV3-15,HK CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ3,CQQYNNWPPITF,IGKV3-15,HK CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ4,CQQYNNWPPITF,IGKV3-15,HK CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ5,CQQYNNWPPITF,IGKV3-15,HK CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ6,CQQYNNWPPITF,IGKV3-15,HK CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDLGIRYFDYW,IGHV3-9,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV24-294,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGGDGYTVDAFDVW,IGHV3-33,IGHJ1,CMQALQPPYIF,IGKV2-28,HK CV24-298,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGGDGYTVDAFDVW,IGHV3-33,IGHJ2,CMQALQPPYIF,IGKV2-28,HK CV24-298,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGGDGYTVDAFDVW,IGHV3-33,IGHJ3,CMQALQPPYIF,IGKV2-28,HK CV24-298,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGGDGYTVDAFDVW,IGHV3-33,IGHJ4,CMQALQPPYIF,IGKV2-28,HK CV24-298,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGGDGYTVDAFDVW,IGHV3-33,IGHJ5,CMQALQPPYIF,IGKV2-28,HK CV24-298,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGWGGDGYTVDAFDVW,IGHV3-33,IGHJ6,CMQALQPPYIF,IGKV2-28,HK CV24-298,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLYSGSYGAYNWFDPW,IGHV1-46,IGHJ1,CLQRINWLTF,IGKV3-11,HK CV24-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLYSGSYGAYNWFDPW,IGHV1-46,IGHJ2,CLQRINWLTF,IGKV3-11,HK CV24-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLYSGSYGAYNWFDPW,IGHV1-46,IGHJ3,CLQRINWLTF,IGKV3-11,HK CV24-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLYSGSYGAYNWFDPW,IGHV1-46,IGHJ4,CLQRINWLTF,IGKV3-11,HK CV24-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLYSGSYGAYNWFDPW,IGHV1-46,IGHJ5,CLQRINWLTF,IGKV3-11,HK CV24-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSLYSGSYGAYNWFDPW,IGHV1-46,IGHJ6,CLQRINWLTF,IGKV3-11,HK CV24-301,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ1,CQQSYSTHTF,IGKV1-39,HK CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ2,CQQSYSTHTF,IGKV1-39,HK CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ3,CQQSYSTHTF,IGKV1-39,HK CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ4,CQQSYSTHTF,IGKV1-39,HK CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ5,CQQSYSTHTF,IGKV1-39,HK CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ6,CQQSYSTHTF,IGKV1-39,HK CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ1,CQAWDSDTVIF,IGLV3-1,HL CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ2,CQAWDSDTVIF,IGLV3-1,HL CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ3,CQAWDSDTVIF,IGLV3-1,HL CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ4,CQAWDSDTVIF,IGLV3-1,HL CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ5,CQAWDSDTVIF,IGLV3-1,HL CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREQVLDPGLYYGIDVW,IGHV4-61,IGHJ6,CQAWDSDTVIF,IGLV3-1,HL CV24-309,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDFW,IGHV1-2,IGHJ1,CMIWPSSDVVF,IGLV5-37,HL CV24-310,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDFW,IGHV1-2,IGHJ2,CMIWPSSDVVF,IGLV5-37,HL CV24-310,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDFW,IGHV1-2,IGHJ3,CMIWPSSDVVF,IGLV5-37,HL CV24-310,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDFW,IGHV1-2,IGHJ4,CMIWPSSDVVF,IGLV5-37,HL CV24-310,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDFW,IGHV1-2,IGHJ5,CMIWPSSDVVF,IGLV5-37,HL CV24-310,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVFHGVITPFDFW,IGHV1-2,IGHJ6,CMIWPSSDVVF,IGLV5-37,HL CV24-310,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGADIFITIFGVVIKENDYW,IGHV1-2,IGHJ1,CSSYTSSSTLVF,IGLV2-18,HL CV24-311,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGADIFITIFGVVIKENDYW,IGHV1-2,IGHJ2,CSSYTSSSTLVF,IGLV2-18,HL CV24-311,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGADIFITIFGVVIKENDYW,IGHV1-2,IGHJ3,CSSYTSSSTLVF,IGLV2-18,HL CV24-311,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGADIFITIFGVVIKENDYW,IGHV1-2,IGHJ4,CSSYTSSSTLVF,IGLV2-18,HL CV24-311,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGADIFITIFGVVIKENDYW,IGHV1-2,IGHJ5,CSSYTSSSTLVF,IGLV2-18,HL CV24-311,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGADIFITIFGVVIKENDYW,IGHV1-2,IGHJ6,CSSYTSSSTLVF,IGLV2-18,HL CV24-311,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKNYGYSDDDLFQHFDYW,IGHV3-30,IGHJ1,CLLHYGSSQLGVF,IGLV7-43,HL CV24-314,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKNYGYSDDDLFQHFDYW,IGHV3-30,IGHJ2,CLLHYGSSQLGVF,IGLV7-43,HL CV24-314,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKNYGYSDDDLFQHFDYW,IGHV3-30,IGHJ3,CLLHYGSSQLGVF,IGLV7-43,HL CV24-314,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKNYGYSDDDLFQHFDYW,IGHV3-30,IGHJ4,CLLHYGSSQLGVF,IGLV7-43,HL CV24-314,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKNYGYSDDDLFQHFDYW,IGHV3-30,IGHJ5,CLLHYGSSQLGVF,IGLV7-43,HL CV24-314,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKNYGYSDDDLFQHFDYW,IGHV3-30,IGHJ6,CLLHYGSSQLGVF,IGLV7-43,HL CV24-314,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALGLSGHGMDVW,IGHV1-69,IGHJ1,CQHSYSTPHTF,IGKV1-39,HK CV24-316,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALGLSGHGMDVW,IGHV1-69,IGHJ2,CQHSYSTPHTF,IGKV1-39,HK CV24-316,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALGLSGHGMDVW,IGHV1-69,IGHJ3,CQHSYSTPHTF,IGKV1-39,HK CV24-316,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALGLSGHGMDVW,IGHV1-69,IGHJ4,CQHSYSTPHTF,IGKV1-39,HK CV24-316,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALGLSGHGMDVW,IGHV1-69,IGHJ5,CQHSYSTPHTF,IGKV1-39,HK CV24-316,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARALGLSGHGMDVW,IGHV1-69,IGHJ6,CQHSYSTPHTF,IGKV1-39,HK CV24-316,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKESWLELWLQGAGFDIW,IGHV4-4,IGHJ1,CCSYGGSYTFVVF,IGLV2-11,HL CV24-317,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKESWLELWLQGAGFDIW,IGHV4-4,IGHJ2,CCSYGGSYTFVVF,IGLV2-11,HL CV24-317,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKESWLELWLQGAGFDIW,IGHV4-4,IGHJ3,CCSYGGSYTFVVF,IGLV2-11,HL CV24-317,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKESWLELWLQGAGFDIW,IGHV4-4,IGHJ4,CCSYGGSYTFVVF,IGLV2-11,HL CV24-317,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKESWLELWLQGAGFDIW,IGHV4-4,IGHJ5,CCSYGGSYTFVVF,IGLV2-11,HL CV24-317,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKESWLELWLQGAGFDIW,IGHV4-4,IGHJ6,CCSYGGSYTFVVF,IGLV2-11,HL CV24-317,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWMEYEYNDSGIQKTADQGMDVW,IGHV1-46,IGHJ1,CQAWDINTVVF,IGLV3-1,HL CV24-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWMEYEYNDSGIQKTADQGMDVW,IGHV1-46,IGHJ2,CQAWDINTVVF,IGLV3-1,HL CV24-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWMEYEYNDSGIQKTADQGMDVW,IGHV1-46,IGHJ3,CQAWDINTVVF,IGLV3-1,HL CV24-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWMEYEYNDSGIQKTADQGMDVW,IGHV1-46,IGHJ4,CQAWDINTVVF,IGLV3-1,HL CV24-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWMEYEYNDSGIQKTADQGMDVW,IGHV1-46,IGHJ5,CQAWDINTVVF,IGLV3-1,HL CV24-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWMEYEYNDSGIQKTADQGMDVW,IGHV1-46,IGHJ6,CQAWDINTVVF,IGLV3-1,HL CV24-319,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ1,CQQANSFPLTF,IGKV1-12,HK CV24-321,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ2,CQQANSFPLTF,IGKV1-12,HK CV24-321,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ3,CQQANSFPLTF,IGKV1-12,HK CV24-321,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ4,CQQANSFPLTF,IGKV1-12,HK CV24-321,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ5,CQQANSFPLTF,IGKV1-12,HK CV24-321,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ6,CQQANSFPLTF,IGKV1-12,HK CV24-321,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ1,CQSADSSGTYDVF,IGLV3-25,HL CV24-322,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ2,CQSADSSGTYDVF,IGLV3-25,HL CV24-322,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ3,CQSADSSGTYDVF,IGLV3-25,HL CV24-322,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ4,CQSADSSGTYDVF,IGLV3-25,HL CV24-322,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ5,CQSADSSGTYDVF,IGLV3-25,HL CV24-322,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRTHTIFGVVVHFDYW,IGHV4-39,IGHJ6,CQSADSSGTYDVF,IGLV3-25,HL CV24-322,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ1,CQQYGSSPITF,IGKV3-20,HK CV24-323,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ2,CQQYGSSPITF,IGKV3-20,HK CV24-323,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ3,CQQYGSSPITF,IGKV3-20,HK CV24-323,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ4,CQQYGSSPITF,IGKV3-20,HK CV24-323,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ5,CQQYGSSPITF,IGKV3-20,HK CV24-323,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ6,CQQYGSSPITF,IGKV3-20,HK CV24-323,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ1,CQQYGSSPITF,IGKV3-20,HK CV24-325,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ2,CQQYGSSPITF,IGKV3-20,HK CV24-325,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ3,CQQYGSSPITF,IGKV3-20,HK CV24-325,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ4,CQQYGSSPITF,IGKV3-20,HK CV24-325,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ5,CQQYGSSPITF,IGKV3-20,HK CV24-325,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ6,CQQYGSSPITF,IGKV3-20,HK CV24-325,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ1,CQQYNNWPPVTF,IGKV3-15,HK CV24-329,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ2,CQQYNNWPPVTF,IGKV3-15,HK CV24-329,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ3,CQQYNNWPPVTF,IGKV3-15,HK CV24-329,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ4,CQQYNNWPPVTF,IGKV3-15,HK CV24-329,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ5,CQQYNNWPPVTF,IGKV3-15,HK CV24-329,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMVRGPNDASDIW,IGHV3-33,IGHJ6,CQQYNNWPPVTF,IGKV3-15,HK CV24-329,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ1,CQQYGSSPITF,IGKV3-20,HK CV24-330,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ2,CQQYGSSPITF,IGKV3-20,HK CV24-330,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ3,CQQYGSSPITF,IGKV3-20,HK CV24-330,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ4,CQQYGSSPITF,IGKV3-20,HK CV24-330,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ5,CQQYGSSPITF,IGKV3-20,HK CV24-330,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ6,CQQYGSSPITF,IGKV3-20,HK CV24-330,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEVPDIIVVAVAVGMDVW,IGHV3-23,IGHJ1,CASWDDSLSGVLF,IGLV1-47,HL CV24-331,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEVPDIIVVAVAVGMDVW,IGHV3-23,IGHJ2,CASWDDSLSGVLF,IGLV1-47,HL CV24-331,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEVPDIIVVAVAVGMDVW,IGHV3-23,IGHJ3,CASWDDSLSGVLF,IGLV1-47,HL CV24-331,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEVPDIIVVAVAVGMDVW,IGHV3-23,IGHJ4,CASWDDSLSGVLF,IGLV1-47,HL CV24-331,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEVPDIIVVAVAVGMDVW,IGHV3-23,IGHJ5,CASWDDSLSGVLF,IGLV1-47,HL CV24-331,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKEVPDIIVVAVAVGMDVW,IGHV3-23,IGHJ6,CASWDDSLSGVLF,IGLV1-47,HL CV24-331,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARETRETYYDILTGYPFYYYFGMDVW,IGHV1-2,IGHJ1,CGTWDGSLSAAVF,IGLV1-51,HL CV24-332,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARETRETYYDILTGYPFYYYFGMDVW,IGHV1-2,IGHJ2,CGTWDGSLSAAVF,IGLV1-51,HL CV24-332,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARETRETYYDILTGYPFYYYFGMDVW,IGHV1-2,IGHJ3,CGTWDGSLSAAVF,IGLV1-51,HL CV24-332,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARETRETYYDILTGYPFYYYFGMDVW,IGHV1-2,IGHJ4,CGTWDGSLSAAVF,IGLV1-51,HL CV24-332,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARETRETYYDILTGYPFYYYFGMDVW,IGHV1-2,IGHJ5,CGTWDGSLSAAVF,IGLV1-51,HL CV24-332,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARETRETYYDILTGYPFYYYFGMDVW,IGHV1-2,IGHJ6,CGTWDGSLSAAVF,IGLV1-51,HL CV24-332,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSSDLPKWGSGMADYW,IGHV3-15,IGHJ1,CVLYMGSDIWAF,IGLV8-61,HL CV24-333,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSSDLPKWGSGMADYW,IGHV3-15,IGHJ2,CVLYMGSDIWAF,IGLV8-61,HL CV24-333,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSSDLPKWGSGMADYW,IGHV3-15,IGHJ3,CVLYMGSDIWAF,IGLV8-61,HL CV24-333,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSSDLPKWGSGMADYW,IGHV3-15,IGHJ4,CVLYMGSDIWAF,IGLV8-61,HL CV24-333,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSSDLPKWGSGMADYW,IGHV3-15,IGHJ5,CVLYMGSDIWAF,IGLV8-61,HL CV24-333,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSSDLPKWGSGMADYW,IGHV3-15,IGHJ6,CVLYMGSDIWAF,IGLV8-61,HL CV24-333,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ1,CQQYGSSPITF,IGKV3-20,HK CV24-336,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ2,CQQYGSSPITF,IGKV3-20,HK CV24-336,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ3,CQQYGSSPITF,IGKV3-20,HK CV24-336,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ4,CQQYGSSPITF,IGKV3-20,HK CV24-336,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ5,CQQYGSSPITF,IGKV3-20,HK CV24-336,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRAQEEKITMIRRIISWFDPW,IGHV3-49,IGHJ6,CQQYGSSPITF,IGKV3-20,HK CV24-336,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYSYSCGMDVW,IGHV3-33,IGHJ1,CLQVYNYPWTF,IGKV1-6,HK CV24-344,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYSYSCGMDVW,IGHV3-33,IGHJ2,CLQVYNYPWTF,IGKV1-6,HK CV24-344,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYSYSCGMDVW,IGHV3-33,IGHJ3,CLQVYNYPWTF,IGKV1-6,HK CV24-344,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYSYSCGMDVW,IGHV3-33,IGHJ4,CLQVYNYPWTF,IGKV1-6,HK CV24-344,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYSYSCGMDVW,IGHV3-33,IGHJ5,CLQVYNYPWTF,IGKV1-6,HK CV24-344,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARREGVADYSYSCGMDVW,IGHV3-33,IGHJ6,CLQVYNYPWTF,IGKV1-6,HK CV24-344,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDDSSGYYYLKEENDAFDIW,IGHV1-69,IGHJ1,CMQGTHWREYTF,IGKV2-30,HK CV24-346,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDDSSGYYYLKEENDAFDIW,IGHV1-69,IGHJ2,CMQGTHWREYTF,IGKV2-30,HK CV24-346,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDDSSGYYYLKEENDAFDIW,IGHV1-69,IGHJ3,CMQGTHWREYTF,IGKV2-30,HK CV24-346,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDDSSGYYYLKEENDAFDIW,IGHV1-69,IGHJ4,CMQGTHWREYTF,IGKV2-30,HK CV24-346,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDDSSGYYYLKEENDAFDIW,IGHV1-69,IGHJ5,CMQGTHWREYTF,IGKV2-30,HK CV24-346,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSDDSSGYYYLKEENDAFDIW,IGHV1-69,IGHJ6,CMQGTHWREYTF,IGKV2-30,HK CV24-346,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLYCSSTSCYTPYYYYYYGMDVW,IGHV1-2,IGHJ1,CQSADSSGTYGVF,IGLV3-25,HL CV24-347,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLYCSSTSCYTPYYYYYYGMDVW,IGHV1-2,IGHJ2,CQSADSSGTYGVF,IGLV3-25,HL CV24-347,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLYCSSTSCYTPYYYYYYGMDVW,IGHV1-2,IGHJ3,CQSADSSGTYGVF,IGLV3-25,HL CV24-347,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLYCSSTSCYTPYYYYYYGMDVW,IGHV1-2,IGHJ4,CQSADSSGTYGVF,IGLV3-25,HL CV24-347,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLYCSSTSCYTPYYYYYYGMDVW,IGHV1-2,IGHJ5,CQSADSSGTYGVF,IGLV3-25,HL CV24-347,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLYCSSTSCYTPYYYYYYGMDVW,IGHV1-2,IGHJ6,CQSADSSGTYGVF,IGLV3-25,HL CV24-347,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVETRGVGFDLW,IGHV3-23,IGHJ1,CQAWDSSTVVF,IGLV3-1,HL CV38-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVETRGVGFDLW,IGHV3-23,IGHJ2,CQAWDSSTVVF,IGLV3-1,HL CV38-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVETRGVGFDLW,IGHV3-23,IGHJ3,CQAWDSSTVVF,IGLV3-1,HL CV38-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVETRGVGFDLW,IGHV3-23,IGHJ4,CQAWDSSTVVF,IGLV3-1,HL CV38-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVETRGVGFDLW,IGHV3-23,IGHJ5,CQAWDSSTVVF,IGLV3-1,HL CV38-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVETRGVGFDLW,IGHV3-23,IGHJ6,CQAWDSSTVVF,IGLV3-1,HL CV38-102,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ1,CQQYNSYPLTF,IGKV1-16,HK CV38-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ2,CQQYNSYPLTF,IGKV1-16,HK CV38-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ3,CQQYNSYPLTF,IGKV1-16,HK CV38-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ4,CQQYNSYPLTF,IGKV1-16,HK CV38-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ5,CQQYNSYPLTF,IGKV1-16,HK CV38-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ6,CQQYNSYPLTF,IGKV1-16,HK CV38-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRVARRRGFGESPFYYGLDVW,IGHV3-74,IGHJ1,CLQNYNFPRTF,IGKV1-6,HK CV38-105,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRVARRRGFGESPFYYGLDVW,IGHV3-74,IGHJ2,CLQNYNFPRTF,IGKV1-6,HK CV38-105,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRVARRRGFGESPFYYGLDVW,IGHV3-74,IGHJ3,CLQNYNFPRTF,IGKV1-6,HK CV38-105,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRVARRRGFGESPFYYGLDVW,IGHV3-74,IGHJ4,CLQNYNFPRTF,IGKV1-6,HK CV38-105,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRVARRRGFGESPFYYGLDVW,IGHV3-74,IGHJ5,CLQNYNFPRTF,IGKV1-6,HK CV38-105,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRVARRRGFGESPFYYGLDVW,IGHV3-74,IGHJ6,CLQNYNFPRTF,IGKV1-6,HK CV38-105,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ1,CSSYAGSNNYVF,IGLV2-8,HL CV38-107,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ2,CSSYAGSNNYVF,IGLV2-8,HL CV38-107,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ3,CSSYAGSNNYVF,IGLV2-8,HL CV38-107,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ4,CSSYAGSNNYVF,IGLV2-8,HL CV38-107,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ5,CSSYAGSNNYVF,IGLV2-8,HL CV38-107,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ6,CSSYAGSNNYVF,IGLV2-8,HL CV38-107,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGRLADAAGDYW,IGHV3-53,IGHJ1,CQQYDNLPSWTF,IGKV1-33,HK CV38-113,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGRLADAAGDYW,IGHV3-53,IGHJ2,CQQYDNLPSWTF,IGKV1-33,HK CV38-113,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGRLADAAGDYW,IGHV3-53,IGHJ3,CQQYDNLPSWTF,IGKV1-33,HK CV38-113,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGRLADAAGDYW,IGHV3-53,IGHJ4,CQQYDNLPSWTF,IGKV1-33,HK CV38-113,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGRLADAAGDYW,IGHV3-53,IGHJ5,CQQYDNLPSWTF,IGKV1-33,HK CV38-113,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGRLADAAGDYW,IGHV3-53,IGHJ6,CQQYDNLPSWTF,IGKV1-33,HK CV38-113,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ1,CQQSYTTPYTF,IGKV1-39,HK CV38-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ2,CQQSYTTPYTF,IGKV1-39,HK CV38-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ3,CQQSYTTPYTF,IGKV1-39,HK CV38-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ4,CQQSYTTPYTF,IGKV1-39,HK CV38-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ5,CQQSYTTPYTF,IGKV1-39,HK CV38-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ6,CQQSYTTPYTF,IGKV1-39,HK CV38-114,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ1,CGADHGSGSNFVQKVF,IGLV9-49,HL CV38-114,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ2,CGADHGSGSNFVQKVF,IGLV9-49,HL CV38-114,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ3,CGADHGSGSNFVQKVF,IGLV9-49,HL CV38-114,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ4,CGADHGSGSNFVQKVF,IGLV9-49,HL CV38-114,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ5,CGADHGSGSNFVQKVF,IGLV9-49,HL CV38-114,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAGNDNSLDYW,IGHV5-51,IGHJ6,CGADHGSGSNFVQKVF,IGLV9-49,HL CV38-114,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYDSSGNGVNWFDPW,IGHV3-7,IGHJ1,CQSYDSSLSGSYVF,IGLV1-40,HL CV38-115,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYDSSGNGVNWFDPW,IGHV3-7,IGHJ2,CQSYDSSLSGSYVF,IGLV1-40,HL CV38-115,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYDSSGNGVNWFDPW,IGHV3-7,IGHJ3,CQSYDSSLSGSYVF,IGLV1-40,HL CV38-115,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYDSSGNGVNWFDPW,IGHV3-7,IGHJ4,CQSYDSSLSGSYVF,IGLV1-40,HL CV38-115,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYDSSGNGVNWFDPW,IGHV3-7,IGHJ5,CQSYDSSLSGSYVF,IGLV1-40,HL CV38-115,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLYYYDSSGNGVNWFDPW,IGHV3-7,IGHJ6,CQSYDSSLSGSYVF,IGLV1-40,HL CV38-115,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVTRIYGSGSYCFDYW,IGHV4-30-4,IGHJ1,CCSYVGSSTFVVF,IGLV2-23,HL CV38-117,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVTRIYGSGSYCFDYW,IGHV4-30-4,IGHJ2,CCSYVGSSTFVVF,IGLV2-23,HL CV38-117,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVTRIYGSGSYCFDYW,IGHV4-30-4,IGHJ3,CCSYVGSSTFVVF,IGLV2-23,HL CV38-117,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVTRIYGSGSYCFDYW,IGHV4-30-4,IGHJ4,CCSYVGSSTFVVF,IGLV2-23,HL CV38-117,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVTRIYGSGSYCFDYW,IGHV4-30-4,IGHJ5,CCSYVGSSTFVVF,IGLV2-23,HL CV38-117,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARVTRIYGSGSYCFDYW,IGHV4-30-4,IGHJ6,CCSYVGSSTFVVF,IGLV2-23,HL CV38-117,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWSSSWYLDYW,IGHV4-59,IGHJ1,CQQRSNWPPVTF,IGKV3-11,HK CV38-118,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWSSSWYLDYW,IGHV4-59,IGHJ2,CQQRSNWPPVTF,IGKV3-11,HK CV38-118,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWSSSWYLDYW,IGHV4-59,IGHJ3,CQQRSNWPPVTF,IGKV3-11,HK CV38-118,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWSSSWYLDYW,IGHV4-59,IGHJ4,CQQRSNWPPVTF,IGKV3-11,HK CV38-118,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWSSSWYLDYW,IGHV4-59,IGHJ5,CQQRSNWPPVTF,IGKV3-11,HK CV38-118,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWSSSWYLDYW,IGHV4-59,IGHJ6,CQQRSNWPPVTF,IGKV3-11,HK CV38-118,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWNFDYW,IGHV4-4,IGHJ1,CCSYAGSSNWVF,IGLV2-23,HL CV38-119,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWNFDYW,IGHV4-4,IGHJ2,CCSYAGSSNWVF,IGLV2-23,HL CV38-119,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWNFDYW,IGHV4-4,IGHJ3,CCSYAGSSNWVF,IGLV2-23,HL CV38-119,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWNFDYW,IGHV4-4,IGHJ4,CCSYAGSSNWVF,IGLV2-23,HL CV38-119,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWNFDYW,IGHV4-4,IGHJ5,CCSYAGSSNWVF,IGLV2-23,HL CV38-119,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAWNFDYW,IGHV4-4,IGHJ6,CCSYAGSSNWVF,IGLV2-23,HL CV38-119,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLDIW,IGHV3-23,IGHJ1,CSSYTSSSTPYVF,IGLV2-14,HL CV38-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLDIW,IGHV3-23,IGHJ2,CSSYTSSSTPYVF,IGLV2-14,HL CV38-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLDIW,IGHV3-23,IGHJ3,CSSYTSSSTPYVF,IGLV2-14,HL CV38-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLDIW,IGHV3-23,IGHJ4,CSSYTSSSTPYVF,IGLV2-14,HL CV38-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLDIW,IGHV3-23,IGHJ5,CSSYTSSSTPYVF,IGLV2-14,HL CV38-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLDIW,IGHV3-23,IGHJ6,CSSYTSSSTPYVF,IGLV2-14,HL CV38-122,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATYYYDSSGYPYGMDVW,IGHV4-59,IGHJ1,CQQLNSYPGF,IGKV1-9,HK CV38-124,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATYYYDSSGYPYGMDVW,IGHV4-59,IGHJ2,CQQLNSYPGF,IGKV1-9,HK CV38-124,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATYYYDSSGYPYGMDVW,IGHV4-59,IGHJ3,CQQLNSYPGF,IGKV1-9,HK CV38-124,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATYYYDSSGYPYGMDVW,IGHV4-59,IGHJ4,CQQLNSYPGF,IGKV1-9,HK CV38-124,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATYYYDSSGYPYGMDVW,IGHV4-59,IGHJ5,CQQLNSYPGF,IGKV1-9,HK CV38-124,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATYYYDSSGYPYGMDVW,IGHV4-59,IGHJ6,CQQLNSYPGF,IGKV1-9,HK CV38-124,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQGYSSSSLGYW,IGHV5-51,IGHJ1,CGADHGSGSNFVYMF,IGLV9-49,HL CV38-125,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQGYSSSSLGYW,IGHV5-51,IGHJ2,CGADHGSGSNFVYMF,IGLV9-49,HL CV38-125,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQGYSSSSLGYW,IGHV5-51,IGHJ3,CGADHGSGSNFVYMF,IGLV9-49,HL CV38-125,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQGYSSSSLGYW,IGHV5-51,IGHJ4,CGADHGSGSNFVYMF,IGLV9-49,HL CV38-125,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQGYSSSSLGYW,IGHV5-51,IGHJ5,CGADHGSGSNFVYMF,IGLV9-49,HL CV38-125,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHQGYSSSSLGYW,IGHV5-51,IGHJ6,CGADHGSGSNFVYMF,IGLV9-49,HL CV38-125,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPEIVVGGVDYW,IGHV3-33,IGHJ1,CMQGTHWPYTF,IGKV2-30,HK CV38-127,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPEIVVGGVDYW,IGHV3-33,IGHJ2,CMQGTHWPYTF,IGKV2-30,HK CV38-127,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPEIVVGGVDYW,IGHV3-33,IGHJ3,CMQGTHWPYTF,IGKV2-30,HK CV38-127,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPEIVVGGVDYW,IGHV3-33,IGHJ4,CMQGTHWPYTF,IGKV2-30,HK CV38-127,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPEIVVGGVDYW,IGHV3-33,IGHJ5,CMQGTHWPYTF,IGKV2-30,HK CV38-127,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPEIVVGGVDYW,IGHV3-33,IGHJ6,CMQGTHWPYTF,IGKV2-30,HK CV38-127,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ1,CQQSYTTPYTF,IGKV1-39,HK CV38-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ2,CQQSYTTPYTF,IGKV1-39,HK CV38-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ3,CQQSYTTPYTF,IGKV1-39,HK CV38-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ4,CQQSYTTPYTF,IGKV1-39,HK CV38-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ5,CQQSYTTPYTF,IGKV1-39,HK CV38-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWNLSGYYGGGRW,IGHV3-11,IGHJ6,CQQSYTTPYTF,IGKV1-39,HK CV38-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGASASWDAFDIW,IGHV4-31,IGHJ1,CQQYGSSLTF,IGKV3-20,HK CV38-129,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGASASWDAFDIW,IGHV4-31,IGHJ2,CQQYGSSLTF,IGKV3-20,HK CV38-129,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGASASWDAFDIW,IGHV4-31,IGHJ3,CQQYGSSLTF,IGKV3-20,HK CV38-129,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGASASWDAFDIW,IGHV4-31,IGHJ4,CQQYGSSLTF,IGKV3-20,HK CV38-129,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGASASWDAFDIW,IGHV4-31,IGHJ5,CQQYGSSLTF,IGKV3-20,HK CV38-129,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQGASASWDAFDIW,IGHV4-31,IGHJ6,CQQYGSSLTF,IGKV3-20,HK CV38-129,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHSVRFLEWLLPYW,IGHV3-11,IGHJ1,CQQLNSYPWTF,IGKV1-9,HK CV38-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHSVRFLEWLLPYW,IGHV3-11,IGHJ2,CQQLNSYPWTF,IGKV1-9,HK CV38-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHSVRFLEWLLPYW,IGHV3-11,IGHJ3,CQQLNSYPWTF,IGKV1-9,HK CV38-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHSVRFLEWLLPYW,IGHV3-11,IGHJ4,CQQLNSYPWTF,IGKV1-9,HK CV38-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHSVRFLEWLLPYW,IGHV3-11,IGHJ5,CQQLNSYPWTF,IGKV1-9,HK CV38-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHSVRFLEWLLPYW,IGHV3-11,IGHJ6,CQQLNSYPWTF,IGKV1-9,HK CV38-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAERSITIFGVVTSAFDYW,IGHV4-31,IGHJ1,CQQYYSTPYTF,IGKV4-1,HK CV38-132,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAERSITIFGVVTSAFDYW,IGHV4-31,IGHJ2,CQQYYSTPYTF,IGKV4-1,HK CV38-132,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAERSITIFGVVTSAFDYW,IGHV4-31,IGHJ3,CQQYYSTPYTF,IGKV4-1,HK CV38-132,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAERSITIFGVVTSAFDYW,IGHV4-31,IGHJ4,CQQYYSTPYTF,IGKV4-1,HK CV38-132,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAERSITIFGVVTSAFDYW,IGHV4-31,IGHJ5,CQQYYSTPYTF,IGKV4-1,HK CV38-132,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAERSITIFGVVTSAFDYW,IGHV4-31,IGHJ6,CQQYYSTPYTF,IGKV4-1,HK CV38-132,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSGWYYPDYW,IGHV4-34,IGHJ1,CQQYGSSPNTF,IGKV3-20,HK CV38-134,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSGWYYPDYW,IGHV4-34,IGHJ2,CQQYGSSPNTF,IGKV3-20,HK CV38-134,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSGWYYPDYW,IGHV4-34,IGHJ3,CQQYGSSPNTF,IGKV3-20,HK CV38-134,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSGWYYPDYW,IGHV4-34,IGHJ4,CQQYGSSPNTF,IGKV3-20,HK CV38-134,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSGWYYPDYW,IGHV4-34,IGHJ5,CQQYGSSPNTF,IGKV3-20,HK CV38-134,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASSGWYYPDYW,IGHV4-34,IGHJ6,CQQYGSSPNTF,IGKV3-20,HK CV38-134,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTGLGNAFDIW,IGHV3-23,IGHJ1,CQAWDSSTVVF,IGLV3-1,HL CV38-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTGLGNAFDIW,IGHV3-23,IGHJ2,CQAWDSSTVVF,IGLV3-1,HL CV38-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTGLGNAFDIW,IGHV3-23,IGHJ3,CQAWDSSTVVF,IGLV3-1,HL CV38-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTGLGNAFDIW,IGHV3-23,IGHJ4,CQAWDSSTVVF,IGLV3-1,HL CV38-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTGLGNAFDIW,IGHV3-23,IGHJ5,CQAWDSSTVVF,IGLV3-1,HL CV38-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVTGLGNAFDIW,IGHV3-23,IGHJ6,CQAWDSSTVVF,IGLV3-1,HL CV38-135,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSSGRGRVVALGSFDPW,IGHV4-4,IGHJ1,CCSYAGSSTWVF,IGLV2-23,HL CV38-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSSGRGRVVALGSFDPW,IGHV4-4,IGHJ2,CCSYAGSSTWVF,IGLV2-23,HL CV38-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSSGRGRVVALGSFDPW,IGHV4-4,IGHJ3,CCSYAGSSTWVF,IGLV2-23,HL CV38-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSSGRGRVVALGSFDPW,IGHV4-4,IGHJ4,CCSYAGSSTWVF,IGLV2-23,HL CV38-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSSGRGRVVALGSFDPW,IGHV4-4,IGHJ5,CCSYAGSSTWVF,IGLV2-23,HL CV38-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSSGRGRVVALGSFDPW,IGHV4-4,IGHJ6,CCSYAGSSTWVF,IGLV2-23,HL CV38-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGHYDLFDYW,IGHV3-53,IGHJ1,CQQLNSYPPGTF,IGKV1-9,HK CV38-139,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGHYDLFDYW,IGHV3-53,IGHJ2,CQQLNSYPPGTF,IGKV1-9,HK CV38-139,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGHYDLFDYW,IGHV3-53,IGHJ3,CQQLNSYPPGTF,IGKV1-9,HK CV38-139,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGHYDLFDYW,IGHV3-53,IGHJ4,CQQLNSYPPGTF,IGKV1-9,HK CV38-139,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGHYDLFDYW,IGHV3-53,IGHJ5,CQQLNSYPPGTF,IGKV1-9,HK CV38-139,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGHYDLFDYW,IGHV3-53,IGHJ6,CQQLNSYPPGTF,IGKV1-9,HK CV38-139,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYDSSGYYPDYW,IGHV4-31,IGHJ1,CQQSYSTLTF,IGKV1-39,HK CV38-140,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYDSSGYYPDYW,IGHV4-31,IGHJ2,CQQSYSTLTF,IGKV1-39,HK CV38-140,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYDSSGYYPDYW,IGHV4-31,IGHJ3,CQQSYSTLTF,IGKV1-39,HK CV38-140,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYDSSGYYPDYW,IGHV4-31,IGHJ4,CQQSYSTLTF,IGKV1-39,HK CV38-140,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYDSSGYYPDYW,IGHV4-31,IGHJ5,CQQSYSTLTF,IGKV1-39,HK CV38-140,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAYDSSGYYPDYW,IGHV4-31,IGHJ6,CQQSYSTLTF,IGKV1-39,HK CV38-140,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIRGVYSSGWIGGDYW,IGHV5-51,IGHJ1,CQQSYSTPRQWTF,IGKV1-39,HK CV38-142,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIRGVYSSGWIGGDYW,IGHV5-51,IGHJ2,CQQSYSTPRQWTF,IGKV1-39,HK CV38-142,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIRGVYSSGWIGGDYW,IGHV5-51,IGHJ3,CQQSYSTPRQWTF,IGKV1-39,HK CV38-142,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIRGVYSSGWIGGDYW,IGHV5-51,IGHJ4,CQQSYSTPRQWTF,IGKV1-39,HK CV38-142,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIRGVYSSGWIGGDYW,IGHV5-51,IGHJ5,CQQSYSTPRQWTF,IGKV1-39,HK CV38-142,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARIRGVYSSGWIGGDYW,IGHV5-51,IGHJ6,CQQSYSTPRQWTF,IGKV1-39,HK CV38-142,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ1,CSSYAGSNNYVF,IGLV2-8,HL CV38-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ2,CSSYAGSNNYVF,IGLV2-8,HL CV38-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ3,CSSYAGSNNYVF,IGLV2-8,HL CV38-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ4,CSSYAGSNNYVF,IGLV2-8,HL CV38-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ5,CSSYAGSNNYVF,IGLV2-8,HL CV38-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGAQYILTGDFDYW,IGHV1-2,IGHJ6,CSSYAGSNNYVF,IGLV2-8,HL CV38-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ1,CQQSYSTLYTF,IGKV1-39,HK CV38-146,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ2,CQQSYSTLYTF,IGKV1-39,HK CV38-146,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ3,CQQSYSTLYTF,IGKV1-39,HK CV38-146,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ4,CQQSYSTLYTF,IGKV1-39,HK CV38-146,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ5,CQQSYSTLYTF,IGKV1-39,HK CV38-146,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ6,CQQSYSTLYTF,IGKV1-39,HK CV38-146,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRIAVAGTGEDYYFDYW,IGHV3-9,IGHJ1,CQVWDSSSDQVVF,IGLV3-21,HL CV38-147,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRIAVAGTGEDYYFDYW,IGHV3-9,IGHJ2,CQVWDSSSDQVVF,IGLV3-21,HL CV38-147,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRIAVAGTGEDYYFDYW,IGHV3-9,IGHJ3,CQVWDSSSDQVVF,IGLV3-21,HL CV38-147,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRIAVAGTGEDYYFDYW,IGHV3-9,IGHJ4,CQVWDSSSDQVVF,IGLV3-21,HL CV38-147,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRIAVAGTGEDYYFDYW,IGHV3-9,IGHJ5,CQVWDSSSDQVVF,IGLV3-21,HL CV38-147,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDRRIAVAGTGEDYYFDYW,IGHV3-9,IGHJ6,CQVWDSSSDQVVF,IGLV3-21,HL CV38-147,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSAPLVGAYSGIYFDYW,IGHV3-66,IGHJ1,CGADHGSGSNFVVF,IGLV9-49,HL CV38-148,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSAPLVGAYSGIYFDYW,IGHV3-66,IGHJ2,CGADHGSGSNFVVF,IGLV9-49,HL CV38-148,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSAPLVGAYSGIYFDYW,IGHV3-66,IGHJ3,CGADHGSGSNFVVF,IGLV9-49,HL CV38-148,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSAPLVGAYSGIYFDYW,IGHV3-66,IGHJ4,CGADHGSGSNFVVF,IGLV9-49,HL CV38-148,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSAPLVGAYSGIYFDYW,IGHV3-66,IGHJ5,CGADHGSGSNFVVF,IGLV9-49,HL CV38-148,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSAPLVGAYSGIYFDYW,IGHV3-66,IGHJ6,CGADHGSGSNFVVF,IGLV9-49,HL CV38-148,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ1,CQQSYSTLYTF,IGKV1-39,HK CV38-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ2,CQQSYSTLYTF,IGKV1-39,HK CV38-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ3,CQQSYSTLYTF,IGKV1-39,HK CV38-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ4,CQQSYSTLYTF,IGKV1-39,HK CV38-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ5,CQQSYSTLYTF,IGKV1-39,HK CV38-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAATYYYDSSGYTPNWFDPW,IGHV1-69,IGHJ6,CQQSYSTLYTF,IGKV1-39,HK CV38-149,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSQWLVLRHAFDIW,IGHV3-30,IGHJ1,CMQSIQLWTF,IGKV2D-29,HK CV38-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSQWLVLRHAFDIW,IGHV3-30,IGHJ2,CMQSIQLWTF,IGKV2D-29,HK CV38-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSQWLVLRHAFDIW,IGHV3-30,IGHJ3,CMQSIQLWTF,IGKV2D-29,HK CV38-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSQWLVLRHAFDIW,IGHV3-30,IGHJ4,CMQSIQLWTF,IGKV2D-29,HK CV38-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSQWLVLRHAFDIW,IGHV3-30,IGHJ5,CMQSIQLWTF,IGKV2D-29,HK CV38-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKSQWLVLRHAFDIW,IGHV3-30,IGHJ6,CMQSIQLWTF,IGKV2D-29,HK CV38-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSQYYYDSSGYDFDYW,IGHV4-59,IGHJ1,CCSYAGSSSWVF,IGLV2-23,HL CV38-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSQYYYDSSGYDFDYW,IGHV4-59,IGHJ2,CCSYAGSSSWVF,IGLV2-23,HL CV38-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSQYYYDSSGYDFDYW,IGHV4-59,IGHJ3,CCSYAGSSSWVF,IGLV2-23,HL CV38-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSQYYYDSSGYDFDYW,IGHV4-59,IGHJ4,CCSYAGSSSWVF,IGLV2-23,HL CV38-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSQYYYDSSGYDFDYW,IGHV4-59,IGHJ5,CCSYAGSSSWVF,IGLV2-23,HL CV38-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFSQYYYDSSGYDFDYW,IGHV4-59,IGHJ6,CCSYAGSSSWVF,IGLV2-23,HL CV38-156,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRWFGELFSAYYYYYGMDVW,IGHV3-15,IGHJ1,CQQRSNWPPIFTF,IGKV3-11,HK CV38-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRWFGELFSAYYYYYGMDVW,IGHV3-15,IGHJ2,CQQRSNWPPIFTF,IGKV3-11,HK CV38-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRWFGELFSAYYYYYGMDVW,IGHV3-15,IGHJ3,CQQRSNWPPIFTF,IGKV3-11,HK CV38-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRWFGELFSAYYYYYGMDVW,IGHV3-15,IGHJ4,CQQRSNWPPIFTF,IGKV3-11,HK CV38-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRWFGELFSAYYYYYGMDVW,IGHV3-15,IGHJ5,CQQRSNWPPIFTF,IGKV3-11,HK CV38-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRWFGELFSAYYYYYGMDVW,IGHV3-15,IGHJ6,CQQRSNWPPIFTF,IGKV3-11,HK CV38-158,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGNTVFWSGPPLDYW,IGHV1-2,IGHJ1,CSSYTSSSTYVF,IGLV2-14,HL CV38-159,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGNTVFWSGPPLDYW,IGHV1-2,IGHJ2,CSSYTSSSTYVF,IGLV2-14,HL CV38-159,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGNTVFWSGPPLDYW,IGHV1-2,IGHJ3,CSSYTSSSTYVF,IGLV2-14,HL CV38-159,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGNTVFWSGPPLDYW,IGHV1-2,IGHJ4,CSSYTSSSTYVF,IGLV2-14,HL CV38-159,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGNTVFWSGPPLDYW,IGHV1-2,IGHJ5,CSSYTSSSTYVF,IGLV2-14,HL CV38-159,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGNTVFWSGPPLDYW,IGHV1-2,IGHJ6,CSSYTSSSTYVF,IGLV2-14,HL CV38-159,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVAGRGNAFDIW,IGHV3-23,IGHJ1,CLLYYGGALF,IGLV7-43,HL CV38-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVAGRGNAFDIW,IGHV3-23,IGHJ2,CLLYYGGALF,IGLV7-43,HL CV38-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVAGRGNAFDIW,IGHV3-23,IGHJ3,CLLYYGGALF,IGLV7-43,HL CV38-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVAGRGNAFDIW,IGHV3-23,IGHJ4,CLLYYGGALF,IGLV7-43,HL CV38-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVAGRGNAFDIW,IGHV3-23,IGHJ5,CLLYYGGALF,IGLV7-43,HL CV38-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVAGRGNAFDIW,IGHV3-23,IGHJ6,CLLYYGGALF,IGLV7-43,HL CV38-160,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ1,CQQYNNWPPAITF,IGKV3-15,HK CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ2,CQQYNNWPPAITF,IGKV3-15,HK CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ3,CQQYNNWPPAITF,IGKV3-15,HK CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ4,CQQYNNWPPAITF,IGKV3-15,HK CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ5,CQQYNNWPPAITF,IGKV3-15,HK CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ6,CQQYNNWPPAITF,IGKV3-15,HK CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ1,CAAWDDSLNGYVF,IGLV1-44,HL CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ2,CAAWDDSLNGYVF,IGLV1-44,HL CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ3,CAAWDDSLNGYVF,IGLV1-44,HL CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ4,CAAWDDSLNGYVF,IGLV1-44,HL CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ5,CAAWDDSLNGYVF,IGLV1-44,HL CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRSLGNYDSSGYDHW,IGHV4-4,IGHJ6,CAAWDDSLNGYVF,IGLV1-44,HL CV38-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGGYNYNW,IGHV3-30-3,IGHJ1,CQAWDSSTVVF,IGLV3-1,HL CV38-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGGYNYNW,IGHV3-30-3,IGHJ2,CQAWDSSTVVF,IGLV3-1,HL CV38-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGGYNYNW,IGHV3-30-3,IGHJ3,CQAWDSSTVVF,IGLV3-1,HL CV38-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGGYNYNW,IGHV3-30-3,IGHJ4,CQAWDSSTVVF,IGLV3-1,HL CV38-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGGYNYNW,IGHV3-30-3,IGHJ5,CQAWDSSTVVF,IGLV3-1,HL CV38-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYGGYNYNW,IGHV3-30-3,IGHJ6,CQAWDSSTVVF,IGLV3-1,HL CV38-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDMVVVAIFGVGPFDYW,IGHV3-9,IGHJ1,CLQDYNYPLTF,IGKV1-6,HK CV38-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDMVVVAIFGVGPFDYW,IGHV3-9,IGHJ2,CLQDYNYPLTF,IGKV1-6,HK CV38-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDMVVVAIFGVGPFDYW,IGHV3-9,IGHJ3,CLQDYNYPLTF,IGKV1-6,HK CV38-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDMVVVAIFGVGPFDYW,IGHV3-9,IGHJ4,CLQDYNYPLTF,IGKV1-6,HK CV38-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDMVVVAIFGVGPFDYW,IGHV3-9,IGHJ5,CLQDYNYPLTF,IGKV1-6,HK CV38-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDMVVVAIFGVGPFDYW,IGHV3-9,IGHJ6,CLQDYNYPLTF,IGKV1-6,HK CV38-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ1,CQQYDNLLFTF,IGKV1-33,HK CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ2,CQQYDNLLFTF,IGKV1-33,HK CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ3,CQQYDNLLFTF,IGKV1-33,HK CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ4,CQQYDNLLFTF,IGKV1-33,HK CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ5,CQQYDNLLFTF,IGKV1-33,HK CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ6,CQQYDNLLFTF,IGKV1-33,HK CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,HL CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,HL CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,HL CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,HL CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,HL CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQRRPPGKRVLTMIVVVYNDAFDIW,IGHV5-51,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,HL CV38-179,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAAAGPRPYDYW,IGHV4-4,IGHJ1,CCSYAGFSTWVF,IGLV2-23,HL CV38-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAAAGPRPYDYW,IGHV4-4,IGHJ2,CCSYAGFSTWVF,IGLV2-23,HL CV38-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAAAGPRPYDYW,IGHV4-4,IGHJ3,CCSYAGFSTWVF,IGLV2-23,HL CV38-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAAAGPRPYDYW,IGHV4-4,IGHJ4,CCSYAGFSTWVF,IGLV2-23,HL CV38-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAAAGPRPYDYW,IGHV4-4,IGHJ5,CCSYAGFSTWVF,IGLV2-23,HL CV38-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRAAAGPRPYDYW,IGHV4-4,IGHJ6,CCSYAGFSTWVF,IGLV2-23,HL CV38-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSYLYGAFDIW,IGHV1-2,IGHJ1,CQQRSNWPTF,IGKV3-11,HK CV38-181,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSYLYGAFDIW,IGHV1-2,IGHJ2,CQQRSNWPTF,IGKV3-11,HK CV38-181,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSYLYGAFDIW,IGHV1-2,IGHJ3,CQQRSNWPTF,IGKV3-11,HK CV38-181,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSYLYGAFDIW,IGHV1-2,IGHJ4,CQQRSNWPTF,IGKV3-11,HK CV38-181,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSYLYGAFDIW,IGHV1-2,IGHJ5,CQQRSNWPTF,IGKV3-11,HK CV38-181,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSYLYGAFDIW,IGHV1-2,IGHJ6,CQQRSNWPTF,IGKV3-11,HK CV38-181,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKELGYSGYGAHRYFDLW,IGHV1-69,IGHJ1,CQSYDSSLSGVVF,IGLV1-40,HL CV38-182,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKELGYSGYGAHRYFDLW,IGHV1-69,IGHJ2,CQSYDSSLSGVVF,IGLV1-40,HL CV38-182,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKELGYSGYGAHRYFDLW,IGHV1-69,IGHJ3,CQSYDSSLSGVVF,IGLV1-40,HL CV38-182,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKELGYSGYGAHRYFDLW,IGHV1-69,IGHJ4,CQSYDSSLSGVVF,IGLV1-40,HL CV38-182,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKELGYSGYGAHRYFDLW,IGHV1-69,IGHJ5,CQSYDSSLSGVVF,IGLV1-40,HL CV38-182,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKELGYSGYGAHRYFDLW,IGHV1-69,IGHJ6,CQSYDSSLSGVVF,IGLV1-40,HL CV38-182,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDGWDNYYYGMDVW,IGHV3-53,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,HL CV38-183,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDGWDNYYYGMDVW,IGHV3-53,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,HL CV38-183,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDGWDNYYYGMDVW,IGHV3-53,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,HL CV38-183,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDGWDNYYYGMDVW,IGHV3-53,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,HL CV38-183,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDGWDNYYYGMDVW,IGHV3-53,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,HL CV38-183,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGDGWDNYYYGMDVW,IGHV3-53,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,HL CV38-183,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLGWFDPW,IGHV4-39,IGHJ1,CQQYYSTPPRTF,IGKV1-NL1,HK CV38-184,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLGWFDPW,IGHV4-39,IGHJ2,CQQYYSTPPRTF,IGKV1-NL1,HK CV38-184,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLGWFDPW,IGHV4-39,IGHJ3,CQQYYSTPPRTF,IGKV1-NL1,HK CV38-184,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLGWFDPW,IGHV4-39,IGHJ4,CQQYYSTPPRTF,IGKV1-NL1,HK CV38-184,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLGWFDPW,IGHV4-39,IGHJ5,CQQYYSTPPRTF,IGKV1-NL1,HK CV38-184,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLGWFDPW,IGHV4-39,IGHJ6,CQQYYSTPPRTF,IGKV1-NL1,HK CV38-184,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQSPDILKSPFDYW,IGHV1-2,IGHJ1,CCSYAGSSTFGF,IGLV2-23,HL CV38-186,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQSPDILKSPFDYW,IGHV1-2,IGHJ2,CCSYAGSSTFGF,IGLV2-23,HL CV38-186,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQSPDILKSPFDYW,IGHV1-2,IGHJ3,CCSYAGSSTFGF,IGLV2-23,HL CV38-186,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQSPDILKSPFDYW,IGHV1-2,IGHJ4,CCSYAGSSTFGF,IGLV2-23,HL CV38-186,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQSPDILKSPFDYW,IGHV1-2,IGHJ5,CCSYAGSSTFGF,IGLV2-23,HL CV38-186,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDQSPDILKSPFDYW,IGHV1-2,IGHJ6,CCSYAGSSTFGF,IGLV2-23,HL CV38-186,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDISRNLHDFRPYYFDYW,IGHV3-11,IGHJ1,CLLSYSGARVF,IGLV7-46,HL CV38-193,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDISRNLHDFRPYYFDYW,IGHV3-11,IGHJ2,CLLSYSGARVF,IGLV7-46,HL CV38-193,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDISRNLHDFRPYYFDYW,IGHV3-11,IGHJ3,CLLSYSGARVF,IGLV7-46,HL CV38-193,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDISRNLHDFRPYYFDYW,IGHV3-11,IGHJ4,CLLSYSGARVF,IGLV7-46,HL CV38-193,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDISRNLHDFRPYYFDYW,IGHV3-11,IGHJ5,CLLSYSGARVF,IGLV7-46,HL CV38-193,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDISRNLHDFRPYYFDYW,IGHV3-11,IGHJ6,CLLSYSGARVF,IGLV7-46,HL CV38-193,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHDVYSSGWYGEGAFDIW,IGHV4-59,IGHJ1,CQSYDSSLSGSWVF,IGLV1-40,HL CV38-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHDVYSSGWYGEGAFDIW,IGHV4-59,IGHJ2,CQSYDSSLSGSWVF,IGLV1-40,HL CV38-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHDVYSSGWYGEGAFDIW,IGHV4-59,IGHJ3,CQSYDSSLSGSWVF,IGLV1-40,HL CV38-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHDVYSSGWYGEGAFDIW,IGHV4-59,IGHJ4,CQSYDSSLSGSWVF,IGLV1-40,HL CV38-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHDVYSSGWYGEGAFDIW,IGHV4-59,IGHJ5,CQSYDSSLSGSWVF,IGLV1-40,HL CV38-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHDVYSSGWYGEGAFDIW,IGHV4-59,IGHJ6,CQSYDSSLSGSWVF,IGLV1-40,HL CV38-194,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYYQDFDYW,IGHV4-59,IGHJ1,CAAWDDSLNGPYVF,IGLV1-44,HL CV38-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYYQDFDYW,IGHV4-59,IGHJ2,CAAWDDSLNGPYVF,IGLV1-44,HL CV38-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYYQDFDYW,IGHV4-59,IGHJ3,CAAWDDSLNGPYVF,IGLV1-44,HL CV38-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYYQDFDYW,IGHV4-59,IGHJ4,CAAWDDSLNGPYVF,IGLV1-44,HL CV38-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYYQDFDYW,IGHV4-59,IGHJ5,CAAWDDSLNGPYVF,IGLV1-44,HL CV38-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARYYQDFDYW,IGHV4-59,IGHJ6,CAAWDDSLNGPYVF,IGLV1-44,HL CV38-199,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDIVLVPAAIPVPIFDYW,IGHV3-30,IGHJ1,CQQRSNWPPTF,IGKV3-11,HK CV38-201,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDIVLVPAAIPVPIFDYW,IGHV3-30,IGHJ2,CQQRSNWPPTF,IGKV3-11,HK CV38-201,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDIVLVPAAIPVPIFDYW,IGHV3-30,IGHJ3,CQQRSNWPPTF,IGKV3-11,HK CV38-201,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDIVLVPAAIPVPIFDYW,IGHV3-30,IGHJ4,CQQRSNWPPTF,IGKV3-11,HK CV38-201,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDIVLVPAAIPVPIFDYW,IGHV3-30,IGHJ5,CQQRSNWPPTF,IGKV3-11,HK CV38-201,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDIVLVPAAIPVPIFDYW,IGHV3-30,IGHJ6,CQQRSNWPPTF,IGKV3-11,HK CV38-201,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSQQQLAYAFDIW,IGHV3-33,IGHJ1,CQAWDSSIVVF,IGLV3-1,HL CV38-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSQQQLAYAFDIW,IGHV3-33,IGHJ2,CQAWDSSIVVF,IGLV3-1,HL CV38-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSQQQLAYAFDIW,IGHV3-33,IGHJ3,CQAWDSSIVVF,IGLV3-1,HL CV38-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSQQQLAYAFDIW,IGHV3-33,IGHJ4,CQAWDSSIVVF,IGLV3-1,HL CV38-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSQQQLAYAFDIW,IGHV3-33,IGHJ5,CQAWDSSIVVF,IGLV3-1,HL CV38-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDSSQQQLAYAFDIW,IGHV3-33,IGHJ6,CQAWDSSIVVF,IGLV3-1,HL CV38-202,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHYPYYYYGMDVW,IGHV4-30-2,IGHJ1,CQSYDSSTVVF,IGLV6-57,HL CV38-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHYPYYYYGMDVW,IGHV4-30-2,IGHJ2,CQSYDSSTVVF,IGLV6-57,HL CV38-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHYPYYYYGMDVW,IGHV4-30-2,IGHJ3,CQSYDSSTVVF,IGLV6-57,HL CV38-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHYPYYYYGMDVW,IGHV4-30-2,IGHJ4,CQSYDSSTVVF,IGLV6-57,HL CV38-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHYPYYYYGMDVW,IGHV4-30-2,IGHJ5,CQSYDSSTVVF,IGLV6-57,HL CV38-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDHYPYYYYGMDVW,IGHV4-30-2,IGHJ6,CQSYDSSTVVF,IGLV6-57,HL CV38-205,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKGNAIDVW,IGHV3-7,IGHJ1,CLQYNSYSWYTF,IGKV1-5,HK CV38-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKGNAIDVW,IGHV3-7,IGHJ2,CLQYNSYSWYTF,IGKV1-5,HK CV38-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKGNAIDVW,IGHV3-7,IGHJ3,CLQYNSYSWYTF,IGKV1-5,HK CV38-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKGNAIDVW,IGHV3-7,IGHJ4,CLQYNSYSWYTF,IGKV1-5,HK CV38-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKGNAIDVW,IGHV3-7,IGHJ5,CLQYNSYSWYTF,IGKV1-5,HK CV38-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARKGNAIDVW,IGHV3-7,IGHJ6,CLQYNSYSWYTF,IGKV1-5,HK CV38-206,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ1,CSSYTNTNTLVF,IGLV2-14,HL CV38-207,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ2,CSSYTNTNTLVF,IGLV2-14,HL CV38-207,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ3,CSSYTNTNTLVF,IGLV2-14,HL CV38-207,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ4,CSSYTNTNTLVF,IGLV2-14,HL CV38-207,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ5,CSSYTNTNTLVF,IGLV2-14,HL CV38-207,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ6,CSSYTNTNTLVF,IGLV2-14,HL CV38-207,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAHQSGNSGPWYFDLW,IGHV4-39,IGHJ1,CVLYMGSGIVVF,IGLV8-61,HL CV38-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAHQSGNSGPWYFDLW,IGHV4-39,IGHJ2,CVLYMGSGIVVF,IGLV8-61,HL CV38-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAHQSGNSGPWYFDLW,IGHV4-39,IGHJ3,CVLYMGSGIVVF,IGLV8-61,HL CV38-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAHQSGNSGPWYFDLW,IGHV4-39,IGHJ4,CVLYMGSGIVVF,IGLV8-61,HL CV38-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAHQSGNSGPWYFDLW,IGHV4-39,IGHJ5,CVLYMGSGIVVF,IGLV8-61,HL CV38-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAHQSGNSGPWYFDLW,IGHV4-39,IGHJ6,CVLYMGSGIVVF,IGLV8-61,HL CV38-208,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVEPDYGGNSFDYW,IGHV4-39,IGHJ1,CQSYDSSLSGYVF,IGLV1-40,HL CV38-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVEPDYGGNSFDYW,IGHV4-39,IGHJ2,CQSYDSSLSGYVF,IGLV1-40,HL CV38-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVEPDYGGNSFDYW,IGHV4-39,IGHJ3,CQSYDSSLSGYVF,IGLV1-40,HL CV38-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVEPDYGGNSFDYW,IGHV4-39,IGHJ4,CQSYDSSLSGYVF,IGLV1-40,HL CV38-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVEPDYGGNSFDYW,IGHV4-39,IGHJ5,CQSYDSSLSGYVF,IGLV1-40,HL CV38-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHVEPDYGGNSFDYW,IGHV4-39,IGHJ6,CQSYDSSLSGYVF,IGLV1-40,HL CV38-210,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDISNKWLRLTQPYSYYGLDVW,IGHV3-9,IGHJ1,CSSYAGSNIPYVF,IGLV2-8,HL CV38-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDISNKWLRLTQPYSYYGLDVW,IGHV3-9,IGHJ2,CSSYAGSNIPYVF,IGLV2-8,HL CV38-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDISNKWLRLTQPYSYYGLDVW,IGHV3-9,IGHJ3,CSSYAGSNIPYVF,IGLV2-8,HL CV38-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDISNKWLRLTQPYSYYGLDVW,IGHV3-9,IGHJ4,CSSYAGSNIPYVF,IGLV2-8,HL CV38-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDISNKWLRLTQPYSYYGLDVW,IGHV3-9,IGHJ5,CSSYAGSNIPYVF,IGLV2-8,HL CV38-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDISNKWLRLTQPYSYYGLDVW,IGHV3-9,IGHJ6,CSSYAGSNIPYVF,IGLV2-8,HL CV38-211,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLIRNGYDILTGYPYDAFDIW,IGHV3-23,IGHJ1,CSSYTSSSTLVF,IGLV2-14,HL CV38-213,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLIRNGYDILTGYPYDAFDIW,IGHV3-23,IGHJ2,CSSYTSSSTLVF,IGLV2-14,HL CV38-213,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLIRNGYDILTGYPYDAFDIW,IGHV3-23,IGHJ3,CSSYTSSSTLVF,IGLV2-14,HL CV38-213,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLIRNGYDILTGYPYDAFDIW,IGHV3-23,IGHJ4,CSSYTSSSTLVF,IGLV2-14,HL CV38-213,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLIRNGYDILTGYPYDAFDIW,IGHV3-23,IGHJ5,CSSYTSSSTLVF,IGLV2-14,HL CV38-213,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVLIRNGYDILTGYPYDAFDIW,IGHV3-23,IGHJ6,CSSYTSSSTLVF,IGLV2-14,HL CV38-213,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGYSAYDFGYW,IGHV3-30-3,IGHJ1,CVLFMGSGTWVF,IGLV8-61,HL CV38-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGYSAYDFGYW,IGHV3-30-3,IGHJ2,CVLFMGSGTWVF,IGLV8-61,HL CV38-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGYSAYDFGYW,IGHV3-30-3,IGHJ3,CVLFMGSGTWVF,IGLV8-61,HL CV38-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGYSAYDFGYW,IGHV3-30-3,IGHJ4,CVLFMGSGTWVF,IGLV8-61,HL CV38-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGYSAYDFGYW,IGHV3-30-3,IGHJ5,CVLFMGSGTWVF,IGLV8-61,HL CV38-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGYSAYDFGYW,IGHV3-30-3,IGHJ6,CVLFMGSGTWVF,IGLV8-61,HL CV38-215,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGPAWELFDYW,IGHV4-30-2,IGHJ1,CQSYHNWPLF,IGKV3-15,HK CV38-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGPAWELFDYW,IGHV4-30-2,IGHJ2,CQSYHNWPLF,IGKV3-15,HK CV38-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGPAWELFDYW,IGHV4-30-2,IGHJ3,CQSYHNWPLF,IGKV3-15,HK CV38-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGPAWELFDYW,IGHV4-30-2,IGHJ4,CQSYHNWPLF,IGKV3-15,HK CV38-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGPAWELFDYW,IGHV4-30-2,IGHJ5,CQSYHNWPLF,IGKV3-15,HK CV38-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGPAWELFDYW,IGHV4-30-2,IGHJ6,CQSYHNWPLF,IGKV3-15,HK CV38-217,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQMRIGTIVVVPAALDYW,IGHV4-39,IGHJ1,CQQYYSSPWTF,IGKV3-20,HK CV38-219,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQMRIGTIVVVPAALDYW,IGHV4-39,IGHJ2,CQQYYSSPWTF,IGKV3-20,HK CV38-219,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQMRIGTIVVVPAALDYW,IGHV4-39,IGHJ3,CQQYYSSPWTF,IGKV3-20,HK CV38-219,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQMRIGTIVVVPAALDYW,IGHV4-39,IGHJ4,CQQYYSSPWTF,IGKV3-20,HK CV38-219,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQMRIGTIVVVPAALDYW,IGHV4-39,IGHJ5,CQQYYSSPWTF,IGKV3-20,HK CV38-219,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQMRIGTIVVVPAALDYW,IGHV4-39,IGHJ6,CQQYYSSPWTF,IGKV3-20,HK CV38-219,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFGDYYFDYW,IGHV3-66,IGHJ1,CQQLYTF,IGKV3-20,HK CV38-221,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFGDYYFDYW,IGHV3-66,IGHJ2,CQQLYTF,IGKV3-20,HK CV38-221,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFGDYYFDYW,IGHV3-66,IGHJ3,CQQLYTF,IGKV3-20,HK CV38-221,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFGDYYFDYW,IGHV3-66,IGHJ4,CQQLYTF,IGKV3-20,HK CV38-221,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFGDYYFDYW,IGHV3-66,IGHJ5,CQQLYTF,IGKV3-20,HK CV38-221,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFGDYYFDYW,IGHV3-66,IGHJ6,CQQLYTF,IGKV3-20,HK CV38-221,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWQVTIFGVVIRYGMDVW,IGHV4-30-4,IGHJ1,CQQLNSYPRTF,IGKV1-9,HK CV38-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWQVTIFGVVIRYGMDVW,IGHV4-30-4,IGHJ2,CQQLNSYPRTF,IGKV1-9,HK CV38-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWQVTIFGVVIRYGMDVW,IGHV4-30-4,IGHJ3,CQQLNSYPRTF,IGKV1-9,HK CV38-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWQVTIFGVVIRYGMDVW,IGHV4-30-4,IGHJ4,CQQLNSYPRTF,IGKV1-9,HK CV38-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWQVTIFGVVIRYGMDVW,IGHV4-30-4,IGHJ5,CQQLNSYPRTF,IGKV1-9,HK CV38-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPWQVTIFGVVIRYGMDVW,IGHV4-30-4,IGHJ6,CQQLNSYPRTF,IGKV1-9,HK CV38-222,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWFGRYWGNWLDPW,IGHV3-11,IGHJ1,CGTWDNSLSAAVF,IGLV1-51,HL CV38-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWFGRYWGNWLDPW,IGHV3-11,IGHJ2,CGTWDNSLSAAVF,IGLV1-51,HL CV38-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWFGRYWGNWLDPW,IGHV3-11,IGHJ3,CGTWDNSLSAAVF,IGLV1-51,HL CV38-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWFGRYWGNWLDPW,IGHV3-11,IGHJ4,CGTWDNSLSAAVF,IGLV1-51,HL CV38-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWFGRYWGNWLDPW,IGHV3-11,IGHJ5,CGTWDNSLSAAVF,IGLV1-51,HL CV38-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLWFGRYWGNWLDPW,IGHV3-11,IGHJ6,CGTWDNSLSAAVF,IGLV1-51,HL CV38-225,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASEGRTTGTIVAYYYFAMDVW,IGHV3-66,IGHJ1,CSSYAGRSNVVF,IGLV2-8,HL CV38-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASEGRTTGTIVAYYYFAMDVW,IGHV3-66,IGHJ2,CSSYAGRSNVVF,IGLV2-8,HL CV38-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASEGRTTGTIVAYYYFAMDVW,IGHV3-66,IGHJ3,CSSYAGRSNVVF,IGLV2-8,HL CV38-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASEGRTTGTIVAYYYFAMDVW,IGHV3-66,IGHJ4,CSSYAGRSNVVF,IGLV2-8,HL CV38-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASEGRTTGTIVAYYYFAMDVW,IGHV3-66,IGHJ5,CSSYAGRSNVVF,IGLV2-8,HL CV38-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASEGRTTGTIVAYYYFAMDVW,IGHV3-66,IGHJ6,CSSYAGRSNVVF,IGLV2-8,HL CV38-227,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDYW,IGHV4-31,IGHJ1,CQQYNSWPRAF,IGKV3-15,HK CV38-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDYW,IGHV4-31,IGHJ2,CQQYNSWPRAF,IGKV3-15,HK CV38-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDYW,IGHV4-31,IGHJ3,CQQYNSWPRAF,IGKV3-15,HK CV38-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDYW,IGHV4-31,IGHJ4,CQQYNSWPRAF,IGKV3-15,HK CV38-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDYW,IGHV4-31,IGHJ5,CQQYNSWPRAF,IGKV3-15,HK CV38-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDYW,IGHV4-31,IGHJ6,CQQYNSWPRAF,IGKV3-15,HK CV38-228,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ1,CSSYTNTNTLVF,IGLV2-14,HL CV38-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ2,CSSYTNTNTLVF,IGLV2-14,HL CV38-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ3,CSSYTNTNTLVF,IGLV2-14,HL CV38-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ4,CSSYTNTNTLVF,IGLV2-14,HL CV38-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ5,CSSYTNTNTLVF,IGLV2-14,HL CV38-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ6,CSSYTNTNTLVF,IGLV2-14,HL CV38-229,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNSSNWYYFDSW,IGHV3-53,IGHJ1,CQSADSSGTYVF,IGLV3-25,HL CV38-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNSSNWYYFDSW,IGHV3-53,IGHJ2,CQSADSSGTYVF,IGLV3-25,HL CV38-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNSSNWYYFDSW,IGHV3-53,IGHJ3,CQSADSSGTYVF,IGLV3-25,HL CV38-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNSSNWYYFDSW,IGHV3-53,IGHJ4,CQSADSSGTYVF,IGLV3-25,HL CV38-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNSSNWYYFDSW,IGHV3-53,IGHJ5,CQSADSSGTYVF,IGLV3-25,HL CV38-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNSSNWYYFDSW,IGHV3-53,IGHJ6,CQSADSSGTYVF,IGLV3-25,HL CV38-230,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ1,CSSYSGTTNFAQF,IGLV2-8,HL CV38-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ2,CSSYSGTTNFAQF,IGLV2-8,HL CV38-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ3,CSSYSGTTNFAQF,IGLV2-8,HL CV38-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ4,CSSYSGTTNFAQF,IGLV2-8,HL CV38-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ5,CSSYSGTTNFAQF,IGLV2-8,HL CV38-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ6,CSSYSGTTNFAQF,IGLV2-8,HL CV38-231,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYRLGDYW,IGHV3-23,IGHJ1,CAAWDDSLDGPVF,IGLV1-44,HL CV38-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYRLGDYW,IGHV3-23,IGHJ2,CAAWDDSLDGPVF,IGLV1-44,HL CV38-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYRLGDYW,IGHV3-23,IGHJ3,CAAWDDSLDGPVF,IGLV1-44,HL CV38-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYRLGDYW,IGHV3-23,IGHJ4,CAAWDDSLDGPVF,IGLV1-44,HL CV38-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYRLGDYW,IGHV3-23,IGHJ5,CAAWDDSLDGPVF,IGLV1-44,HL CV38-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASGTYRLGDYW,IGHV3-23,IGHJ6,CAAWDDSLDGPVF,IGLV1-44,HL CV38-232,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTGGRWRFDPW,IGHV4-4,IGHJ1,CCSYAGTYTYWLF,IGLV2-11,HL CV38-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTGGRWRFDPW,IGHV4-4,IGHJ2,CCSYAGTYTYWLF,IGLV2-11,HL CV38-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTGGRWRFDPW,IGHV4-4,IGHJ3,CCSYAGTYTYWLF,IGLV2-11,HL CV38-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTGGRWRFDPW,IGHV4-4,IGHJ4,CCSYAGTYTYWLF,IGLV2-11,HL CV38-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTGGRWRFDPW,IGHV4-4,IGHJ5,CCSYAGTYTYWLF,IGLV2-11,HL CV38-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTGGRWRFDPW,IGHV4-4,IGHJ6,CCSYAGTYTYWLF,IGLV2-11,HL CV38-233,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDLSSSDPWYFDFW,IGHV3-23,IGHJ1,CQQYGDSPRTF,IGKV3D-20,HK CV38-235,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDLSSSDPWYFDFW,IGHV3-23,IGHJ2,CQQYGDSPRTF,IGKV3D-20,HK CV38-235,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDLSSSDPWYFDFW,IGHV3-23,IGHJ3,CQQYGDSPRTF,IGKV3D-20,HK CV38-235,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDLSSSDPWYFDFW,IGHV3-23,IGHJ4,CQQYGDSPRTF,IGKV3D-20,HK CV38-235,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDLSSSDPWYFDFW,IGHV3-23,IGHJ5,CQQYGDSPRTF,IGKV3D-20,HK CV38-235,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRDLSSSDPWYFDFW,IGHV3-23,IGHJ6,CQQYGDSPRTF,IGKV3D-20,HK CV38-235,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYEIVVVPDYYYYGMDVW,IGHV3-64,IGHJ1,CQQYKDF,IGKV3-20,HK CV38-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYEIVVVPDYYYYGMDVW,IGHV3-64,IGHJ2,CQQYKDF,IGKV3-20,HK CV38-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYEIVVVPDYYYYGMDVW,IGHV3-64,IGHJ3,CQQYKDF,IGKV3-20,HK CV38-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYEIVVVPDYYYYGMDVW,IGHV3-64,IGHJ4,CQQYKDF,IGKV3-20,HK CV38-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYEIVVVPDYYYYGMDVW,IGHV3-64,IGHJ5,CQQYKDF,IGKV3-20,HK CV38-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGGYEIVVVPDYYYYGMDVW,IGHV3-64,IGHJ6,CQQYKDF,IGKV3-20,HK CV38-236,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPLNCSSTRCYTAWIYYYYGMDVW,IGHV3-30,IGHJ1,CMQSIQLPLTF,IGKV2D-29,HK CV38-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPLNCSSTRCYTAWIYYYYGMDVW,IGHV3-30,IGHJ2,CMQSIQLPLTF,IGKV2D-29,HK CV38-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPLNCSSTRCYTAWIYYYYGMDVW,IGHV3-30,IGHJ3,CMQSIQLPLTF,IGKV2D-29,HK CV38-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPLNCSSTRCYTAWIYYYYGMDVW,IGHV3-30,IGHJ4,CMQSIQLPLTF,IGKV2D-29,HK CV38-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPLNCSSTRCYTAWIYYYYGMDVW,IGHV3-30,IGHJ5,CMQSIQLPLTF,IGKV2D-29,HK CV38-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDPLNCSSTRCYTAWIYYYYGMDVW,IGHV3-30,IGHJ6,CMQSIQLPLTF,IGKV2D-29,HK CV38-238,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSVKGYSSGWYYYYYGMDVW,IGHV3-30,IGHJ1,CMQSIQLPLTF,IGKV2D-29,HK CV38-240,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSVKGYSSGWYYYYYGMDVW,IGHV3-30,IGHJ2,CMQSIQLPLTF,IGKV2D-29,HK CV38-240,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSVKGYSSGWYYYYYGMDVW,IGHV3-30,IGHJ3,CMQSIQLPLTF,IGKV2D-29,HK CV38-240,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSVKGYSSGWYYYYYGMDVW,IGHV3-30,IGHJ4,CMQSIQLPLTF,IGKV2D-29,HK CV38-240,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSVKGYSSGWYYYYYGMDVW,IGHV3-30,IGHJ5,CMQSIQLPLTF,IGKV2D-29,HK CV38-240,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDSVKGYSSGWYYYYYGMDVW,IGHV3-30,IGHJ6,CMQSIQLPLTF,IGKV2D-29,HK CV38-240,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSSDPWYFDFW,IGHV3-23,IGHJ1,CQQYGDSPRTF,IGKV3D-20,HK CV38-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSSDPWYFDFW,IGHV3-23,IGHJ2,CQQYGDSPRTF,IGKV3D-20,HK CV38-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSSDPWYFDFW,IGHV3-23,IGHJ3,CQQYGDSPRTF,IGKV3D-20,HK CV38-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSSDPWYFDFW,IGHV3-23,IGHJ4,CQQYGDSPRTF,IGKV3D-20,HK CV38-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSSDPWYFDFW,IGHV3-23,IGHJ5,CQQYGDSPRTF,IGKV3D-20,HK CV38-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSSSDPWYFDFW,IGHV3-23,IGHJ6,CQQYGDSPRTF,IGKV3D-20,HK CV38-242,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRSGWYRNLFDYW,IGHV3-21,IGHJ1,CMQALQASITF,IGKV2-28,HK CV38-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRSGWYRNLFDYW,IGHV3-21,IGHJ2,CMQALQASITF,IGKV2-28,HK CV38-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRSGWYRNLFDYW,IGHV3-21,IGHJ3,CMQALQASITF,IGKV2-28,HK CV38-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRSGWYRNLFDYW,IGHV3-21,IGHJ4,CMQALQASITF,IGKV2-28,HK CV38-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRSGWYRNLFDYW,IGHV3-21,IGHJ5,CMQALQASITF,IGKV2-28,HK CV38-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRSGWYRNLFDYW,IGHV3-21,IGHJ6,CMQALQASITF,IGKV2-28,HK CV38-243,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDFDHADSFDIW,IGHV3-49,IGHJ1,CMQALHTPRYTF,IGKV2-28,HK CV38-245,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDFDHADSFDIW,IGHV3-49,IGHJ2,CMQALHTPRYTF,IGKV2-28,HK CV38-245,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDFDHADSFDIW,IGHV3-49,IGHJ3,CMQALHTPRYTF,IGKV2-28,HK CV38-245,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDFDHADSFDIW,IGHV3-49,IGHJ4,CMQALHTPRYTF,IGKV2-28,HK CV38-245,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDFDHADSFDIW,IGHV3-49,IGHJ5,CMQALHTPRYTF,IGKV2-28,HK CV38-245,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDFDHADSFDIW,IGHV3-49,IGHJ6,CMQALHTPRYTF,IGKV2-28,HK CV38-245,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGFYDSGPW,IGHV3-30,IGHJ1,CMQGTHWKTF,IGKV2-30,HK CV38-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGFYDSGPW,IGHV3-30,IGHJ2,CMQGTHWKTF,IGKV2-30,HK CV38-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGFYDSGPW,IGHV3-30,IGHJ3,CMQGTHWKTF,IGKV2-30,HK CV38-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGFYDSGPW,IGHV3-30,IGHJ4,CMQGTHWKTF,IGKV2-30,HK CV38-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGFYDSGPW,IGHV3-30,IGHJ5,CMQGTHWKTF,IGKV2-30,HK CV38-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGFYDSGPW,IGHV3-30,IGHJ6,CMQGTHWKTF,IGKV2-30,HK CV38-248,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQTVSFFYYGMDVW,IGHV3-23,IGHJ1,CATWDDSLSGYVF,IGLV1-47,HL CV38-251,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQTVSFFYYGMDVW,IGHV3-23,IGHJ2,CATWDDSLSGYVF,IGLV1-47,HL CV38-251,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQTVSFFYYGMDVW,IGHV3-23,IGHJ3,CATWDDSLSGYVF,IGLV1-47,HL CV38-251,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQTVSFFYYGMDVW,IGHV3-23,IGHJ4,CATWDDSLSGYVF,IGLV1-47,HL CV38-251,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQTVSFFYYGMDVW,IGHV3-23,IGHJ5,CATWDDSLSGYVF,IGLV1-47,HL CV38-251,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDQTVSFFYYGMDVW,IGHV3-23,IGHJ6,CATWDDSLSGYVF,IGLV1-47,HL CV38-251,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNTNTWFGSIEYW,IGHV1-3,IGHJ1,CQQNYATPLTF,IGKV4-1,HK CV38-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNTNTWFGSIEYW,IGHV1-3,IGHJ2,CQQNYATPLTF,IGKV4-1,HK CV38-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNTNTWFGSIEYW,IGHV1-3,IGHJ3,CQQNYATPLTF,IGKV4-1,HK CV38-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNTNTWFGSIEYW,IGHV1-3,IGHJ4,CQQNYATPLTF,IGKV4-1,HK CV38-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNTNTWFGSIEYW,IGHV1-3,IGHJ5,CQQNYATPLTF,IGKV4-1,HK CV38-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDNTNTWFGSIEYW,IGHV1-3,IGHJ6,CQQNYATPLTF,IGKV4-1,HK CV38-252,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVREATRGAHFDCW,IGHV3-9,IGHJ1,CSSYVGFNNLDNFVF,IGLV2-8,HL CV38-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVREATRGAHFDCW,IGHV3-9,IGHJ2,CSSYVGFNNLDNFVF,IGLV2-8,HL CV38-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVREATRGAHFDCW,IGHV3-9,IGHJ3,CSSYVGFNNLDNFVF,IGLV2-8,HL CV38-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVREATRGAHFDCW,IGHV3-9,IGHJ4,CSSYVGFNNLDNFVF,IGLV2-8,HL CV38-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVREATRGAHFDCW,IGHV3-9,IGHJ5,CSSYVGFNNLDNFVF,IGLV2-8,HL CV38-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVREATRGAHFDCW,IGHV3-9,IGHJ6,CSSYVGFNNLDNFVF,IGLV2-8,HL CV38-255,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRIYYGDLGNWNFDLW,IGHV4-34,IGHJ1,CQQYNSYPLTF,IGKV1-16,HK CV38-257,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRIYYGDLGNWNFDLW,IGHV4-34,IGHJ2,CQQYNSYPLTF,IGKV1-16,HK CV38-257,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRIYYGDLGNWNFDLW,IGHV4-34,IGHJ3,CQQYNSYPLTF,IGKV1-16,HK CV38-257,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRIYYGDLGNWNFDLW,IGHV4-34,IGHJ4,CQQYNSYPLTF,IGKV1-16,HK CV38-257,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRIYYGDLGNWNFDLW,IGHV4-34,IGHJ5,CQQYNSYPLTF,IGKV1-16,HK CV38-257,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARRIYYGDLGNWNFDLW,IGHV4-34,IGHJ6,CQQYNSYPLTF,IGKV1-16,HK CV38-257,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLGYCSGGSCFPTGVFGYW,IGHV1-69,IGHJ1,CLLSYSGARSWVF,IGLV7-46,HL CV38-259,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLGYCSGGSCFPTGVFGYW,IGHV1-69,IGHJ2,CLLSYSGARSWVF,IGLV7-46,HL CV38-259,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLGYCSGGSCFPTGVFGYW,IGHV1-69,IGHJ3,CLLSYSGARSWVF,IGLV7-46,HL CV38-259,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLGYCSGGSCFPTGVFGYW,IGHV1-69,IGHJ4,CLLSYSGARSWVF,IGLV7-46,HL CV38-259,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLGYCSGGSCFPTGVFGYW,IGHV1-69,IGHJ5,CLLSYSGARSWVF,IGLV7-46,HL CV38-259,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATLGYCSGGSCFPTGVFGYW,IGHV1-69,IGHJ6,CLLSYSGARSWVF,IGLV7-46,HL CV38-259,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDSW,IGHV4-31,IGHJ1,CQQYNSWPRAF,IGKV3-15,HK CV38-263,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDSW,IGHV4-31,IGHJ2,CQQYNSWPRAF,IGKV3-15,HK CV38-263,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDSW,IGHV4-31,IGHJ3,CQQYNSWPRAF,IGKV3-15,HK CV38-263,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDSW,IGHV4-31,IGHJ4,CQQYNSWPRAF,IGKV3-15,HK CV38-263,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDSW,IGHV4-31,IGHJ5,CQQYNSWPRAF,IGKV3-15,HK CV38-263,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDSW,IGHV4-31,IGHJ6,CQQYNSWPRAF,IGKV3-15,HK CV38-263,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDGHSMVRGVTMWGEFYYYYGMDVW,IGHV3-23,IGHJ1,CQQYNNWPPYTF,IGKV3-15,HK CV38-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDGHSMVRGVTMWGEFYYYYGMDVW,IGHV3-23,IGHJ2,CQQYNNWPPYTF,IGKV3-15,HK CV38-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDGHSMVRGVTMWGEFYYYYGMDVW,IGHV3-23,IGHJ3,CQQYNNWPPYTF,IGKV3-15,HK CV38-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDGHSMVRGVTMWGEFYYYYGMDVW,IGHV3-23,IGHJ4,CQQYNNWPPYTF,IGKV3-15,HK CV38-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDGHSMVRGVTMWGEFYYYYGMDVW,IGHV3-23,IGHJ5,CQQYNNWPPYTF,IGKV3-15,HK CV38-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDGHSMVRGVTMWGEFYYYYGMDVW,IGHV3-23,IGHJ6,CQQYNNWPPYTF,IGKV3-15,HK CV38-265,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRSRWQLTSSAFDMW,IGHV3-9,IGHJ1,CQQLNKYPITF,IGKV1-9,HK CV38-270,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRSRWQLTSSAFDMW,IGHV3-9,IGHJ2,CQQLNKYPITF,IGKV1-9,HK CV38-270,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRSRWQLTSSAFDMW,IGHV3-9,IGHJ3,CQQLNKYPITF,IGKV1-9,HK CV38-270,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRSRWQLTSSAFDMW,IGHV3-9,IGHJ4,CQQLNKYPITF,IGKV1-9,HK CV38-270,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRSRWQLTSSAFDMW,IGHV3-9,IGHJ5,CQQLNKYPITF,IGKV1-9,HK CV38-270,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVRSRWQLTSSAFDMW,IGHV3-9,IGHJ6,CQQLNKYPITF,IGKV1-9,HK CV38-270,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDPW,IGHV4-31,IGHJ1,CQQYNSWPRAF,IGKV3-15,HK CV38-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDPW,IGHV4-31,IGHJ2,CQQYNSWPRAF,IGKV3-15,HK CV38-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDPW,IGHV4-31,IGHJ3,CQQYNSWPRAF,IGKV3-15,HK CV38-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDPW,IGHV4-31,IGHJ4,CQQYNSWPRAF,IGKV3-15,HK CV38-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDPW,IGHV4-31,IGHJ5,CQQYNSWPRAF,IGKV3-15,HK CV38-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREKGTGDYYLDPW,IGHV4-31,IGHJ6,CQQYNSWPRAF,IGKV3-15,HK CV38-271,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYYYDSSGYRNYYYYGMDVW,IGHV1-2,IGHJ1,CSLYTSSSTYVF,IGLV2-18,HL CV38-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYYYDSSGYRNYYYYGMDVW,IGHV1-2,IGHJ2,CSLYTSSSTYVF,IGLV2-18,HL CV38-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYYYDSSGYRNYYYYGMDVW,IGHV1-2,IGHJ3,CSLYTSSSTYVF,IGLV2-18,HL CV38-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYYYDSSGYRNYYYYGMDVW,IGHV1-2,IGHJ4,CSLYTSSSTYVF,IGLV2-18,HL CV38-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYYYDSSGYRNYYYYGMDVW,IGHV1-2,IGHJ5,CSLYTSSSTYVF,IGLV2-18,HL CV38-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYYYDSSGYRNYYYYGMDVW,IGHV1-2,IGHJ6,CSLYTSSSTYVF,IGLV2-18,HL CV38-273,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRGNSITIFGVVIIDRPYW,IGHV3-15,IGHJ1,CQQYGSSF,IGKV3-20,HK CV38-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRGNSITIFGVVIIDRPYW,IGHV3-15,IGHJ2,CQQYGSSF,IGKV3-20,HK CV38-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRGNSITIFGVVIIDRPYW,IGHV3-15,IGHJ3,CQQYGSSF,IGKV3-20,HK CV38-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRGNSITIFGVVIIDRPYW,IGHV3-15,IGHJ4,CQQYGSSF,IGKV3-20,HK CV38-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRGNSITIFGVVIIDRPYW,IGHV3-15,IGHJ5,CQQYGSSF,IGKV3-20,HK CV38-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTDRGNSITIFGVVIIDRPYW,IGHV3-15,IGHJ6,CQQYGSSF,IGKV3-20,HK CV38-275,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEGSPGLDYYGMDVW,IGHV3-21,IGHJ1,CSSYTSNTTLVVF,IGLV2-14,HL CV38-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEGSPGLDYYGMDVW,IGHV3-21,IGHJ2,CSSYTSNTTLVVF,IGLV2-14,HL CV38-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEGSPGLDYYGMDVW,IGHV3-21,IGHJ3,CSSYTSNTTLVVF,IGLV2-14,HL CV38-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEGSPGLDYYGMDVW,IGHV3-21,IGHJ4,CSSYTSNTTLVVF,IGLV2-14,HL CV38-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEGSPGLDYYGMDVW,IGHV3-21,IGHJ5,CSSYTSNTTLVVF,IGLV2-14,HL CV38-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDEGSPGLDYYGMDVW,IGHV3-21,IGHJ6,CSSYTSNTTLVVF,IGLV2-14,HL CV38-276,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ1,CSSYTNTNTLVF,IGLV2-14,HL CV38-278,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ2,CSSYTNTNTLVF,IGLV2-14,HL CV38-278,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ3,CSSYTNTNTLVF,IGLV2-14,HL CV38-278,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ4,CSSYTNTNTLVF,IGLV2-14,HL CV38-278,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ5,CSSYTNTNTLVF,IGLV2-14,HL CV38-278,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKIRVRAGFRWAFDIW,IGHV4-30-4,IGHJ6,CSSYTNTNTLVF,IGLV2-14,HL CV38-278,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMNYKYYYDSSGYPLLDYW,IGHV3-11,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,HL CV38-281,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMNYKYYYDSSGYPLLDYW,IGHV3-11,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,HL CV38-281,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMNYKYYYDSSGYPLLDYW,IGHV3-11,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,HL CV38-281,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMNYKYYYDSSGYPLLDYW,IGHV3-11,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,HL CV38-281,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMNYKYYYDSSGYPLLDYW,IGHV3-11,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,HL CV38-281,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDMNYKYYYDSSGYPLLDYW,IGHV3-11,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,HL CV38-281,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRARYYYDSSATFDYW,IGHV3-49,IGHJ1,CQQCYSLPSTF,IGKV1-39,HK CV38-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRARYYYDSSATFDYW,IGHV3-49,IGHJ2,CQQCYSLPSTF,IGKV1-39,HK CV38-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRARYYYDSSATFDYW,IGHV3-49,IGHJ3,CQQCYSLPSTF,IGKV1-39,HK CV38-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRARYYYDSSATFDYW,IGHV3-49,IGHJ4,CQQCYSLPSTF,IGKV1-39,HK CV38-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRARYYYDSSATFDYW,IGHV3-49,IGHJ5,CQQCYSLPSTF,IGKV1-39,HK CV38-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CIRARYYYDSSATFDYW,IGHV3-49,IGHJ6,CQQCYSLPSTF,IGKV1-39,HK CV38-284,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDASSPVYDFWSGYYNHLGMDVW,IGHV3-30,IGHJ1,CQVWDSSSDQGVF,IGLV3-21,HL CV38-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDASSPVYDFWSGYYNHLGMDVW,IGHV3-30,IGHJ2,CQVWDSSSDQGVF,IGLV3-21,HL CV38-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDASSPVYDFWSGYYNHLGMDVW,IGHV3-30,IGHJ3,CQVWDSSSDQGVF,IGLV3-21,HL CV38-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDASSPVYDFWSGYYNHLGMDVW,IGHV3-30,IGHJ4,CQVWDSSSDQGVF,IGLV3-21,HL CV38-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDASSPVYDFWSGYYNHLGMDVW,IGHV3-30,IGHJ5,CQVWDSSSDQGVF,IGLV3-21,HL CV38-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDASSPVYDFWSGYYNHLGMDVW,IGHV3-30,IGHJ6,CQVWDSSSDQGVF,IGLV3-21,HL CV38-286,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYTVTTGGVDGMDVW,IGHV3-66,IGHJ1,CQQRSNWPPWTF,IGKV3-11,HK CV38-288,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYTVTTGGVDGMDVW,IGHV3-66,IGHJ2,CQQRSNWPPWTF,IGKV3-11,HK CV38-288,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYTVTTGGVDGMDVW,IGHV3-66,IGHJ3,CQQRSNWPPWTF,IGKV3-11,HK CV38-288,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYTVTTGGVDGMDVW,IGHV3-66,IGHJ4,CQQRSNWPPWTF,IGKV3-11,HK CV38-288,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYTVTTGGVDGMDVW,IGHV3-66,IGHJ5,CQQRSNWPPWTF,IGKV3-11,HK CV38-288,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDYTVTTGGVDGMDVW,IGHV3-66,IGHJ6,CQQRSNWPPWTF,IGKV3-11,HK CV38-288,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSRAAVGQPEYW,IGHV3-23,IGHJ1,CQQAYTLPRVTF,IGKV1D-12,HK CV38-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSRAAVGQPEYW,IGHV3-23,IGHJ2,CQQAYTLPRVTF,IGKV1D-12,HK CV38-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSRAAVGQPEYW,IGHV3-23,IGHJ3,CQQAYTLPRVTF,IGKV1D-12,HK CV38-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSRAAVGQPEYW,IGHV3-23,IGHJ4,CQQAYTLPRVTF,IGKV1D-12,HK CV38-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSRAAVGQPEYW,IGHV3-23,IGHJ5,CQQAYTLPRVTF,IGKV1D-12,HK CV38-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVSRAAVGQPEYW,IGHV3-23,IGHJ6,CQQAYTLPRVTF,IGKV1D-12,HK CV38-289,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSRFYDYWNTFGLLLGSGLTFYHMDVW,IGHV3-49,IGHJ1,CQQYCYTPWTF,IGKV4-1,HK CV48-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSRFYDYWNTFGLLLGSGLTFYHMDVW,IGHV3-49,IGHJ2,CQQYCYTPWTF,IGKV4-1,HK CV48-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSRFYDYWNTFGLLLGSGLTFYHMDVW,IGHV3-49,IGHJ3,CQQYCYTPWTF,IGKV4-1,HK CV48-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSRFYDYWNTFGLLLGSGLTFYHMDVW,IGHV3-49,IGHJ4,CQQYCYTPWTF,IGKV4-1,HK CV48-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSRFYDYWNTFGLLLGSGLTFYHMDVW,IGHV3-49,IGHJ5,CQQYCYTPWTF,IGKV4-1,HK CV48-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSRFYDYWNTFGLLLGSGLTFYHMDVW,IGHV3-49,IGHJ6,CQQYCYTPWTF,IGKV4-1,HK CV48-103,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGQQLVRGWFDPW,IGHV1-69,IGHJ1,CSSYTSSSTLYVF,IGLV2-14,HL CV48-104,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGQQLVRGWFDPW,IGHV1-69,IGHJ2,CSSYTSSSTLYVF,IGLV2-14,HL CV48-104,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGQQLVRGWFDPW,IGHV1-69,IGHJ3,CSSYTSSSTLYVF,IGLV2-14,HL CV48-104,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGQQLVRGWFDPW,IGHV1-69,IGHJ4,CSSYTSSSTLYVF,IGLV2-14,HL CV48-104,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGQQLVRGWFDPW,IGHV1-69,IGHJ5,CSSYTSSSTLYVF,IGLV2-14,HL CV48-104,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGQQLVRGWFDPW,IGHV1-69,IGHJ6,CSSYTSSSTLYVF,IGLV2-14,HL CV48-104,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASENDYGEHDYW,IGHV4-39,IGHJ1,CETWDSNTRKVVF,IGKV4-60,HL CV48-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASENDYGEHDYW,IGHV4-39,IGHJ2,CETWDSNTRKVVF,IGKV4-60,HL CV48-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASENDYGEHDYW,IGHV4-39,IGHJ3,CETWDSNTRKVVF,IGKV4-60,HL CV48-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASENDYGEHDYW,IGHV4-39,IGHJ4,CETWDSNTRKVVF,IGKV4-60,HL CV48-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASENDYGEHDYW,IGHV4-39,IGHJ5,CETWDSNTRKVVF,IGKV4-60,HL CV48-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASENDYGEHDYW,IGHV4-39,IGHJ6,CETWDSNTRKVVF,IGKV4-60,HL CV48-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGDTSAYWPSSLLISW,IGHV3-30,IGHJ1,CGSYATGSSPVVF,IGLV2-14,HL CV48-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGDTSAYWPSSLLISW,IGHV3-30,IGHJ2,CGSYATGSSPVVF,IGLV2-14,HL CV48-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGDTSAYWPSSLLISW,IGHV3-30,IGHJ3,CGSYATGSSPVVF,IGLV2-14,HL CV48-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGDTSAYWPSSLLISW,IGHV3-30,IGHJ4,CGSYATGSSPVVF,IGLV2-14,HL CV48-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGDTSAYWPSSLLISW,IGHV3-30,IGHJ5,CGSYATGSSPVVF,IGLV2-14,HL CV48-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGDTSAYWPSSLLISW,IGHV3-30,IGHJ6,CGSYATGSSPVVF,IGLV2-14,HL CV48-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDARYSAYELPDYFFDLW,IGHV3-33,IGHJ1,CQQYKGSSWATF,IGKV1-5,HK CV48-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDARYSAYELPDYFFDLW,IGHV3-33,IGHJ2,CQQYKGSSWATF,IGKV1-5,HK CV48-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDARYSAYELPDYFFDLW,IGHV3-33,IGHJ3,CQQYKGSSWATF,IGKV1-5,HK CV48-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDARYSAYELPDYFFDLW,IGHV3-33,IGHJ4,CQQYKGSSWATF,IGKV1-5,HK CV48-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDARYSAYELPDYFFDLW,IGHV3-33,IGHJ5,CQQYKGSSWATF,IGKV1-5,HK CV48-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDARYSAYELPDYFFDLW,IGHV3-33,IGHJ6,CQQYKGSSWATF,IGKV1-5,HK CV48-110,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ1,CQTWGTGINVVF,IGLV4-69,HL CV48-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ2,CQTWGTGINVVF,IGLV4-69,HL CV48-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ3,CQTWGTGINVVF,IGLV4-69,HL CV48-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ4,CQTWGTGINVVF,IGLV4-69,HL CV48-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ5,CQTWGTGINVVF,IGLV4-69,HL CV48-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDGLDDDYIWGSFKIRYYYMDVW,IGHV3-33,IGHJ6,CQTWGTGINVVF,IGLV4-69,HL CV48-113,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTDRHWNHCDW,IGHV3-23,IGHJ1,CSSYTGSSTLVAF,IGLV2-14,HL CV48-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTDRHWNHCDW,IGHV3-23,IGHJ2,CSSYTGSSTLVAF,IGLV2-14,HL CV48-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTDRHWNHCDW,IGHV3-23,IGHJ3,CSSYTGSSTLVAF,IGLV2-14,HL CV48-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTDRHWNHCDW,IGHV3-23,IGHJ4,CSSYTGSSTLVAF,IGLV2-14,HL CV48-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTDRHWNHCDW,IGHV3-23,IGHJ5,CSSYTGSSTLVAF,IGLV2-14,HL CV48-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTDRHWNHCDW,IGHV3-23,IGHJ6,CSSYTGSSTLVAF,IGLV2-14,HL CV48-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNGGGLDQW,IGHV1-3,IGHJ1,CCSSTTSSTAVF,IGLV2-14,HL CV48-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNGGGLDQW,IGHV1-3,IGHJ2,CCSSTTSSTAVF,IGLV2-14,HL CV48-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNGGGLDQW,IGHV1-3,IGHJ3,CCSSTTSSTAVF,IGLV2-14,HL CV48-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNGGGLDQW,IGHV1-3,IGHJ4,CCSSTTSSTAVF,IGLV2-14,HL CV48-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNGGGLDQW,IGHV1-3,IGHJ5,CCSSTTSSTAVF,IGLV2-14,HL CV48-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARNGGGLDQW,IGHV1-3,IGHJ6,CCSSTTSSTAVF,IGLV2-14,HL CV48-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSPRPLIVVAEDGMDVW,IGHV1-69,IGHJ1,CQQYGSSPFTF,IGKV3-20,HK CV-X1-102,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSPRPLIVVAEDGMDVW,IGHV1-69,IGHJ2,CQQYGSSPFTF,IGKV3-20,HK CV-X1-102,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSPRPLIVVAEDGMDVW,IGHV1-69,IGHJ3,CQQYGSSPFTF,IGKV3-20,HK CV-X1-102,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSPRPLIVVAEDGMDVW,IGHV1-69,IGHJ4,CQQYGSSPFTF,IGKV3-20,HK CV-X1-102,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSPRPLIVVAEDGMDVW,IGHV1-69,IGHJ5,CQQYGSSPFTF,IGKV3-20,HK CV-X1-102,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSPRPLIVVAEDGMDVW,IGHV1-69,IGHJ6,CQQYGSSPFTF,IGKV3-20,HK CV-X1-102,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPLFWDTAMANFDYW,IGHV1-2,IGHJ1,,IGLV2-14,HL CV-X1-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPLFWDTAMANFDYW,IGHV1-2,IGHJ2,,IGLV2-14,HL CV-X1-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPLFWDTAMANFDYW,IGHV1-2,IGHJ3,,IGLV2-14,HL CV-X1-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPLFWDTAMANFDYW,IGHV1-2,IGHJ4,,IGLV2-14,HL CV-X1-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPLFWDTAMANFDYW,IGHV1-2,IGHJ5,,IGLV2-14,HL CV-X1-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGPLFWDTAMANFDYW,IGHV1-2,IGHJ6,,IGLV2-14,HL CV-X1-109,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CNRELHNSVVVGVMGYW,IGHV3-49,IGHJ1,CHHYYSPPYAF,IGKV4-1,HK CV-X1-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CNRELHNSVVVGVMGYW,IGHV3-49,IGHJ2,CHHYYSPPYAF,IGKV4-1,HK CV-X1-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CNRELHNSVVVGVMGYW,IGHV3-49,IGHJ3,CHHYYSPPYAF,IGKV4-1,HK CV-X1-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CNRELHNSVVVGVMGYW,IGHV3-49,IGHJ4,CHHYYSPPYAF,IGKV4-1,HK CV-X1-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CNRELHNSVVVGVMGYW,IGHV3-49,IGHJ5,CHHYYSPPYAF,IGKV4-1,HK CV-X1-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CNRELHNSVVVGVMGYW,IGHV3-49,IGHJ6,CHHYYSPPYAF,IGKV4-1,HK CV-X1-111,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGSGWYAFDYW,IGHV3-23,IGHJ1,CQQYNKWPRTF,IGKV3-15,HK CV-X1-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGSGWYAFDYW,IGHV3-23,IGHJ2,CQQYNKWPRTF,IGKV3-15,HK CV-X1-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGSGWYAFDYW,IGHV3-23,IGHJ3,CQQYNKWPRTF,IGKV3-15,HK CV-X1-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGSGWYAFDYW,IGHV3-23,IGHJ4,CQQYNKWPRTF,IGKV3-15,HK CV-X1-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGSGWYAFDYW,IGHV3-23,IGHJ5,CQQYNKWPRTF,IGKV3-15,HK CV-X1-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKVGSGWYAFDYW,IGHV3-23,IGHJ6,CQQYNKWPRTF,IGKV3-15,HK CV-X1-112,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRIMPLSYYYYYGMDVW,IGHV4-59,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,HL CV-X1-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRIMPLSYYYYYGMDVW,IGHV4-59,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,HL CV-X1-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRIMPLSYYYYYGMDVW,IGHV4-59,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,HL CV-X1-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRIMPLSYYYYYGMDVW,IGHV4-59,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,HL CV-X1-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRIMPLSYYYYYGMDVW,IGHV4-59,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,HL CV-X1-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRIMPLSYYYYYGMDVW,IGHV4-59,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,HL CV-X1-119,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSEGGMDVW,IGHV3-53,IGHJ1,CQQANGFPPLF,IGKV1-12,HK CV-X1-126,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSEGGMDVW,IGHV3-53,IGHJ2,CQQANGFPPLF,IGKV1-12,HK CV-X1-126,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSEGGMDVW,IGHV3-53,IGHJ3,CQQANGFPPLF,IGKV1-12,HK CV-X1-126,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSEGGMDVW,IGHV3-53,IGHJ4,CQQANGFPPLF,IGKV1-12,HK CV-X1-126,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSEGGMDVW,IGHV3-53,IGHJ5,CQQANGFPPLF,IGKV1-12,HK CV-X1-126,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLSEGGMDVW,IGHV3-53,IGHJ6,CQQANGFPPLF,IGKV1-12,HK CV-X1-126,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYDFWSGFDYYGMDVW,IGHV5-51,IGHJ1,CQQRSNWPTF,IGKV3-11,HK CV-X1-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYDFWSGFDYYGMDVW,IGHV5-51,IGHJ2,CQQRSNWPTF,IGKV3-11,HK CV-X1-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYDFWSGFDYYGMDVW,IGHV5-51,IGHJ3,CQQRSNWPTF,IGKV3-11,HK CV-X1-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYDFWSGFDYYGMDVW,IGHV5-51,IGHJ4,CQQRSNWPTF,IGKV3-11,HK CV-X1-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYDFWSGFDYYGMDVW,IGHV5-51,IGHJ5,CQQRSNWPTF,IGKV3-11,HK CV-X1-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARTYDFWSGFDYYGMDVW,IGHV5-51,IGHJ6,CQQRSNWPTF,IGKV3-11,HK CV-X1-128,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMATTYPEHDPSLYW,IGHV3-30,IGHJ1,CQVWDSSSDHWVF,IGLV3-21,HL CV-X1-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMATTYPEHDPSLYW,IGHV3-30,IGHJ2,CQVWDSSSDHWVF,IGLV3-21,HL CV-X1-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMATTYPEHDPSLYW,IGHV3-30,IGHJ3,CQVWDSSSDHWVF,IGLV3-21,HL CV-X1-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMATTYPEHDPSLYW,IGHV3-30,IGHJ4,CQVWDSSSDHWVF,IGLV3-21,HL CV-X1-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMATTYPEHDPSLYW,IGHV3-30,IGHJ5,CQVWDSSSDHWVF,IGLV3-21,HL CV-X1-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARMATTYPEHDPSLYW,IGHV3-30,IGHJ6,CQVWDSSSDHWVF,IGLV3-21,HL CV-X1-131,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAWRGFAATGFDSW,IGHV4-31,IGHJ1,CQQLKSYPLTF,IGKV1-9,HK CV-X1-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAWRGFAATGFDSW,IGHV4-31,IGHJ2,CQQLKSYPLTF,IGKV1-9,HK CV-X1-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAWRGFAATGFDSW,IGHV4-31,IGHJ3,CQQLKSYPLTF,IGKV1-9,HK CV-X1-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAWRGFAATGFDSW,IGHV4-31,IGHJ4,CQQLKSYPLTF,IGKV1-9,HK CV-X1-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAWRGFAATGFDSW,IGHV4-31,IGHJ5,CQQLKSYPLTF,IGKV1-9,HK CV-X1-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAAWRGFAATGFDSW,IGHV4-31,IGHJ6,CQQLKSYPLTF,IGKV1-9,HK CV-X1-136,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATEGTILTTMTAGAFDLW,IGHV1-8,IGHJ1,CQQTDNFPYTF,IGKV1-12,HK CV-X1-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATEGTILTTMTAGAFDLW,IGHV1-8,IGHJ2,CQQTDNFPYTF,IGKV1-12,HK CV-X1-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATEGTILTTMTAGAFDLW,IGHV1-8,IGHJ3,CQQTDNFPYTF,IGKV1-12,HK CV-X1-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATEGTILTTMTAGAFDLW,IGHV1-8,IGHJ4,CQQTDNFPYTF,IGKV1-12,HK CV-X1-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATEGTILTTMTAGAFDLW,IGHV1-8,IGHJ5,CQQTDNFPYTF,IGKV1-12,HK CV-X1-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATEGTILTTMTAGAFDLW,IGHV1-8,IGHJ6,CQQTDNFPYTF,IGKV1-12,HK CV-X1-137,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFGGTSQSSGYYGFDNW,IGHV1-69,IGHJ1,CMQPLQTPYTF,IGKV2-28,HK CV-X1-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFGGTSQSSGYYGFDNW,IGHV1-69,IGHJ2,CMQPLQTPYTF,IGKV2-28,HK CV-X1-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFGGTSQSSGYYGFDNW,IGHV1-69,IGHJ3,CMQPLQTPYTF,IGKV2-28,HK CV-X1-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFGGTSQSSGYYGFDNW,IGHV1-69,IGHJ4,CMQPLQTPYTF,IGKV2-28,HK CV-X1-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFGGTSQSSGYYGFDNW,IGHV1-69,IGHJ5,CMQPLQTPYTF,IGKV2-28,HK CV-X1-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARFGGTSQSSGYYGFDNW,IGHV1-69,IGHJ6,CMQPLQTPYTF,IGKV2-28,HK CV-X1-140,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTHDFPDWPPGGGMDVW,IGHV3-23,IGHJ1,CQSYDWSNQGVF,IGLV6-57,HL CV-X1-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTHDFPDWPPGGGMDVW,IGHV3-23,IGHJ2,CQSYDWSNQGVF,IGLV6-57,HL CV-X1-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTHDFPDWPPGGGMDVW,IGHV3-23,IGHJ3,CQSYDWSNQGVF,IGLV6-57,HL CV-X1-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTHDFPDWPPGGGMDVW,IGHV3-23,IGHJ4,CQSYDWSNQGVF,IGLV6-57,HL CV-X1-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTHDFPDWPPGGGMDVW,IGHV3-23,IGHJ5,CQSYDWSNQGVF,IGLV6-57,HL CV-X1-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVTHDFPDWPPGGGMDVW,IGHV3-23,IGHJ6,CQSYDWSNQGVF,IGLV6-57,HL CV-X1-141,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSTRGMAPHDYW,IGHV1-18,IGHJ1,CHQTYDTWTF,IGKV1-39,HK CV-X1-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSTRGMAPHDYW,IGHV1-18,IGHJ2,CHQTYDTWTF,IGKV1-39,HK CV-X1-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSTRGMAPHDYW,IGHV1-18,IGHJ3,CHQTYDTWTF,IGKV1-39,HK CV-X1-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSTRGMAPHDYW,IGHV1-18,IGHJ4,CHQTYDTWTF,IGKV1-39,HK CV-X1-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSTRGMAPHDYW,IGHV1-18,IGHJ5,CHQTYDTWTF,IGKV1-39,HK CV-X1-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CSTRGMAPHDYW,IGHV1-18,IGHJ6,CHQTYDTWTF,IGKV1-39,HK CV-X1-142,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSTRFDYW,IGHV3-11,IGHJ1,CQQYDNLPLTF,IGKV1-33,HK CV-X1-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSTRFDYW,IGHV3-11,IGHJ2,CQQYDNLPLTF,IGKV1-33,HK CV-X1-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSTRFDYW,IGHV3-11,IGHJ3,CQQYDNLPLTF,IGKV1-33,HK CV-X1-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSTRFDYW,IGHV3-11,IGHJ4,CQQYDNLPLTF,IGKV1-33,HK CV-X1-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSTRFDYW,IGHV3-11,IGHJ5,CQQYDNLPLTF,IGKV1-33,HK CV-X1-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDLGYSTRFDYW,IGHV3-11,IGHJ6,CQQYDNLPLTF,IGKV1-33,HK CV-X1-143,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDLTGPDYW,IGHV5-51,IGHJ1,CMQGTHWPNTF,IGKV2-30,HK CV-X1-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDLTGPDYW,IGHV5-51,IGHJ2,CMQGTHWPNTF,IGKV2-30,HK CV-X1-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDLTGPDYW,IGHV5-51,IGHJ3,CMQGTHWPNTF,IGKV2-30,HK CV-X1-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDLTGPDYW,IGHV5-51,IGHJ4,CMQGTHWPNTF,IGKV2-30,HK CV-X1-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDLTGPDYW,IGHV5-51,IGHJ5,CMQGTHWPNTF,IGKV2-30,HK CV-X1-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAREDLTGPDYW,IGHV5-51,IGHJ6,CMQGTHWPNTF,IGKV2-30,HK CV-X1-145,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANNYYDNSGPDYW,IGHV3-23,IGHJ1,CQSNDGSPSWVF,IGLV6-57,HL CV-X1-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANNYYDNSGPDYW,IGHV3-23,IGHJ2,CQSNDGSPSWVF,IGLV6-57,HL CV-X1-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANNYYDNSGPDYW,IGHV3-23,IGHJ3,CQSNDGSPSWVF,IGLV6-57,HL CV-X1-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANNYYDNSGPDYW,IGHV3-23,IGHJ4,CQSNDGSPSWVF,IGLV6-57,HL CV-X1-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANNYYDNSGPDYW,IGHV3-23,IGHJ5,CQSNDGSPSWVF,IGLV6-57,HL CV-X1-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANNYYDNSGPDYW,IGHV3-23,IGHJ6,CQSNDGSPSWVF,IGLV6-57,HL CV-X1-146,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLVCGGSCYPFDYW,IGHV5-51,IGHJ1,CQVWDSSSDHQVF,IGLV3-21,HL CV-X1-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLVCGGSCYPFDYW,IGHV5-51,IGHJ2,CQVWDSSSDHQVF,IGLV3-21,HL CV-X1-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLVCGGSCYPFDYW,IGHV5-51,IGHJ3,CQVWDSSSDHQVF,IGLV3-21,HL CV-X1-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLVCGGSCYPFDYW,IGHV5-51,IGHJ4,CQVWDSSSDHQVF,IGLV3-21,HL CV-X1-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLVCGGSCYPFDYW,IGHV5-51,IGHJ5,CQVWDSSSDHQVF,IGLV3-21,HL CV-X1-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARHLVCGGSCYPFDYW,IGHV5-51,IGHJ6,CQVWDSSSDHQVF,IGLV3-21,HL CV-X1-150,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWFWRLGGVDYW,IGHV3-33,IGHJ1,CVLYMGSGLVVF,IGLV8-61,HL CV-X1-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWFWRLGGVDYW,IGHV3-33,IGHJ2,CVLYMGSGLVVF,IGLV8-61,HL CV-X1-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWFWRLGGVDYW,IGHV3-33,IGHJ3,CVLYMGSGLVVF,IGLV8-61,HL CV-X1-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWFWRLGGVDYW,IGHV3-33,IGHJ4,CVLYMGSGLVVF,IGLV8-61,HL CV-X1-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWFWRLGGVDYW,IGHV3-33,IGHJ5,CVLYMGSGLVVF,IGLV8-61,HL CV-X1-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDWFWRLGGVDYW,IGHV3-33,IGHJ6,CVLYMGSGLVVF,IGLV8-61,HL CV-X1-153,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSYYDPSSAYSAHYAMDVW,IGHV3-48,IGHJ1,CTSYTSLSPVVF,IGLV2-14,HL CV-X1-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSYYDPSSAYSAHYAMDVW,IGHV3-48,IGHJ2,CTSYTSLSPVVF,IGLV2-14,HL CV-X1-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSYYDPSSAYSAHYAMDVW,IGHV3-48,IGHJ3,CTSYTSLSPVVF,IGLV2-14,HL CV-X1-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSYYDPSSAYSAHYAMDVW,IGHV3-48,IGHJ4,CTSYTSLSPVVF,IGLV2-14,HL CV-X1-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSYYDPSSAYSAHYAMDVW,IGHV3-48,IGHJ5,CTSYTSLSPVVF,IGLV2-14,HL CV-X1-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATSYYDPSSAYSAHYAMDVW,IGHV3-48,IGHJ6,CTSYTSLSPVVF,IGLV2-14,HL CV-X1-157,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSFGGFGGNYGMDVW,IGHV1-2,IGHJ1,CQQSYSTPITF,IGKV1-39,HK CV-X1-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSFGGFGGNYGMDVW,IGHV1-2,IGHJ2,CQQSYSTPITF,IGKV1-39,HK CV-X1-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSFGGFGGNYGMDVW,IGHV1-2,IGHJ3,CQQSYSTPITF,IGKV1-39,HK CV-X1-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSFGGFGGNYGMDVW,IGHV1-2,IGHJ4,CQQSYSTPITF,IGKV1-39,HK CV-X1-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSFGGFGGNYGMDVW,IGHV1-2,IGHJ5,CQQSYSTPITF,IGKV1-39,HK CV-X1-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARSFGGFGGNYGMDVW,IGHV1-2,IGHJ6,CQQSYSTPITF,IGKV1-39,HK CV-X1-164,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPIGTGSDYW,IGHV3-48,IGHJ1,CGTWDSSLNAGVF,IGLV1-51,HL CV-X1-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPIGTGSDYW,IGHV3-48,IGHJ2,CGTWDSSLNAGVF,IGLV1-51,HL CV-X1-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPIGTGSDYW,IGHV3-48,IGHJ3,CGTWDSSLNAGVF,IGLV1-51,HL CV-X1-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPIGTGSDYW,IGHV3-48,IGHJ4,CGTWDSSLNAGVF,IGLV1-51,HL CV-X1-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPIGTGSDYW,IGHV3-48,IGHJ5,CGTWDSSLNAGVF,IGLV1-51,HL CV-X1-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDPIGTGSDYW,IGHV3-48,IGHJ6,CGTWDSSLNAGVF,IGLV1-51,HL CV-X1-165,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAHSTTLYGWFDPW,IGHV3-74,IGHJ1,CQHYVSSPLTF,IGKV3-20,HK CV-X1-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAHSTTLYGWFDPW,IGHV3-74,IGHJ2,CQHYVSSPLTF,IGKV3-20,HK CV-X1-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAHSTTLYGWFDPW,IGHV3-74,IGHJ3,CQHYVSSPLTF,IGKV3-20,HK CV-X1-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAHSTTLYGWFDPW,IGHV3-74,IGHJ4,CQHYVSSPLTF,IGKV3-20,HK CV-X1-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAHSTTLYGWFDPW,IGHV3-74,IGHJ5,CQHYVSSPLTF,IGKV3-20,HK CV-X1-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAHSTTLYGWFDPW,IGHV3-74,IGHJ6,CQHYVSSPLTF,IGKV3-20,HK CV-X1-167,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFRKGSTFNW,IGHV4-34,IGHJ1,CSSYTTSNTREF,IGLV2-14,HL CV-X1-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFRKGSTFNW,IGHV4-34,IGHJ2,CSSYTTSNTREF,IGLV2-14,HL CV-X1-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFRKGSTFNW,IGHV4-34,IGHJ3,CSSYTTSNTREF,IGLV2-14,HL CV-X1-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFRKGSTFNW,IGHV4-34,IGHJ4,CSSYTTSNTREF,IGLV2-14,HL CV-X1-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFRKGSTFNW,IGHV4-34,IGHJ5,CSSYTTSNTREF,IGLV2-14,HL CV-X1-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGFRKGSTFNW,IGHV4-34,IGHJ6,CSSYTTSNTREF,IGLV2-14,HL CV-X1-171,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLTIFGVAIDYYGMDVW,IGHV3-48,IGHJ1,CQQANSFPALTF,IGKV1-12,HK CV-X1-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLTIFGVAIDYYGMDVW,IGHV3-48,IGHJ2,CQQANSFPALTF,IGKV1-12,HK CV-X1-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLTIFGVAIDYYGMDVW,IGHV3-48,IGHJ3,CQQANSFPALTF,IGKV1-12,HK CV-X1-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLTIFGVAIDYYGMDVW,IGHV3-48,IGHJ4,CQQANSFPALTF,IGKV1-12,HK CV-X1-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLTIFGVAIDYYGMDVW,IGHV3-48,IGHJ5,CQQANSFPALTF,IGKV1-12,HK CV-X1-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRLTIFGVAIDYYGMDVW,IGHV3-48,IGHJ6,CQQANSFPALTF,IGKV1-12,HK CV-X1-172,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYDSALCTGGTCTFDAFDFW,IGHV3-30,IGHJ1,CQNYNSAPPWTF,IGKV1-27,HK CV-X1-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYDSALCTGGTCTFDAFDFW,IGHV3-30,IGHJ2,CQNYNSAPPWTF,IGKV1-27,HK CV-X1-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYDSALCTGGTCTFDAFDFW,IGHV3-30,IGHJ3,CQNYNSAPPWTF,IGKV1-27,HK CV-X1-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYDSALCTGGTCTFDAFDFW,IGHV3-30,IGHJ4,CQNYNSAPPWTF,IGKV1-27,HK CV-X1-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYDSALCTGGTCTFDAFDFW,IGHV3-30,IGHJ5,CQNYNSAPPWTF,IGKV1-27,HK CV-X1-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKDYDSALCTGGTCTFDAFDFW,IGHV3-30,IGHJ6,CQNYNSAPPWTF,IGKV1-27,HK CV-X1-173,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATVQGDYVAGRAYYYGMDVW,IGHV3-21,IGHJ1,CQAWDSSTAVF,IGLV3-1,HL CV-X1-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATVQGDYVAGRAYYYGMDVW,IGHV3-21,IGHJ2,CQAWDSSTAVF,IGLV3-1,HL CV-X1-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATVQGDYVAGRAYYYGMDVW,IGHV3-21,IGHJ3,CQAWDSSTAVF,IGLV3-1,HL CV-X1-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATVQGDYVAGRAYYYGMDVW,IGHV3-21,IGHJ4,CQAWDSSTAVF,IGLV3-1,HL CV-X1-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATVQGDYVAGRAYYYGMDVW,IGHV3-21,IGHJ5,CQAWDSSTAVF,IGLV3-1,HL CV-X1-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATVQGDYVAGRAYYYGMDVW,IGHV3-21,IGHJ6,CQAWDSSTAVF,IGLV3-1,HL CV-X1-174,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLQGTHLDCW,IGHV1-69,IGHJ1,CQQYYSTGFTF,IGKV4-1,HK CV-X1-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLQGTHLDCW,IGHV1-69,IGHJ2,CQQYYSTGFTF,IGKV4-1,HK CV-X1-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLQGTHLDCW,IGHV1-69,IGHJ3,CQQYYSTGFTF,IGKV4-1,HK CV-X1-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLQGTHLDCW,IGHV1-69,IGHJ4,CQQYYSTGFTF,IGKV4-1,HK CV-X1-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLQGTHLDCW,IGHV1-69,IGHJ5,CQQYYSTGFTF,IGKV4-1,HK CV-X1-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGLQGTHLDCW,IGHV1-69,IGHJ6,CQQYYSTGFTF,IGKV4-1,HK CV-X1-175,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAETPASEIDYW,IGHV3-30,IGHJ1,CQAWDSSHVVF,IGLV3-1,HL CV-X1-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAETPASEIDYW,IGHV3-30,IGHJ2,CQAWDSSHVVF,IGLV3-1,HL CV-X1-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAETPASEIDYW,IGHV3-30,IGHJ3,CQAWDSSHVVF,IGLV3-1,HL CV-X1-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAETPASEIDYW,IGHV3-30,IGHJ4,CQAWDSSHVVF,IGLV3-1,HL CV-X1-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAETPASEIDYW,IGHV3-30,IGHJ5,CQAWDSSHVVF,IGLV3-1,HL CV-X1-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARAETPASEIDYW,IGHV3-30,IGHJ6,CQAWDSSHVVF,IGLV3-1,HL CV-X1-177,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDRPIDYGDLHIYYYGLDVW,IGHV3-49,IGHJ1,CMQALQTPPTF,IGKV2-28,HK CV-X1-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDRPIDYGDLHIYYYGLDVW,IGHV3-49,IGHJ2,CMQALQTPPTF,IGKV2-28,HK CV-X1-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDRPIDYGDLHIYYYGLDVW,IGHV3-49,IGHJ3,CMQALQTPPTF,IGKV2-28,HK CV-X1-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDRPIDYGDLHIYYYGLDVW,IGHV3-49,IGHJ4,CMQALQTPPTF,IGKV2-28,HK CV-X1-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDRPIDYGDLHIYYYGLDVW,IGHV3-49,IGHJ5,CMQALQTPPTF,IGKV2-28,HK CV-X1-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRDRPIDYGDLHIYYYGLDVW,IGHV3-49,IGHJ6,CMQALQTPPTF,IGKV2-28,HK CV-X1-178,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLKDRTLQGNWFDPW,IGHV4-39,IGHJ1,CQQRRDWPPVTF,IGKV3-11,HK CV-X1-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLKDRTLQGNWFDPW,IGHV4-39,IGHJ2,CQQRRDWPPVTF,IGKV3-11,HK CV-X1-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLKDRTLQGNWFDPW,IGHV4-39,IGHJ3,CQQRRDWPPVTF,IGKV3-11,HK CV-X1-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLKDRTLQGNWFDPW,IGHV4-39,IGHJ4,CQQRRDWPPVTF,IGKV3-11,HK CV-X1-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLKDRTLQGNWFDPW,IGHV4-39,IGHJ5,CQQRRDWPPVTF,IGKV3-11,HK CV-X1-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CLKDRTLQGNWFDPW,IGHV4-39,IGHJ6,CQQRRDWPPVTF,IGKV3-11,HK CV-X1-180,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASKSPERGSFDYW,IGHV3-30,IGHJ1,CSSYTNGSSLYVF,IGLV2-14,HL CV-X1-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASKSPERGSFDYW,IGHV3-30,IGHJ2,CSSYTNGSSLYVF,IGLV2-14,HL CV-X1-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASKSPERGSFDYW,IGHV3-30,IGHJ3,CSSYTNGSSLYVF,IGLV2-14,HL CV-X1-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASKSPERGSFDYW,IGHV3-30,IGHJ4,CSSYTNGSSLYVF,IGLV2-14,HL CV-X1-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASKSPERGSFDYW,IGHV3-30,IGHJ5,CSSYTNGSSLYVF,IGLV2-14,HL CV-X1-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CASKSPERGSFDYW,IGHV3-30,IGHJ6,CSSYTNGSSLYVF,IGLV2-14,HL CV-X1-183,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGPIVAW,IGHV4-4,IGHJ1,CETWDSNTRLF,IGKV4-60,HL CV-X1-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGPIVAW,IGHV4-4,IGHJ2,CETWDSNTRLF,IGKV4-60,HL CV-X1-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGPIVAW,IGHV4-4,IGHJ3,CETWDSNTRLF,IGKV4-60,HL CV-X1-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGPIVAW,IGHV4-4,IGHJ4,CETWDSNTRLF,IGKV4-60,HL CV-X1-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGPIVAW,IGHV4-4,IGHJ5,CETWDSNTRLF,IGKV4-60,HL CV-X1-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGGGPIVAW,IGHV4-4,IGHJ6,CETWDSNTRLF,IGKV4-60,HL CV-X1-188,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRRYYDFWSGPMPYGMDVW,IGHV3-23,IGHJ1,CSSYTSSSTLGVF,IGLV2-14,HL CV-X1-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRRYYDFWSGPMPYGMDVW,IGHV3-23,IGHJ2,CSSYTSSSTLGVF,IGLV2-14,HL CV-X1-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRRYYDFWSGPMPYGMDVW,IGHV3-23,IGHJ3,CSSYTSSSTLGVF,IGLV2-14,HL CV-X1-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRRYYDFWSGPMPYGMDVW,IGHV3-23,IGHJ4,CSSYTSSSTLGVF,IGLV2-14,HL CV-X1-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRRYYDFWSGPMPYGMDVW,IGHV3-23,IGHJ5,CSSYTSSSTLGVF,IGLV2-14,HL CV-X1-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKGRRYYDFWSGPMPYGMDVW,IGHV3-23,IGHJ6,CSSYTSSSTLGVF,IGLV2-14,HL CV-X1-189,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANTSPGRGSFDYW,IGHV3-30,IGHJ1,CSSYTNSSTLYVF,IGLV2-14,HL CV-X1-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANTSPGRGSFDYW,IGHV3-30,IGHJ2,CSSYTNSSTLYVF,IGLV2-14,HL CV-X1-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANTSPGRGSFDYW,IGHV3-30,IGHJ3,CSSYTNSSTLYVF,IGLV2-14,HL CV-X1-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANTSPGRGSFDYW,IGHV3-30,IGHJ4,CSSYTNSSTLYVF,IGLV2-14,HL CV-X1-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANTSPGRGSFDYW,IGHV3-30,IGHJ5,CSSYTNSSTLYVF,IGLV2-14,HL CV-X1-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CANTSPGRGSFDYW,IGHV3-30,IGHJ6,CSSYTNSSTLYVF,IGLV2-14,HL CV-X1-190,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQLRFLEWQYFDYW,IGHV4-31,IGHJ1,CQQYDNLLTF,IGKV1-33,HK CV-X1-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQLRFLEWQYFDYW,IGHV4-31,IGHJ2,CQQYDNLLTF,IGKV1-33,HK CV-X1-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQLRFLEWQYFDYW,IGHV4-31,IGHJ3,CQQYDNLLTF,IGKV1-33,HK CV-X1-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQLRFLEWQYFDYW,IGHV4-31,IGHJ4,CQQYDNLLTF,IGKV1-33,HK CV-X1-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQLRFLEWQYFDYW,IGHV4-31,IGHJ5,CQQYDNLLTF,IGKV1-33,HK CV-X1-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARQLRFLEWQYFDYW,IGHV4-31,IGHJ6,CQQYDNLLTF,IGKV1-33,HK CV-X1-191,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGWGVKASSLGGDYW,IGHV3-64,IGHJ1,CHQRSDWPRLTF,IGKV3-11,HK CV-X1-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGWGVKASSLGGDYW,IGHV3-64,IGHJ2,CHQRSDWPRLTF,IGKV3-11,HK CV-X1-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGWGVKASSLGGDYW,IGHV3-64,IGHJ3,CHQRSDWPRLTF,IGKV3-11,HK CV-X1-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGWGVKASSLGGDYW,IGHV3-64,IGHJ4,CHQRSDWPRLTF,IGKV3-11,HK CV-X1-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGWGVKASSLGGDYW,IGHV3-64,IGHJ5,CHQRSDWPRLTF,IGKV3-11,HK CV-X1-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CVKGWGVKASSLGGDYW,IGHV3-64,IGHJ6,CHQRSDWPRLTF,IGKV3-11,HK CV-X1-195,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWRLGQDWFDPW,IGHV3-15,IGHJ1,CQQSYSAPLTF,IGKV1-39,HK CV-X2-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWRLGQDWFDPW,IGHV3-15,IGHJ2,CQQSYSAPLTF,IGKV1-39,HK CV-X2-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWRLGQDWFDPW,IGHV3-15,IGHJ3,CQQSYSAPLTF,IGKV1-39,HK CV-X2-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWRLGQDWFDPW,IGHV3-15,IGHJ4,CQQSYSAPLTF,IGKV1-39,HK CV-X2-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWRLGQDWFDPW,IGHV3-15,IGHJ5,CQQSYSAPLTF,IGKV1-39,HK CV-X2-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTTWRLGQDWFDPW,IGHV3-15,IGHJ6,CQQSYSAPLTF,IGKV1-39,HK CV-X2-103,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRRFDPNQRNDYYYALDFW,IGHV3-73,IGHJ1,CSAWDDSLNGYVF,IGLV1-44,HL CV-X2-105,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRRFDPNQRNDYYYALDFW,IGHV3-73,IGHJ2,CSAWDDSLNGYVF,IGLV1-44,HL CV-X2-105,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRRFDPNQRNDYYYALDFW,IGHV3-73,IGHJ3,CSAWDDSLNGYVF,IGLV1-44,HL CV-X2-105,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRRFDPNQRNDYYYALDFW,IGHV3-73,IGHJ4,CSAWDDSLNGYVF,IGLV1-44,HL CV-X2-105,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRRFDPNQRNDYYYALDFW,IGHV3-73,IGHJ5,CSAWDDSLNGYVF,IGLV1-44,HL CV-X2-105,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CTRRFDPNQRNDYYYALDFW,IGHV3-73,IGHJ6,CSAWDDSLNGYVF,IGLV1-44,HL CV-X2-105,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATRKETTVTTSLVYGMDVW,IGHV1-69,IGHJ1,CQQSYSTPYTF,IGKV1-39,HK CV-X2-106,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATRKETTVTTSLVYGMDVW,IGHV1-69,IGHJ2,CQQSYSTPYTF,IGKV1-39,HK CV-X2-106,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATRKETTVTTSLVYGMDVW,IGHV1-69,IGHJ3,CQQSYSTPYTF,IGKV1-39,HK CV-X2-106,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATRKETTVTTSLVYGMDVW,IGHV1-69,IGHJ4,CQQSYSTPYTF,IGKV1-39,HK CV-X2-106,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATRKETTVTTSLVYGMDVW,IGHV1-69,IGHJ5,CQQSYSTPYTF,IGKV1-39,HK CV-X2-106,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CATRKETTVTTSLVYGMDVW,IGHV1-69,IGHJ6,CQQSYSTPYTF,IGKV1-39,HK CV-X2-106,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEYW,IGHV3-66,IGHJ1,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEYW,IGHV3-66,IGHJ2,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEYW,IGHV3-66,IGHJ3,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEYW,IGHV3-66,IGHJ4,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEYW,IGHV3-66,IGHJ5,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEYW,IGHV3-66,IGHJ6,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-107,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ1,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ2,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ3,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ4,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ5,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ6,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-108,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLAHYYDRSGYSRADDAFDVW,IGHV5-51,IGHJ1,CQQYNNWPPVYTF,IGKV3-15,HK CV-X2-109,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLAHYYDRSGYSRADDAFDVW,IGHV5-51,IGHJ2,CQQYNNWPPVYTF,IGKV3-15,HK CV-X2-109,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLAHYYDRSGYSRADDAFDVW,IGHV5-51,IGHJ3,CQQYNNWPPVYTF,IGKV3-15,HK CV-X2-109,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLAHYYDRSGYSRADDAFDVW,IGHV5-51,IGHJ4,CQQYNNWPPVYTF,IGKV3-15,HK CV-X2-109,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLAHYYDRSGYSRADDAFDVW,IGHV5-51,IGHJ5,CQQYNNWPPVYTF,IGKV3-15,HK CV-X2-109,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARLAHYYDRSGYSRADDAFDVW,IGHV5-51,IGHJ6,CQQYNNWPPVYTF,IGKV3-15,HK CV-X2-109,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ1,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ2,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ3,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ4,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ5,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGKVGATGFEDW,IGHV3-66,IGHJ6,CQQYGSSPPMYTF,IGKV3-20,HK CV-X2-117,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTGGPYCSGGSCYSALMDYW,IGHV3-30,IGHJ1,CQQYDNLPPTF,IGKV1-33,HK CV-X2-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTGGPYCSGGSCYSALMDYW,IGHV3-30,IGHJ2,CQQYDNLPPTF,IGKV1-33,HK CV-X2-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTGGPYCSGGSCYSALMDYW,IGHV3-30,IGHJ3,CQQYDNLPPTF,IGKV1-33,HK CV-X2-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTGGPYCSGGSCYSALMDYW,IGHV3-30,IGHJ4,CQQYDNLPPTF,IGKV1-33,HK CV-X2-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTGGPYCSGGSCYSALMDYW,IGHV3-30,IGHJ5,CQQYDNLPPTF,IGKV1-33,HK CV-X2-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CAKTGGPYCSGGSCYSALMDYW,IGHV3-30,IGHJ6,CQQYDNLPPTF,IGKV1-33,HK CV-X2-118,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTREGYHDTLTGEFYFYGTDVW,IGHV4-4,IGHJ1,CQQYAMSPVTF,IGKV3-20,HK CV-X2-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTREGYHDTLTGEFYFYGTDVW,IGHV4-4,IGHJ2,CQQYAMSPVTF,IGKV3-20,HK CV-X2-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTREGYHDTLTGEFYFYGTDVW,IGHV4-4,IGHJ3,CQQYAMSPVTF,IGKV3-20,HK CV-X2-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTREGYHDTLTGEFYFYGTDVW,IGHV4-4,IGHJ4,CQQYAMSPVTF,IGKV3-20,HK CV-X2-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTREGYHDTLTGEFYFYGTDVW,IGHV4-4,IGHJ5,CQQYAMSPVTF,IGKV3-20,HK CV-X2-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARDRTREGYHDTLTGEFYFYGTDVW,IGHV4-4,IGHJ6,CQQYAMSPVTF,IGKV3-20,HK CV-X2-123,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ1,CQQYYNWPLTF,IGKV3-15,COV2-2997,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ2,CQQYYNWPLTF,IGKV3-15,COV2-2997,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ3,CQQYYNWPLTF,IGKV3-15,COV2-2997,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ4,CQQYYNWPLTF,IGKV3-15,COV2-2997,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ5,CQQYYNWPLTF,IGKV3-15,COV2-2997,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ6,CQQYYNWPLTF,IGKV3-15,COV2-2997,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ1,CQQSYEIPPWTF,IGKV1-39,COV2-3012,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ2,CQQSYEIPPWTF,IGKV1-39,COV2-3012,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ3,CQQSYEIPPWTF,IGKV1-39,COV2-3012,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ4,CQQSYEIPPWTF,IGKV1-39,COV2-3012,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ5,CQQSYEIPPWTF,IGKV1-39,COV2-3012,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ6,CQQSYEIPPWTF,IGKV1-39,COV2-3012,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ1,CQHYGSSRGWTF,IGKV3-20,COV2-2961,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ2,CQHYGSSRGWTF,IGKV3-20,COV2-2961,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ3,CQHYGSSRGWTF,IGKV3-20,COV2-2961,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ4,CQHYGSSRGWTF,IGKV3-20,COV2-2961,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ5,CQHYGSSRGWTF,IGKV3-20,COV2-2961,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ6,CQHYGSSRGWTF,IGKV3-20,COV2-2961,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ1,CQHYGSSRGWTF,IGKV3-20,COV2-3025,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ2,CQHYGSSRGWTF,IGKV3-20,COV2-3025,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ3,CQHYGSSRGWTF,IGKV3-20,COV2-3025,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ4,CQHYGSSRGWTF,IGKV3-20,COV2-3025,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ5,CQHYGSSRGWTF,IGKV3-20,COV2-3025,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ6,CQHYGSSRGWTF,IGKV3-20,COV2-3025,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAHSTGHQYYYGMDVW,IGHV3-9,IGHJ1,CQQSYNTPYTF,IGKV1-39,COV2-2046,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAHSTGHQYYYGMDVW,IGHV3-9,IGHJ2,CQQSYNTPYTF,IGKV1-39,COV2-2046,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAHSTGHQYYYGMDVW,IGHV3-9,IGHJ3,CQQSYNTPYTF,IGKV1-39,COV2-2046,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAHSTGHQYYYGMDVW,IGHV3-9,IGHJ4,CQQSYNTPYTF,IGKV1-39,COV2-2046,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAHSTGHQYYYGMDVW,IGHV3-9,IGHJ5,CQQSYNTPYTF,IGKV1-39,COV2-2046,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAHSTGHQYYYGMDVW,IGHV3-9,IGHJ6,CQQSYNTPYTF,IGKV1-39,COV2-2046,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ1,CQHYGSSRGWTF,IGKV3-20,COV2-2196,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ2,CQHYGSSRGWTF,IGKV3-20,COV2-2196,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ3,CQHYGSSRGWTF,IGKV3-20,COV2-2196,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ4,CQHYGSSRGWTF,IGKV3-20,COV2-2196,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ5,CQHYGSSRGWTF,IGKV3-20,COV2-2196,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ6,CQHYGSSRGWTF,IGKV3-20,COV2-2196,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ1,CVAWDDSRNGLVF,IGLV1-40,COV2-2901,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ2,CVAWDDSRNGLVF,IGLV1-40,COV2-2901,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ3,CVAWDDSRNGLVF,IGLV1-40,COV2-2901,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ4,CVAWDDSRNGLVF,IGLV1-40,COV2-2901,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ5,CVAWDDSRNGLVF,IGLV1-40,COV2-2901,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ6,CVAWDDSRNGLVF,IGLV1-40,COV2-2901,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ1,CQQSYTTLLTF,IGKV1-39,COV2-2070,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ2,CQQSYTTLLTF,IGKV1-39,COV2-2070,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ3,CQQSYTTLLTF,IGKV1-39,COV2-2070,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ4,CQQSYTTLLTF,IGKV1-39,COV2-2070,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ5,CQQSYTTLLTF,IGKV1-39,COV2-2070,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ6,CQQSYTTLLTF,IGKV1-39,COV2-2070,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ1,CQQYDNLPPVF,IGKV1-33,COV2-2132,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ2,CQQYDNLPPVF,IGKV1-33,COV2-2132,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ3,CQQYDNLPPVF,IGKV1-33,COV2-2132,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ4,CQQYDNLPPVF,IGKV1-33,COV2-2132,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ5,CQQYDNLPPVF,IGKV1-33,COV2-2132,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ6,CQQYDNLPPVF,IGKV1-33,COV2-2132,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMSRGYNYAYTFDIW,IGHV4-39,IGHJ1,CCSYAGSVLF,IGLV2-23,COV2-2911,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMSRGYNYAYTFDIW,IGHV4-39,IGHJ2,CCSYAGSVLF,IGLV2-23,COV2-2911,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMSRGYNYAYTFDIW,IGHV4-39,IGHJ3,CCSYAGSVLF,IGLV2-23,COV2-2911,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMSRGYNYAYTFDIW,IGHV4-39,IGHJ4,CCSYAGSVLF,IGLV2-23,COV2-2911,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMSRGYNYAYTFDIW,IGHV4-39,IGHJ5,CCSYAGSVLF,IGLV2-23,COV2-2911,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMSRGYNYAYTFDIW,IGHV4-39,IGHJ6,CCSYAGSVLF,IGLV2-23,COV2-2911,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ1,CHQYNNWPQTF,IGKV3-15,COV2-2098,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ2,CHQYNNWPQTF,IGKV3-15,COV2-2098,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ3,CHQYNNWPQTF,IGKV3-15,COV2-2098,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ4,CHQYNNWPQTF,IGKV3-15,COV2-2098,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ5,CHQYNNWPQTF,IGKV3-15,COV2-2098,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ6,CHQYNNWPQTF,IGKV3-15,COV2-2098,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGVDYGGKLAYFDSW,IGHV3-9,IGHJ1,CMQALQTPLTF,IGKV2-28,COV2-2108,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGVDYGGKLAYFDSW,IGHV3-9,IGHJ2,CMQALQTPLTF,IGKV2-28,COV2-2108,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGVDYGGKLAYFDSW,IGHV3-9,IGHJ3,CMQALQTPLTF,IGKV2-28,COV2-2108,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGVDYGGKLAYFDSW,IGHV3-9,IGHJ4,CMQALQTPLTF,IGKV2-28,COV2-2108,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGVDYGGKLAYFDSW,IGHV3-9,IGHJ5,CMQALQTPLTF,IGKV2-28,COV2-2108,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGVDYGGKLAYFDSW,IGHV3-9,IGHJ6,CMQALQTPLTF,IGKV2-28,COV2-2108,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,COV2-2114,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,COV2-2114,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,COV2-2114,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,COV2-2114,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,COV2-2114,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,COV2-2114,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPVWVDGELLSGGIPFDYW,IGHV3-21,IGHJ1,CAAWDDSLNGVVF,IGLV1-44,COV2-2304,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPVWVDGELLSGGIPFDYW,IGHV3-21,IGHJ2,CAAWDDSLNGVVF,IGLV1-44,COV2-2304,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPVWVDGELLSGGIPFDYW,IGHV3-21,IGHJ3,CAAWDDSLNGVVF,IGLV1-44,COV2-2304,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPVWVDGELLSGGIPFDYW,IGHV3-21,IGHJ4,CAAWDDSLNGVVF,IGLV1-44,COV2-2304,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPVWVDGELLSGGIPFDYW,IGHV3-21,IGHJ5,CAAWDDSLNGVVF,IGLV1-44,COV2-2304,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPVWVDGELLSGGIPFDYW,IGHV3-21,IGHJ6,CAAWDDSLNGVVF,IGLV1-44,COV2-2304,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ1,CQSYDSSLSDSVF,IGLV1-40,COV2-2078,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ2,CQSYDSSLSDSVF,IGLV1-40,COV2-2078,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ3,CQSYDSSLSDSVF,IGLV1-40,COV2-2078,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ4,CQSYDSSLSDSVF,IGLV1-40,COV2-2078,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ5,CQSYDSSLSDSVF,IGLV1-40,COV2-2078,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ6,CQSYDSSLSDSVF,IGLV1-40,COV2-2078,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ1,CQQSYSTPWTF,IGKV1-39,COV2-2299,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ2,CQQSYSTPWTF,IGKV1-39,COV2-2299,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ3,CQQSYSTPWTF,IGKV1-39,COV2-2299,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ4,CQQSYSTPWTF,IGKV1-39,COV2-2299,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ5,CQQSYSTPWTF,IGKV1-39,COV2-2299,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ6,CQQSYSTPWTF,IGKV1-39,COV2-2299,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRFYGPSSFDYW,IGHV5-51,IGHJ1,CSSGDSSTDHHVVF,IGLV3-19,COV2-2351,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRFYGPSSFDYW,IGHV5-51,IGHJ2,CSSGDSSTDHHVVF,IGLV3-19,COV2-2351,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRFYGPSSFDYW,IGHV5-51,IGHJ3,CSSGDSSTDHHVVF,IGLV3-19,COV2-2351,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRFYGPSSFDYW,IGHV5-51,IGHJ4,CSSGDSSTDHHVVF,IGLV3-19,COV2-2351,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRFYGPSSFDYW,IGHV5-51,IGHJ5,CSSGDSSTDHHVVF,IGLV3-19,COV2-2351,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRFYGPSSFDYW,IGHV5-51,IGHJ6,CSSGDSSTDHHVVF,IGLV3-19,COV2-2351,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ1,CQQSYSTPGTF,IGKV1-39,COV2-2318,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ2,CQQSYSTPGTF,IGKV1-39,COV2-2318,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ3,CQQSYSTPGTF,IGKV1-39,COV2-2318,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ4,CQQSYSTPGTF,IGKV1-39,COV2-2318,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ5,CQQSYSTPGTF,IGKV1-39,COV2-2318,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ6,CQQSYSTPGTF,IGKV1-39,COV2-2318,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGGYNWNFDYW,IGHV3-13,IGHJ1,CQQSYSTPPITF,IGKV1-39,COV2-2703,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGGYNWNFDYW,IGHV3-13,IGHJ2,CQQSYSTPPITF,IGKV1-39,COV2-2703,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGGYNWNFDYW,IGHV3-13,IGHJ3,CQQSYSTPPITF,IGKV1-39,COV2-2703,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGGYNWNFDYW,IGHV3-13,IGHJ4,CQQSYSTPPITF,IGKV1-39,COV2-2703,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGGYNWNFDYW,IGHV3-13,IGHJ5,CQQSYSTPPITF,IGKV1-39,COV2-2703,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGGYNWNFDYW,IGHV3-13,IGHJ6,CQQSYSTPPITF,IGKV1-39,COV2-2703,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVPTTVTAFTVFTYW,IGHV3-30,IGHJ1,CQQSYSTPGLTF,IGKV1-39,COV2-2277,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVPTTVTAFTVFTYW,IGHV3-30,IGHJ2,CQQSYSTPGLTF,IGKV1-39,COV2-2277,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVPTTVTAFTVFTYW,IGHV3-30,IGHJ3,CQQSYSTPGLTF,IGKV1-39,COV2-2277,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVPTTVTAFTVFTYW,IGHV3-30,IGHJ4,CQQSYSTPGLTF,IGKV1-39,COV2-2277,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVPTTVTAFTVFTYW,IGHV3-30,IGHJ5,CQQSYSTPGLTF,IGKV1-39,COV2-2277,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVPTTVTAFTVFTYW,IGHV3-30,IGHJ6,CQQSYSTPGLTF,IGKV1-39,COV2-2277,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ1,CQSYDSRLSGFVVF,IGLV1-40,COV2-2068,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ2,CQSYDSRLSGFVVF,IGLV1-40,COV2-2068,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ3,CQSYDSRLSGFVVF,IGLV1-40,COV2-2068,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ4,CQSYDSRLSGFVVF,IGLV1-40,COV2-2068,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ5,CQSYDSRLSGFVVF,IGLV1-40,COV2-2068,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ6,CQSYDSRLSGFVVF,IGLV1-40,COV2-2068,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ1,CAAWDDSLNALVF,IGLV1-44,COV2-2504,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ2,CAAWDDSLNALVF,IGLV1-44,COV2-2504,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ3,CAAWDDSLNALVF,IGLV1-44,COV2-2504,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ4,CAAWDDSLNALVF,IGLV1-44,COV2-2504,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ5,CAAWDDSLNALVF,IGLV1-44,COV2-2504,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ6,CAAWDDSLNALVF,IGLV1-44,COV2-2504,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWGPDYGDYASNDYW,IGHV7-4-1,IGHJ1,CYSAADNNRVF,IGLV3-27,COV2-2510,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWGPDYGDYASNDYW,IGHV7-4-1,IGHJ2,CYSAADNNRVF,IGLV3-27,COV2-2510,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWGPDYGDYASNDYW,IGHV7-4-1,IGHJ3,CYSAADNNRVF,IGLV3-27,COV2-2510,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWGPDYGDYASNDYW,IGHV7-4-1,IGHJ4,CYSAADNNRVF,IGLV3-27,COV2-2510,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWGPDYGDYASNDYW,IGHV7-4-1,IGHJ5,CYSAADNNRVF,IGLV3-27,COV2-2510,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWGPDYGDYASNDYW,IGHV7-4-1,IGHJ6,CYSAADNNRVF,IGLV3-27,COV2-2510,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ1,CHQYNNWPQTF,IGKV3-15,COV2-2308,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ2,CHQYNNWPQTF,IGKV3-15,COV2-2308,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ3,CHQYNNWPQTF,IGKV3-15,COV2-2308,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ4,CHQYNNWPQTF,IGKV3-15,COV2-2308,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ5,CHQYNNWPQTF,IGKV3-15,COV2-2308,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVKGLFDWFPLW,IGHV3-23,IGHJ6,CHQYNNWPQTF,IGKV3-15,COV2-2308,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ1,CAVWDDSLNGLVF,IGLV1-44,COV2-2391,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ2,CAVWDDSLNGLVF,IGLV1-44,COV2-2391,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ3,CAVWDDSLNGLVF,IGLV1-44,COV2-2391,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ4,CAVWDDSLNGLVF,IGLV1-44,COV2-2391,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ5,CAVWDDSLNGLVF,IGLV1-44,COV2-2391,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ6,CAVWDDSLNGLVF,IGLV1-44,COV2-2391,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ1,CVAWDDSRNGLVF,IGLV1-50,COV2-2767,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ2,CVAWDDSRNGLVF,IGLV1-50,COV2-2767,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ3,CVAWDDSRNGLVF,IGLV1-50,COV2-2767,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ4,CVAWDDSRNGLVF,IGLV1-50,COV2-2767,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ5,CVAWDDSRNGLVF,IGLV1-50,COV2-2767,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ6,CVAWDDSRNGLVF,IGLV1-50,COV2-2767,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ1,CQQYYNWPLTF,IGKV3-15,COV2-2081,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ2,CQQYYNWPLTF,IGKV3-15,COV2-2081,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ3,CQQYYNWPLTF,IGKV3-15,COV2-2081,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ4,CQQYYNWPLTF,IGKV3-15,COV2-2081,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ5,CQQYYNWPLTF,IGKV3-15,COV2-2081,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ6,CQQYYNWPLTF,IGKV3-15,COV2-2081,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ1,CQQYDNLPPVF,IGKV1-33,COV2-2113,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ2,CQQYDNLPPVF,IGKV1-33,COV2-2113,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ3,CQQYDNLPPVF,IGKV1-33,COV2-2113,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ4,CQQYDNLPPVF,IGKV1-33,COV2-2113,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ5,CQQYDNLPPVF,IGKV1-33,COV2-2113,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ6,CQQYDNLPPVF,IGKV1-33,COV2-2113,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ1,CLVWDDSLNGLVF,IGLV1-44,COV2-2290,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ2,CLVWDDSLNGLVF,IGLV1-44,COV2-2290,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ3,CLVWDDSLNGLVF,IGLV1-44,COV2-2290,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ4,CLVWDDSLNGLVF,IGLV1-44,COV2-2290,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ5,CLVWDDSLNGLVF,IGLV1-44,COV2-2290,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ6,CLVWDDSLNGLVF,IGLV1-44,COV2-2290,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTAGSYYYDTVGPGLPEGKFDYW,IGHV3-15,IGHJ1,CQQYYSTLTF,IGKV4-1,COV2-2130,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTAGSYYYDTVGPGLPEGKFDYW,IGHV3-15,IGHJ2,CQQYYSTLTF,IGKV4-1,COV2-2130,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTAGSYYYDTVGPGLPEGKFDYW,IGHV3-15,IGHJ3,CQQYYSTLTF,IGKV4-1,COV2-2130,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTAGSYYYDTVGPGLPEGKFDYW,IGHV3-15,IGHJ4,CQQYYSTLTF,IGKV4-1,COV2-2130,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTAGSYYYDTVGPGLPEGKFDYW,IGHV3-15,IGHJ5,CQQYYSTLTF,IGKV4-1,COV2-2130,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTAGSYYYDTVGPGLPEGKFDYW,IGHV3-15,IGHJ6,CQQYYSTLTF,IGKV4-1,COV2-2130,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ1,CAAWDDSLNALVF,IGLV1-44,COV2-2050,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ2,CAAWDDSLNALVF,IGLV1-44,COV2-2050,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ3,CAAWDDSLNALVF,IGLV1-44,COV2-2050,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ4,CAAWDDSLNALVF,IGLV1-44,COV2-2050,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ5,CAAWDDSLNALVF,IGLV1-44,COV2-2050,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ6,CAAWDDSLNALVF,IGLV1-44,COV2-2050,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ1,CLVWDDSLNGLVF,IGLV1-44,COV2-2064,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ2,CLVWDDSLNGLVF,IGLV1-44,COV2-2064,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ3,CLVWDDSLNGLVF,IGLV1-44,COV2-2064,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ4,CLVWDDSLNGLVF,IGLV1-44,COV2-2064,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ5,CLVWDDSLNGLVF,IGLV1-44,COV2-2064,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ6,CLVWDDSLNGLVF,IGLV1-44,COV2-2064,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ1,CQQYNNWWRTF,IGKV3-20,COV2-2684,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ2,CQQYNNWWRTF,IGKV3-20,COV2-2684,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ3,CQQYNNWWRTF,IGKV3-20,COV2-2684,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ4,CQQYNNWWRTF,IGKV3-20,COV2-2684,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ5,CQQYNNWWRTF,IGKV3-20,COV2-2684,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ6,CQQYNNWWRTF,IGKV3-20,COV2-2684,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,COV2-2072,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,COV2-2072,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,COV2-2072,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,COV2-2072,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,COV2-2072,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,COV2-2072,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ1,CLAWDDSLNGLVF,IGLV1-44,COV2-2539,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ2,CLAWDDSLNGLVF,IGLV1-44,COV2-2539,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ3,CLAWDDSLNGLVF,IGLV1-44,COV2-2539,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ4,CLAWDDSLNGLVF,IGLV1-44,COV2-2539,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ5,CLAWDDSLNGLVF,IGLV1-44,COV2-2539,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ6,CLAWDDSLNGLVF,IGLV1-44,COV2-2539,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ1,CQQSYSTPWTF,IGKV1-39,COV2-2389,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ2,CQQSYSTPWTF,IGKV1-39,COV2-2389,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ3,CQQSYSTPWTF,IGKV1-39,COV2-2389,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ4,CQQSYSTPWTF,IGKV1-39,COV2-2389,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ5,CQQSYSTPWTF,IGKV1-39,COV2-2389,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ6,CQQSYSTPWTF,IGKV1-39,COV2-2389,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ1,CVAWDDSRNGLVF,IGLV1-44,COV2-2532,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ2,CVAWDDSRNGLVF,IGLV1-44,COV2-2532,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ3,CVAWDDSRNGLVF,IGLV1-44,COV2-2532,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ4,CVAWDDSRNGLVF,IGLV1-44,COV2-2532,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ5,CVAWDDSRNGLVF,IGLV1-44,COV2-2532,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ6,CVAWDDSRNGLVF,IGLV1-44,COV2-2532,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ1,CAVWDDSLNGLVF,IGLV1-44,COV2-2096,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ2,CAVWDDSLNGLVF,IGLV1-44,COV2-2096,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ3,CAVWDDSLNGLVF,IGLV1-44,COV2-2096,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ4,CAVWDDSLNGLVF,IGLV1-44,COV2-2096,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ5,CAVWDDSLNGLVF,IGLV1-44,COV2-2096,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDFW,IGHV1-8,IGHJ6,CAVWDDSLNGLVF,IGLV1-44,COV2-2096,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ1,CQQSYSTPGTF,IGKV1-39,COV2-2051,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ2,CQQSYSTPGTF,IGKV1-39,COV2-2051,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ3,CQQSYSTPGTF,IGKV1-39,COV2-2051,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ4,CQQSYSTPGTF,IGKV1-39,COV2-2051,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ5,CQQSYSTPGTF,IGKV1-39,COV2-2051,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVTYDYW,IGHV2-70,IGHJ6,CQQSYSTPGTF,IGKV1-39,COV2-2051,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTPTLYNWFHPW,IGHV5-51,IGHJ1,CAAWDDSLNGSWVF,IGLV1-44,COV2-2759,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTPTLYNWFHPW,IGHV5-51,IGHJ2,CAAWDDSLNGSWVF,IGLV1-44,COV2-2759,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTPTLYNWFHPW,IGHV5-51,IGHJ3,CAAWDDSLNGSWVF,IGLV1-44,COV2-2759,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTPTLYNWFHPW,IGHV5-51,IGHJ4,CAAWDDSLNGSWVF,IGLV1-44,COV2-2759,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTPTLYNWFHPW,IGHV5-51,IGHJ5,CAAWDDSLNGSWVF,IGLV1-44,COV2-2759,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTPTLYNWFHPW,IGHV5-51,IGHJ6,CAAWDDSLNGSWVF,IGLV1-44,COV2-2759,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGYTISRQWLVGEFDYW,IGHV3-9,IGHJ1,CSAYAGSNNLVF,IGLV2-8,COV2-2240,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGYTISRQWLVGEFDYW,IGHV3-9,IGHJ2,CSAYAGSNNLVF,IGLV2-8,COV2-2240,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGYTISRQWLVGEFDYW,IGHV3-9,IGHJ3,CSAYAGSNNLVF,IGLV2-8,COV2-2240,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGYTISRQWLVGEFDYW,IGHV3-9,IGHJ4,CSAYAGSNNLVF,IGLV2-8,COV2-2240,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGYTISRQWLVGEFDYW,IGHV3-9,IGHJ5,CSAYAGSNNLVF,IGLV2-8,COV2-2240,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGYTISRQWLVGEFDYW,IGHV3-9,IGHJ6,CSAYAGSNNLVF,IGLV2-8,COV2-2240,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDYW,IGHV1-8,IGHJ1,CAVWDDSLNGLVF,IGLV1-44,COV2-2413,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDYW,IGHV1-8,IGHJ2,CAVWDDSLNGLVF,IGLV1-44,COV2-2413,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDYW,IGHV1-8,IGHJ3,CAVWDDSLNGLVF,IGLV1-44,COV2-2413,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDYW,IGHV1-8,IGHJ4,CAVWDDSLNGLVF,IGLV1-44,COV2-2413,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDYW,IGHV1-8,IGHJ5,CAVWDDSLNGLVF,IGLV1-44,COV2-2413,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDYW,IGHV1-8,IGHJ6,CAVWDDSLNGLVF,IGLV1-44,COV2-2413,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASAKLVATISYFDYW,IGHV4-31,IGHJ1,CAAWDDSLNGVVF,IGLV1-36,COV2-2416,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASAKLVATISYFDYW,IGHV4-31,IGHJ2,CAAWDDSLNGVVF,IGLV1-36,COV2-2416,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASAKLVATISYFDYW,IGHV4-31,IGHJ3,CAAWDDSLNGVVF,IGLV1-36,COV2-2416,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASAKLVATISYFDYW,IGHV4-31,IGHJ4,CAAWDDSLNGVVF,IGLV1-36,COV2-2416,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASAKLVATISYFDYW,IGHV4-31,IGHJ5,CAAWDDSLNGVVF,IGLV1-36,COV2-2416,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASAKLVATISYFDYW,IGHV4-31,IGHJ6,CAAWDDSLNGVVF,IGLV1-36,COV2-2416,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYRDWIW,IGHV3-66,IGHJ1,CQQYHNLPRTF,IGKV1-33,COV2-2399,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYRDWIW,IGHV3-66,IGHJ2,CQQYHNLPRTF,IGKV1-33,COV2-2399,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYRDWIW,IGHV3-66,IGHJ3,CQQYHNLPRTF,IGKV1-33,COV2-2399,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYRDWIW,IGHV3-66,IGHJ4,CQQYHNLPRTF,IGKV1-33,COV2-2399,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYRDWIW,IGHV3-66,IGHJ5,CQQYHNLPRTF,IGKV1-33,COV2-2399,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYRDWIW,IGHV3-66,IGHJ6,CQQYHNLPRTF,IGKV1-33,COV2-2399,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKWAGPIVMKYYLQYW,IGHV3-23,IGHJ1,CQSYDISLGGWVF,IGLV1-40,COV2-2756,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKWAGPIVMKYYLQYW,IGHV3-23,IGHJ2,CQSYDISLGGWVF,IGLV1-40,COV2-2756,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKWAGPIVMKYYLQYW,IGHV3-23,IGHJ3,CQSYDISLGGWVF,IGLV1-40,COV2-2756,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKWAGPIVMKYYLQYW,IGHV3-23,IGHJ4,CQSYDISLGGWVF,IGLV1-40,COV2-2756,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKWAGPIVMKYYLQYW,IGHV3-23,IGHJ5,CQSYDISLGGWVF,IGLV1-40,COV2-2756,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKWAGPIVMKYYLQYW,IGHV3-23,IGHJ6,CQSYDISLGGWVF,IGLV1-40,COV2-2756,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVPTRGPVAWFDPW,IGHV4-31,IGHJ1,CQQSYSTLLYTF,IGKV1-39,COV2-2819,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVPTRGPVAWFDPW,IGHV4-31,IGHJ2,CQQSYSTLLYTF,IGKV1-39,COV2-2819,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVPTRGPVAWFDPW,IGHV4-31,IGHJ3,CQQSYSTLLYTF,IGKV1-39,COV2-2819,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVPTRGPVAWFDPW,IGHV4-31,IGHJ4,CQQSYSTLLYTF,IGKV1-39,COV2-2819,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVPTRGPVAWFDPW,IGHV4-31,IGHJ5,CQQSYSTLLYTF,IGKV1-39,COV2-2819,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVPTRGPVAWFDPW,IGHV4-31,IGHJ6,CQQSYSTLLYTF,IGKV1-39,COV2-2819,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSRTSCHDAFDIW,IGHV1-58,IGHJ1,CQHFGSSSQWTF,IGKV3-20,COV2-2381,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSRTSCHDAFDIW,IGHV1-58,IGHJ2,CQHFGSSSQWTF,IGKV3-20,COV2-2381,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSRTSCHDAFDIW,IGHV1-58,IGHJ3,CQHFGSSSQWTF,IGKV3-20,COV2-2381,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSRTSCHDAFDIW,IGHV1-58,IGHJ4,CQHFGSSSQWTF,IGKV3-20,COV2-2381,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSRTSCHDAFDIW,IGHV1-58,IGHJ5,CQHFGSSSQWTF,IGKV3-20,COV2-2381,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSRTSCHDAFDIW,IGHV1-58,IGHJ6,CQHFGSSSQWTF,IGKV3-20,COV2-2381,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ1,CHQSYFTPQTF,IGKV1-39,COV2-2628,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ2,CHQSYFTPQTF,IGKV1-39,COV2-2628,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ3,CHQSYFTPQTF,IGKV1-39,COV2-2628,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ4,CHQSYFTPQTF,IGKV1-39,COV2-2628,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ5,CHQSYFTPQTF,IGKV1-39,COV2-2628,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ6,CHQSYFTPQTF,IGKV1-39,COV2-2628,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ1,CQSYDSSLSGSVF,IGLV1-40,COV2-2909,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ2,CQSYDSSLSGSVF,IGLV1-40,COV2-2909,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ3,CQSYDSSLSGSVF,IGLV1-40,COV2-2909,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ4,CQSYDSSLSGSVF,IGLV1-40,COV2-2909,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ5,CQSYDSSLSGSVF,IGLV1-40,COV2-2909,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ6,CQSYDSSLSGSVF,IGLV1-40,COV2-2909,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGVSKYCSGGRCLSGGSNWFDPW,IGHV5-51,IGHJ1,CQQYNNWPPMYTF,IGKV3-15,COV2-2353,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGVSKYCSGGRCLSGGSNWFDPW,IGHV5-51,IGHJ2,CQQYNNWPPMYTF,IGKV3-15,COV2-2353,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGVSKYCSGGRCLSGGSNWFDPW,IGHV5-51,IGHJ3,CQQYNNWPPMYTF,IGKV3-15,COV2-2353,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGVSKYCSGGRCLSGGSNWFDPW,IGHV5-51,IGHJ4,CQQYNNWPPMYTF,IGKV3-15,COV2-2353,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGVSKYCSGGRCLSGGSNWFDPW,IGHV5-51,IGHJ5,CQQYNNWPPMYTF,IGKV3-15,COV2-2353,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGVSKYCSGGRCLSGGSNWFDPW,IGHV5-51,IGHJ6,CQQYNNWPPMYTF,IGKV3-15,COV2-2353,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIQYQLNGMDVW,IGHV2-70,IGHJ1,CQQSYSTPYTF,IGKV1-39,COV2-2589,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIQYQLNGMDVW,IGHV2-70,IGHJ2,CQQSYSTPYTF,IGKV1-39,COV2-2589,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIQYQLNGMDVW,IGHV2-70,IGHJ3,CQQSYSTPYTF,IGKV1-39,COV2-2589,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIQYQLNGMDVW,IGHV2-70,IGHJ4,CQQSYSTPYTF,IGKV1-39,COV2-2589,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIQYQLNGMDVW,IGHV2-70,IGHJ5,CQQSYSTPYTF,IGKV1-39,COV2-2589,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIQYQLNGMDVW,IGHV2-70,IGHJ6,CQQSYSTPYTF,IGKV1-39,COV2-2589,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ1,CQSYDSSLSDSVF,IGLV1-40,COV2-2485,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ2,CQSYDSSLSDSVF,IGLV1-40,COV2-2485,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ3,CQSYDSSLSDSVF,IGLV1-40,COV2-2485,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ4,CQSYDSSLSDSVF,IGLV1-40,COV2-2485,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ5,CQSYDSSLSDSVF,IGLV1-40,COV2-2485,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGVSGFKSGSNWYFDLW,IGHV1-69,IGHJ6,CQSYDSSLSDSVF,IGLV1-40,COV2-2485,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDLW,IGHV1-8,IGHJ1,CAVWDDSLNGLVF,IGLV1-44,COV2-2693,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDLW,IGHV1-8,IGHJ2,CAVWDDSLNGLVF,IGLV1-44,COV2-2693,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDLW,IGHV1-8,IGHJ3,CAVWDDSLNGLVF,IGLV1-44,COV2-2693,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDLW,IGHV1-8,IGHJ4,CAVWDDSLNGLVF,IGLV1-44,COV2-2693,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDLW,IGHV1-8,IGHJ5,CAVWDDSLNGLVF,IGLV1-44,COV2-2693,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDLW,IGHV1-8,IGHJ6,CAVWDDSLNGLVF,IGLV1-44,COV2-2693,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQRYCSSSSCHVWDYW,IGHV4-39,IGHJ1,CCSYAGSSTWLF,IGLV2-23,COV2-2762,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQRYCSSSSCHVWDYW,IGHV4-39,IGHJ2,CCSYAGSSTWLF,IGLV2-23,COV2-2762,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQRYCSSSSCHVWDYW,IGHV4-39,IGHJ3,CCSYAGSSTWLF,IGLV2-23,COV2-2762,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQRYCSSSSCHVWDYW,IGHV4-39,IGHJ4,CCSYAGSSTWLF,IGLV2-23,COV2-2762,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQRYCSSSSCHVWDYW,IGHV4-39,IGHJ5,CCSYAGSSTWLF,IGLV2-23,COV2-2762,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQRYCSSSSCHVWDYW,IGHV4-39,IGHJ6,CCSYAGSSTWLF,IGLV2-23,COV2-2762,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ1,CQLLNSHPLTF,IGKV1-9,COV2-2080,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ2,CQLLNSHPLTF,IGKV1-9,COV2-2080,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ3,CQLLNSHPLTF,IGKV1-9,COV2-2080,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ4,CQLLNSHPLTF,IGKV1-9,COV2-2080,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ5,CQLLNSHPLTF,IGKV1-9,COV2-2080,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ6,CQLLNSHPLTF,IGKV1-9,COV2-2080,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARFRRSYGSGSYYNISFDYW,IGHV4-30-4,IGHJ1,CCSYVGSSTYVVF,IGLV2-23,COV2-2527,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARFRRSYGSGSYYNISFDYW,IGHV4-30-4,IGHJ2,CCSYVGSSTYVVF,IGLV2-23,COV2-2527,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARFRRSYGSGSYYNISFDYW,IGHV4-30-4,IGHJ3,CCSYVGSSTYVVF,IGLV2-23,COV2-2527,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARFRRSYGSGSYYNISFDYW,IGHV4-30-4,IGHJ4,CCSYVGSSTYVVF,IGLV2-23,COV2-2527,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARFRRSYGSGSYYNISFDYW,IGHV4-30-4,IGHJ5,CCSYVGSSTYVVF,IGLV2-23,COV2-2527,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARFRRSYGSGSYYNISFDYW,IGHV4-30-4,IGHJ6,CCSYVGSSTYVVF,IGLV2-23,COV2-2527,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-20,IGHJ1,CAVWDDSLNGVVF,IGLV1-44,COV2-2618,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-20,IGHJ2,CAVWDDSLNGVVF,IGLV1-44,COV2-2618,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-20,IGHJ3,CAVWDDSLNGVVF,IGLV1-44,COV2-2618,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-20,IGHJ4,CAVWDDSLNGVVF,IGLV1-44,COV2-2618,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-20,IGHJ5,CAVWDDSLNGVVF,IGLV1-44,COV2-2618,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-20,IGHJ6,CAVWDDSLNGVVF,IGLV1-44,COV2-2618,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATWLRDAFGIW,IGHV4-59,IGHJ1,CQSFDSGNVVF,IGLV6-57,COV2-2531,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATWLRDAFGIW,IGHV4-59,IGHJ2,CQSFDSGNVVF,IGLV6-57,COV2-2531,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATWLRDAFGIW,IGHV4-59,IGHJ3,CQSFDSGNVVF,IGLV6-57,COV2-2531,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATWLRDAFGIW,IGHV4-59,IGHJ4,CQSFDSGNVVF,IGLV6-57,COV2-2531,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATWLRDAFGIW,IGHV4-59,IGHJ5,CQSFDSGNVVF,IGLV6-57,COV2-2531,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATWLRDAFGIW,IGHV4-59,IGHJ6,CQSFDSGNVVF,IGLV6-57,COV2-2531,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTMATINAFDIW,IGHV2-70,IGHJ1,CQQSFSTPRTF,IGKV1-39,COV2-2919,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTMATINAFDIW,IGHV2-70,IGHJ2,CQQSFSTPRTF,IGKV1-39,COV2-2919,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTMATINAFDIW,IGHV2-70,IGHJ3,CQQSFSTPRTF,IGKV1-39,COV2-2919,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTMATINAFDIW,IGHV2-70,IGHJ4,CQQSFSTPRTF,IGKV1-39,COV2-2919,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTMATINAFDIW,IGHV2-70,IGHJ5,CQQSFSTPRTF,IGKV1-39,COV2-2919,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTMATINAFDIW,IGHV2-70,IGHJ6,CQQSFSTPRTF,IGKV1-39,COV2-2919,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLNEHGLDVW,IGHV3-53,IGHJ1,CQQTNSFPTF,IGKV1-12,COV2-2037,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLNEHGLDVW,IGHV3-53,IGHJ2,CQQTNSFPTF,IGKV1-12,COV2-2037,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLNEHGLDVW,IGHV3-53,IGHJ3,CQQTNSFPTF,IGKV1-12,COV2-2037,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLNEHGLDVW,IGHV3-53,IGHJ4,CQQTNSFPTF,IGKV1-12,COV2-2037,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLNEHGLDVW,IGHV3-53,IGHJ5,CQQTNSFPTF,IGKV1-12,COV2-2037,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLNEHGLDVW,IGHV3-53,IGHJ6,CQQTNSFPTF,IGKV1-12,COV2-2037,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRYSSSGGHIFDYW,IGHV4-34,IGHJ1,CQQYDNLPYTF,IGKV1-33,COV2-2780,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRYSSSGGHIFDYW,IGHV4-34,IGHJ2,CQQYDNLPYTF,IGKV1-33,COV2-2780,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRYSSSGGHIFDYW,IGHV4-34,IGHJ3,CQQYDNLPYTF,IGKV1-33,COV2-2780,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRYSSSGGHIFDYW,IGHV4-34,IGHJ4,CQQYDNLPYTF,IGKV1-33,COV2-2780,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRYSSSGGHIFDYW,IGHV4-34,IGHJ5,CQQYDNLPYTF,IGKV1-33,COV2-2780,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRYSSSGGHIFDYW,IGHV4-34,IGHJ6,CQQYDNLPYTF,IGKV1-33,COV2-2780,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDHW,IGHV1-8,IGHJ1,CVAWDDSRNGLVF,IGLV1-44,COV2-2710,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDHW,IGHV1-8,IGHJ2,CVAWDDSRNGLVF,IGLV1-44,COV2-2710,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDHW,IGHV1-8,IGHJ3,CVAWDDSRNGLVF,IGLV1-44,COV2-2710,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDHW,IGHV1-8,IGHJ4,CVAWDDSRNGLVF,IGLV1-44,COV2-2710,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDHW,IGHV1-8,IGHJ5,CVAWDDSRNGLVF,IGLV1-44,COV2-2710,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRSGWPTHGRPDDHW,IGHV1-8,IGHJ6,CVAWDDSRNGLVF,IGLV1-44,COV2-2710,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ1,CQQSYSTPWTF,IGKV1-39,COV2-2097,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ2,CQQSYSTPWTF,IGKV1-39,COV2-2097,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ3,CQQSYSTPWTF,IGKV1-39,COV2-2097,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ4,CQQSYSTPWTF,IGKV1-39,COV2-2097,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ5,CQQSYSTPWTF,IGKV1-39,COV2-2097,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ6,CQQSYSTPWTF,IGKV1-39,COV2-2097,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQSRGYSYAWSFDYW,IGHV4-39,IGHJ1,CCSYAGIVLF,IGLV2-23,COV2-2243,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQSRGYSYAWSFDYW,IGHV4-39,IGHJ2,CCSYAGIVLF,IGLV2-23,COV2-2243,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQSRGYSYAWSFDYW,IGHV4-39,IGHJ3,CCSYAGIVLF,IGLV2-23,COV2-2243,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQSRGYSYAWSFDYW,IGHV4-39,IGHJ4,CCSYAGIVLF,IGLV2-23,COV2-2243,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQSRGYSYAWSFDYW,IGHV4-39,IGHJ5,CCSYAGIVLF,IGLV2-23,COV2-2243,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQSRGYSYAWSFDYW,IGHV4-39,IGHJ6,CCSYAGIVLF,IGLV2-23,COV2-2243,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDHSGYYDSTSLMSPFFDYW,IGHV1-69,IGHJ1,CQSYDSSLNGDVF,IGLV1-40,COV2-2694,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDHSGYYDSTSLMSPFFDYW,IGHV1-69,IGHJ2,CQSYDSSLNGDVF,IGLV1-40,COV2-2694,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDHSGYYDSTSLMSPFFDYW,IGHV1-69,IGHJ3,CQSYDSSLNGDVF,IGLV1-40,COV2-2694,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDHSGYYDSTSLMSPFFDYW,IGHV1-69,IGHJ4,CQSYDSSLNGDVF,IGLV1-40,COV2-2694,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDHSGYYDSTSLMSPFFDYW,IGHV1-69,IGHJ5,CQSYDSSLNGDVF,IGLV1-40,COV2-2694,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDHSGYYDSTSLMSPFFDYW,IGHV1-69,IGHJ6,CQSYDSSLNGDVF,IGLV1-40,COV2-2694,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ1,CCSYAGSSTWLF,IGLV2-23,COV2-2826,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ2,CCSYAGSSTWLF,IGLV2-23,COV2-2826,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ3,CCSYAGSSTWLF,IGLV2-23,COV2-2826,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ4,CCSYAGSSTWLF,IGLV2-23,COV2-2826,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ5,CCSYAGSSTWLF,IGLV2-23,COV2-2826,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ6,CCSYAGSSTWLF,IGLV2-23,COV2-2826,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ1,CQQYDNLPRTF,IGKV1-33,COV2-2813,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ2,CQQYDNLPRTF,IGKV1-33,COV2-2813,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ3,CQQYDNLPRTF,IGKV1-33,COV2-2813,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ4,CQQYDNLPRTF,IGKV1-33,COV2-2813,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ5,CQQYDNLPRTF,IGKV1-33,COV2-2813,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ6,CQQYDNLPRTF,IGKV1-33,COV2-2813,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETYSAYEMPPYFDYW,IGHV4-31,IGHJ1,CCSYARSSTRVF,IGLV2-23,COV2-2796,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETYSAYEMPPYFDYW,IGHV4-31,IGHJ2,CCSYARSSTRVF,IGLV2-23,COV2-2796,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETYSAYEMPPYFDYW,IGHV4-31,IGHJ3,CCSYARSSTRVF,IGLV2-23,COV2-2796,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETYSAYEMPPYFDYW,IGHV4-31,IGHJ4,CCSYARSSTRVF,IGLV2-23,COV2-2796,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETYSAYEMPPYFDYW,IGHV4-31,IGHJ5,CCSYARSSTRVF,IGLV2-23,COV2-2796,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETYSAYEMPPYFDYW,IGHV4-31,IGHJ6,CCSYARSSTRVF,IGLV2-23,COV2-2796,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ1,CQQYANLPFTF,IGKV1-33,COV2-2812,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ2,CQQYANLPFTF,IGKV1-33,COV2-2812,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ3,CQQYANLPFTF,IGKV1-33,COV2-2812,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ4,CQQYANLPFTF,IGKV1-33,COV2-2812,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ5,CQQYANLPFTF,IGKV1-33,COV2-2812,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDALYYNGPGRDGMDVW,IGHV3-53,IGHJ6,CQQYANLPFTF,IGKV1-33,COV2-2812,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ1,CQQYGSSPPRYTF,IGKV3-20,COV2-2941,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ2,CQQYGSSPPRYTF,IGKV3-20,COV2-2941,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ3,CQQYGSSPPRYTF,IGKV3-20,COV2-2941,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ4,CQQYGSSPPRYTF,IGKV3-20,COV2-2941,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ5,CQQYGSSPPRYTF,IGKV3-20,COV2-2941,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ6,CQQYGSSPPRYTF,IGKV3-20,COV2-2941,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVAATPGWFDPW,IGHV1-69,IGHJ1,CQQYNNFLTF,IGKV3-15,COV2-2479,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVAATPGWFDPW,IGHV1-69,IGHJ2,CQQYNNFLTF,IGKV3-15,COV2-2479,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVAATPGWFDPW,IGHV1-69,IGHJ3,CQQYNNFLTF,IGKV3-15,COV2-2479,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVAATPGWFDPW,IGHV1-69,IGHJ4,CQQYNNFLTF,IGKV3-15,COV2-2479,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVAATPGWFDPW,IGHV1-69,IGHJ5,CQQYNNFLTF,IGKV3-15,COV2-2479,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGVVAATPGWFDPW,IGHV1-69,IGHJ6,CQQYNNFLTF,IGKV3-15,COV2-2479,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ1,CQSYDSRLSGFVVF,IGLV1-40,COV2-2790,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ2,CQSYDSRLSGFVVF,IGLV1-40,COV2-2790,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ3,CQSYDSRLSGFVVF,IGLV1-40,COV2-2790,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ4,CQSYDSRLSGFVVF,IGLV1-40,COV2-2790,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ5,CQSYDSRLSGFVVF,IGLV1-40,COV2-2790,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSYDILTGYRDAFDIW,IGHV3-53,IGHJ6,CQSYDSRLSGFVVF,IGLV1-40,COV2-2790,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASMTRMSEQTYYGMDVW,IGHV1-3,IGHJ1,CQQSYTTLLTF,IGKV1-39,COV2-2809,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASMTRMSEQTYYGMDVW,IGHV1-3,IGHJ2,CQQSYTTLLTF,IGKV1-39,COV2-2809,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASMTRMSEQTYYGMDVW,IGHV1-3,IGHJ3,CQQSYTTLLTF,IGKV1-39,COV2-2809,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASMTRMSEQTYYGMDVW,IGHV1-3,IGHJ4,CQQSYTTLLTF,IGKV1-39,COV2-2809,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASMTRMSEQTYYGMDVW,IGHV1-3,IGHJ5,CQQSYTTLLTF,IGKV1-39,COV2-2809,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASMTRMSEQTYYGMDVW,IGHV1-3,IGHJ6,CQQSYTTLLTF,IGKV1-39,COV2-2809,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAAVPAAGEFDYW,IGHV1-46,IGHJ1,CQQYNSYSYTF,IGKV1-5,COV2-2891,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAAVPAAGEFDYW,IGHV1-46,IGHJ2,CQQYNSYSYTF,IGKV1-5,COV2-2891,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAAVPAAGEFDYW,IGHV1-46,IGHJ3,CQQYNSYSYTF,IGKV1-5,COV2-2891,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAAVPAAGEFDYW,IGHV1-46,IGHJ4,CQQYNSYSYTF,IGKV1-5,COV2-2891,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAAVPAAGEFDYW,IGHV1-46,IGHJ5,CQQYNSYSYTF,IGKV1-5,COV2-2891,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAAVPAAGEFDYW,IGHV1-46,IGHJ6,CQQYNSYSYTF,IGKV1-5,COV2-2891,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ1,CQSYDGINRWLVF,IGLV6-57,COV2-2370,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ2,CQSYDGINRWLVF,IGLV6-57,COV2-2370,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ3,CQSYDGINRWLVF,IGLV6-57,COV2-2370,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ4,CQSYDGINRWLVF,IGLV6-57,COV2-2370,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ5,CQSYDGINRWLVF,IGLV6-57,COV2-2370,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ6,CQSYDGINRWLVF,IGLV6-57,COV2-2370,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ1,CQLLNSHPLTF,IGKV1-9,COV2-2952,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ2,CQLLNSHPLTF,IGKV1-9,COV2-2952,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ3,CQLLNSHPLTF,IGKV1-9,COV2-2952,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ4,CQLLNSHPLTF,IGKV1-9,COV2-2952,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ5,CQLLNSHPLTF,IGKV1-9,COV2-2952,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ6,CQLLNSHPLTF,IGKV1-9,COV2-2952,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ1,CLVWDDSLNGLVF,IGLV1-44,COV2-2562,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ2,CLVWDDSLNGLVF,IGLV1-44,COV2-2562,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ3,CLVWDDSLNGLVF,IGLV1-44,COV2-2562,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ4,CLVWDDSLNGLVF,IGLV1-44,COV2-2562,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ5,CLVWDDSLNGLVF,IGLV1-44,COV2-2562,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARMRTGWPTHGRPDDFW,IGHV1-8,IGHJ6,CLVWDDSLNGLVF,IGLV1-44,COV2-2562,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ1,CQSYDGINRWLVF,IGLV6-57,COV2-2137,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ2,CQSYDGINRWLVF,IGLV6-57,COV2-2137,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ3,CQSYDGINRWLVF,IGLV6-57,COV2-2137,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ4,CQSYDGINRWLVF,IGLV6-57,COV2-2137,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ5,CQSYDGINRWLVF,IGLV6-57,COV2-2137,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ6,CQSYDGINRWLVF,IGLV6-57,COV2-2137,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHPVDGYNYGYSDLW,IGHV4-39,IGHJ1,CQQYGNSPFTF,IGKV3D-20,COV2-2631,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHPVDGYNYGYSDLW,IGHV4-39,IGHJ2,CQQYGNSPFTF,IGKV3D-20,COV2-2631,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHPVDGYNYGYSDLW,IGHV4-39,IGHJ3,CQQYGNSPFTF,IGKV3D-20,COV2-2631,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHPVDGYNYGYSDLW,IGHV4-39,IGHJ4,CQQYGNSPFTF,IGKV3D-20,COV2-2631,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHPVDGYNYGYSDLW,IGHV4-39,IGHJ5,CQQYGNSPFTF,IGKV3D-20,COV2-2631,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHPVDGYNYGYSDLW,IGHV4-39,IGHJ6,CQQYGNSPFTF,IGKV3D-20,COV2-2631,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDDNSPQGSGWYFYYYYAMDVW,IGHV3-30-3,IGHJ1,CGTWDSSLSAYVF,IGLV1-51,COV2-2768,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDDNSPQGSGWYFYYYYAMDVW,IGHV3-30-3,IGHJ2,CGTWDSSLSAYVF,IGLV1-51,COV2-2768,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDDNSPQGSGWYFYYYYAMDVW,IGHV3-30-3,IGHJ3,CGTWDSSLSAYVF,IGLV1-51,COV2-2768,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDDNSPQGSGWYFYYYYAMDVW,IGHV3-30-3,IGHJ4,CGTWDSSLSAYVF,IGLV1-51,COV2-2768,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDDNSPQGSGWYFYYYYAMDVW,IGHV3-30-3,IGHJ5,CGTWDSSLSAYVF,IGLV1-51,COV2-2768,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDDNSPQGSGWYFYYYYAMDVW,IGHV3-30-3,IGHJ6,CGTWDSSLSAYVF,IGLV1-51,COV2-2768,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHIPAWGYKW,IGHV3-53,IGHJ1,CHQYDYLPYTF,IGKV1-33,COV2-2434,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHIPAWGYKW,IGHV3-53,IGHJ2,CHQYDYLPYTF,IGKV1-33,COV2-2434,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHIPAWGYKW,IGHV3-53,IGHJ3,CHQYDYLPYTF,IGKV1-33,COV2-2434,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHIPAWGYKW,IGHV3-53,IGHJ4,CHQYDYLPYTF,IGKV1-33,COV2-2434,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHIPAWGYKW,IGHV3-53,IGHJ5,CHQYDYLPYTF,IGKV1-33,COV2-2434,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHIPAWGYKW,IGHV3-53,IGHJ6,CHQYDYLPYTF,IGKV1-33,COV2-2434,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ1,CQQYDNLPPVF,IGKV1-33,COV2-2752,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ2,CQQYDNLPPVF,IGKV1-33,COV2-2752,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ3,CQQYDNLPPVF,IGKV1-33,COV2-2752,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ4,CQQYDNLPPVF,IGKV1-33,COV2-2752,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ5,CQQYDNLPPVF,IGKV1-33,COV2-2752,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDFLRWHDLW,IGHV3-53,IGHJ6,CQQYDNLPPVF,IGKV1-33,COV2-2752,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGGYYSPFDYW,IGHV3-66,IGHJ1,CQQSYSTPQTF,IGKV1-39,COV2-2832,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGGYYSPFDYW,IGHV3-66,IGHJ2,CQQSYSTPQTF,IGKV1-39,COV2-2832,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGGYYSPFDYW,IGHV3-66,IGHJ3,CQQSYSTPQTF,IGKV1-39,COV2-2832,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGGYYSPFDYW,IGHV3-66,IGHJ4,CQQSYSTPQTF,IGKV1-39,COV2-2832,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGGYYSPFDYW,IGHV3-66,IGHJ5,CQQSYSTPQTF,IGKV1-39,COV2-2832,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGGYYSPFDYW,IGHV3-66,IGHJ6,CQQSYSTPQTF,IGKV1-39,COV2-2832,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ1,CQLLNSHPLTF,IGKV1-9,COV2-2165,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ2,CQLLNSHPLTF,IGKV1-9,COV2-2165,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ3,CQLLNSHPLTF,IGKV1-9,COV2-2165,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ4,CQLLNSHPLTF,IGKV1-9,COV2-2165,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ5,CQLLNSHPLTF,IGKV1-9,COV2-2165,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLVTYGLDVW,IGHV3-66,IGHJ6,CQLLNSHPLTF,IGKV1-9,COV2-2165,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGPNKEVLYFGELLDYGMDVW,IGHV3-30,IGHJ1,CMQSIQLPYTF,IGKV2D-29,COV2-2955,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGPNKEVLYFGELLDYGMDVW,IGHV3-30,IGHJ2,CMQSIQLPYTF,IGKV2D-29,COV2-2955,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGPNKEVLYFGELLDYGMDVW,IGHV3-30,IGHJ3,CMQSIQLPYTF,IGKV2D-29,COV2-2955,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGPNKEVLYFGELLDYGMDVW,IGHV3-30,IGHJ4,CMQSIQLPYTF,IGKV2D-29,COV2-2955,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGPNKEVLYFGELLDYGMDVW,IGHV3-30,IGHJ5,CMQSIQLPYTF,IGKV2D-29,COV2-2955,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGPNKEVLYFGELLDYGMDVW,IGHV3-30,IGHJ6,CMQSIQLPYTF,IGKV2D-29,COV2-2955,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHTVDCGGDCFPNDAFDIW,IGHV4-39,IGHJ1,CNFRDSSGHHPVF,IGLV3-19,COV2-2499,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHTVDCGGDCFPNDAFDIW,IGHV4-39,IGHJ2,CNFRDSSGHHPVF,IGLV3-19,COV2-2499,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHTVDCGGDCFPNDAFDIW,IGHV4-39,IGHJ3,CNFRDSSGHHPVF,IGLV3-19,COV2-2499,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHTVDCGGDCFPNDAFDIW,IGHV4-39,IGHJ4,CNFRDSSGHHPVF,IGLV3-19,COV2-2499,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHTVDCGGDCFPNDAFDIW,IGHV4-39,IGHJ5,CNFRDSSGHHPVF,IGLV3-19,COV2-2499,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHTVDCGGDCFPNDAFDIW,IGHV4-39,IGHJ6,CNFRDSSGHHPVF,IGLV3-19,COV2-2499,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCSSTTCPAETYYYMDVW,IGHV3-9,IGHJ1,CQVWDGINDRVVF,IGLV3-21,COV2-2751,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCSSTTCPAETYYYMDVW,IGHV3-9,IGHJ2,CQVWDGINDRVVF,IGLV3-21,COV2-2751,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCSSTTCPAETYYYMDVW,IGHV3-9,IGHJ3,CQVWDGINDRVVF,IGLV3-21,COV2-2751,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCSSTTCPAETYYYMDVW,IGHV3-9,IGHJ4,CQVWDGINDRVVF,IGLV3-21,COV2-2751,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCSSTTCPAETYYYMDVW,IGHV3-9,IGHJ5,CQVWDGINDRVVF,IGLV3-21,COV2-2751,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCSSTTCPAETYYYMDVW,IGHV3-9,IGHJ6,CQVWDGINDRVVF,IGLV3-21,COV2-2751,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVVGYFDCW,IGHV3-66,IGHJ1,CQQLNSYPGYTF,IGKV1-9,COV2-2835,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVVGYFDCW,IGHV3-66,IGHJ2,CQQLNSYPGYTF,IGKV1-9,COV2-2835,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVVGYFDCW,IGHV3-66,IGHJ3,CQQLNSYPGYTF,IGKV1-9,COV2-2835,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVVGYFDCW,IGHV3-66,IGHJ4,CQQLNSYPGYTF,IGKV1-9,COV2-2835,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVVGYFDCW,IGHV3-66,IGHJ5,CQQLNSYPGYTF,IGKV1-9,COV2-2835,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVVGYFDCW,IGHV3-66,IGHJ6,CQQLNSYPGYTF,IGKV1-9,COV2-2835,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQIVVLFDMW,IGHV2-5,IGHJ1,CSSYTSSSTLVLF,IGLV2-14,COV2-2268,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQIVVLFDMW,IGHV2-5,IGHJ2,CSSYTSSSTLVLF,IGLV2-14,COV2-2268,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQIVVLFDMW,IGHV2-5,IGHJ3,CSSYTSSSTLVLF,IGLV2-14,COV2-2268,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQIVVLFDMW,IGHV2-5,IGHJ4,CSSYTSSSTLVLF,IGLV2-14,COV2-2268,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQIVVLFDMW,IGHV2-5,IGHJ5,CSSYTSSSTLVLF,IGLV2-14,COV2-2268,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHQIVVLFDMW,IGHV2-5,IGHJ6,CSSYTSSSTLVLF,IGLV2-14,COV2-2268,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ1,CAAWDDSLSGLIF,IGLV1-47,COV2-2760,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ2,CAAWDDSLSGLIF,IGLV1-47,COV2-2760,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ3,CAAWDDSLSGLIF,IGLV1-47,COV2-2760,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ4,CAAWDDSLSGLIF,IGLV1-47,COV2-2760,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ5,CAAWDDSLSGLIF,IGLV1-47,COV2-2760,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ6,CAAWDDSLSGLIF,IGLV1-47,COV2-2760,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ1,CQQYVEPPFTF,IGKV3-20,COV2-2632,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ2,CQQYVEPPFTF,IGKV3-20,COV2-2632,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ3,CQQYVEPPFTF,IGKV3-20,COV2-2632,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ4,CQQYVEPPFTF,IGKV3-20,COV2-2632,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ5,CQQYVEPPFTF,IGKV3-20,COV2-2632,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVLGYGRPNNYYDGRNVWDYW,IGHV1-2,IGHJ6,CQQYVEPPFTF,IGKV3-20,COV2-2632,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAGYYAYVWGSYRFEYFDNW,IGHV3-9,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV2-2730,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAGYYAYVWGSYRFEYFDNW,IGHV3-9,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV2-2730,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAGYYAYVWGSYRFEYFDNW,IGHV3-9,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV2-2730,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAGYYAYVWGSYRFEYFDNW,IGHV3-9,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV2-2730,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAGYYAYVWGSYRFEYFDNW,IGHV3-9,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV2-2730,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKAGYYAYVWGSYRFEYFDNW,IGHV3-9,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV2-2730,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGTLIPAHRGAFDIW,IGHV1-46,IGHJ1,CQQYGNSPQF,IGKV3-20,COV2-2039,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGTLIPAHRGAFDIW,IGHV1-46,IGHJ2,CQQYGNSPQF,IGKV3-20,COV2-2039,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGTLIPAHRGAFDIW,IGHV1-46,IGHJ3,CQQYGNSPQF,IGKV3-20,COV2-2039,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGTLIPAHRGAFDIW,IGHV1-46,IGHJ4,CQQYGNSPQF,IGKV3-20,COV2-2039,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGTLIPAHRGAFDIW,IGHV1-46,IGHJ5,CQQYGNSPQF,IGKV3-20,COV2-2039,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGTLIPAHRGAFDIW,IGHV1-46,IGHJ6,CQQYGNSPQF,IGKV3-20,COV2-2039,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ1,CNSRDSSGNAVVF,IGLV3-19,COV2-2518,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ2,CNSRDSSGNAVVF,IGLV3-19,COV2-2518,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ3,CNSRDSSGNAVVF,IGLV3-19,COV2-2518,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ4,CNSRDSSGNAVVF,IGLV3-19,COV2-2518,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ5,CNSRDSSGNAVVF,IGLV3-19,COV2-2518,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDIIRQGEDGMDVW,IGHV3-9,IGHJ6,CNSRDSSGNAVVF,IGLV3-19,COV2-2518,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLHQDWVVVVAANVYGMDVW,IGHV3-33,IGHJ1,CNSRDSSGNPRWF,IGLV3-19,COV2-2939,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLHQDWVVVVAANVYGMDVW,IGHV3-33,IGHJ2,CNSRDSSGNPRWF,IGLV3-19,COV2-2939,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLHQDWVVVVAANVYGMDVW,IGHV3-33,IGHJ3,CNSRDSSGNPRWF,IGLV3-19,COV2-2939,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLHQDWVVVVAANVYGMDVW,IGHV3-33,IGHJ4,CNSRDSSGNPRWF,IGLV3-19,COV2-2939,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLHQDWVVVVAANVYGMDVW,IGHV3-33,IGHJ5,CNSRDSSGNPRWF,IGLV3-19,COV2-2939,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLHQDWVVVVAANVYGMDVW,IGHV3-33,IGHJ6,CNSRDSSGNPRWF,IGLV3-19,COV2-2939,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETPVTAIDYW,IGHV2-70,IGHJ1,CQQSYSTPRTF,IGKV1-39,COV2-2807,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETPVTAIDYW,IGHV2-70,IGHJ2,CQQSYSTPRTF,IGKV1-39,COV2-2807,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETPVTAIDYW,IGHV2-70,IGHJ3,CQQSYSTPRTF,IGKV1-39,COV2-2807,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETPVTAIDYW,IGHV2-70,IGHJ4,CQQSYSTPRTF,IGKV1-39,COV2-2807,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETPVTAIDYW,IGHV2-70,IGHJ5,CQQSYSTPRTF,IGKV1-39,COV2-2807,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARETPVTAIDYW,IGHV2-70,IGHJ6,CQQSYSTPRTF,IGKV1-39,COV2-2807,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ1,CQHYGSSRGWTF,IGKV3-20,COV2-2838,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ2,CQHYGSSRGWTF,IGKV3-20,COV2-2838,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ3,CQHYGSSRGWTF,IGKV3-20,COV2-2838,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ4,CQHYGSSRGWTF,IGKV3-20,COV2-2838,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ5,CQHYGSSRGWTF,IGKV3-20,COV2-2838,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ6,CQHYGSSRGWTF,IGKV3-20,COV2-2838,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDYYGSGSVYWYFDLW,IGHV3-48,IGHJ1,CCSYAGIWVF,IGLV2-11,COV2-2585,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDYYGSGSVYWYFDLW,IGHV3-48,IGHJ2,CCSYAGIWVF,IGLV2-11,COV2-2585,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDYYGSGSVYWYFDLW,IGHV3-48,IGHJ3,CCSYAGIWVF,IGLV2-11,COV2-2585,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDYYGSGSVYWYFDLW,IGHV3-48,IGHJ4,CCSYAGIWVF,IGLV2-11,COV2-2585,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDYYGSGSVYWYFDLW,IGHV3-48,IGHJ5,CCSYAGIWVF,IGLV2-11,COV2-2585,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDYYGSGSVYWYFDLW,IGHV3-48,IGHJ6,CCSYAGIWVF,IGLV2-11,COV2-2585,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ1,CQQSYSSLSITF,IGKV1-39,COV2-2110,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ2,CQQSYSSLSITF,IGKV1-39,COV2-2110,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ3,CQQSYSSLSITF,IGKV1-39,COV2-2110,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ4,CQQSYSSLSITF,IGKV1-39,COV2-2110,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ5,CQQSYSSLSITF,IGKV1-39,COV2-2110,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ6,CQQSYSSLSITF,IGKV1-39,COV2-2110,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,COV2-2355,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,COV2-2355,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,COV2-2355,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,COV2-2355,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,COV2-2355,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPHCNRTSCYDAFDLW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,COV2-2355,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ1,CQQSYSNPSYTF,IGKV1-9,COV2-2822,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ2,CQQSYSNPSYTF,IGKV1-9,COV2-2822,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ3,CQQSYSNPSYTF,IGKV1-9,COV2-2822,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ4,CQQSYSNPSYTF,IGKV1-9,COV2-2822,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ5,CQQSYSNPSYTF,IGKV1-9,COV2-2822,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ6,CQQSYSNPSYTF,IGKV1-9,COV2-2822,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ1,CQQLNSYSFETF,IGKV1-9,COV2-2733,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ2,CQQLNSYSFETF,IGKV1-9,COV2-2733,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ3,CQQLNSYSFETF,IGKV1-9,COV2-2733,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ4,CQQLNSYSFETF,IGKV1-9,COV2-2733,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ5,CQQLNSYSFETF,IGKV1-9,COV2-2733,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPEPDAFDIW,IGHV3-53,IGHJ6,CQQLNSYSFETF,IGKV1-9,COV2-2733,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRWLRGGIDFW,IGHV4-59,IGHJ1,CQSYDSNNQVF,IGLV6-57,COV2-2841,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRWLRGGIDFW,IGHV4-59,IGHJ2,CQSYDSNNQVF,IGLV6-57,COV2-2841,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRWLRGGIDFW,IGHV4-59,IGHJ3,CQSYDSNNQVF,IGLV6-57,COV2-2841,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRWLRGGIDFW,IGHV4-59,IGHJ4,CQSYDSNNQVF,IGLV6-57,COV2-2841,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRWLRGGIDFW,IGHV4-59,IGHJ5,CQSYDSNNQVF,IGLV6-57,COV2-2841,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLRWLRGGIDFW,IGHV4-59,IGHJ6,CQSYDSNNQVF,IGLV6-57,COV2-2841,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ1,CATWDDSLNGPVF,IGLV1-44,COV2-2789,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ2,CATWDDSLNGPVF,IGLV1-44,COV2-2789,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ3,CATWDDSLNGPVF,IGLV1-44,COV2-2789,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ4,CATWDDSLNGPVF,IGLV1-44,COV2-2789,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ5,CATWDDSLNGPVF,IGLV1-44,COV2-2789,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGFHVPAALRNWFDPW,IGHV1-46,IGHJ6,CATWDDSLNGPVF,IGLV1-44,COV2-2789,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ1,CQQSYEIPPWTF,IGKV1-39,COV2-2786,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ2,CQQSYEIPPWTF,IGKV1-39,COV2-2786,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ3,CQQSYEIPPWTF,IGKV1-39,COV2-2786,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ4,CQQSYEIPPWTF,IGKV1-39,COV2-2786,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ5,CQQSYEIPPWTF,IGKV1-39,COV2-2786,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ6,CQQSYEIPPWTF,IGKV1-39,COV2-2786,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ1,CQQYYNWPLTF,IGKV3-15,COV2-2853,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ2,CQQYYNWPLTF,IGKV3-15,COV2-2853,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ3,CQQYYNWPLTF,IGKV3-15,COV2-2853,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ4,CQQYYNWPLTF,IGKV3-15,COV2-2853,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ5,CQQYYNWPLTF,IGKV3-15,COV2-2853,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAIPPNSRAEIDYW,IGHV1-46,IGHJ6,CQQYYNWPLTF,IGKV3-15,COV2-2853,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGEWRIVPGGRDYFDYW,IGHV1-46,IGHJ1,CHQSYGVPITF,IGKV1-39,COV2-2352,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGEWRIVPGGRDYFDYW,IGHV1-46,IGHJ2,CHQSYGVPITF,IGKV1-39,COV2-2352,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGEWRIVPGGRDYFDYW,IGHV1-46,IGHJ3,CHQSYGVPITF,IGKV1-39,COV2-2352,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGEWRIVPGGRDYFDYW,IGHV1-46,IGHJ4,CHQSYGVPITF,IGKV1-39,COV2-2352,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGEWRIVPGGRDYFDYW,IGHV1-46,IGHJ5,CHQSYGVPITF,IGKV1-39,COV2-2352,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGEWRIVPGGRDYFDYW,IGHV1-46,IGHJ6,CHQSYGVPITF,IGKV1-39,COV2-2352,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARERSGTYFFDYW,IGHV1-46,IGHJ1,CAVWDDSLHSYVF,IGLV1-44,COV2-2801,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARERSGTYFFDYW,IGHV1-46,IGHJ2,CAVWDDSLHSYVF,IGLV1-44,COV2-2801,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARERSGTYFFDYW,IGHV1-46,IGHJ3,CAVWDDSLHSYVF,IGLV1-44,COV2-2801,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARERSGTYFFDYW,IGHV1-46,IGHJ4,CAVWDDSLHSYVF,IGLV1-44,COV2-2801,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARERSGTYFFDYW,IGHV1-46,IGHJ5,CAVWDDSLHSYVF,IGLV1-44,COV2-2801,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARERSGTYFFDYW,IGHV1-46,IGHJ6,CAVWDDSLHSYVF,IGLV1-44,COV2-2801,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPWLRGDIDYW,IGHV3-74,IGHJ1,CQSYDGSNHAVVF,IGLV6-57,COV2-2253,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPWLRGDIDYW,IGHV3-74,IGHJ2,CQSYDGSNHAVVF,IGLV6-57,COV2-2253,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPWLRGDIDYW,IGHV3-74,IGHJ3,CQSYDGSNHAVVF,IGLV6-57,COV2-2253,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPWLRGDIDYW,IGHV3-74,IGHJ4,CQSYDGSNHAVVF,IGLV6-57,COV2-2253,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPWLRGDIDYW,IGHV3-74,IGHJ5,CQSYDGSNHAVVF,IGLV6-57,COV2-2253,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPWLRGDIDYW,IGHV3-74,IGHJ6,CQSYDGSNHAVVF,IGLV6-57,COV2-2253,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ1,CQQYNSYPYTF,IGKV1-5,COV2-3010,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ2,CQQYNSYPYTF,IGKV1-5,COV2-3010,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ3,CQQYNSYPYTF,IGKV1-5,COV2-3010,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ4,CQQYNSYPYTF,IGKV1-5,COV2-3010,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ5,CQQYNSYPYTF,IGKV1-5,COV2-3010,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ6,CQQYNSYPYTF,IGKV1-5,COV2-3010,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ1,CQQYANLPFTF,IGKV1-33,COV2-3013,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ2,CQQYANLPFTF,IGKV1-33,COV2-3013,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ3,CQQYANLPFTF,IGKV1-33,COV2-3013,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ4,CQQYANLPFTF,IGKV1-33,COV2-3013,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ5,CQQYANLPFTF,IGKV1-33,COV2-3013,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ6,CQQYANLPFTF,IGKV1-33,COV2-3013,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLDVGGYDFVSGHYYAFDIW,IGHV3-9,IGHJ1,CMQGTHWPYTF,IGKV2-30,COV2-2945,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLDVGGYDFVSGHYYAFDIW,IGHV3-9,IGHJ2,CMQGTHWPYTF,IGKV2-30,COV2-2945,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLDVGGYDFVSGHYYAFDIW,IGHV3-9,IGHJ3,CMQGTHWPYTF,IGKV2-30,COV2-2945,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLDVGGYDFVSGHYYAFDIW,IGHV3-9,IGHJ4,CMQGTHWPYTF,IGKV2-30,COV2-2945,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLDVGGYDFVSGHYYAFDIW,IGHV3-9,IGHJ5,CMQGTHWPYTF,IGKV2-30,COV2-2945,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLDVGGYDFVSGHYYAFDIW,IGHV3-9,IGHJ6,CMQGTHWPYTF,IGKV2-30,COV2-2945,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ1,CQSYDGINRAWVF,IGLV6-57,COV2-2103,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ2,CQSYDGINRAWVF,IGLV6-57,COV2-2103,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ3,CQSYDGINRAWVF,IGLV6-57,COV2-2103,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ4,CQSYDGINRAWVF,IGLV6-57,COV2-2103,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ5,CQSYDGINRAWVF,IGLV6-57,COV2-2103,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ6,CQSYDGINRAWVF,IGLV6-57,COV2-2103,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ1,CQQSYEIPPWTF,IGKV1-39,COV2-2111,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ2,CQQSYEIPPWTF,IGKV1-39,COV2-2111,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ3,CQQSYEIPPWTF,IGKV1-39,COV2-2111,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ4,CQQSYEIPPWTF,IGKV1-39,COV2-2111,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ5,CQQSYEIPPWTF,IGKV1-39,COV2-2111,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ6,CQQSYEIPPWTF,IGKV1-39,COV2-2111,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLLWLRGHFDYW,IGHV4-39,IGHJ1,CQSYDSSNYWVF,IGLV6-57,COV2-2677,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLLWLRGHFDYW,IGHV4-39,IGHJ2,CQSYDSSNYWVF,IGLV6-57,COV2-2677,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLLWLRGHFDYW,IGHV4-39,IGHJ3,CQSYDSSNYWVF,IGLV6-57,COV2-2677,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLLWLRGHFDYW,IGHV4-39,IGHJ4,CQSYDSSNYWVF,IGLV6-57,COV2-2677,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLLWLRGHFDYW,IGHV4-39,IGHJ5,CQSYDSSNYWVF,IGLV6-57,COV2-2677,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLLWLRGHFDYW,IGHV4-39,IGHJ6,CQSYDSSNYWVF,IGLV6-57,COV2-2677,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASSSWLRGAFDIW,IGHV3-53,IGHJ1,CQSYDSSKYVVF,IGLV6-57,COV2-2354,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASSSWLRGAFDIW,IGHV3-53,IGHJ2,CQSYDSSKYVVF,IGLV6-57,COV2-2354,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASSSWLRGAFDIW,IGHV3-53,IGHJ3,CQSYDSSKYVVF,IGLV6-57,COV2-2354,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASSSWLRGAFDIW,IGHV3-53,IGHJ4,CQSYDSSKYVVF,IGLV6-57,COV2-2354,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASSSWLRGAFDIW,IGHV3-53,IGHJ5,CQSYDSSKYVVF,IGLV6-57,COV2-2354,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASSSWLRGAFDIW,IGHV3-53,IGHJ6,CQSYDSSKYVVF,IGLV6-57,COV2-2354,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ1,CQSYDSSDVVF,IGLV6-57,COV2-2842,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ2,CQSYDSSDVVF,IGLV6-57,COV2-2842,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ3,CQSYDSSDVVF,IGLV6-57,COV2-2842,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ4,CQSYDSSDVVF,IGLV6-57,COV2-2842,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ5,CQSYDSSDVVF,IGLV6-57,COV2-2842,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGFVPNVLYYFDYW,IGHV1-46,IGHJ6,CQSYDSSDVVF,IGLV6-57,COV2-2842,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ1,CQSYDGINRWLVF,IGLV6-57,COV2-2734,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ2,CQSYDGINRWLVF,IGLV6-57,COV2-2734,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ3,CQSYDGINRWLVF,IGLV6-57,COV2-2734,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ4,CQSYDGINRWLVF,IGLV6-57,COV2-2734,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ5,CQSYDGINRWLVF,IGLV6-57,COV2-2734,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSPVPPTIVGASYW,IGHV4-61,IGHJ6,CQSYDGINRWLVF,IGLV6-57,COV2-2734,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTTQGGDYGDNLYYLDYW,IGHV1-69,IGHJ1,CQVWDSSSDRLYVF,IGLV3-21,COV2-2821,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTTQGGDYGDNLYYLDYW,IGHV1-69,IGHJ2,CQVWDSSSDRLYVF,IGLV3-21,COV2-2821,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTTQGGDYGDNLYYLDYW,IGHV1-69,IGHJ3,CQVWDSSSDRLYVF,IGLV3-21,COV2-2821,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTTQGGDYGDNLYYLDYW,IGHV1-69,IGHJ4,CQVWDSSSDRLYVF,IGLV3-21,COV2-2821,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTTQGGDYGDNLYYLDYW,IGHV1-69,IGHJ5,CQVWDSSSDRLYVF,IGLV3-21,COV2-2821,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTTQGGDYGDNLYYLDYW,IGHV1-69,IGHJ6,CQVWDSSSDRLYVF,IGLV3-21,COV2-2821,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ1,CQQSYSSLSITF,IGKV1-39,COV2-2358,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ2,CQQSYSSLSITF,IGKV1-39,COV2-2358,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ3,CQQSYSSLSITF,IGKV1-39,COV2-2358,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ4,CQQSYSSLSITF,IGKV1-39,COV2-2358,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ5,CQQSYSSLSITF,IGKV1-39,COV2-2358,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDIDSGYDPTPVFDYW,IGHV3-30-3,IGHJ6,CQQSYSSLSITF,IGKV1-39,COV2-2358,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CSRVRGSFYGSVGKNYGMDVW,IGHV3-49,IGHJ1,CMQALQTPLYTF,IGKV2-28,COV2-2357,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CSRVRGSFYGSVGKNYGMDVW,IGHV3-49,IGHJ2,CMQALQTPLYTF,IGKV2-28,COV2-2357,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CSRVRGSFYGSVGKNYGMDVW,IGHV3-49,IGHJ3,CMQALQTPLYTF,IGKV2-28,COV2-2357,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CSRVRGSFYGSVGKNYGMDVW,IGHV3-49,IGHJ4,CMQALQTPLYTF,IGKV2-28,COV2-2357,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CSRVRGSFYGSVGKNYGMDVW,IGHV3-49,IGHJ5,CMQALQTPLYTF,IGKV2-28,COV2-2357,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CSRVRGSFYGSVGKNYGMDVW,IGHV3-49,IGHJ6,CMQALQTPLYTF,IGKV2-28,COV2-2357,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ1,CQSYDGINRAWVF,IGLV6-57,COV2-2878,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ2,CQSYDGINRAWVF,IGLV6-57,COV2-2878,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ3,CQSYDGINRAWVF,IGLV6-57,COV2-2878,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ4,CQSYDGINRAWVF,IGLV6-57,COV2-2878,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ5,CQSYDGINRAWVF,IGLV6-57,COV2-2878,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGFYYGGADYW,IGHV3-7,IGHJ6,CQSYDGINRAWVF,IGLV6-57,COV2-2878,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGDGYNLRVPAYFDLW,IGHV4-31,IGHJ1,CQSADSSGYVF,IGLV3-25,COV2-2464,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGDGYNLRVPAYFDLW,IGHV4-31,IGHJ2,CQSADSSGYVF,IGLV3-25,COV2-2464,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGDGYNLRVPAYFDLW,IGHV4-31,IGHJ3,CQSADSSGYVF,IGLV3-25,COV2-2464,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGDGYNLRVPAYFDLW,IGHV4-31,IGHJ4,CQSADSSGYVF,IGLV3-25,COV2-2464,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGDGYNLRVPAYFDLW,IGHV4-31,IGHJ5,CQSADSSGYVF,IGLV3-25,COV2-2464,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGDGYNLRVPAYFDLW,IGHV4-31,IGHJ6,CQSADSSGYVF,IGLV3-25,COV2-2464,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ1,CQQYDNLPLAF,IGKV1-33,COV2-2808,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ2,CQQYDNLPLAF,IGKV1-33,COV2-2808,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ3,CQQYDNLPLAF,IGKV1-33,COV2-2808,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ4,CQQYDNLPLAF,IGKV1-33,COV2-2808,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ5,CQQYDNLPLAF,IGKV1-33,COV2-2808,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAPYCSSISCNDGFDIW,IGHV1-58,IGHJ6,CQQYDNLPLAF,IGKV1-33,COV2-2808,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARENDYGDYVEPRDYYYGMDVW,IGHV1-46,IGHJ1,CQSADSSAAYVVF,IGLV3-25,COV2-2863,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARENDYGDYVEPRDYYYGMDVW,IGHV1-46,IGHJ2,CQSADSSAAYVVF,IGLV3-25,COV2-2863,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARENDYGDYVEPRDYYYGMDVW,IGHV1-46,IGHJ3,CQSADSSAAYVVF,IGLV3-25,COV2-2863,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARENDYGDYVEPRDYYYGMDVW,IGHV1-46,IGHJ4,CQSADSSAAYVVF,IGLV3-25,COV2-2863,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARENDYGDYVEPRDYYYGMDVW,IGHV1-46,IGHJ5,CQSADSSAAYVVF,IGLV3-25,COV2-2863,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARENDYGDYVEPRDYYYGMDVW,IGHV1-46,IGHJ6,CQSADSSAAYVVF,IGLV3-25,COV2-2863,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ1,CQSVDSSGTYPHVIF,IGLV3-25,COV2-3029,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ2,CQSVDSSGTYPHVIF,IGLV3-25,COV2-3029,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ3,CQSVDSSGTYPHVIF,IGLV3-25,COV2-3029,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ4,CQSVDSSGTYPHVIF,IGLV3-25,COV2-3029,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ5,CQSVDSSGTYPHVIF,IGLV3-25,COV2-3029,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ6,CQSVDSSGTYPHVIF,IGLV3-25,COV2-3029,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ1,CQQSYEMPPWTF,IGKV1-39,COV2-2462,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ2,CQQSYEMPPWTF,IGKV1-39,COV2-2462,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ3,CQQSYEMPPWTF,IGKV1-39,COV2-2462,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ4,CQQSYEMPPWTF,IGKV1-39,COV2-2462,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ5,CQQSYEMPPWTF,IGKV1-39,COV2-2462,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVLYDSSGFYNWFDPW,IGHV3-13,IGHJ6,CQQSYEMPPWTF,IGKV1-39,COV2-2462,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ1,CQQYANLPFTF,IGKV1-33,COV2-2083,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ2,CQQYANLPFTF,IGKV1-33,COV2-2083,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ3,CQQYANLPFTF,IGKV1-33,COV2-2083,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ4,CQQYANLPFTF,IGKV1-33,COV2-2083,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ5,CQQYANLPFTF,IGKV1-33,COV2-2083,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ6,CQQYANLPFTF,IGKV1-33,COV2-2083,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSSITSLLGYYFDSW,IGHV3-9,IGHJ1,CQHRSNWPPRLTF,IGKV3-11,COV2-2313,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSSITSLLGYYFDSW,IGHV3-9,IGHJ2,CQHRSNWPPRLTF,IGKV3-11,COV2-2313,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSSITSLLGYYFDSW,IGHV3-9,IGHJ3,CQHRSNWPPRLTF,IGKV3-11,COV2-2313,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSSITSLLGYYFDSW,IGHV3-9,IGHJ4,CQHRSNWPPRLTF,IGKV3-11,COV2-2313,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSSITSLLGYYFDSW,IGHV3-9,IGHJ5,CQHRSNWPPRLTF,IGKV3-11,COV2-2313,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSSITSLLGYYFDSW,IGHV3-9,IGHJ6,CQHRSNWPPRLTF,IGKV3-11,COV2-2313,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ1,CQVWDSSSDHHVVF,IGLV3-21,COV2-2231,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ2,CQVWDSSSDHHVVF,IGLV3-21,COV2-2231,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ3,CQVWDSSSDHHVVF,IGLV3-21,COV2-2231,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ4,CQVWDSSSDHHVVF,IGLV3-21,COV2-2231,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ5,CQVWDSSSDHHVVF,IGLV3-21,COV2-2231,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ6,CQVWDSSSDHHVVF,IGLV3-21,COV2-2231,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQQIVPHADGFDIW,IGHV1-46,IGHJ1,CQQRSNWPPRTWTF,IGKV3-11,COV2-2516,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQQIVPHADGFDIW,IGHV1-46,IGHJ2,CQQRSNWPPRTWTF,IGKV3-11,COV2-2516,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQQIVPHADGFDIW,IGHV1-46,IGHJ3,CQQRSNWPPRTWTF,IGKV3-11,COV2-2516,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQQIVPHADGFDIW,IGHV1-46,IGHJ4,CQQRSNWPPRTWTF,IGKV3-11,COV2-2516,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQQIVPHADGFDIW,IGHV1-46,IGHJ5,CQQRSNWPPRTWTF,IGKV3-11,COV2-2516,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQQIVPHADGFDIW,IGHV1-46,IGHJ6,CQQRSNWPPRTWTF,IGKV3-11,COV2-2516,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVFETKVIRGGRYYYYYYMDVW,IGHV3-13,IGHJ1,CQQSYSNPSYTF,IGKV1-39,COV2-2817,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVFETKVIRGGRYYYYYYMDVW,IGHV3-13,IGHJ2,CQQSYSNPSYTF,IGKV1-39,COV2-2817,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVFETKVIRGGRYYYYYYMDVW,IGHV3-13,IGHJ3,CQQSYSNPSYTF,IGKV1-39,COV2-2817,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVFETKVIRGGRYYYYYYMDVW,IGHV3-13,IGHJ4,CQQSYSNPSYTF,IGKV1-39,COV2-2817,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVFETKVIRGGRYYYYYYMDVW,IGHV3-13,IGHJ5,CQQSYSNPSYTF,IGKV1-39,COV2-2817,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVFETKVIRGGRYYYYYYMDVW,IGHV3-13,IGHJ6,CQQSYSNPSYTF,IGKV1-39,COV2-2817,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ1,CQSYDSGNPIF,IGLV6-57,COV2-2331,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ2,CQSYDSGNPIF,IGLV6-57,COV2-2331,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ3,CQSYDSGNPIF,IGLV6-57,COV2-2331,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ4,CQSYDSGNPIF,IGLV6-57,COV2-2331,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ5,CQSYDSGNPIF,IGLV6-57,COV2-2331,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ6,CQSYDSGNPIF,IGLV6-57,COV2-2331,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ1,CQVWDSSSDHHVVF,IGLV3-21,COV2-2765,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ2,CQVWDSSSDHHVVF,IGLV3-21,COV2-2765,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ3,CQVWDSSSDHHVVF,IGLV3-21,COV2-2765,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ4,CQVWDSSSDHHVVF,IGLV3-21,COV2-2765,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ5,CQVWDSSSDHHVVF,IGLV3-21,COV2-2765,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ6,CQVWDSSSDHHVVF,IGLV3-21,COV2-2765,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGDSGYDLGAWYFDLW,IGHV3-13,IGHJ1,CQQSYSMPPITF,IGKV1-39,COV2-2758,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGDSGYDLGAWYFDLW,IGHV3-13,IGHJ2,CQQSYSMPPITF,IGKV1-39,COV2-2758,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGDSGYDLGAWYFDLW,IGHV3-13,IGHJ3,CQQSYSMPPITF,IGKV1-39,COV2-2758,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGDSGYDLGAWYFDLW,IGHV3-13,IGHJ4,CQQSYSMPPITF,IGKV1-39,COV2-2758,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGDSGYDLGAWYFDLW,IGHV3-13,IGHJ5,CQQSYSMPPITF,IGKV1-39,COV2-2758,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGDSGYDLGAWYFDLW,IGHV3-13,IGHJ6,CQQSYSMPPITF,IGKV1-39,COV2-2758,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ1,CQQYDNLPLAF,IGKV1-33,COV2-2944,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ2,CQQYDNLPLAF,IGKV1-33,COV2-2944,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ3,CQQYDNLPLAF,IGKV1-33,COV2-2944,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ4,CQQYDNLPLAF,IGKV1-33,COV2-2944,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ5,CQQYDNLPLAF,IGKV1-33,COV2-2944,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ6,CQQYDNLPLAF,IGKV1-33,COV2-2944,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTEWLLSDNWFDSW,IGHV2-26,IGHJ1,CQSSDSSGVVF,IGLV3-25,COV2-2031,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTEWLLSDNWFDSW,IGHV2-26,IGHJ2,CQSSDSSGVVF,IGLV3-25,COV2-2031,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTEWLLSDNWFDSW,IGHV2-26,IGHJ3,CQSSDSSGVVF,IGLV3-25,COV2-2031,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTEWLLSDNWFDSW,IGHV2-26,IGHJ4,CQSSDSSGVVF,IGLV3-25,COV2-2031,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTEWLLSDNWFDSW,IGHV2-26,IGHJ5,CQSSDSSGVVF,IGLV3-25,COV2-2031,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTEWLLSDNWFDSW,IGHV2-26,IGHJ6,CQSSDSSGVVF,IGLV3-25,COV2-2031,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ1,CAAWDDSLSSWVF,IGLV1-47,COV2-2329,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ2,CAAWDDSLSSWVF,IGLV1-47,COV2-2329,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ3,CAAWDDSLSSWVF,IGLV1-47,COV2-2329,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ4,CAAWDDSLSSWVF,IGLV1-47,COV2-2329,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ5,CAAWDDSLSSWVF,IGLV1-47,COV2-2329,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ6,CAAWDDSLSSWVF,IGLV1-47,COV2-2329,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLTGSSAYKDEIYFDYW,IGHV1-69,IGHJ1,CQSADSSGSRF,IGLV3-25,COV2-2783,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLTGSSAYKDEIYFDYW,IGHV1-69,IGHJ2,CQSADSSGSRF,IGLV3-25,COV2-2783,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLTGSSAYKDEIYFDYW,IGHV1-69,IGHJ3,CQSADSSGSRF,IGLV3-25,COV2-2783,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLTGSSAYKDEIYFDYW,IGHV1-69,IGHJ4,CQSADSSGSRF,IGLV3-25,COV2-2783,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLTGSSAYKDEIYFDYW,IGHV1-69,IGHJ5,CQSADSSGSRF,IGLV3-25,COV2-2783,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLTGSSAYKDEIYFDYW,IGHV1-69,IGHJ6,CQSADSSGSRF,IGLV3-25,COV2-2783,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGDGSYLMDYFDYW,IGHV3-30,IGHJ1,CQQYDDWPPEVTF,IGKV3-15,COV2-2894,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGDGSYLMDYFDYW,IGHV3-30,IGHJ2,CQQYDDWPPEVTF,IGKV3-15,COV2-2894,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGDGSYLMDYFDYW,IGHV3-30,IGHJ3,CQQYDDWPPEVTF,IGKV3-15,COV2-2894,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGDGSYLMDYFDYW,IGHV3-30,IGHJ4,CQQYDDWPPEVTF,IGKV3-15,COV2-2894,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGDGSYLMDYFDYW,IGHV3-30,IGHJ5,CQQYDDWPPEVTF,IGKV3-15,COV2-2894,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGDGSYLMDYFDYW,IGHV3-30,IGHJ6,CQQYDDWPPEVTF,IGKV3-15,COV2-2894,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNDGRPNPLEYYFDYW,IGHV3-7,IGHJ1,CQSADSSGTSVLF,IGLV3-25,COV2-2794,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNDGRPNPLEYYFDYW,IGHV3-7,IGHJ2,CQSADSSGTSVLF,IGLV3-25,COV2-2794,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNDGRPNPLEYYFDYW,IGHV3-7,IGHJ3,CQSADSSGTSVLF,IGLV3-25,COV2-2794,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNDGRPNPLEYYFDYW,IGHV3-7,IGHJ4,CQSADSSGTSVLF,IGLV3-25,COV2-2794,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNDGRPNPLEYYFDYW,IGHV3-7,IGHJ5,CQSADSSGTSVLF,IGLV3-25,COV2-2794,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNDGRPNPLEYYFDYW,IGHV3-7,IGHJ6,CQSADSSGTSVLF,IGLV3-25,COV2-2794,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ1,CQQSYTTLLTF,IGKV1-39,COV2-2749,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ2,CQQSYTTLLTF,IGKV1-39,COV2-2749,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ3,CQQSYTTLLTF,IGKV1-39,COV2-2749,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ4,CQQSYTTLLTF,IGKV1-39,COV2-2749,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ5,CQQSYTTLLTF,IGKV1-39,COV2-2749,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGYSQGYYYYYMDVW,IGHV4-34,IGHJ6,CQQSYTTLLTF,IGKV1-39,COV2-2749,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ1,CQQYANLPFTF,IGKV1-33,COV2-2709,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ2,CQQYANLPFTF,IGKV1-33,COV2-2709,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ3,CQQYANLPFTF,IGKV1-33,COV2-2709,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ4,CQQYANLPFTF,IGKV1-33,COV2-2709,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ5,CQQYANLPFTF,IGKV1-33,COV2-2709,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30,IGHJ6,CQQYANLPFTF,IGKV1-33,COV2-2709,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ1,CQQYNSYPYTF,IGKV1-5,COV2-2736,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ2,CQQYNSYPYTF,IGKV1-5,COV2-2736,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ3,CQQYNSYPYTF,IGKV1-5,COV2-2736,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ4,CQQYNSYPYTF,IGKV1-5,COV2-2736,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ5,CQQYNSYPYTF,IGKV1-5,COV2-2736,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLSTTWYLEMWGPDAFDIW,IGHV3-30-3,IGHJ6,CQQYNSYPYTF,IGKV1-5,COV2-2736,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLPPYASGWYEGGFDYW,IGHV3-30,IGHJ1,CLLYYGGPWVF,IGLV7-43,COV2-2382,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLPPYASGWYEGGFDYW,IGHV3-30,IGHJ2,CLLYYGGPWVF,IGLV7-43,COV2-2382,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLPPYASGWYEGGFDYW,IGHV3-30,IGHJ3,CLLYYGGPWVF,IGLV7-43,COV2-2382,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLPPYASGWYEGGFDYW,IGHV3-30,IGHJ4,CLLYYGGPWVF,IGLV7-43,COV2-2382,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLPPYASGWYEGGFDYW,IGHV3-30,IGHJ5,CLLYYGGPWVF,IGLV7-43,COV2-2382,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLPPYASGWYEGGFDYW,IGHV3-30,IGHJ6,CLLYYGGPWVF,IGLV7-43,COV2-2382,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDHVNVRDYW,IGHV4-4,IGHJ1,CSSYTSSSIPYVF,IGLV2-14,COV2-2465,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDHVNVRDYW,IGHV4-4,IGHJ2,CSSYTSSSIPYVF,IGLV2-14,COV2-2465,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDHVNVRDYW,IGHV4-4,IGHJ3,CSSYTSSSIPYVF,IGLV2-14,COV2-2465,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDHVNVRDYW,IGHV4-4,IGHJ4,CSSYTSSSIPYVF,IGLV2-14,COV2-2465,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDHVNVRDYW,IGHV4-4,IGHJ5,CSSYTSSSIPYVF,IGLV2-14,COV2-2465,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDHVNVRDYW,IGHV4-4,IGHJ6,CSSYTSSSIPYVF,IGLV2-14,COV2-2465,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGTVVTHFDYW,IGHV3-30,IGHJ1,CQQSYSTPPWTF,IGKV1-39,COV2-2705,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGTVVTHFDYW,IGHV3-30,IGHJ2,CQQSYSTPPWTF,IGKV1-39,COV2-2705,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGTVVTHFDYW,IGHV3-30,IGHJ3,CQQSYSTPPWTF,IGKV1-39,COV2-2705,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGTVVTHFDYW,IGHV3-30,IGHJ4,CQQSYSTPPWTF,IGKV1-39,COV2-2705,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGTVVTHFDYW,IGHV3-30,IGHJ5,CQQSYSTPPWTF,IGKV1-39,COV2-2705,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGTVVTHFDYW,IGHV3-30,IGHJ6,CQQSYSTPPWTF,IGKV1-39,COV2-2705,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ1,CQSVDSSGTYPHVIF,IGLV3-25,COV2-2713,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ2,CQSVDSSGTYPHVIF,IGLV3-25,COV2-2713,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ3,CQSVDSSGTYPHVIF,IGLV3-25,COV2-2713,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ4,CQSVDSSGTYPHVIF,IGLV3-25,COV2-2713,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ5,CQSVDSSGTYPHVIF,IGLV3-25,COV2-2713,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDEMAYPPSHHYYYYYMDVW,IGHV3-43,IGHJ6,CQSVDSSGTYPHVIF,IGLV3-25,COV2-2713,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAYHPYRDYGDDDYYYYYGMDVW,IGHV3-30,IGHJ1,CQSADSSGTYRVF,IGLV3-25,COV2-2848,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAYHPYRDYGDDDYYYYYGMDVW,IGHV3-30,IGHJ2,CQSADSSGTYRVF,IGLV3-25,COV2-2848,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAYHPYRDYGDDDYYYYYGMDVW,IGHV3-30,IGHJ3,CQSADSSGTYRVF,IGLV3-25,COV2-2848,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAYHPYRDYGDDDYYYYYGMDVW,IGHV3-30,IGHJ4,CQSADSSGTYRVF,IGLV3-25,COV2-2848,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAYHPYRDYGDDDYYYYYGMDVW,IGHV3-30,IGHJ5,CQSADSSGTYRVF,IGLV3-25,COV2-2848,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAYHPYRDYGDDDYYYYYGMDVW,IGHV3-30,IGHJ6,CQSADSSGTYRVF,IGLV3-25,COV2-2848,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ1,CNSRDSSGNAVVF,IGLV3-19,COV2-2678,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ2,CNSRDSSGNAVVF,IGLV3-19,COV2-2678,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ3,CNSRDSSGNAVVF,IGLV3-19,COV2-2678,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ4,CNSRDSSGNAVVF,IGLV3-19,COV2-2678,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ5,CNSRDSSGNAVVF,IGLV3-19,COV2-2678,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ6,CNSRDSSGNAVVF,IGLV3-19,COV2-2678,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSGWLGYAMDVW,IGHV1-69,IGHJ1,CTSYTSSSTLNVVF,IGLV2-14,COV2-2722,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSGWLGYAMDVW,IGHV1-69,IGHJ2,CTSYTSSSTLNVVF,IGLV2-14,COV2-2722,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSGWLGYAMDVW,IGHV1-69,IGHJ3,CTSYTSSSTLNVVF,IGLV2-14,COV2-2722,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSGWLGYAMDVW,IGHV1-69,IGHJ4,CTSYTSSSTLNVVF,IGLV2-14,COV2-2722,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSGWLGYAMDVW,IGHV1-69,IGHJ5,CTSYTSSSTLNVVF,IGLV2-14,COV2-2722,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSGWLGYAMDVW,IGHV1-69,IGHJ6,CTSYTSSSTLNVVF,IGLV2-14,COV2-2722,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGPSEQYYDLLTGYYDAFDIW,IGHV3-20,IGHJ1,CQQYGGSLTF,IGKV3-20,COV2-2258,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGPSEQYYDLLTGYYDAFDIW,IGHV3-20,IGHJ2,CQQYGGSLTF,IGKV3-20,COV2-2258,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGPSEQYYDLLTGYYDAFDIW,IGHV3-20,IGHJ3,CQQYGGSLTF,IGKV3-20,COV2-2258,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGPSEQYYDLLTGYYDAFDIW,IGHV3-20,IGHJ4,CQQYGGSLTF,IGKV3-20,COV2-2258,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGPSEQYYDLLTGYYDAFDIW,IGHV3-20,IGHJ5,CQQYGGSLTF,IGKV3-20,COV2-2258,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARGPSEQYYDLLTGYYDAFDIW,IGHV3-20,IGHJ6,CQQYGGSLTF,IGKV3-20,COV2-2258,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDFDILTGYYSNW,IGHV3-13,IGHJ1,CQQSYSSEWTF,IGKV1-39,COV2-2753,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDFDILTGYYSNW,IGHV3-13,IGHJ2,CQQSYSSEWTF,IGKV1-39,COV2-2753,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDFDILTGYYSNW,IGHV3-13,IGHJ3,CQQSYSSEWTF,IGKV1-39,COV2-2753,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDFDILTGYYSNW,IGHV3-13,IGHJ4,CQQSYSSEWTF,IGKV1-39,COV2-2753,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDFDILTGYYSNW,IGHV3-13,IGHJ5,CQQSYSSEWTF,IGKV1-39,COV2-2753,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVDFDILTGYYSNW,IGHV3-13,IGHJ6,CQQSYSSEWTF,IGKV1-39,COV2-2753,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLIIESTIAARPGYYGMDVW,IGHV5-51,IGHJ1,CQSADSRGAVF,IGLV3-25,COV2-2797,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLIIESTIAARPGYYGMDVW,IGHV5-51,IGHJ2,CQSADSRGAVF,IGLV3-25,COV2-2797,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLIIESTIAARPGYYGMDVW,IGHV5-51,IGHJ3,CQSADSRGAVF,IGLV3-25,COV2-2797,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLIIESTIAARPGYYGMDVW,IGHV5-51,IGHJ4,CQSADSRGAVF,IGLV3-25,COV2-2797,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLIIESTIAARPGYYGMDVW,IGHV5-51,IGHJ5,CQSADSRGAVF,IGLV3-25,COV2-2797,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLIIESTIAARPGYYGMDVW,IGHV5-51,IGHJ6,CQSADSRGAVF,IGLV3-25,COV2-2797,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLVPAARNAFDIW,IGHV1-46,IGHJ1,CQQYNSYSWTF,IGKV1-5,COV2-2032,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLVPAARNAFDIW,IGHV1-46,IGHJ2,CQQYNSYSWTF,IGKV1-5,COV2-2032,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLVPAARNAFDIW,IGHV1-46,IGHJ3,CQQYNSYSWTF,IGKV1-5,COV2-2032,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLVPAARNAFDIW,IGHV1-46,IGHJ4,CQQYNSYSWTF,IGKV1-5,COV2-2032,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLVPAARNAFDIW,IGHV1-46,IGHJ5,CQQYNSYSWTF,IGKV1-5,COV2-2032,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLVPAARNAFDIW,IGHV1-46,IGHJ6,CQQYNSYSWTF,IGKV1-5,COV2-2032,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ1,CQQSSSSPITF,IGKV1-39,COV2-2740,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ2,CQQSSSSPITF,IGKV1-39,COV2-2740,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ3,CQQSSSSPITF,IGKV1-39,COV2-2740,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ4,CQQSSSSPITF,IGKV1-39,COV2-2740,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ5,CQQSSSSPITF,IGKV1-39,COV2-2740,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKKGGPYCGGGNCYAGYFDYW,IGHV3-30,IGHJ6,CQQSSSSPITF,IGKV1-39,COV2-2740,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGLTYYMDVW,IGHV1-8,IGHJ1,CQVWDSSYYHPVVF,IGLV3-21,COV2-2287,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGLTYYMDVW,IGHV1-8,IGHJ2,CQVWDSSYYHPVVF,IGLV3-21,COV2-2287,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGLTYYMDVW,IGHV1-8,IGHJ3,CQVWDSSYYHPVVF,IGLV3-21,COV2-2287,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGLTYYMDVW,IGHV1-8,IGHJ4,CQVWDSSYYHPVVF,IGLV3-21,COV2-2287,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGLTYYMDVW,IGHV1-8,IGHJ5,CQVWDSSYYHPVVF,IGLV3-21,COV2-2287,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGYGLTYYMDVW,IGHV1-8,IGHJ6,CQVWDSSYYHPVVF,IGLV3-21,COV2-2287,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ1,CNSRDSSGNAVVF,IGLV3-19,COV2-2514,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ2,CNSRDSSGNAVVF,IGLV3-19,COV2-2514,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ3,CNSRDSSGNAVVF,IGLV3-19,COV2-2514,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ4,CNSRDSSGNAVVF,IGLV3-19,COV2-2514,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ5,CNSRDSSGNAVVF,IGLV3-19,COV2-2514,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ6,CNSRDSSGNAVVF,IGLV3-19,COV2-2514,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPSILTGFYNPLDYW,IGHV1-8,IGHJ1,CQQSYSTPYTF,IGKV1-39,COV2-2717,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPSILTGFYNPLDYW,IGHV1-8,IGHJ2,CQQSYSTPYTF,IGKV1-39,COV2-2717,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPSILTGFYNPLDYW,IGHV1-8,IGHJ3,CQQSYSTPYTF,IGKV1-39,COV2-2717,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPSILTGFYNPLDYW,IGHV1-8,IGHJ4,CQQSYSTPYTF,IGKV1-39,COV2-2717,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPSILTGFYNPLDYW,IGHV1-8,IGHJ5,CQQSYSTPYTF,IGKV1-39,COV2-2717,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPSILTGFYNPLDYW,IGHV1-8,IGHJ6,CQQSYSTPYTF,IGKV1-39,COV2-2717,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGYYYYYMDVW,IGHV4-34,IGHJ1,CQQSYTTLLTF,IGKV1-39,COV2-2417,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGYYYYYMDVW,IGHV4-34,IGHJ2,CQQSYTTLLTF,IGKV1-39,COV2-2417,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGYYYYYMDVW,IGHV4-34,IGHJ3,CQQSYTTLLTF,IGKV1-39,COV2-2417,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGYYYYYMDVW,IGHV4-34,IGHJ4,CQQSYTTLLTF,IGKV1-39,COV2-2417,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGYYYYYMDVW,IGHV4-34,IGHJ5,CQQSYTTLLTF,IGKV1-39,COV2-2417,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGYYYYYMDVW,IGHV4-34,IGHJ6,CQQSYTTLLTF,IGKV1-39,COV2-2417,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPFGELLPYYFDYW,IGHV3-9,IGHJ1,CQQRSNWPPYTF,IGKV3-11,COV2-2015,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPFGELLPYYFDYW,IGHV3-9,IGHJ2,CQQRSNWPPYTF,IGKV3-11,COV2-2015,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPFGELLPYYFDYW,IGHV3-9,IGHJ3,CQQRSNWPPYTF,IGKV3-11,COV2-2015,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPFGELLPYYFDYW,IGHV3-9,IGHJ4,CQQRSNWPPYTF,IGKV3-11,COV2-2015,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPFGELLPYYFDYW,IGHV3-9,IGHJ5,CQQRSNWPPYTF,IGKV3-11,COV2-2015,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPFGELLPYYFDYW,IGHV3-9,IGHJ6,CQQRSNWPPYTF,IGKV3-11,COV2-2015,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ1,CQQYDNLYSVHF,IGKV1-33,COV2-2461,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ2,CQQYDNLYSVHF,IGKV1-33,COV2-2461,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ3,CQQYDNLYSVHF,IGKV1-33,COV2-2461,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ4,CQQYDNLYSVHF,IGKV1-33,COV2-2461,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ5,CQQYDNLYSVHF,IGKV1-33,COV2-2461,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ6,CQQYDNLYSVHF,IGKV1-33,COV2-2461,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTGVVAAPAEYFQHW,IGHV3-11,IGHJ1,CQVWDSSSDPFYVF,IGLV3-21,COV2-2873,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTGVVAAPAEYFQHW,IGHV3-11,IGHJ2,CQVWDSSSDPFYVF,IGLV3-21,COV2-2873,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTGVVAAPAEYFQHW,IGHV3-11,IGHJ3,CQVWDSSSDPFYVF,IGLV3-21,COV2-2873,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTGVVAAPAEYFQHW,IGHV3-11,IGHJ4,CQVWDSSSDPFYVF,IGLV3-21,COV2-2873,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTGVVAAPAEYFQHW,IGHV3-11,IGHJ5,CQVWDSSSDPFYVF,IGLV3-21,COV2-2873,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTGVVAAPAEYFQHW,IGHV3-11,IGHJ6,CQVWDSSSDPFYVF,IGLV3-21,COV2-2873,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHSGPPDLSPVLSQGWFDPW,IGHV2-5,IGHJ1,CQSADSTGWVF,IGLV3-25,COV2-2953,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHSGPPDLSPVLSQGWFDPW,IGHV2-5,IGHJ2,CQSADSTGWVF,IGLV3-25,COV2-2953,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHSGPPDLSPVLSQGWFDPW,IGHV2-5,IGHJ3,CQSADSTGWVF,IGLV3-25,COV2-2953,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHSGPPDLSPVLSQGWFDPW,IGHV2-5,IGHJ4,CQSADSTGWVF,IGLV3-25,COV2-2953,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHSGPPDLSPVLSQGWFDPW,IGHV2-5,IGHJ5,CQSADSTGWVF,IGLV3-25,COV2-2953,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHSGPPDLSPVLSQGWFDPW,IGHV2-5,IGHJ6,CQSADSTGWVF,IGLV3-25,COV2-2953,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSILWWLIDYW,IGHV3-21,IGHJ1,CQSYDSTSRVVF,IGLV6-57,COV2-2828,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSILWWLIDYW,IGHV3-21,IGHJ2,CQSYDSTSRVVF,IGLV6-57,COV2-2828,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSILWWLIDYW,IGHV3-21,IGHJ3,CQSYDSTSRVVF,IGLV6-57,COV2-2828,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSILWWLIDYW,IGHV3-21,IGHJ4,CQSYDSTSRVVF,IGLV6-57,COV2-2828,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSILWWLIDYW,IGHV3-21,IGHJ5,CQSYDSTSRVVF,IGLV6-57,COV2-2828,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSILWWLIDYW,IGHV3-21,IGHJ6,CQSYDSTSRVVF,IGLV6-57,COV2-2828,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVFWVPAASSFDYW,IGHV1-46,IGHJ1,CQQLNSYLGTF,IGKV1-9,COV2-2554,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVFWVPAASSFDYW,IGHV1-46,IGHJ2,CQQLNSYLGTF,IGKV1-9,COV2-2554,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVFWVPAASSFDYW,IGHV1-46,IGHJ3,CQQLNSYLGTF,IGKV1-9,COV2-2554,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVFWVPAASSFDYW,IGHV1-46,IGHJ4,CQQLNSYLGTF,IGKV1-9,COV2-2554,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVFWVPAASSFDYW,IGHV1-46,IGHJ5,CQQLNSYLGTF,IGKV1-9,COV2-2554,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVFWVPAASSFDYW,IGHV1-46,IGHJ6,CQQLNSYLGTF,IGKV1-9,COV2-2554,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPIRDGVWGLNENDYW,IGHV3-11,IGHJ1,CETWDSNTRVF,IGLV4-60,COV2-2552,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPIRDGVWGLNENDYW,IGHV3-11,IGHJ2,CETWDSNTRVF,IGLV4-60,COV2-2552,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPIRDGVWGLNENDYW,IGHV3-11,IGHJ3,CETWDSNTRVF,IGLV4-60,COV2-2552,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPIRDGVWGLNENDYW,IGHV3-11,IGHJ4,CETWDSNTRVF,IGLV4-60,COV2-2552,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPIRDGVWGLNENDYW,IGHV3-11,IGHJ5,CETWDSNTRVF,IGLV4-60,COV2-2552,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPIRDGVWGLNENDYW,IGHV3-11,IGHJ6,CETWDSNTRVF,IGLV4-60,COV2-2552,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGSESKIDYYYYGMDVW,IGHV5-51,IGHJ1,CQQSYSTPPTF,IGKV1-39,COV2-2906,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGSESKIDYYYYGMDVW,IGHV5-51,IGHJ2,CQQSYSTPPTF,IGKV1-39,COV2-2906,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGSESKIDYYYYGMDVW,IGHV5-51,IGHJ3,CQQSYSTPPTF,IGKV1-39,COV2-2906,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGSESKIDYYYYGMDVW,IGHV5-51,IGHJ4,CQQSYSTPPTF,IGKV1-39,COV2-2906,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGSESKIDYYYYGMDVW,IGHV5-51,IGHJ5,CQQSYSTPPTF,IGKV1-39,COV2-2906,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGSESKIDYYYYGMDVW,IGHV5-51,IGHJ6,CQQSYSTPPTF,IGKV1-39,COV2-2906,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSATYYYYYYGMDVW,IGHV3-30,IGHJ1,CQQYDNLLFTF,IGKV1-33,COV2-2007,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSATYYYYYYGMDVW,IGHV3-30,IGHJ2,CQQYDNLLFTF,IGKV1-33,COV2-2007,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSATYYYYYYGMDVW,IGHV3-30,IGHJ3,CQQYDNLLFTF,IGKV1-33,COV2-2007,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSATYYYYYYGMDVW,IGHV3-30,IGHJ4,CQQYDNLLFTF,IGKV1-33,COV2-2007,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSATYYYYYYGMDVW,IGHV3-30,IGHJ5,CQQYDNLLFTF,IGKV1-33,COV2-2007,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVSATYYYYYYGMDVW,IGHV3-30,IGHJ6,CQQYDNLLFTF,IGKV1-33,COV2-2007,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKQGGLYCSGTNCWGGYLDYW,IGHV3-30,IGHJ1,CQQYHNLPPITF,IGKV1-33,COV2-2450,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKQGGLYCSGTNCWGGYLDYW,IGHV3-30,IGHJ2,CQQYHNLPPITF,IGKV1-33,COV2-2450,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKQGGLYCSGTNCWGGYLDYW,IGHV3-30,IGHJ3,CQQYHNLPPITF,IGKV1-33,COV2-2450,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKQGGLYCSGTNCWGGYLDYW,IGHV3-30,IGHJ4,CQQYHNLPPITF,IGKV1-33,COV2-2450,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKQGGLYCSGTNCWGGYLDYW,IGHV3-30,IGHJ5,CQQYHNLPPITF,IGKV1-33,COV2-2450,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKQGGLYCSGTNCWGGYLDYW,IGHV3-30,IGHJ6,CQQYHNLPPITF,IGKV1-33,COV2-2450,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRPPSYHGWCYFDYW,IGHV2-5,IGHJ1,CQQSYSTHMSTF,IGKV1-39,COV2-2342,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRPPSYHGWCYFDYW,IGHV2-5,IGHJ2,CQQSYSTHMSTF,IGKV1-39,COV2-2342,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRPPSYHGWCYFDYW,IGHV2-5,IGHJ3,CQQSYSTHMSTF,IGKV1-39,COV2-2342,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRPPSYHGWCYFDYW,IGHV2-5,IGHJ4,CQQSYSTHMSTF,IGKV1-39,COV2-2342,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRPPSYHGWCYFDYW,IGHV2-5,IGHJ5,CQQSYSTHMSTF,IGKV1-39,COV2-2342,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRPPSYHGWCYFDYW,IGHV2-5,IGHJ6,CQQSYSTHMSTF,IGKV1-39,COV2-2342,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSYCSSTRCYTVGWFDPW,IGHV7-4-1,IGHJ1,CQVWDSSSDPVVF,IGLV3-21,COV2-2256,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSYCSSTRCYTVGWFDPW,IGHV7-4-1,IGHJ2,CQVWDSSSDPVVF,IGLV3-21,COV2-2256,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSYCSSTRCYTVGWFDPW,IGHV7-4-1,IGHJ3,CQVWDSSSDPVVF,IGLV3-21,COV2-2256,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSYCSSTRCYTVGWFDPW,IGHV7-4-1,IGHJ4,CQVWDSSSDPVVF,IGLV3-21,COV2-2256,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSYCSSTRCYTVGWFDPW,IGHV7-4-1,IGHJ5,CQVWDSSSDPVVF,IGLV3-21,COV2-2256,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSYCSSTRCYTVGWFDPW,IGHV7-4-1,IGHJ6,CQVWDSSSDPVVF,IGLV3-21,COV2-2256,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLPTPQLLPSFENWFDPW,IGHV2-5,IGHJ1,CASWDDSLIGPVF,IGLV1-36,COV2-2834,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLPTPQLLPSFENWFDPW,IGHV2-5,IGHJ2,CASWDDSLIGPVF,IGLV1-36,COV2-2834,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLPTPQLLPSFENWFDPW,IGHV2-5,IGHJ3,CASWDDSLIGPVF,IGLV1-36,COV2-2834,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLPTPQLLPSFENWFDPW,IGHV2-5,IGHJ4,CASWDDSLIGPVF,IGLV1-36,COV2-2834,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLPTPQLLPSFENWFDPW,IGHV2-5,IGHJ5,CASWDDSLIGPVF,IGLV1-36,COV2-2834,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLPTPQLLPSFENWFDPW,IGHV2-5,IGHJ6,CASWDDSLIGPVF,IGLV1-36,COV2-2834,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ1,CNSRDSSGNAVVF,IGLV3-19,COV2-2082,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ2,CNSRDSSGNAVVF,IGLV3-19,COV2-2082,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ3,CNSRDSSGNAVVF,IGLV3-19,COV2-2082,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ4,CNSRDSSGNAVVF,IGLV3-19,COV2-2082,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ5,CNSRDSSGNAVVF,IGLV3-19,COV2-2082,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGGAFDIW,IGHV3-20,IGHJ6,CNSRDSSGNAVVF,IGLV3-19,COV2-2082,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ1,CQSYDSGNPIF,IGLV6-57,COV2-2128,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ2,CQSYDSGNPIF,IGLV6-57,COV2-2128,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ3,CQSYDSGNPIF,IGLV6-57,COV2-2128,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ4,CQSYDSGNPIF,IGLV6-57,COV2-2128,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ5,CQSYDSGNPIF,IGLV6-57,COV2-2128,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARILVIFTLNWFDPW,IGHV4-39,IGHJ6,CQSYDSGNPIF,IGLV6-57,COV2-2128,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ1,CNSRDSSGNAVVF,IGLV3-19,COV2-2094,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ2,CNSRDSSGNAVVF,IGLV3-19,COV2-2094,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ3,CNSRDSSGNAVVF,IGLV3-19,COV2-2094,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ4,CNSRDSSGNAVVF,IGLV3-19,COV2-2094,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ5,CNSRDSSGNAVVF,IGLV3-19,COV2-2094,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAVIMSPIPRYSGYDWAGDAFDIW,IGHV3-20,IGHJ6,CNSRDSSGNAVVF,IGLV3-19,COV2-2094,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ1,CQVWDSSSDHHVVF,IGLV3-21,COV2-2055,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ2,CQVWDSSSDHHVVF,IGLV3-21,COV2-2055,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ3,CQVWDSSSDHHVVF,IGLV3-21,COV2-2055,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ4,CQVWDSSSDHHVVF,IGLV3-21,COV2-2055,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ5,CQVWDSSSDHHVVF,IGLV3-21,COV2-2055,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGAGYTSYMDVW,IGHV3-9,IGHJ6,CQVWDSSSDHHVVF,IGLV3-21,COV2-2055,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ1,CQQYDNLYSVHF,IGKV1-33,COV2-2158,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ2,CQQYDNLYSVHF,IGKV1-33,COV2-2158,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ3,CQQYDNLYSVHF,IGKV1-33,COV2-2158,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ4,CQQYDNLYSVHF,IGKV1-33,COV2-2158,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ5,CQQYDNLYSVHF,IGKV1-33,COV2-2158,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGSGSYSLFDYW,IGHV4-31,IGHJ6,CQQYDNLYSVHF,IGKV1-33,COV2-2158,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAAPAVMTAGWFDPW,IGHV1-24,IGHJ1,CSSYTSSTTWVF,IGLV2-14,COV2-2016,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAAPAVMTAGWFDPW,IGHV1-24,IGHJ2,CSSYTSSTTWVF,IGLV2-14,COV2-2016,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAAPAVMTAGWFDPW,IGHV1-24,IGHJ3,CSSYTSSTTWVF,IGLV2-14,COV2-2016,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAAPAVMTAGWFDPW,IGHV1-24,IGHJ4,CSSYTSSTTWVF,IGLV2-14,COV2-2016,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAAPAVMTAGWFDPW,IGHV1-24,IGHJ5,CSSYTSSTTWVF,IGLV2-14,COV2-2016,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAAAPAVMTAGWFDPW,IGHV1-24,IGHJ6,CSSYTSSTTWVF,IGLV2-14,COV2-2016,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATQPAAIGGTPPYYW,IGHV1-24,IGHJ1,CAAWDASLSGHVVF,IGLV1-47,COV2-2021,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATQPAAIGGTPPYYW,IGHV1-24,IGHJ2,CAAWDASLSGHVVF,IGLV1-47,COV2-2021,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATQPAAIGGTPPYYW,IGHV1-24,IGHJ3,CAAWDASLSGHVVF,IGLV1-47,COV2-2021,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATQPAAIGGTPPYYW,IGHV1-24,IGHJ4,CAAWDASLSGHVVF,IGLV1-47,COV2-2021,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATQPAAIGGTPPYYW,IGHV1-24,IGHJ5,CAAWDASLSGHVVF,IGLV1-47,COV2-2021,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATQPAAIGGTPPYYW,IGHV1-24,IGHJ6,CAAWDASLSGHVVF,IGLV1-47,COV2-2021,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATSFPIRGDPSYYYYYYGMDVW,IGHV1-24,IGHJ1,CQQYNSYPWTF,IGKV1-16,COV2-2026,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATSFPIRGDPSYYYYYYGMDVW,IGHV1-24,IGHJ2,CQQYNSYPWTF,IGKV1-16,COV2-2026,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATSFPIRGDPSYYYYYYGMDVW,IGHV1-24,IGHJ3,CQQYNSYPWTF,IGKV1-16,COV2-2026,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATSFPIRGDPSYYYYYYGMDVW,IGHV1-24,IGHJ4,CQQYNSYPWTF,IGKV1-16,COV2-2026,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATSFPIRGDPSYYYYYYGMDVW,IGHV1-24,IGHJ5,CQQYNSYPWTF,IGKV1-16,COV2-2026,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATSFPIRGDPSYYYYYYGMDVW,IGHV1-24,IGHJ6,CQQYNSYPWTF,IGKV1-16,COV2-2026,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ1,CQQLNSYPVTF,IGKV1-9,COV2-2146,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ2,CQQLNSYPVTF,IGKV1-9,COV2-2146,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ3,CQQLNSYPVTF,IGKV1-9,COV2-2146,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ4,CQQLNSYPVTF,IGKV1-9,COV2-2146,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ5,CQQLNSYPVTF,IGKV1-9,COV2-2146,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ6,CQQLNSYPVTF,IGKV1-9,COV2-2146,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ1,CQVWDSSSDHPGVF,IGLV3-21,COV2-2150,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ2,CQVWDSSSDHPGVF,IGLV3-21,COV2-2150,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ3,CQVWDSSSDHPGVF,IGLV3-21,COV2-2150,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ4,CQVWDSSSDHPGVF,IGLV3-21,COV2-2150,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ5,CQVWDSSSDHPGVF,IGLV3-21,COV2-2150,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ6,CQVWDSSSDHPGVF,IGLV3-21,COV2-2150,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ1,CSSYTSSSTHVVF,IGLV2-14,COV2-2190,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ2,CSSYTSSSTHVVF,IGLV2-14,COV2-2190,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ3,CSSYTSSSTHVVF,IGLV2-14,COV2-2190,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ4,CSSYTSSSTHVVF,IGLV2-14,COV2-2190,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ5,CSSYTSSSTHVVF,IGLV2-14,COV2-2190,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ6,CSSYTSSSTHVVF,IGLV2-14,COV2-2190,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ1,CQAWDSSTVVF,IGLV3-1,COV2-2199,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ2,CQAWDSSTVVF,IGLV3-1,COV2-2199,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ3,CQAWDSSTVVF,IGLV3-1,COV2-2199,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ4,CQAWDSSTVVF,IGLV3-1,COV2-2199,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ5,CQAWDSSTVVF,IGLV3-1,COV2-2199,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ6,CQAWDSSTVVF,IGLV3-1,COV2-2199,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ1,CQQANSFPPTF,IGKV1-12,COV2-2210,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ2,CQQANSFPPTF,IGKV1-12,COV2-2210,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ3,CQQANSFPPTF,IGKV1-12,COV2-2210,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ4,CQQANSFPPTF,IGKV1-12,COV2-2210,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ5,CQQANSFPPTF,IGKV1-12,COV2-2210,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ6,CQQANSFPPTF,IGKV1-12,COV2-2210,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ1,CQQRGNWWTF,IGKV3-11,COV2-2212,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ2,CQQRGNWWTF,IGKV3-11,COV2-2212,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ3,CQQRGNWWTF,IGKV3-11,COV2-2212,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ4,CQQRGNWWTF,IGKV3-11,COV2-2212,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ5,CQQRGNWWTF,IGKV3-11,COV2-2212,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ6,CQQRGNWWTF,IGKV3-11,COV2-2212,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ1,CQQCYNWPPWTF,IGKV3-15,COV2-2215,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ2,CQQCYNWPPWTF,IGKV3-15,COV2-2215,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ3,CQQCYNWPPWTF,IGKV3-15,COV2-2215,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ4,CQQCYNWPPWTF,IGKV3-15,COV2-2215,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ5,CQQCYNWPPWTF,IGKV3-15,COV2-2215,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ6,CQQCYNWPPWTF,IGKV3-15,COV2-2215,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ1,CCSYAVSTTYVIF,IGLV2-23,COV2-2222,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ2,CCSYAVSTTYVIF,IGLV2-23,COV2-2222,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ3,CCSYAVSTTYVIF,IGLV2-23,COV2-2222,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ4,CCSYAVSTTYVIF,IGLV2-23,COV2-2222,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ5,CCSYAVSTTYVIF,IGLV2-23,COV2-2222,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ6,CCSYAVSTTYVIF,IGLV2-23,COV2-2222,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ1,CQQYNYWPPLTF,IGKV3-15,COV2-2228,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ2,CQQYNYWPPLTF,IGKV3-15,COV2-2228,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ3,CQQYNYWPPLTF,IGKV3-15,COV2-2228,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ4,CQQYNYWPPLTF,IGKV3-15,COV2-2228,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ5,CQQYNYWPPLTF,IGKV3-15,COV2-2228,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ6,CQQYNYWPPLTF,IGKV3-15,COV2-2228,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ1,CLLYYGGAWVF,IGLV7-43,COV2-2251,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ2,CLLYYGGAWVF,IGLV7-43,COV2-2251,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ3,CLLYYGGAWVF,IGLV7-43,COV2-2251,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ4,CLLYYGGAWVF,IGLV7-43,COV2-2251,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ5,CLLYYGGAWVF,IGLV7-43,COV2-2251,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ6,CLLYYGGAWVF,IGLV7-43,COV2-2251,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHVAAWESCYYW,IGHV4-61,IGHJ1,CMQALQTPQTF,IGKV2-28,COV2-2257,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHVAAWESCYYW,IGHV4-61,IGHJ2,CMQALQTPQTF,IGKV2-28,COV2-2257,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHVAAWESCYYW,IGHV4-61,IGHJ3,CMQALQTPQTF,IGKV2-28,COV2-2257,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHVAAWESCYYW,IGHV4-61,IGHJ4,CMQALQTPQTF,IGKV2-28,COV2-2257,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHVAAWESCYYW,IGHV4-61,IGHJ5,CMQALQTPQTF,IGKV2-28,COV2-2257,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHVAAWESCYYW,IGHV4-61,IGHJ6,CMQALQTPQTF,IGKV2-28,COV2-2257,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQMGPLGSTSSAADYW,IGHV3-23,IGHJ1,CQAWDSSLVVF,IGLV3-1,COV2-2260,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQMGPLGSTSSAADYW,IGHV3-23,IGHJ2,CQAWDSSLVVF,IGLV3-1,COV2-2260,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQMGPLGSTSSAADYW,IGHV3-23,IGHJ3,CQAWDSSLVVF,IGLV3-1,COV2-2260,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQMGPLGSTSSAADYW,IGHV3-23,IGHJ4,CQAWDSSLVVF,IGLV3-1,COV2-2260,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQMGPLGSTSSAADYW,IGHV3-23,IGHJ5,CQAWDSSLVVF,IGLV3-1,COV2-2260,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQMGPLGSTSSAADYW,IGHV3-23,IGHJ6,CQAWDSSLVVF,IGLV3-1,COV2-2260,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ1,CQQLNSYPVTF,IGKV1-9,COV2-2263,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ2,CQQLNSYPVTF,IGKV1-9,COV2-2263,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ3,CQQLNSYPVTF,IGKV1-9,COV2-2263,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ4,CQQLNSYPVTF,IGKV1-9,COV2-2263,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ5,CQQLNSYPVTF,IGKV1-9,COV2-2263,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRSYRSSWYYYYGMDVW,IGHV3-48,IGHJ6,CQQLNSYPVTF,IGKV1-9,COV2-2263,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNERITMLVVVTLFDYW,IGHV3-23,IGHJ1,CGTWDSSLSAVVF,IGLV1-51,COV2-2293,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNERITMLVVVTLFDYW,IGHV3-23,IGHJ2,CGTWDSSLSAVVF,IGLV1-51,COV2-2293,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNERITMLVVVTLFDYW,IGHV3-23,IGHJ3,CGTWDSSLSAVVF,IGLV1-51,COV2-2293,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNERITMLVVVTLFDYW,IGHV3-23,IGHJ4,CGTWDSSLSAVVF,IGLV1-51,COV2-2293,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNERITMLVVVTLFDYW,IGHV3-23,IGHJ5,CGTWDSSLSAVVF,IGLV1-51,COV2-2293,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNERITMLVVVTLFDYW,IGHV3-23,IGHJ6,CGTWDSSLSAVVF,IGLV1-51,COV2-2293,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAILWRGSSWADRHYYYYSMDVW,IGHV4-39,IGHJ1,CAAWDDSLNGWVF,IGLV1-44,COV2-2305,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAILWRGSSWADRHYYYYSMDVW,IGHV4-39,IGHJ2,CAAWDDSLNGWVF,IGLV1-44,COV2-2305,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAILWRGSSWADRHYYYYSMDVW,IGHV4-39,IGHJ3,CAAWDDSLNGWVF,IGLV1-44,COV2-2305,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAILWRGSSWADRHYYYYSMDVW,IGHV4-39,IGHJ4,CAAWDDSLNGWVF,IGLV1-44,COV2-2305,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAILWRGSSWADRHYYYYSMDVW,IGHV4-39,IGHJ5,CAAWDDSLNGWVF,IGLV1-44,COV2-2305,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAILWRGSSWADRHYYYYSMDVW,IGHV4-39,IGHJ6,CAAWDDSLNGWVF,IGLV1-44,COV2-2305,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGRGLDPW,IGHV3-30-3,IGHJ1,CQAWDSSTAVF,IGLV3-1,COV2-2307,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGRGLDPW,IGHV3-30-3,IGHJ2,CQAWDSSTAVF,IGLV3-1,COV2-2307,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGRGLDPW,IGHV3-30-3,IGHJ3,CQAWDSSTAVF,IGLV3-1,COV2-2307,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGRGLDPW,IGHV3-30-3,IGHJ4,CQAWDSSTAVF,IGLV3-1,COV2-2307,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGRGLDPW,IGHV3-30-3,IGHJ5,CQAWDSSTAVF,IGLV3-1,COV2-2307,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLGRGLDPW,IGHV3-30-3,IGHJ6,CQAWDSSTAVF,IGLV3-1,COV2-2307,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHDGSGEMDTITWGPIYYYMDVW,IGHV4-39,IGHJ1,CSSYTSSTLNVLF,IGLV2-14,COV2-2335,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHDGSGEMDTITWGPIYYYMDVW,IGHV4-39,IGHJ2,CSSYTSSTLNVLF,IGLV2-14,COV2-2335,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHDGSGEMDTITWGPIYYYMDVW,IGHV4-39,IGHJ3,CSSYTSSTLNVLF,IGLV2-14,COV2-2335,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHDGSGEMDTITWGPIYYYMDVW,IGHV4-39,IGHJ4,CSSYTSSTLNVLF,IGLV2-14,COV2-2335,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHDGSGEMDTITWGPIYYYMDVW,IGHV4-39,IGHJ5,CSSYTSSTLNVLF,IGLV2-14,COV2-2335,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARHDGSGEMDTITWGPIYYYMDVW,IGHV4-39,IGHJ6,CSSYTSSTLNVLF,IGLV2-14,COV2-2335,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ1,CQQYNYWPPLTF,IGKV3-15,COV2-2346,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ2,CQQYNYWPPLTF,IGKV3-15,COV2-2346,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ3,CQQYNYWPPLTF,IGKV3-15,COV2-2346,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ4,CQQYNYWPPLTF,IGKV3-15,COV2-2346,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ5,CQQYNYWPPLTF,IGKV3-15,COV2-2346,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPPQAARIHYYYYMDVW,IGHV4-34,IGHJ6,CQQYNYWPPLTF,IGKV3-15,COV2-2346,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTTWGTWIQAWYFDIW,IGHV2-26,IGHJ1,CCSYAGGNTFVVF,IGLV2-23,COV2-2384,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTTWGTWIQAWYFDIW,IGHV2-26,IGHJ2,CCSYAGGNTFVVF,IGLV2-23,COV2-2384,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTTWGTWIQAWYFDIW,IGHV2-26,IGHJ3,CCSYAGGNTFVVF,IGLV2-23,COV2-2384,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTTWGTWIQAWYFDIW,IGHV2-26,IGHJ4,CCSYAGGNTFVVF,IGLV2-23,COV2-2384,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTTWGTWIQAWYFDIW,IGHV2-26,IGHJ5,CCSYAGGNTFVVF,IGLV2-23,COV2-2384,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTTWGTWIQAWYFDIW,IGHV2-26,IGHJ6,CCSYAGGNTFVVF,IGLV2-23,COV2-2384,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ1,CQQCYNWPPWTF,IGKV3-15,COV2-2394,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ2,CQQCYNWPPWTF,IGKV3-15,COV2-2394,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ3,CQQCYNWPPWTF,IGKV3-15,COV2-2394,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ4,CQQCYNWPPWTF,IGKV3-15,COV2-2394,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ5,CQQCYNWPPWTF,IGKV3-15,COV2-2394,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARWLQLRSDYYYFGMDVW,IGHV3-21,IGHJ6,CQQCYNWPPWTF,IGKV3-15,COV2-2394,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASLWFGDLYSFDYW,IGHV4-39,IGHJ1,CQKYNSAPWTF,IGKV1-27,COV2-2405,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASLWFGDLYSFDYW,IGHV4-39,IGHJ2,CQKYNSAPWTF,IGKV1-27,COV2-2405,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASLWFGDLYSFDYW,IGHV4-39,IGHJ3,CQKYNSAPWTF,IGKV1-27,COV2-2405,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASLWFGDLYSFDYW,IGHV4-39,IGHJ4,CQKYNSAPWTF,IGKV1-27,COV2-2405,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASLWFGDLYSFDYW,IGHV4-39,IGHJ5,CQKYNSAPWTF,IGKV1-27,COV2-2405,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASLWFGDLYSFDYW,IGHV4-39,IGHJ6,CQKYNSAPWTF,IGKV1-27,COV2-2405,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLLGSGITLDNDAFDIW,IGHV3-23,IGHJ1,CQQTYSTPLYTF,IGKV1-39,COV2-2438,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLLGSGITLDNDAFDIW,IGHV3-23,IGHJ2,CQQTYSTPLYTF,IGKV1-39,COV2-2438,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLLGSGITLDNDAFDIW,IGHV3-23,IGHJ3,CQQTYSTPLYTF,IGKV1-39,COV2-2438,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLLGSGITLDNDAFDIW,IGHV3-23,IGHJ4,CQQTYSTPLYTF,IGKV1-39,COV2-2438,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLLGSGITLDNDAFDIW,IGHV3-23,IGHJ5,CQQTYSTPLYTF,IGKV1-39,COV2-2438,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKLLGSGITLDNDAFDIW,IGHV3-23,IGHJ6,CQQTYSTPLYTF,IGKV1-39,COV2-2438,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGSGIVGATGFDFW,IGHV3-23,IGHJ1,CQSADSSGTYVVF,IGLV3-25,COV2-2444,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGSGIVGATGFDFW,IGHV3-23,IGHJ2,CQSADSSGTYVVF,IGLV3-25,COV2-2444,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGSGIVGATGFDFW,IGHV3-23,IGHJ3,CQSADSSGTYVVF,IGLV3-25,COV2-2444,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGSGIVGATGFDFW,IGHV3-23,IGHJ4,CQSADSSGTYVVF,IGLV3-25,COV2-2444,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGSGIVGATGFDFW,IGHV3-23,IGHJ5,CQSADSSGTYVVF,IGLV3-25,COV2-2444,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGSGIVGATGFDFW,IGHV3-23,IGHJ6,CQSADSSGTYVVF,IGLV3-25,COV2-2444,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ1,CSSYTSSSTHVVF,IGLV2-14,COV2-2455,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ2,CSSYTSSSTHVVF,IGLV2-14,COV2-2455,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ3,CSSYTSSSTHVVF,IGLV2-14,COV2-2455,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ4,CSSYTSSSTHVVF,IGLV2-14,COV2-2455,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ5,CSSYTSSSTHVVF,IGLV2-14,COV2-2455,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARSRYFDWLPSYYFDYW,IGHV3-48,IGHJ6,CSSYTSSSTHVVF,IGLV2-14,COV2-2455,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGNYYDSKNWFDPW,IGHV4-39,IGHJ1,CQQYNNWPPMYTF,IGKV3-15,COV2-2459,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGNYYDSKNWFDPW,IGHV4-39,IGHJ2,CQQYNNWPPMYTF,IGKV3-15,COV2-2459,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGNYYDSKNWFDPW,IGHV4-39,IGHJ3,CQQYNNWPPMYTF,IGKV3-15,COV2-2459,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGNYYDSKNWFDPW,IGHV4-39,IGHJ4,CQQYNNWPPMYTF,IGKV3-15,COV2-2459,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGNYYDSKNWFDPW,IGHV4-39,IGHJ5,CQQYNNWPPMYTF,IGKV3-15,COV2-2459,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGNYYDSKNWFDPW,IGHV4-39,IGHJ6,CQQYNNWPPMYTF,IGKV3-15,COV2-2459,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ1,CQQRGNWWTF,IGKV3-11,COV2-2466,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ2,CQQRGNWWTF,IGKV3-11,COV2-2466,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ3,CQQRGNWWTF,IGKV3-11,COV2-2466,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ4,CQQRGNWWTF,IGKV3-11,COV2-2466,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ5,CQQRGNWWTF,IGKV3-11,COV2-2466,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNGNSNWNFGSYYYYYMDVW,IGHV3-21,IGHJ6,CQQRGNWWTF,IGKV3-11,COV2-2466,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ1,CQQYGSSPFTF,IGKV3-20,COV2-2489,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ2,CQQYGSSPFTF,IGKV3-20,COV2-2489,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ3,CQQYGSSPFTF,IGKV3-20,COV2-2489,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ4,CQQYGSSPFTF,IGKV3-20,COV2-2489,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ5,CQQYGSSPFTF,IGKV3-20,COV2-2489,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ6,CQQYGSSPFTF,IGKV3-20,COV2-2489,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPYDLYGDYGGTFDYW,IGHV3-7,IGHJ1,CQQYNSYSLTF,IGKV1-5,COV2-2490,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPYDLYGDYGGTFDYW,IGHV3-7,IGHJ2,CQQYNSYSLTF,IGKV1-5,COV2-2490,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPYDLYGDYGGTFDYW,IGHV3-7,IGHJ3,CQQYNSYSLTF,IGKV1-5,COV2-2490,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPYDLYGDYGGTFDYW,IGHV3-7,IGHJ4,CQQYNSYSLTF,IGKV1-5,COV2-2490,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPYDLYGDYGGTFDYW,IGHV3-7,IGHJ5,CQQYNSYSLTF,IGKV1-5,COV2-2490,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPYDLYGDYGGTFDYW,IGHV3-7,IGHJ6,CQQYNSYSLTF,IGKV1-5,COV2-2490,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREDYYGSGSLVDPYYYYRMDVW,IGHV1-69,IGHJ1,CQQYNNWWRTF,IGKV3-15,COV2-2495,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREDYYGSGSLVDPYYYYRMDVW,IGHV1-69,IGHJ2,CQQYNNWWRTF,IGKV3-15,COV2-2495,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREDYYGSGSLVDPYYYYRMDVW,IGHV1-69,IGHJ3,CQQYNNWWRTF,IGKV3-15,COV2-2495,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREDYYGSGSLVDPYYYYRMDVW,IGHV1-69,IGHJ4,CQQYNNWWRTF,IGKV3-15,COV2-2495,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREDYYGSGSLVDPYYYYRMDVW,IGHV1-69,IGHJ5,CQQYNNWWRTF,IGKV3-15,COV2-2495,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREDYYGSGSLVDPYYYYRMDVW,IGHV1-69,IGHJ6,CQQYNNWWRTF,IGKV3-15,COV2-2495,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDPASGIVGPTHFDYW,IGHV3-23,IGHJ1,CQSWDTGIGVF,IGLV4-69,COV2-2525,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDPASGIVGPTHFDYW,IGHV3-23,IGHJ2,CQSWDTGIGVF,IGLV4-69,COV2-2525,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDPASGIVGPTHFDYW,IGHV3-23,IGHJ3,CQSWDTGIGVF,IGLV4-69,COV2-2525,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDPASGIVGPTHFDYW,IGHV3-23,IGHJ4,CQSWDTGIGVF,IGLV4-69,COV2-2525,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDPASGIVGPTHFDYW,IGHV3-23,IGHJ5,CQSWDTGIGVF,IGLV4-69,COV2-2525,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDPASGIVGPTHFDYW,IGHV3-23,IGHJ6,CQSWDTGIGVF,IGLV4-69,COV2-2525,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ1,CQAWDSSTVVF,IGLV3-1,COV2-2526,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ2,CQAWDSSTVVF,IGLV3-1,COV2-2526,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ3,CQAWDSSTVVF,IGLV3-1,COV2-2526,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ4,CQAWDSSTVVF,IGLV3-1,COV2-2526,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ5,CQAWDSSTVVF,IGLV3-1,COV2-2526,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGFAVFGRAAVPYW,IGHV1-24,IGHJ6,CQAWDSSTVVF,IGLV3-1,COV2-2526,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREANDSGSFYNGPFDYW,IGHV4-31,IGHJ1,CQQYYSTRTF,IGKV4-1,COV2-2533,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREANDSGSFYNGPFDYW,IGHV4-31,IGHJ2,CQQYYSTRTF,IGKV4-1,COV2-2533,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREANDSGSFYNGPFDYW,IGHV4-31,IGHJ3,CQQYYSTRTF,IGKV4-1,COV2-2533,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREANDSGSFYNGPFDYW,IGHV4-31,IGHJ4,CQQYYSTRTF,IGKV4-1,COV2-2533,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREANDSGSFYNGPFDYW,IGHV4-31,IGHJ5,CQQYYSTRTF,IGKV4-1,COV2-2533,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREANDSGSFYNGPFDYW,IGHV4-31,IGHJ6,CQQYYSTRTF,IGKV4-1,COV2-2533,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ1,CQQANSFPPTF,IGKV1-12,COV2-2558,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ2,CQQANSFPPTF,IGKV1-12,COV2-2558,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ3,CQQANSFPPTF,IGKV1-12,COV2-2558,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ4,CQQANSFPPTF,IGKV1-12,COV2-2558,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ5,CQQANSFPPTF,IGKV1-12,COV2-2558,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQEWFRELFLFDYW,IGHV3-30-3,IGHJ6,CQQANSFPPTF,IGKV1-12,COV2-2558,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWGWGAVAGRAEYYFDYW,IGHV4-34,IGHJ1,CCSYAGSSTWGF,IGLV2-23,COV2-2563,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWGWGAVAGRAEYYFDYW,IGHV4-34,IGHJ2,CCSYAGSSTWGF,IGLV2-23,COV2-2563,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWGWGAVAGRAEYYFDYW,IGHV4-34,IGHJ3,CCSYAGSSTWGF,IGLV2-23,COV2-2563,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWGWGAVAGRAEYYFDYW,IGHV4-34,IGHJ4,CCSYAGSSTWGF,IGLV2-23,COV2-2563,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWGWGAVAGRAEYYFDYW,IGHV4-34,IGHJ5,CCSYAGSSTWGF,IGLV2-23,COV2-2563,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWGWGAVAGRAEYYFDYW,IGHV4-34,IGHJ6,CCSYAGSSTWGF,IGLV2-23,COV2-2563,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQRQFQLLGRFGWFDPW,IGHV4-59,IGHJ1,CQQYNNWPRTF,IGKV3-15,COV2-2571,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQRQFQLLGRFGWFDPW,IGHV4-59,IGHJ2,CQQYNNWPRTF,IGKV3-15,COV2-2571,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQRQFQLLGRFGWFDPW,IGHV4-59,IGHJ3,CQQYNNWPRTF,IGKV3-15,COV2-2571,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQRQFQLLGRFGWFDPW,IGHV4-59,IGHJ4,CQQYNNWPRTF,IGKV3-15,COV2-2571,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQRQFQLLGRFGWFDPW,IGHV4-59,IGHJ5,CQQYNNWPRTF,IGKV3-15,COV2-2571,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQRQFQLLGRFGWFDPW,IGHV4-59,IGHJ6,CQQYNNWPRTF,IGKV3-15,COV2-2571,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWYFDYW,IGHV4-4,IGHJ1,CYSYAGSSTWVF,IGLV2-23,COV2-2622,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWYFDYW,IGHV4-4,IGHJ2,CYSYAGSSTWVF,IGLV2-23,COV2-2622,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWYFDYW,IGHV4-4,IGHJ3,CYSYAGSSTWVF,IGLV2-23,COV2-2622,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWYFDYW,IGHV4-4,IGHJ4,CYSYAGSSTWVF,IGLV2-23,COV2-2622,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWYFDYW,IGHV4-4,IGHJ5,CYSYAGSSTWVF,IGLV2-23,COV2-2622,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWYFDYW,IGHV4-4,IGHJ6,CYSYAGSSTWVF,IGLV2-23,COV2-2622,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ1,CLLYYGGAWVF,IGLV7-43,COV2-2673,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ2,CLLYYGGAWVF,IGLV7-43,COV2-2673,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ3,CLLYYGGAWVF,IGLV7-43,COV2-2673,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ4,CLLYYGGAWVF,IGLV7-43,COV2-2673,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ5,CLLYYGGAWVF,IGLV7-43,COV2-2673,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIVLGASGTYPSPGFDPW,IGHV2-26,IGHJ6,CLLYYGGAWVF,IGLV7-43,COV2-2673,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ1,CQVWDSSSDHPGVF,IGLV3-21,COV2-2769,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ2,CQVWDSSSDHPGVF,IGLV3-21,COV2-2769,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ3,CQVWDSSSDHPGVF,IGLV3-21,COV2-2769,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ4,CQVWDSSSDHPGVF,IGLV3-21,COV2-2769,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ5,CQVWDSSSDHPGVF,IGLV3-21,COV2-2769,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDWAPTYYDMPSAFDIW,IGHV3-30-3,IGHJ6,CQVWDSSSDHPGVF,IGLV3-21,COV2-2769,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ1,CCSYAVSTTYVIF,IGLV2-23,COV2-2816,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ2,CCSYAVSTTYVIF,IGLV2-23,COV2-2816,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ3,CCSYAVSTTYVIF,IGLV2-23,COV2-2816,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ4,CCSYAVSTTYVIF,IGLV2-23,COV2-2816,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ5,CCSYAVSTTYVIF,IGLV2-23,COV2-2816,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPRERLQWGEYYFDYW,IGHV4-59,IGHJ6,CCSYAVSTTYVIF,IGLV2-23,COV2-2816,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDSRSGIAGVDAFDIW,IGHV3-23,IGHJ1,CQVWDSGSDHVVF,IGLV3-21,COV2-2830,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDSRSGIAGVDAFDIW,IGHV3-23,IGHJ2,CQVWDSGSDHVVF,IGLV3-21,COV2-2830,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDSRSGIAGVDAFDIW,IGHV3-23,IGHJ3,CQVWDSGSDHVVF,IGLV3-21,COV2-2830,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDSRSGIAGVDAFDIW,IGHV3-23,IGHJ4,CQVWDSGSDHVVF,IGLV3-21,COV2-2830,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDSRSGIAGVDAFDIW,IGHV3-23,IGHJ5,CQVWDSGSDHVVF,IGLV3-21,COV2-2830,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDSRSGIAGVDAFDIW,IGHV3-23,IGHJ6,CQVWDSGSDHVVF,IGLV3-21,COV2-2830,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQDSGYPTYYYYYMDVW,IGHV7-4-1,IGHJ1,CMQSIQPPLTF,IGKV2D-29,COV2-2582,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQDSGYPTYYYYYMDVW,IGHV7-4-1,IGHJ2,CMQSIQPPLTF,IGKV2D-29,COV2-2582,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQDSGYPTYYYYYMDVW,IGHV7-4-1,IGHJ3,CMQSIQPPLTF,IGKV2D-29,COV2-2582,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQDSGYPTYYYYYMDVW,IGHV7-4-1,IGHJ4,CMQSIQPPLTF,IGKV2D-29,COV2-2582,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQDSGYPTYYYYYMDVW,IGHV7-4-1,IGHJ5,CMQSIQPPLTF,IGKV2D-29,COV2-2582,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQDSGYPTYYYYYMDVW,IGHV7-4-1,IGHJ6,CMQSIQPPLTF,IGKV2D-29,COV2-2582,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDSGGNYGDSYFDYW,IGHV3-30,IGHJ1,CQSVDRSGTYFNWVF,IGLV3-25,COV2-2248,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDSGGNYGDSYFDYW,IGHV3-30,IGHJ2,CQSVDRSGTYFNWVF,IGLV3-25,COV2-2248,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDSGGNYGDSYFDYW,IGHV3-30,IGHJ3,CQSVDRSGTYFNWVF,IGLV3-25,COV2-2248,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDSGGNYGDSYFDYW,IGHV3-30,IGHJ4,CQSVDRSGTYFNWVF,IGLV3-25,COV2-2248,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDSGGNYGDSYFDYW,IGHV3-30,IGHJ5,CQSVDRSGTYFNWVF,IGLV3-25,COV2-2248,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDSGGNYGDSYFDYW,IGHV3-30,IGHJ6,CQSVDRSGTYFNWVF,IGLV3-25,COV2-2248,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSSGEGGLYYYYGMDVW,IGHV3-33,IGHJ1,CQSGDSSGTYVVF,IGLV3-25,COV2-2245,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSSGEGGLYYYYGMDVW,IGHV3-33,IGHJ2,CQSGDSSGTYVVF,IGLV3-25,COV2-2245,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSSGEGGLYYYYGMDVW,IGHV3-33,IGHJ3,CQSGDSSGTYVVF,IGLV3-25,COV2-2245,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSSGEGGLYYYYGMDVW,IGHV3-33,IGHJ4,CQSGDSSGTYVVF,IGLV3-25,COV2-2245,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSSGEGGLYYYYGMDVW,IGHV3-33,IGHJ5,CQSGDSSGTYVVF,IGLV3-25,COV2-2245,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGSSGEGGLYYYYGMDVW,IGHV3-33,IGHJ6,CQSGDSSGTYVVF,IGLV3-25,COV2-2245,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKPYGMDVW,IGHV3-23,IGHJ1,CSSYTSTSTPWVF,IGLV2-14,COV2-2418,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKPYGMDVW,IGHV3-23,IGHJ2,CSSYTSTSTPWVF,IGLV2-14,COV2-2418,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKPYGMDVW,IGHV3-23,IGHJ3,CSSYTSTSTPWVF,IGLV2-14,COV2-2418,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKPYGMDVW,IGHV3-23,IGHJ4,CSSYTSTSTPWVF,IGLV2-14,COV2-2418,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKPYGMDVW,IGHV3-23,IGHJ5,CSSYTSTSTPWVF,IGLV2-14,COV2-2418,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKPYGMDVW,IGHV3-23,IGHJ6,CSSYTSTSTPWVF,IGLV2-14,COV2-2418,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRDTDFDYW,IGHV5-51,IGHJ1,CGADHGSGSNFVYVVF,IGLV9-49,COV2-2378,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRDTDFDYW,IGHV5-51,IGHJ2,CGADHGSGSNFVYVVF,IGLV9-49,COV2-2378,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRDTDFDYW,IGHV5-51,IGHJ3,CGADHGSGSNFVYVVF,IGLV9-49,COV2-2378,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRDTDFDYW,IGHV5-51,IGHJ4,CGADHGSGSNFVYVVF,IGLV9-49,COV2-2378,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRDTDFDYW,IGHV5-51,IGHJ5,CGADHGSGSNFVYVVF,IGLV9-49,COV2-2378,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRDTDFDYW,IGHV5-51,IGHJ6,CGADHGSGSNFVYVVF,IGLV9-49,COV2-2378,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ1,CQTWGTF,IGLV4-69,COV2-2574,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ2,CQTWGTF,IGLV4-69,COV2-2574,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ3,CQTWGTF,IGLV4-69,COV2-2574,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ4,CQTWGTF,IGLV4-69,COV2-2574,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ5,CQTWGTF,IGLV4-69,COV2-2574,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARQWKWFGEAWYFDLW,IGHV4-39,IGHJ6,CQTWGTF,IGLV4-69,COV2-2574,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAGVPAALGCWFDPW,IGHV1-46,IGHJ1,CQQRSNWPLIFTF,IGKV3-11,COV2-2697,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAGVPAALGCWFDPW,IGHV1-46,IGHJ2,CQQRSNWPLIFTF,IGKV3-11,COV2-2697,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAGVPAALGCWFDPW,IGHV1-46,IGHJ3,CQQRSNWPLIFTF,IGKV3-11,COV2-2697,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAGVPAALGCWFDPW,IGHV1-46,IGHJ4,CQQRSNWPLIFTF,IGKV3-11,COV2-2697,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAGVPAALGCWFDPW,IGHV1-46,IGHJ5,CQQRSNWPLIFTF,IGKV3-11,COV2-2697,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLAGVPAALGCWFDPW,IGHV1-46,IGHJ6,CQQRSNWPLIFTF,IGKV3-11,COV2-2697,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVEQLAHMVDYW,IGHV3-74,IGHJ1,CQSADSSGTSWVF,IGLV3-25,COV2-2488,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVEQLAHMVDYW,IGHV3-74,IGHJ2,CQSADSSGTSWVF,IGLV3-25,COV2-2488,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVEQLAHMVDYW,IGHV3-74,IGHJ3,CQSADSSGTSWVF,IGLV3-25,COV2-2488,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVEQLAHMVDYW,IGHV3-74,IGHJ4,CQSADSSGTSWVF,IGLV3-25,COV2-2488,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVEQLAHMVDYW,IGHV3-74,IGHJ5,CQSADSSGTSWVF,IGLV3-25,COV2-2488,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREVEQLAHMVDYW,IGHV3-74,IGHJ6,CQSADSSGTSWVF,IGLV3-25,COV2-2488,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRGGIGIEYGMDVW,IGHV5-51,IGHJ1,CQSTASSGTYVVF,IGLV3-25,COV2-2368,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRGGIGIEYGMDVW,IGHV5-51,IGHJ2,CQSTASSGTYVVF,IGLV3-25,COV2-2368,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRGGIGIEYGMDVW,IGHV5-51,IGHJ3,CQSTASSGTYVVF,IGLV3-25,COV2-2368,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRGGIGIEYGMDVW,IGHV5-51,IGHJ4,CQSTASSGTYVVF,IGLV3-25,COV2-2368,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRGGIGIEYGMDVW,IGHV5-51,IGHJ5,CQSTASSGTYVVF,IGLV3-25,COV2-2368,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRGGIGIEYGMDVW,IGHV5-51,IGHJ6,CQSTASSGTYVVF,IGLV3-25,COV2-2368,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRDLALFEVVIQQGVW,IGHV3-33,IGHJ1,CYSTDSSGNHWVF,IGLV3-10,COV2-2496,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRDLALFEVVIQQGVW,IGHV3-33,IGHJ2,CYSTDSSGNHWVF,IGLV3-10,COV2-2496,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRDLALFEVVIQQGVW,IGHV3-33,IGHJ3,CYSTDSSGNHWVF,IGLV3-10,COV2-2496,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRDLALFEVVIQQGVW,IGHV3-33,IGHJ4,CYSTDSSGNHWVF,IGLV3-10,COV2-2496,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRDLALFEVVIQQGVW,IGHV3-33,IGHJ5,CYSTDSSGNHWVF,IGLV3-10,COV2-2496,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRDLALFEVVIQQGVW,IGHV3-33,IGHJ6,CYSTDSSGNHWVF,IGLV3-10,COV2-2496,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHNRFQYCSSTTCYTLLPFDYW,IGHV2-5,IGHJ1,CQQLNSYPFTF,IGKV1-9,COV2-2400,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHNRFQYCSSTTCYTLLPFDYW,IGHV2-5,IGHJ2,CQQLNSYPFTF,IGKV1-9,COV2-2400,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHNRFQYCSSTTCYTLLPFDYW,IGHV2-5,IGHJ3,CQQLNSYPFTF,IGKV1-9,COV2-2400,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHNRFQYCSSTTCYTLLPFDYW,IGHV2-5,IGHJ4,CQQLNSYPFTF,IGKV1-9,COV2-2400,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHNRFQYCSSTTCYTLLPFDYW,IGHV2-5,IGHJ5,CQQLNSYPFTF,IGKV1-9,COV2-2400,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHNRFQYCSSTTCYTLLPFDYW,IGHV2-5,IGHJ6,CQQLNSYPFTF,IGKV1-9,COV2-2400,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ1,CQQYNTYSGTF,IGKV1-5,COV2-2445,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ2,CQQYNTYSGTF,IGKV1-5,COV2-2445,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ3,CQQYNTYSGTF,IGKV1-5,COV2-2445,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ4,CQQYNTYSGTF,IGKV1-5,COV2-2445,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ5,CQQYNTYSGTF,IGKV1-5,COV2-2445,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ6,CQQYNTYSGTF,IGKV1-5,COV2-2445,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ1,CSSYTSSSTLLYVF,IGLV2-14,COV2-2147,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ2,CSSYTSSSTLLYVF,IGLV2-14,COV2-2147,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ3,CSSYTSSSTLLYVF,IGLV2-14,COV2-2147,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ4,CSSYTSSSTLLYVF,IGLV2-14,COV2-2147,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ5,CSSYTSSSTLLYVF,IGLV2-14,COV2-2147,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ6,CSSYTSSSTLLYVF,IGLV2-14,COV2-2147,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTGGYSSYAASDYW,IGHV3-15,IGHJ1,CSSFTSRGALVLF,IGLV2-14,COV2-2584,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTGGYSSYAASDYW,IGHV3-15,IGHJ2,CSSFTSRGALVLF,IGLV2-14,COV2-2584,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTGGYSSYAASDYW,IGHV3-15,IGHJ3,CSSFTSRGALVLF,IGLV2-14,COV2-2584,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTGGYSSYAASDYW,IGHV3-15,IGHJ4,CSSFTSRGALVLF,IGLV2-14,COV2-2584,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTGGYSSYAASDYW,IGHV3-15,IGHJ5,CSSFTSRGALVLF,IGLV2-14,COV2-2584,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTGGYSSYAASDYW,IGHV3-15,IGHJ6,CSSFTSRGALVLF,IGLV2-14,COV2-2584,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ1,CQQYYTAPLTF,IGKV4-1,COV2-2195,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ2,CQQYYTAPLTF,IGKV4-1,COV2-2195,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ3,CQQYYTAPLTF,IGKV4-1,COV2-2195,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ4,CQQYYTAPLTF,IGKV4-1,COV2-2195,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ5,CQQYYTAPLTF,IGKV4-1,COV2-2195,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ6,CQQYYTAPLTF,IGKV4-1,COV2-2195,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQMAATTGIDYW,IGHV3-33,IGHJ1,CYSTDTSGNHWVF,IGLV3-10,COV2-2473,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQMAATTGIDYW,IGHV3-33,IGHJ2,CYSTDTSGNHWVF,IGLV3-10,COV2-2473,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQMAATTGIDYW,IGHV3-33,IGHJ3,CYSTDTSGNHWVF,IGLV3-10,COV2-2473,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQMAATTGIDYW,IGHV3-33,IGHJ4,CYSTDTSGNHWVF,IGLV3-10,COV2-2473,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQMAATTGIDYW,IGHV3-33,IGHJ5,CYSTDTSGNHWVF,IGLV3-10,COV2-2473,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQMAATTGIDYW,IGHV3-33,IGHJ6,CYSTDTSGNHWVF,IGLV3-10,COV2-2473,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGWELSIDAFDLW,IGHV3-9,IGHJ1,CQHYGSSRSTF,IGKV3-20,COV2-2586,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGWELSIDAFDLW,IGHV3-9,IGHJ2,CQHYGSSRSTF,IGKV3-20,COV2-2586,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGWELSIDAFDLW,IGHV3-9,IGHJ3,CQHYGSSRSTF,IGKV3-20,COV2-2586,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGWELSIDAFDLW,IGHV3-9,IGHJ4,CQHYGSSRSTF,IGKV3-20,COV2-2586,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGWELSIDAFDLW,IGHV3-9,IGHJ5,CQHYGSSRSTF,IGKV3-20,COV2-2586,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKVGWELSIDAFDLW,IGHV3-9,IGHJ6,CQHYGSSRSTF,IGKV3-20,COV2-2586,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ1,CQQYNTYSGTF,IGKV1-5,COV2-2173,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ2,CQQYNTYSGTF,IGKV1-5,COV2-2173,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ3,CQQYNTYSGTF,IGKV1-5,COV2-2173,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ4,CQQYNTYSGTF,IGKV1-5,COV2-2173,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ5,CQQYNTYSGTF,IGKV1-5,COV2-2173,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ6,CQQYNTYSGTF,IGKV1-5,COV2-2173,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGGDNTAMVEYFFDFW,IGHV3-30,IGHJ1,CQQYNSYSPTF,IGKV1-5,COV2-2369,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGGDNTAMVEYFFDFW,IGHV3-30,IGHJ2,CQQYNSYSPTF,IGKV1-5,COV2-2369,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGGDNTAMVEYFFDFW,IGHV3-30,IGHJ3,CQQYNSYSPTF,IGKV1-5,COV2-2369,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGGDNTAMVEYFFDFW,IGHV3-30,IGHJ4,CQQYNSYSPTF,IGKV1-5,COV2-2369,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGGDNTAMVEYFFDFW,IGHV3-30,IGHJ5,CQQYNSYSPTF,IGKV1-5,COV2-2369,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDFGGDNTAMVEYFFDFW,IGHV3-30,IGHJ6,CQQYNSYSPTF,IGKV1-5,COV2-2369,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ1,CQQGNSFPLTF,IGKV1-12,COV2-2427,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ2,CQQGNSFPLTF,IGKV1-12,COV2-2427,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ3,CQQGNSFPLTF,IGKV1-12,COV2-2427,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ4,CQQGNSFPLTF,IGKV1-12,COV2-2427,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ5,CQQGNSFPLTF,IGKV1-12,COV2-2427,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ6,CQQGNSFPLTF,IGKV1-12,COV2-2427,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ1,CQQYNTYSGTF,IGKV1-5,COV2-2191,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ2,CQQYNTYSGTF,IGKV1-5,COV2-2191,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ3,CQQYNTYSGTF,IGKV1-5,COV2-2191,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ4,CQQYNTYSGTF,IGKV1-5,COV2-2191,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ5,CQQYNTYSGTF,IGKV1-5,COV2-2191,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRRSSSRYSSGWYMYYYYMDVW,IGHV3-20,IGHJ6,CQQYNTYSGTF,IGKV1-5,COV2-2191,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARYFDWIFEGSDYYYYGMDVW,IGHV1-8,IGHJ1,CSSYTSSSLRVF,IGLV2-18,COV2-2262,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARYFDWIFEGSDYYYYGMDVW,IGHV1-8,IGHJ2,CSSYTSSSLRVF,IGLV2-18,COV2-2262,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARYFDWIFEGSDYYYYGMDVW,IGHV1-8,IGHJ3,CSSYTSSSLRVF,IGLV2-18,COV2-2262,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARYFDWIFEGSDYYYYGMDVW,IGHV1-8,IGHJ4,CSSYTSSSLRVF,IGLV2-18,COV2-2262,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARYFDWIFEGSDYYYYGMDVW,IGHV1-8,IGHJ5,CSSYTSSSLRVF,IGLV2-18,COV2-2262,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREARYFDWIFEGSDYYYYGMDVW,IGHV1-8,IGHJ6,CSSYTSSSLRVF,IGLV2-18,COV2-2262,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADPYQLLGQHYYYGMDVW,IGHV3-13,IGHJ1,CQQYGSSPLITF,IGKV3-20,COV2-2660,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADPYQLLGQHYYYGMDVW,IGHV3-13,IGHJ2,CQQYGSSPLITF,IGKV3-20,COV2-2660,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADPYQLLGQHYYYGMDVW,IGHV3-13,IGHJ3,CQQYGSSPLITF,IGKV3-20,COV2-2660,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADPYQLLGQHYYYGMDVW,IGHV3-13,IGHJ4,CQQYGSSPLITF,IGKV3-20,COV2-2660,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADPYQLLGQHYYYGMDVW,IGHV3-13,IGHJ5,CQQYGSSPLITF,IGKV3-20,COV2-2660,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADPYQLLGQHYYYGMDVW,IGHV3-13,IGHJ6,CQQYGSSPLITF,IGKV3-20,COV2-2660,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ1,CQQSDNLPMYTF,IGKV1-33,COV2-2054,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ2,CQQSDNLPMYTF,IGKV1-33,COV2-2054,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ3,CQQSDNLPMYTF,IGKV1-33,COV2-2054,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ4,CQQSDNLPMYTF,IGKV1-33,COV2-2054,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ5,CQQSDNLPMYTF,IGKV1-33,COV2-2054,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRGYSNYGASYYMDVW,IGHV1-69,IGHJ6,CQQSDNLPMYTF,IGKV1-33,COV2-2054,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ1,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2226,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ2,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2226,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ3,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2226,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ4,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2226,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ5,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2226,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ6,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2226,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30-3,IGHJ1,CQSYDSSLSGYVF,IGLV1-40,COV2-2700,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30-3,IGHJ2,CQSYDSSLSGYVF,IGLV1-40,COV2-2700,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30-3,IGHJ3,CQSYDSSLSGYVF,IGLV1-40,COV2-2700,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30-3,IGHJ4,CQSYDSSLSGYVF,IGLV1-40,COV2-2700,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30-3,IGHJ5,CQSYDSSLSGYVF,IGLV1-40,COV2-2700,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKNLGPYCSGGTCYSLVGDYW,IGHV3-30-3,IGHJ6,CQSYDSSLSGYVF,IGLV1-40,COV2-2700,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGDFWSGYYTGWFDPW,IGHV3-33,IGHJ1,CQQYNNWPRTF,IGKV3-15,COV2-2386,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGDFWSGYYTGWFDPW,IGHV3-33,IGHJ2,CQQYNNWPRTF,IGKV3-15,COV2-2386,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGDFWSGYYTGWFDPW,IGHV3-33,IGHJ3,CQQYNNWPRTF,IGKV3-15,COV2-2386,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGDFWSGYYTGWFDPW,IGHV3-33,IGHJ4,CQQYNNWPRTF,IGKV3-15,COV2-2386,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGDFWSGYYTGWFDPW,IGHV3-33,IGHJ5,CQQYNNWPRTF,IGKV3-15,COV2-2386,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGDFWSGYYTGWFDPW,IGHV3-33,IGHJ6,CQQYNNWPRTF,IGKV3-15,COV2-2386,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDRTAVFLFFGLGDAFDIW,IGHV3-30,IGHJ1,CQVWDSSSDHWVF,IGLV3-21,COV2-2521,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDRTAVFLFFGLGDAFDIW,IGHV3-30,IGHJ2,CQVWDSSSDHWVF,IGLV3-21,COV2-2521,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDRTAVFLFFGLGDAFDIW,IGHV3-30,IGHJ3,CQVWDSSSDHWVF,IGLV3-21,COV2-2521,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDRTAVFLFFGLGDAFDIW,IGHV3-30,IGHJ4,CQVWDSSSDHWVF,IGLV3-21,COV2-2521,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDRTAVFLFFGLGDAFDIW,IGHV3-30,IGHJ5,CQVWDSSSDHWVF,IGLV3-21,COV2-2521,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDRTAVFLFFGLGDAFDIW,IGHV3-30,IGHJ6,CQVWDSSSDHWVF,IGLV3-21,COV2-2521,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSGSYYGWFDPW,IGHV3-30,IGHJ1,CHQSSSLPPTF,IGKV6-21,COV2-2675,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSGSYYGWFDPW,IGHV3-30,IGHJ2,CHQSSSLPPTF,IGKV6-21,COV2-2675,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSGSYYGWFDPW,IGHV3-30,IGHJ3,CHQSSSLPPTF,IGKV6-21,COV2-2675,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSGSYYGWFDPW,IGHV3-30,IGHJ4,CHQSSSLPPTF,IGKV6-21,COV2-2675,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSGSYYGWFDPW,IGHV3-30,IGHJ5,CHQSSSLPPTF,IGKV6-21,COV2-2675,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSGSYYGWFDPW,IGHV3-30,IGHJ6,CHQSSSLPPTF,IGKV6-21,COV2-2675,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ1,CQSVDSSGTYRVF,IGLV3-25,COV2-2942,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ2,CQSVDSSGTYRVF,IGLV3-25,COV2-2942,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ3,CQSVDSSGTYRVF,IGLV3-25,COV2-2942,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ4,CQSVDSSGTYRVF,IGLV3-25,COV2-2942,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ5,CQSVDSSGTYRVF,IGLV3-25,COV2-2942,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARATTFFYGMDVW,IGHV2-70,IGHJ6,CQSVDSSGTYRVF,IGLV3-25,COV2-2942,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCNGVTCNSNYW,IGHV3-33,IGHJ1,CQQYYSSHWTF,IGKV4-1,COV2-2621,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCNGVTCNSNYW,IGHV3-33,IGHJ2,CQQYYSSHWTF,IGKV4-1,COV2-2621,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCNGVTCNSNYW,IGHV3-33,IGHJ3,CQQYYSSHWTF,IGKV4-1,COV2-2621,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCNGVTCNSNYW,IGHV3-33,IGHJ4,CQQYYSSHWTF,IGKV4-1,COV2-2621,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCNGVTCNSNYW,IGHV3-33,IGHJ5,CQQYYSSHWTF,IGKV4-1,COV2-2621,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDYCNGVTCNSNYW,IGHV3-33,IGHJ6,CQQYYSSHWTF,IGKV4-1,COV2-2621,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ1,CQQANSLPLTF,IGKV1-12,COV2-2300,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ2,CQQANSLPLTF,IGKV1-12,COV2-2300,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ3,CQQANSLPLTF,IGKV1-12,COV2-2300,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ4,CQQANSLPLTF,IGKV1-12,COV2-2300,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ5,CQQANSLPLTF,IGKV1-12,COV2-2300,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASRWGDYFDSSGAYDSW,IGHV4-4,IGHJ6,CQQANSLPLTF,IGKV1-12,COV2-2300,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPRVVVTARMYNWFDPW,IGHV4-39,IGHJ1,CQQYNNWPPMYTF,IGKV3-15,COV2-2570,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPRVVVTARMYNWFDPW,IGHV4-39,IGHJ2,CQQYNNWPPMYTF,IGKV3-15,COV2-2570,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPRVVVTARMYNWFDPW,IGHV4-39,IGHJ3,CQQYNNWPPMYTF,IGKV3-15,COV2-2570,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPRVVVTARMYNWFDPW,IGHV4-39,IGHJ4,CQQYNNWPPMYTF,IGKV3-15,COV2-2570,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPRVVVTARMYNWFDPW,IGHV4-39,IGHJ5,CQQYNNWPPMYTF,IGKV3-15,COV2-2570,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPRVVVTARMYNWFDPW,IGHV4-39,IGHJ6,CQQYNNWPPMYTF,IGKV3-15,COV2-2570,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPGSRYSGGWYDYYYAMDVW,IGHV3-66,IGHJ1,CQQYGSSPPYTF,IGKV3-20,COV2-2373,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPGSRYSGGWYDYYYAMDVW,IGHV3-66,IGHJ2,CQQYGSSPPYTF,IGKV3-20,COV2-2373,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPGSRYSGGWYDYYYAMDVW,IGHV3-66,IGHJ3,CQQYGSSPPYTF,IGKV3-20,COV2-2373,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPGSRYSGGWYDYYYAMDVW,IGHV3-66,IGHJ4,CQQYGSSPPYTF,IGKV3-20,COV2-2373,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPGSRYSGGWYDYYYAMDVW,IGHV3-66,IGHJ5,CQQYGSSPPYTF,IGKV3-20,COV2-2373,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPGSRYSGGWYDYYYAMDVW,IGHV3-66,IGHJ6,CQQYGSSPPYTF,IGKV3-20,COV2-2373,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGPFGDREASGAFDVW,IGHV3-33,IGHJ1,CYSTDSSGKGVF,IGLV3-10,COV2-2872,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGPFGDREASGAFDVW,IGHV3-33,IGHJ2,CYSTDSSGKGVF,IGLV3-10,COV2-2872,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGPFGDREASGAFDVW,IGHV3-33,IGHJ3,CYSTDSSGKGVF,IGLV3-10,COV2-2872,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGPFGDREASGAFDVW,IGHV3-33,IGHJ4,CYSTDSSGKGVF,IGLV3-10,COV2-2872,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGPFGDREASGAFDVW,IGHV3-33,IGHJ5,CYSTDSSGKGVF,IGLV3-10,COV2-2872,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGPFGDREASGAFDVW,IGHV3-33,IGHJ6,CYSTDSSGKGVF,IGLV3-10,COV2-2872,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRRGILTEDAFDIW,IGHV2-5,IGHJ1,CQQSYNTPRTF,IGKV1-39,COV2-2035,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRRGILTEDAFDIW,IGHV2-5,IGHJ2,CQQSYNTPRTF,IGKV1-39,COV2-2035,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRRGILTEDAFDIW,IGHV2-5,IGHJ3,CQQSYNTPRTF,IGKV1-39,COV2-2035,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRRGILTEDAFDIW,IGHV2-5,IGHJ4,CQQSYNTPRTF,IGKV1-39,COV2-2035,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRRGILTEDAFDIW,IGHV2-5,IGHJ5,CQQSYNTPRTF,IGKV1-39,COV2-2035,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRRGILTEDAFDIW,IGHV2-5,IGHJ6,CQQSYNTPRTF,IGKV1-39,COV2-2035,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQGRGGYYSPFDDW,IGHV3-30,IGHJ1,CQQYNNWPLAF,IGKV3-15,COV2-2383,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQGRGGYYSPFDDW,IGHV3-30,IGHJ2,CQQYNNWPLAF,IGKV3-15,COV2-2383,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQGRGGYYSPFDDW,IGHV3-30,IGHJ3,CQQYNNWPLAF,IGKV3-15,COV2-2383,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQGRGGYYSPFDDW,IGHV3-30,IGHJ4,CQQYNNWPLAF,IGKV3-15,COV2-2383,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQGRGGYYSPFDDW,IGHV3-30,IGHJ5,CQQYNNWPLAF,IGKV3-15,COV2-2383,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAQGRGGYYSPFDDW,IGHV3-30,IGHJ6,CQQYNNWPLAF,IGKV3-15,COV2-2383,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQGTYLDYW,IGHV3-33,IGHJ1,CCSTDSSGNQRVF,IGLV3-10,COV2-2454,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQGTYLDYW,IGHV3-33,IGHJ2,CCSTDSSGNQRVF,IGLV3-10,COV2-2454,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQGTYLDYW,IGHV3-33,IGHJ3,CCSTDSSGNQRVF,IGLV3-10,COV2-2454,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQGTYLDYW,IGHV3-33,IGHJ4,CCSTDSSGNQRVF,IGLV3-10,COV2-2454,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQGTYLDYW,IGHV3-33,IGHJ5,CCSTDSSGNQRVF,IGLV3-10,COV2-2454,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQGTYLDYW,IGHV3-33,IGHJ6,CCSTDSSGNQRVF,IGLV3-10,COV2-2454,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSCGDCYSADLDFW,IGHV1-69,IGHJ1,CQRRSNWPPFTF,IGKV3-11,COV2-2676,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSCGDCYSADLDFW,IGHV1-69,IGHJ2,CQRRSNWPPFTF,IGKV3-11,COV2-2676,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSCGDCYSADLDFW,IGHV1-69,IGHJ3,CQRRSNWPPFTF,IGKV3-11,COV2-2676,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSCGDCYSADLDFW,IGHV1-69,IGHJ4,CQRRSNWPPFTF,IGKV3-11,COV2-2676,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSCGDCYSADLDFW,IGHV1-69,IGHJ5,CQRRSNWPPFTF,IGKV3-11,COV2-2676,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSCGDCYSADLDFW,IGHV1-69,IGHJ6,CQRRSNWPPFTF,IGKV3-11,COV2-2676,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPGKAAAFDYW,IGHV7-4-1,IGHJ1,CMQALQTPWTF,IGKV2-28,COV2-2934,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPGKAAAFDYW,IGHV7-4-1,IGHJ2,CMQALQTPWTF,IGKV2-28,COV2-2934,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPGKAAAFDYW,IGHV7-4-1,IGHJ3,CMQALQTPWTF,IGKV2-28,COV2-2934,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPGKAAAFDYW,IGHV7-4-1,IGHJ4,CMQALQTPWTF,IGKV2-28,COV2-2934,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPGKAAAFDYW,IGHV7-4-1,IGHJ5,CMQALQTPWTF,IGKV2-28,COV2-2934,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPGKAAAFDYW,IGHV7-4-1,IGHJ6,CMQALQTPWTF,IGKV2-28,COV2-2934,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ1,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2241,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ2,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2241,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ3,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2241,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ4,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2241,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ5,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2241,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ6,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2241,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQWPNQAFDIW,IGHV3-33,IGHJ1,CQAWDSSTHVVF,IGLV3-1,COV2-2549,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQWPNQAFDIW,IGHV3-33,IGHJ2,CQAWDSSTHVVF,IGLV3-1,COV2-2549,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQWPNQAFDIW,IGHV3-33,IGHJ3,CQAWDSSTHVVF,IGLV3-1,COV2-2549,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQWPNQAFDIW,IGHV3-33,IGHJ4,CQAWDSSTHVVF,IGLV3-1,COV2-2549,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQWPNQAFDIW,IGHV3-33,IGHJ5,CQAWDSSTHVVF,IGLV3-1,COV2-2549,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAREGQWPNQAFDIW,IGHV3-33,IGHJ6,CQAWDSSTHVVF,IGLV3-1,COV2-2549,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARKGPLWRFDYW,IGHV3-33,IGHJ1,CQSYDSSLSAWVF,IGLV1-40,COV2-2428,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARKGPLWRFDYW,IGHV3-33,IGHJ2,CQSYDSSLSAWVF,IGLV1-40,COV2-2428,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARKGPLWRFDYW,IGHV3-33,IGHJ3,CQSYDSSLSAWVF,IGLV1-40,COV2-2428,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARKGPLWRFDYW,IGHV3-33,IGHJ4,CQSYDSSLSAWVF,IGLV1-40,COV2-2428,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARKGPLWRFDYW,IGHV3-33,IGHJ5,CQSYDSSLSAWVF,IGLV1-40,COV2-2428,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARKGPLWRFDYW,IGHV3-33,IGHJ6,CQSYDSSLSAWVF,IGLV1-40,COV2-2428,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPPVTTFFVFSLLFDPW,IGHV4-34,IGHJ1,CAAWDASLSGWVF,IGLV1-47,COV2-2545,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPPVTTFFVFSLLFDPW,IGHV4-34,IGHJ2,CAAWDASLSGWVF,IGLV1-47,COV2-2545,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPPVTTFFVFSLLFDPW,IGHV4-34,IGHJ3,CAAWDASLSGWVF,IGLV1-47,COV2-2545,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPPVTTFFVFSLLFDPW,IGHV4-34,IGHJ4,CAAWDASLSGWVF,IGLV1-47,COV2-2545,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPPVTTFFVFSLLFDPW,IGHV4-34,IGHJ5,CAAWDASLSGWVF,IGLV1-47,COV2-2545,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGPPVTTFFVFSLLFDPW,IGHV4-34,IGHJ6,CAAWDASLSGWVF,IGLV1-47,COV2-2545,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGEGVDSYYYGMDVW,IGHV1-69,IGHJ1,CQSTDSSGSYVVF,IGLV3-25,COV2-2624,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGEGVDSYYYGMDVW,IGHV1-69,IGHJ2,CQSTDSSGSYVVF,IGLV3-25,COV2-2624,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGEGVDSYYYGMDVW,IGHV1-69,IGHJ3,CQSTDSSGSYVVF,IGLV3-25,COV2-2624,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGEGVDSYYYGMDVW,IGHV1-69,IGHJ4,CQSTDSSGSYVVF,IGLV3-25,COV2-2624,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGEGVDSYYYGMDVW,IGHV1-69,IGHJ5,CQSTDSSGSYVVF,IGLV3-25,COV2-2624,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGEGVDSYYYGMDVW,IGHV1-69,IGHJ6,CQSTDSSGSYVVF,IGLV3-25,COV2-2624,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDGGNAYSSGWYRYYYHMDVW,IGHV4-59,IGHJ1,CQQYNNWPYTF,IGKV3-15,COV2-2784,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDGGNAYSSGWYRYYYHMDVW,IGHV4-59,IGHJ2,CQQYNNWPYTF,IGKV3-15,COV2-2784,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDGGNAYSSGWYRYYYHMDVW,IGHV4-59,IGHJ3,CQQYNNWPYTF,IGKV3-15,COV2-2784,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDGGNAYSSGWYRYYYHMDVW,IGHV4-59,IGHJ4,CQQYNNWPYTF,IGKV3-15,COV2-2784,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDGGNAYSSGWYRYYYHMDVW,IGHV4-59,IGHJ5,CQQYNNWPYTF,IGKV3-15,COV2-2784,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDGGNAYSSGWYRYYYHMDVW,IGHV4-59,IGHJ6,CQQYNNWPYTF,IGKV3-15,COV2-2784,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPSNWYFDLW,IGHV3-30,IGHJ1,CCSYASSSIVVF,IGLV2-23,COV2-2726,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPSNWYFDLW,IGHV3-30,IGHJ2,CCSYASSSIVVF,IGLV2-23,COV2-2726,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPSNWYFDLW,IGHV3-30,IGHJ3,CCSYASSSIVVF,IGLV2-23,COV2-2726,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPSNWYFDLW,IGHV3-30,IGHJ4,CCSYASSSIVVF,IGLV2-23,COV2-2726,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPSNWYFDLW,IGHV3-30,IGHJ5,CCSYASSSIVVF,IGLV2-23,COV2-2726,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPSNWYFDLW,IGHV3-30,IGHJ6,CCSYASSSIVVF,IGLV2-23,COV2-2726,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRTYYDLWSAYSSTAYYCMDVW,IGHV4-39,IGHJ1,CQQLNSYPLTF,IGKV1-9,COV2-2718,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRTYYDLWSAYSSTAYYCMDVW,IGHV4-39,IGHJ2,CQQLNSYPLTF,IGKV1-9,COV2-2718,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRTYYDLWSAYSSTAYYCMDVW,IGHV4-39,IGHJ3,CQQLNSYPLTF,IGKV1-9,COV2-2718,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRTYYDLWSAYSSTAYYCMDVW,IGHV4-39,IGHJ4,CQQLNSYPLTF,IGKV1-9,COV2-2718,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRTYYDLWSAYSSTAYYCMDVW,IGHV4-39,IGHJ5,CQQLNSYPLTF,IGKV1-9,COV2-2718,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRTYYDLWSAYSSTAYYCMDVW,IGHV4-39,IGHJ6,CQQLNSYPLTF,IGKV1-9,COV2-2718,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTLTYYYDSSAYLNDAFDIW,IGHV3-15,IGHJ1,CYSTDSSGNHRVF,IGLV3-10,COV2-2474,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTLTYYYDSSAYLNDAFDIW,IGHV3-15,IGHJ2,CYSTDSSGNHRVF,IGLV3-10,COV2-2474,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTLTYYYDSSAYLNDAFDIW,IGHV3-15,IGHJ3,CYSTDSSGNHRVF,IGLV3-10,COV2-2474,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTLTYYYDSSAYLNDAFDIW,IGHV3-15,IGHJ4,CYSTDSSGNHRVF,IGLV3-10,COV2-2474,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTLTYYYDSSAYLNDAFDIW,IGHV3-15,IGHJ5,CYSTDSSGNHRVF,IGLV3-10,COV2-2474,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTTLTYYYDSSAYLNDAFDIW,IGHV3-15,IGHJ6,CYSTDSSGNHRVF,IGLV3-10,COV2-2474,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLISLFRGAIFHYYYGMDVW,IGHV7-4-1,IGHJ1,CCSYAGRYTWVF,IGLV2-11,COV2-2947,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLISLFRGAIFHYYYGMDVW,IGHV7-4-1,IGHJ2,CCSYAGRYTWVF,IGLV2-11,COV2-2947,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLISLFRGAIFHYYYGMDVW,IGHV7-4-1,IGHJ3,CCSYAGRYTWVF,IGLV2-11,COV2-2947,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLISLFRGAIFHYYYGMDVW,IGHV7-4-1,IGHJ4,CCSYAGRYTWVF,IGLV2-11,COV2-2947,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLISLFRGAIFHYYYGMDVW,IGHV7-4-1,IGHJ5,CCSYAGRYTWVF,IGLV2-11,COV2-2947,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLISLFRGAIFHYYYGMDVW,IGHV7-4-1,IGHJ6,CCSYAGRYTWVF,IGLV2-11,COV2-2947,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ1,CQQTYSTFWTF,IGKV1-39,COV2-2177,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ2,CQQTYSTFWTF,IGKV1-39,COV2-2177,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ3,CQQTYSTFWTF,IGKV1-39,COV2-2177,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ4,CQQTYSTFWTF,IGKV1-39,COV2-2177,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ5,CQQTYSTFWTF,IGKV1-39,COV2-2177,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ6,CQQTYSTFWTF,IGKV1-39,COV2-2177,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSNLERLVMTFGGIIAGAFDIW,IGHV3-30,IGHJ1,CQQYHVWPPITF,IGKV3-15,COV2-2420,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSNLERLVMTFGGIIAGAFDIW,IGHV3-30,IGHJ2,CQQYHVWPPITF,IGKV3-15,COV2-2420,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSNLERLVMTFGGIIAGAFDIW,IGHV3-30,IGHJ3,CQQYHVWPPITF,IGKV3-15,COV2-2420,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSNLERLVMTFGGIIAGAFDIW,IGHV3-30,IGHJ4,CQQYHVWPPITF,IGKV3-15,COV2-2420,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSNLERLVMTFGGIIAGAFDIW,IGHV3-30,IGHJ5,CQQYHVWPPITF,IGKV3-15,COV2-2420,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSNLERLVMTFGGIIAGAFDIW,IGHV3-30,IGHJ6,CQQYHVWPPITF,IGKV3-15,COV2-2420,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ1,CQQYGSSPPRYTF,IGKV3-20,COV2-2818,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ2,CQQYGSSPPRYTF,IGKV3-20,COV2-2818,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ3,CQQYGSSPPRYTF,IGKV3-20,COV2-2818,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ4,CQQYGSSPPRYTF,IGKV3-20,COV2-2818,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ5,CQQYGSSPPRYTF,IGKV3-20,COV2-2818,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ6,CQQYGSSPPRYTF,IGKV3-20,COV2-2818,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAIYGYYYYGLDVW,IGHV3-30,IGHJ1,CQSADSSGTYFWVF,IGLV3-25,COV2-2027,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAIYGYYYYGLDVW,IGHV3-30,IGHJ2,CQSADSSGTYFWVF,IGLV3-25,COV2-2027,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAIYGYYYYGLDVW,IGHV3-30,IGHJ3,CQSADSSGTYFWVF,IGLV3-25,COV2-2027,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAIYGYYYYGLDVW,IGHV3-30,IGHJ4,CQSADSSGTYFWVF,IGLV3-25,COV2-2027,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAIYGYYYYGLDVW,IGHV3-30,IGHJ5,CQSADSSGTYFWVF,IGLV3-25,COV2-2027,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAIYGYYYYGLDVW,IGHV3-30,IGHJ6,CQSADSSGTYFWVF,IGLV3-25,COV2-2027,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVHRHVSGAFDYW,IGHV2-5,IGHJ1,CQAWDSSTGGVF,IGLV3-1,COV2-2451,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVHRHVSGAFDYW,IGHV2-5,IGHJ2,CQAWDSSTGGVF,IGLV3-1,COV2-2451,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVHRHVSGAFDYW,IGHV2-5,IGHJ3,CQAWDSSTGGVF,IGLV3-1,COV2-2451,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVHRHVSGAFDYW,IGHV2-5,IGHJ4,CQAWDSSTGGVF,IGLV3-1,COV2-2451,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVHRHVSGAFDYW,IGHV2-5,IGHJ5,CQAWDSSTGGVF,IGLV3-1,COV2-2451,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVHRHVSGAFDYW,IGHV2-5,IGHJ6,CQAWDSSTGGVF,IGLV3-1,COV2-2451,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGEWELRGNALDIW,IGHV3-30,IGHJ1,CQSVDGSGSSVVF,IGLV3-25,COV2-2546,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGEWELRGNALDIW,IGHV3-30,IGHJ2,CQSVDGSGSSVVF,IGLV3-25,COV2-2546,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGEWELRGNALDIW,IGHV3-30,IGHJ3,CQSVDGSGSSVVF,IGLV3-25,COV2-2546,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGEWELRGNALDIW,IGHV3-30,IGHJ4,CQSVDGSGSSVVF,IGLV3-25,COV2-2546,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGEWELRGNALDIW,IGHV3-30,IGHJ5,CQSVDGSGSSVVF,IGLV3-25,COV2-2546,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGEWELRGNALDIW,IGHV3-30,IGHJ6,CQSVDGSGSSVVF,IGLV3-25,COV2-2546,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ1,CQQSYSTPGTF,IGKV1-39,COV2-2643,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ2,CQQSYSTPGTF,IGKV1-39,COV2-2643,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ3,CQQSYSTPGTF,IGKV1-39,COV2-2643,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ4,CQQSYSTPGTF,IGKV1-39,COV2-2643,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ5,CQQSYSTPGTF,IGKV1-39,COV2-2643,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ6,CQQSYSTPGTF,IGKV1-39,COV2-2643,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGPTYYYGSGSPHYGMDVW,IGHV1-18,IGHJ1,CMQRIEFPWTF,IGKV2-40,COV2-2022,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGPTYYYGSGSPHYGMDVW,IGHV1-18,IGHJ2,CMQRIEFPWTF,IGKV2-40,COV2-2022,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGPTYYYGSGSPHYGMDVW,IGHV1-18,IGHJ3,CMQRIEFPWTF,IGKV2-40,COV2-2022,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGPTYYYGSGSPHYGMDVW,IGHV1-18,IGHJ4,CMQRIEFPWTF,IGKV2-40,COV2-2022,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGPTYYYGSGSPHYGMDVW,IGHV1-18,IGHJ5,CMQRIEFPWTF,IGKV2-40,COV2-2022,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQGPTYYYGSGSPHYGMDVW,IGHV1-18,IGHJ6,CMQRIEFPWTF,IGKV2-40,COV2-2022,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLTFGGSGSYYFYYNGMDVW,IGHV5-51,IGHJ1,CQQYGRSSGTF,IGKV3-20,COV2-2656,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLTFGGSGSYYFYYNGMDVW,IGHV5-51,IGHJ2,CQQYGRSSGTF,IGKV3-20,COV2-2656,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLTFGGSGSYYFYYNGMDVW,IGHV5-51,IGHJ3,CQQYGRSSGTF,IGKV3-20,COV2-2656,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLTFGGSGSYYFYYNGMDVW,IGHV5-51,IGHJ4,CQQYGRSSGTF,IGKV3-20,COV2-2656,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLTFGGSGSYYFYYNGMDVW,IGHV5-51,IGHJ5,CQQYGRSSGTF,IGKV3-20,COV2-2656,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLTFGGSGSYYFYYNGMDVW,IGHV5-51,IGHJ6,CQQYGRSSGTF,IGKV3-20,COV2-2656,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVREYGSGHPLPIW,IGHV7-4-1,IGHJ1,CQSADSSSHWVF,IGLV3-25,COV2-2529,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVREYGSGHPLPIW,IGHV7-4-1,IGHJ2,CQSADSSSHWVF,IGLV3-25,COV2-2529,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVREYGSGHPLPIW,IGHV7-4-1,IGHJ3,CQSADSSSHWVF,IGLV3-25,COV2-2529,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVREYGSGHPLPIW,IGHV7-4-1,IGHJ4,CQSADSSSHWVF,IGLV3-25,COV2-2529,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVREYGSGHPLPIW,IGHV7-4-1,IGHJ5,CQSADSSSHWVF,IGLV3-25,COV2-2529,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVREYGSGHPLPIW,IGHV7-4-1,IGHJ6,CQSADSSSHWVF,IGLV3-25,COV2-2529,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSPPASYYNPSTGYFDYW,IGHV3-30,IGHJ1,CQQSYSTPMHTF,IGKV1-39,COV2-2553,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSPPASYYNPSTGYFDYW,IGHV3-30,IGHJ2,CQQSYSTPMHTF,IGKV1-39,COV2-2553,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSPPASYYNPSTGYFDYW,IGHV3-30,IGHJ3,CQQSYSTPMHTF,IGKV1-39,COV2-2553,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSPPASYYNPSTGYFDYW,IGHV3-30,IGHJ4,CQQSYSTPMHTF,IGKV1-39,COV2-2553,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSPPASYYNPSTGYFDYW,IGHV3-30,IGHJ5,CQQSYSTPMHTF,IGKV1-39,COV2-2553,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSPPASYYNPSTGYFDYW,IGHV3-30,IGHJ6,CQQSYSTPMHTF,IGKV1-39,COV2-2553,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESADISSRLDYW,IGHV3-33,IGHJ1,CYSTDSSGNVF,IGLV3-10,COV2-2611,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESADISSRLDYW,IGHV3-33,IGHJ2,CYSTDSSGNVF,IGLV3-10,COV2-2611,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESADISSRLDYW,IGHV3-33,IGHJ3,CYSTDSSGNVF,IGLV3-10,COV2-2611,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESADISSRLDYW,IGHV3-33,IGHJ4,CYSTDSSGNVF,IGLV3-10,COV2-2611,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESADISSRLDYW,IGHV3-33,IGHJ5,CYSTDSSGNVF,IGLV3-10,COV2-2611,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESADISSRLDYW,IGHV3-33,IGHJ6,CYSTDSSGNVF,IGLV3-10,COV2-2611,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRAVILNFDHW,IGHV2-5,IGHJ1,CQAWDNDAGVVF,IGLV3-1,COV2-2238,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRAVILNFDHW,IGHV2-5,IGHJ2,CQAWDNDAGVVF,IGLV3-1,COV2-2238,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRAVILNFDHW,IGHV2-5,IGHJ3,CQAWDNDAGVVF,IGLV3-1,COV2-2238,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRAVILNFDHW,IGHV2-5,IGHJ4,CQAWDNDAGVVF,IGLV3-1,COV2-2238,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRAVILNFDHW,IGHV2-5,IGHJ5,CQAWDNDAGVVF,IGLV3-1,COV2-2238,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRAVILNFDHW,IGHV2-5,IGHJ6,CQAWDNDAGVVF,IGLV3-1,COV2-2238,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ1,CQSYDSSLGALF,IGLV1-40,COV2-2207,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ2,CQSYDSSLGALF,IGLV1-40,COV2-2207,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ3,CQSYDSSLGALF,IGLV1-40,COV2-2207,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ4,CQSYDSSLGALF,IGLV1-40,COV2-2207,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ5,CQSYDSSLGALF,IGLV1-40,COV2-2207,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ6,CQSYDSSLGALF,IGLV1-40,COV2-2207,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGGSGSLRYYYYGMDVW,IGHV3-66,IGHJ1,CAAWDDSLNGYVF,IGLV1-44,COV2-2143,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGGSGSLRYYYYGMDVW,IGHV3-66,IGHJ2,CAAWDDSLNGYVF,IGLV1-44,COV2-2143,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGGSGSLRYYYYGMDVW,IGHV3-66,IGHJ3,CAAWDDSLNGYVF,IGLV1-44,COV2-2143,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGGSGSLRYYYYGMDVW,IGHV3-66,IGHJ4,CAAWDDSLNGYVF,IGLV1-44,COV2-2143,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGGSGSLRYYYYGMDVW,IGHV3-66,IGHJ5,CAAWDDSLNGYVF,IGLV1-44,COV2-2143,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKEGGSGSLRYYYYGMDVW,IGHV3-66,IGHJ6,CAAWDDSLNGYVF,IGLV1-44,COV2-2143,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSAYYDILTGYSGDVW,IGHV3-66,IGHJ1,CQQYSIYSWTF,IGKV1-5,COV2-2296,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSAYYDILTGYSGDVW,IGHV3-66,IGHJ2,CQQYSIYSWTF,IGKV1-5,COV2-2296,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSAYYDILTGYSGDVW,IGHV3-66,IGHJ3,CQQYSIYSWTF,IGKV1-5,COV2-2296,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSAYYDILTGYSGDVW,IGHV3-66,IGHJ4,CQQYSIYSWTF,IGKV1-5,COV2-2296,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSAYYDILTGYSGDVW,IGHV3-66,IGHJ5,CQQYSIYSWTF,IGKV1-5,COV2-2296,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSAYYDILTGYSGDVW,IGHV3-66,IGHJ6,CQQYSIYSWTF,IGKV1-5,COV2-2296,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ1,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2446,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ2,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2446,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ3,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2446,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ4,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2446,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ5,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2446,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATHRCSGGFCYLAYW,IGHV5-51,IGHJ6,CGADHGSGSNFVFVVF,IGLV9-49,COV2-2446,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ1,CQQYGRSPITF,IGKV3-20,COV2-2197,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ2,CQQYGRSPITF,IGKV3-20,COV2-2197,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ3,CQQYGRSPITF,IGKV3-20,COV2-2197,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ4,CQQYGRSPITF,IGKV3-20,COV2-2197,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ5,CQQYGRSPITF,IGKV3-20,COV2-2197,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ6,CQQYGRSPITF,IGKV3-20,COV2-2197,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ1,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2142,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ2,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2142,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ3,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2142,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ4,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2142,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ5,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2142,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARRGEAAGIWYFDLW,IGHV5-51,IGHJ6,CGADHGSGSNFEYVVF,IGLV9-49,COV2-2142,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRGWNYGLDYW,IGHV3-48,IGHJ1,CFSMDSSGDLRVF,IGLV3-10,COV2-2274,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRGWNYGLDYW,IGHV3-48,IGHJ2,CFSMDSSGDLRVF,IGLV3-10,COV2-2274,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRGWNYGLDYW,IGHV3-48,IGHJ3,CFSMDSSGDLRVF,IGLV3-10,COV2-2274,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRGWNYGLDYW,IGHV3-48,IGHJ4,CFSMDSSGDLRVF,IGLV3-10,COV2-2274,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRGWNYGLDYW,IGHV3-48,IGHJ5,CFSMDSSGDLRVF,IGLV3-10,COV2-2274,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRGWNYGLDYW,IGHV3-48,IGHJ6,CFSMDSSGDLRVF,IGLV3-10,COV2-2274,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ1,CQQYNSYSLTF,IGKV3-15,COV2-2614,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ2,CQQYNSYSLTF,IGKV3-15,COV2-2614,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ3,CQQYNSYSLTF,IGKV3-15,COV2-2614,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ4,CQQYNSYSLTF,IGKV3-15,COV2-2614,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ5,CQQYNSYSLTF,IGKV3-15,COV2-2614,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ6,CQQYNSYSLTF,IGKV3-15,COV2-2614,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ1,CQSFDIGRGGWIF,IGLV1-40,COV2-2904,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ2,CQSFDIGRGGWIF,IGLV1-40,COV2-2904,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ3,CQSFDIGRGGWIF,IGLV1-40,COV2-2904,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ4,CQSFDIGRGGWIF,IGLV1-40,COV2-2904,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ5,CQSFDIGRGGWIF,IGLV1-40,COV2-2904,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARCRQMGNFYYYYMDVW,IGHV4-34,IGHJ6,CQSFDIGRGGWIF,IGLV1-40,COV2-2904,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARALNKGFDPW,IGHV3-30,IGHJ1,CQQYYSSPYTF,IGKV4-1,COV2-2681,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARALNKGFDPW,IGHV3-30,IGHJ2,CQQYYSSPYTF,IGKV4-1,COV2-2681,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARALNKGFDPW,IGHV3-30,IGHJ3,CQQYYSSPYTF,IGKV4-1,COV2-2681,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARALNKGFDPW,IGHV3-30,IGHJ4,CQQYYSSPYTF,IGKV4-1,COV2-2681,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARALNKGFDPW,IGHV3-30,IGHJ5,CQQYYSSPYTF,IGKV4-1,COV2-2681,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARALNKGFDPW,IGHV3-30,IGHJ6,CQQYYSSPYTF,IGKV4-1,COV2-2681,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGNYLTFFDSW,IGHV3-30,IGHJ1,CQQYNNWPGTF,IGKV3-15,COV2-2371,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGNYLTFFDSW,IGHV3-30,IGHJ2,CQQYNNWPGTF,IGKV3-15,COV2-2371,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGNYLTFFDSW,IGHV3-30,IGHJ3,CQQYNNWPGTF,IGKV3-15,COV2-2371,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGNYLTFFDSW,IGHV3-30,IGHJ4,CQQYNNWPGTF,IGKV3-15,COV2-2371,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGNYLTFFDSW,IGHV3-30,IGHJ5,CQQYNNWPGTF,IGKV3-15,COV2-2371,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGRGNYLTFFDSW,IGHV3-30,IGHJ6,CQQYNNWPGTF,IGKV3-15,COV2-2371,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAGGGSYRGPFDYW,IGHV3-30,IGHJ1,CSAYAGSNNLVF,IGLV2-11,COV2-2639,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAGGGSYRGPFDYW,IGHV3-30,IGHJ2,CSAYAGSNNLVF,IGLV2-11,COV2-2639,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAGGGSYRGPFDYW,IGHV3-30,IGHJ3,CSAYAGSNNLVF,IGLV2-11,COV2-2639,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAGGGSYRGPFDYW,IGHV3-30,IGHJ4,CSAYAGSNNLVF,IGLV2-11,COV2-2639,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAGGGSYRGPFDYW,IGHV3-30,IGHJ5,CSAYAGSNNLVF,IGLV2-11,COV2-2639,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAGGGSYRGPFDYW,IGHV3-30,IGHJ6,CSAYAGSNNLVF,IGLV2-11,COV2-2639,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ1,CQSYDSSLGALF,IGLV1-40,COV2-2524,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ2,CQSYDSSLGALF,IGLV1-40,COV2-2524,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ3,CQSYDSSLGALF,IGLV1-40,COV2-2524,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ4,CQSYDSSLGALF,IGLV1-40,COV2-2524,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ5,CQSYDSSLGALF,IGLV1-40,COV2-2524,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASALRERGVQLWSVW,IGHV5-51,IGHJ6,CQSYDSSLGALF,IGLV1-40,COV2-2524,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPFQLLDKYYFFYYMDVW,IGHV4-39,IGHJ1,CQQRSNWPPGVTF,IGKV3-11,COV2-2430,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPFQLLDKYYFFYYMDVW,IGHV4-39,IGHJ2,CQQRSNWPPGVTF,IGKV3-11,COV2-2430,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPFQLLDKYYFFYYMDVW,IGHV4-39,IGHJ3,CQQRSNWPPGVTF,IGKV3-11,COV2-2430,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPFQLLDKYYFFYYMDVW,IGHV4-39,IGHJ4,CQQRSNWPPGVTF,IGKV3-11,COV2-2430,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPFQLLDKYYFFYYMDVW,IGHV4-39,IGHJ5,CQQRSNWPPGVTF,IGKV3-11,COV2-2430,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAPFQLLDKYYFFYYMDVW,IGHV4-39,IGHJ6,CQQRSNWPPGVTF,IGKV3-11,COV2-2430,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSGNYRDAFDIW,IGHV3-30,IGHJ1,CQQYYSSYTF,IGKV4-1,COV2-3058,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSGNYRDAFDIW,IGHV3-30,IGHJ2,CQQYYSSYTF,IGKV4-1,COV2-3058,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSGNYRDAFDIW,IGHV3-30,IGHJ3,CQQYYSSYTF,IGKV4-1,COV2-3058,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSGNYRDAFDIW,IGHV3-30,IGHJ4,CQQYYSSYTF,IGKV4-1,COV2-3058,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSGNYRDAFDIW,IGHV3-30,IGHJ5,CQQYYSSYTF,IGKV4-1,COV2-3058,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRSGNYRDAFDIW,IGHV3-30,IGHJ6,CQQYYSSYTF,IGKV4-1,COV2-3058,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ1,CQQYGRSPITF,IGKV3-20,COV2-2602,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ2,CQQYGRSPITF,IGKV3-20,COV2-2602,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ3,CQQYGRSPITF,IGKV3-20,COV2-2602,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ4,CQQYGRSPITF,IGKV3-20,COV2-2602,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ5,CQQYGRSPITF,IGKV3-20,COV2-2602,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPDYSSGWFSYWYFDLW,IGHV5-51,IGHJ6,CQQYGRSPITF,IGKV3-20,COV2-2602,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRLGDGSYLGGGYYGMDVW,IGHV1-46,IGHJ1,CQQYGSSPRLTF,IGKV3-20,COV2-2685,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRLGDGSYLGGGYYGMDVW,IGHV1-46,IGHJ2,CQQYGSSPRLTF,IGKV3-20,COV2-2685,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRLGDGSYLGGGYYGMDVW,IGHV1-46,IGHJ3,CQQYGSSPRLTF,IGKV3-20,COV2-2685,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRLGDGSYLGGGYYGMDVW,IGHV1-46,IGHJ4,CQQYGSSPRLTF,IGKV3-20,COV2-2685,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRLGDGSYLGGGYYGMDVW,IGHV1-46,IGHJ5,CQQYGSSPRLTF,IGKV3-20,COV2-2685,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDRLGDGSYLGGGYYGMDVW,IGHV1-46,IGHJ6,CQQYGSSPRLTF,IGKV3-20,COV2-2685,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARPDYYYYYAMDVW,IGHV4-61,IGHJ1,CQQYNSYSTWTF,IGKV1-5,COV2-2041,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARPDYYYYYAMDVW,IGHV4-61,IGHJ2,CQQYNSYSTWTF,IGKV1-5,COV2-2041,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARPDYYYYYAMDVW,IGHV4-61,IGHJ3,CQQYNSYSTWTF,IGKV1-5,COV2-2041,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARPDYYYYYAMDVW,IGHV4-61,IGHJ4,CQQYNSYSTWTF,IGKV1-5,COV2-2041,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARPDYYYYYAMDVW,IGHV4-61,IGHJ5,CQQYNSYSTWTF,IGKV1-5,COV2-2041,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARPDYYYYYAMDVW,IGHV4-61,IGHJ6,CQQYNSYSTWTF,IGKV1-5,COV2-2041,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDMVEPLFSHYYYYGMDVW,IGHV3-30,IGHJ1,CQSYDSSLSGYVF,IGLV1-40,COV2-2814,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDMVEPLFSHYYYYGMDVW,IGHV3-30,IGHJ2,CQSYDSSLSGYVF,IGLV1-40,COV2-2814,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDMVEPLFSHYYYYGMDVW,IGHV3-30,IGHJ3,CQSYDSSLSGYVF,IGLV1-40,COV2-2814,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDMVEPLFSHYYYYGMDVW,IGHV3-30,IGHJ4,CQSYDSSLSGYVF,IGLV1-40,COV2-2814,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDMVEPLFSHYYYYGMDVW,IGHV3-30,IGHJ5,CQSYDSSLSGYVF,IGLV1-40,COV2-2814,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDMVEPLFSHYYYYGMDVW,IGHV3-30,IGHJ6,CQSYDSSLSGYVF,IGLV1-40,COV2-2814,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CIRDYDFWGGYYYHPLRAFDIW,IGHV3-49,IGHJ1,CCSYAGSYTYVF,IGLV2-11,COV2-2266,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CIRDYDFWGGYYYHPLRAFDIW,IGHV3-49,IGHJ2,CCSYAGSYTYVF,IGLV2-11,COV2-2266,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CIRDYDFWGGYYYHPLRAFDIW,IGHV3-49,IGHJ3,CCSYAGSYTYVF,IGLV2-11,COV2-2266,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CIRDYDFWGGYYYHPLRAFDIW,IGHV3-49,IGHJ4,CCSYAGSYTYVF,IGLV2-11,COV2-2266,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CIRDYDFWGGYYYHPLRAFDIW,IGHV3-49,IGHJ5,CCSYAGSYTYVF,IGLV2-11,COV2-2266,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CIRDYDFWGGYYYHPLRAFDIW,IGHV3-49,IGHJ6,CCSYAGSYTYVF,IGLV2-11,COV2-2266,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLTIVVIPAAPNFDYW,IGHV3-30,IGHJ1,CSSYTSSSTPVVF,IGLV2-14,COV2-2387,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLTIVVIPAAPNFDYW,IGHV3-30,IGHJ2,CSSYTSSSTPVVF,IGLV2-14,COV2-2387,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLTIVVIPAAPNFDYW,IGHV3-30,IGHJ3,CSSYTSSSTPVVF,IGLV2-14,COV2-2387,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLTIVVIPAAPNFDYW,IGHV3-30,IGHJ4,CSSYTSSSTPVVF,IGLV2-14,COV2-2387,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLTIVVIPAAPNFDYW,IGHV3-30,IGHJ5,CSSYTSSSTPVVF,IGLV2-14,COV2-2387,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDLTIVVIPAAPNFDYW,IGHV3-30,IGHJ6,CSSYTSSSTPVVF,IGLV2-14,COV2-2387,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVPVMVRGVYFDYW,IGHV3-30-3,IGHJ1,CISYTSSRTLVF,IGLV2-14,COV2-2281,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVPVMVRGVYFDYW,IGHV3-30-3,IGHJ2,CISYTSSRTLVF,IGLV2-14,COV2-2281,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVPVMVRGVYFDYW,IGHV3-30-3,IGHJ3,CISYTSSRTLVF,IGLV2-14,COV2-2281,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVPVMVRGVYFDYW,IGHV3-30-3,IGHJ4,CISYTSSRTLVF,IGLV2-14,COV2-2281,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVPVMVRGVYFDYW,IGHV3-30-3,IGHJ5,CISYTSSRTLVF,IGLV2-14,COV2-2281,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVPVMVRGVYFDYW,IGHV3-30-3,IGHJ6,CISYTSSRTLVF,IGLV2-14,COV2-2281,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ1,CQQYNTYSQTF,IGKV1-5,COV2-2235,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ2,CQQYNTYSQTF,IGKV1-5,COV2-2235,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ3,CQQYNTYSQTF,IGKV1-5,COV2-2235,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ4,CQQYNTYSQTF,IGKV1-5,COV2-2235,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ5,CQQYNTYSQTF,IGKV1-5,COV2-2235,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ6,CQQYNTYSQTF,IGKV1-5,COV2-2235,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLVTTVTTANGLYYYSYYYMDVW,IGHV3-7,IGHJ1,CQSYASSLSAHVVF,IGLV1-40,COV2-3057,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLVTTVTTANGLYYYSYYYMDVW,IGHV3-7,IGHJ2,CQSYASSLSAHVVF,IGLV1-40,COV2-3057,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLVTTVTTANGLYYYSYYYMDVW,IGHV3-7,IGHJ3,CQSYASSLSAHVVF,IGLV1-40,COV2-3057,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLVTTVTTANGLYYYSYYYMDVW,IGHV3-7,IGHJ4,CQSYASSLSAHVVF,IGLV1-40,COV2-3057,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLVTTVTTANGLYYYSYYYMDVW,IGHV3-7,IGHJ5,CQSYASSLSAHVVF,IGLV1-40,COV2-3057,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLVTTVTTANGLYYYSYYYMDVW,IGHV3-7,IGHJ6,CQSYASSLSAHVVF,IGLV1-40,COV2-3057,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ1,CQQYYTAPLTF,IGKV4-1,COV2-2025,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ2,CQQYYTAPLTF,IGKV4-1,COV2-2025,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ3,CQQYYTAPLTF,IGKV4-1,COV2-2025,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ4,CQQYYTAPLTF,IGKV4-1,COV2-2025,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ5,CQQYYTAPLTF,IGKV4-1,COV2-2025,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ6,CQQYYTAPLTF,IGKV4-1,COV2-2025,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ1,CQQSYSTPYTF,IGKV1-39,COV2-2203,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ2,CQQSYSTPYTF,IGKV1-39,COV2-2203,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ3,CQQSYSTPYTF,IGKV1-39,COV2-2203,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ4,CQQSYSTPYTF,IGKV1-39,COV2-2203,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ5,CQQSYSTPYTF,IGKV1-39,COV2-2203,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ6,CQQSYSTPYTF,IGKV1-39,COV2-2203,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARLLGYCSSTSCYTIGWGAFDIW,IGHV7-4-1,IGHJ1,CQQYDNLPPGVSTTF,IGKV1-33,COV2-2453,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARLLGYCSSTSCYTIGWGAFDIW,IGHV7-4-1,IGHJ2,CQQYDNLPPGVSTTF,IGKV1-33,COV2-2453,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARLLGYCSSTSCYTIGWGAFDIW,IGHV7-4-1,IGHJ3,CQQYDNLPPGVSTTF,IGKV1-33,COV2-2453,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARLLGYCSSTSCYTIGWGAFDIW,IGHV7-4-1,IGHJ4,CQQYDNLPPGVSTTF,IGKV1-33,COV2-2453,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARLLGYCSSTSCYTIGWGAFDIW,IGHV7-4-1,IGHJ5,CQQYDNLPPGVSTTF,IGKV1-33,COV2-2453,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARARLLGYCSSTSCYTIGWGAFDIW,IGHV7-4-1,IGHJ6,CQQYDNLPPGVSTTF,IGKV1-33,COV2-2453,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ1,CQQSYSTPTF,IGKV1-39,COV2-2189,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ2,CQQSYSTPTF,IGKV1-39,COV2-2189,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ3,CQQSYSTPTF,IGKV1-39,COV2-2189,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ4,CQQSYSTPTF,IGKV1-39,COV2-2189,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ5,CQQSYSTPTF,IGKV1-39,COV2-2189,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ6,CQQSYSTPTF,IGKV1-39,COV2-2189,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ1,CQQSYSTPTF,IGKV1-39,COV2-2513,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ2,CQQSYSTPTF,IGKV1-39,COV2-2513,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ3,CQQSYSTPTF,IGKV1-39,COV2-2513,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ4,CQQSYSTPTF,IGKV1-39,COV2-2513,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ5,CQQSYSTPTF,IGKV1-39,COV2-2513,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTKASRYCSSTICYWNWFDPW,IGHV3-9,IGHJ6,CQQSYSTPTF,IGKV1-39,COV2-2513,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ1,CQQYYSISWTF,IGKV4-1,COV2-2401,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ2,CQQYYSISWTF,IGKV4-1,COV2-2401,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ3,CQQYYSISWTF,IGKV4-1,COV2-2401,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ4,CQQYYSISWTF,IGKV4-1,COV2-2401,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ5,CQQYYSISWTF,IGKV4-1,COV2-2401,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ6,CQQYYSISWTF,IGKV4-1,COV2-2401,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLPIKVVVPAADYNWFDPW,IGHV1-18,IGHJ1,CQQSYSTPPTF,IGKV1-39,COV2-2034,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLPIKVVVPAADYNWFDPW,IGHV1-18,IGHJ2,CQQSYSTPPTF,IGKV1-39,COV2-2034,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLPIKVVVPAADYNWFDPW,IGHV1-18,IGHJ3,CQQSYSTPPTF,IGKV1-39,COV2-2034,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLPIKVVVPAADYNWFDPW,IGHV1-18,IGHJ4,CQQSYSTPPTF,IGKV1-39,COV2-2034,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLPIKVVVPAADYNWFDPW,IGHV1-18,IGHJ5,CQQSYSTPPTF,IGKV1-39,COV2-2034,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDLPIKVVVPAADYNWFDPW,IGHV1-18,IGHJ6,CQQSYSTPPTF,IGKV1-39,COV2-2034,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGYRSQFDPW,IGHV3-30,IGHJ1,CQQYGSSYTF,IGKV3-20,COV2-2322,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGYRSQFDPW,IGHV3-30,IGHJ2,CQQYGSSYTF,IGKV3-20,COV2-2322,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGYRSQFDPW,IGHV3-30,IGHJ3,CQQYGSSYTF,IGKV3-20,COV2-2322,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGYRSQFDPW,IGHV3-30,IGHJ4,CQQYGSSYTF,IGKV3-20,COV2-2322,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGYRSQFDPW,IGHV3-30,IGHJ5,CQQYGSSYTF,IGKV3-20,COV2-2322,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGYRSQFDPW,IGHV3-30,IGHJ6,CQQYGSSYTF,IGKV3-20,COV2-2322,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ1,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2933,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ2,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2933,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ3,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2933,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ4,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2933,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ5,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2933,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ6,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2933,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDQARVQDYIWGSYRSYGMDVW,IGHV3-23,IGHJ1,CMQALQTPRTF,IGKV2-28,COV2-2388,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDQARVQDYIWGSYRSYGMDVW,IGHV3-23,IGHJ2,CMQALQTPRTF,IGKV2-28,COV2-2388,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDQARVQDYIWGSYRSYGMDVW,IGHV3-23,IGHJ3,CMQALQTPRTF,IGKV2-28,COV2-2388,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDQARVQDYIWGSYRSYGMDVW,IGHV3-23,IGHJ4,CMQALQTPRTF,IGKV2-28,COV2-2388,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDQARVQDYIWGSYRSYGMDVW,IGHV3-23,IGHJ5,CMQALQTPRTF,IGKV2-28,COV2-2388,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDQARVQDYIWGSYRSYGMDVW,IGHV3-23,IGHJ6,CMQALQTPRTF,IGKV2-28,COV2-2388,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ1,CHYRSNWPPVLTF,IGKV3-11,COV2-2151,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ2,CHYRSNWPPVLTF,IGKV3-11,COV2-2151,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ3,CHYRSNWPPVLTF,IGKV3-11,COV2-2151,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ4,CHYRSNWPPVLTF,IGKV3-11,COV2-2151,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ5,CHYRSNWPPVLTF,IGKV3-11,COV2-2151,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ6,CHYRSNWPPVLTF,IGKV3-11,COV2-2151,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGDVYNFLLVRNWFDPW,IGHV3-30,IGHJ1,CSSYTSSSTLYVF,IGLV2-14,COV2-2403,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGDVYNFLLVRNWFDPW,IGHV3-30,IGHJ2,CSSYTSSSTLYVF,IGLV2-14,COV2-2403,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGDVYNFLLVRNWFDPW,IGHV3-30,IGHJ3,CSSYTSSSTLYVF,IGLV2-14,COV2-2403,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGDVYNFLLVRNWFDPW,IGHV3-30,IGHJ4,CSSYTSSSTLYVF,IGLV2-14,COV2-2403,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGDVYNFLLVRNWFDPW,IGHV3-30,IGHJ5,CSSYTSSSTLYVF,IGLV2-14,COV2-2403,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGDGDVYNFLLVRNWFDPW,IGHV3-30,IGHJ6,CSSYTSSSTLYVF,IGLV2-14,COV2-2403,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ1,CQQYYTAPLTF,IGKV4-1,COV2-2013,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ2,CQQYYTAPLTF,IGKV4-1,COV2-2013,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ3,CQQYYTAPLTF,IGKV4-1,COV2-2013,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ4,CQQYYTAPLTF,IGKV4-1,COV2-2013,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ5,CQQYYTAPLTF,IGKV4-1,COV2-2013,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ6,CQQYYTAPLTF,IGKV4-1,COV2-2013,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVSGYGDYGAYSDYW,IGHV1-69,IGHJ1,CQQRSNWPPRLTF,IGKV3-11,COV2-2617,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVSGYGDYGAYSDYW,IGHV1-69,IGHJ2,CQQRSNWPPRLTF,IGKV3-11,COV2-2617,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVSGYGDYGAYSDYW,IGHV1-69,IGHJ3,CQQRSNWPPRLTF,IGKV3-11,COV2-2617,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVSGYGDYGAYSDYW,IGHV1-69,IGHJ4,CQQRSNWPPRLTF,IGKV3-11,COV2-2617,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVSGYGDYGAYSDYW,IGHV1-69,IGHJ5,CQQRSNWPPRLTF,IGKV3-11,COV2-2617,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVSGYGDYGAYSDYW,IGHV1-69,IGHJ6,CQQRSNWPPRLTF,IGKV3-11,COV2-2617,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ1,CSSYTSSSTLLYVF,IGLV2-14,COV2-2341,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ2,CSSYTSSSTLLYVF,IGLV2-14,COV2-2341,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ3,CSSYTSSSTLLYVF,IGLV2-14,COV2-2341,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ4,CSSYTSSSTLLYVF,IGLV2-14,COV2-2341,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ5,CSSYTSSSTLLYVF,IGLV2-14,COV2-2341,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ6,CSSYTSSSTLLYVF,IGLV2-14,COV2-2341,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGEEVRGVKLYYYYAMDVW,IGHV4-39,IGHJ1,CSSYTSISTWVF,IGLV2-14,COV2-2273,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGEEVRGVKLYYYYAMDVW,IGHV4-39,IGHJ2,CSSYTSISTWVF,IGLV2-14,COV2-2273,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGEEVRGVKLYYYYAMDVW,IGHV4-39,IGHJ3,CSSYTSISTWVF,IGLV2-14,COV2-2273,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGEEVRGVKLYYYYAMDVW,IGHV4-39,IGHJ4,CSSYTSISTWVF,IGLV2-14,COV2-2273,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGEEVRGVKLYYYYAMDVW,IGHV4-39,IGHJ5,CSSYTSISTWVF,IGLV2-14,COV2-2273,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAGEEVRGVKLYYYYAMDVW,IGHV4-39,IGHJ6,CSSYTSISTWVF,IGLV2-14,COV2-2273,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ1,CQQSYSTPGTF,IGKV1-39,COV2-2337,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ2,CQQSYSTPGTF,IGKV1-39,COV2-2337,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ3,CQQSYSTPGTF,IGKV1-39,COV2-2337,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ4,CQQSYSTPGTF,IGKV1-39,COV2-2337,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ5,CQQSYSTPGTF,IGKV1-39,COV2-2337,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ6,CQQSYSTPGTF,IGKV1-39,COV2-2337,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLVGRIDPW,IGHV7-4-1,IGHJ1,CQQYDNLLLFTF,IGKV1-33,COV2-2515,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLVGRIDPW,IGHV7-4-1,IGHJ2,CQQYDNLLLFTF,IGKV1-33,COV2-2515,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLVGRIDPW,IGHV7-4-1,IGHJ3,CQQYDNLLLFTF,IGKV1-33,COV2-2515,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLVGRIDPW,IGHV7-4-1,IGHJ4,CQQYDNLLLFTF,IGKV1-33,COV2-2515,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLVGRIDPW,IGHV7-4-1,IGHJ5,CQQYDNLLLFTF,IGKV1-33,COV2-2515,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGLVGRIDPW,IGHV7-4-1,IGHJ6,CQQYDNLLLFTF,IGKV1-33,COV2-2515,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRSYGLSLGYW,IGHV7-4-1,IGHJ1,CQQYDNLLQFTF,IGKV1-33,COV2-2610,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRSYGLSLGYW,IGHV7-4-1,IGHJ2,CQQYDNLLQFTF,IGKV1-33,COV2-2610,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRSYGLSLGYW,IGHV7-4-1,IGHJ3,CQQYDNLLQFTF,IGKV1-33,COV2-2610,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRSYGLSLGYW,IGHV7-4-1,IGHJ4,CQQYDNLLQFTF,IGKV1-33,COV2-2610,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRSYGLSLGYW,IGHV7-4-1,IGHJ5,CQQYDNLLQFTF,IGKV1-33,COV2-2610,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRSYGLSLGYW,IGHV7-4-1,IGHJ6,CQQYDNLLQFTF,IGKV1-33,COV2-2610,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNSGSYYSYFDYW,IGHV3-30,IGHJ1,CQQYYSTPLTF,IGKV4-1,COV2-2422,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNSGSYYSYFDYW,IGHV3-30,IGHJ2,CQQYYSTPLTF,IGKV4-1,COV2-2422,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNSGSYYSYFDYW,IGHV3-30,IGHJ3,CQQYYSTPLTF,IGKV4-1,COV2-2422,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNSGSYYSYFDYW,IGHV3-30,IGHJ4,CQQYYSTPLTF,IGKV4-1,COV2-2422,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNSGSYYSYFDYW,IGHV3-30,IGHJ5,CQQYYSTPLTF,IGKV4-1,COV2-2422,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVNSGSYYSYFDYW,IGHV3-30,IGHJ6,CQQYYSTPLTF,IGKV4-1,COV2-2422,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ1,CQQSYSTPYTF,IGKV1-39,COV2-2250,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ2,CQQSYSTPYTF,IGKV1-39,COV2-2250,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ3,CQQSYSTPYTF,IGKV1-39,COV2-2250,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ4,CQQSYSTPYTF,IGKV1-39,COV2-2250,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ5,CQQSYSTPYTF,IGKV1-39,COV2-2250,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGSAGNYYYGMDVW,IGHV3-30,IGHJ6,CQQSYSTPYTF,IGKV1-39,COV2-2250,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ1,CQVWDSSSDHHVVF,IGLV3-21,COV2-2844,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ2,CQVWDSSSDHHVVF,IGLV3-21,COV2-2844,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ3,CQVWDSSSDHHVVF,IGLV3-21,COV2-2844,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ4,CQVWDSSSDHHVVF,IGLV3-21,COV2-2844,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ5,CQVWDSSSDHHVVF,IGLV3-21,COV2-2844,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ6,CQVWDSSSDHHVVF,IGLV3-21,COV2-2844,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVGGYSGYDLGFDYYYYMDVW,IGHV3-7,IGHJ1,CNSRDSSGYIWGWMF,IGLV3-19,COV2-2520,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVGGYSGYDLGFDYYYYMDVW,IGHV3-7,IGHJ2,CNSRDSSGYIWGWMF,IGLV3-19,COV2-2520,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVGGYSGYDLGFDYYYYMDVW,IGHV3-7,IGHJ3,CNSRDSSGYIWGWMF,IGLV3-19,COV2-2520,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVGGYSGYDLGFDYYYYMDVW,IGHV3-7,IGHJ4,CNSRDSSGYIWGWMF,IGLV3-19,COV2-2520,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVGGYSGYDLGFDYYYYMDVW,IGHV3-7,IGHJ5,CNSRDSSGYIWGWMF,IGLV3-19,COV2-2520,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDVGGYSGYDLGFDYYYYMDVW,IGHV3-7,IGHJ6,CNSRDSSGYIWGWMF,IGLV3-19,COV2-2520,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ1,CMQSIQLAF,IGKV2D-29,COV2-2960,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ2,CMQSIQLAF,IGKV2D-29,COV2-2960,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ3,CMQSIQLAF,IGKV2D-29,COV2-2960,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ4,CMQSIQLAF,IGKV2D-29,COV2-2960,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ5,CMQSIQLAF,IGKV2D-29,COV2-2960,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ6,CMQSIQLAF,IGKV2D-29,COV2-2960,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPQSGGYYAPLDYW,IGHV3-30-3,IGHJ1,CQQYGSSPWTF,IGKV3-20,COV2-2006,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPQSGGYYAPLDYW,IGHV3-30-3,IGHJ2,CQQYGSSPWTF,IGKV3-20,COV2-2006,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPQSGGYYAPLDYW,IGHV3-30-3,IGHJ3,CQQYGSSPWTF,IGKV3-20,COV2-2006,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPQSGGYYAPLDYW,IGHV3-30-3,IGHJ4,CQQYGSSPWTF,IGKV3-20,COV2-2006,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPQSGGYYAPLDYW,IGHV3-30-3,IGHJ5,CQQYGSSPWTF,IGKV3-20,COV2-2006,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPQSGGYYAPLDYW,IGHV3-30-3,IGHJ6,CQQYGSSPWTF,IGKV3-20,COV2-2006,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGGSSWHFDYW,IGHV3-7,IGHJ1,CQAWSSSTAVF,IGLV3-1,COV2-2333,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGGSSWHFDYW,IGHV3-7,IGHJ2,CQAWSSSTAVF,IGLV3-1,COV2-2333,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGGSSWHFDYW,IGHV3-7,IGHJ3,CQAWSSSTAVF,IGLV3-1,COV2-2333,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGGSSWHFDYW,IGHV3-7,IGHJ4,CQAWSSSTAVF,IGLV3-1,COV2-2333,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGGSSWHFDYW,IGHV3-7,IGHJ5,CQAWSSSTAVF,IGLV3-1,COV2-2333,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGGSSWHFDYW,IGHV3-7,IGHJ6,CQAWSSSTAVF,IGLV3-1,COV2-2333,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSPLVLITSIDYW,IGHV3-30,IGHJ1,CQSADTIGTYWVF,IGLV3-25,COV2-2458,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSPLVLITSIDYW,IGHV3-30,IGHJ2,CQSADTIGTYWVF,IGLV3-25,COV2-2458,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSPLVLITSIDYW,IGHV3-30,IGHJ3,CQSADTIGTYWVF,IGLV3-25,COV2-2458,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSPLVLITSIDYW,IGHV3-30,IGHJ4,CQSADTIGTYWVF,IGLV3-25,COV2-2458,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSPLVLITSIDYW,IGHV3-30,IGHJ5,CQSADTIGTYWVF,IGLV3-25,COV2-2458,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDPSPLVLITSIDYW,IGHV3-30,IGHJ6,CQSADTIGTYWVF,IGLV3-25,COV2-2458,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDTATYVLLWSGDFNLDYW,IGHV3-30,IGHJ1,CSSYTSSSTLWVF,IGLV2-14,COV2-2009,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDTATYVLLWSGDFNLDYW,IGHV3-30,IGHJ2,CSSYTSSSTLWVF,IGLV2-14,COV2-2009,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDTATYVLLWSGDFNLDYW,IGHV3-30,IGHJ3,CSSYTSSSTLWVF,IGLV2-14,COV2-2009,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDTATYVLLWSGDFNLDYW,IGHV3-30,IGHJ4,CSSYTSSSTLWVF,IGLV2-14,COV2-2009,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDTATYVLLWSGDFNLDYW,IGHV3-30,IGHJ5,CSSYTSSSTLWVF,IGLV2-14,COV2-2009,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDTATYVLLWSGDFNLDYW,IGHV3-30,IGHJ6,CSSYTSSSTLWVF,IGLV2-14,COV2-2009,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-72,IGHJ1,CQYYGSSPFGF,IGKV3-20,COV2-2616,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-72,IGHJ2,CQYYGSSPFGF,IGKV3-20,COV2-2616,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-72,IGHJ3,CQYYGSSPFGF,IGKV3-20,COV2-2616,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-72,IGHJ4,CQYYGSSPFGF,IGKV3-20,COV2-2616,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-72,IGHJ5,CQYYGSSPFGF,IGKV3-20,COV2-2616,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASVITFGGVIVRSYW,IGHV3-72,IGHJ6,CQYYGSSPFGF,IGKV3-20,COV2-2616,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ1,CHYRSNWPPVLTF,IGKV3-11,COV2-2517,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ2,CHYRSNWPPVLTF,IGKV3-11,COV2-2517,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ3,CHYRSNWPPVLTF,IGKV3-11,COV2-2517,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ4,CHYRSNWPPVLTF,IGKV3-11,COV2-2517,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ5,CHYRSNWPPVLTF,IGKV3-11,COV2-2517,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGSYPEYFQHW,IGHV1-69,IGHJ6,CHYRSNWPPVLTF,IGKV3-11,COV2-2517,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ1,CQAWDSSTGVF,IGLV3-1,COV2-2397,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ2,CQAWDSSTGVF,IGLV3-1,COV2-2397,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ3,CQAWDSSTGVF,IGLV3-1,COV2-2397,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ4,CQAWDSSTGVF,IGLV3-1,COV2-2397,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ5,CQAWDSSTGVF,IGLV3-1,COV2-2397,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ6,CQAWDSSTGVF,IGLV3-1,COV2-2397,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ1,CQQTYSTFWTF,IGKV1-39,COV2-2325,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ2,CQQTYSTFWTF,IGKV1-39,COV2-2325,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ3,CQQTYSTFWTF,IGKV1-39,COV2-2325,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ4,CQQTYSTFWTF,IGKV1-39,COV2-2325,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ5,CQQTYSTFWTF,IGKV1-39,COV2-2325,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ6,CQQTYSTFWTF,IGKV1-39,COV2-2325,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDTW,IGHV4-4,IGHJ1,CSVWDDSLNGPLF,IGLV1-44,COV2-2033,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDTW,IGHV4-4,IGHJ2,CSVWDDSLNGPLF,IGLV1-44,COV2-2033,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDTW,IGHV4-4,IGHJ3,CSVWDDSLNGPLF,IGLV1-44,COV2-2033,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDTW,IGHV4-4,IGHJ4,CSVWDDSLNGPLF,IGLV1-44,COV2-2033,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDTW,IGHV4-4,IGHJ5,CSVWDDSLNGPLF,IGLV1-44,COV2-2033,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDTW,IGHV4-4,IGHJ6,CSVWDDSLNGPLF,IGLV1-44,COV2-2033,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGYIGTYYYYMDVW,IGHV4-61,IGHJ1,CQQSYSTLTF,IGKV1-39,COV2-2310,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGYIGTYYYYMDVW,IGHV4-61,IGHJ2,CQQSYSTLTF,IGKV1-39,COV2-2310,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGYIGTYYYYMDVW,IGHV4-61,IGHJ3,CQQSYSTLTF,IGKV1-39,COV2-2310,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGYIGTYYYYMDVW,IGHV4-61,IGHJ4,CQQSYSTLTF,IGKV1-39,COV2-2310,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGYIGTYYYYMDVW,IGHV4-61,IGHJ5,CQQSYSTLTF,IGKV1-39,COV2-2310,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CATGYIGTYYYYMDVW,IGHV4-61,IGHJ6,CQQSYSTLTF,IGKV1-39,COV2-2310,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ1,CQQYYTAPLTF,IGKV4-1,COV2-2669,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ2,CQQYYTAPLTF,IGKV4-1,COV2-2669,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ3,CQQYYTAPLTF,IGKV4-1,COV2-2669,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ4,CQQYYTAPLTF,IGKV4-1,COV2-2669,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ5,CQQYYTAPLTF,IGKV4-1,COV2-2669,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDGSGWAWDGDNPPTDYW,IGHV3-30,IGHJ6,CQQYYTAPLTF,IGKV4-1,COV2-2669,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRLGVSSWYFDYW,IGHV3-7,IGHJ1,CQAWGSSRGVF,IGLV3-1,COV2-2774,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRLGVSSWYFDYW,IGHV3-7,IGHJ2,CQAWGSSRGVF,IGLV3-1,COV2-2774,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRLGVSSWYFDYW,IGHV3-7,IGHJ3,CQAWGSSRGVF,IGLV3-1,COV2-2774,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRLGVSSWYFDYW,IGHV3-7,IGHJ4,CQAWGSSRGVF,IGLV3-1,COV2-2774,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRLGVSSWYFDYW,IGHV3-7,IGHJ5,CQAWGSSRGVF,IGLV3-1,COV2-2774,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRLGVSSWYFDYW,IGHV3-7,IGHJ6,CQAWGSSRGVF,IGLV3-1,COV2-2774,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPSAFSWLDPW,IGHV1-3,IGHJ1,CQSYDSSLSGWSVF,IGLV1-40,COV2-2340,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPSAFSWLDPW,IGHV1-3,IGHJ2,CQSYDSSLSGWSVF,IGLV1-40,COV2-2340,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPSAFSWLDPW,IGHV1-3,IGHJ3,CQSYDSSLSGWSVF,IGLV1-40,COV2-2340,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPSAFSWLDPW,IGHV1-3,IGHJ4,CQSYDSSLSGWSVF,IGLV1-40,COV2-2340,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPSAFSWLDPW,IGHV1-3,IGHJ5,CQSYDSSLSGWSVF,IGLV1-40,COV2-2340,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAMGPSAFSWLDPW,IGHV1-3,IGHJ6,CQSYDSSLSGWSVF,IGLV1-40,COV2-2340,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARELMSVGW,IGHV3-30,IGHJ1,CQSYDSSLSGWVF,IGLV1-40,COV2-2811,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARELMSVGW,IGHV3-30,IGHJ2,CQSYDSSLSGWVF,IGLV1-40,COV2-2811,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARELMSVGW,IGHV3-30,IGHJ3,CQSYDSSLSGWVF,IGLV1-40,COV2-2811,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARELMSVGW,IGHV3-30,IGHJ4,CQSYDSSLSGWVF,IGLV1-40,COV2-2811,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARELMSVGW,IGHV3-30,IGHJ5,CQSYDSSLSGWVF,IGLV1-40,COV2-2811,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARELMSVGW,IGHV3-30,IGHJ6,CQSYDSSLSGWVF,IGLV1-40,COV2-2811,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRSGSYYAYFDYW,IGHV3-30-3,IGHJ1,CQQYNSHPPTF,IGKV1-16,COV2-2239,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRSGSYYAYFDYW,IGHV3-30-3,IGHJ2,CQQYNSHPPTF,IGKV1-16,COV2-2239,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRSGSYYAYFDYW,IGHV3-30-3,IGHJ3,CQQYNSHPPTF,IGKV1-16,COV2-2239,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRSGSYYAYFDYW,IGHV3-30-3,IGHJ4,CQQYNSHPPTF,IGKV1-16,COV2-2239,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRSGSYYAYFDYW,IGHV3-30-3,IGHJ5,CQQYNSHPPTF,IGKV1-16,COV2-2239,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRSGSYYAYFDYW,IGHV3-30-3,IGHJ6,CQQYNSHPPTF,IGKV1-16,COV2-2239,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ1,CQQYNTYSQTF,IGKV1-5,COV2-2429,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ2,CQQYNTYSQTF,IGKV1-5,COV2-2429,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ3,CQQYNTYSQTF,IGKV1-5,COV2-2429,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ4,CQQYNTYSQTF,IGKV1-5,COV2-2429,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ5,CQQYNTYSQTF,IGKV1-5,COV2-2429,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARESTQW,IGHV3-53,IGHJ6,CQQYNTYSQTF,IGKV1-5,COV2-2429,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ1,CQQYYSTPWTF,IGKV4-1,COV2-2883,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ2,CQQYYSTPWTF,IGKV4-1,COV2-2883,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ3,CQQYYSTPWTF,IGKV4-1,COV2-2883,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ4,CQQYYSTPWTF,IGKV4-1,COV2-2883,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ5,CQQYYSTPWTF,IGKV4-1,COV2-2883,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ6,CQQYYSTPWTF,IGKV4-1,COV2-2883,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLLWFGGAGNYMDVW,IGHV4-61,IGHJ1,CQQYYSTPPYTF,IGKV4-1,COV2-2536,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLLWFGGAGNYMDVW,IGHV4-61,IGHJ2,CQQYYSTPPYTF,IGKV4-1,COV2-2536,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLLWFGGAGNYMDVW,IGHV4-61,IGHJ3,CQQYYSTPPYTF,IGKV4-1,COV2-2536,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLLWFGGAGNYMDVW,IGHV4-61,IGHJ4,CQQYYSTPPYTF,IGKV4-1,COV2-2536,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLLWFGGAGNYMDVW,IGHV4-61,IGHJ5,CQQYYSTPPYTF,IGKV4-1,COV2-2536,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGLLWFGGAGNYMDVW,IGHV4-61,IGHJ6,CQQYYSTPPYTF,IGKV4-1,COV2-2536,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ1,CQQYYTAPLTF,IGKV4-1,COV2-2028,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ2,CQQYYTAPLTF,IGKV4-1,COV2-2028,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ3,CQQYYTAPLTF,IGKV4-1,COV2-2028,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ4,CQQYYTAPLTF,IGKV4-1,COV2-2028,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ5,CQQYYTAPLTF,IGKV4-1,COV2-2028,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGGDSSGWAWDGDNPPTDYW,IGHV3-30,IGHJ6,CQQYYTAPLTF,IGKV4-1,COV2-2028,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRGAMAWFDPW,IGHV4-59,IGHJ1,CQSFDSSLSGSDVF,IGLV1-40,COV2-2017,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRGAMAWFDPW,IGHV4-59,IGHJ2,CQSFDSSLSGSDVF,IGLV1-40,COV2-2017,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRGAMAWFDPW,IGHV4-59,IGHJ3,CQSFDSSLSGSDVF,IGLV1-40,COV2-2017,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRGAMAWFDPW,IGHV4-59,IGHJ4,CQSFDSSLSGSDVF,IGLV1-40,COV2-2017,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRGAMAWFDPW,IGHV4-59,IGHJ5,CQSFDSSLSGSDVF,IGLV1-40,COV2-2017,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CVRGAMAWFDPW,IGHV4-59,IGHJ6,CQSFDSSLSGSDVF,IGLV1-40,COV2-2017,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHTGNYYYGMDVW,IGHV3-30-3,IGHJ1,CQQSYSTFTF,IGKV1-39,COV2-2011,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHTGNYYYGMDVW,IGHV3-30-3,IGHJ2,CQQSYSTFTF,IGKV1-39,COV2-2011,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHTGNYYYGMDVW,IGHV3-30-3,IGHJ3,CQQSYSTFTF,IGKV1-39,COV2-2011,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHTGNYYYGMDVW,IGHV3-30-3,IGHJ4,CQQSYSTFTF,IGKV1-39,COV2-2011,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHTGNYYYGMDVW,IGHV3-30-3,IGHJ5,CQQSYSTFTF,IGKV1-39,COV2-2011,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGHTGNYYYGMDVW,IGHV3-30-3,IGHJ6,CQQSYSTFTF,IGKV1-39,COV2-2011,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRGGSYQTCFDYW,IGHV3-30-3,IGHJ1,CQQYNNWPGTF,IGKV3-15,COV2-2509,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRGGSYQTCFDYW,IGHV3-30-3,IGHJ2,CQQYNNWPGTF,IGKV3-15,COV2-2509,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRGGSYQTCFDYW,IGHV3-30-3,IGHJ3,CQQYNNWPGTF,IGKV3-15,COV2-2509,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRGGSYQTCFDYW,IGHV3-30-3,IGHJ4,CQQYNNWPGTF,IGKV3-15,COV2-2509,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRGGSYQTCFDYW,IGHV3-30-3,IGHJ5,CQQYNNWPGTF,IGKV3-15,COV2-2509,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPRGGSYQTCFDYW,IGHV3-30-3,IGHJ6,CQQYNNWPGTF,IGKV3-15,COV2-2509,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGRSSWNFDYW,IGHV3-7,IGHJ1,CQAWDSSTGVF,IGLV3-1,COV2-2406,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGRSSWNFDYW,IGHV3-7,IGHJ2,CQAWDSSTGVF,IGLV3-1,COV2-2406,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGRSSWNFDYW,IGHV3-7,IGHJ3,CQAWDSSTGVF,IGLV3-1,COV2-2406,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGRSSWNFDYW,IGHV3-7,IGHJ4,CQAWDSSTGVF,IGLV3-1,COV2-2406,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGRSSWNFDYW,IGHV3-7,IGHJ5,CQAWDSSTGVF,IGLV3-1,COV2-2406,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLGRSSWNFDYW,IGHV3-7,IGHJ6,CQAWDSSTGVF,IGLV3-1,COV2-2406,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ1,CQHRTNWPPLFTF,IGKV3-11,COV2-2441,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ2,CQHRTNWPPLFTF,IGKV3-11,COV2-2441,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ3,CQHRTNWPPLFTF,IGKV3-11,COV2-2441,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ4,CQHRTNWPPLFTF,IGKV3-11,COV2-2441,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ5,CQHRTNWPPLFTF,IGKV3-11,COV2-2441,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ6,CQHRTNWPPLFTF,IGKV3-11,COV2-2441,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ1,CQVWDSSSDHHVVF,IGLV3-21,COV2-2564,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ2,CQVWDSSSDHHVVF,IGLV3-21,COV2-2564,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ3,CQVWDSSSDHHVVF,IGLV3-21,COV2-2564,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ4,CQVWDSSSDHHVVF,IGLV3-21,COV2-2564,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ5,CQVWDSSSDHHVVF,IGLV3-21,COV2-2564,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARAQGGNYYYGMDVW,IGHV3-30-3,IGHJ6,CQVWDSSSDHHVVF,IGLV3-21,COV2-2564,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVEVATNKGIHGVDYYYYYYMDVW,IGHV3-7,IGHJ1,CNSRDNSGNLNWVF,IGLV3-19,COV2-2776,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVEVATNKGIHGVDYYYYYYMDVW,IGHV3-7,IGHJ2,CNSRDNSGNLNWVF,IGLV3-19,COV2-2776,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVEVATNKGIHGVDYYYYYYMDVW,IGHV3-7,IGHJ3,CNSRDNSGNLNWVF,IGLV3-19,COV2-2776,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVEVATNKGIHGVDYYYYYYMDVW,IGHV3-7,IGHJ4,CNSRDNSGNLNWVF,IGLV3-19,COV2-2776,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVEVATNKGIHGVDYYYYYYMDVW,IGHV3-7,IGHJ5,CNSRDNSGNLNWVF,IGLV3-19,COV2-2776,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVVVEVATNKGIHGVDYYYYYYMDVW,IGHV3-7,IGHJ6,CNSRDNSGNLNWVF,IGLV3-19,COV2-2776,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ1,CQQSYSTPTF,IGKV1-39,COV2-2587,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ2,CQQSYSTPTF,IGKV1-39,COV2-2587,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ3,CQQSYSTPTF,IGKV1-39,COV2-2587,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ4,CQQSYSTPTF,IGKV1-39,COV2-2587,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ5,CQQSYSTPTF,IGKV1-39,COV2-2587,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAHRLWFRDAFDIW,IGHV2-5,IGHJ6,CQQSYSTPTF,IGKV1-39,COV2-2587,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASGPPYMATFSYYFDYW,IGHV4-39,IGHJ1,CSSYTSSSTPFVF,IGLV2-14,COV2-2551,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASGPPYMATFSYYFDYW,IGHV4-39,IGHJ2,CSSYTSSSTPFVF,IGLV2-14,COV2-2551,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASGPPYMATFSYYFDYW,IGHV4-39,IGHJ3,CSSYTSSSTPFVF,IGLV2-14,COV2-2551,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASGPPYMATFSYYFDYW,IGHV4-39,IGHJ4,CSSYTSSSTPFVF,IGLV2-14,COV2-2551,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASGPPYMATFSYYFDYW,IGHV4-39,IGHJ5,CSSYTSSSTPFVF,IGLV2-14,COV2-2551,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CASGPPYMATFSYYFDYW,IGHV4-39,IGHJ6,CSSYTSSSTPFVF,IGLV2-14,COV2-2551,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWFGELLKGTYWFDPW,IGHV1-69,IGHJ1,CQQYYSTPGF,IGKV4-1,COV2-2481,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWFGELLKGTYWFDPW,IGHV1-69,IGHJ2,CQQYYSTPGF,IGKV4-1,COV2-2481,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWFGELLKGTYWFDPW,IGHV1-69,IGHJ3,CQQYYSTPGF,IGKV4-1,COV2-2481,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWFGELLKGTYWFDPW,IGHV1-69,IGHJ4,CQQYYSTPGF,IGKV4-1,COV2-2481,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWFGELLKGTYWFDPW,IGHV1-69,IGHJ5,CQQYYSTPGF,IGKV4-1,COV2-2481,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGWFGELLKGTYWFDPW,IGHV1-69,IGHJ6,CQQYYSTPGF,IGKV4-1,COV2-2481,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDIW,IGHV4-4,IGHJ1,CSVWDDSLNGPLF,IGLV1-44,COV2-2029,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDIW,IGHV4-4,IGHJ2,CSVWDDSLNGPLF,IGLV1-44,COV2-2029,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDIW,IGHV4-4,IGHJ3,CSVWDDSLNGPLF,IGLV1-44,COV2-2029,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDIW,IGHV4-4,IGHJ4,CSVWDDSLNGPLF,IGLV1-44,COV2-2029,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDIW,IGHV4-4,IGHJ5,CSVWDDSLNGPLF,IGLV1-44,COV2-2029,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPTAGAGGAFDIW,IGHV4-4,IGHJ6,CSVWDDSLNGPLF,IGLV1-44,COV2-2029,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRVGYVGSGSRGYYYYYDMDVW,IGHV1-8,IGHJ1,CNSRDSSGNHLRVF,IGLV3-19,COV2-2590,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRVGYVGSGSRGYYYYYDMDVW,IGHV1-8,IGHJ2,CNSRDSSGNHLRVF,IGLV3-19,COV2-2590,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRVGYVGSGSRGYYYYYDMDVW,IGHV1-8,IGHJ3,CNSRDSSGNHLRVF,IGLV3-19,COV2-2590,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRVGYVGSGSRGYYYYYDMDVW,IGHV1-8,IGHJ4,CNSRDSSGNHLRVF,IGLV3-19,COV2-2590,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRVGYVGSGSRGYYYYYDMDVW,IGHV1-8,IGHJ5,CNSRDSSGNHLRVF,IGLV3-19,COV2-2590,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGRVGYVGSGSRGYYYYYDMDVW,IGHV1-8,IGHJ6,CNSRDSSGNHLRVF,IGLV3-19,COV2-2590,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGISPYYYYYYMDVW,IGHV4-61,IGHJ1,CQQLNSYPITF,IGKV1-9,COV2-2408,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGISPYYYYYYMDVW,IGHV4-61,IGHJ2,CQQLNSYPITF,IGKV1-9,COV2-2408,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGISPYYYYYYMDVW,IGHV4-61,IGHJ3,CQQLNSYPITF,IGKV1-9,COV2-2408,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGISPYYYYYYMDVW,IGHV4-61,IGHJ4,CQQLNSYPITF,IGKV1-9,COV2-2408,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGISPYYYYYYMDVW,IGHV4-61,IGHJ5,CQQLNSYPITF,IGKV1-9,COV2-2408,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGGISPYYYYYYMDVW,IGHV4-61,IGHJ6,CQQLNSYPITF,IGKV1-9,COV2-2408,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAASFDYW,IGHV4-61,IGHJ1,CMQALQTPLTF,IGKV2-28,COV2-2565,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAASFDYW,IGHV4-61,IGHJ2,CMQALQTPLTF,IGKV2-28,COV2-2565,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAASFDYW,IGHV4-61,IGHJ3,CMQALQTPLTF,IGKV2-28,COV2-2565,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAASFDYW,IGHV4-61,IGHJ4,CMQALQTPLTF,IGKV2-28,COV2-2565,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAASFDYW,IGHV4-61,IGHJ5,CMQALQTPLTF,IGKV2-28,COV2-2565,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGAASFDYW,IGHV4-61,IGHJ6,CMQALQTPLTF,IGKV2-28,COV2-2565,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKSYNGNYYDAFDIW,IGHV3-30,IGHJ1,CQQYGSSYTF,IGKV3-20,COV2-2641,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKSYNGNYYDAFDIW,IGHV3-30,IGHJ2,CQQYGSSYTF,IGKV3-20,COV2-2641,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKSYNGNYYDAFDIW,IGHV3-30,IGHJ3,CQQYGSSYTF,IGKV3-20,COV2-2641,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKSYNGNYYDAFDIW,IGHV3-30,IGHJ4,CQQYGSSYTF,IGKV3-20,COV2-2641,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKSYNGNYYDAFDIW,IGHV3-30,IGHJ5,CQQYGSSYTF,IGKV3-20,COV2-2641,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKSYNGNYYDAFDIW,IGHV3-30,IGHJ6,CQQYGSSYTF,IGKV3-20,COV2-2641,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARASYNSNWSIGEYFRDW,IGHV3-30,IGHJ1,CQQYYSPPWTF,IGKV4-1,COV2-2449,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARASYNSNWSIGEYFRDW,IGHV3-30,IGHJ2,CQQYYSPPWTF,IGKV4-1,COV2-2449,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARASYNSNWSIGEYFRDW,IGHV3-30,IGHJ3,CQQYYSPPWTF,IGKV4-1,COV2-2449,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARASYNSNWSIGEYFRDW,IGHV3-30,IGHJ4,CQQYYSPPWTF,IGKV4-1,COV2-2449,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARASYNSNWSIGEYFRDW,IGHV3-30,IGHJ5,CQQYYSPPWTF,IGKV4-1,COV2-2449,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARASYNSNWSIGEYFRDW,IGHV3-30,IGHJ6,CQQYYSPPWTF,IGKV4-1,COV2-2449,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ1,CLVWDDSLNGLVF,IGLV1-47,COV2-2619,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ2,CLVWDDSLNGLVF,IGLV1-47,COV2-2619,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ3,CLVWDDSLNGLVF,IGLV1-47,COV2-2619,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ4,CLVWDDSLNGLVF,IGLV1-47,COV2-2619,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ5,CLVWDDSLNGLVF,IGLV1-47,COV2-2619,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVEGDWLLGGPYYHYYGMDVW,IGHV3-23,IGHJ6,CLVWDDSLNGLVF,IGLV1-47,COV2-2619,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ1,CHKRSNWPPSLTF,IGKV3-11,COV2-2367,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ2,CHKRSNWPPSLTF,IGKV3-11,COV2-2367,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ3,CHKRSNWPPSLTF,IGKV3-11,COV2-2367,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ4,CHKRSNWPPSLTF,IGKV3-11,COV2-2367,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ5,CHKRSNWPPSLTF,IGKV3-11,COV2-2367,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ6,CHKRSNWPPSLTF,IGKV3-11,COV2-2367,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ1,CMQSIQLAF,IGKV2D-29,COV2-2343,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ2,CMQSIQLAF,IGKV2D-29,COV2-2343,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ3,CMQSIQLAF,IGKV2D-29,COV2-2343,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ4,CMQSIQLAF,IGKV2D-29,COV2-2343,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ5,CMQSIQLAF,IGKV2D-29,COV2-2343,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVQRRRLDYW,IGHV1-18,IGHJ6,CMQSIQLAF,IGKV2D-29,COV2-2343,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAITYYYDSSGYWWDDW,IGHV1-69,IGHJ1,CQQRSNWPPSYTF,IGKV3-11,COV2-2270,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAITYYYDSSGYWWDDW,IGHV1-69,IGHJ2,CQQRSNWPPSYTF,IGKV3-11,COV2-2270,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAITYYYDSSGYWWDDW,IGHV1-69,IGHJ3,CQQRSNWPPSYTF,IGKV3-11,COV2-2270,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAITYYYDSSGYWWDDW,IGHV1-69,IGHJ4,CQQRSNWPPSYTF,IGKV3-11,COV2-2270,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAITYYYDSSGYWWDDW,IGHV1-69,IGHJ5,CQQRSNWPPSYTF,IGKV3-11,COV2-2270,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAITYYYDSSGYWWDDW,IGHV1-69,IGHJ6,CQQRSNWPPSYTF,IGKV3-11,COV2-2270,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ1,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2187,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ2,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2187,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ3,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2187,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ4,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2187,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ5,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2187,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGATNFDYW,IGHV3-30-3,IGHJ6,CQVWDSSSDHPEWVF,IGLV3-21,COV2-2187,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGIYYDIFMPLLDW,IGHV3-9,IGHJ1,CHQYGTSPYTF,IGKV3-20,COV2-2478,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGIYYDIFMPLLDW,IGHV3-9,IGHJ2,CHQYGTSPYTF,IGKV3-20,COV2-2478,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGIYYDIFMPLLDW,IGHV3-9,IGHJ3,CHQYGTSPYTF,IGKV3-20,COV2-2478,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGIYYDIFMPLLDW,IGHV3-9,IGHJ4,CHQYGTSPYTF,IGKV3-20,COV2-2478,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGIYYDIFMPLLDW,IGHV3-9,IGHJ5,CHQYGTSPYTF,IGKV3-20,COV2-2478,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKGIYYDIFMPLLDW,IGHV3-9,IGHJ6,CHQYGTSPYTF,IGKV3-20,COV2-2478,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ1,CMQALQTPFTF,IGKV2-28,COV2-2820,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ2,CMQALQTPFTF,IGKV2-28,COV2-2820,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ3,CMQALQTPFTF,IGKV2-28,COV2-2820,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ4,CMQALQTPFTF,IGKV2-28,COV2-2820,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ5,CMQALQTPFTF,IGKV2-28,COV2-2820,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ6,CMQALQTPFTF,IGKV2-28,COV2-2820,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ1,CSSYTSSRAVLF,IGLV2-14,COV2-2620,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ2,CSSYTSSRAVLF,IGLV2-14,COV2-2620,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ3,CSSYTSSRAVLF,IGLV2-14,COV2-2620,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ4,CSSYTSSRAVLF,IGLV2-14,COV2-2620,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ5,CSSYTSSRAVLF,IGLV2-14,COV2-2620,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ6,CSSYTSSRAVLF,IGLV2-14,COV2-2620,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ1,CQAWDSSTGVF,IGLV3-1,COV2-2171,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ2,CQAWDSSTGVF,IGLV3-1,COV2-2171,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ3,CQAWDSSTGVF,IGLV3-1,COV2-2171,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ4,CQAWDSSTGVF,IGLV3-1,COV2-2171,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ5,CQAWDSSTGVF,IGLV3-1,COV2-2171,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ6,CQAWDSSTGVF,IGLV3-1,COV2-2171,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGIYYLVRGFIIGYYGMDVW,IGHV1-8,IGHJ1,CQQYYSTPLTF,IGKV4-1,COV2-2583,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGIYYLVRGFIIGYYGMDVW,IGHV1-8,IGHJ2,CQQYYSTPLTF,IGKV4-1,COV2-2583,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGIYYLVRGFIIGYYGMDVW,IGHV1-8,IGHJ3,CQQYYSTPLTF,IGKV4-1,COV2-2583,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGIYYLVRGFIIGYYGMDVW,IGHV1-8,IGHJ4,CQQYYSTPLTF,IGKV4-1,COV2-2583,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGIYYLVRGFIIGYYGMDVW,IGHV1-8,IGHJ5,CQQYYSTPLTF,IGKV4-1,COV2-2583,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARGGIYYLVRGFIIGYYGMDVW,IGHV1-8,IGHJ6,CQQYYSTPLTF,IGKV4-1,COV2-2583,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ1,CMQALQTPFTF,IGKV2-28,COV2-2227,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ2,CMQALQTPFTF,IGKV2-28,COV2-2227,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ3,CMQALQTPFTF,IGKV2-28,COV2-2227,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ4,CMQALQTPFTF,IGKV2-28,COV2-2227,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ5,CMQALQTPFTF,IGKV2-28,COV2-2227,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARDQSQGAYILTGYRGYGMDVW,IGHV3-33,IGHJ6,CMQALQTPFTF,IGKV2-28,COV2-2227,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ1,CSSYTSSSTLLYVF,IGLV2-14,COV2-2160,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ2,CSSYTSSSTLLYVF,IGLV2-14,COV2-2160,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ3,CSSYTSSSTLLYVF,IGLV2-14,COV2-2160,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ4,CSSYTSSSTLLYVF,IGLV2-14,COV2-2160,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ5,CSSYTSSSTLLYVF,IGLV2-14,COV2-2160,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ6,CSSYTSSSTLLYVF,IGLV2-14,COV2-2160,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGSSSWYFDYW,IGHV3-7,IGHJ1,CQAWDSSTAVF,IGLV3-1,COV2-2178,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGSSSWYFDYW,IGHV3-7,IGHJ2,CQAWDSSTAVF,IGLV3-1,COV2-2178,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGSSSWYFDYW,IGHV3-7,IGHJ3,CQAWDSSTAVF,IGLV3-1,COV2-2178,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGSSSWYFDYW,IGHV3-7,IGHJ4,CQAWDSSTAVF,IGLV3-1,COV2-2178,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGSSSWYFDYW,IGHV3-7,IGHJ5,CQAWDSSTAVF,IGLV3-1,COV2-2178,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARVGSSSWYFDYW,IGHV3-7,IGHJ6,CQAWDSSTAVF,IGLV3-1,COV2-2178,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ1,CSSYTSSSTLLYVF,IGLV2-14,COV2-2159,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ2,CSSYTSSSTLLYVF,IGLV2-14,COV2-2159,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ3,CSSYTSSSTLLYVF,IGLV2-14,COV2-2159,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ4,CSSYTSSSTLLYVF,IGLV2-14,COV2-2159,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ5,CSSYTSSSTLLYVF,IGLV2-14,COV2-2159,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARSTSGSYYYGMDVW,IGHV3-30-3,IGHJ6,CSSYTSSSTLLYVF,IGLV2-14,COV2-2159,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ1,CQHRTNWPPLFTF,IGKV3-11,COV2-2166,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ2,CQHRTNWPPLFTF,IGKV3-11,COV2-2166,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ3,CQHRTNWPPLFTF,IGKV3-11,COV2-2166,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ4,CQHRTNWPPLFTF,IGKV3-11,COV2-2166,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ5,CQHRTNWPPLFTF,IGKV3-11,COV2-2166,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ6,CQHRTNWPPLFTF,IGKV3-11,COV2-2166,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ1,CQQYYSTPWTF,IGKV4-1,COV2-2224,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ2,CQQYYSTPWTF,IGKV4-1,COV2-2224,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ3,CQQYYSTPWTF,IGKV4-1,COV2-2224,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ4,CQQYYSTPWTF,IGKV4-1,COV2-2224,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ5,CQQYYSTPWTF,IGKV4-1,COV2-2224,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CAKDGSIAAADYW,IGHV3-30,IGHJ6,CQQYYSTPWTF,IGKV4-1,COV2-2224,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ1,CQHRTNWPPLFTF,IGKV3-11,COV2-2214,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ2,CQHRTNWPPLFTF,IGKV3-11,COV2-2214,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ3,CQHRTNWPPLFTF,IGKV3-11,COV2-2214,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ4,CQHRTNWPPLFTF,IGKV3-11,COV2-2214,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ5,CQHRTNWPPLFTF,IGKV3-11,COV2-2214,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARIGHFDSSGYYLDYW,IGHV1-69,IGHJ6,CQHRTNWPPLFTF,IGKV3-11,COV2-2214,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ1,CQQYYSISWTF,IGKV4-1,COV2-2218,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ2,CQQYYSISWTF,IGKV4-1,COV2-2218,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ3,CQQYYSISWTF,IGKV4-1,COV2-2218,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ4,CQQYYSISWTF,IGKV4-1,COV2-2218,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ5,CQQYYSISWTF,IGKV4-1,COV2-2218,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARPYTGSYKSYMDVW,IGHV3-30,IGHJ6,CQQYYSISWTF,IGKV4-1,COV2-2218,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ1,CHKRSNWPPSLTF,IGKV3-11,COV2-2216,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ2,CHKRSNWPPSLTF,IGKV3-11,COV2-2216,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ3,CHKRSNWPPSLTF,IGKV3-11,COV2-2216,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ4,CHKRSNWPPSLTF,IGKV3-11,COV2-2216,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ5,CHKRSNWPPSLTF,IGKV3-11,COV2-2216,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ6,CHKRSNWPPSLTF,IGKV3-11,COV2-2216,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ1,CHKRSNWPPSLTF,IGKV3-11,COV2-2169,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ2,CHKRSNWPPSLTF,IGKV3-11,COV2-2169,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ3,CHKRSNWPPSLTF,IGKV3-11,COV2-2169,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ4,CHKRSNWPPSLTF,IGKV3-11,COV2-2169,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ5,CHKRSNWPPSLTF,IGKV3-11,COV2-2169,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARTSHYDSSGSYFEYW,IGHV1-69,IGHJ6,CHKRSNWPPSLTF,IGKV3-11,COV2-2169,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ1,CQAWDSSTGVF,IGLV3-1,COV2-2175,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ2,CQAWDSSTGVF,IGLV3-1,COV2-2175,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ3,CQAWDSSTGVF,IGLV3-1,COV2-2175,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ4,CQAWDSSTGVF,IGLV3-1,COV2-2175,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ5,CQAWDSSTGVF,IGLV3-1,COV2-2175,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARLSGSSWDFDYW,IGHV3-7,IGHJ6,CQAWDSSTGVF,IGLV3-1,COV2-2175,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ1,CSSYTSSRAVLF,IGLV2-14,COV2-2183,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ2,CSSYTSSRAVLF,IGLV2-14,COV2-2183,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ3,CSSYTSSRAVLF,IGLV2-14,COV2-2183,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ4,CSSYTSSRAVLF,IGLV2-14,COV2-2183,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ5,CSSYTSSRAVLF,IGLV2-14,COV2-2183,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CARADTMVRGTYFEYW,IGHV3-30-3,IGHJ6,CSSYTSSRAVLF,IGLV2-14,COV2-2183,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
CTRAGWELRLDAFDIW,IGHV3-21,IGHJ1,CNSRDSSGILF,IGLV3-19, 2-38 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CTRAGWELRLDAFDIW,IGHV3-21,IGHJ2,CNSRDSSGILF,IGLV3-19, 2-38 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CTRAGWELRLDAFDIW,IGHV3-21,IGHJ3,CNSRDSSGILF,IGLV3-19, 2-38 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CTRAGWELRLDAFDIW,IGHV3-21,IGHJ4,CNSRDSSGILF,IGLV3-19, 2-38 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CTRAGWELRLDAFDIW,IGHV3-21,IGHJ5,CNSRDSSGILF,IGLV3-19, 2-38 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CTRAGWELRLDAFDIW,IGHV3-21,IGHJ6,CNSRDSSGILF,IGLV3-19, 2-38 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAHHKIERIFDYW,IGHV2-5,IGHJ1,CSSYTTSSTVF,IGLV2-14, 2-7 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAHHKIERIFDYW,IGHV2-5,IGHJ2,CSSYTTSSTVF,IGLV2-14, 2-7 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAHHKIERIFDYW,IGHV2-5,IGHJ3,CSSYTTSSTVF,IGLV2-14, 2-7 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAHHKIERIFDYW,IGHV2-5,IGHJ4,CSSYTTSSTVF,IGLV2-14, 2-7 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAHHKIERIFDYW,IGHV2-5,IGHJ5,CSSYTTSSTVF,IGLV2-14, 2-7 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAHHKIERIFDYW,IGHV2-5,IGHJ6,CSSYTTSSTVF,IGLV2-14, 2-7 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGIAVIGPPPSTYYYYGMDVW,IGHV1-24,IGHJ1,CSSYTSSSTYVF,IGLV2-14, 1-87 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGIAVIGPPPSTYYYYGMDVW,IGHV1-24,IGHJ2,CSSYTSSSTYVF,IGLV2-14, 1-87 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGIAVIGPPPSTYYYYGMDVW,IGHV1-24,IGHJ3,CSSYTSSSTYVF,IGLV2-14, 1-87 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGIAVIGPPPSTYYYYGMDVW,IGHV1-24,IGHJ4,CSSYTSSSTYVF,IGLV2-14, 1-87 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGIAVIGPPPSTYYYYGMDVW,IGHV1-24,IGHJ5,CSSYTSSSTYVF,IGLV2-14, 1-87 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGIAVIGPPPSTYYYYGMDVW,IGHV1-24,IGHJ6,CSSYTSSSTYVF,IGLV2-14, 1-87 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAVAGSSDVWYYYYGMDVW,IGHV1-24,IGHJ1,CSSYTSSSTYVF,IGLV2-18, 1-68 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAVAGSSDVWYYYYGMDVW,IGHV1-24,IGHJ2,CSSYTSSSTYVF,IGLV2-18, 1-68 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAVAGSSDVWYYYYGMDVW,IGHV1-24,IGHJ3,CSSYTSSSTYVF,IGLV2-18, 1-68 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAVAGSSDVWYYYYGMDVW,IGHV1-24,IGHJ4,CSSYTSSSTYVF,IGLV2-18, 1-68 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAVAGSSDVWYYYYGMDVW,IGHV1-24,IGHJ5,CSSYTSSSTYVF,IGLV2-18, 1-68 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAVAGSSDVWYYYYGMDVW,IGHV1-24,IGHJ6,CSSYTSSSTYVF,IGLV2-18, 1-68 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAYKSTWYFGYW,IGHV1-24,IGHJ1,CSSYAGSRMGF,IGLV2-8, 2-51 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAYKSTWYFGYW,IGHV1-24,IGHJ2,CSSYAGSRMGF,IGLV2-8, 2-51 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAYKSTWYFGYW,IGHV1-24,IGHJ3,CSSYAGSRMGF,IGLV2-8, 2-51 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAYKSTWYFGYW,IGHV1-24,IGHJ4,CSSYAGSRMGF,IGLV2-8, 2-51 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAYKSTWYFGYW,IGHV1-24,IGHJ5,CSSYAGSRMGF,IGLV2-8, 2-51 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CATGWAYKSTWYFGYW,IGHV1-24,IGHJ6,CSSYAGSRMGF,IGLV2-8, 2-51 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAKDSGYNYGYSWFDPW,IGHV3-30,IGHJ1,CQSTDNSGTYPNWVF,IGLV3-25, 4-18 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAKDSGYNYGYSWFDPW,IGHV3-30,IGHJ2,CQSTDNSGTYPNWVF,IGLV3-25, 4-18 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAKDSGYNYGYSWFDPW,IGHV3-30,IGHJ3,CQSTDNSGTYPNWVF,IGLV3-25, 4-18 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAKDSGYNYGYSWFDPW,IGHV3-30,IGHJ4,CQSTDNSGTYPNWVF,IGLV3-25, 4-18 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAKDSGYNYGYSWFDPW,IGHV3-30,IGHJ5,CQSTDNSGTYPNWVF,IGLV3-25, 4-18 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAKDSGYNYGYSWFDPW,IGHV3-30,IGHJ6,CQSTDNSGTYPNWVF,IGLV3-25, 4-18 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSAKHWLAPPGDYYYYMDVW,IGHV4-59,IGHJ1,CQQLNSYLTF,IGKV1-9, 4-19 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSAKHWLAPPGDYYYYMDVW,IGHV4-59,IGHJ2,CQQLNSYLTF,IGKV1-9, 4-19 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSAKHWLAPPGDYYYYMDVW,IGHV4-59,IGHJ3,CQQLNSYLTF,IGKV1-9, 4-19 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSAKHWLAPPGDYYYYMDVW,IGHV4-59,IGHJ4,CQQLNSYLTF,IGKV1-9, 4-19 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSAKHWLAPPGDYYYYMDVW,IGHV4-59,IGHJ5,CQQLNSYLTF,IGKV1-9, 4-19 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSAKHWLAPPGDYYYYMDVW,IGHV4-59,IGHJ6,CQQLNSYLTF,IGKV1-9, 4-19 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARPGGGSYQEFDYW,IGHV1-46,IGHJ1,CQQSYNTLQVTF,IGKV1-39, 4-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARPGGGSYQEFDYW,IGHV1-46,IGHJ2,CQQSYNTLQVTF,IGKV1-39, 4-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARPGGGSYQEFDYW,IGHV1-46,IGHJ3,CQQSYNTLQVTF,IGKV1-39, 4-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARPGGGSYQEFDYW,IGHV1-46,IGHJ4,CQQSYNTLQVTF,IGKV1-39, 4-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARPGGGSYQEFDYW,IGHV1-46,IGHJ5,CQQSYNTLQVTF,IGKV1-39, 4-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARPGGGSYQEFDYW,IGHV1-46,IGHJ6,CQQSYNTLQVTF,IGKV1-39, 4-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAREVYYYDRSGYYASDGFDIW,IGHV4-61,IGHJ1,CQQYGSSPQTF,IGKV3-20, 2-36 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAREVYYYDRSGYYASDGFDIW,IGHV4-61,IGHJ2,CQQYGSSPQTF,IGKV3-20, 2-36 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAREVYYYDRSGYYASDGFDIW,IGHV4-61,IGHJ3,CQQYGSSPQTF,IGKV3-20, 2-36 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAREVYYYDRSGYYASDGFDIW,IGHV4-61,IGHJ4,CQQYGSSPQTF,IGKV3-20, 2-36 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAREVYYYDRSGYYASDGFDIW,IGHV4-61,IGHJ5,CQQYGSSPQTF,IGKV3-20, 2-36 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CAREVYYYDRSGYYASDGFDIW,IGHV4-61,IGHJ6,CQQYGSSPQTF,IGKV3-20, 2-36 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDPRDYYDFWSGYDYYYGLDVW,IGHV3-33,IGHJ1,CQQYGSSGALTF,IGKV3-20, 5-24 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDPRDYYDFWSGYDYYYGLDVW,IGHV3-33,IGHJ2,CQQYGSSGALTF,IGKV3-20, 5-24 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDPRDYYDFWSGYDYYYGLDVW,IGHV3-33,IGHJ3,CQQYGSSGALTF,IGKV3-20, 5-24 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDPRDYYDFWSGYDYYYGLDVW,IGHV3-33,IGHJ4,CQQYGSSGALTF,IGKV3-20, 5-24 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDPRDYYDFWSGYDYYYGLDVW,IGHV3-33,IGHJ5,CQQYGSSGALTF,IGKV3-20, 5-24 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDPRDYYDFWSGYDYYYGLDVW,IGHV3-33,IGHJ6,CQQYGSSGALTF,IGKV3-20, 5-24 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDRSWAVVYYYMDVW,IGHV1-2,IGHJ1,CSSYAGSNNLVF,IGLV2-8, 2-4 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDRSWAVVYYYMDVW,IGHV1-2,IGHJ2,CSSYAGSNNLVF,IGLV2-8, 2-4 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDRSWAVVYYYMDVW,IGHV1-2,IGHJ3,CSSYAGSNNLVF,IGLV2-8, 2-4 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDRSWAVVYYYMDVW,IGHV1-2,IGHJ4,CSSYAGSNNLVF,IGLV2-8, 2-4 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDRSWAVVYYYMDVW,IGHV1-2,IGHJ5,CSSYAGSNNLVF,IGLV2-8, 2-4 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDRSWAVVYYYMDVW,IGHV1-2,IGHJ6,CSSYAGSNNLVF,IGLV2-8, 2-4 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDREPHSDSSGYWDSLKYYYYYALDVW,IGHV1-46,IGHJ1,CQQLNTYPFTF,IGKV1-9, 5-7 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDREPHSDSSGYWDSLKYYYYYALDVW,IGHV1-46,IGHJ2,CQQLNTYPFTF,IGKV1-9, 5-7 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDREPHSDSSGYWDSLKYYYYYALDVW,IGHV1-46,IGHJ3,CQQLNTYPFTF,IGKV1-9, 5-7 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDREPHSDSSGYWDSLKYYYYYALDVW,IGHV1-46,IGHJ4,CQQLNTYPFTF,IGKV1-9, 5-7 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDREPHSDSSGYWDSLKYYYYYALDVW,IGHV1-46,IGHJ5,CQQLNTYPFTF,IGKV1-9, 5-7 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDREPHSDSSGYWDSLKYYYYYALDVW,IGHV1-46,IGHJ6,CQQLNTYPFTF,IGKV1-9, 5-7 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDLFYYGMDVW,IGHV3-53,IGHJ1,CQQLNSYPCF,IGKV1-9, 1-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDLFYYGMDVW,IGHV3-53,IGHJ2,CQQLNSYPCF,IGKV1-9, 1-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDLFYYGMDVW,IGHV3-53,IGHJ3,CQQLNSYPCF,IGKV1-9, 1-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDLFYYGMDVW,IGHV3-53,IGHJ4,CQQLNSYPCF,IGKV1-9, 1-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDLFYYGMDVW,IGHV3-53,IGHJ5,CQQLNSYPCF,IGKV1-9, 1-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARDLFYYGMDVW,IGHV3-53,IGHJ6,CQQLNSYPCF,IGKV1-9, 1-20 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGGSRCSGGNCYGWAYDAFDIW,IGHV1-2,IGHJ1,CSSYTSSSTFVF,IGLV2-14, 2-15 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGGSRCSGGNCYGWAYDAFDIW,IGHV1-2,IGHJ2,CSSYTSSSTFVF,IGLV2-14, 2-15 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGGSRCSGGNCYGWAYDAFDIW,IGHV1-2,IGHJ3,CSSYTSSSTFVF,IGLV2-14, 2-15 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGGSRCSGGNCYGWAYDAFDIW,IGHV1-2,IGHJ4,CSSYTSSSTFVF,IGLV2-14, 2-15 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGGSRCSGGNCYGWAYDAFDIW,IGHV1-2,IGHJ5,CSSYTSSSTFVF,IGLV2-14, 2-15 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGGSRCSGGNCYGWAYDAFDIW,IGHV1-2,IGHJ6,CSSYTSSSTFVF,IGLV2-14, 2-15 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVGYRGVIPLNWFDPW,IGHV1-69,IGHJ1,CQQYNNWPPFTF,IGKV3-15, 2-17 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVGYRGVIPLNWFDPW,IGHV1-69,IGHJ2,CQQYNNWPPFTF,IGKV3-15, 2-17 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVGYRGVIPLNWFDPW,IGHV1-69,IGHJ3,CQQYNNWPPFTF,IGKV3-15, 2-17 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVGYRGVIPLNWFDPW,IGHV1-69,IGHJ4,CQQYNNWPPFTF,IGKV3-15, 2-17 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVGYRGVIPLNWFDPW,IGHV1-69,IGHJ5,CQQYNNWPPFTF,IGKV3-15, 2-17 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVGYRGVIPLNWFDPW,IGHV1-69,IGHJ6,CQQYNNWPPFTF,IGKV3-15, 2-17 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSILYGGGMDVW,IGHV3-30,IGHJ1,CQQLNSYPLTF,IGKV1-9, 2-30 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSILYGGGMDVW,IGHV3-30,IGHJ2,CQQLNSYPLTF,IGKV1-9, 2-30 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSILYGGGMDVW,IGHV3-30,IGHJ3,CQQLNSYPLTF,IGKV1-9, 2-30 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSILYGGGMDVW,IGHV3-30,IGHJ4,CQQLNSYPLTF,IGKV1-9, 2-30 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSILYGGGMDVW,IGHV3-30,IGHJ5,CQQLNSYPLTF,IGKV1-9, 2-30 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARSILYGGGMDVW,IGHV3-30,IGHJ6,CQQLNSYPLTF,IGKV1-9, 2-30 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGLGVGCSGGNCYLDYYYMDVW,IGHV1-2,IGHJ1,CSSYTSSSTWVF,IGLV2-14, 2-43 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGLGVGCSGGNCYLDYYYMDVW,IGHV1-2,IGHJ2,CSSYTSSSTWVF,IGLV2-14, 2-43 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGLGVGCSGGNCYLDYYYMDVW,IGHV1-2,IGHJ3,CSSYTSSSTWVF,IGLV2-14, 2-43 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGLGVGCSGGNCYLDYYYMDVW,IGHV1-2,IGHJ4,CSSYTSSSTWVF,IGLV2-14, 2-43 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGLGVGCSGGNCYLDYYYMDVW,IGHV1-2,IGHJ5,CSSYTSSSTWVF,IGLV2-14, 2-43 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGLGVGCSGGNCYLDYYYMDVW,IGHV1-2,IGHJ6,CSSYTSSSTWVF,IGLV2-14, 2-43 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CASLQTVDTAIEKYYGMDVW,IGHV1-69,IGHJ1,CQAWDSSTAVF,IGLV3-1, 4-8 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CASLQTVDTAIEKYYGMDVW,IGHV1-69,IGHJ2,CQAWDSSTAVF,IGLV3-1, 4-8 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CASLQTVDTAIEKYYGMDVW,IGHV1-69,IGHJ3,CQAWDSSTAVF,IGLV3-1, 4-8 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CASLQTVDTAIEKYYGMDVW,IGHV1-69,IGHJ4,CQAWDSSTAVF,IGLV3-1, 4-8 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CASLQTVDTAIEKYYGMDVW,IGHV1-69,IGHJ5,CQAWDSSTAVF,IGLV3-1, 4-8 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CASLQTVDTAIEKYYGMDVW,IGHV1-69,IGHJ6,CQAWDSSTAVF,IGLV3-1, 4-8 ,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARVHRWAYCINGVCFGAYSDYW,IGHV3-72,IGHJ1,CQQYGSSPSTF,IGKV3-20, 1-57 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARVHRWAYCINGVCFGAYSDYW,IGHV3-72,IGHJ2,CQQYGSSPSTF,IGKV3-20, 1-57 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARVHRWAYCINGVCFGAYSDYW,IGHV3-72,IGHJ3,CQQYGSSPSTF,IGKV3-20, 1-57 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARVHRWAYCINGVCFGAYSDYW,IGHV3-72,IGHJ4,CQQYGSSPSTF,IGKV3-20, 1-57 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARVHRWAYCINGVCFGAYSDYW,IGHV3-72,IGHJ5,CQQYGSSPSTF,IGKV3-20, 1-57 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARVHRWAYCINGVCFGAYSDYW,IGHV3-72,IGHJ6,CQQYGSSPSTF,IGKV3-20, 1-57 ,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
CARGVNYYDRNGYYRNDGFDIW,IGHV4-39,IGHJ1,CLQHNTYPFTF,IGKV1-17,MnC4t2p1_F5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARGVNYYDRNGYYRNDGFDIW,IGHV4-39,IGHJ2,CLQHNTYPFTF,IGKV1-17,MnC4t2p1_F5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARGVNYYDRNGYYRNDGFDIW,IGHV4-39,IGHJ3,CLQHNTYPFTF,IGKV1-17,MnC4t2p1_F5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARGVNYYDRNGYYRNDGFDIW,IGHV4-39,IGHJ4,CLQHNTYPFTF,IGKV1-17,MnC4t2p1_F5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARGVNYYDRNGYYRNDGFDIW,IGHV4-39,IGHJ5,CLQHNTYPFTF,IGKV1-17,MnC4t2p1_F5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARGVNYYDRNGYYRNDGFDIW,IGHV4-39,IGHJ6,CLQHNTYPFTF,IGKV1-17,MnC4t2p1_F5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDLRRQDYYADWYFDLW,IGHV3-9,IGHJ1,CQQGNSFPFTF,IGKV1-12,MnC4t2p1_E6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDLRRQDYYADWYFDLW,IGHV3-9,IGHJ2,CQQGNSFPFTF,IGKV1-12,MnC4t2p1_E6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDLRRQDYYADWYFDLW,IGHV3-9,IGHJ3,CQQGNSFPFTF,IGKV1-12,MnC4t2p1_E6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDLRRQDYYADWYFDLW,IGHV3-9,IGHJ4,CQQGNSFPFTF,IGKV1-12,MnC4t2p1_E6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDLRRQDYYADWYFDLW,IGHV3-9,IGHJ5,CQQGNSFPFTF,IGKV1-12,MnC4t2p1_E6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDLRRQDYYADWYFDLW,IGHV3-9,IGHJ6,CQQGNSFPFTF,IGKV1-12,MnC4t2p1_E6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CATGARFGESPFDYW,IGHV3-66,IGHJ1,CQQANSFPGTF,IGKV1D-12,MnC2t1p1_C5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CATGARFGESPFDYW,IGHV3-66,IGHJ2,CQQANSFPGTF,IGKV1D-12,MnC2t1p1_C5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CATGARFGESPFDYW,IGHV3-66,IGHJ3,CQQANSFPGTF,IGKV1D-12,MnC2t1p1_C5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CATGARFGESPFDYW,IGHV3-66,IGHJ4,CQQANSFPGTF,IGKV1D-12,MnC2t1p1_C5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CATGARFGESPFDYW,IGHV3-66,IGHJ5,CQQANSFPGTF,IGKV1D-12,MnC2t1p1_C5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CATGARFGESPFDYW,IGHV3-66,IGHJ6,CQQANSFPGTF,IGKV1D-12,MnC2t1p1_C5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARSLRGANLVPW,IGHV7-4-1,IGHJ1,CQQYDNLPLTF,IGKV1-33,FnC1t2p1_G5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARSLRGANLVPW,IGHV7-4-1,IGHJ2,CQQYDNLPLTF,IGKV1-33,FnC1t2p1_G5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARSLRGANLVPW,IGHV7-4-1,IGHJ3,CQQYDNLPLTF,IGKV1-33,FnC1t2p1_G5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARSLRGANLVPW,IGHV7-4-1,IGHJ4,CQQYDNLPLTF,IGKV1-33,FnC1t2p1_G5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARSLRGANLVPW,IGHV7-4-1,IGHJ5,CQQYDNLPLTF,IGKV1-33,FnC1t2p1_G5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARSLRGANLVPW,IGHV7-4-1,IGHJ6,CQQYDNLPLTF,IGKV1-33,FnC1t2p1_G5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ1,CMQALQTPGTF,IGKV2-28,CnC2t1p1_D6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ2,CMQALQTPGTF,IGKV2-28,CnC2t1p1_D6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ3,CMQALQTPGTF,IGKV2-28,CnC2t1p1_D6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ4,CMQALQTPGTF,IGKV2-28,CnC2t1p1_D6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ5,CMQALQTPGTF,IGKV2-28,CnC2t1p1_D6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ6,CMQALQTPGTF,IGKV2-28,CnC2t1p1_D6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ1,CMQALQTPGTF,IGKV2-28,CnC2t1p1_E12 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ2,CMQALQTPGTF,IGKV2-28,CnC2t1p1_E12 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ3,CMQALQTPGTF,IGKV2-28,CnC2t1p1_E12 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ4,CMQALQTPGTF,IGKV2-28,CnC2t1p1_E12 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ5,CMQALQTPGTF,IGKV2-28,CnC2t1p1_E12 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTRVRRLWFGSYYYGMDVW,IGHV3-49,IGHJ6,CMQALQTPGTF,IGKV2-28,CnC2t1p1_E12 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDINYDSGGYHKNYFDYW,IGHV3-9,IGHJ1,CQQSYSNPLTF,IGKV1-39,HbnC4t1p1_D5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDINYDSGGYHKNYFDYW,IGHV3-9,IGHJ2,CQQSYSNPLTF,IGKV1-39,HbnC4t1p1_D5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDINYDSGGYHKNYFDYW,IGHV3-9,IGHJ3,CQQSYSNPLTF,IGKV1-39,HbnC4t1p1_D5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDINYDSGGYHKNYFDYW,IGHV3-9,IGHJ4,CQQSYSNPLTF,IGKV1-39,HbnC4t1p1_D5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDINYDSGGYHKNYFDYW,IGHV3-9,IGHJ5,CQQSYSNPLTF,IGKV1-39,HbnC4t1p1_D5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKDINYDSGGYHKNYFDYW,IGHV3-9,IGHJ6,CQQSYSNPLTF,IGKV1-39,HbnC4t1p1_D5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CALASGSYFGGANYW,IGHV3-23,IGHJ1,CLLSYTGARVF,IGLV7-46,MnC1t3p1_G9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CALASGSYFGGANYW,IGHV3-23,IGHJ2,CLLSYTGARVF,IGLV7-46,MnC1t3p1_G9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CALASGSYFGGANYW,IGHV3-23,IGHJ3,CLLSYTGARVF,IGLV7-46,MnC1t3p1_G9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CALASGSYFGGANYW,IGHV3-23,IGHJ4,CLLSYTGARVF,IGLV7-46,MnC1t3p1_G9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CALASGSYFGGANYW,IGHV3-23,IGHJ5,CLLSYTGARVF,IGLV7-46,MnC1t3p1_G9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CALASGSYFGGANYW,IGHV3-23,IGHJ6,CLLSYTGARVF,IGLV7-46,MnC1t3p1_G9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKIGSRNSLGVW,IGHV7-4-1,IGHJ1,CQHFGTSSVTF,IGKV3-20,MnC4t2p2_A4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKIGSRNSLGVW,IGHV7-4-1,IGHJ2,CQHFGTSSVTF,IGKV3-20,MnC4t2p2_A4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKIGSRNSLGVW,IGHV7-4-1,IGHJ3,CQHFGTSSVTF,IGKV3-20,MnC4t2p2_A4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKIGSRNSLGVW,IGHV7-4-1,IGHJ4,CQHFGTSSVTF,IGKV3-20,MnC4t2p2_A4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKIGSRNSLGVW,IGHV7-4-1,IGHJ5,CQHFGTSSVTF,IGKV3-20,MnC4t2p2_A4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKIGSRNSLGVW,IGHV7-4-1,IGHJ6,CQHFGTSSVTF,IGKV3-20,MnC4t2p2_A4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKGGDYEWELLESW,IGHV3-30,IGHJ1,CQHYHSFPLTF,IGKV1-5,HbnC3t1p1_F4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKGGDYEWELLESW,IGHV3-30,IGHJ2,CQHYHSFPLTF,IGKV1-5,HbnC3t1p1_F4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKGGDYEWELLESW,IGHV3-30,IGHJ3,CQHYHSFPLTF,IGKV1-5,HbnC3t1p1_F4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKGGDYEWELLESW,IGHV3-30,IGHJ4,CQHYHSFPLTF,IGKV1-5,HbnC3t1p1_F4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKGGDYEWELLESW,IGHV3-30,IGHJ5,CQHYHSFPLTF,IGKV1-5,HbnC3t1p1_F4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAKGGDYEWELLESW,IGHV3-30,IGHJ6,CQHYHSFPLTF,IGKV1-5,HbnC3t1p1_F4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDFGDFFFDYW,IGHV3-66,IGHJ1,CQQYGSSPRTF,IGKV3-20,HbnC3t1p1_G4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDFGDFFFDYW,IGHV3-66,IGHJ2,CQQYGSSPRTF,IGKV3-20,HbnC3t1p1_G4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDFGDFFFDYW,IGHV3-66,IGHJ3,CQQYGSSPRTF,IGKV3-20,HbnC3t1p1_G4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDFGDFFFDYW,IGHV3-66,IGHJ4,CQQYGSSPRTF,IGKV3-20,HbnC3t1p1_G4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDFGDFFFDYW,IGHV3-66,IGHJ5,CQQYGSSPRTF,IGKV3-20,HbnC3t1p1_G4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDFGDFFFDYW,IGHV3-66,IGHJ6,CQQYGSSPRTF,IGKV3-20,HbnC3t1p1_G4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAREGGLDYFGSRNSGWTYTWFDPW,IGHV1-69,IGHJ1,CQQSYSTLYSF,IGKV1-39,MnC2t2p1_C11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAREGGLDYFGSRNSGWTYTWFDPW,IGHV1-69,IGHJ2,CQQSYSTLYSF,IGKV1-39,MnC2t2p1_C11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAREGGLDYFGSRNSGWTYTWFDPW,IGHV1-69,IGHJ3,CQQSYSTLYSF,IGKV1-39,MnC2t2p1_C11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAREGGLDYFGSRNSGWTYTWFDPW,IGHV1-69,IGHJ4,CQQSYSTLYSF,IGKV1-39,MnC2t2p1_C11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAREGGLDYFGSRNSGWTYTWFDPW,IGHV1-69,IGHJ5,CQQSYSTLYSF,IGKV1-39,MnC2t2p1_C11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAREGGLDYFGSRNSGWTYTWFDPW,IGHV1-69,IGHJ6,CQQSYSTLYSF,IGKV1-39,MnC2t2p1_C11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDGELLGWFDPW,IGHV1-18,IGHJ1,CCSYAGSSTWVF,IGLV2-23,CnC2t1p1_B4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDGELLGWFDPW,IGHV1-18,IGHJ2,CCSYAGSSTWVF,IGLV2-23,CnC2t1p1_B4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDGELLGWFDPW,IGHV1-18,IGHJ3,CCSYAGSSTWVF,IGLV2-23,CnC2t1p1_B4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDGELLGWFDPW,IGHV1-18,IGHJ4,CCSYAGSSTWVF,IGLV2-23,CnC2t1p1_B4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDGELLGWFDPW,IGHV1-18,IGHJ5,CCSYAGSSTWVF,IGLV2-23,CnC2t1p1_B4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDGELLGWFDPW,IGHV1-18,IGHJ6,CCSYAGSSTWVF,IGLV2-23,CnC2t1p1_B4 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDYGDYFFDYW,IGHV3-66,IGHJ1,CQQYGSSPRTF,IGKV3-20,HbnC3t1p2_B10,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDYGDYFFDYW,IGHV3-66,IGHJ2,CQQYGSSPRTF,IGKV3-20,HbnC3t1p2_B10,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDYGDYFFDYW,IGHV3-66,IGHJ3,CQQYGSSPRTF,IGKV3-20,HbnC3t1p2_B10,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDYGDYFFDYW,IGHV3-66,IGHJ4,CQQYGSSPRTF,IGKV3-20,HbnC3t1p2_B10,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDYGDYFFDYW,IGHV3-66,IGHJ5,CQQYGSSPRTF,IGKV3-20,HbnC3t1p2_B10,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARDYGDYFFDYW,IGHV3-66,IGHJ6,CQQYGSSPRTF,IGKV3-20,HbnC3t1p2_B10,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARATTDCSSTSCWSLDFWSGYYTGGREKIFDYW,IGHV1-8,IGHJ1,CQQYGSSPGTF,IGKV3-20,FnC1t1p2_A5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARATTDCSSTSCWSLDFWSGYYTGGREKIFDYW,IGHV1-8,IGHJ2,CQQYGSSPGTF,IGKV3-20,FnC1t1p2_A5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARATTDCSSTSCWSLDFWSGYYTGGREKIFDYW,IGHV1-8,IGHJ3,CQQYGSSPGTF,IGKV3-20,FnC1t1p2_A5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARATTDCSSTSCWSLDFWSGYYTGGREKIFDYW,IGHV1-8,IGHJ4,CQQYGSSPGTF,IGKV3-20,FnC1t1p2_A5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARATTDCSSTSCWSLDFWSGYYTGGREKIFDYW,IGHV1-8,IGHJ5,CQQYGSSPGTF,IGKV3-20,FnC1t1p2_A5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARATTDCSSTSCWSLDFWSGYYTGGREKIFDYW,IGHV1-8,IGHJ6,CQQYGSSPGTF,IGKV3-20,FnC1t1p2_A5 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARVSGYDSSGYWGDYW,IGHV1-69,IGHJ1,CQQRSNWPPALTF,IGKV3-11,CnC2t1p1_B10 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARVSGYDSSGYWGDYW,IGHV1-69,IGHJ2,CQQRSNWPPALTF,IGKV3-11,CnC2t1p1_B10 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARVSGYDSSGYWGDYW,IGHV1-69,IGHJ3,CQQRSNWPPALTF,IGKV3-11,CnC2t1p1_B10 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARVSGYDSSGYWGDYW,IGHV1-69,IGHJ4,CQQRSNWPPALTF,IGKV3-11,CnC2t1p1_B10 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARVSGYDSSGYWGDYW,IGHV1-69,IGHJ5,CQQRSNWPPALTF,IGKV3-11,CnC2t1p1_B10 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARVSGYDSSGYWGDYW,IGHV1-69,IGHJ6,CQQRSNWPPALTF,IGKV3-11,CnC2t1p1_B10 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CASSKGFCSGGSCSDYW,IGHV3-48,IGHJ1,CHQYGSSPWTF,IGKV3-20,MnC4t1p1_A11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CASSKGFCSGGSCSDYW,IGHV3-48,IGHJ2,CHQYGSSPWTF,IGKV3-20,MnC4t1p1_A11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CASSKGFCSGGSCSDYW,IGHV3-48,IGHJ3,CHQYGSSPWTF,IGKV3-20,MnC4t1p1_A11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CASSKGFCSGGSCSDYW,IGHV3-48,IGHJ4,CHQYGSSPWTF,IGKV3-20,MnC4t1p1_A11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CASSKGFCSGGSCSDYW,IGHV3-48,IGHJ5,CHQYGSSPWTF,IGKV3-20,MnC4t1p1_A11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CASSKGFCSGGSCSDYW,IGHV3-48,IGHJ6,CHQYGSSPWTF,IGKV3-20,MnC4t1p1_A11 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARAARRPVVTDTMAYYMDVW,IGHV3-33,IGHJ1,CQQRSNWPPTWTF,IGKV3-11,HbnC2t1p2_D9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARAARRPVVTDTMAYYMDVW,IGHV3-33,IGHJ2,CQQRSNWPPTWTF,IGKV3-11,HbnC2t1p2_D9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARAARRPVVTDTMAYYMDVW,IGHV3-33,IGHJ3,CQQRSNWPPTWTF,IGKV3-11,HbnC2t1p2_D9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARAARRPVVTDTMAYYMDVW,IGHV3-33,IGHJ4,CQQRSNWPPTWTF,IGKV3-11,HbnC2t1p2_D9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARAARRPVVTDTMAYYMDVW,IGHV3-33,IGHJ5,CQQRSNWPPTWTF,IGKV3-11,HbnC2t1p2_D9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARAARRPVVTDTMAYYMDVW,IGHV3-33,IGHJ6,CQQRSNWPPTWTF,IGKV3-11,HbnC2t1p2_D9 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVATITDFDYW,IGHV1-2,IGHJ1,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_G6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVATITDFDYW,IGHV1-2,IGHJ2,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_G6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVATITDFDYW,IGHV1-2,IGHJ3,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_G6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVATITDFDYW,IGHV1-2,IGHJ4,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_G6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVATITDFDYW,IGHV1-2,IGHJ5,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_G6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVATITDFDYW,IGHV1-2,IGHJ6,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_G6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVSTITDFDYW,IGHV1-2,IGHJ1,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_E8 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVSTITDFDYW,IGHV1-2,IGHJ2,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_E8 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVSTITDFDYW,IGHV1-2,IGHJ3,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_E8 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVSTITDFDYW,IGHV1-2,IGHJ4,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_E8 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVSTITDFDYW,IGHV1-2,IGHJ5,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_E8 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CARASVSTITDFDYW,IGHV1-2,IGHJ6,CCSYAGVRTVVF,IGLV2-23,CnC2t1p1_E8 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPRCSGGSCYDGFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,MnC5t2p1_G1 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPRCSGGSCYDGFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,MnC5t2p1_G1 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPRCSGGSCYDGFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,MnC5t2p1_G1 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPRCSGGSCYDGFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,MnC5t2p1_G1 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPRCSGGSCYDGFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,MnC5t2p1_G1 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPRCSGGSCYDGFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,MnC5t2p1_G1 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPYCSSTRCYDAFDIW,IGHV1-58,IGHJ1,CQQYGRSPWTF,IGKV3-20,HbnC3t1p2_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPYCSSTRCYDAFDIW,IGHV1-58,IGHJ2,CQQYGRSPWTF,IGKV3-20,HbnC3t1p2_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPYCSSTRCYDAFDIW,IGHV1-58,IGHJ3,CQQYGRSPWTF,IGKV3-20,HbnC3t1p2_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPYCSSTRCYDAFDIW,IGHV1-58,IGHJ4,CQQYGRSPWTF,IGKV3-20,HbnC3t1p2_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPYCSSTRCYDAFDIW,IGHV1-58,IGHJ5,CQQYGRSPWTF,IGKV3-20,HbnC3t1p2_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPYCSSTRCYDAFDIW,IGHV1-58,IGHJ6,CQQYGRSPWTF,IGKV3-20,HbnC3t1p2_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPHCSSTICYDGFDIW,IGHV1-58,IGHJ1,CQQYGSSPWTF,IGKV3-20,HbnC3t1p1_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPHCSSTICYDGFDIW,IGHV1-58,IGHJ2,CQQYGSSPWTF,IGKV3-20,HbnC3t1p1_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPHCSSTICYDGFDIW,IGHV1-58,IGHJ3,CQQYGSSPWTF,IGKV3-20,HbnC3t1p1_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPHCSSTICYDGFDIW,IGHV1-58,IGHJ4,CQQYGSSPWTF,IGKV3-20,HbnC3t1p1_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPHCSSTICYDGFDIW,IGHV1-58,IGHJ5,CQQYGSSPWTF,IGKV3-20,HbnC3t1p1_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CAAPHCSSTICYDGFDIW,IGHV1-58,IGHJ6,CQQYGSSPWTF,IGKV3-20,HbnC3t1p1_C6 ,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CTTARWDWYFDLW,IGHV3-15,IGHJ1,CQQHDDLPPTF,IGKV1-33,REGN10934,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CTTARWDWYFDLW,IGHV3-15,IGHJ2,CQQHDDLPPTF,IGKV1-33,REGN10934,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CTTARWDWYFDLW,IGHV3-15,IGHJ3,CQQHDDLPPTF,IGKV1-33,REGN10934,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CTTARWDWYFDLW,IGHV3-15,IGHJ4,CQQHDDLPPTF,IGKV1-33,REGN10934,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CTTARWDWYFDLW,IGHV3-15,IGHJ5,CQQHDDLPPTF,IGKV1-33,REGN10934,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CTTARWDWYFDLW,IGHV3-15,IGHJ6,CQQHDDLPPTF,IGKV1-33,REGN10934,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CANMVRGVYEDDYW,IGHV4-59,IGHJ1,CQQNYNTPLTF,IGKV1-39,REGN10964,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CANMVRGVYEDDYW,IGHV4-59,IGHJ2,CQQNYNTPLTF,IGKV1-39,REGN10964,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CANMVRGVYEDDYW,IGHV4-59,IGHJ3,CQQNYNTPLTF,IGKV1-39,REGN10964,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CANMVRGVYEDDYW,IGHV4-59,IGHJ4,CQQNYNTPLTF,IGKV1-39,REGN10964,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CANMVRGVYEDDYW,IGHV4-59,IGHJ5,CQQNYNTPLTF,IGKV1-39,REGN10964,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CANMVRGVYEDDYW,IGHV4-59,IGHJ6,CQQNYNTPLTF,IGKV1-39,REGN10964,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARTPFYYDSSGYYLDYW,IGHV1-69,IGHJ1,CQQYVRSPRTF,IGKV3-20,REGN10977,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARTPFYYDSSGYYLDYW,IGHV1-69,IGHJ2,CQQYVRSPRTF,IGKV3-20,REGN10977,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARTPFYYDSSGYYLDYW,IGHV1-69,IGHJ3,CQQYVRSPRTF,IGKV3-20,REGN10977,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARTPFYYDSSGYYLDYW,IGHV1-69,IGHJ4,CQQYVRSPRTF,IGKV3-20,REGN10977,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARTPFYYDSSGYYLDYW,IGHV1-69,IGHJ5,CQQYVRSPRTF,IGKV3-20,REGN10977,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARTPFYYDSSGYYLDYW,IGHV1-69,IGHJ6,CQQYVRSPRTF,IGKV3-20,REGN10977,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDHGMAAAGYNYW,IGHV3-66,IGHJ1,CQQYDNLPPAF,IGKV1-33,REGN10954,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDHGMAAAGYNYW,IGHV3-66,IGHJ2,CQQYDNLPPAF,IGKV1-33,REGN10954,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDHGMAAAGYNYW,IGHV3-66,IGHJ3,CQQYDNLPPAF,IGKV1-33,REGN10954,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDHGMAAAGYNYW,IGHV3-66,IGHJ4,CQQYDNLPPAF,IGKV1-33,REGN10954,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDHGMAAAGYNYW,IGHV3-66,IGHJ5,CQQYDNLPPAF,IGKV1-33,REGN10954,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDHGMAAAGYNYW,IGHV3-66,IGHJ6,CQQYDNLPPAF,IGKV1-33,REGN10954,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDRGTTMVPFDYW,IGHV3-11,IGHJ1,CQQYDNLPLTF,IGKV1-33,REGN10933,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDRGTTMVPFDYW,IGHV3-11,IGHJ2,CQQYDNLPLTF,IGKV1-33,REGN10933,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDRGTTMVPFDYW,IGHV3-11,IGHJ3,CQQYDNLPLTF,IGKV1-33,REGN10933,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDRGTTMVPFDYW,IGHV3-11,IGHJ4,CQQYDNLPLTF,IGKV1-33,REGN10933,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDRGTTMVPFDYW,IGHV3-11,IGHJ5,CQQYDNLPLTF,IGKV1-33,REGN10933,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDRGTTMVPFDYW,IGHV3-11,IGHJ6,CQQYDNLPLTF,IGKV1-33,REGN10933,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARALPYGDLHFDYW,IGHV3-66,IGHJ1,CQSYDSSLSDSYVF,IGLV1-40,REGN10986,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARALPYGDLHFDYW,IGHV3-66,IGHJ2,CQSYDSSLSDSYVF,IGLV1-40,REGN10986,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARALPYGDLHFDYW,IGHV3-66,IGHJ3,CQSYDSSLSDSYVF,IGLV1-40,REGN10986,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARALPYGDLHFDYW,IGHV3-66,IGHJ4,CQSYDSSLSDSYVF,IGLV1-40,REGN10986,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARALPYGDLHFDYW,IGHV3-66,IGHJ5,CQSYDSSLSDSYVF,IGLV1-40,REGN10986,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARALPYGDLHFDYW,IGHV3-66,IGHJ6,CQSYDSSLSDSYVF,IGLV1-40,REGN10986,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGSRYDWNQNNWFDPW,IGHV1-2,IGHJ1,CSSFTTSSTVVF,IGLV2-14,REGN10989,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGSRYDWNQNNWFDPW,IGHV1-2,IGHJ2,CSSFTTSSTVVF,IGLV2-14,REGN10989,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGSRYDWNQNNWFDPW,IGHV1-2,IGHJ3,CSSFTTSSTVVF,IGLV2-14,REGN10989,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGSRYDWNQNNWFDPW,IGHV1-2,IGHJ4,CSSFTTSSTVVF,IGLV2-14,REGN10989,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGSRYDWNQNNWFDPW,IGHV1-2,IGHJ5,CSSFTTSSTVVF,IGLV2-14,REGN10989,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGSRYDWNQNNWFDPW,IGHV1-2,IGHJ6,CSSFTTSSTVVF,IGLV2-14,REGN10989,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGELGIPYGMDVW,IGHV3-66,IGHJ1,CGTWDSSLSAGVF,IGLV1-51,REGN10984,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGELGIPYGMDVW,IGHV3-66,IGHJ2,CGTWDSSLSAGVF,IGLV1-51,REGN10984,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGELGIPYGMDVW,IGHV3-66,IGHJ3,CGTWDSSLSAGVF,IGLV1-51,REGN10984,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGELGIPYGMDVW,IGHV3-66,IGHJ4,CGTWDSSLSAGVF,IGLV1-51,REGN10984,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGELGIPYGMDVW,IGHV3-66,IGHJ5,CGTWDSSLSAGVF,IGLV1-51,REGN10984,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARGELGIPYGMDVW,IGHV3-66,IGHJ6,CGTWDSSLSAGVF,IGLV1-51,REGN10984,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CASGSDYGDYLLVYW,IGHV3-30,IGHJ1,CNSLTSISTWVF,IGLV2-14,REGN10987,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CASGSDYGDYLLVYW,IGHV3-30,IGHJ2,CNSLTSISTWVF,IGLV2-14,REGN10987,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CASGSDYGDYLLVYW,IGHV3-30,IGHJ3,CNSLTSISTWVF,IGLV2-14,REGN10987,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CASGSDYGDYLLVYW,IGHV3-30,IGHJ4,CNSLTSISTWVF,IGLV2-14,REGN10987,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CASGSDYGDYLLVYW,IGHV3-30,IGHJ5,CNSLTSISTWVF,IGLV2-14,REGN10987,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CASGSDYGDYLLVYW,IGHV3-30,IGHJ6,CNSLTSISTWVF,IGLV2-14,REGN10987,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CARDLDVSGGMDVW,IGHV3-53,IGHJ1,CQQYGSSPQTF,IGKV3-20,CV30,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
CARDLDVSGGMDVW,IGHV3-53,IGHJ2,CQQYGSSPQTF,IGKV3-20,CV30,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
CARDLDVSGGMDVW,IGHV3-53,IGHJ3,CQQYGSSPQTF,IGKV3-20,CV30,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
CARDLDVSGGMDVW,IGHV3-53,IGHJ4,CQQYGSSPQTF,IGKV3-20,CV30,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
CARDLDVSGGMDVW,IGHV3-53,IGHJ5,CQQYGSSPQTF,IGKV3-20,CV30,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
CARDLDVSGGMDVW,IGHV3-53,IGHJ6,CQQYGSSPQTF,IGKV3-20,CV30,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ1,CQQSYTTPLTF,IGKV1-39,MD17,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ2,CQQSYTTPLTF,IGKV1-39,MD17,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ3,CQQSYTTPLTF,IGKV1-39,MD17,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ4,CQQSYTTPLTF,IGKV1-39,MD17,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ5,CQQSYTTPLTF,IGKV1-39,MD17,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ6,CQQSYTTPLTF,IGKV1-39,MD17,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ1,CHQTYTSPYTF,IGKV1-39,MD29,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ2,CHQTYTSPYTF,IGKV1-39,MD29,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ3,CHQTYTSPYTF,IGKV1-39,MD29,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ4,CHQTYTSPYTF,IGKV1-39,MD29,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ5,CHQTYTSPYTF,IGKV1-39,MD29,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSSSWYDAFDIW,IGHV3-64D,IGHJ6,CHQTYTSPYTF,IGKV1-39,MD29,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSNSWYDAFDIW,IGHV3-64D,IGHJ1,CQQSYSTPYTF,IGKV1-39,MD63,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSNSWYDAFDIW,IGHV3-64D,IGHJ2,CQQSYSTPYTF,IGKV1-39,MD63,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSNSWYDAFDIW,IGHV3-64D,IGHJ3,CQQSYSTPYTF,IGKV1-39,MD63,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSNSWYDAFDIW,IGHV3-64D,IGHJ4,CQQSYSTPYTF,IGKV1-39,MD63,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSNSWYDAFDIW,IGHV3-64D,IGHJ5,CQQSYSTPYTF,IGKV1-39,MD63,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CVKDQDSNSWYDAFDIW,IGHV3-64D,IGHJ6,CQQSYSTPYTF,IGKV1-39,MD63,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ1,CQQYGVSPEIIF,IGKV3-20,MD45,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ2,CQQYGVSPEIIF,IGKV3-20,MD45,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ3,CQQYGVSPEIIF,IGKV3-20,MD45,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ4,CQQYGVSPEIIF,IGKV3-20,MD45,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ5,CQQYGVSPEIIF,IGKV3-20,MD45,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ6,CQQYGVSPEIIF,IGKV3-20,MD45,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ1,CQQFGSSPLTF,IGKV3-20,MD67,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ2,CQQFGSSPLTF,IGKV3-20,MD67,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ3,CQQFGSSPLTF,IGKV3-20,MD67,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ4,CQQFGSSPLTF,IGKV3-20,MD67,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ5,CQQFGSSPLTF,IGKV3-20,MD67,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLSVRGGMDVW,IGHV3-53,IGHJ6,CQQFGSSPLTF,IGKV3-20,MD67,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLQYYGMDVW,IGHV3-53,IGHJ1,CQQANSFPLTF,IGKV1-12,MD62,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLQYYGMDVW,IGHV3-53,IGHJ2,CQQANSFPLTF,IGKV1-12,MD62,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLQYYGMDVW,IGHV3-53,IGHJ3,CQQANSFPLTF,IGKV1-12,MD62,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLQYYGMDVW,IGHV3-53,IGHJ4,CQQANSFPLTF,IGKV1-12,MD62,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLQYYGMDVW,IGHV3-53,IGHJ5,CQQANSFPLTF,IGKV1-12,MD62,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CARDLQYYGMDVW,IGHV3-53,IGHJ6,CQQANSFPLTF,IGKV1-12,MD62,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CAKDLVTAPSYEAFDIW,IGHV3-23,IGHJ1,CQVWDSSSHHHVVF,IGLV3-21,MD47,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CAKDLVTAPSYEAFDIW,IGHV3-23,IGHJ2,CQVWDSSSHHHVVF,IGLV3-21,MD47,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CAKDLVTAPSYEAFDIW,IGHV3-23,IGHJ3,CQVWDSSSHHHVVF,IGLV3-21,MD47,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CAKDLVTAPSYEAFDIW,IGHV3-23,IGHJ4,CQVWDSSSHHHVVF,IGLV3-21,MD47,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CAKDLVTAPSYEAFDIW,IGHV3-23,IGHJ5,CQVWDSSSHHHVVF,IGLV3-21,MD47,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
CAKDLVTAPSYEAFDIW,IGHV3-23,IGHJ6,CQVWDSSSHHHVVF,IGLV3-21,MD47,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
